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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
 
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
 
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section.  
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
 
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues: 
 Section 1.6 How Can (Chemical X) Affect Children? 
 Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 Section 3.7 Children’s Susceptibility 
 Section 6.6 Exposures of Children 
 
Other Sections of Interest: 
 Section 3.8  Biomarkers of Exposure and Effect 
 Section 3.11  Methods for Reducing Toxic Effects 
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 E-mail:   atsdric@cdc.gov  Internet:   http://www.atsdr.cdc.gov 
 
The following additional material can be ordered through the ATSDR Information Center: 
 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 











Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III—
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
 
 
Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 





The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
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1.  PUBLIC HEALTH STATEMENT—PBBs 
 
This public health statement tells you about polybrominated biphenyls (PBBs) and the effects of 
exposure to PBBs.   
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  PBBs have been found in at least nine of the 1,647 current 
or former NPL sites.  Although the total number of NPL sites evaluated for these substances is 
not known, the possibility exists that the number of sites at which PBBs are found may increase 
in the future as more sites are evaluated.  This information is important because these sites may 
be sources of exposure and exposure to these substances may harm you. 
 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment.  Such a release does not always 
lead to exposure.  You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
 
If you are exposed to PBBs, many factors will determine whether you will be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
PBBs.  You must also consider any other chemicals you are exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health. 
 
1.1   WHAT ARE PBBs? 
 
Polybrominated biphenyls (PBBs) are chemicals that were added to plastics used in a variety of 
consumer products, such as computer monitors, televisions, textiles, and plastic foams, to make 
them difficult to burn.  Because PBBs were mixed into plastics rather than bound to them, they 
were able to leave the plastic and find their way into the environment.  Commercial production 
of PBBs began in the 1970s.  Manufacture of PBBs was discontinued in the United States in 
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1976.  Concern regarding PBBs is mainly related to exposures resulting from an agriculture 
contamination episode that occurred in Michigan over a 10-month period during 1973–1974.   
 
There are no known natural sources of PBBs in the environment.  PBBs are solids and are 
colorless to off-white.  PBBs enter the environment as mixtures containing a variety of 
individual brominated biphenyl (for PBBs) components, known as congeners.  Some commercial 
PBB mixtures are known in the United States under the industrial trade name, FireMaster®.  
However, other flame retardant chemicals also may be identified by this name.  PBBs are no 
longer used in North America because the agriculture contamination episode that occurred in 
Michigan in 1973–1974 led to the cessation of its production.  More information on the physical 
properties and uses of PBBs can be found in Chapters 6 and 7. 
 
1.2   WHAT HAPPENS TO PBBs WHEN THEY ENTER THE ENVIRONMENT? 
 
In the past, PBBs entered the air, water, and soil during their manufacture and use.  In addition, 
animal feed was accidentally mixed with 500–1,000 pounds of PBBs in lower Michigan in 1973.  
This contamination of the food chain affected millions of farm animals and humans living in 
Michigan at this time.  PBBs entered the environment during the disposal of contaminated 
animal feed and animal products during the agriculture contamination episode.  PBBs also 
entered the environment from PBB-containing wastes that manufacturers disposed of in waste 
sites.  Small quantities of PBBs also entered the environment from accidental spills during 
transport.  PBBs are no longer manufactured in North America, but very small amounts of PBBs 
may be released into the environment from poorly maintained hazardous waste sites and 
improper incineration of plastics that contain PBBs. 
 
More information about what happens to PBBs in the environment can be found in Chapter 8. 
 
PBBs AND PBDEs  3 
 








1.3   HOW MIGHT I BE EXPOSED TO PBBs? 
 
PBBs are no longer produced or used in the United States.  Thus, the general population 
exposure to PBBs will only be from past releases.  For people living in the lower peninsula of 
Michigan, especially near PBB contaminated areas, exposure to PBBs may still be occurring 
today.  However, environmental levels have decreased since the 1970s and current exposure, if 
any, will be at low levels.  For other regions of the United States, the levels of exposure will 
either be very low or none.   
 
Measured data in air, water, soil, and food, as well as body burden data (blood, urine, breast 
milk, and body fat), indicate that most people within the state of Michigan who were exposed to 
PBBs received very low levels of PBBs.  The levels from exposure were slightly higher for 
people living in the lower peninsula of Michigan and highest among people living on 
contaminated dairy farms.  Consumption of contaminated meat and dairy products caused the 
higher levels of PBBs in the body.  Monitoring of the workplace environment, as well as the 
blood, urine, and body fat of workers indicated that those in PBB industries were exposed to 
higher levels of PBBs than the general population.  These workers were exposed to PBBs by 
breathing contaminated workplace air and by skin contact with PBBs.  Occupational exposure 
also could have occurred from the incineration of materials containing PBBs.  Exposure in 
workplaces is no longer likely because PBBs are no longer manufactured.  People who live near 
hazardous waste sites that contain PBBs may be exposed primarily by breathing air that contains 
PBBs. 
 
More information about exposure to PBBs can be found in Chapter 8. 
 
1.4   HOW CAN PBBs ENTER AND LEAVE MY BODY? 
 
If you breathe air that contains PBBs, or swallow food, water, or soil contaminated with PBBs, 
they can enter your body through your lungs and stomach and pass into the bloodstream.  We 
don’t know how much of the PBBs will pass into the blood from the lungs; although most will 
probably pass into the blood from the stomach and intestines.  If you touch soil containing PBBs, 
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it is highly unlikely that PBBs would pass through your skin into the bloodstream.  It is not 
known how fast PBBs enter the blood from the lungs or stomach.  There are no known current 
sources of PBBs because they are no longer produced and used in North America.  They are 
rarely found in air and drinking water away from production plants and contaminated sites.  
Once PBBs are in your body, they can partially change into breakdown products called 
metabolites.  Some metabolites and unchanged PBBs could leave your body, mainly in the feces 
and in very small amounts in the urine, within a few days.  Other unchanged PBBs might stay in 
your body for many years.  PBBs are stored mainly in your body fat, tend to concentrate in breast 
milk fat, and can enter the bodies of children through breast feeding.  PBBs also can enter the 
bodies of unborn babies through the placenta.  More information on how PBBs can enter and 
leave your body can be found in Chapter 5. 
 
1.5   HOW CAN PBBs AFFECT MY HEALTH? 
 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  That sometimes involves animal testing.  Animal testing may 
help identify health effects such as cancer or birth defects.  Without laboratory animals, scientists 
would lose a basic method for getting information needed to make wise decisions that protect 
public health.  Scientists have the responsibility to treat research animals with care and 
compassion.  Scientists must comply with strict animal care guidelines because laws today 
protect the welfare of research animals. 
 
Much of what is known about the health effects of PBBs in people comes from studies of 
ingestion in Michigan in the early-to-mid 1970s, where feed for farm animals was accidentally 
contaminated with a fire retardant containing PBBs.  People were exposed to PBBs for several 
months when they ate meat, milk, and eggs from the contaminated animals.  After news of the 
contamination episode became widespread, many Michigan residents complained of various 
health problems, including nausea, abdominal pain, loss of appetite, joint pain, fatigue, and 
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weakness.  However, it could not be clearly established that any of the problems were caused by 
eating the food contaminated with PBBs.  PBBs also did not cause any definite changes in the 
livers or immune systems of the Michigan residents.  However, some people who ate the 
contaminated food developed skin disorders, such as acne and hair loss.  It is likely that PBBs 
caused the skin problems because other chemicals similar to PBBs also cause these effects.  
Workers who were exposed to PBBs for a few days to months by breathing and skin contact also 
developed acne, although not all persons exposed to PBBs developed acne.  Very little is known 
about the health of people who are exposed to low levels of PBBs for long periods by eating, 
breathing, or skin contact. 
 
Laboratory animals fed PBBs had body weight loss, skin disorders, and nervous system effects, 
and their livers, kidneys, thyroid glands, and immune systems were seriously injured.  Some 
animals fed high amounts died.  PBBs also caused birth defects in animals, but it is not known 
for sure whether PBBs make males or females infertile.  Most of the effects in animals occurred 
after they ate large amounts of PBBs for short periods or smaller amounts for several weeks or 
months.  Body weight loss and effects on the livers, kidneys, and thyroid glands were observed.  
A lifetime study of rats and mice fed PBBs at doses higher than those expected from 
environmental exposure.  A few studies tested animals exposed to PBBs by skin contact.  These 
animals had injuries to the liver and skin.  Only one study tested animals exposed to PBBs by 
breathing, and no health effects were observed. 
 
We do not know if PBBs caused or will cause cancer in people who ate food contaminated with 
PBBs.  Rats developed cancer in their livers after eating a large amount of a PBB mixture only 
once.  The babies of exposed rats developed cancer in their livers after eating a large amount of 
the same PBB mixture only once.  Liver cancer also developed in rats and mice that ate smaller 
amounts of the PBB mixture for several months.  Mice that had skin contact with a small amount 
of a PBB mixture for several months did not develop skin cancer.  There are no cancer studies in 
animals that breathed PBBs.  Because animals fed PBBs did develop cancer, the National 
Toxicology Program (NTP) of the Department of Health and Human Services (DHHS) 
determined that PBBs may reasonably be anticipated to be carcinogens.  Similarly, the 
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International Agency for Research on Cancer (IARC) has determined that PBBs are possibly 
carcinogenic to humans.  The EPA has not classified the carcinogenicity of PBBs. 
 
We do not know whether the effects found in animals exposed to PBBs would also occur in 
people exposed in the same way.  The amounts of PBBs that caused health effects in animals are 
much greater than levels of PBBs normally found in the environment.  Long-term exposure to 
these chemicals has a greater potential to cause health effects than does short-term exposure to 
low levels because they tend to build up in your body over many years.  More information on 
how PBBs can affect your health can be found in Chapter 5. 
 
1.6   HOW CAN PBBs AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.  
 
Children are exposed to PBBs in generally the same way as are adults, mainly by eating 
contaminated food.  Because of their smaller weight, children’s intake of PBBs per kilogram (or 
pound) of body weight may be greater than that of adults.  The most likely way that infants will 
be exposed is from breast milk that contains PBBs, although fetuses in the womb are also 
exposed.  Children who live near hazardous waste sites might accidentally eat some PBBs by 
putting dirty hands or other soil/dirt-covered objects in their mouths, by eating without washing 
their hands, or similar behavior.  Some children also eat dirt on purpose.  It is not possible that 
children could be exposed to PBBs following transport of the chemical on clothing from the 
parent’s workplace to the home because PBBs are no longer being produced or used.  
 
Some information on health effects of PBBs in children is available from studies of the Michigan 
contamination episode.  Symptoms of ill health were not associated with increased exposure to 
PBBs, and general neurological examinations did not show any abnormalities.  More detailed 
studies of physical and neuropsychological development showed no effects that were clearly 
related to PBBs among Michigan children exposed during the episode.  Changes in nerve and 
brain function have been seen in animals that were exposed to PBBs in the womb and by 
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nursing.  Animal studies also found that exposure to PBBs during pregnancy or lactation caused 
changes in thyroid hormone levels in the newborn animals and, at high doses, increases in 
prenatal death and structural birth defects. 
 
As indicated above, children can be exposed to PBBs before birth and from breast milk.  PBBs 
are stored in the mother’s body and can be released during pregnancy, cross the placenta, and 
enter fetal tissues.  Because PBBs dissolve readily in fat, they can accumulate in breast milk fat 
and be transferred to babies and young children.  PBBs have been found in breast milk; however, 
in most cases, the benefits of breast-feeding outweigh any risks from exposure in mother’s milk.  
You should consult your health care provider if you have any concerns about PBBs and breast 
feeding.  Because the nervous system and thyroid are still developing in the fetus and child, the 
effects of PBBs on these target systems might be more profound from exposure before and soon 
after birth.  That could mean fetuses and children are more susceptible to PBBs than are adults.  
 
1.7   HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBBs? 
 
If your doctor finds that you have been exposed to substantial amounts of PBBs, ask whether 
your children might also have been exposed.  Your doctor might need to ask your state health 
department to investigate. 
 
Because PBBs are no longer produced or used, the risk of exposure to these compounds is 
limited.  You and your children could be exposed to PBBs by eating fish or wildlife caught from 
contaminated locations.  Children who live near hazardous waste sites should be discouraged 
from playing in the dirt near these sites because they could still contain PBBs.  Children should 
also be discouraged from eating the dirt, and careful handwashing practices should be followed. 
 
1.8   IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO PBBs? 
 
Special tests can determine whether PBBs are in the blood, body fat, and breast milk.  These are 
not regular or routine clinical tests, but could be ordered by a doctor to detect PBBs in people 
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exposed to them in the environment and at work.  If your PBB levels are higher than the normal 
levels, this will show that you have been exposed to high levels of the chemicals.  However, 
these measurements cannot determine the exact amount or type of PBBs that you have been 
exposed to, or how long you have been exposed.  Although these tests can indicate whether you 
have been exposed to PBBs to a greater extent than the general population, they do not predict 
whether you will be harmed.  Blood tests are the easiest, safest, and probably the best method for 
detecting recent or past exposures to large amounts of PBBs.  Results of such tests should be 
reviewed and carefully interpreted by physicians with a background in environmental and 
occupational medicine.  Exposures to PBBs have been of greatest concern in Michigan as 
explained in Sections 1.3 and 1.5.  More information on tests used to determine whether you 
have been exposed to PBBs can be found in Chapter 5 (Section 5.11) and Chapter 9 
(Section 9.1). 
 
1.9   WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law.  The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
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Recommendations and regulations are also updated periodically as more information becomes 
available.  For the most current information, check with the federal agency or organization that 
provides it.  Some regulations and recommendations for PBBs include the following: 
 
At present, there are no federal guidelines or recommendations for protecting human health from 
exposure to PBBs. 
 
1.10   WHERE CAN I GET MORE INFORMATION? 
 
If you have any more questions or concerns about PBBs, please contact your community or state 
health or environmental quality department, or contact ATSDR at the address and phone number 
below. 
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov/toxpro2.html and on 
CD-ROM.  You may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-
free information and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by 
e-mail at atsdric@cdc.gov, or by writing to:  
 
  Agency for Toxic Substances and Disease Registry 
  Division of Toxicology 
  1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
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Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
 










2.  PUBLIC HEALTH STATEMENT—PBDEs 
 
This public health statement tells you about polybrominated diphenyl ethers (PBDEs) and the 
effects of exposure to PBDEs.   
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  PBDEs have not been found in the 1,647 current or former 
NPL sites.  Although the total number of NPL sites evaluated for these substances is not known, 
the possibility exists that PBDEs may be found in the future as more sites are evaluated.  This 
information is important because these sites may be sources of exposure and exposure to these 
substances may harm you. 
 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment.  Such a release does not always 
lead to exposure.  You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
 
If you are exposed to PBDEs, many factors will determine whether you will be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
PBDEs.  You must also consider any other chemicals you are exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health. 
 
2.1   WHAT ARE PBDEs? 
 
PBDEs are flame-retardant chemicals that are added to a variety of consumer products to make 
them difficult to burn.  Because PBDEs are added rather than reacted to the product, they could 
leave the product under ideal conditions and enter the environment, but this rarely happens.  The 
first commercial productions of PBDEs began in the 1970s in Germany.  Production of PBDEs 
has continued until the present.  There are three commercial PBDE products (i.e., penta-, octa-, 
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and decabromodiphenyl ethers).  Deca- and octa-brominated types of PBDEs are also produced 
outside of the United States (in China and Israel).  Decabromodiphenyl ether (decaBDE) makes 
up 82% of these products manufactured globally.  Its main use is for electronic enclosures, such 
as television cabinets.  Octabromodiphenyl ether (octaBDE) product is used in plastics for 
business equipment.  Pentabromodiphenyl ether (pentaBDE) product is used in foam for 
cushioning in upholstery.  PBDEs have not been associated with actual health-related effects.  
Concerns have increased, however, because some of these chemicals (particularly PBDEs in the 
pentaBDEs) have been found in the environment at varying concentrations.  Environmental 
concentrations of lower brominated PBDEs, which may be leveling off in Europe, appear to be 
increasing in certain areas of Canada and the United States.  
 
PBDEs are a group of synthetic organic chemicals with no known natural sources in the 
environment, except for a few marine organisms that produce forms of PBDEs that contain 
higher levels of oxygen.  Commercial decaBDE and octaBDE products are colorless to off-white 
solids, whereas commercial pentaBDE product is a thick liquid.  PBDEs are not expected to 
evaporate into the air.  PBDEs in the air are mostly found with dust rather than as a vapor.  
PBDEs enter the environment as mixtures containing a variety of individual brominated diphenyl 
ether (for PBDEs) components, known as congeners.  Congeners are distinct members of a class 
of chemical substances.  Some commercial mixtures of PBDEs may be known by their industrial 
trade names, (i.e., DE-60F Special, DE-61, DE-62, DE-71, DE-79, DE-83R, Saytex® 102E).  
PBDEs are still produced and widely used in the United States, although the sole manufacturer of 
penta- and octaPBDE commercial products in the United States is expected to quit making these 
chemicals by the end of 2004.  More information on the physical properties and uses of PBDEs 
can be found in Chapters 6 and 7. 
 
2.2   WHAT HAPPENS TO PBDEs WHEN THEY ENTER THE ENVIRONMENT? 
 
PBDEs enter air, water, and soil during their manufacture and use in consumer products.  When 
PBDEs are suspended in air, they can be present as particles.  They eventually return to land or 
water as the dust settles and are washed out by snow and rainwater.  It is not yet possible to say 
how long PBDEs remain in the air.  PBDEs do not dissolve easily in water, and therefore, high 
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levels of PBDEs are not found in water.  The very small amounts of PBDEs that do occur in 
water stick to particles and eventually settle to the bottom.  Sediments at the bottom of bodies of 
water, such as lakes and rivers, generally act as reservoirs for decaBDEs, which can remain there 
for years.  Some lower brominated PBDEs (e.g., tetra- and penta-congeners of PBDE) in water 
may build up in fish to low concentrations (about 10 billionths of a gram to 1 millionth of a gram 
of PDBE per gram of fresh fish [or 10x10-9–1x10-6 grams of PBDE per gram of fresh fish]).  
However, higher brominated PBDEs, such as decaBDE, are not found in fish at measurable 
concentrations.  In general, the breakdown of PBDEs in soil is very slow, so they may remain in 
soil for several years.  PBDEs bind strongly to soil particles.  Rainwater is not expected to spread 
them much below the soil surface; thus, it is unlikely that PBDEs will enter groundwater. 
 
More information about what happens to PBDEs in the environment can be found in Chapter 8. 
 
2.3   HOW MIGHT I BE EXPOSED TO PBDEs? 
 
Certain PBDE mixtures, especially decaBDE, are produced in many places in the world.  
Currently, the United States is the only producer of the pentaBDE mixture for commerce.  
However, production pentaBDE and octaBDE for commerce soon will begin to be phased out in 
the United States and elsewhere.  Lower brominated PBDEs, such as tetraBDE and pentaBDE 
congeners, are found throughout the environment and are found at low levels in air, sediments, 
animals, and food.  The concentrations of lower brominated PBDEs in blood, breast milk, and 
body fat indicate that most people are exposed to low levels of these PBDEs.  Concentrations of 
lower brominated PBDEs have been increasing in tissues and body fluids of individuals living in 
the United States.  Currently, levels of lower brominated PBDE congeners in individuals living 
in the United States are greater than levels reported in other regions of the world.  Highly 
brominated congeners, such as decaBDE, are not commonly found throughout the environment.  
They may be found at low levels close to places where they are produced or used.  In 2001, 
PBDEs were detected in dust and smoke samples taken near the World Trade Center disaster 
site.  Although no definitive studies in the United States have been conducted to identify the 
sources of exposure, people appear to be exposed to the lower brominated congeners of PBDEs 
by eating food that contains these PBDEs.  In the United States, the concentration of PBDEs 
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(primarily the tetra- and penta-brominated congeners of PBDEs) in outdoor air ranges from 2 to 
77 trillionths of a gram per cubic meter (or 2–77x10-12 grams/m3), which indicates low levels of 
exposure of the general population to these PBDEs.  Indoor air concentrations of PBDEs in 
lecture halls, indoor environments with computers, and rooms with computers or other electronic 
devices, such as television sets, also have low levels of PBDEs in suspended dust.  Workers 
involved in the manufacture and production of PBDE-containing resins are exposed to higher 
concentrations of PBDEs.  Occupational exposure can also occur in confined workplaces where 
plastic and foam products containing PBDEs are recycled, or where computer monitors 
containing PBDEs are repaired.  People who live near hazardous waste sites may be exposed to 
PBDEs by breathing air containing PBDE-contaminated dust.  However, PBDE eventually 
settles or washes out of the air, so this potential exposure route likely to be minimal. 
 
More information about exposure to PBDEs can be found in Chapter 8. 
 
2.4   HOW CAN PBDEs ENTER AND LEAVE MY BODY? 
 
The main source of exposure to PBDEs may be through foods, particularly those with high fat 
content, such as fatty fish.  Some lower brominated PBDEs have been detected in air samples, 
indicating that people can also be exposed by inhalation.  The ways that PBDEs might enter and 
leave your body depend on the chemical structures of the congener components.  The higher 
brominated PBDEs, particularly decaBDE (the major PBDE in use today), act much differently 
in the body than do lower brominated PBDEs.  If you breathe air that contains PBDEs, or 
swallow food, water, or soil contaminated with PBDEs, the lower brominated congeners are 
much more likely than decaBDE to enter your body through your lungs and stomach and pass 
into the bloodstream.  If you touch soil containing PBDEs, which could happen at a hazardous 
waste site, it is highly unlikely that either lower or higher brominated PBDEs would pass through 
your skin into the bloodstream.  Once PBDEs are in your body, the congeners might partially 
change into breakdown products called metabolites.  DecaBDE might leave your body 
unchanged or as metabolites, mainly in the feces and in very small amounts in the urine, within a 
few days.  Lower brominated PBDEs, generally tetra-, penta-, and hexaBDE congeners, might 
stay in your body for many years, stored mainly in body fat.  The lower brominated PBDEs also 
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tend to concentrate in breast milk fat, and can enter the bodies of children through breast feeding.  
PBDEs also can enter the bodies of unborn babies through the placenta.  More information on 
how PBDEs can enter and leave your body can be found in Chapter 5. 
 
2.5   HOW CAN PBDEs AFFECT MY HEALTH? 
 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal care guidelines because 
laws today protect the welfare of research animals. 
 
Nothing definite is known about the health effects of PBDEs in people.  Practically all of the 
available information is from studies of laboratory animals.  Animal studies indicate that 
commercial decaBDE mixtures are generally much less toxic than the products containing lower 
brominated PBDEs.  Because of its very different toxicity, decaBDE is expected to have 
relatively little effect on the health of humans.  Rats and mice that ate food containing moderate 
amounts of lower brominated PBDEs for short periods of time had mainly thyroid effects.  Rats 
and mice that ate smaller amounts over several weeks or months developed effects in the liver 
and in the thyroid.  It is speculated that many of the thyroid effects of PBDEs are specific to the 
species of test animals, suggesting that they are less likely to occur in humans.  Subtle behavioral 
changes have been observed in animals exposed to PBDEs as infants.  One possible explanation 
for the behavioral effects might be related to changes in the thyroid, because development of the 
nervous system is dependent on thyroid hormones.  PBDEs have not caused other kinds of birth 
defects in animals, but more studies are needed to determine if PBDEs can impair reproduction.  
Preliminary findings from short-term animal studies suggest that some PBDEs might impair the 
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immune system.  Animals exposed to PBDEs by skin contact showed signs of skin 
irritation only if they had been scratched. 
 
We don’t know if PBDEs can cause cancer in people, although liver tumors developed in rats 
and mice that ate extremely large amounts of decaBDE throughout their lifetime.  On the basis of 
evidence for cancer in animals, decaBDE is classified as a possible human carcinogen by EPA.  
Lower brominated PBDEs have not yet been tested for cancer.  Neither the U.S. Department of 
Health and Human Services (DHHS) nor the International Agency for Research on Cancer 
(IARC) have classified the carcinogenicity of any PBDEs. 
 
We don’t know whether the effects found in animals exposed to PBDEs would also occur in 
people exposed in the same way.  The amounts of PBDEs that caused health effects in animals 
are much greater than levels of PBDEs normally found in the environment.  Long-term exposure 
to PBDEs has a greater potential to cause health effects than does short-term exposure to low 
levels because of their tendency to build up in your body over many years.  Additionally, the 
lower brominated commercial pentaBDE and octaBDE products are much more likely to cause 
health effects than is decaBDE.  More information on how PBDEs can affect your health can be 
found in Chapter 5. 
 
2.6   HOW CAN PBDEs AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.  
 
Children are exposed to PBDEs in generally the same way as are adults, probably mainly by 
eating contaminated food.  Because of their smaller weight, children’s intake of PBDEs per 
kilogram (or pound) of body weight may be greater than that of adults.  The most likely way that 
infants might be exposed to PBDEs is from breast milk containing lower brominated congeners, 
although fetuses in the womb could also be exposed.  DecaBDE is poorly absorbed in the body 
and, therefore, is unlikely to be found in breast milk or the fetus to any significant extent.  
Children who live near hazardous waste sites might accidentally eat some PBDEs by putting 
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dirty hands or other soil/dirt covered objects in their mouths, or through eating without washing 
their hands.  Some children also eat dirt on purpose.  It is also possible that children could be 
exposed to PBDEs following transport of the chemical on clothing from the parent’s workplace 
to the home.  
 
As indicated above, children can be exposed to PBDEs—mainly the lower brominated 
congeners—both before birth and from breast milk.  The lower brominated PBDEs are much 
more likely than decaBDE to be stored in the mother’s body and released during pregnancy, 
cross the placenta, and entering fetal tissues.  Because lower brominated PBDEs dissolve readily 
in fat, they can accumulate in breast milk fat and be transferred to babies and young children.  
Lower brominated PBDEs have been found in breast milk.  In most cases, however, the benefits 
of breast-feeding outweigh any risks from exposure in mother’s milk.  You should consult your 
health care provider if you have any concerns about PBDEs and breast feeding.  The nervous 
system and thyroid are still developing in the fetus and child.  That means the effects of lower 
brominated PBDEs on these systems might be more significant if exposure occurs during the 
periods before and soon after birth.  That suggests that fetuses and children are more susceptible 
to PBDEs than adults.  
 
More information regarding children’s health and exposure to PBDEs can be found in Chapter 5 
(Section 5.7). 
 
2.7   HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBDEs? 
 
If your doctor finds that you have been exposed to substantial amounts of PBDEs, ask whether 
your children might also have been exposed.  Your doctor might need to ask your state health 
department to investigate. 
 
PBDEs are currently in widespread production and use.  However, production of commercial 
pentaBDE and octaBDE products will soon begin to be phased out in the United States and 
elsewhere.  You and your children may by exposed to lower brominated PBDEs by eating fish or 
wildlife from contaminated locations.  Children who live near hazardous waste sites should be 
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discouraged from playing in the dirt near these sites because they could contain PBDEs.  
Children should also be discouraged from eating dirt, and careful handwashing practices should 
be followed.  
 
As mentioned in Section 2.3, workplace exposure to PBDEs can occur during the production of 
commercial PBDE mixtures and of PBDE-containing plastic products.  Workers involved in 
recycling plastic products, or who repair computers in confined workplaces can also be exposed 
to PBDEs.  If you are exposed to PBDEs while at work, you may carry them home on your 
clothes or body.  Your occupational health and safety officer at work can tell you whether the 
products you work with may contain PBDEs and whether those are likely to be carried home.  If 
this is the case, you should shower and change clothing before leaving work.  Your work clothes 
should be kept separate from other clothes and laundered separately. 
 
2.8   IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO PBDEs? 
 
Special tests can determine whether PBDEs are in the blood, body fat, and breast milk.  These 
are not regular or routine clinical tests, but could be ordered by a doctor to detect PBDEs in 
people exposed to them in the environment and at work.  If your PBDE levels are higher than the 
normal levels, this will show that you have been exposed to high levels of the chemicals.  
However, these measurements cannot determine the exact amount or type of PBDEs that you 
have been exposed to, or how long you have been exposed.  Blood tests cannot distinguish 
between recent or past exposures to PBDEs because these chemicals remain in the body a long 
time.  Although tests can indicate whether you have been exposed to PBDEs to a greater extent 
than the general population, they do not predict whether you will be harmed.  Blood tests are the 
easiest, safest, and probably the best method for detecting recent exposures to large amounts of 
PBDEs.  Results of such tests should be reviewed and carefully interpreted by physicians with a 
background in environmental and occupational medicine.  Nearly everyone has been exposed to 
pentaBDE commercial mixtures because they are found throughout the environment.  That 
means people are more likely to have detectable amounts of the lower brominated PBDEs in 
their blood, fat, and breast milk.  Recent studies have shown that levels of lower brominated 
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PBDEs in the general population of the United States continue to rise.  The U.S. levels are 10–
100 times higher than levels in individuals living in Europe.    
 
More information on tests used to determine whether you have been exposed to PBDEs can be 
found in Chapter 5 (Section 5.11) and Chapter 9 (Section 9.1). 
 
2.9   WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law.  The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals.  Those levels are then adjusted to levels that will help protect 
humans.  Sometimes these not-to-exceed levels differ among federal organizations because they 
used different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or 
other factors. 
 
Recommendations and regulations are also updated periodically as more information becomes 
available.  For the most current information, check with the federal agency or organization that 
provides it.  Some regulations and recommendations for PBDEs include the following: 
 
EPA requires that companies that transport, store, or dispose of p-bromodiphenyl ether (a 
particular PBDE compound not found in any commercial PBDE product) follow the rules and 
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regulations of the federal hazardous waste management program.  EPA also limits the amount of 
p-bromodiphenyl ether put into publicly owned waste water treatment plants.  To minimize 
exposure of people to p-bromodiphenyl ether, EPA requires that industry tell the National 
Response Center each time 100 pounds or more of p-bromodiphenyl ether have been released to 
the environment.   
 
For more information on federal and state regulations and guidelines for PBDEs, see Chapter 10. 
 
2.10   WHERE CAN I GET MORE INFORMATION? 
 
If you have more questions or concerns about PBDEs, please contact your community or state 
health or environmental quality department, or contact ATSDR at the address and phone number 
below. 
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov/toxpro2.html and on 
CD-ROM.  You may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-
free information and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by 
e-mail at atsdric@cdc.gov, or by writing to:  
 
  Agency for Toxic Substances and Disease Registry 
  Division of Toxicology 
  1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
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Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 














3.  RELEVANCE TO PUBLIC HEALTH—PBBs 
 
3.1   BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PBBs IN THE UNITED 
STATES  
 
Polybrominated biphenyls (PBBs) are brominated organic compounds used as flame retardant additives in 
plastics, textiles, and other materials.  As additives, they are physically mixed into product applications, 
rather than chemically bound.  Therefore, they have the potential to migrate from the plastic matrix into 
the environment when conditions are ideal.  Commercial production of PBBs began in approximately 
1970 and manufacture was discontinued in the United States in 1976, subsequent to a major agricultural 
contamination episode that occurred in Michigan in 1973.  Concern regarding the health effects of PBBs 
is mainly related to exposures that have resulted from the regionally localized Michigan episode.   
 
PBBs are classes of structurally similar brominated hydrocarbons in which 2–10 bromine atoms are 
attached to the molecular structure (i.e., biphenyl).  Monobrominated structures (i.e., one bromine atom 
attached to the molecule) are often included when describing PBBs.  There are 209 different molecular 
combinations, or congeners, that are possible for PBBs.  However, unlike polychlorinated biphenyls 
(PCBs), only a subset of these 209 congeners exists in commercial mixtures.  Based on the number of 
bromine substituents, there are 10 homologous groups of PBB congeners (monobrominated through 
decabrominated), with each homologous group containing one or more isomers.  The mono-, di-, tri-, 
tetra-, penta-, hexa-, hepta-, octa-, nona-, and decabromo- congeners can exist in 3, 12, 24, 42, 46, 42, 24, 
12, 3, and 1 isomers, respectively.  The general chemical structures of PBBs are similar when viewed in 












where m + n = 1–10 
 
Due to the position and number of bromine atoms, there are important three-dimensional differences in 
the structures of PBBs that can influence the molecules’ receptor interactions and toxicological properties 
(see Section 5.5, Mechanisms of Action). 
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People are environmentally exposed to PBBs of different congeneric composition than the source 
commercial mixtures due to differential partitioning and transformation of the individual congeners in the 
environment, including transformation in food animals (e.g., dairy cattle in the case of PBBs).  
Additionally, as discussed in Section 5.4, because PBBs are lipophilic and some congeners are not readily 
metabolized, they are likely to be retained in the body for long periods of time (years). 
 
Three commercial PBB mixtures were manufactured:  hexabromobiphenyl, octabromobiphenyl, and 
decabromobiphenyl.  The two main commercial hexabromobiphenyl PBB mixtures had the trade names 
FireMaster BP-6 and FireMaster FF-1.  FireMaster FF-1 was produced by grinding FireMaster BP-6 and 
adding 2% calcium polysilicate as an anticaking agent.  The hexabromobiphenyl mixtures contained 
varying proportions of di- through octabrominated homologues.  2,2',4,4',5,5'-Hexabromobiphenyl is the 
most abundant congener in the mixtures (53.9–68.0%), followed by 7.0–27.3% of 2,2',3,4,4',5,5'-hepta-
bromobiphenyl.  Commercial octabromobiphenyl mixtures contained a large proportion (47.4–60.0%) of 
nonabromobiphenyl congeners, whereas commercial decabromobiphenyls contain predominately (96.8%) 
decabromobiphenyl congener. 
 
Limited data are available on health effects of commercial decabromobiphenyl and octabromobiphenyl 
mixtures, although the hexabromobiphenyl mixtures FireMaster BP-6 and FireMaster FF-1 have been 
extensively tested.  Most of the information on human health effects of PBBs comes from studies of 
Michigan residents who accidentally ingested milk, meat, and eggs that came from farms that used animal 
feed contaminated with FireMaster FF-1.  In 1973, livestock on certain farms in Michigan were exposed 
to FireMaster FF-1 after it was mistaken as a feed supplement and mixed with feed that was distributed 
within the state for several months before being discovered.  Health problems in dairy cattle, reported in 
the fall of 1973, were the first signs that this episode occurred, but the accidental addition of PBBs to 
animal feed was not identified as the cause of the problem until the spring of 1974. 
 
Available information on the metabolism of PBBs in livestock is insufficient to ascertain whether the 
people affected in Michigan ingested the original PBB mixtures or metabolic products of the PBBs.  
Based on limited information in dairy cattle and additional data in laboratory animals as discussed in 
Section 5.4.2.2, it is reasonable to assume that mainly unchanged penta-, hexa-, and heptabromobiphenyl 
congeners were consumed in animal products during the contamination episode.  PBBs were excreted in 
cattle manure and, as such, were also environmentally distributed in Michigan via waste disposal on 
farms.  The general population outside of Michigan could possibly have been exposed to PBBs by the 
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oral route via the food chain, and the inhalation and dermal routes represent the most likely routes of 
exposure to PBBs in occupational settings. 
 
3.2   SUMMARY OF HEALTH EFFECTS  
 
Most of the information on human health effects of PBBs comes from studies of Michigan populations 
where PBB-contaminated cattle feed accidentally led to entrance into the feed/food chain, and some 
information is available on health effects in PPB-exposed chemical workers.  Although the human studies 
consist largely of observations on groups that are not well defined and lack accurate intake data, they do 
provide a picture of the health status of the affected people and an indication of potential effects for the 
general population who may be exposed to lower levels of PBBs.  Thus far, there is little convincing 
evidence linking exposure to PBBs and adverse health effects in Michigan farm residents.  A variety of 
symptoms (e.g., neurological and neuropsychiatric, gastrointestinal, hepatic, dermal, and musculoskeletal) 
have been reported, but the prevalence of these symptoms has not been definitively linked to the extent or 
types of exposure.  Other reported effects in humans include neurodevelopmental effects in exposed 
children and immunological changes.  Physical examinations and laboratory tests have shown few 
abnormalities that corresponded to the complaints, and prevalences of symptoms have not been correlated 
with serum PBB levels.  However, the possibility of long-term effects cannot be ruled out.  
 
Most toxicity studies of PBBs in animals involved oral exposure, and numerous effects have been 
documented including hepatic, renal, dermal/ocular, immunological, neurological, and developmental.  
Other effects of oral exposure to PBBs include decreased thyroid function, body weight loss, and liver 
cancer.  Adverse hepatic effects, as well as dermal and ocular effects, also have been observed in a 
limited number of dermal studies in animals.  No significant adverse effects were observed in animal 
inhalation studies of PBBs, but only two studies have been conducted, and the mixtures that were tested 
(octabromobiphenyl and decabromobiphenyl) are not the lower brominated products (i.e., Firemaster 
mixtures) expected to be the most toxic based on oral data.  A number of PBB effects are dioxin-like and 
consistent with the Ah receptor-mediated mechanism of action, including altered vitamin A homeostasis, 
thymic atrophy, dermal and ocular effects (e.g., chloracne and inflammation of eyelids), and body weight 
changes (wasting syndrome).  The main health effects of PBBs are discussed in detail below. 
 
Thyroid Effects.    The thyroid gland is an unequivocal target of PBBs in animals, and evidence in 
humans is suggestive of a similar relationship.  Effects in workers exposed to unspecified PBBs and/or 
decabromobiphenyl included increased serum thyrotropin, low or borderline low serum thyroxine (T4), 
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and increased thyroid antimicrosomal antibody titers.  A spectrum of effects has been observed in rats 
exposed for acute and intermediate durations, ranging from decreases in serum levels of serum T4 and 
serum triiodothyronine (T3) to histological and ultrastructural changes in the follicles.  The preponderance 
of these studies tested FireMaster FF-1 or FireMaster BP-6 in rats, although chronic exposure to 
FireMaster FF-1 induced thyroid follicular hyperplasia in mice.  Similar thyroid effects also occurred in 
offspring of treated rats and pigs. 
 
Thyroid effects were produced in rats in acute-duration studies at doses as low as 3 mg/kg/day (reduced 
serum levels of T4 hormone), but not at 1 mg/kg/day, and in rats in intermediate-duration studies at doses 
as low as 0.05 mg/kg/day (increased number and decreased size of follicles).  No information is available 
on possible changes in thyroid hormones following chronic exposure.  Histological examinations in 
chronic-duration studies found no thyroid alterations in rats at doses as high as 1.5 mg/kg/day (highest 
tested dose), although follicular cell hyperplasia was induced in mice at ≥1.3 mg/kg/day.  The no-
observed-adverse-effect level (NOAEL) of 1 mg/kg/day was used as the basis for an acute-duration 
minimal risk level (MRL) for oral exposure.  The acute-duration lowest-observed-adverse-effect level 
(LOAEL) for hepatic effects is identical to the LOAEL for acute thyroid toxicity, but is a less appropriate 
basis for the MRL because organ functional implications are not as clear.  The intermediate-duration 
LOAELs for thyroid and hepatic effects are also comparable to each other, but neither of these LOAELs 
is suitable for an intermediate MRL because reproductive and developmental toxicity occurred at a lower 
dosage.  The thyroid LOAEL for chronic-duration exposure is unsuitable for deriving a chronic MRL 
because decreased survival occurred at the same dose (lower doses were not tested), and thyroid, liver, 
and other effects occurred at lower doses in intermediate-duration studies. 
 
Hepatic Effects.    Histologically and ultrastructurally documented liver damage is a consistent and 
prominent finding among animals exposed to PBBs by the oral route, but studies of Michigan residents 
who were likely to have ingested PBB-contaminated food are inconclusive.  The human studies do not 
demonstrate any clear association between abnormal liver-associated serum indices (serum glutamic-
oxaloacetic transaminase [SGOT], serum glutamic pyruvic transaminase [SGPT], lactic dehydrogenase 
[LDH], bilirubin) or liver enlargement and PBB exposure.  No information is available on hepatic effects 
of PBBs in humans exposed by the inhalation or dermal routes.  Although the available studies on liver 
effects in humans are largely inconclusive, the animal data, as summarized below, suggest that humans 
may also be affected. 
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Hepatic effects ranging from microsomal enzyme induction and liver enlargement to fatty changes and 
necrosis have been observed in rodents and other laboratory animal species exposed orally to FireMaster 
PBBs in acute-, intermediate-, and/or chronic-duration studies.  Acute- and intermediate-duration oral 
data for octabromobiphenyl mixtures are only available for rats and suggest that hepatic histopathologic 
effects are milder than for FireMaster mixtures at similar doses.  Similarly, intermediate-duration oral 
data for decabromobiphenyl mixture suggest that this PBB mixture is a less potent hepatotoxicant than an 
octabromobiphenyl mixture.  No pathologic effects were reported in the liver of rats exposed to an 
octabromobiphenyl mixture in acute- and intermediate-duration inhalation studies, or in an intermediate-
duration study with a decabromobiphenyl mixture, but it is unclear if histology was evaluated following 
the intermediate-duration octabromobiphenyl mixture exposure.  Acute dermal exposure to commercial 
mixtures of hexabromobiphenyl, but not octabromobiphenyl, has been reported to produce gross necrotic 
changes in the liver of rabbits.  Hepatocyte enlargement and degenerative changes (vacuoles or necrosis) 
are the most sensitive adverse hepatic effects that have been observed in the acute-, intermediate-, and 
chronic-duration oral studies with FireMaster PBBs.  The lowest hepatic LOAELs for acute and 
intermediate durations are identical or essentially the same as the LOAELs for thyroid effects.  The acute-
duration LOAEL for thyroid toxicity is used as the basis for an acute oral MRL, but neither hepatic nor 
thyroid LOAELs for intermediate-duration exposure are suitable for MRL derivation because 
reproductive and developmental toxicity occurred at a lower dosage.  Hepatotoxicity occurred at the 
lowest dosage tested in chronic studies with rats and mice, and the hepatic LOAEL in mice also caused 
thyroid effects.  Neither the rat nor the mouse LOAEL is a suitable basis for a chronic MRL, however, 
due to decreased survival at the same dosage and weight loss and developmental toxicity in monkeys at a 
lower chronic dosage. 
 
Altered vitamin A homeostasis, primarily manifested as decreased hepatic storage of vitamin A, is 
another established effect of PBBs in animals.  Vitamin A is essential for normal growth and cell 
differentiation, particularly differentiation of epithelial cells, and some PBB-induced epithelial lesions 
resemble those produced by vitamin A deficiency.  Because it is the primary storage site for vitamin A, 
the liver has a major role in retinol metabolism.  Esterification of dietary vitamin A, hydrolysis of stored 
vitamin A, mobilization and release into the blood of vitamin A bound to retinol-binding protein, and 
much of the synthesis of retinol-binding protein occurs in the liver. 
 
Immunological and Lymphoreticular Effects.    Altered lymphocyte transformation responses 
among populations exposed to PBB following the Michigan contamination episode have been reported by 
some investigators.  Others have not been able to confirm these findings.  However, it is clear that no 
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correlation can be established between altered immune parameters and PBB levels in serum.  Some have 
suggested that PBBs associated with white blood cells is possibly the cause of the immunological 
dysfunction resulting from exposure to PBBs.  This would imply that total PBB in plasma is not 
necessarily a good marker for immune dysfunction.  Continuous examination of this cohort may resolve 
the controversy. 
 
Studies in animals, mostly intermediate-duration studies in rodents, indicate that a variety of 
immunological parameters such as spleen and thymus weights, antibody production, and lympho-
proliferative responses can be affected by treatment with commercial PBB mixtures.  The only chronic 
study found increased splenic hematopoiesis in mice, but no histological changes in the spleen, thymus, 
or lymph nodes of rats.  It is apparent, however, that some of these effects are only seen at PBB levels that 
cause overt toxicity.  Steroids are known to influence the immune response.  Corticosterone levels were 
elevated in plasma of mice that were exposed to FireMaster BP-6 in the diet for 30 days, although the 
increase was not enough to be responsible for the observed immunological effect (reduced antibody-
mediated response to sheep red blood cells).  Thymic atrophy and a reduction in lymphocyte markers 
were reported in cows treated with PBB doses of 67 mg/kg/day for ≤60 days.  However, these results 
should be interpreted with caution since the animals approached death at this dose.  Based on the data 
available, it is difficult to suggest any particular species as the most sensitive.  This is because different 
studies usually examined different end points, using different exposure protocols.  It is unclear whether 
morphological changes in the reticuloendothelial system are more sensitive indicators of altered immune 
status than are functional changes.  Although the limited data on humans are largely inconclusive, PBBs 
have altered immune responses in a variety of animal species, which suggests that humans may also be 
affected. 
 
Neurological Effects.    Data from studies on Michigan residents exposed to PBBs as a result of the 
1973 feed contamination episode and data from a limited number of animal studies both suggest that 
exposure to PBBs may cause subtle effects on neuropsychological performance and development in 
humans.  Symptoms of neurological effects, including fatigue, weakness, and decrements in the capacity 
to perform physical or intellectual work, were reported frequently by groups of farm families and 
residents of Michigan who were likely to have consumed farm products (milk, meat, and eggs) 
contaminated with PBBs; however, associations between PBB levels in serum or fat and the frequency of 
subjectively reported neurological symptoms were not found in several studies.  The administration of 
neuropsychological tests to orally-exposed Michigan residents has not revealed abnormalities or 
associations between test performance and PBB levels in serum or fat.  Similarly, no association between 
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performance in neuropsychological tests and serum PBB levels was made in a study of a small number of 
chemical workers exposed to unspecified PBBs via inhalation and/or dermal contact. 
 
Examinations of a small number of children (19) believed to have been exposed in utero or in early 
infancy during the peak of the Michigan PBB-feed contamination episode have not found consistent or 
marked effects on neuropsychological development.  One study found a statistically significant 
association between performance in neuropsychological development tests and PBB levels in adipose 
tissues when the children were ≈2.5–4 years old, but a later examination when the children were ≈4–
6 years old did not find such an association for the same tests. 
 
Studies with rats have shown that oral exposure to PBBs at dose levels of ≈10 mg/kg/day for intermediate 
durations (1–6 months) produced decreased motor activity and weakness of the hind limb, but not operant 
behavior deficits or histopathological alterations of brain or spinal nerve tissue.  Performance deficits in 
tests of learning behavior were observed in the offspring of female rats and female mice treated with oral 
doses of PBBs at approximate daily dose levels ranging from 0.2 to 10 mg/kg during gestation and 
lactation.  Effects on acquisition of forward locomotion, cliff avoidance, cage emergence, and open-field 
activity were found in offspring of rats that were exposed to 2 mg/kg/day from day 6 of gestation through 
day 24 postpartum and observed until postnatal day 60. 
 
Dermal and Ocular Effects.    Dermal lesions characterized as acne have been observed in humans 
occupationally exposed to PBBs.  Increased prevalences of skin disorder symptoms, including rashes, 
acne, darkening or thickening of the skin, discoloration or deformity of fingernails or toenails, peeling and 
scaling, erythema, and hair loss, were reported by Michigan residents who were likely to have ingested 
PBB contaminated food.  There was no association between serum PBB levels and prevalence of 
symptoms in one study, but physical examinations in the other study confirmed a slightly increased 
incidence of alopecia.  Polymer fibers containing octabromobiphenyl mixture caused no dermal effects 
when placed on covered human skin for 6 days. 
 
Acute-, intermediate-, and chronic-duration oral studies have found no histological alterations in the skin, 
pinnae, ear canals, or salivary glands of rats or mice exposed to FireMaster FF-1 or FireMaster BP-6.  
Alopecia, loss of eyelashes, generalized subcutaneous edema, dry scaly skin, and periorbital edema 
developed in three monkeys that were exposed to low doses of FireMaster FF-1 for several months; 
related histological findings included sebaceous gland atrophy and metaplasia and keratinization of hair 
follicles.  Uncharacterized dermatosis was observed in similarly treated pigs.  Hyperkeratosis of the 
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eyelids and metaplasia of the tarsal glands with keratin cysts developed in cows that ingested FireMaster 
BP-6 for up to 60 days.  Acute dermal application of FireMaster FF-1 induced hyperkeratosis, dilation 
and keratinization of hair follicles, and partial atrophy of the sebaceous glands in rabbits, but effects of 
octabromobiphenyl and decabromobiphenyl mixtures were generally mild (slight erythema and edema).  
Octabromobiphenyl mixture was not a sensitizer when applied to guinea pig skin.  Although somewhat 
limited, the animal and human data are generally consistent and indicate that although PBBs can cause 
local responses such as irritation by direct dermal contact, exposure does not need to occur by the dermal 
route to produce cutaneous effects. 
 
Unspecified signs of ocular irritation were observed in rats intermittently exposed to a high (5,000 mg/m3) 
dust concentration of decabromobiphenyl mixture for 4 weeks, but severity was not reported, and 
recovery was not assessed.  Octabromobiphenyl and decabromobiphenyl mixtures caused mild eye 
irritation in rabbits when applied as a dry solid.  Histopathological changes have not been observed in the 
eyes of rats or mice exposed orally to FireMaster FF-1 or FireMaster BP-6 in studies of acute, 
intermediate, or chronic duration.  Xerophthalmia (extreme dryness of the conjunctiva) was reported in 
rats fed FireMaster BP-6 in an intermediate-duration study.  Based on effects in animals, direct exposure 
to PBBs is likely to be irritating to human eyes. 
 
Body Weight Effects.    Animal studies provide strong evidence that oral exposure to FireMaster 
PBBs causes a wasting syndrome characterized by progressive decreased weight gain, with immediate 
moderate to severe body weight loss generally preceding death.  Effects on body weight have been 
observed in single dose, intermediate- and chronic-duration oral studies with rats, mice, guinea pigs, 
mink, monkeys, and/or cows.  Changes in body weight were also observed in rabbits following acute 
dermal exposure to commercial mixtures hexabromobiphenyl, but not octabromobiphenyl, suggesting that 
the syndrome is independent of exposure route and is a potential effect of PBBs in humans.  
 
Reproductive Effects.    A limited amount of data is available regarding the reproductive effects of 
PBBs in humans.  The distribution of sperm counts, sperm motility, and sperm morphology was 
investigated in a small number (50) of male Michigan residents who ingested food produced on PBB-
contaminated farms or who worked in a PBB manufacturing company.  The study found no evidence for 
PBB-related effects compared with a putatively unexposed control group.  No relationship was found 
between serum PBB levels and frequency and duration of breast-feeding in a retrospective study of 
women exposed to PBBs during the Michigan episode.  A study of fetal mortality rates in Michigan 
counties did not include data for fetal mortalities occurring during the first trimester of pregnancy. 
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Animal studies provide limited evidence that FireMaster FF-1 and FireMaster BP-6 PBBs cause adverse 
reproductive effects in a variety of species.  Increased menstrual cycle duration and prolonged 
implantation bleeding were observed in female monkeys fed approximate daily dose levels of 
0.012 mg/kg for 7 months before breeding and during pregnancy.  A corresponding decrease in serum 
levels of progesterone suggests that the reproductive effects in the monkeys are related to PBB-induced 
endocrine imbalance.  This dosage (0.012 mg/kg/day) is the lowest tested in any intermediate-duration 
study and also caused fetal deaths in the monkeys after ≈1 year of exposure.  Although the reproductive 
effects are less serious, concern for serious developmental toxicity following exposures of <1 year 
precludes deriving an MRL for intermediate-duration exposure.  Implantation was completely blocked in 
40–67% of female rats treated with gavage dose levels ≥28.6 mg/kg on alternate days between gestation 
days 0 and 14.  Alterations in male reproductive organs were observed at doses that caused death in male 
rats (necrosis of the epithelial lining of the ductus deferens after 100 mg/kg for 4–5 weeks) and in a 
monkey (hypoactive seminiferous tubules after ≈0.73 mg/kg/day for 25 weeks).  No alterations in litter 
size or fertility were observed in a study of male and female minks fed ≤0.39 mg/kg/day for 6–7 months 
prior to breeding and during pregnancy or in the F1 or F2 generations of female parental rats fed as much 
as 5 mg/kg/day during the postimplantation phase of gestation and through weaning. 
 
Based on the observations of adverse effects on reproduction in animals exposed to PBBs, the possibility 
that PBBs may cause reproductive harm in humans cannot be refuted and suggests that exposure of 
women to PBBs prior to and during the early phases of pregnancy may be of particular concern. 
 
Developmental Effects.    Consistent or marked abnormalities have not been found in examinations of 
the physical and neuropsychological development of children exposed in utero or in early infancy during 
the peak of the Michigan PBB episode.  Likewise, a comparison of fetal mortality rates for Michigan 
counties with a high percentage of quarantined farms and those for Michigan counties with no 
quarantined farms did not clearly establish or refute the possibility that the Michigan PBB episode caused 
developmental problems in exposed people. 
 
Fetotoxic and developmental effects have been observed in studies of FireMaster FF-1 or FireMaster 
BP-6 in several species of laboratory animals.  Embryolethal effects or increased mortality among nursing 
young were observed in rats after oral exposure during gestation and in monkeys after exposure before 
conception and during pregnancy.  Because the dosage (0.012 mg/kg/day) causing these serious 
developmental effects in monkeys is the lowest tested in any chronic study of PBBs, it is not possible to 
PBBs and PBDEs  32 
 








derive an MRL for chronic-duration exposure.  Structural malformations in fetuses, including cleft palate, 
were also observed in rats and mice after exposure to these PBBs during gestation.  Increased incidences 
of fetuses with extra ribs were reported in a study of rats orally exposed to commercial 
octabromobiphenyl mixture during gestation, but oral exposure to commercial decabromobiphenyl 
mixture was not embryotoxic, fetotoxic, or teratogenic in rats.  Studies with FireMaster FF-1 and 
FireMaster BP-6 found that body weight gain was reduced in the offspring of rats and mice after exposure 
during gestation, in rat offspring after exposure during gestation and lactation, and in mink kits after 
parental exposure before and during pregnancy.  Liver effects, including increased liver weight and 
hepatic cytochrome P-450 enzymic activity, hepatocyte enlargement, vacuolization, and other 
degenerative changes, were observed in the offspring of rats, mice, and/or swine fed FireMaster FF-1 or 
FireMaster BP-6 during gestation and/or lactation.  Performance deficits in tests of operant behavior were 
observed in offspring of rats and mice after oral exposure to FireMaster FF-1 or FireMaster BP-6 during 
pregnancy and lactation. 
 
Although the available human data regarding developmental effects of PBBs are inconclusive, the results 
from animal studies strongly suggest that PBBs may cause mild to severe developmental effects in 
humans, including growth retardation, alteration of neuropsychological development, and structural 
malformations. 
 
Cancer.    There is no epidemiological evidence of an association between exposure to PBBs and 
increased prevalence of cancer (all sites) in Michigan residents who were likely to have ingested PBB-
contaminated food.  These data are inconclusive due to a short latency period of 4 years.  Suggestive 
relationships between increasing serum levels of PBBs and risks of breast cancer, digestive system 
cancer, and lymphoma (not otherwise specified) were found in case-control studies of Michigan PBB 
registry enrollees who were followed for approximately 20 years. 
 
Oral studies with rats and mice demonstrate that FireMaster FF-1 is an unequivocal hepatocarcinogen.  
Hepatocellular adenomas, carcinomas, and/or liver neoplastic nodules were induced in these species 
following single or repeated (intermediate- and chronic-duration) exposures.  These types of liver 
neoplasms even developed in the offspring of rats administered a single gavage dose during gestation or 
offspring of mice treated by diet during the perinatal period (throughout gestation and lactation).  Liver 
neoplasm incidences were much higher in rats and mice exposed for up to 2 years in the only chronic 
bioassay than in the other studies that involved shorter-duration exposures of up to 6 months followed by 
an observation period of up to 2 years.  Based on findings in male rats and mice of both sexes in this 
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study, there is some evidence that combined perinatal and adult dietary exposure to FireMaster FF-1 
enhanced the susceptibility of hepatocellular neoplasms in animals receiving adult exposure.   
 
Tumors were not clearly or consistently observed in nonhepatic tissues of animals exposed to FireMaster 
FF-1.  Induction of thyroid follicular cell adenoma was inconclusive in mice in both National Toxicology 
Program bioassays.  Equivocal increases in incidences of mononuclear cell leukemia were observed in 
adult-only exposed rats in the NTP chronic study, and combined perinatal and adult exposure showed no 
significant increase.  Combined analysis of the incidences of this leukemia in the adult-only, perinatal 
only, and combined perinatal and adult exposure groups, however, showed an apparent association 
between increasing incidences and dose, and incidences in some of the groups exceeded historical control 
ranges.  Evidence is available that oral administration of FireMaster BP-6 promotes development of 
initiated tumors in rats (liver enzyme-altered foci assays) and hamsters (tracheal papilloma assay).  
 
Based on the results of the oral studies of FireMaster FF-1 in rats, there is sufficient evidence to conclude 
that PBBs are carcinogenic in animals and potentially carcinogenic in humans.  PBBs, as a group, have 
been classified as possibly carcinogenic to humans by IARC (Group 2B).  This classification is based on 
sufficient evidence for carcinogenicity to animals and inadequate evidence of carcinogenesis in humans.  
NTP concluded that PBBs are reasonably anticipated to be human carcinogens based on sufficient 
evidence of carcinogenicity in animals.  The EPA has not classified the carcinogenicity of PBBs.  
Because there is insufficient information about which constituents of the PBB mixtures are carcinogenic 
and the congener profile to which people may be exposed environmentally is likely to be different from 
the original PBB source, it is assumed that PBB mixtures of any composition are potentially carcinogenic.  
This assumption has uncertainty since it cannot be verified with current knowledge, and because the 
mechanism of PBB carcinogenesis in rodents has not been definitively elucidated. 
 
3.3   MINIMAL RISK LEVELS  
 
A number of the toxic effects of PBBs, including immunotoxicity, inhibition of body weight gain, and 
hepatic changes, appear to be mediated by a common mechanism of toxic action that involves a specific 
cytosolic molecular receptor (Ah receptor) (see Chapter 5, Section 5.5.2, Mechanisms of Toxicity).  
Although numerous factors can influence the toxicity of PBBs; including differences in absorption, 
distribution, and retention among animal species, at the tissue level, the potency of some individual 
congeners is determined by the magnitude of the response that is initiated by its binding with the Ah 
receptor.  The binding affinity, in turn, is determined by the substitution pattern of the congener, and 
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many of the most toxic congeners resemble the structural configuration of 2,3,7,8-TCDD, and therefore 
are dioxin-like in toxicity.  However, congeners that exhibit Ah receptor-mediated responses constitute a 
fraction of the components in commercial PBB mixtures.  Therefore, it is presumed that congeners that 
act by other mechanisms also contribute to the toxicity of PBB mixtures, and the toxicity of PBBs is 
commonly classified as either “dioxin-like” or “nondioxin-like.”  The mechanism(s) of toxicity for 
nondioxin-like PBB congeners is less clearly elucidated, but also may involve receptors (e.g., the estrogen 
receptor), or the involvement of reactive intermediates (e.g., arene oxides) that can form potentially toxic 
covalently bound substrate-macromolecular adducts. 
 
People are environmentally exposed to PBB mixtures of different congeneric composition than the 
original commercial PBB products.  Although the toxicity or potency of environmental PBB mixtures 
consequently may be greater or less than that of commercial mixtures, there are insufficient mixture 
toxicity data on which to directly base MRLs for environmental PBBs.  Due to the likelihoods that 
(1) multiple mechanisms (Ah-receptor-dependent mechanisms, Ah-receptor independent mechanisms, or 
both) may be involved in health effects induced by PBBs, (2) different PBB congeners may produce 
effects by different mechanisms, and (3) humans are exposed to complex mixtures of interacting PBBs 
with differing biological activities, as well as to the lack of a suitable approach for quantitatively 
evaluating joint toxic action from concurrent exposures to PBBs and other structurally similarly 
compounds (e.g., PCBs, CDDs, CDFs, and PBDEs) in the environment, data from commercial PBB 




No MRLs have been derived for inhalation exposure to PBBs because human and animal data for all 
durations are either insufficient or lacking.  Insufficiencies in the human inhalation data include mixed-
chemical and unquantified exposures.  The animal inhalation database is limited by inadequately reported 




• An MRL of 0.01 mg/kg/day has been derived for acute oral exposure (14 days or less) to PBBs. 
 
The acute oral MRL was based on a NOAEL for decreased serum levels of thyroid T4 hormone identified 
in groups of 8–11 male rats that were treated with 0, 1, 3, or 6 mg/kg/day doses of an unspecified mixture 
of PBBs in lecithin liposomes by gavage for 10 days (Allen-Rowlands et al. 1981).  The MRL was 
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estimated by dividing the NOAEL by an uncertainty factor of 100 (component factors of 10 for animal to 
human extrapolation and 10 for human variability).  Levels of serum T4 were significantly (p<0.05) 
reduced at ≥3 mg/kg/day, indicating that the lowest dose (1 mg/kg/day) is the NOAEL.  Despite the fact 
that an appropriate statistical test (t-test rather than an ANOVA with multiple comparison tests) was used 
to analyze the data, ATSDR is confident with the designation of the NOAEL and LOAEL values.  The 
data in the manuscript are presented graphically, with the animal numbers presented as a range (8–
11 animals/group); thus, an ANOVA could not be performed from published report.  However, using the 
graphical data, the change in plasma T4 levels in the 3 mg/kg/day groups is clearly on the order of 20–
30%, which represents a biologically significant change.  As such, the identification of 3 mg/kg/day as a 
LOAEL, and 1 mg/kg/day as a NOAEL, is not contraindicated by the lack of appropriate statistical 
analysis. 
 
Decreased serum T4 is considered adverse due to unequivocal evidence from numerous studies that the 
thyroid is a target of PBBs with a spectrum of effects, including decreases in serum T3 and T4 hormone, 
thyroid enlargement, effects in the follicular cells (e.g., reduced size, hyperplasia with columnar 
appearance and papillary projections), and accumulation of colloid droplets (Akoso et al. 1982b; Byrne et 
al. 1987; NTP 1983; Gupta and Moore 1979; Kasza et al. 1978a; Norris et al. 1975a, 1975b; Sepkovic and 
Byrne 1984; Sleight et al. 1978).  Additional information on the derivation of the acute-duration oral 
MRL for PBBs is provided in Appendix A. 
 
Intermediate- and chronic-duration oral MRLs were not derived because serious developmental and 
reproductive effects were observed in monkeys that had been exposed to PBBs for durations that spanned 
the intermediate and chronic categories at the lowest dose tested in the database.  This dose 
(0.012 mg/kg/day) caused increased menstrual cycle duration and implantation bleeding after 6–7 months 
of exposure and fetal deaths (fetal abortion and stillbirth) after ≈1 year of exposure in monkeys, with 
surviving infants having decreased birth weight and decreased postnatal weight gain (Allen et al. 1978, 
1979; Lambrecht et al. 1978).  Additionally, weight loss occurred in the maternal monkeys.  The 
0.012 mg/kg/day serious LOAEL for developmental and reproductive effects is lower than the lowest less 
serious LOAELs for thyroid effects in rats (0.05 mg/kg/day) (Akoso et al. 1982b) and hepatic effects in 
guinea pigs (0.04 mg/kg/day) (Sleight and Sanger 1976).  As the most sensitive effect seen following 
intermediate-duration oral exposure was a serious LOAEL, without an accompanying NOAEL, concern 
for serious developmental and reproductive toxicity following exposures of <1 year therefore precludes 
deriving an MRL for intermediate-duration exposure.  Derivation of an MRL for chronic oral exposure is 
similarly precluded by the serious developmental effect (stillbirth) that occurred following exposures 
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exceeding 1 year in duration.  The serious LOAEL in monkeys is lower than the lowest chronic dosages 
tested in other species (0.5 and 1.3 mg/kg/day in rats and mice, respectively) that caused decreased 
survival (NTP 1992).  ATSDR’s classification of LOAELs into less serious and serious effects is 
discussed in the introduction to Section 5.2.   
 
 










4.  RELEVANCE TO PUBLIC HEALTH—PBDEs 
 
4.1   BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PBDEs IN THE UNITED 
STATES  
 
Polybrominated diphenyl ethers (PBDEs) are brominated organic compounds used as flame retardant 
additives in plastics, textiles, and other materials.  As additives, they are physically mixed into product 
applications, rather than chemically bound.  Therefore, they have the potential to migrate from the plastic 
matrix into the environment when conditions are ideal.  Production of PBDEs began in the 1970s and has 
continued to the present.  Concern for the possible health effects of PBDEs has heightened recently due to 
evidence that components of pentabromodiphenyl ether (pentaBDE) commercial mixtures are 
ubiquitously distributed at very low levels in the environment, biota, human tissues, and breast milk.  
Body-burden data indicate that the general population is exposed to low levels of primarily lower 
brominated (e.g., tetra- and penta-) BDEs.  For example, the median concentrations of BDE 47, BDE 153, 
BDE 183, BDE 209, and total PBDEs (sum of four congeners) were 0.63, 0.35, 0.17, <1, and 2.2 ng/g 
lipid weight, respectively.  DecaBDE was found at levels above the limit of quantification (1 pmol/g 
lipid).  Environmental concentrations of lower brominated PBDEs (i.e., tetraBDE and pentaBDE) appear 
to be leveling off in Europe, but appear to be increasing in certain areas in Canada and the United States, 
although data are too sparse to make broad statements regarding trends.  The concentration of total 
PBDEs in air ranges from 5.5 pg/m3 in rural environments to 52 pg/m3 in urban air.  Because PBDEs are 
hydrophobic in nature, this class of compounds has not been detected in water to any significant extent.  
Environmental concentrations of higher brominated commercial mixtures (e.g., decabromodiphenyl ether 
or decaBDE) are principally concentrated in soils and sediment near industrial point sources. 
 
PBDEs are classes of structurally similar brominated hydrocarbons in which 2–10 bromine atoms are 
attached to the molecular structure (i.e., diphenyl ether).  Monobrominated structures (i.e., one bromine 
atom attached to the molecule) are often included when describing PBDEs.  There are 209 different 
molecular combinations, or congeners, that are possible for PBDEs, although only a limited number exist 
in commercial mixtures.  Based on the number of bromine substituents, there are 10 homologous groups 
of PBDE congeners (monobrominated through decabrominated), with each homologous group containing 
one or more isomers.  The mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, and decabromo-
congeners can exist in 3, 12, 24, 42, 46, 42, 24, 12, 3, and 1 isomers, respectively.  The general chemical 
structure of PBDEs is shown below: 
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where m + n = 1–10 
 
Due to the ether linkage and the position and number of bromine atoms, there are important three-
dimensional differences in the structures of PBDEs that can influence the molecules’ receptor interactions 
and toxicological properties as discussed in Section 5.5, Mechanisms of Action.  In general, PBDEs are 
not expected to have the same array of three-dimensional conformations as either PBBs or 
polychlorinated biphenyls (PCBs).  
 
People are environmentally exposed to PBDEs of different congeneric composition than the source 
commercial mixtures, which have specific congeneric compositions.  People are also environmentally 
exposed to lower brominated PBDEs (e.g., tetra- and penta- brominated congeners) due to differential 
partitioning and transformation of the individual congeners in the environment, including transformation 
in food animals.  Additionally, as discussed in Section 5.4, because PBDEs are lipophilic and some 
congeners are not readily metabolized, they are likely to be retained in the body for long periods of time 
(years). 
 
Three commercial PBDE mixtures have been and continue to be produced:  decaBDE, octaBDE, and 
pentaBDE.  DecaBDE has accounted for more than 80% of world PBDE usage.  The composition of 
commercial decaBDE is ≥97% decaBDE, with the remainder mainly nonabromodiphenyl ether 
(nonaBDE).  Commercial octaBDE is a mixture of congeners ranging from hexabromodiphenyl ether 
(hexaBDE) to nonaBDE, and mixtures of pentaBDE are comprised of tetrabromodiphenyl ether 
(tetraBDE) to hexaBDE congeners.  Congeners with less than four bromine atoms are generally not found 
in commercial PBDEs.  The main isomers in the commercial pentaBDE product are 2,2’,4,4’,5-penta-
bromodiphenyl ether (i.e., 2,2',4,4',5-pentaBDE or BDE 99; see Section 6-1) and 2,2’,4,4’-tetrabromo-
diphenyl ether (i.e., 2,2',4,4'-tetraBDE or BDE 47; see Section 6-1).  DecaBDE seems to be largely 
resistant to environmental degradation.  However, there is very little information on the environmental 
degradation of decaBDEs and the data that exist are controversial.  Octa- and pentaBDE commercial 
mixture components, that have a total of four or less bromines, likely undergo differential partitioning 
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(e.g., bioconcentration in aquatic organisms) and possibly some type of transformation process (e.g., 
photodegradation) as well.  The octa- and pentaBDE mixture components have more readily yielded the 
predominance of lower-brominated tetra- and penta-congeners, particularly BDE 47, BDE 99, and 
2,2’,4,4’,6-pentaBDE (i.e., 2,2’,4,4’,6-pentaBDE or BDE 100; see Section 6.1), which have been detected 
in environmental and human tissue samples (including breast milk).  Most studies indicate that levels of 
lower brominated BDEs in body fluids are a factor of 10–100 higher for individuals living in the United 
States compared to individuals living in other regions of the world (e.g., Europe).  The main source of 
human exposure to lower brominated PBDE congeners may be from dietary intake, particularly from 
foods with high fat content (e.g., fatty fish).  Lower-brominated tetra- and penta- congeners have been 
detected in air samples, including those taken from remote areas, indicating that inhalation may also be a 
potential exposure route for the general population. 
 
4.2   SUMMARY OF HEALTH EFFECTS  
 
Information is available on the potential health effects of all three classes of commercial PBDE products, 
i.e., decaBDE (also referred to as DBDPO), octaBDE, and pentaBDE.  As subsequently discussed, the 
toxicity of decaBDE is generally much less pronounced than for octa- and pentaBDE commercial 
products following acute and repeated-dose exposures.  This dissimilar toxicity is likely related to the 
preferential accumulation of lower brominated congeners in the body, due to their greater partitioning and 
retention in lipid-rich tissues and lower rates of metabolism and elimination relative to decaBDE.  In 
particular, in comparison with the lower brominated mixtures, oral studies in rats found that decaBDE is 
minimally absorbed (0.3–2%), has a relatively short half-life (<24 hours), and is rapidly eliminated via 
fecal excretion (>99% in 72 hours).  These toxicokinetic differences appear to be related to the number 
and location of bromines on the diphenyl oxide molecule, and correlate with environmental monitoring 
data indicating that decaBDE has low bioaccumulation potential.  Three-dimensional differences in 
molecular structure might also contribute to the dissimilar toxicity between congeners (see discussions in 
Section 4.3 and Section 5.5.2). 
 
The preponderance of health effects data on PBDEs is from studies of orally exposed laboratory animals.  
Based on the information summarized below and detailed in Chapter 5 (Health Effects), the animal data 
indicate that decaBDE is much less likely than lower brominated PBDEs to cause health effects in 
humans, and that main targets of concern for lower brominated PBDEs in humans are the liver, thyroid, 
and neurobehavioral development.  Intermediate- and chronic-duration oral studies in rats and mice found 
that penta- and octaBDE commercial mixtures caused effects mainly in the liver and thyroid, particularly 
PBBs and PBDEs  40 
 








enlargement and histological alterations in both organs and changes in serum levels of thyroid hormones.  
Little information is available on potential neurotoxic effects of PBDEs.  PBDEs have not been tested for 
neurotoxicity using comprehensive test batteries, and most studies used a single dose level of a single 
congener.  Mild impairments in spontaneous motor behavior and learning and memory were found in 
mice that were exposed to single low doses of 2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE 
(BDE 99), 2,2',4,4',5,5’-hexaBDE (BDE 153), and/or 2,2',3,3’,4,4',5,5’,6,6’-decaBDE (BDE 209) during 
perinatal and/or early postnatal periods and tested later in life.  Concern for neurodevelopmental toxicity 
of PBDEs is further raised by the documented effects of lower brominated commercial mixtures  on 
thyroid hormone homeostasis, and critical involvement of thyroid hormones in central nervous system 
development..  Several acute-duration studies with commercial pentaBDE mixtures and the single 
congener, 2,2’,4,4’-tetraBDE (BDE 47), suggest that immune suppression might be another important 
health end point for lower brominated BDEs, although comprehensive immunological evaluations have 
not been performed on any congener or commercial mixture.  Information on the reproductive toxicity of 
PBDEs is limited to a one-generation study of a low-purity decaBDE product (77.4% decaBDE, 21.8% 
nonaBDE, 0.8% octaBDE) in rats that found no exposure-related functional effects.  Developmental 
toxicity studies have shown no evidence of teratogenicity of penta- and octaBDEs in rats and rabbits, 
although fetotoxic effects, including skeletal ossification variations at maternally toxic doses, have 
occurred.  No fetotoxic or teratogenic effects were induced in rats exposed to high, but not maternally 
toxic, doses of commercial decaBDE.  Information on the carcinogenicity of PBDEs is limited to one 
chronic oral study of decaBDE and one chronic oral study of lower-brominated PBDEs.  The decaBDE 
study found that lifetime exposure to a high-purity commercial product decaBDE caused neoplastic 
changes in the liver, including neoplastic nodules in rats and hepatocellular adenomas and carcinomas in 
mice.  Equivocal increases in thyroid gland follicular cell tumors were also observed in mice.  The study 
of lower brominated PBDEs used a former commercial product containing 77.4% decaBDE, 21.8% 
nonaBDE, and 0.8% octaBDE.  No neoplastic effects occurred in rats exposed to this mixture for 
approximately 2 years, but the power of this study to detect carcinogenic effects is limited by very low 
dose levels and testing of only one species.  The weight of available genotoxicity evidence indicates that 
PBDEs are not genotoxic.  Dermal application studies in rabbits showed that decaBDE, octaBDE, and 
pentaBDE were nonirritating to intact skin and caused some erythematous and edematous responses in 
abraded skin.  DecaBDE was not a skin sensitizer in humans and octaBDE and pentaBDE were 
nonsensitizing in guinea pigs, indicating that the PBDEs did not cause delayed contact hypersensitivity.  
 
Thyroid Effects.    Limited information is available on thyroid effects in PBDE-exposed humans.  
There are suggestive occupational data as shown by effects that included increased serum thyroid 
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stimulating hormone (TSH), low or borderline low serum T4, and increased thyroid antimicrosomal 
antibody titers in workers exposed to decaBDE and/or unspecified PBBs.  Due to the mixed nature of the 
exposure, the possible effects cannot be solely attributed to either chemical.  There was no clear 
association between plasma levels of BDE 47 and thyroid hormone levels (free and total T3 and T4, TSH, 
free testosterone, follicle-stimulating hormone, lutenizing hormone, and prolactin) in men who consumed 
varying amounts of fatty fish from the Baltic Sea.  Based on evidence in animals as summarized below, 
the thyroid is particularly sensitive to lower brominated PBDEs and a possible target of toxicity in 
exposed humans. 
 
Thyroid effects, which mainly included reduced serum T4 hormone levels and follicular cell hyperplasia, 
were consistently observed in rats and mice orally exposed to lower brominated commercial PBDE 
mixtures.  Accompanying changes in serum TSH levels were not found, and the depression of serum T4 
seems to involve enhanced metabolic formation of hydroxylated metabolites of PBDEs, which bind with 
high affinity to thyroid transport proteins.  Acute duration studies showed decreases in serum T4 in rats 
exposed to ≥10 mg/kg/day octaBDE or ≥30 mg/kg/day pentaBDE for 4 days and in rats and mice exposed 
to ≥18 mg/kg/day pentaBDE for 14 days.  Effects observed in intermediate-duration studies included 
thyroid hyperplasia in rats exposed to ≥8 mg/kg/day octaBDE for 30 days and reduced serum T4 in rats 
exposed to ≥10 mg/kg/day pentaBDE for 90 days.  Exposure to pentaBDE on gestation day 6 through 
postnatal day 21 caused serum T4 reductions at 30 mg/kg/day in maternal rats and ≥10 mg/kg/day in their 
fetuses and neonatal offspring.  Intermediate-duration exposure to a 77% decaBDE/22% nonaBDE 
commercial mixture caused thyroid hyperplasia in rats at doses ≥80 mg/kg/day for 30 days.  Chronic 
(103-week) exposure to a high-purity (≥97%) commercial decaBDE mixture did not induce thyroid 
histopathological changes in rats at ≤2,550 mg/kg/day, although follicular cell hyperplasia was increased 
in mice exposed to 2,240 mg/kg/day of the same commercial product. 
 
The extent that PBDEs affect circulating levels of T4 or T3 might vary with species and rats are often 
regarded as more sensitive than humans.  The main basis for this opinion seems to be studies showing that 
PBDEs affect binding of thyroid hormones to transthyretin (TTR), the primary transport protein in rats.  
Because TTR is not the major transport protein in humans, the findings have been interpreted as evidence 
that humans will be less sensitive than rats to thryoid effects of PBDEs.  As discussed in Section 5.5.3, 
the greater sensitivity of rats is thought to be related to a smaller and more rapid turnover of the hormone 
pool in the rat thyroid, and to a more rapid clearance of secreted hormone in the rat; the latter being, in 
part, related to the absence of thyroid binding globulin (TBG) in rats.  Whereas TTR is the major thyroid 
hormone binding protein in rats, TBG is the main binding protein in humans and most other mammals.  
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However, although TTR is not the main transport protein in human serum, it is the principal protein 
involved in transport of T4 to the brain in both rats and man.  Therefore, without specific evidence that 
rats are more sensitive to PBDEs than humans, and considering the importance of TTR for the transport 
of thyroid hormones in the human brain, it is misleading to assume that PBDEs are unlikely to affect 
thyroid function in humans, or that humans are less sensitive to these effects than rats. 
 
Neurological Effects.    A limited amount of information is available on neurological effects of 
commercial PBDE mixtures.  No clinical signs of neurotoxicity or neurohistopathology were observed in 
rats or mice exposed to commercial decaBDE in dietary doses as high as 16,000–19,000 mg/kg/day for 
14 days, 8,000–9,000 mg/kg/day for 13 weeks, or 2,550–7,780 mg/kg/day for 103 weeks.  Although the 
high doses and extended exposure durations provided opportunities for the induction and/or development 
of clinical signs, the study is limited by lack of testing for subtle behavioral changes and neuro-
developmental effects.  A commercial pentaBDE mixture was evaluated for several behavioral end points 
in offspring of rats that were perinatally exposed to 1–100 mg/kg/day by gavage on gestation day (GD) 
6 through postnatal day (PND) 21.  Evaluation of the offspring as adults showed no alterations in motor 
or sensory development as assessed by motor activity, habituation, and auditory startle response, although 
suggestive decreases in fear conditioning were observed.   
 
Neurobehavioral effects of individual PBDE congeners were evaluated in mice that were exposed during 
perinatal and/or early postnatal periods to 2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE (BDE 99), 
2,2',4,4',5,5’-hexaBDE (BDE 153), or 2,2',3,3’,4,4',5,5’,6,6’-decaBDE (BDE 209).  Most of these studies 
used similar single oral dose experimental designs and evaluated spontaneous motor behavior and swim 
maze performance at 2–6 months of age.  The findings collectively indicate that the nervous system is a 
target of particular PBDE congeners during a defined critical phase of neonatal brain development, as 
shown by mild impairments in spontaneous motor behavior and learning and memory in older mice.  One 
study used a different experimental design in which mice were exposed to BDE 99 from GD 6 to 
PND 21, and evaluated using a variety of somatic (body weight gain, hair growth, day of eyelid and ear 
opening, day of incisor eruption) and neurobehavioral (righting reflex, forelimb stick grasping reflex, 
forelimb placing reflexes, negative geotaxis, screen grasping and climbing, pole grasping, ultrasonic 
vocalizations, homing test) end points during PNDs 2–22, as well as spontaneous activity end points on 
PNDs 22–120.  Findings were suggestive of delayed sensorimotor development and altered spontaneous 
behavior.  Based on the limited available information (most of the studies were reported as abstracts), and 
considering the known effects of lower brominated PBDEs on thyroid hormone homeostasis and the 
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critical role that thyroid hormones play in development of the central nervous system, neurobehavioral 
development is a potential effect of concern for lower brominated PBDEs in humans.  
 
Hepatic Effects.    The hepatotoxic potential of lower brominated PBDE mixtures is well-documented 
in animals by oral exposure.  The spectrum of observed hepatic effects includes microsomal enzyme 
induction, liver enlargement, and degenerative histopathologic alterations that progress to tumors.  
Repeated dietary exposure to PBDEs typically caused liver enlargement with or without degenerative 
changes, and effects were generally dose-related in incidence and severity, more frequent and pronounced 
in males than females, and more severe with octaBDE and pentaBDE than decaBDE.  For example, 
subchronic oral studies in rats showed that commercial pentaBDE mixtures were hepatotoxic at doses 
≤10 mg/kg/day.  Increased liver weight and hepatocellular enlargement with vacuolation occurred in rats 
exposed to commercial pentaBDE doses as low as 2–9 mg/kg/day for 4–13 weeks.  Increased incidences 
of degeneration and necrosis of individual hepatocytes were observed 24 weeks following exposure to 
≥2 mg/kg/day of commercial pentaBDE for 90 days in rats.  In contrast, high purity commercial decaBDE 
caused no liver pathology in rats and mice at estimated doses as high as 2,000–8,000 and 2,375–
9,500 mg/kg/day, respectively.  High purity commercial decaBDE caused liver effects only following 
lifetime exposure to doses that were still very high.  Exposure to 94–97% decaBDE for 103 weeks caused 
liver thrombosis and degeneration in rats at 2,240 mg/kg/day, and centrilobular hypertrophy and 
granulomas in mice at ≥3,200 mg/kg/day.  No studies are available on hepatic effects of PBDEs in 
humans.  Based on the evidence in animals, lower brominated PBDEs are potentially hepatotoxic in 
humans. 
 
Immunological and Lymphoreticular Effects.    Information regarding the immunosuppressive 
potential of PBDE mixtures is essentially limited to evidence from acute-duration oral studies of 
pentaBDE in animals.  The plaque-forming splenic cell antibody response to injected sheep red blood 
cells was significantly reduced in mice exposed to 72 mg/kg/day pentaBDE for 14 days; single doses as 
high as 500 mg/kg had no effect.  In the same study, exposure to up to 72 mg/kg/day had no effect on 
natural killer cell (NKC) activity.  In vitro production of IgG immunoglobulin from pokeweed mitogen-
stimulated splenocytes was reduced in mice exposed to 36 mg/kg/day pentaBDE for 14 days.  Other 
14-day studies in mice found no changes in natural killer cell activity to murine YAC-1 target cells at 
≤72 mg/kg/day or numbers of splenic and thymic lymphocyte subsets at ≤36 mg/kg/day, although 
18 mg/kg/day of the single congener BDE 47 caused significantly reduced numbers of total lymphocytes 
and CD4+, CD8+, and CD45R+ subtypes in spleen.  Chronic ingestion of decaBDE caused splenic 
lesions (hematopoiesis, fibrosis, lymphoid hyperplasia) in rats exposed to ≥1,200 mg/kg/day for 
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103 weeks, indicating that it is considerably less immunotoxic than pentaBDE.  No studies are available 
on immunological effects of PBDEs in humans.  Due to the limited amount of data in animals, 
insufficient information is currently available to adequately characterize the human immunotoxic 
potential of PBDEs. 
 
Developmental Effects.    Oral developmental toxicity studies of deca-, octa-, and pentaBDE have 
shown no evidence of teratogenicity in animals.  Gestational exposure to a high (1,000 mg/kg/day) but 
maternally nontoxic dose of decaBDE was fetotoxic in rats as shown by subcutaneous edema and delayed 
skull bone ossification; however, it is of note that this preparation was only 77% decaBDE.  A later study 
of decaBDE, using a >97% pure compound, reported no maternal or fetal toxicity at doses up to 
1,000 mg/kg/day.  Commercial mixtures of octaBDE caused skeletal ossification variations in rats and 
rabbits at maternally toxic levels and other indications of fetotoxicity at lower doses.  Effects of 
gestational exposure to octaBDE included minimally increased postimplantation loss in rats at 
≥10 mg/kg/day, increased resorptions in rats at 25 mg/kg/day, and increased skeletal variations in rabbits 
at 15 mg/kg/day and rats at 50 mg/kg/day.  No evidence of fetotoxicity was found in the only available 
study of pentaBDE in rats at maternally toxic doses ≤200 mg/kg/day.  No studies are available on 
developmental effects of PBDEs in humans.  Based on the evidence in animals, PBDEs are unlikely to 
cause developmental toxicity at expected levels of exposure. 
 
Cancer.    The only information regarding carcinogenicity of PBDEs in humans is available from a case-
control study that found no clear association between risk of non-Hodgkin’s lymphoma and exposure to 
BDE 47 in a small group of Swedish men and women.   
 
For most PBDEs, including pentaBDE and octaBDE, animal studies of carcinogenic effects are not 
available; cancer data on PBDEs in animals are limited to results of studies on commercial decaBDE 
products.  In a bioassay conducted by the NTP, male and female rats were exposed to high purity 
commercial decaBDE (lots that were 96 or 94–97% pure) in the diet in low doses of 1,120 and 
1,200 mg/kg/day, respectively, and high doses of 2,240 and 2,550 mg/kg/day, respectively, for 
103 weeks.  Male and female mice were similarly exposed to low doses of 3,200 and 3,760 mg/kg/day, 
respectively, and high doses of 6,650 and 7,780 mg/kg/day, respectively.  Incidences of neoplastic 
nodules in the liver were significantly increased in the male and female rats, although the term neoplastic 
nodule is poorly defined and understood, and is no longer used by NTP to characterize hepatoproliferative 
lesions in rats.  Incidences of hepatocellular adenoma or carcinoma (combined) were significantly 
increased in the male mice.  Slightly elevated incidences of thyroid gland follicular cell adenoma or 
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carcinoma (combined) were additionally observed in exposed male mice, although the increases were not 
statistically significant.  Carcinogenicity was additionally evaluated in rats that were exposed to 0.01, 0.1, 
or 1.0 mg/kg/day dietary doses of a 77.4% decaBDE mixture (containing 21.8% nonaBDPO and 0.8% 
octaDBDPO) for approximately 2 years.  No exposure-related neoplastic changes were found, but the 
power of this study to detect carcinogenic effects is limited by the very low dose levels in comparison to 
those tested in the NTP bioassay. 
 
Based on the limited evidence of carcinogenicity in animals in the NTP bioassay (significantly increased 
incidences of neoplastic liver nodules in rats and combined hepatocellular adenomas and carcinomas in 
mice), as well as the lack of human data, decaBDE has been classified in EPA Group C (possible human 
carcinogen) and IARC Group 3 (not classifiable as to its carcinogenicity to humans).  EPA Group D 
classifications (not classifiable as to human carcinogenicity) were assigned to nona-, octa-, hexa-, penta-, 
tetra-, tri-, and p,p’-diBDE based on no human data and no or inadequate animal data.  The U.S. 
Department of Health and Human Services has not classified the carcinogenicity of any PBDE mixture. 
 
4.3   MINIMAL RISK LEVELS (MRLs) 
 
PBDEs share some toxicological properties with other structurally similar polyhalogenated aromatic 
compounds, particularly PBBs, PCBs, chlorinated dibenzo-p-dioxins (CDDs), and chlorinated 
dibenzofurans (CDFs) (Agency for Toxic Substances and Disease Registry 1994, 1998, 2000).  However, 
although these chemicals are structurally similar in two dimensions, PBDEs (and PCDEs) differ from the 
other classes on a three-dimensional basis.  In particular, the oxygen bridge of the ether linkage in the 
diphenyl oxide molecule increases the distance between the biphenyl rings.  This apparently reduces 
steric interactions between ortho substituents on the adjacent rings, such that the presence of ortho 
bromines is unlikely to present a barrier to rotation that would prevent the two aromatic rings from 
assuming a fully coplanar configuration (Chen et al. 2001; Hardy 2002b; Howie et al. 1990).  In other 
words, the ether bridge makes PBDEs more noncoplanar in nature, and introducing ortho substitutions 
into PBDEs does not create a spatial impediment for the two phenyl rings to assume a semi-flat position 
with respect to each other, as it does for PBBs or PCBs.  Therefore, for PBDEs, the influences of the ether 
bridge and bromine position preclude clearly classifying the congeners as either dioxin-like (coplanar) or 
nondioxin-like (noncoplanar).  This has implications not only for dioxin-type toxicities, which are 
mediated by the Ah (aryl hydrocarbon) receptor (AhR) pathway (and therefore might not be a significant 
issue for PBDEs), but also for nondioxin-type effects.  The assumption that PBDEs share many 
toxicological characteristics with PCBs also does not consider geometrical differences due to the higher 
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atomic weight and considerably larger molecular volume of bromine compared to chlorine (Hardy 2000, 
2002b).  These differences contribute to dissimilar physical/chemical properties that can influence the 
relative toxicokinetics and toxicities of the chemicals.  The geometrical differences in bromine and 
chlorine also have implications for understanding the mechanism(s) of effects for nondioxin-like PBB 
congeners, which are not as well characterized as for PCBs.  In particular, it cannot necessarily be 
assumed, on the basis of two-dimensional structure, that the mechanisms and effects for nondioxin-like 
PBBs and PCBs are similar. 
 
People are environmentally exposed to PBDE mixtures of different congeneric composition than the 
original commercial PBDE products.  Although the toxicity or potency of environmental mixtures of 
congeners consequently might be greater or less than that of the original commercial PBDE product, there 
are insufficient mixture toxicity data on which to directly base MRLs for environmental PBDEs.  Due to 
the likelihoods that (1) multiple mechanisms (Ah-receptor-dependent mechanisms, Ah-receptor 
independent mechanisms, or both) may be involved in health effects induced by PBDEs, (2) different 
PBDE congeners may produce effects by different mechanisms, and (3) humans are exposed to complex 
mixtures of interacting PBDEs with differing biological activities, as well as to the lack of a suitable 
approach for quantitatively evaluating joint toxic action from concurrent exposures to PBDEs, PBBs, 
PCBs, CDDs, and/or CDFs in the environment, data from commercial PBDE mixtures are used to 
develop MRLs for assessing health risks from environmental exposures to PBDEs. 
 
There are important differences in the environmental chemistry and toxicity of decaBDE compared to 
lower brominated BDEs.  DecaBDE seems to be largely resistant to environmental degradation, whereas 
octa- and pentaBDE commercial mixture components are likely to undergo differential partitioning and 
transformation, such that tetra- and pentaBDEs are the predominant congeneric forms that have been 
detected in the environment.  Tetra- and pentaBDE congeners are also the main PBDEs in human tissues 
(blood, adipose, and breast milk), and BDE 47, BDE 99, and BDE 100 are particularly prevalent in both 
environmental and biological samples.  The preferential accumulation of the lower brominated BDEs is 
likely due to their partitioning and retention in lipid-rich tissues; decaDBE does not appreciably partition 
into lipid-rich tissues and has higher rates of metabolism and elimination.  These characteristics seem to 
be a function of both the number and location of bromines on the diphenyl oxide molecule.  The tetra- and 
pentaBDEs appear to be relatively well absorbed, whereas the fully brominated decaBDE, a large poorly 
soluble molecule, is very poorly absorbed (≈1% or less of an oral dose) and rapidly eliminated (≈99% of 
the dose within 72 hours).  Further, decaBDE is significantly less toxic than lower brominated BDE 
mixtures.  For example, subchronic oral studies in rats showed that commercial octa- or pentaBDE 
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mixtures were hepatotoxic at doses as low as 2–10 mg/kg/day, while high purity commercial decaBDE 
caused no liver pathology at doses as high as 8,000–9,500 mg/kg/day (IRDC 1976, 1977; NTP 1986; WIL 
Research Laboratories 1984).  Liver effects (thrombosis and degeneration) of commercial decaBDE in 
rats were only induced following lifetime exposure, and doses were still very high (2,240 mg/kg/day) 
(NTP 1986).  A study in weanling rats showed that acute oral exposure to commercial decaBDE had no 
effect on thyroid hormones, while similar exposures to commercial octaBDE or pentaBDE mixtures 
caused decreases in serum T4 and T3 levels (Zhou et al. 2001).  Similarly, acute postnatal oral exposure to 
pure decaBDE congener (BDE 99) was less potent than BDE 47, BDE 99, and 2,2',4,4',5,5’-hexaBDE 
(BDE 153) in inducing behavioral effects in adult mice (Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 
2001a, 2001b, 2002a, 2002b, 2003b).  Due to the dissimilar toxicity and environmental chemistry of 






No MRLs were derived for acute-, intermediate-, or chronic-duration inhalation exposure to decaBDE 
due to a lack of inhalation studies on this BDE congener. 
 
Lower Brominated BDEs 
 
Derivation of an acute-duration MRL for lower brominated BDEs is not recommended at this time due to 
insufficient information.  The inhalation database for acute-duration exposure to PBDEs is essentially 
limited to two 14-day unpublished industry-sponsored studies of octaBDE in rats (Great Lakes Chemical 
Corporation 1978, 2000).  Liver and nasal effect levels were identified in these studies, but are 
inappropriate bases for MRL estimation.  As discussed below, derivation of an acute MRL is precluded 
by inconsistencies between the studies and a lack of suitable information on thyroid hormone levels or 
another sufficiently sensitive end point. 
 
In the Great Lakes Chemical Corporation (1978) study, groups of five male and five female Charles River 
CD rats were whole-body exposed to dust of an unspecified commercial octaBDE mixture in mean 
analytical concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 for 8 hours/day for 14 consecutive days.  
The average mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of 
the particles were 3.5 µm and 2, respectively.  Study end points included clinical signs (including 
observations for respiratory distress and nasal and ocular irritation), body weight and food consumption, 
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hematology (5 indices), blood chemistry (5 indices, thyroid hormones not assessed), urinalysis 
(10 indices), organ weights (5 organs including thyroid/parathyroid), gross pathology, and histology 
(21 tissues including nasal turbinates, trachea, lungs, and thyroid).  The clinical laboratory tests were 
limited to rats in the control and two highest dose groups.  The histological exams were limited to the 
control and highest dose groups, except for the liver, which was examined in all groups.  Signs of 
increased respiration rate (rapid breathing) were observed by the end of each exposure period in rats 
exposed to ≥24 mg/m3; this effect always disappeared by the following morning.  Liver weight was 
significantly increased and hepatic lesions occurred in rats exposed to ≥3.7 mg/m3.  At 3.7 mg/m3, the 
liver lesions consisted of very slight to slight, focal to multifocal cytoplasmic enlargement of the 
hepatocytes, accompanied by focal acidophilic degeneration of individual to small groups of cells.  The 
liver lesions were similar in the higher dose groups except that that the hepatocyte enlargement was 
multifocal to diffuse in distribution, and the presence of focal, small to large areas of hepatocellular 
necrosis of very slight to marked degree.  There were no exposure-related histological changes in other 
tissues. 
 
The Great Lakes Chemical Corporation (2000) study is currently only available as a secondary summary.  
This study was summarized in a recent European Union Risk Assessment Report (EU 2003a), but a report 
is not currently available in the Toxic Substances Control Act Test Submissions (TSCATS) database.  
The only pertinent information in the TSCATS database (as of March 2004) is a notice that the study was 
initiated (Great Lakes Chemical Corporation 2000), strongly suggesting that the completed study was 
never submitted. 
 
In the Great Lakes Chemical Corporation (2000) study, a commercial octaBDE product (bromine content 
78.7%, not otherwise identified) was administered to groups of five male and five female Crl:CD(SD)IGS 
BR rats, by nose-only inhalation as a dust aerosol, in measured concentrations of 0 (air only), 1.0, 10, 
110, or 250 mg/m3 for 6 hours/day, 5 days/week, for 2 weeks.  MMADs in the low to high level groups 
were 2.9, 3.2, 2.9, and 2.9 µm; GSDs were not reported in the available study summary.  Clinical signs, 
body weight, food consumption, and survival were evaluated throughout the study.  Hematology, serum 
chemistry, urine indices, and thyroid hormones were not assessed.  Necropsies, organ weight 
measurements, and histological examinations were performed following exposure termination.  The 
histological examinations included nasal cavity, larynx, trachea, lungs, liver, kidneys, adrenals, brain, 
spleen, testes, and ovaries, but excluded thyroid and heart.  Exposure-related effects occurred in the liver 
and nasal cavity.  Hepatic effects included increased mean absolute and/or relative liver weights at 
≥10 mg/m3 in males and ≥110 mg/m3 in females, with the greatest increases at 110 and 250 mg/m3 (21–
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44%).  Centribobular hypertrophy similarly occurred in the liver at ≥10 mg/m3 in both sexes (100% 
incidences in all groups except 4/5 females at 10 mg/m3).  Nasal effects included minimal to mild Goblet 
cell hyperplasia and/or hypertrophy at ≥1 mg/m3 in males and ≥10 mg/m3 in females.  The nasal Goblet 
cell hyperplasia/hypertrophy occurred in nasal levels II and III in males at 1 mg/m3, and generally in nasal 
levels II–VI in both sexes at ≥10 mg/m3.  No changes were found in the remaining squamous, respiratory, 
and olfactory nasal epithelia, or other parts of the respiratory tract. 
 
As detailed above, hepatocellular hypertrophy was found at concentrations at ≥3.7 mg/m3 in the Great 
Lakes Chemical Corporation (1978) study and ≥10 mg/m3 in the Great Lakes Chemical Corporation 
(2000) study.  This liver effect was accompanied by some degenerative hepatocellular changes in the 
1978 study, but this was not confirmed by the later study.  Additionally, slight histological changes in 
nasal Goblet cells occurred at ≥1 mg/m3 in the Great Lakes Chemical Corporation (2000) study, but there 
were no nasal effects in the earlier study.  Interpretation of the significance and adversity of the liver and 
nasal alterations is complicated by the inconsistency of findings between the studies and other factors, 
including the small numbers of animals per study (five/sex/level) and different methods of inhalation 
exposure (whole-body versus nose-only).  Additionally, a well designed 13-week study (Great Lakes 
Chemical Corporation 2001a, 2001b) found (1) hepatocellular hypertrophy, but no degenerative liver 
changes, at higher a minimum effect level (16 mg/m3) than in both 14-day studies, and (2) no clearly 
exposure-related changes in nasal Goblet cells at concentrations below 202 mg/m3 (study summarized in 
intermediate MRL section).  Further, the adversity of the slight nasal Goblet cell changes, which were 
predominantly minimal in severity and possibly suggestive of very slight nasal irritation in both the 
14-day and 13-week studies, is unclear.   
 
The available information indicates that there are insufficient bases for considering the hepatic and nasal 
changes as adverse acute effects.  More importantly, exposure to ≥16 mg/m3 caused changes in serum 
levels of thyroid hormones (decreased T3, increased TSH) in the 13-week study.  Thyroid hormone levels 
were not determined in either of the 14-day studies.  Therefore, due to the lack thyroid hormone data in 
the 14-day studies, as well as the lack of any clear lowest-observed-adverse-effect levels (LOAELs) for 
the other end points in the 14-day studies, particularly at exposures levels below the LOAEL for thyroid 
effects in the 13-week study, there is no sufficiently sensitive basis for derivation of an MRL for acute-
duration exposure. 
 
• An MRL of 0.006 mg/m3 has been derived for intermediate-duration inhalation exposure (15–
364 days) to lower brominated BDEs. 
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The intermediate-duration inhalation MRL is based on a no-observed-adverse-effect level (NOAEL) of 
1.1 mg/m3 for changes in thyroid hormones in rats that were intermittently exposed to octaBDE for 
13 weeks (Great Lakes Chemical Corporation 2001a, 2001b).  Calculation of the MRL is detailed below. 
 
The inhalation database for intermediate-duration exposure to PBDEs consists of one well-conducted 
13-week study (Great Lakes Chemical Corporation 2001a, 2001b).  This is an unpublished industry-
sponsored study in which a commercial octaBDE product (bromine content 78.7%) was administered to 
groups of 10 male and 10 female Crl:CD(SD)IGS BR rats, via nose-only inhalation as a dust aerosol, in 
measured concentrations of 0 (air only), 1.1, 16, or 202 mg/m3 for 6 hours/day, 5 days/week, for 
13 weeks.  The mean MMADs in the low to high exposure groups were 2.0, 2.7, and 2.8 µm, and the 
corresponding mean GSDs were 3.37, 3.72, and 3.01.  Clinical and physical signs, body weight, food 
consumption, and survival were evaluated throughout the study.  Ophthalmic, hematology (11 indices), 
serum chemistry (18 indices), and serum thyroid hormone (TSH, total T3, and total T4) evaluations were 
performed near the end of the exposure period.  Urinalyses were not conducted.  Comprehensive 
necropies, organ weight measurements, and histological examinations (including respiratory tract and 
thyroid) were performed following exposure termination.   
 
Hepatic, nasal, lung, thyroid, and ovarian effects were observed (Great Lakes Chemical Corporation 
2001a, 2001b).  The liver was affected in both sexes as shown by dose-related increases in centrilobular 
hepatocellular hypertrophy at ≥16 mg/m3 and liver weight (absolute and relative) at 202 mg/m3.  Total 
incidences of centrilobular hepatocellular hypertrophy in the 0, 1.1, 16, and 202 mg/m3 groups were 1/10, 
0/10, 3/10, and 10/10 in males, and 0/10, 0/10, 3/10, and 6/10 in females; severity was predominantly 
minimal in all groups and was not dose-related.  Changes in nasal Goblet cells were increased at 
202 mg/m3, but showed no clear dose-related increasing trends for incidence or severity.  Total incidences 
of nasal Goblet cell hypertrophy were slightly increased in nasal level II of both sexes at ≥1.1 mg/m3; 
incidences in the 0, 1.1, 16, and 202 mg/m3 exposure groups were 4/10 (all minimal), 9/10 (7 minimal, 
2 mild), 6/10 (all minimal), and 10/10 (9 minimal, 1 mild) in males, and 2/10 (all minimal), 6/10 (all 
minimal), 4/10 (all minimal), and 8/10 (all minimal) in females.  Nasal Goblet cell hypertrophy was also 
slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 0/10, 1/10, and 8/10, all minimal 
severity, not increased in females).  Histological changes in the lungs included alveolar histiocytosis and 
chronic active inflammation that were only clearly increased in incidence at 202 mg/m3.  Total incidences 
of alveolar histiocytosis at 0, 1.1, 16, and 202 mg/m3 were 3/10, 5/10, 5/10, and 10/10 in males, and 0/10, 
5/10, 2/10, and 10/10 in females.  Corresponding total incidences of chronic active lung inflammation 
were 0/10, 0/10, 2/10, and 10/10 in males, and 0/10, 1/10, 1/10, and 10/10 in females.  The severity of 
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both lesion types tended to increase from minimal to mild/moderate at 202 mg/m3.  Gross lung changes 
also occurred in both sexes at 202 mg/m3; these included lung firmness and white discoloration and/or 
enlargement in the bronchial and/or mediastinal lymph nodes.  The lymph node effects correlated with the 
histological finding of granulomatous inflammation.  There were no exposure-related gross or 
histopathological changes in the spleen, bone marrow, thymus, or other tissues, including thyroid.  
Thyroid hormone assessments, however, showed exposure-related decreases in mean thyroxine (total T4) 
at ≥16 mg/m3 in both sexes, and increases in TSH at ≥16 mg/m3 in males and 202 mg/m3 in females.  The 
changes were usually statistically significant (p<0.05 or p<0.01) compared to controls and were 
considered to be consistent with chemical-induced hypothyroidism.  There were no serum T3 changes.  
Qualitative histological evaluations of step sections of ovaries showed an absence of corpora lutea in 
3/10 females at 202 mg/m3, compared to 0/10 in the control and lower exposure groups.  This 30% 
incidence was interpreted to be a treatment-related effect because an absence of corpora lutea was 
considered unusual in rats at 20 weeks of age.  
 
Considering the questionable adversity of minimal severity nasal Goblet cell hypertrophy, lack of clear 
dose-related increasing trends for incidences and severity of this nasal effect, clear identification of both a 
NOAEL (1.1 mg/m3) and LOAEL (16 mg/m3) for changes in serum levels of thyroid hormones, and 
abundant evidence for thyroid effects of PBDEs in oral studies, the effects on thyroid hormones are the 
most appropriate basis for estimation of an intermediate-duration inhalation MRL.  The MRL of 
0.006 mg/m3 was derived by dividing the NOAELHEC of 0.53 mg/m3 by an uncertainty factor of 30 (3 for 
species to species extrapolation with dosimetric adjustments and 10 for human variability) and a 
modifying factor of 3 (for an incomplete database reflecting a single study in one species).  The 
NOAELHEC was calculated using the following equations: 
 
 NOAELADJ = 1.1 mg/m3 x 6 hours/24 hours x 5 days/7 days = 0.196 mg/m3 
 NOAELHEC = NOAELADJ x RDDR = 0.196 mg/m3 x 2.7 = 0.53 mg/m3 
 
The RDDR for the extrathoracic (ET) region was used to extrapolate deposited doses in rats to deposited 
doses in humans.  The following parameters were used to calculate the RDDR:  MMAD of 2.0 µm with a 
mean GSD (sigma g) of 3.37, default human body weight of 70 kg, and a default female F344 rat body 
weight of 0.18 kg.  Additional information on the derivation of the intermediate-duration inhalation MRL 
for lower brominated BDEs is provided in Appendix A. 
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No MRL was derived for acute-duration oral exposure to decaBDE due to insufficient data.  Information 
is available on effects of acute exposure on body and liver weights, microsomal enzyme induction in the 
liver, and serum thyroid levels in weanling rats (Carlson 1980b; NTP 1986; Zhou et al. 2001), but the 
database is limited by lack of LOAELs and/or sufficiently sensitive end points. 
 
• An MRL of 10 mg/kg/day has been derived for intermediate-duration oral exposure (15–
364 days) to decabromodiphenyl ether. 
 
The MRL was derived based on a NOAEL of 1,000 mg/kg/day for developmental toxicity in rats exposed 
to decaBDE for 19 days during gestation (Hardy et al. 2002).  The MRL was estimated by dividing the 
NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability).. 
 
A commercial decaBDPE product (97.34% DBDPO, 2.66% nonaBDE and octaBDE) was administered to 
groups of 25 mated female Sprague-Dawley rats by gavage in corn oil in daily doses of 0, 100, 300, or 
1,000 mg/kg/day on gestation days 0 through 19 (Hardy et al. 2002).  Each female was sacrificed on 
gestation day 20 and necropsied.  End points examined included maternal clinical observations, maternal 
body weight/weight gain and food consumption, maternal gravid uterine and liver weights, maternal gross 
lesions, total number of corpora lutea, uterine implantations, early and late resorptions, viable and 
nonviable fetuses, and fetal weight and sex.  Fetuses were examined grossly (all fetuses), evaluated for 
skeletal/cartilaginous malformations and ossification variations (approximately half of each litter), and 
evaluated for visceral malformations (remaining fetuses).  No treatment-related effects on any maternal or 
fetal end points were observed, indicating that 1,000 mg/kg/day was the NOAEL for maternal and 
developmental toxicity. 
 
Only one intermediate-duration systemic toxicity study of high purity decaBDE has been conducted.  In 
this study, a commercial decaBDE product (94B97% pure) was fed to F344 rats (10/sex/level) in 
estimated doses of 496–8,000 mg/kg/day, or B6C3F1 mice (10/sex/level) in estimated dietary doses of 
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589–9,500 mg/kg/day, for 13 weeks (NTP 1986).  All animals were observed daily, weighed weekly, and 
necropsied at the end of the exposure period.  Comprehensive histological examinations were performed, 
but limited to the control and high-dose groups.  No hematology, clinical chemistry, or urine indices, or 
thyroid hormone levels, were evaluated.  There were no compound-related clinical signs, deaths, body 
weight or food consumption changes, gross pathology, or histopathology, indicating that 8,000 and 
9,500 mg/kg/day are intermediate-duration NOAELs for systemic toxicity in rats and mice, respectively.  
As discussed above, the NOAEL for developmental toxicity is 1,000 mg/kg/day (Hardy et al. 2002).  
Because doses of decaBDE higher than 1,000 mg/kg/day have not been tested for developmental toxicity, 
and the NTP (1986) study indicates that this dose is also a NOAEL for systemic toxicity, the 
1,000 mg/kg/day developmental toxicity NOAEL is used as the basis for the MRL.  Additional 
information on the derivation of the intermediate-duration oral MRL for decaBDE is provided in 
Appendix A.  
 
No MRL was derived for chronic-duration oral exposure to decaBDE.  Only one chronic study of high 
purity decaBDE has been conducted.  In this study, a commercial decaBDE product (94B97% pure) was 
fed to F344 rats (50/sex/dose level) in dietary doses of 1,120/1,200 mg/kg/day (males/females) or 
2,240/2,550 mg/kg/day, and B6C3F1 mice (50/sex/dose level) in doses of 3,200/3,760 mg/kg/day or 
6,650/7,780 mg/kg/day, for 103 weeks (NTP 1986).  Animals were examined daily for clinical signs.  
Body weights and food consumption were measured throughout the study, and comprehensive gross and 
histological examinations were performed on all animals in all dose groups, including those that were 
moribund or died during the study.  No hematology, clinical chemistry, or urine indices, or thyroid 
hormone levels, were evaluated.  Liver degeneration and thrombosis were significantly (p<0.05) 
increased in male rats at 2,240 mg/kg/day; respective incidences in the control, low, and high dose groups 
were 13/50, 19/50, and 22/50 for degeneration, and 1/50, 0/50, and 9/50 for thrombosis.  The thrombosis 
was characterized by a near total occlusion of a major hepatic blood vessel by a dense fibrin coagulum.  
Neoplastic nodules in the liver were increased in males at ≥1,120 mg/kg/day and in females at 
2,550 mg/kg/day in incidences that were dose-related and statistically significant, although no treatment-
related increases in hepatocellular carcinomas were observed.  Other effects in exposed rats included 
fibrosis of the spleen, lymphoid hyperplasia of the mandibular lymph nodes, and acanthosis of the 
forestomach at 2,240 mg/kg/day.  In mice, histopathological changes occurred in 3,200 mg/kg/day in 
males in the liver (centrilobular hypertrophy and granulomas) and thyroid (follicular cell hyperplasia).  
An MRL was not derived because the lowest tested dose, 1,120 mg/kg/day in male rats, is a LOAEL for a 
liver lesion (neoplastic nodules) that is precancerous and associated with thrombosis in the same tissue.    
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Lower Brominated Diphenyl Ethers 
 
• An MRL of 0.03 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
lower brominated diphenyl ethers. 
 
The acute oral MRL is based on a NOAEL of 1 mg/kg/day for reduced serum levels of thyroid T4 
hormone in fetal rats that were exposed to pentaBDE on days 4–20 of gestation (Zhou et al. 2002).  The 
MRL was estimated by dividing the NOAEL by an uncertainty factor of 30 (component factors of 10 for 
animal to human extrapolation and 3 for human variability).  A component factor of 10 was not used for 
human variability because the MRL is based on effects observed in a sensitive subgroup.  Thyroid 
hormone levels were determined in Long-Evans rats that were administered a technical pentaBDE 
mixture (DE-71) in corn oil by gavage from GD 6 through PND 21, except for PND 0 (day of birth) 
(Zhou et al. 2002).  Dams were sacrificed on GD 20 and PND 22, and offspring were sacrificed on GD 20 
and PNDs 4, 14, 36, and 90).  Study end points included serum total T4 and T3 concentrations measured at 
each age point.  The maternal exposure to pentaBDE caused reductions in serum total T4 that were 
significantly (p<0.05) different from controls in dams at 30 mg/kg/day on GD 20 and PND 22 (48 and 
44%, respectively, relative to controls), and in fetuses and offspring at ≥10 mg/kg/day on GD 20 (at least 
15% reduced) and PNDs 4 and 14 (50 and 64% maximal in the 10 and 30 mg/kg/day groups, 
respectively).  The effect on T4 concentrations in the offspring was age-dependent as values returned to 
control levels by PND 36.  There were no exposure-related effects on serum total T3 concentrations in the 
dams or offspring at any time, although T3 was not be measured in fetuses on GD 20 due to insufficient 
serum sample volume.  The critical NOAEL of 1 mg/kg/day and LOAEL of 10 mg/kg/day for reduced 
serum T4 hormone levels in fetal rats that were exposed to pentaBDE (Zhou et al. 2002) are supported by 
a NOAEL of 3 mg/kg/day and a LOAEL of 10 mg/kg/day for reduced serum T4 levels in weanling 
(28-day-old) rats that were exposed to octaBDE for 4 days (Zhou et al. 2001).  Data from other acute-
duration studies of PBDEs that support the selection of the critical NOAEL and LOAEL include a 
NOAEL of 2.5 mg/kg/day and LOAEL of 10 mg/kg/day for fetotoxicity in rats exposed to octaBDE for 
10 days during gestation (Life Science Research Israel Ltd. 1987), a NOAEL of 5 mg/kg/day and LOAEL 
of 15 mg/kg/day for fetotoxicity in rabbits exposed to octaBDE for 13 days during gestation (Breslin et al. 
1989), and LOAELs of 18 mg/kg/day for reduced serum T4 in rats and mice exposed to pentaBDE for 
14 days (Fowles et al. 1994; Hallgren et al. 2001).  Additional information on the derivation of the acute-
duration oral MRL for lower brominated BDEs is provided in Appendix A. 
 
The human relevance of thyroid effects in rats is debatable.  As discussed in the thyroid effects part of 
Section 4.2, mechanistic data indicate that humans are generally less sensitive than rodents because 
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(1) PBDEs likely affect thyroid function by displacing T4 from serum-binding proteins in blood and by 
increasing liver metabolism of thyroid hormones, (2) the major plasma thyroid hormone transporter 
protein in rats, transthyretin (TTR), is only a minor binding protein in humans, and (3) a thyroid hormone 
binding globulin, not TTR, is the major transporter protein in humans (Blay et al. 1993; Capen 1997; 
Sinjari et al. 1998).  The importance of the role of TTR in human thyroid homeostasis is unclear because, 
although it is not is the main transport protein in humans, TTR is necessary for thyroid hormone transport 
to the developing human fetus.  Consequently, it is appropriate to use reduced serum T4 in fetal rats as the 
critical effect for the MRL.  Support for the relevance of this effect is provided by the lack of changes in 
thyroid hormones in the maternal animals at the dose that caused the effect on T4 in the offspring. 
 
• An MRL of 0.007 mg/kg/day has been derived for intermediate-duration oral exposure (15–
364 days) to lower brominated BDEs. 
 
The intermediate oral MRL is based on a LOAEL of 2 mg/kg/day for minimal liver effects in rats that 
were exposed to pentaBDE for 90 days (WIL Research Laboratories 1984).  The MRL was estimated by 
dividing the LOAEL by an uncertainty factor of 300 (component factors of 3 for use of a minimal 
LOAEL, 10 for animal to human extrapolation, and 10 for human variability).  Groups of 30 male and 
30 female Sprague-Dawley rats were exposed to pentaBDE (commercial mixture DE-71) in the diet at 
dosage levels of 0, 2, 10, or 100 mg/kg/day for up to 90 days.  Study end points included clinical signs, 
body weight, food consumption, hematology, clinical chemistry (including serum T3 and T4), urine 
indices, gross pathology, and selected organ weights (brain, gonads, heart, liver, kidneys, thymus, and 
thyroid).  Histological examinations were performed on the liver, thyroid, thymus, kidney, and lung in all 
dose groups and in all tissues (comprehensive evaluation) at 0 and 100 mg/kg/day.  Hepatocytomegaly 
was observed in males at 2 mg/kg/day and in both sexes at ≥10 mg/kg/day.  The hepatocytomegaly was 
similar in incidence and severity after 4 and 13 weeks of exposure, was dose-related with respect to 
severity (some affected hepatocytes had vacuoles that likely contained lipid), and was still observed in 
males at ≥10 mg/kg/day and females at 2 and 100 mg/kg/day at 24 weeks postexposure (in lessened 
severity and incidence).  Examinations at 24 weeks following exposure also showed an increase in 
individual hepatocytes with degeneration and necrosis, effects that were considered to be likely exposure-
related and indicative of final loss of previously damaged cells.  No NOAEL was identified because liver 
changes were observed at all dose levels.  Nonhepatic effects included decreases in serum T4 levels at 
≥10 mg/kg/day and thyroid follicular cell hyperplasia at 100 mg/kg/day.  Based on the observations of 
hypertrophy, mild degeneration, and slight necrosis, 2 mg/kg/day is considered to be a minimal LOAEL 
for liver effects.  Data from other intermediate-duration studies that support selection of the 2 mg/kg/day 
minimal LOAEL include hepatic LOAELs of 5 mg/kg/day for cytomegaly (with vacuolation and necrosis 
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at higher doses) in rats exposed to octaBDE for 13 weeks (IRDC 1977), and 9 mg/kg/day for 
hepatocellular enlargement and increased liver weight in rats exposed to octaBDE or pentaBDE for 
28 days (IRDC 1976).  Other relevant effect levels from intermediate-duration studies include a thyroid 
LOAEL of 10 mg/kg/day for reduced serum T4 levels in fetuses and neonatal offspring of rats that were 
exposed to pentaBDE from GD 6 through PND 21 (Zhou et al. 2002).  Additional information on the 
derivation of the intermediate-duration oral MRL for PBDEs is provided in Appendix A. 
 
A chronic-duration oral MRL was not derived for lower brominated BDEs due to insufficient data.  Only 
one chronic study of PBDEs other than high purity decaBDE has been conducted (Kociba et al. 1975; 
Norris et al. 1975b).  In this study, Sprague-Dawley rats (25/sex/dose level) were fed a 77.4% pure 
commercial decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for approximately 
2 years.  Evaluations that included clinical signs, body weight, food consumption, hematology, clinical 
chemistry, urine indices, and comprehensive histological examinations showed no exposure-related 
effects.  The highest NOAEL is 1 mg/kg/day (highest tested dose), but this NOAEL is not appropriate for 
MRL estimation due to insufficient sensitivity of the study.  In particular, using the NOAEL of 
1 mg/kg/day and an uncertainty factor of 100, a chronic oral MRL based on this study would be 5 times 
higher than the 0.002 mg/kg/day intermediate MRL.  A similar pattern was observed for thyroid effects in 
the study used to derive the acute-duration oral MRL (Zhou et al. 2001) as summarized above.  Due to the 
insufficiencies of the chronic data for MRL derivation, the intermediate oral MRL could be used as a 














5.  HEALTH EFFECTS 
 
5.1  INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of polybrominated 
biphenyls (PBBs) and polybrominated diphenyl ethers (PBDEs).  It contains descriptions and evaluations 
of toxicological studies and epidemiological investigations and provides conclusions, where possible, on 
the relevance of toxicity and toxicokinetic data to public health. 
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
 
PBBs and PBDEs are classes of brominated hydrocarbons that are used as flame retardant additives in 
plastics, textiles, and other materials.  Both classes of chemicals are comprised of compounds in which 1–
10 bromine atoms are attached to the biphenyl structure in up to 209 different combinations.  Based on 
the number of bromine substituents, there are 10 homologous groups of PBBs and PBDEs (mono-
brominated through decabrominated), each containing one or more isomers.  PBBs and PBDEs are 
structurally similar when viewed in one dimension, differing only in the ether linkage between the two 
phenyl rings in PBDEs, but the oxygen bridge confers three-dimensional conformational differences that 
can influence toxicological properties.  Consequently, on the basis of chemical structure, it cannot be 
assumed that the health effects of PBBs and PBDEs are necessarily similar.  
 
Commercial production of PBBs began in approximately 1970, and manufacture was discontinued in the 
United States in 1976 following a contamination episode that occurred in Michigan in 1973–1974.  Three 
main commercial mixtures of PBBs were produced:  hexabromobiphenyl, octabrombiphenyl, and deca-
bromobiphenyl.  The most prevalent hexabromobiphenyl PBB mixtures had the trade names FireMaster 
BP-6 and FireMaster FF-1.  FireMaster FF-1 was produced by grinding FireMaster BP-6 and adding 2% 
calcium polysilicate as an anticaking agent.  The hexabromobiphenyl mixtures contained varying 
proportions (depending on lot number) of di- through octabrominated homologues, and 2,2',4,4',5,5'-hexa-
bromobiphenyl (BB 153) was the most abundant congener (53.9–68.0%) followed by 2,2',3,4,4',5,5'-
heptabromobiphenyl (7.0–27.3%).  Commercial octabromobiphenyl PBB mixtures contained a large 
proportion (47.4–60.0%) of nonabromobiphenyl congeners, whereas commercial decabromobiphenyls 
contained predominately (96.8%) decabromobiphenyl congener.  The general names hexabromobiphenyl, 
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octabromobiphenyl, and decabromobiphenyl are used in this profile to refer to unspecified commercial 
mixtures of these PBBs. 
 
Concern regarding the health effects of PBBs is largely related to exposures that resulted from the 
Michigan contamination episode.  Livestock on farms in Michigan were exposed to FireMaster FF-1 over 
a period of approximately 10 months after it was accidentally mistaken for the feed supplement 
magnesium oxide and mixed with animal feed that was distributed within the state.  Health problems in 
dairy cattle (decreased feed consumption and decreased milk production), reported in the fall of 1973, 
were the first signs that the contamination episode occurred, but accidental addition of PBBs to animal 
feed was not identified as the cause of the problem until late spring of 1974 (Fries 1985a; Jackson and 
Halbert 1974).  The U.S. Food and Drug Administration (FDA) established tolerances of 1 ppm in milk 
and meat fat and 0.1 ppm in eggs in May 1974, which were revised downward to 0.3 and 0.05 ppm, 
respectively, in November 1974 due to improved analytical sensitivity (Dunckel 1975; Fries 1985a).  The 
Michigan Department of Agriculture (MDA) subsequently lowered the FDA tolerance in meat fat from 
0.3 to 0.02 ppm, but there currently are no FDA or MDA tolerances for PBBs (FDA 1989; Fries 1985a).  
As a result of a farm animal testing and quarantining program established by the MDA in May 1974, 
about 30,000 dairy cattle, 2,000 swine, 400 sheep, and over 2,000,000 chickens were found to contain 
PBBs at concentrations requiring their destruction (Dunckel 1975; Fries 1985a; Mercer et al. 1976). 
 
Most of the information that is available on health effects of PBBs in humans comes from studies of 
Michigan residents who ingested milk, meat, and eggs that were produced on farms that used the 
FireMaster-contaminated animal feed.  In the interval of more than 9 months between the accident, the 
detection and identification of its cause, and the beginning of testing and the establishment of quarantines, 
PBB-contaminated food products were consumed, not only by farm families and people that acquired 
produce directly from PBB-contaminated farms, but also by people who purchased food from markets 
(Anderson et al. 1979).  The Michigan PBB contamination episode led to the establishment of 
epidemiological studies (that are still ongoing) of Michigan residents who were expected to have 
consumed PBB-contaminated food, as well as to a substantial increase in research activity regarding the 
health effects of PBBs in cattle, poultry, and laboratory animals.  Compared to the FireMaster 
(commercial hexabromobiphenyl) PBBs, relatively limited data are available on health effects of 
commercial mixtures of octabromobiphenyl and decabromobiphenyl.  Reviews of the research results on 
the toxicity of PBBs include those by Damstra et al. (1982), DiCarlo et al. (1978), Fries (1985a), Kay 
(1977), Kimbrough (1987), Kimbrough et al. (1978a), and WHO (1994a). 
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This profile discusses information regarding health effects of PBBs in humans and laboratory animals; 
some research on cattle and poultry is also discussed, but its relevance to human health effects is 
uncertain due to interspecies physiological differences.  Although the toxicity in livestock from Michigan 
farms that used large amounts of contaminated feed is generally attributed to PBBs, data on effects in 
animals from farms with low PBB contamination have generated some controversy, because the signs of 
toxicosis in these animals have not been reproduced in cattle experimentally exposed to PBBs at levels 
that caused tissue residue concentrations ≈100 times greater than those in the farm animals (Jackson and 
Halbert 1974; Moorhead et al. 1977).  This led some investigators to suggest that some signs of toxicosis 
reported in Michigan cattle reflected farm management procedures, nutritional deficiencies, microbial and 
parasitic infections, or exposure to unknown contaminants in the feed (Durst et al. 1977; Fries 1985a; 
Moorhead et al. 1977).  Although exposure by ingestion occurred during the Michigan contamination 
episode, existing information on the metabolism of PBBs in livestock is insufficient to ascertain whether 
the people ingested PBBs or metabolic products of PBBs.  However, based on available data discussed in 
Section 5.4.2.2, it is reasonable to assume that mainly unchanged penta-, hexa-, and heptabromobiphenyl 
congeners in animal products were consumed. 
 
Unlike PBBs, PBDEs have been continuously produced and used as flame-retardant additives since the 
1970s.  Concern for health effects of PBDEs has heightened due to relatively recent evidence that some 
PBDE congeners have become ubiquitously distributed in the environment and are present in tissues and 
breast milk of the general population at levels that continue to increase.  Three commercial PBDE 
mixtures have been produced:  decabromodiphenyl ether (decaBDE), octabromodiphenyl ether 
(octaBDE), and pentabromodiphenyl ether (pentaBDE).  DecaBDE has accounted for more than 80% of 
PBDE usage.  The composition of commercial decaBDE is ≥97% of the pure congener with the 
remainder mainly nonaBDE.  Commercial octaBDE is a mixture of congeners ranging from nona- to 
hexaBDE, and mixtures of pentaBDE are comprised of tetra-, penta-, and hexaBDE congeners.  
Congeners with less than four bromine atoms are generally not found in commercial PBDEs.  Reviews on 
the health effects and other aspects of PBDEs include those by Darnerud et al. (2001), de Boer et al. 
(2000), de Wit (2002), Hardy (1999, 2002a, 2002b), McDonald (2002), NAS (2002), Rahman et al. 
(2001), Silberhorn et al. (1990), and WHO (1994b).  Penta- and octa-BDEs are apparently being phased 
out of production and use.  Great Lakes Chemical Corporation will cease production of penta- and 
octaBDE by the end of 2004 (Tullo 2003) and the European Union has banned the sale of all products 
containing more than 0.1% (by mass) penta- or octaBDE (EU 2003b). 
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Toxicity data for individual PBB and PBDE congeners are included in some discussions in this profile 
when these data corroborate or provide information on effects not documented for the PBB and PBDE 
mixtures.  Congener-specific toxicity data are currently not practical for determining exposure levels of 
PBB and PBDE mixtures associated with adverse health effects at hazardous waste sites.  This is due in 
part to the fact that standardized analytical procedures for congener mixtures and commercially available 
standards for all congeners are lacking, and congener-specific analyses are not routinely performed.  
Additionally, using current health effects evaluation procedures, toxicity data for individual congeners 
may overestimate or underestimate the actual health risk of PBB and PBDE mixtures because congeners 
vary in toxic potency and may be influenced by other congeners in an additive or less-than-additive way.  
It is also important to recognize that the PBBs and PBDEs to which people may be exposed may be 
different from the original PBB and PBDE source because of possible changes in congener composition 
resulting from differential partitioning and transformation in the environment and/or differential 
biological metabolism and retention. 
 
5.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
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"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.   
 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for PBBs and PBDEs.  An MRL is defined as an estimate of daily human exposure to a substance 
that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified 
duration of exposure.  MRLs are derived when reliable and sufficient data exist to identify the target 
organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of 
exposure.  MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  
MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral 
routes.  Appropriate methodology does not exist to develop MRLs for dermal exposure. 
 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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5.2.1  Inhalation Exposure  
 
A few studies have examined groups of chemical workers involved in the manufacture and distribution of 
PBBs and/or PBDEs (Bahn et al. 1980; Brown et al. 1981; Chanda et al. 1982; Landrigan et al. 1979; 
Rosenman et al. 1979; Stross et al. 1981).  These people are believed to have been exposed predominately 
by dermal contact and inhalation, although the oral route cannot be ruled out.  Results from these studies, 
therefore, are discussed in this section as well as in Section 5.2.3.  The highest NOAEL and all LOAEL 
values from each reliable inhalation study of health effects end points in each species and duration 
category for PBDEs are recorded in Table 5-1 and plotted in Figure 5-1; due to the general lack of data 
regarding inhalation exposure to PBBs, no equivalent table is presented for PBBs. 
 
5.2.1.1  Death  
 
Polybrominated Biphenyls.  No studies were located regarding death in humans after inhalation exposure 
to PBBs. 
 
Nose-only exposure to the highest attainable dust concentration of octabromobiphenyl mixture for 4 hours 
(960 mg/m3 as a time-weighted average) was not lethal to six male rats observed for 7 days (Waritz et al. 
1977).  No deaths occurred in groups of five male and five female rats that were exposed to a decabromo-
biphenyl dust mixture at concentrations ranging from 5 to 5,000 mg/m3 concurrently with starch dust 
(6 mg/m3) for 6 hours/day, 5 days/week for 4 weeks (Millischer et al. 1980).  Information on lethality of 
inhaled hexabromobiphenyl PBB mixtures was not located. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding death in humans after inhalation 
exposure to PBDEs. 
 
No deaths occurred in groups of five male and five female rats that were chamber-exposed to pentaBDE 
aerosol (compound dissolved in corn oil), octaBDE dust, or decaBDE dust in concentrations as high as 
200,000, 60,000, or 48,200 mg/m3, respectively, for 1 hour and observed for the following 14 days (IRDC 
1974, 1975a, 1975b).  Confidence in these studies is limited by a lack of control data.  There was no 
mortality in rats that were exposed to dusts of commercial octaBDE products at levels of 174 mg/m3 for 
8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978), ≤250 mg/m3 for 
6 hours/day, 5 days/week for 14 days (Great Lakes Chemical Corporation 2000), or ≤202 mg/m3 for 
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a The number corresponds to entries in Figure 5 1.
b Used to derive an intermediate-duration (15-364 days) inhalation minimal risk level (MRL) of 0.006 mg/m3 for lower brominated diphenyl ethers.  The MRL was derived by
converting the animal NOAEL of 1.1 mg/m3 to a duration-adjusted human equivalent concentration (NOAELHEC) of 0.53 mg/m3, and dividing by an uncertainty factor of 30 (3 for
species to species extrapolation with dosimetric adjustments and 10 for human variability) and a modifying factor of 3 (for an incomplete data base).
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = female;  gastro = gastrointestinal; hemato = hematological; hr = hour(s); LOAEL = lowest
observed adverse effect level; M = male; metab = metabolic; min = minute; mo = month(s); Musc/skel = muscular/skeletal; NOAEL = no observed adverse effect level; Resp =
respiratory; T4 = thyroxine ; TSH = thyroid stimulating hormone; wk = week(s)
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5.2.1.2  Systemic Effects  
 
Systemic effects that have been observed in humans and animals following inhalation exposure to PBBs 
and PBDEs are described below.   
 
Respiratory Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding respiratory effects in humans after 
inhalation exposure to PBBs. 
 
Slight dyspnea was observed in five male and five female rats that were exposed to a decabromobiphenyl 
dust mixture at 5,000 mg/m3 concurrently with starch dust (6 mg/m3) for 6 hours/day, 5 days/week for 
4 weeks (Millischer et al. 1980).  This effect was not observed at 500 mg/m3 and lower concentrations or 
in air only-exposed controls, and there were no changes in pulmonary resistance and compliance in 
urethane-anesthetized rats, blood gases, and lung histology at any of the exposure levels.  Lung function 
and blood gases were not evaluated in starch-exposed controls, but this is unlikely to be a serious study 
deficiency as the ratio of PBB to starch was ≈1,000 in the high exposure group. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding respiratory effects in humans after 
inhalation exposure to PBDEs. 
 
Transient signs of respiratory distress that included tachynpea or dyspnea developed in rats that were 
chamber-exposed to pentaBDE aerosol (compound dissolved in corn oil), octaBDE dust, or decaBDE 
dust in very high concentrations of 200,000, 60,000, and 48,200 mg/m3, respectively, for 1 hour (IRDC 
1974, 1975a, 1975b).  Confidence in these effect levels is low due to a small number of tested animals 
and lack of control data.   
 
Two 14-day inhalation studies of commercial octaBDE have been conducted.  In one study, rats were 
chamber-exposed to concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 as powdered dust for 8 hours/day 
for 14 consecutive days (Great Lakes Chemical Corporation 1978).  Increased respiration rate occurred at 
≥23.9 mg/m3.  The rapid breathing pattern developed by the end of each exposure period, always 
disappeared by the following morning, and was not observed at lower exposure levels.  Histological 
examinations of the control and 165.2 mg/m3 rats (other groups not examined) showed no changes in 
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tissues that included nasal turbinates, trachea, lungs, and mediastinal lymph nodes).  In the other study, 
rats were nose-only exposed to 0, 1.0, 10, 110, or 250 mg/m3 as dust aerosol for 6 hours/day, 5 days/week 
for 2 weeks (Great Lakes Chemical Corporation 2001a, 2001b).  Histological examinations showed nasal 
alterations, consisting of minimal to mild goblet cell hyperplasia and/or hypertrophy at ≥1 mg/m3 in males 
and ≥10 mg/m3 in females.  The nasal goblet cell changes occurred in nasal levels II and III at 1 mg/m3 
and generally in levels II-VI at ≥10 mg/m3, and were considered indicative of very slight nasal irritation.  
No histopathology in the lungs or toxicolgically significant clinical signs were observed. 
 
Histological changes in the lungs, but not clearly in the nasal cavity, were found in a study of rats that 
were nose-only exposed to 0, 1.1, 16, or 202 mg/m3 as dust aerosol for 6 hours/day, 5 days/week for 
13 weeks (Great Lakes Chemical Corporation 2001a, 2001b).  The pulmonary effects included alveolar 
histiocytosis and chronic active inflammation, occurred in both sexes, and were only clearly induced at 
202 mg/m3.  Total incidences of alveolar histiocytosis in the 0, 1.1, 16, and 202 mg/m3 exposure groups 
were 3/10, 5/10, 5/10, and 10/10 in males, respectively, and 0/10, 5/10, 2/10, and 10/10 in females, 
respectively.  Respective total incidences of chronic active lung inflammation were 0/10, 0/10, 2/10, and 
10/10 in males, and 0/10, 1/10, 1/10, and 10/10 in females.  Both lesions were predominantly minimal or 
mild in severity, with moderate severity occurring in a few high-dose animals.  Additional effects 
included gross pulmonary changes in both sexes at 202 mg/m3; these included lung firmness and white 
discoloration and/or enlargement in the bronchial and/or mediastinal lymph nodes.  The gross lymph node 
changes correlated with the histological granulomatous inflammation.  Effects in nasal tissues were 
equivocal.  Incidences of nasal goblet cell hypertrophy were slightly increased in nasal level II of both 
sexes at ≥1.1 mg/m3, but incidences were not clearly dose-related and there was essentially no increase in 
severity from minimal with increasing dose.  Total incidences of goblet cell hypertrophy in nasal level II 
in the 0, 1.1, 16, and 202 mg/m3 exposure groups were 4/10, 9/10, 6/10, and 10/10 respectively, in males, 
and 2/10, 6/10, 4/10, and 8/10, respectively, in females.  Minimal severity goblet cell hypertrophy was 
also slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 0/10, 1/10, and 8/10), but not in 
females. 
 
Cardiovascular Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding cardiovascular effects in humans or 
animals after inhalation exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding cardiovascular effects in humans 
after inhalation exposure to PBDEs. 
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No histopathological changes were observed in the heart of rats that were exposed to dusts of commercial 
octaBDE products at levels of 174 mg/m3 for 8 hours/day for 14 consecutive days (Great Lakes Chemical 
Corporation 1978), or ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks (Great Lakes Chemical 
Corporation 2001a, 2001b). 
 
Gastrointestinal Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding gastrointestinal effects in humans or 
animals after inhalation exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding gastrointestinal effects in humans 
after inhalation exposure to PBDEs. 
 
No histopathological changes were observed in the stomach and lower gastrointestinal tract tissues of rats 
that were exposed to dusts of commercial octaBDE products at levels of 174 mg/m3 for 8 hours/day for 
14 consecutive days (Great Lakes Chemical Corporation 1978), or ≤202 mg/m3 for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2001a, 2001b).  
 
Hematological Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding hematological effects in humans after 
inhalation exposure to PBBs. 
 
Hematology was normal in groups of five male and five female rats that were exposed to a decabromo-
biphenyl dust mixture at concentrations of 5 or 5,000 mg/m3 concurrently with starch dust (6 mg/m3) for 
6 hours/day, 5 days/week for 4 weeks (Millischer et al. 1980).  The evaluation included erythrocyte and 
leucocyte counts, differential leukocyte count, hematocrit, and hemoglobin level. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding hematological effects in humans 
after inhalation exposure to PBDEs. 
 
No adverse hematological changes occurred in rats that were exposed to 24.4 or 174 mg/m3 of 
commercial octaBDE dust aerosol for 8 hours/day for 14 consecutive days (Great Lakes Chemical 
Corporation 1978).  Evaluation of a limited number of indices (hemoglobin, hematocrit, total erythrocyte 
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count, and total and differential leukocyte counts) showed no remarkable responses except for an 
elevation in leukocyte numbers.  The observed increase in leukocyte counts was considered to be an 
unusual response by the investigators, although it was within the normal range for control rats in their 
laboratory.  Comprehensive hematological assessments showed no unusual changes in rats exposed to 
commercial octaBDE as dust aerosol at concentrations of ≤202 mg/m3 for 6 hours/day, 5 days/week for 
13 weeks (Great Lakes Chemical Corporation 2001a, 2001b). 
 
Hepatic Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding hepatic effects in humans after inhalation 
exposure to PBBs. 
 
No significant (p<0.05) increase in relative liver weight or hepatic histological changes were found in six 
male rats nose-only exposed to a octabromobiphenyl dust mixture at 960 mg/m3 for 4 hours (time-
weighted average, highest attainable concentration), and observed for 7 days (Waritz et al. 1977).  
Toxicity of octabromobiphenyl mixture vapor was investigated in groups of six rats almost continuously 
exposed (23 hours/day, 7 days/week) for 2, 4, 7, 9, 11, 13, or 15 weeks (Waritz et al. 1977).  The 
exposure level was 0.00035 µg/m3, which is the reported equilibrium concentration at 28 °C.  Gross 
pathologic examination and measurement of relative liver weight showed no exposure-related changes at 
any of the sacrifices, but it is unclear if liver histology was evaluated. 
 
Relative liver weight was increased ≈25% in groups of 5 or 10 rats that were exposed to a decabromo-
biphenyl dust mixture at concentrations of 50–5,000 mg/m3 concurrently with starch dust (6 mg/m3) for 
6 hours/day, 5 days/week for 4 weeks (Millischer et al. 1980).  The increased liver weight was not 
accompanied by hepatic histologic changes, and therefore may be an adaptive response because PBBs are 
hepatic inducers and cause cellular proliferation (see Section 5.2.2.2 Hepatic Effects).  No effects on liver 
weight or histology were observed at 5 mg/m3. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding hepatic effects in humans after 
inhalation exposure to PBDEs. 
 
Hepatic effects were observed in 14-day inhalation studies of dusts of commercial octaBDE mixtures.  In 
one study, rats were chamber-exposed to concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 as powdered 
dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978).  Increased liver 
weight and hepatic histological changes occurred at 3.7 mg/m3 and higher levels of exposure.  At 
PBBs and PBDEs  73 
 








3.7 mg/m3, the liver lesions consisted of very slight to slight severity focal to multifocal cytoplasmic 
enlargement of the hepatocytes, accompanied by focal acidophilic degeneration of individual to small 
groups of cells.  The liver lesions were similar at ≥24.4 mg/m3), except that the hepatocyte enlargement 
was multifocal to diffuse in distribution and accompanied by focal, small to large areas of hepatocellular 
necrosis of very slight to marked degree.  In another study, rats were nose-only exposed to 0, 1.0, 10, 110, 
or 250 mg/m3 as dust aerosol for 6 hours/day, 5 days/week for 2 weeks (Great Lakes Chemical 
Corporation 2001a, 2001b).  Hepatic effects included increased mean absolute and/or relative liver 
weights at ≥10 mg/m3 in males and ≥110 mg/m3 in females, with the greatest increases at 110 and 
250 mg/m3 (21–44%).  Centribobular hypertrophy similarly occurred in the liver at ≥10 mg/m3 in both 
sexes (100% incidences except for 4/5 females at 10 mg/m3).   
 
Similar hepatic changes were found in a study of rats that were nose-only exposed to 0, 1.1, 16, or 
202 mg/m3 commercial octaBDE as dust aerosol for 6 hours/day, 5 days/week for 13 weeks (Great Lakes 
Chemical Corporation 2001a, 2001b).  The liver was affected in both sexes as shown by dose-related 
increased centrilobular hepatocellular hypertrophy at ≥16 mg/m3 and increased liver weight (absolute and 
relative) at 202 mg/m3.  Respective total incidences of centrilobular hepatocellular hypertrophy 
(predominantly minimal to mild) in the 0, 1.1, 16, and 202 mg/m3 groups were 1/10, 0/10, 3/10, and 
10/10 in males, and 0/10, 0/10, 3/10, and 6/10 in females.  Serum chemistry evaluations showed no clear 
effects of exposure.  Serum cholesterol was significantly increased (39.8% less than controls, p<0.01) in 
202 mg/m3 females, but the magnitude of the elevation was not considered toxicologically significant.  
Some other statistically significant serum chemistry alterations (increased mean globulin and total 
protein, decreased albumin/globulin ratio) also occurred in the 202 mg/m3 females, but were not 
considered exposure-related due to small magnitudes of changes and lack of similar changes in the males. 
 
Renal Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding renal effects in humans after inhalation 
exposure to PBBs. 
 
Groups of six rats were exposed to 0.00035 µg/m3 of octabromobiphenyl mixture vapor (equilibrium 
concentration) 23 hours/day, 7 days/week for 2, 4, 7, 9, 11, 13, or 15 weeks (Waritz et al. 1977).  Gross 
pathologic examination at each sacrifice and measurement of relative kidney weight at the last sacrifice 
showed no exposure-related changes, but it is unclear if kidney histology was evaluated. 
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Urinalysis was normal in groups of five male and five female rats that were exposed to a 
decabromobiphenyl dust mixture at concentrations ranging from 5 to 5,000 mg/m3 concurrently with 
starch dust (6 mg/m3) for 6 hours/day, 5 days/week for 4 weeks (Millischer et al. 1980).  The analysis 
included pH, specific gravity, proteins, glucose, ketone bodies, biliary pigments, urobilinogen, blood, and 
microscopic examination of sediment.  A comprehensive histology evaluation was performed in this 
study, but the only tissues specifically mentioned as having been examined are the liver and lungs.  
However, a total of 21 tissues were examined; therefore, it is probable that the kidney was examined, but 
was not discussed because no histological alterations were found. 
 
Polybrominated Diphenyl Ethers.  No studies were located renal respiratory effects in humans after 
inhalation exposure to PBDEs. 
 
No histopathological changes were observed in the kidneys or urinary bladder of rats that were exposed to 
dusts of commercial octaBDE products at levels of 174 mg/m3 for 8 hours/day for 14 consecutive days 
(Great Lakes Chemical Corporation 1978), ≤250 mg/m3 for 6 hours/day, 5 days/week for 14 days (Great 
Lakes Chemical Corporation 2000), or ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks (Great 
Lakes Chemical Corporation 2001a, 2001b).  Urinalyses were not performed in any of these studies. 
 
Endocrine Effects.    
 
Polybrominated Biphenyls.  Hypothyroidism was diagnosed in 4 of 35 men who were occupationally 
exposed to unspecified PBBs and/or decaBDE (Bahn et al. 1980).  The cohort consisted of workers (mean 
age 35.9 years) who had been employed at a production plant for at least 6 weeks during a 52-month 
period during which PBBs and decaBDE were the only chemicals manufactured and who had volunteered 
for a comprehensive medical evaluation performed 3 months after the end of the 52-month period.  There 
was no further description of exposure, and it was assumed to have occurred by both inhalation and 
dermal routes.  The cohort was matched by sex, race, and age to 89 unexposed control subjects.  Four 
subjects (22–50 years old, employed for 9–46 months not entirely during the 52-month production period) 
had elevated serum thyrotropin levels (mean 37.5 versus ≤1.5–8 µU/ml normal range), low or borderline 
low serum T4 levels (4.4 versus 4.5–11.5 µg/dL) and free-thyroxine indices (3.7 versus 3.8–10.8), and 
markedly elevated thyroid antimicrosomal antibody titers (1:6,400 or above).  Serum T4 levels measured 
7 months earlier in two of the four men were normal.  Antithyroglobulin antibodies were elevated in one 
of the four subjects (not evaluated in other workers).  The exposed cohort had significantly more subjects 
with elevated serum thyrotropin (p=0.006), but free thyroxine index (p=0.06), serum T4 level (p=0.11) 
and antimicrosomal antibody titer (p=0.06) did not differ significantly from the controls.  Questioning 
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about exposure to 74 occupational toxicants showed that three of the four hypothyroid subjects had only 
three common chemical exposures (PBBs, decaBDE, and bromine); the fourth worker was hired after 
PBB production ceased and was exposed only to decaBDE and bromine, but it is not clear if PBBs were 
still present in the work environment.  Except for one control subject who had an enlarged thyroid, none 
of the exposed or control subjects had signs of thyroid enlargement, thyroid nodularity or hypothyroidism 
on physical examination, or had reported taking thyroid medication or having thyroid problems within the 
previous 5 years.  Reevaluation of three of the four subjects 1 year later (none had been treated with 
thyroid hormone) showed that two still had low free-thyroxine indices and high serum thyrotropin, one 
had a normal free-thyroxine index and a high-normal serum thyrotropin, and all three still had markedly 
elevated thyroid antimicrosomal antibody titers.  The findings of this study suggest that occupational 
exposure to PBBs, decaBDE, and/or bromine affected the thyroid, but the mixed chemical exposure and a 
lack of data on serum or tissue levels of the chemicals preclude attributing effects solely to any particular 
congener or mixture of congeners. 
 
Polybrominated Diphenyl Ethers.  There is suggestive evidence of hypothyroidism in a small group of 
workers who were occupationally exposed to decaBDE as well as PBBs (Bahn et al. 1980), as 
summarized in the preceding subsection on endocrine effects of PBBs.  In another study, plasma levels of 
thyroid hormones (T3 and free T4) and eight PBDE congeners (tetra- to heptaBDEs) were monitored for 
198–221 days in three electronic dismantling workers (Pettersson et al. 2002).  The hormones remained 
within normal ranges and there were no correlations between levels of hormones and congeners.  
 
Inhalation studies of commercial octaBDE dust in rats showed no histopathological changes in the 
thyroids, parathyroids, adrenals, or pituitary following chamber exposure to 174 mg/m3 as powdered dust 
for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978), or in the adrenals 
(only endocrine tissue examined) following nose-only exposure to ≤250 mg/m3 as dust aerosol for 
6 hours/day, 5 days/week for 14 days (Great Lakes Chemical Corporation 2000).  Rats that were nose-
only exposed to commercial octaBDE at levels of 1.1, 16, or 202 mg/m3 for 6 hours/day, 5 days/week for 
13 weeks similarly showed no histological changes in the adrenals, pancreas, parathyroids, pituitary, or 
thyroids (Great Lakes Chemical Corporation 2001a, 2001b).  Measurements of serum levels of thyroid 
hormones in the 13-week rat study, however, showed exposure-related decreases in mean thyroxine (total 
T4) at ≥16 mg/m3 in both sexes, and increases in thyroid stimulating hormone (TSH) at ≥16 mg/m3 in 
males and 202 mg/m3 in females.  The changes were usually statistically significant (p<0.05 or p<0.01) 
compared to controls and were considered by the investigators to be consistent with chemical-induced 
hypothyroidism.  There were no serum T3 changes, thyroid-attributable clinical signs or body weight 
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effects, or gross or histopathological changes in the thyroid.  The 1.1 mg/m3 LOAEL for thyroid effects 
was used as the basis for the intermediate-duration MRL for inhalation exposure to octaBDE, as indicated 
in the footnote to Table 5-1 and discussed in Chapter 4 and Appendix A. 
 
Dermal Effects.     
 
Polybrominated Biphenyls.  In a medical history survey study, 7 of 10 (70%) workers in the production 
department of a PBB manufacturing plant reported that they experienced symptoms of skin disorders, 
compared with 31% of 45 workers in other departments in the same plant and 18% in a control group of 
153 Wisconsin farm residents (Chanda et al. 1982).  The survey covered a period of 3 years of potential 
exposure, but exposure levels were not reported.  The dermatological symptoms were described as 
"almost uniformly" halogen acne (bromacne).  Mean serum PBB levels for the respective PBB groups 
(with ranges listed in parentheses) were 603.9 ppb (11.4–1,729 ppb) and 16.5 ppb (4–234 ppb); PBBs 
were not detected in serum of the control subjects (Chanda et al. 1982).  Physical examination confirmed 
the occurrence of bromacne in 13% of PBB workers compared with no acne in the control group.  No 
other studies were located regarding dermal effects in humans after occupational exposure to PBBs. 
 
No studies were located regarding dermal effects in animals after inhalation exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding dermal effects in humans after 
inhalation exposure to PBDEs. 
 
No gross or histological changes in the skin were observed in rats that were nose-only exposed to 
commercial octaBDE as dust aerosol at levels of ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks 
(Great Lakes Chemical Corporation 2001a, 2001b). 
 
Ocular Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding ocular effects in humans after inhalation 
exposure to PBBs. 
 
Signs of ocular irritation (no further description) were observed in five male and five female rats that 
were exposed to a decabromobiphenyl dust mixture at 5,000 mg/m3 concurrently with starch dust 
(6 mg/m3) for 6 hours/day, 5 days/week for 4 weeks (Millischer et al. 1980).  The seriousness of this 
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effect is unclear as severity was not reported and recovery was not assessed.  Ocular irritation was not 
observed at 500 mg/m3 and lower concentrations. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding ocular effects in humans after 
inhalation exposure to PBDEs. 
 
Transient signs of ocular irritation that included eye squint, erythema, and/or ocular discharge were 
observed in rats that were chamber-exposed to pentaBDE aerosol (compound dissolved in corn oil), 
octaBDE dust, or decaBDE dust in concentrations of 2,000, 2,000, and 48,200 mg/m3, respectively, for 
1 hour (IRDC 1974, 1975a, 1975b).  Confidence in these effect levels is low due to a small number of 
tested animals and lack of control data.   
 
No histopathological changes were observed in eyes of rats that were chamber-exposed to ≤174 mg/m3 of 
commercial octaBDE as powdered dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical 
Corporation 1978).  Opthalmoscopic and histological examinations showed no ocular effects in rats 
following nose-only exposure to ≤202 mg/m3 of commercial octaBDE dust aerosol for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2001a, 2001b). 
 
5.2.1.3  Immunological and Lymphoreticular Effects  
 
Polybrominated Biphenyls.  Several immunological parameters were evaluated in a group of 28 workers 
from the Michigan Chemical Company who were involved in manufacturing and distributing PBBs 
(Stross et al. 1981).  This company manufactured the FireMaster FF-1 that was involved in the 
agricultural contamination episode in Michigan in 1973–1974.  The subjects had worked directly with 
PBBs during the previous 5 years, but exposure levels were not reported.  Immunological analyses 
included determination of immunoglobulin levels, skin testing, and lymphocyte transformation studies.  
No abnormalities in lymphocyte number or function could be determined when compared to an 
unexposed group.  One of three blastogenic responses (pokeweed mitogen [PWM]) was significantly 
reduced (p<0.01) relative to concurrent controls, but was within the normal control range for the 
laboratory.  PWM is a mitogenic lectin that stimulates both human T and B cells.  No specific information 
was provided regarding the skin testing and immunoglobulin levels. 
 
No studies were located regarding immunological or lymphoreticular effects in animals after inhalation 
exposure to PBBs. 
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Polybrominated Diphenyl Ethers.  No studies were located regarding immunological or lymphoreticular 
effects in humans after inhalation exposure to PBDEs.   
 
No histopathological changes were observed in lymph nodes or bone marrow from rats that were exposed 
to 174 mg/m3 of octaBDE dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical 
Corporation 1978). 
 
Inhalation studies of commercial octaBDE dusts in rats showed no histopathological changes in the 
spleen, mesenteric or mediastinal lymph nodes, bone marrow, or spleen following chamber exposure to 
174 mg/m3 as powdered dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 
1978), or in the spleens (only lymphoreticular tissue reported) following nose-only exposure to 
≤250 mg/m3 as dust aerosol for 6 hours/day, 5 days/week for 14 days (Great Lakes Chemical Corporation 
2000).  Rats that were nose-only exposed to commercial octaBDE at levels of 1.1, 16, or 202 mg/m3 as 
dust aerosol for 6 hours/day, 5 days/week for 13 weeks similarly showed no effects in bone marrow, 
spleen, or thymus, although gross changes in pulmonary lymph nodes were observed at 202 mg/m3.  The 
effects included discolored and/or enlarged bronchial and mediastinal lymph nodes, and appeared to be 
associated with concurrent granulomatous inflammation of the lungs.   
 
5.2.1.4  Neurological Effects  
 
Polybrominated Biphenyls.  Twenty-five workers at a PBB-manufacturing plant (exposure duration and 
levels not reported) displayed mean scores on tests of memory and learning that were typical for people of 
their age, and educational, occupational, and cultural backgrounds, even though they had an elevated 
mean PBB concentration in adipose tissue (9.33 ppm) (Brown et al. 1981).  Workers with the highest 
concentrations of PBBs in adipose tissue showed no evidence of memory dysfunction in these tests. 
 
No studies were located regarding neurological effects in animals after inhalation exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding neurological effects in humans 
after inhalation exposure to PBDEs. 
 
No clinical signs of neurotoxicity were observed in rats that were exposed to dusts of commercial 
octaBDE products at levels of 174 mg/m3 for 8 hours/day for 14 consecutive days (Great Lakes Chemical 
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Corporation 1978), or ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks (Great Lakes Chemical 
Corporation 2001a, 2001b).  Histological examinations of nervous system tissues, performed only in the 
13-week study, showed no effects in the brain (forebrain, midbrain, hindbrain), optic nerve, or a 
peripheral nerve (sciatic). 
 
5.2.1.5  Reproductive Effects  
 
Polybrominated Biphenyls.  Eleven workers in a PBB manufacturing company (exposure duration and 
levels not reported) displayed no differences in the distribution of sperm counts, motility, or sperm 
morphology compared with a control group of 52 nonexposed men (Rosenman et al. 1979).  PBBs were 
detected in the serum of all exposed subjects and in only one nonexposed subject, but no mean or 
individual serum PBB values were reported. 
 
No studies were located regarding reproductive effects in animals after inhalation exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding reproductive effects in humans 
after inhalation exposure to PBDEs. 
 
No histopathological changes were observed in testes or ovaries from rats that were exposed to 
commercial octaBDE at concentrations of ≤174 mg/m3 as powdered dust for 8 hours/day for 
14 consecutive days (Great Lakes Chemical Corporation 1978), or ≤250 mg/m3 as dust aerosol for 
6 hours/day, 5 days/week for 2 weeks (Great Lakes Chemical Corporation 2001a, 2001b).  A histological 
effect in the ovaries was found in a study of rats that were nose-only exposed to 0, 1.1, 16, or 202 mg/m3 
as dust aerosol for 6 hours/day, 5 days/week for 13 weeks (Great Lakes Chemical Corporation 2001a, 
2001b).  Absence of corpora lutea, based on qualitative evaluation of step sections of the ovary, was 
found in 3/10 females at 202 mg/m3, compared to 0/10 incidences in the control and both lower exposure 
groups.  The investigators interpreted this 30% increase in incidence be treatment-related because an 
absence of corpora lutea was considered unusual in rats at 20 weeks of age.  No gross or histopathological 
changes were observed in the oviduct, uterus, or vagina, or in male reproductive tissues (testes with 
epididymides and vas deferens). 
 
PBBs and PBDEs  80 
 








5.2.1.6  Developmental Effects  
 
No studies were located regarding developmental effects in humans or animals after inhalation exposure 
to PBBs or PBDEs. 
 
5.2.1.7  Cancer  
 
No studies were located regarding cancer in humans or animals after inhalation exposure to PBBs or 
PBDEs. 
 
5.2.2  Oral Exposure  
 
The highest NOAEL and all LOAEL values from each reliable study of health effects end points in each 
species and duration category for PBDEs are recorded in Tables 5-2 (PBBs), 5-3 (lower PDBEs), or 5-4 
(decaBDE) and plotted in Figures 5-2 (PBBs), 5-3 (lower PDBEs), or 5-4 (decaBDE). 
 
5.2.2.1  Death  
 
Polybrominated Biphenyls.  No studies were located regarding death in humans after oral exposure to 
PBBs. 
 
Limited information is available on lethal amounts of PBBs in animals.  In general, dosing regimen and 
magnitude affect response.  The lack of decreased survival in some studies does not necessarily indicate 
low toxicity because observation periods may not be sufficient to observe effects that develop slowly. 
 
Except as noted below, acute-duration studies administered PBBs by gavage in oil vehicle.  A single 
1,000 mg/kg dose of FireMaster FF-1 did not significantly increase mortality in rats observed for ≤2 years 
posttreatment (Kimbrough et al. 1978b, 1981).  Exposing pregnant rats to ≤800 mg/kg FireMaster BP-6 
on one of gestation days 6–14 did not significantly increase mortality, but the animals were not observed 
beyond pregnancy (Beaudoin 1977).  Administration of 1,000 mg/kg/day FireMaster FF-1 for 6–10 doses 
(5 days/week), however, caused 100% mortality in rats; the mean time to death was 12.3 days in females 
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Monkey Lambrecht et al. 1978; Allen et al. 1978;








0.5 (CEL: hepatocellular adenoma
and carcinoma)
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Rat NTP 1992, Chhabra et al. 1993
(FF-1)
123
a The number corresponds to entries in Figure 5-2.
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.01 mg/kg/day.  The MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 for extrapolation
from animals to humans, 10 for human variability.
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 5-2. Where such differences exist, only the levels of effect for the
most sensitive gender are presented.
Ad lib - ad libitum; Bd Wt = body weight; BP-6 = FireMaster BP-6; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); DBB = deca=brominated biphenyl; DW = drinking
water; endocr =  endocrine; (F)= feed; F = female; FF-1 = FireMaster FF-1; (G) = gavage; gastro = gastrointestinal; Gd = gestation day; Gn Pig - Guinea Pig; (GO) = gavage in oil;
Gwk = gestation week; HBB = hexa-brominated biphenyl; hemato = hematological; hr = hour(s); LD50 = lethal dose; 50% kill; LOAEL = lowest observed adverse effect level; M =
male; min = minute(s); mo = month(s); Musc/skel = musculoskeletal; NOAEL = no observed adverse effect level; NS = not specified; OBB octa-brominated biphenyl; observ =
observation; ppd = post partum day; ppwk = post partum week; Resp = respiratory; T4 = thyroxine; wk = week(s); x = time(s)
364
3.9
3.9 (thyroid follicular cell adenoma)
1.3
1.3 (CEL: hepatocellular adenoma
and carcinoma)
116 wks
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*Doses represent the lowest dose tested per study that produced a tumorigenic
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a The number corresponds to entries in Figure 5- 3.
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.03 mg/kg/day.  The MRL was derived by dividing the NOAEL by an uncertainty factor of 30 (10 for extrapolation
from animals to humans, 3 for human variability because effects were observed in a sensitive subgroup).
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.007 mg/kg/day.  The MRL was derived by dividing the LOAEL by an uncertainty factor of 300 (3 for
converting a minimal LOAEL to an NOAEL, 10 for extrapolation from animals to humans, 10 for human variability)
d Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 5-3. Where such differences exist, only the levels of effect for the
most sensitive gender are presented.
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (DW) = drinking water; endocr =  endocrine; (F)= feed; F = female; Gd = gestation day; (G) = gavage; gastro =
gastrointestinal; (GO) = gavage in oil; hemato = hematological; hr = hour(s); LD50 = lethal dose; 50% kill; LOAEL = lowest observed adverse effect level;min = minute(s); M = male;
Musc/skel = musculoskeletal; NOAEL = no observed adverse effect level; NS = not specified; pnd = post natal day; Resp = respiratory; T4 = thyroxine ; wk = week(s); x = time(s)
2086
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10 (reduced serum T4 in fetuses
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Table 5-4  Levels of Significant Exposure to Decabromodiphenyl Ether  -  Oral
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Rat Kociba et al. 1975; Norris et al. 1975b
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a The number corresponds to entries in Figure 5 4.
b Used to derive an intermediate-duration (15-364 days) oral minimal risk level (MRL) of 10 mg/kg/day for decaBDE.  The MRL was derived by dividing the 1,000 mg/kg/day NOAEL
by an uncertainty factor of 100 (10 for species to species extrapolation and 10 for human variability).
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 5-4. Where such differences exist, only the levels of effect for the
most sensitive gender are presented.
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); (DW) = drinking water; endocr = endocrine; (F)= feed; F = female; Gd = gestation day; (G) =
gavage; gastro = gastrointestinal; (GO) = gavage in oil; hemato = hematological; hr = hour(s); LOAEL = lowest observed adverse effect level; M = male; min = minute(s); Musc/skel =
musculoskeletal; NOAEL = no observed adverse effect level; NS = not specified; Resp = respiratory; wk = week(s); x = time(s); yr = year(s)
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general statement indicated that the rats had hunchback posture, rough coat, and sunken eyes, were 
lethargic, and appeared dehydrated and emaciated.  No deaths occurred in rats administered octabromo-
biphenyl mixture in a single dose ≤1,000 mg/kg with 4 weeks of observation (Lee et al. 1975a), 
2,000 mg/kg with 2 weeks of observation (Norris et al. 1975a), 17,000 mg/kg with 1 week of observation 
(Lee et al. 1975a; Waritz et al. 1977), or 3,000 mg/kg/day on 2 consecutive days with 4 weeks of 
observation (Lee et al. 1975a).  The 17,000 mg/kg dose was the highest that was feasible to administer, 
apparently due to gavage volume because it had to be administered as divided doses given in a 4-hour 
period.  Dietary administration of octabromobiphenyl mixture in estimated dosages of ≤70 mg/kg/day for 
2 weeks was not lethal in rats, but there was no posttreatment observation period (Lee et al. 1975b; Waritz 
et al. 1977).  In the only study of a decabromobiphenyl mixture, a single dose as high as 5,000 mg/kg 
caused no deaths in rats observed for 14 days (Millischer et al. 1980).  In mice, dietary administration of 
FireMaster BP-6 for 2 weeks produced death (cause not reported) at estimated doses of 130 mg/kg/day, 
but not ≤36 mg/kg/day (Cagen et al. 1977; Fraker 1980; Fraker and Aust 1978).  Information on acute 
oral lethality in species other than rats and mice was not located. 
 
In intermediate-duration studies with rats, no deaths were induced by dietary administration of FireMaster 
BP-6 at estimated dosages of ≤5 mg/kg/day for ≤82 days (Darjono et al. 1983) or ≤10 mg/kg/day for 
30 days (Akoso et al. 1982a).  No deaths were observed in rats fed ≤50 mg/kg/day of an unspecified PBB 
mixture for 30 or 60 days (Sleight and Sanger 1976).  Twice weekly gavage with 100 mg/kg FireMaster 
FF-1 in corn oil for two 3-week dosing periods, separated by ≈6 weeks, was not lethal in rats observed for 
2 years (Kimbrough et al. 1981).  Twenty-two gavage doses of 100 mg/kg FireMaster FF-1 in corn oil 
(5 days/week for 4.5 weeks) produced 38 and 100% mortality in male and female rats, respectively; the 
average times to death were 46.7 and 60.3 days, respectively (Gupta and Moore 1979).  Similar treatment 
with 30 mg/kg/day FireMaster FF-1 was not lethal in rats observed for ≈5 months.  Based on these gavage 
data, the calculated LD50 in rats observed for ≈60 days posttreatment (i.e., 90-day LD50) was 149 and 
65 mg/kg/day for male and female rats, respectively (Gupta and Moore 1979).  This study did not 
specifically address the cause of death, but emaciated appearance and gross loss of subcutaneous and 
visceral adipose tissue indicate wasting was a contributing factor.  Rats that were treated with FireMaster 
FF-1 in corn oil by gavage on 5 days/week for 25 weeks exhibited dose-related decreased survival at 
≥0.3 mg/kg/day (cause of death not discussed), but not at 0.1 mg/kg/day (NTP 1983).  The decreased 
survival was only apparent when the rats were observed for a lifetime (≈15–22 months posttreatment) and 
consistent only in males.  Survival was also decreased in male but not female rats given ≥0.5 mg/kg/day 
FireMaster FF-1 in the diet for up to 104 weeks (Chhabra et al. 1993; NTP 1992).  The decreased survival 
appeared to be related to increased incidences of mononuclear cell leukemia.  No deaths were observed in 
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rats treated with octabromobiphenyl mixture in the diet at estimated dosages of ≤71 mg/kg/day for 
4 weeks and observed for ≤18 weeks (Lee et al. 1975b; Waritz et al. 1977).  Rats treated with 
≤1 mg/kg/day dietary octabromobiphenyl mixture for 8 months did not die, but there were some deaths 
(number and cause not reported) in rats treated with higher dietary dosages (8–800 mg/kg/day) for 
30 days (Norris et al. 1975a).  Insufficient information is available to determine if the deaths were 
treatment-related, since incidences and other pertinent information were not reported. 
 
Survival data for intermediate-duration exposure to PBBs are less extensive for species other than rat, but 
indicate that guinea pigs and mink are particularly susceptible.  High mortality occurred in guinea pigs 
fed estimated dosages of 2 mg/kg/day FireMaster BP-6 for 45 days (Vos and van Genderen 1973, 1974) 
or ≥4 mg/kg/day of an unspecified PBB mixture for 30 days (Sleight and Sanger 1976); dosages of 
≤0.4 mg/kg/day of either mixture were not lethal.  The Litchfield and Wilcoxon procedure was used to 
calculate dietary LD50 values of 0.47 and 0.61 mg/kg/day (estimated dosages) for male and female mink, 
respectively, exposed to FireMaster FF-1 for life (63–294 days) (Aulerich and Ringer 1979; Ringer et al. 
1981).  Dosages ≤0.18 mg/kg/day did not significantly increase mortality in the mink.  Dietary 
administration of FireMaster BP-6 in an estimated dosage of 21.7 mg/kg/day for 12 weeks caused some 
deaths in mice (number not reported), leading to sacrifice of other test animals (Martino et al. 1981; 
Wilson-Martino et al. 1980).  Mean survival time decreased significantly in female mice treated with 
10 mg/kg/day of FireMaster FF-1 in corn oil by gavage on 5 days/week for 25 weeks, but not 
≤3 mg/kg/day (NTP 1983).  Decreased survival was only apparent when the mice were observed for 
≤24 months posttreatment (lifetime observation) and not observed in similarly treated males.  Survival 
was also decreased in female mice given ≥1.3 mg/kg/day FireMaster FF-1 in the diet for up to 105 weeks; 
decreased survival occurred in similarly treated male mice at 3.9 mg/kg/day (Chhabra et al. 1993; NTP 
1992).  The cause of death was not discussed in the NTP (1983, 1992) mouse studies, but hepatocellular 
tumors increased significantly in both sexes at dosages that decreased survival. 
 
No deaths occurred in two swine that ingested estimated dosages of ≤8 mg/kg/day for 16 weeks; one pig 
was observed for 102 days following exposure and the other for 14 weeks following exposure (Ku et al. 
1978).  An adult male monkey died after consuming 0.73 mg/kg/day FireMaster FF-1 in the diet for 
25 weeks (Allen et al. 1978; Lambrecht et al. 1978).  The death was attributed to severe gastrointestinal 
changes, including ulcerative colitis.  The only other animal in this study was a juvenile female who 
survived 50 weeks of a dietary dosage of 1.43 mg/kg/day.  In another study, one juvenile female monkey 
that consumed 18 mg/kg/day FireMaster FF-1 in the diet died after 137 days of continuous exposure 
(Allen et al. 1978).  Although only one or two monkeys were tested in these studies, effects characteristic 
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of PBB poisoning (e.g., dermal changes, body weight loss) indicate that the deaths were exposure-related.  
Pregnant cows given 67 mg/kg/day FireMaster BP-6 in capsules for 60 days (dosing began ≥10 days after 
pregnancy diagnosis) were sacrificed between days 33 and 66 because of impending death (Moorhead et 
al. 1977).  Clinical signs developed progressively and included anorexia, emaciation, and depressed 
general condition.  No mortality occurred in cows treated with ≤0.65 mg/kg/day and observed for 1 or 
140 days following the end of treatment. 
 
The LD50 value and reliable LOAEL values for death in each species in the acute- and intermediate-
duration categories are recorded in Table 5-2 and plotted in Figure 5-2.  
 
Polybrominated Diphenyl Ethers.  No deaths occurred in rats that were treated with a single gavage dose 
of ≤5,000 mg/kg of decaBDE or ≤2,000 mg/kg of 77.4% decaBDE (containing 21.8% nonaBDE and 
0.8% octaDBE) and observed for the following 14 days (IRDC 1974; Norris et al. 1975b).  No mortality 
was observed in rats and mice that were exposed to decaBDE via diet in estimated doses of ≤16,000 and 
≤19,000 mg/kg/day, respectively, for 14 days (NTP 1986).   
 
In intermediate-duration dietary studies with decaBDE, there was no exposure-related mortality in rats 
that were exposed to estimated dietary doses of ≤90 mg/kg/day for 28 days (IRDC 1976) or rats and mice 
fed estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic 
studies, there were no effects on survival in rats that were fed 0.01–1.0 mg/kg/day of a 77.4% decaBDE 
mixture (containing 21.8% nonaBDE and 0.8% octaDBE) for 2 years (Kociba et al. 1975; Norris et al. 
1975b), or in rats and mice fed decaBDE in estimated doses of ≤2,550 and ≤7,780 mg/kg/day, 
respectively, for 103 weeks (NTP 1986). 
 
No deaths occurred in rats that were administered octaBDE by gavage in single doses ≤5,000 mg/kg and 
observed for the following 14 days (IRDC 1975a).  Intermediate-duration dietary studies with octaBDE, 
observed no mortality in rats exposed to estimated dietary doses of ≤90 mg/kg/day for 28 days or 
≤750 mg/kg/day for 13 weeks (IRDC 1976, 1977). 
 
Single-dose gavage LD50 values of 5,000 and 6,200 mg/kg were determined for pentaBDE (Saytex 115 
and DE-71, respectively) in rats that were observed for 14 days (British Industrial Biological Research 
Association 1977; Pharmakon Research International Inc. 1984).  Another study found that a single 
5,000 mg/kg dose of pentaBDE caused deaths in four of five rats in the 14 days following treatment, 
whereas doses ≤500 mg/kg caused no mortality (IRDC 1975b).  No deaths occurred in rats exposed to 
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pentaBDE in estimated dietary doses of ≤90 mg/kg/day for 28 days (IRDC 1976) or ≤100 mg/kg/day for 
90 days (WIL Research Laboratories 1984). 
 
The LD50 and LOAEL values for death in the acute-duration BDE studies in rats are recorded in 
Tables 5-3 (lower BDEs) and 5-4 (decaBDE) and plotted in Figures 5-3 (lower BDEs) and 5-4 
(decaBDE). 
 
5.2.2.2  Systemic Effects  
 
The systemic effects in humans and animals following oral exposure to PBBs and PBDEs are described 
below.  The highest NOAEL and all LOAEL values from each reliable study for systemic end points in 
each species and duration category are recorded in Tables 5-2 (PBBs), 5-3 (lower PDBEs), or 5-4 
(decaBDE) and plotted in Figures 5-2 (PBBs), 5-3 (lower PDBEs), or 5-4 (decaBDE). 
 
Respiratory Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding respiratory effects in humans after oral 
exposure to PBBs. 
 
The preponderance of data does not indicate that PBBs are respiratory system toxicants in animals, even 
at doses sufficient to cause death.  No exposure-related histological changes were observed in the lungs or 
trachea of rats that were administered FireMaster FF-1 in a single dose of 200 or 1,000 mg/kg and 
observed for 2–23 months posttreatment (Kimbrough et al. 1978b, 1981).  Rats and mice exposed to 
≤30 mg/kg/day FireMaster FF-1 for 2 weeks also showed no histological alterations in the lung, trachea, 
or nasal turbinates (Gupta et al. 1981).  Information on acute-duration respiratory effects in other species 
was not located. 
 
In intermediate- and chronic-duration studies with rats, histology of the lung, trachea, or nasal turbinate 
was not altered by FireMaster FF-1 or FireMaster BP-6 dosages of ≤30 mg/kg/day by gavage for 30 days 
(Gupta et al. 1981), ≤10 mg/kg/day in the diet for 30 days (Akoso et al. 1982a; Sleight et al. 1978), 
≤10 mg/kg/day by gavage for 25 weeks (NTP 1983), or ≤1.5 mg/kg/day in the diet for up to 104 weeks 
(NTP 1992).  Rat lung histology also was not affected by exposure to 50 mg/kg/day of an unspecified 
PBB mixture in the feed for 30 days (Sleight and Sanger 1976).  In studies with mice, FireMaster FF-1 
produced no histopathological changes in the lungs, trachea, or nasal turbinates following gavage 
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exposure to ≤10 mg/kg/day for 25 weeks (NTP 1983) or ≤30 mg/kg/day for 30 days (Gupta et al. 1981), 
or dietary exposure to ≤3.9 mg/kg/day for up to 105 weeks (NTP 1992).  Guinea pig lung histology was 
unaffected by exposures of ≤20 mg/kg/day of an unspecified PBB mixture in the feed for 30 days (Sleight 
and Sanger 1976).  Relative lung weights increased in mink that died following exposure to 
≤2.4 mg/kg/day FireMaster FF-1 for 313 days, but it is unclear if this effect is adverse because the 
animals had lost weight and histopathology was not reported (Aulerich and Ringer 1979; Ringer et al. 
1981).  Effects in six pregnant cows given 67 mg/kg/day of FireMaster BP-6 in capsules for up to 60 days 
included increased respiratory rate and occasional nasal discharge (Moorhead et al. 1977).  Necropsy 
following sacrifice between days 33 and 66 because of impending death due to poor health showed gross 
pneumonia (one cow), microscopic lesions of early purulent bronchopneumonia (two cows), and petechial 
hemorrhages of the tracheal mucosa (one cow).  No histological changes were observed in the trachea or 
lungs treated with ≤0.65 mg/kg/day and observed for 1–140 days following the end of treatment.  
Information on respiratory effects of octabromobiphenyl mixture or other PBB mixtures in animals was 
not located. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding respiratory effects in humans after 
oral exposure to PBDEs. 
 
Effects of PBDEs on respiratory function have not been studied in orally-exposed animals.  No 
histopathological changes in respiratory tract tissues were found in rats and mice fed decaBDE in 
estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic 
dietary studies, there was no respiratory tract histopathology in rats that were fed ≤1.0 mg/kg/day of a 
77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaDBDE) for 2 years (Kociba et al. 
1975; Norris et al. 1975b), or in rats and mice exposed to decaBDE at estimated doses of ≤2,550 and 
≤7,780 mg/kg/day, respectively, for 103 weeks (NTP 1986). 
 
No histopathological changes in the respiratory tract were found in dietary studies of rats exposed to 
≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977) or ≤100 mg/kg/day of pentaBDE for 90 days 
(WIL Research Laboratories 1984).   
 
Cardiovascular Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding cardiovascular effects in humans after 
oral exposure to PBBs. 
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Animal data do not generally indicate cardiovascular toxicity of PBBs even at lethal doses, but 
cardiovascular function was not evaluated in most studies.  No exposure-related histological changes in 
the heart were observed in rats administered FireMaster FF-1 in a single dose of 200 or ≤1,000 mg/kg and 
observed for 2–23 months posttreatment (Kimbrough et al. 1978a, 1981), or ≤30 mg/kg/day for 2 weeks 
(Gupta et al. 1981; Kimbrough et al. 1978b, 1981).  Mice exposed to ≤30 mg/kg/day FireMaster FF-1 for 
2 weeks also showed no histological alterations in the heart (Gupta et al. 1981).  In intermediate-and 
chronic-duration studies with rats, FireMaster FF-1 or FireMaster BP-6 dosages of ≤30 mg/kg/day by 
gavage for 30 days (Gupta et al. 1981), ≤10 mg/kg/day in the diet for 30 days (Akoso et al. 1982a; Sleight 
et al. 1978), ≤10 mg/kg/day by gavage for 25 weeks (NTP 1983), or ≤1.5 mg/kg/day in the diet for up to 
104 weeks (NTP 1992) did not alter heart weight or histology.  Rat heart histology also was unaffected by 
exposure to 50 mg/kg/day of an unspecified PBB mixture for 30 days (Sleight and Sanger 1976).  Rats 
exposed to ≤5 mg/kg/day FireMaster BP-6 for 30 days exhibited no exposure-related changes in blood 
pressure, but histology or other cardiovascular end points were not evaluated (McCormack et al. 1978).  
Rats exposed to octabromobiphenyl mixture in dosages of ≤1 mg/kg/day for 8 months or ≤800 mg/kg/day 
for 30 days showed no changes in heart weight, but histology or function was not evaluated (Norris et al. 
1975a).  In studies with mice, FireMaster FF-1 produced no changes in heart weight or histology 
following gavage exposure to ≤10 mg/kg/day for 25 days (Gupta et al. 1981), ≤30 mg/kg/day for 30 days 
(NTP 1983), or dietary exposure to ≤3.9 mg/kg/day for up to 105 weeks (Chhabra et al. 1993; NTP 1992).  
No effects on heart relative weight or histology were reported in mink that died following exposure to 
≤2.4 mg/kg/day FireMaster FF-1 for 313 days (Aulerich and Ringer 1979; Ringer et al. 1981).  Relative 
heart weights were increased in swine exposed to ≤8 mg/kg/day of an unspecified PBB mixture for 
16 weeks, but gross pathology was normal and histology was not evaluated (Ku et al. 1978).  Necropsy of 
a monkey that died following ingestion of 0.73 mg/kg/day FireMaster FF-1 for 25 weeks showed an 
enlarged heart, but histology was not evaluated and a similar effect was not reported in two other 
monkeys exposed to higher dosages (Allen et al. 1978; Lambrecht et al. 1978).  Mean heart rate was 32% 
lower than the pre-exposure value in pregnant cows that were treated with 67 mg/kg/day of FireMaster 
BP-6 in capsules for 10 days (Moorhead et al. 1977).  Necropsy following sacrifice between days 33 and 
66 because of impending death due to poor health showed petechial and ecchymotic hemorrhages of the 
myocardium and endocardium in two of six cows.  No cardiovascular effects were observed in cows 
given ≤0.65 mg/kg/day and observed for 1–140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding cardiovascular effects in humans 
after oral exposure to PBDEs. 
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Effects of PBDEs on cardiovascular function have not been studied in orally exposed animals.  No 
histopathological changes in the heart were found in rats and mice fed decaBDE in estimated doses of 
≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic dietary studies, there 
was no cardiac histopathology in rats that were fed ≤1.0 mg/kg/day of a 77.4% decaBDE mixture 
(containing 21.8% nonaBDE and 0.8% octaDBDE) for 2 years (Norris et al. 1975b), or in rats and mice 
exposed to decaBDE in estimated doses of ≤2,550 and ≤7,780 mg/kg/day, respectively, for 103 weeks 
(NTP 1986). 
 
No histopathological changes in the heart were found in dietary studies of rats exposed to 
≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977) or ≤100 mg/kg/day of pentaBDE for 90 days 
(WIL Research Laboratories 1984). 
 
Gastrointestinal Effects.     
 
Polybrominated Biphenyls.  No symptoms of gastrointestinal effects were reported by residents of 
quarantined Michigan farms in an epidemiological study conducted by the U.S. Center for Disease 
Control and the Michigan Department of Public Health (Landrigan et al. 1979).  In a medical history 
survey conducted by the Environmental Science Laboratory of the Mount Sinai School of Medicine, no 
statistically significant difference was observed between the prevalence rates of gastrointestinal 
symptoms for 933 Michigan residents who were likely to have ingested PBB-contaminated food and the 
rates for a control group of 229 Wisconsin farm residents (Anderson et al. 1978c).  The Michigan 
residents were examined ≈3 years after the contamination episode occurred.  No other studies were 
located regarding gastrointestinal effects in humans after oral exposure to PBBs. 
 
Gastric lesions have developed in various animals that ingested PBBs, particularly after prolonged 
exposure to FireMaster FF-1 or FireMaster BP-6.  No exposure-related histological changes in the 
gastrointestinal tract or esophagus were observed in rats administered FireMaster FF-1 in a single dose 
≤1,000 mg/kg and observed for 2–23 months posttreatment (Kimbrough et al. 1978b, 1981).  Rats or mice 
exposed to ≤30 mg/kg/day FireMaster FF-1 for 2 weeks also showed no histological alterations in the 
gastrointestinal tract (esophagus not examined) (Gupta et al. 1981).  In intermediate-duration studies, the 
gastrointestinal tract of rats exposed to FireMaster BP-6 or FireMaster FF-1 by gavage or diet at 
≤50 mg/kg/day for 4–4.5 weeks showed no histopathological changes (esophagus not examined) (Akoso 
et al. 1982a; Gupta and Moore 1979; Gupta et al. 1981; Sleight and Sanger 1976; Sleight et al. 1978).  
Histological examination of the gastrointestinal tract of rats administered FireMaster FF-1 by gavage for 
25 weeks showed significantly increased incidences of gastric ulcers at ≥1 mg/kg/day and hyperplastic 
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gastropathy at ≥3 mg/kg/day after lifetime observation (23 months).  These gastric effects were not 
observed in rats examined at the end of the gavage treatment period, although similar changes 
(forestomach hyperplasia, inflammation, and ulceration) occurred in rats exposed to 1.5 mg/kg/day 
FireMaster FF-1 in the diet for up to 104 weeks (Chhabra et al. 1993; NTP 1992).  In the only study of a 
decabromobiphenyl mixture, rats were fed estimated dosages as high as 100 mg/kg/day for 13 weeks 
(Millischer et al. 1980).  A comprehensive histology evaluation was performed in this study, but the liver 
is the only tissue specifically mentioned as having been examined.  Due to the total number of tissues 
examined (21) and route of exposure, it is probable that the gastrointestinal tract was examined but not 
discussed because no histopathologic changes were observed. 
 
Gastrointestinal tract histology was normal in mice exposed to FireMaster FF-1 dosages of 
≤10 mg/kg/day by gavage for 25 weeks or ≤3.9 mg/kg/day in the diet for up to 105 weeks (NTP 1983, 
1992).  FireMaster FF-1 produced no histological changes in the gastrointestinal tract of mice exposed to 
≤30 mg/kg/day for 30 days (Gupta et al. 1981).  Gross pathologic examination of swine administered an 
unspecified PBB mixture for 16 weeks showed that the glandular portion of the stomach "appeared 
somewhat hyperplastic" (additional details were not reported, and histology was not evaluated) at 
8 mg/kg/day, but not at 1 mg/kg/day (Ku et al. 1978).  Biopsies of two monkeys performed following 
their ingestion of 0.73 or 1.43 mg/kg/day FireMaster FF-1 for 12 weeks showed proliferation of gastric 
mucosal cells, focal areas of infiltration of chronic inflammatory cells, and isolated penetrations of the 
gastric mucosa into the underlying submucosa (Allen et al. 1978; Lambrecht et al. 1978).  Necropsies 
performed after 25 or 50 weeks of exposure also showed hyperplastic gastroenteritis and, in the low-dose 
monkey (that died of "severe gastrointestinal changes"), severe ulcerative colitis.  Hyperplastic 
gastroenteritis was described in another monkey exposed to a higher dosage (18 mg/kg/day) of FireMaster 
FF-1 for 137 days (Allen et al. 1978).  Gastrointestinal effects in six pregnant cows that were 
administered 67 mg/kg/day of FireMaster BP-6 in capsules for up to 60 days included diarrhea, 
dehydration (possibly a result of the diarrhea), and occasional constipation (Moorhead et al. 1977).  
Necropsy following sacrifice between days 33 and 66 because of impending death due to poor health 
showed edema and hemorrhage of the colon and rectum mucosa, although histology was normal in the 
esophagus, rumen, omasum, and reticulum.  No histological changes were observed in the gastrointestinal 
tract of cows with ≤0.65 mg/kg/day and observed 1 or 140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding gastrointestinal effects in humans 
after oral exposure to PBDEs. 
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No histopathological changes in gastrointestinal tract tissues were found in rats and mice fed decaBDE in 
estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic 
dietary studies, there was no gastrointestinal tract histopathology in rats that were fed ≤1.0 mg/kg/day of a 
77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaDBDE) for 2 years (Kociba et al. 
1975; Norris et al. 1975b).  Higher dietary doses of decaBDE for 103 weeks caused acanthosis of the 
forestomach in rats exposed to 2,240 mg/kg/day (no effects at ≤1,200 mg/kg/day) and stomach ulcers in 
mice exposed to 7,780 mg/kg/day (no effects at ≤3,760 mg/kg/day) (NTP 1986). 
 
No histopathological changes in the gastrointestinal tract were found in dietary studies of rats exposed to 
≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977) or ≤100 mg/kg/day of pentaBDE for 90 days 
(WIL Research Laboratories 1984).   
 
Hematological Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding hematological effects in humans after oral 
exposure to PBBs. 
 
In animals, hematologic changes indicative of possible anemia are common findings in animals resulting 
from longer-term exposure to PBBs.  Comprehensive hematological examinations in rats and mice 
administered ≤30 mg/kg/day FireMaster FF-1 for 2 weeks showed no exposure-related changes (Gupta et 
al. 1981).  No additional information on hematology in animals following acute-duration exposure to 
PBBs was located.  In intermediate-duration studies, no consistent hematological changes were found in 
rats exposed to ≤10 mg/kg/day FireMaster BP-6 for 30 days (Akoso et al. 1982a; Sleight et al. 1978).  
Some hematologic effects occurred in rats at higher dosages or longer durations.  Exposure to 
30 mg/kg/day FireMaster FF-1 for 4.5 weeks significantly reduced hemoglobin concentration, packed cell 
volume (PCV), and platelet count in rats evaluated up to ≈60 days postexposure (Gupta and Moore 1979).  
In another study in which rats were administered the same dosages of FireMaster FF-1 (≤30 mg/kg/day) 
for 30 days, longer postexposure (up to 90 days) evaluation revealed transient responses (Gupta et al. 
1981).  Transitory and slight but significant (p<0.05) decreases in red blood cell count, hemoglobin 
concentration, and PCV values were found; they returned to control levels by 60-days post-dosing.  No 
consistent hematological changes were observed in rats administered ≤50 mg/kg/day of an unspecified 
PBB mixture for 30 days (Sleight and Sanger 1976) or ≤10 mg/kg/day FireMaster FF-1 for 6 months 
(Luster et al. 1980).  Rats exposed to FireMaster FF-1 for 25 weeks showed no hematological changes at 
0.1 mg/kg/day, but had dose-related, significantly decreased hemoglobin, mean corpuscular hemoglobin 
(MCH), mean corpuscular volume (MCV), and PCV at ≥0.3 mg/kg/day, and increased total leukocytes at 
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≥1 mg/kg/day; there were no effects on erythrocyte or platelet counts (NTP 1983).  Mice similarly treated 
for 25 weeks had decreased erythrocyte count and MCV at ≥0.3 mg/kg/day and decreased platelets and 
lymphocytes at ≥1 mg/kg/day, but no hematological effects were noted at 0.1 mg/kg/day (NTP 1983).  No 
hematologic alterations were found in mice exposed to FireMaster FF-1 at dosages of ≤10 mg/kg/day for 
6 months or ≤30 mg/kg/day for 30 days (Gupta et al. 1981; Luster et al. 1980). 
 
Hematologic evaluation of swine treated with an unspecified PBB mixture for 16 weeks showed 
significantly decreased hemoglobin and hematocrit values in two of four animals exposed to 8 mg/kg/day 
at week 6, after which values returned to normal or near-normal within 2 weeks (Ku et al. 1978).  
Decreased PCV and serum protein developed in monkeys exposed to FireMaster FF-1 in dosages of 
≥0.73 mg/kg/day for ≥25 weeks (two animals); additional hematologic effects observed in one monkey 
exposed to 18 mg/kg/day for 137 days were decreased erythrocyte and white blood cell counts (Allen et 
al. 1978; Lambrecht et al. 1978).  No hematological changes were measured in cows treated with 
≤0.65 mg/kg/day FireMaster BP-6 in capsules for 60 days, and observed for up to 140 days following the 
end of treatment (Moorhead et al. 1977).  Similar treatment with 67 mg/kg/day did not cause abnormal 
hematologic indices in four of six cows; changes in the other two animals (e.g., leukocytosis, increased 
PCV) have uncertain toxicologic significance because the animals at this dose were sacrificed 
between days 33 and 66 because of impending death due to poor health. 
 
Studies of hematologic effects of octabromobiphenyl mixture, performed only in rats, showed 
significantly decreased red blood cell count and PCV following 800 mg/kg/day for 30 days, but no 
hematological changes resulting from ≤1 mg/kg/day for 8 months (Norris et al. 1975a).  In the only study 
of a decabromobiphenyl mixture, dietary administration of 100 mg/kg/day for 13 weeks caused no 
hematologic changes in rats (Millischer et al. 1980).  Erythrocyte and leucocyte counts, differential 
leukocyte count, and hematocrit and hemoglobin levels were measured. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding hematological effects in humans 
after oral exposure to PBDEs. 
 
OctaBDE caused red blood cell effects in an intermediate-duration dietary studies in rats in which 
erythrocytes, hematocrit, and hemoglobin were reduced following exposure to 750 mg/kg/day for 
13 weeks (no effects at ≤70 mg/kg/day) (IRDC 1977). 
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DecaBDE and pentaBDE did not induce hematological effects in animals.  In dietary studies with 
decaBDE, no hematological changes were found in rats exposed to ≤800 mg/kg/day for 30 days (Norris et 
al. 1973, 1975a, 1975b), ≤8,000 mg/kg/day for 13 weeks (NTP 1986), or ≤2,550 mg/kg/day for 
103 weeks (NTP 1986), or in mice exposed to ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day for 
103 weeks (NTP 1986).  There also were no hematological effects in rats exposed by diet to 
≤1.0 mg/kg/day of a 77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaDBE) for 
2 years (Kociba et al. 1975; Norris et al. 1975b) or ≤100 mg/kg/day of pentaBDE for 90 days (WIL 
Research Laboratories 1984).   
 
Musculoskeletal Effects.     
 
Polybrominated Biphenyls.  Symptoms of musculoskeletal effects, described as "joint pain" and 
"swelling in joints," were frequently cited health complaints in two epidemiological studies of groups of 
Michigan residents who were likely to have ingested PBB-contaminated food (Anderson et al. 1978c; 
Landrigan et al. 1979).  Although one study demonstrated a statistically significant difference between the 
prevalence rate for these types of symptoms in Michigan residents compared with nonexposed residents 
of Wisconsin farms (Anderson et al. 1978c), neither study demonstrated a positive association between 
serum PBB levels and the prevalence rates for symptoms of musculoskeletal effects. 
 
There are no pathology data indicating that PBBs produce effects in musculoskeletal tissues of animals.  
No exposure-related histological changes in muscle or bone marrow were observed in rats that were 
administered a single 1,000 mg/kg dose of FireMaster FF-1 and observed for 2 years (Kimbrough et al. 
1981).  Rats and mice exposed to ≤30 mg/kg/day FireMaster FF-1 for 2 weeks showed no histological 
alterations in muscle or sternum (Gupta et al. 1981).  In intermediate-and chronic-duration studies, rats 
and/or mice exposed to FireMaster FF-1 or FireMaster BP-6 dosages of ≤30 mg/kg/day by gavage for 
30 days (Gupta et al. 1981), ≤10 mg/kg/day in the diet for 30 days (Akoso et al. 1982a; Sleight et al. 
1978), ≤10 mg/kg/day by gavage for 25 weeks (NTP 1983), or ≤3.9 mg/kg/day in the diet for up to 
105 weeks (NTP 1992) showed no histopathological changes in muscle or bone.  A dosage of an 
unspecified PBB mixture as high as 50 mg/kg/day for 30 days produced no histopathological changes in 
rat muscle (Sleight and Sanger 1976).  Excess porphyrins were detected in bone and/or teeth by 
fluorescence under ultraviolet light in some of the rat studies (Gupta and Moore 1979; NTP 1983), but 
this appears to be a consequence of altered porphyrin metabolism (Hill 1985).  No histological alterations 
were observed in sternebrae bone marrow of pregnant cows given FireMaster BP-6 in capsules for up to 
60 days (Moorhead et al. 1977).  Cows treated with 67 mg/kg/day were necropsied following sacrifice 
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between days 33 and 66 because of impending death due to poor health, and those treated with nonlethal 
lower dosages of ≤0.65 mg/kg/day were examined 1 or 140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding musculoskeletal effects in humans 
after oral exposure to PBDEs. 
 
Dietary studies with decaBDE found no histopathological changes in musculoskeletal tissues in rats 
exposed to ≤8,000 mg/kg/day for 13 weeks (NTP 1986), ≤1.0 mg/kg/day (77.4% containing 21.8% 
nonaBDE and 0.8% octaDBE) for 2 years (Kociba et al. 1975; Norris et al. 1975b), or ≤2,550 mg/kg/day 
for 103 weeks (NTP 1986), or in mice exposed to ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day 
for 103 weeks (NTP 1986).  A study of pentaBDE found no musculoskeletal changes in rats exposed 
dietary doses of ≤100 mg/kg/day for 90 days (WIL Research Laboratories 1984).  No information was 
located on possible musculoskeletal effects of octaBDE. 
 
Hepatic Effects.     
 
Polybrominated Biphenyls.  Results from several studies of humans exposed to PBBs do not 
demonstrate, in general, a conclusive association between adverse effects on the liver and oral exposure to 
PBBs.  In a study in which serum was collected in 1974, 1977, 1978, and 1979 from 89, 240, 220, and 
200 individuals, respectively, who were predominately residents of quarantined Michigan farms, no 
consistent statistically significant correlations were found between serum PBB levels and levels of serum 
glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) or serum 
bilirubin (Kreiss et al. 1982).  The prevalence rates of Michigan residents with abnormally high levels of 
SGPT (12.7% prevalence rate), SGOT (12.7%), or lactate dehydrogenase (8.6%) were statistically 
significantly higher than comparable rates for residents of Wisconsin farms (2.7, 2.0, and 3.3%) 
(Anderson et al. 1979).  A contingency table analysis indicated that the prevalence of abnormal SGPT 
values in Michigan residents with serum PBB levels ≤1 ppb (8%) was lower than the prevalence rate for 
residents with serum PBB levels ≥1 ppb (14%), but correlation coefficients for serum PBB levels and 
serum liver enzyme levels were uniformly low (r<0.1) (Anderson et al. 1979).  Physical examinations of 
Michigan residents (37 men and 9 women) with known exposure to PBBs and a history of incapacitating 
health care complaints revealed that 72% of the subjects displayed mildly enlarged livers, which were 
associated with elevations in serum liver enzymes (SGOT and SGPT) predominately less than 2-fold 
above normal values (Stross et al. 1979).  Mildly enlarged livers, confirmed by liver scanning, were 
observed in 4 of 23 (17%) Michigan residents with known PBB exposure and incapacitating health 
complaints and in 2 of 28 (7%) workers involved in the manufacture and distribution of PBBs, 
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respectively; however, these workers had histories of either substantial alcohol intake or exposure to 
multiple chemicals (Stross et al. 1981).  Results of a caffeine breath test, discussed in Section 5.8.2, 
suggest that PBBs may have induced hepatic microsomal enzymes in exposed Michigan residents 
(Lambert et al. 1990). 
 
Hepatic effects of PBBs are documented in various animal species although rats have been the species 
tested most extensively.  The changes appear to be similar among species and reversible when mild.  
Characteristic hepatic effects include proliferation of the smooth endoplasmic reticulum, microsomal 
enzyme induction, increased serum levels of liver-associated enzymes indicative of possible 
hepatocellular damage, liver enlargement, hepatocyte vacuolation and fat deposition, fibrosis, and 
necrosis.  PBBs also cause alterations in levels of cholesterol and other lipids in liver and serum, levels of 
vitamin A in liver and urine, and levels of porphyrins in liver, other tissues, and urine.  These changes 
could be secondary to liver damage or due to direct effects on lipid, vitamin A, and porphyrin 
metabolism, which occurs primarily in the liver.  Induction of microsomal enzymes by PBBs is a 
sensitive effect generally regarded as an adaptive response of the liver rather than as a manifestation of 
hepatotoxicity per se (Guzelian 1985).  Although not necessarily adverse, induction of microsomal 
enzymes could alter the rate or pathways of metabolism of other xenobiotic or endogenous substances and 
increase activation of promutagens and procarcinogens or increase detoxification pathways.  In addition, 
the induction of some microsomal enzyme activities is an indicator of exposure to PBBs and related 
compounds (AhR agonists), which elicit a well known pattern of toxic responses (see Chapters 3 and 4).  
PBB-related liver enlargement is usually associated with hepatocyte enlargement and an increase in 
smooth endoplasmic reticulum and/or increased microsomal enzymatic activity; therefore, it is not 
considered an adverse effect unless accompanied by other biochemical changes and/or histological 
alterations. 
 
Rats administered FireMaster FF-1 in a single 1,000 mg/kg dose and observed for 2–23 months 
posttreatment or a lethal dose of 1,000 mg/kg/day for 2 weeks developed enlarged livers with fatty and 
necrotic changes leading to fibrosis (Gupta and Moore 1979; Kimbrough et al. 1978b, 1981).  Lower 
single doses of FireMaster FF-1 caused vacuolation and some biochemical changes (e.g., increased serum 
cholesterol and phospholipids, decreased serum retinol) at 500 mg/kg (Bernert et al. 1983; Kimbrough et 
al. 1980), and hepatic porphyrin accumulation with no histologic changes at 200 mg/kg (Kimbrough et al. 
1981).  Repeated exposure to lower dosages of ≥3 mg/kg/day FireMaster FF-1 for 2 weeks (Gupta et al. 
1981) or 5 mg/kg/day FireMaster BP-6 for 10 days (Raber and Carter 1986) caused hepatocyte 
enlargement and some fatty and single-cell necrotic changes in weanling and young rats.  A limited 
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amount of data suggest that octabromobiphenyl mixture-induced hepatic effects in rats are milder than for 
FireMaster mixtures at similar dosages.  Fatty changes appear to be the most severe hepatic 
histopathologic effect of octabromobiphenyl observed following a single 1,000 mg/kg dose or doses of 
3,000 mg/kg/day for 2 days and 6.53 mg/kg/day (but not 0.66 mg/kg/day) for 2 weeks (Lee et al. 1975a, 
1975b; Waritz et al. 1977).  In studies with mice, a single dose of 36 mg/kg FireMaster BP-6 increased 
liver weight (histology not evaluated) and had no consistent effects on disposition of injected ouabain or 
indocyanine green, indicating that hepatic function was not compromised (Cagen et al. 1977).  Sporadic 
increases in the clearance of ouabain and indocyanine green were attributed to increased liver size.  
Exposure to 130 mg/kg/day FireMaster BP-6, for 11 days caused focal areas of coagulative necrosis 
(Corbett et al. 1975) and ≥3 mg/kg/day FireMaster FF-1 for 2 weeks caused scattered necrosis in mice 
(Gupta et al. 1981). 
 
In intermediate-duration studies with rats, dosages ≥0.05 mg/kg/day FireMaster BP-6 for 20 days induced 
hepatic microsomal enzymes but histology was not evaluated (Babish et al. 1978).  Dose-related 
hepatocyte swelling and vacuolation were induced by ≥0.1 mg/kg/day FireMaster BP-6 for 30 days 
(Akoso et al. 1982a), lipid accumulation, porphyrin levels, and atypical foci were increased by 
≥0.3 mg/kg/day FireMaster FF-1 for 25 weeks (lethal dose) (NTP 1983), and bile duct hyperplasia was 
induced by 0.5 mg/kg/day FireMaster BP-6 for 82 days (Darjono et al. 1983).  Rats exposed to higher, but 
not necessarily lethal, dosages of FireMaster FF-1 or FireMaster BP-6 for 1–3 months showed 
progression of these effects, including marked degenerative changes and porphyrin accumulation in these 
and other studies (Gupta and Moore 1979; Gupta et al. 1981; Kasza et al. 1978a; McCormack et al. 1978; 
Sleight and Sanger 1976; Sleight et al. 1978).  In the only chronic study, incidences of hepatocellular 
hypertrophy, cytoplasmic vacuolation, atypical foci, and oval cell hyperplasia were increased in rats fed 
≥0.5 mg/kg/day FireMaster FF-1 for up to 104 weeks (Chhabra et al. 1993; NTP 1992).  Compared to this 
adult-only exposure, combined perinatal and adult exposure resulted in increased incidences of oval cell 
hyperplasia at 0.5 mg/kg/day and hypertrophy, cytoplasmic vacuolation, and bile duct fibrosis at 
1.5 mg/kg/day.  Studies of octabromobiphenyl mixture in rats have shown hepatic effects (e.g., 
hypertrophy and hyperplasia of centrilobular cells, vacuolation, and other fatty degenerative changes) at 
dosages ≥6.53 mg/kg/day for 4 weeks (Lee et al. 1975b; Norris et al. 1975a; Waritz et al. 1977), but 
normal liver histology at ≤1 mg/kg/day for 8 months (Norris et al. 1975a).  A 13-week dietary study with 
decabromobiphenyl mixture found that hepatic effects in rats, including vacuolization and distension of 
centrilobular hepatocytes often accompanied by slightly increased lipid, did not occur at dosages 
<100 mg/kg/day (Millischer et al. 1980).  Information on hepatic effects of octabromobiphenyl mixture 
and decabromobiphenyl in species other than the rat was not located. 
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In mice, exposure to FireMaster FF-1 for 25 weeks increased liver weight, porphyrin content, and SGOT 
at ≥0.3 mg/kg/day and hepatocyte swelling occurred at ≥1 mg/kg/day (NTP 1983).  Hepatic effects in 
mice exposed to ≥1.3 mg/kg/day FireMaster FF-1 for up to 105 weeks included hepatocyte hypertrophy, 
vacuolization, and necrosis; bile duct hyperplasia also developed (NTP 1992).  Dosages ≥3 mg/kg/day for 
4–6 weeks, but not 0.3 mg/kg/day, also induced hepatocyte necrosis and/or vacuolation in mice (Gupta et 
al. 1981; Loose et al. 1981; NTP 1983).  Fatty changes and centrilobular necrosis developed in pregnant 
swine fed ≥1.25 mg/kg/day, but not 0.125 mg/kg/day, FireMaster BP-6 for 12 weeks during the second 
half of gestation through lactation (Werner and Sleight 1981).  This adverse effect level cannot be 
corroborated in nonpregnant swine exposed to ≤8 mg/kg/day of unspecified PBBs for 16 weeks due to 
lack of liver histology evaluations, although relative liver weight increased at ≥1 mg/kg/day and no gross 
changes were observed (Ku et al. 1978).  Guinea pigs appear to be particularly susceptible to hepatic 
effects of PBBs (unspecified) as indicated by ultrastructural vacuolation and formation of myelin bodies 
in hepatocytes following exposure to ≥0.04 mg/kg/day for 30 days; liver weights were increased at 
0.4 mg/kg/day and histological vacuolation and severe centrilobular fatty change were observed at a lethal 
dose of 4 mg/kg/day (Sleight and Sanger 1976).  Mink that ingested ≥0.24 mg/kg/day FireMaster FF-1 for 
≤313 days showed increased liver weight and fatty infiltration (Aulerich and Ringer 1979; Ringer et al. 
1981).  In monkeys, lethal FireMaster FF-1 dosages ≥0.73 mg/kg/day for 25–50 weeks caused hepatocyte 
enlargement with increased lipid droplets, bile duct hyperplasia, increased SGPT, and decreased serum 
cholesterol (Allen et al. 1978; Lambrecht et al. 1978).  Effects in six pregnant cows given 67 mg/kg/day 
of FireMaster BP-6 in capsules for up to 60 days included increased serum lactic dehydrogenase (LDH) 
and SGOT (Moorhead et al. 1977).  Necropsy following sacrifice between days 33 and 66 because of 
impending death due to poor health showed increased liver weight and pathologic liver changes including 
friable appearance, glycogen depletion in hepatocytes, sinusoidal dilation, and scattered areas of early 
fatty degeneration.  In general, the hepatic effects observed in cows are less pronounced than in other 
species at lethal doses.  No adverse hepatic effects were observed in cows treated with ≤0.65 mg/kg/day 
and examined 1 or 140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding hepatic effects in humans after oral 
exposure to PBDEs. 
 
No information was located on adverse hepatic effects of acute-duration oral exposure to PBDEs in 
animals.  Intermediate- and chronic-duration studies in rodents indicate that the liver is a target of toxicity 
of PBDEs.  As discussed below, repeated dietary exposure to commercial PBDE products typically 
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caused liver enlargement with or without degenerative changes, and effects were generally dose-related in 
incidence and severity, more frequent and pronounced in males than females, and more severe and 
induced by lower doses with octaBDE and pentaBDE than decaBDE.  Regarding decaBDE, the low 
purity former mixture (77.4% pure containing 21.8% nonaBDE and 0.8% octaBDE) was much more 
hepatotoxic than the current day commercial product (≈99% pure).  In particular, hepatic effects included 
increased liver weights at ≥80 mg/kg/day with centrilobular cytoplasmic enlargement and vacuolation at 
800 mg/kg/day in male rats exposed to 77% decaBDE for 30 days (Norris et al. 1973, 1975a, 1975b), 
whereas exposure to 94–97% decaBDE for 13 weeks caused no liver pathology in rats and mice exposed 
to estimated doses as high as 2,000–8,000 and 2,375–9,500 mg/kg/day, respectively (NTP 1986).  The 
NOAEL for hepatic effects from the NTP (1986) 13-week study (8,000 mg/kg/day) was used as the basis 
for the intermediate-duration MRL for oral exposure to decaBDE, as indicated in a footnote to Table 5-4 
and discussed in Chapter  4 and Appendix A.  In chronic studies, exposure to 94–97% decaBDE for 
103 weeks caused liver lesions that included neoplastic nodules in rats at ≥1,120 mg/kg/day, thrombosis 
and degeneration in rats at 2,240 mg/kg/day, and centrilobular hypertrophy and granulomas in mice at 
≥3,200 mg/kg/day (NTP 1986).  The thrombosis in the rats was characterized by a near total occlusion of 
a major heptatic blood vessel by a dense fibrin coagulum.  A NOAEL was not identified in the rats or 
mice.  The only other chronic study of decaBDE found that exposure to 1 mg/kg/day of the 77% pure 
mixture for 2 years caused no liver effects in rats; higher doses were not tested, precluding identification 
of a LOAEL (Kociba et al. 1975; Norris et al. 1975b).  Unlike the decaBDE used in the NTP (1986) 
study, the composition of the mixture tested by Kociba et al. (1975) is substantially different than that of 
current-day commercial decaBDE products (≈99%). 
 
OctaBDE caused increased liver weight and histopathological changes such as hepatocellular enlargement 
and vacuolation in rats exposed to doses as low as 5mg/kg/day (lowest tested dose) for 4–13 weeks 
(IRDC 1976, 1977).  Hepatic effects in rats exposed to octaBDE for 13 weeks included increases in 
absolute and/or relative liver weight at ≥5–7 mg/kg/day and liver lesions in 40% of males at 5 mg/kg/day 
and 100% of both sexes at ≥50 mg/kg/day (IRDC 1977).  The lesions were dose-related in severity as 
well as incidence and characterized by cytomegaly, change in hepatocytic cytoplasm to a finely granular, 
homogeneous type, and cytoplasmic vacuolation.  At ≥600 mg/kg/day many of the livers had vacuolation 
of centrolobular hepatocytes and some had hepatocyte necrosis.  Examinations performed at 8 weeks and 
6 months postexposure showed that the liver effects persisted in the rats exposed to ≥50 mg/kg/day for 
13 weeks (IRDC 1977). 
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PentaBDE induced liver effects in rats exposed to ≥9 mg/kg/day for 28 days (increased liver weight and 
enlargement of centrolobular and midzonal liver parenchymal cells) (IRDC 1976) and ≥2 mg/kg/day for 
90 days (hepatocytomegaly) (WIL Research Laboratories 1984).  The hepatomegaly in the 90-day study 
was dose-related with respect to severity (some affected hepatocytes at higher doses had vacuoles that 
likely contained lipid) and not completely reversible, as it was still evident in ≥10 mg/kg/day males and 
100 mg/kg/day females at 24 weeks postexposure in lessened severity and incidence.  Females exposed to 
2 and 100 mg/kg/day pentaBDE for 90 days had an increased incidence of degeneration and necrosis of 
individual liver parenchymal cells at 24 weeks postexposure; the investigators concluded that this may 
represent the final loss of previously damaged cells and probably should be considered compound-related 
(WIL Research Laboratories 1984).  The 2 mg/kg/day LOAEL for hepatic effects of pentaBDE was used 
as the basis for the intermediate-duration MRL for oral exposure to tetra- to heptaBDEs as indicated in 
the footnote to Table 5-3 and discussed in Chapter 4 and Appendix A.  Liver vitamin A concentrations 
were increased in rats and mice exposed to a commercial pentaBDE mixture (Bromkal 70-5 DE) by 
gavage in doses of 18 and 36 mg/kg/day, respectively, for 90 days (Hallgren et al. 2001). 
 
Hepatic microsomal enzyme induction is a well-documented effect for the pentaBDE and octaBDE 
commercial products, but has not been observed for decaBDE (Carlson 1980b; Zhou et al. 2001).  
Microsomal enzyme activity was induced in rats exposed by gavage to doses as low as 0.6 mg/kg/day of 
octaBDE and 0.4 mg/kg/day of pentaBDE for 90 days as indicated by increases in O-ethyl O-p-nitro-
phenyl phenylphosphonothioate (EPN) detoxification, p-nitroanisole demethylation, and cytochrome c 
reductase and cytochrome P-450 levels (Carlson 1980a).  Some of these changes were persistent, lasting 
for 30-60 days after cessation of treatment, but not considered to be adverse due to the lack of any 
accompanying hepatic histological abnormalities.  Rats that were treated with equimolar 
(0.1 mmol/kg/day) gavage doses of deca-, octa-, or pentaBDE (95.9, 76.6, or 56.4 mg/kg/day, 
respectively) for 14 days had octa- and pentaBDE-induced increases in liver weight and microsomal 
enzyme activity (e.g., increased EPN detoxification, p-nitroanisole demethylation, uridinediphosphate-
glucuronyltransferase [UDPGT] activity, and benzo[a]pyrene hydroxylase activity); exposure to decaBDE 
only increased liver weight (Carlson 1980b).  DecaBDE also had no effect on hepatic UDPGT, 
ethoxyresorufin-o-deethylase (EROD), or pentoxyresorufin-o-deethylase (PROD) activities in weanling 
rats that were treated with ≤100 mg/kg/day by gavage for 4 days (Zhou et al. 2001).  Similar exposure to 
0.3–300 mg/kg/day pentaBDE caused significantly increased EROD and PROD at ≥10 mg/kg/day and 
UDPGT at ≥30 mg/kg/day, and octaBDE induced PROD at ≥10 mg/kg/day and EROD and UDPGT at 
≥30 mg/kg/day; neither of these PBDEs caused induction at ≤1 mg/kg/day. 
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Hepatic EROD, PROD, and methoxyresorufin-o-deethylase (MROD) were increased in mice exposed to 
≥18 mg/kg/day (lowest tested dose) of pentaBDE by gavage for 14 days, although UDPGT was 
unchanged at ≤36 mg/kg/day (Fowles et al. 1994; Hallgren et al. 2001).  Rats that were similarly treated 
with pentaBDE for 14 days had increased activities of EROD, MROD, and PROD at ≥18 mg/kg/day 
(lowest tested dose) and increased UDPGT at 36 mg/kg/day (Hallgren et al. 2001).  PentaBDE also 
increased hepatic microsomal enzyme activity in maternally-exposed rats and their offspring (Zhou et al. 
2002).  Exposure to 1, 10, or 30 mg/kg/day by gavage from gestation day (GD) 6 through postnatal day 
(PND) 21 caused significantly increased hepatic EROD and PROD at ≥10 mg/kg/day in dams (GD 20 and 
PND 22) and offspring (GD 20 and PNDs 4, 14, and 36), as well as increased UDPGT at 30 mg/kg/day in 
dams (GD 20 and PND 22) and offspring (GD 20 and PNDs 4 and 14). 
 
Renal Effects.     
 
Polybrominated Biphenyls.  No statistically significant correlations were found between serum PBB 
levels and serum levels of blood urea nitrogen (BUN) or creatinine in a study of residents of quarantined 
Michigan farms after the 1973 PBB contamination episode (Kreiss et al. 1982).  No other studies were 
located with information pertinent to renal effects in humans after oral exposure to PBBs. 
 
Studies with animals have shown some renal effects following prolonged exposure to PBBs, but findings 
are generally inconsistent, and the functional significance is uncertain.  No exposure-related histological 
changes in kidneys or bladder were observed in rats administered FireMaster FF-1 in a single dose of 
200 or 1,000 mg/kg (Kimbrough et al. 1978b, 1981) and observed for 2–23 months posttreatment 
(Kimbrough et al. 1978a, 1981), or ≤30 mg/kg/day for 2 weeks (Gupta et al. 1981).  Gross examination of 
rats exposed to 1,000 mg/kg/day for 2 weeks showed darkened kidneys (Gupta and Moore 1979).  Other 
renal information was not reported, but the dosage was lethal.  Urinalysis was normal in rats following 
exposure to ≤30 mg/kg/day for 2 weeks (Gupta et al. 1981); urinalysis was not evaluated in the other rat 
studies.  Bladder histology, examined in some of the rat studies, was also reported to be normal (Gupta et 
al. 1981; Kimbrough et al. 1981).  Kidney histology was not altered in rats exposed to ≤71 mg/kg/day 
octabromobiphenyl mixture for 2 weeks (Lee et al. 1975b; Waritz et al. 1977).  Mice exposed to 
≤30 mg/kg/day FireMaster FF-1 for 2 weeks showed no abnormal kidney or bladder histology or 
urinalysis findings (Gupta et al. 1981).  Information on acute-duration renal effects in other species was 
not located. 
 
In intermediate-duration studies with rats, dietary exposure to FireMaster BP-6 for 30 days produced no 
PBB-related alterations in urinalysis indices or BUN at 5 mg/kg/day (highest tested dose) or kidney 
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histology at ≤10 mg/kg/day (Akoso et al. 1982a; Sleight et al. 1978).  However, 5 mg/kg/day FireMaster 
BP-6 in the diet for 3 months caused progressive obsolescence of glomeruli in rats (Bowman's membrane 
was shrunken and glomerular tufts were shrunken, inactive, or had been largely replaced by scar tissue), 
although relative kidney weight, BUN, and renal function tests (clearance of inulin, p-aminohippurate, or 
fractional sodium excretion) were normal (McCormack et al. 1978).  Also, in vitro accumulation of 
p-aminohippurate and N-methylnicotinamide, and ammoniagenesis and gluconeogenesis were not 
affected in renal cortical slices from these treated rats.  Administration of FireMaster FF-1 by gavage for 
25 weeks caused no renal effects at 0.1 mg/kg/day, but produced chronic progressive nephropathy at 
≥1 mg/kg/day, and more serious histopathology at 10 mg/kg/day (NTP 1983).  Renal pathology at the 
10 mg/kg/day dosage included atrophy and edema of glomerular tufts with marked dilation of Bowman's 
capsule and dilation of some renal tubules, with either serous fluid or proteinaceous casts in both cortical 
and medullary regions, and no changes in BUN (NTP 1983).  Chronic administration of FireMaster FF-1 
in the diet for up to 104 weeks, however, failed to produce any treatment-related histopathologic changes 
at dosages as high as 1.5 mg/kg/day (NTP 1992).  The reason for the inconsistency between this finding 
and the results of the NTP (1983) study is unclear, but the different methods of oral treatment could be a 
factor. 
 
Intermediate-duration gavage exposure to a higher FireMaster FF-1 dose of 30 mg/kg/day for 4.5 weeks 
caused dilation of Bowman's capsule with serous fluid in rats observed for ≈60 days posttreatment (Gupta 
and Moore 1979); however, rats that were similarly treated (≤30 mg/kg/day for 30 days) but observed 
longer (90 days posttreatment) had normal kidney histology, urinalysis values, and BUN (Gupta et al. 
1981).  Rats administered 50 mg/kg/day of an unspecified PBB mixture in the diet for 30 days with no 
posttreatment observation had increased BUN but no changes in urinalysis values or kidney histology 
(Sleight and Sanger 1976).  In studies with octabromobiphenyl mixture in rats, dietary exposure to 
≥8 mg/kg/day for 30 days caused hyaline degenerative cytoplasmic changes in kidneys with normal 
urinalysis values (Norris et al. 1975a).  This finding is inconsistent with a report of normal kidney 
histology in rats exposed to ≤71 mg/kg/day octabromobiphenyl mixture in the diet for 4 weeks (urinalysis 
not constructed) (Lee et al. 1975b; Waritz et al. 1977); the reason for the discrepancy cannot be discerned 
from the reports.  Kidney histology and urinalysis findings were also normal in rats administered 
≤1 mg/kg/day octabromobiphenyl mixture for 8 months (Norris et al. 1975a).  In the only study of a 
decabromobiphenyl mixture, urinalysis was normal in rats fed 100 mg/kg/day for 13 weeks (Millischer et 
al. 1980).  Comprehensive histology evaluations were performed at this and lower dosages in this study, 
but the liver is the only tissue specifically mentioned as having been examined.  Due to the total number 
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tissues examined (21) and the route of exposure, it is probable that kidneys were examined but were not 
discussed because no histopathologic changes were found. 
 
In gavage studies with mice, FireMaster FF-1 produced no renal histopathologic changes following 
exposure to ≤10 mg/kg/day for 25 weeks (BUN was normal) (NTP 1983) or ≤30 mg/kg/day for 30 days 
(normal BUN and urinalysis) (Gupta et al. 1981).  Dietary exposure to 3.9 mg/kg/day FireMaster FF-1 for 
up to 105 weeks, however, caused an increased incidence of chronic progressive nephropathy in mice; 
this effect was not found at 1.3 mg/kg/day (NTP 1992).  Kidney histological alterations were not reported 
in mink exposed to ≤2.4 mg/kg/day FireMaster FF-1 for 313 days (Aulerich and Ringer 1979; Ringer et 
al. 1981).  Swine exposed to unspecified PBBs for 16 weeks had increased relative kidney weight at 
≥1 mg/kg/day, but the adversity of this change is unclear since no gross renal pathology was observed 
(≤8 mg/kg/day) and histology was not evaluated (Ku et al. 1978).  Monkeys that ingested 18 mg/kg/day 
FireMaster FF-1 for 137 days developed hyperplasia of the bladder epithelium, but histological changes 
in the kidneys were not reported (Allen et al. 1978).  Urine alterations in six pregnant cows given 
67 mg/kg/day of FireMaster BP-6 in capsules for up to 60 days included increased protein concentration 
and BUN, and decreased pH and specific gravity (Moorhead et al. 1977).  Necropsy following sacrifice 
between days 33 and 66 because of impending death due to poor health showed enlarged, distended, and 
discolored kidneys, extreme dilation of the collecting ducts and convoluted tubules, degenerative changes 
in the tubular epithelium, and congestion with scattered microscopic hemorrhages in the medulla.  The 
renal effects in cows appear to be more severe than those generally observed in other species at lethal 
doses.  No urinalysis alterations or changes in kidney histology were observed in other cows treated with 
≤0.65 mg/kg/day and examined 1 or 140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding renal effects in humans after oral 
exposure to PBDEs. 
 
Dietary studies of PBDEs in animals observed kidney effects that are mainly attributable to octaBDE.  
Renal effects induced by octaBDE included noninflammatory kidney changes in male rats exposed to 
600 mg/kg/day for 13 weeks (IRDC 1977).  The incidence and severity of the kidney lesions (tubule 
regeneration, intratubular casts, and cellular debris occurred in most 600 mg/kg/day males) suggested a 
compound-related effect (IRDC 1977).  Another study of octaBDE found no histopathological changes in 
the kidneys of rats exposed to ≤90 mg/kg/day for 90 days (IRDC 1976).  Studies of pentaBDE found no 
renal histopathology in rats exposed dietary doses of ≤90 mg/kg/day for 28 days (IRDC 1976) or 
≤100 mg/kg/day for 90 days (WIL Research Laboratories 1984).   
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Studies of low purity (≈77%) commercial decaBDE mixtures found kidney pathology (hyaline 
degenerative cytoplasmic changes) in male rats exposed to 800 mg/kg/day for 30 days (Norris et al. 1973, 
1975a, 1975b), but not in rats exposed to ≤90 mg/kg/day for 90 days (IRDC 1976) or ≤1.0 mg/kg/day for 
2 years (Kociba et al. 1975; Norris et al. 1975b).  Interpretation of this finding is complicated by the fact 
that hyaline degenerative cytoplasmic changes are not uncommon in adult male rats and might be induced 
by a mechanism specific to certain aged male rats.  No renal histopathological changes were induced by 
94–97% pure commercial decaBDE in rats exposed to ≤8,000 mg/kg/day for 13 weeks or 
≤2,550 mg/kg/day for 103 weeks (NTP 1986), or in mice exposed to ≤9,500 mg/kg/day for 13 weeks or 
≤7,780 mg/kg/day for 103 weeks (NTP 1986).   
 
Endocrine Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding endocrine effects in humans after oral 
exposure to PBBs. 
 
Thyroid effects have been observed in animals treated with PBBs by gavage or diet in acute-, 
intermediate-, and chronic-duration studies.  Characteristic changes include decreases in serum levels of 
serum thyroxine (T4) and serum triiodothyronine (T3) hormones, thyroid enlargement, and effects in the 
follicular cells including reduced size, hyperplasia with columnar appearance and papillary projections, 
and accumulation of colloid droplets.  In the only acute study that investigated thyroid end points more 
sensitive than histology, rats administered an unspecified PBB mixture for 10 days showed serum T4 
levels (T3 not evaluated) that were significantly reduced (p≤0.05) at ≥3 mg/kg/day, but not at 1 mg/kg/day 
(Allen-Rowlands et al. 1981).  The reduction in T4 levels was both dose- and time-dependent as shown by 
20-day results discussed below with intermediate-duration studies.  Based on the NOAEL for decreased 
serum T4, an acute oral MRL of 0.01 mg/kg/day was calculated as indicated in the footnote to Table 5-2 
and discussed in Chapter 3 and Appendix A.  A single ≤286 mg/kg dose of an unspecified PBB mixture 
caused no change in 4-hour thyroidal 131I uptake and incorporation into thyroglobulin in rats (Allen-
Rowlands et al. 1981).  No thyroid histological alterations were observed in rats in acute-duration studies 
with FireMaster FF-1, even with a single dose ≤1,000 mg/kg and up to 2 years posttreatment observation 
(Kimbrough et al. 1978b, 1981) or dosages of ≤1,000 mg/kg/day for 2 weeks (Gupta and Moore 1979; 
Gupta et al. 1981).  The only information on thyroid effects of acute exposure to octabromobiphenyl 
mixture is a lack of histological changes in rats administered ≤71 mg/kg/day for 2 weeks (Lee et al. 
1975b; Waritz et al. 1977).  The only information on acute-duration thyroid effects of PBBs in species 
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other than rat is the normal histologic integrity of the thyroid in mice at FireMaster FF-1 dosages of 
≤30 mg/kg/day for 2 weeks (Gupta et al. 1981). 
 
In intermediate-duration studies with rats, serum levels of T3 or T4 decreased at FireMaster dosages as 
low as 0.3 mg/kg/day FireMaster FF-1 for 25 weeks (NTP 1983), 0.45 mg/kg/day FireMaster BP-6 for 
7 months (Byrne et al. 1987), 5 mg/kg/day FireMaster BP-6 for 30 days (Akoso et al. 1982b) or 
1 mg/kg/day of an unspecified PBB mixture for 20 days (Allen-Rowlands et al. 1981).  In the latter study, 
8–11 rats were evaluated after exposure to 1, 3, or 6 mg/kg/day for 20 days.  Other thyroid effects in these 
rats included significantly increased absolute thyroid weight at ≥3 mg/kg/day (not evaluated at 
1 mg/kg/day), and increased plasma TSH levels, increased 5-hour thyroid uptake of 131I and deceased 
incorporation of 131I into monoiodotyrosine (MIT) at 6 mg/kg/day (Allen-Rowlands et al. 1981).  No 
effects on incorporation of 131I into diiodotyrosine (DIT), T3, or T4 were observed.  Serum T4 levels were 
also reduced at ≥1 mg/kg/day in rats exposed for 20 days and evaluated after being placed on restricted 
food intake for ≥2 months following treatment (Allen-Rowlands et al. 1981).  Rats administered 
2.5 mg/kg/day of an unspecified hexabromobiphenyl mixture for 7 months showed no significant changes 
in serum T3, but serum T4 was not evaluated (Sepkovic and Byrne 1984).  Thyroid ultrastructural changes 
were produced in rats by FireMaster BP-6 dosages as low as 0.05 mg/kg/day for 30–35 days (Akoso et al. 
1982b; Kasza et al. 1978a), and histologic changes of the thyroid were observed at ≥5 mg/kg/day 
FireMaster BP-6 for 30 days (Sleight et al. 1978) and ≥30 mg/kg/day FireMaster FF-1 for 4.5 weeks 
(Gupta and Moore 1979).  In the study that evaluated thyroid effects at the lowest dose, rats were 
administered estimated doses of 0.05, 0.5, or 5 mg/kg/day FireMaster BP-6 in the diet for 30 days (Akoso 
et al. 1982b).  Effects were dose-dependent and included increased number and decreased size of follicles 
(especially at the peripheral location) at ≥0.05 mg/kg/day, follicles with epithelial tall columnar 
appearance and some papillary projections in the lumen at ≥0.5 mg/kg/day, and extensive follicular 
changes (hyperplasia and hypertrophy of follicular cells, prominent, and numerous papillary projections), 
increased relative thyroid weight, and decreased serum T3 and T4 at 5 mg/kg/day.  Chronic exposure to 
≤1.5 mg/kg/day FireMaster FF-1 for up to 104 weeks caused no thyroid histological alterations, but 
ultrastructure and serum thyroid hormones were not assayed (NTP 1992). 
 
In the only intermediate-duration rat study of octabromobiphenyl mixture that assessed thyroid hormones, 
a dose of 2.5 mg/kg/day for 7 months produced no significant changes in serum T3, but serum T4 was not 
evaluated (Sepkovic and Byrne 1984).  The histologic integrity of the thyroid was normal in rats fed 
octabromobiphenyl mixture at dosages as high as 1 mg/kg/day for 8 months (Norris et al. 1975a), 
2.5 mg/kg/day for 7 months (Sepkovic and Byrne 1984), and 71 mg/kg/day for 4 weeks (Lee et al. 1975b; 
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Waritz et al. 1977), although ≥8 mg/kg/day for 30 days induced dose-related thyroid hyperplasia (Norris 
et al. 1975a).  An explanation for the discrepancy in the octabromobiphenyl mixture NOAELs of 
≤71 mg/kg/day and LOAELs of ≥8 mg/kg/day is not apparent, particularly since treatment durations were 
similar, methods of treatment (diet) and animal strain and sex (male) were the same, and only the NOAEL 
study appears to have observed the animals (for 2–18 weeks) posttreatment. 
 
Effects on the adrenal gland also have been observed in animals exposed to PBBs.  As found for thyroid 
as discussed above, acute-duration exposure to FireMaster FF-1 produced no changes in rat adrenal 
histology following a single dose as high as 1,000 mg/kg (Gupta et al. 1981; Kimbrough et al. 1978b, 
1981).  Dosages of 1,000 mg/kg/day FireMaster FF-1 for 2 weeks caused gross adrenal damage (darkened 
glands) in rats, but ≤30 mg/kg/day caused no gross or histologic damage (Gupta and Moore 1979; Gupta 
et al. 1981).  The only information on acute-duration adrenal effects of PBBs in species other than rat is 
normal adrenal histology in mice at FireMaster FF-1 dosages of ≤30 mg/kg/day for 2 weeks (Gupta et al. 
1981).  No acute-duration studies of PBBs measure serum corticosteroid levels.  In intermediate-duration 
studies, serum corticosterone B, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate 
(DHS) decreased in rats fed ≥0.25 mg/kg/day FireMaster BP-6 for 5–7 months, but not 0.05 mg/kg/day 
(Byrne et al. 1988).  Serum corticosterone levels and adrenal weight did not change in rats exposed to 
≤6 mg/kg/day of an unspecified PBB mixture for a shorter duration of 20 days (other adrenal hormones 
were not evaluated) (Castracane et al. 1982).  Adrenal histology was not evaluated in these studies, but no 
treatment-related alterations were observed in rats in other intermediate-duration studies with FireMaster 
BP-6 or FireMaster FF-1 (Akoso et al. 1982b; NTP 1983; Sleight and Sanger 1976; Sleight et al. 1978), 
except at lethal dosages (Gupta and Moore 1979), or in a chronic study with FireMaster FF-1 (NTP 
1992).  Necropsies of rats treated with 100–1,000 mg/kg/day FireMaster FF-1 for 4.5 weeks showed 
darkened adrenals (Gupta and Moore 1979).  In the only rat study of octabromobiphenyl mixture that 
examined the adrenal gland, 2.5 mg/kg/day for 7 months produced no changes in relative adrenal weight; 
histology or serum corticosteroids were not evaluated (Sepkovic and Byrne 1984).  Intermediate- or 
chronic-duration studies with FireMaster FF-1 in mice showed no adrenal histological effects at 
≤3.9 mg/kg/day for up to 105 weeks (NTP 1992), ≤10 mg/kg/day for 25 weeks (NTP 1983), or 
≤30 mg/kg/day for 30 days (Gupta et al. 1981). 
 
Polybrominated Diphenyl Ethers.  Plasma levels of the congener 2,2',4,4'-tetraBDE (BDE 47) and 
various other persistent organohalogen compounds (non-PBDEs), as well as hormone levels (free and 
total T3 and T4, thyroid stimulating hormone [TSH], free testosterone, follicle-stimulating hormone, 
lutenizing hormone, and prolactin), were analyzed in 110 men who consumed varying amounts of fatty 
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fish (0–32 meals per month) from the Baltic Sea (Hagmar et al. 2001).  There was a weak negative 
correlation between BDE 47 and plasma TSH after age adjustment, but the congener could not explain 
more than 10% of the variance in TSH (r2=0.10, p<0.001).  The fact that BDE 47 could only explain 10% 
of the variance in TSH is not surprising due to the occurrence of PCBs and other likely similarly acting 
compounds in the Baltic fisherman.  
 
Hyperplasia of the thyroid was observed in rats and mice following repeated dietary exposures to 
decaBDE.  Thyroid follicular cell hyperplasia was increased in male B6C3F1 mice that were exposed to 
≥94% pure commercial decaBDE for 103 weeks (NTP 1986).  Incidences of the lesion were 2/50 (4%), 
10/50 (20%), and 19/50 (38%) in the 0, 3,200, and 6,650 mg/kg/day dose groups of this study.  Slight 
increases in follicular cell tumors that were considered to be equivocal evidence of thyroid 
carcinogenicity were also observed in the male mice (see Section 5.2.2.7, Cancer).  No decaBDE-related 
histopathological changes in the thyroid were found after 103 weeks of exposure to ≤7,780 mg/kg/day in 
female mice, ≤2,240 mg/kg/day in male Sprague-Dawley rats, or ≤2,550 mg/kg/day in female rats (NTP 
1986).  Dose-related increases in thyroid hyperplasia were reported for male Sprague-Dawley rats 
exposed to 80 and 800 mg/kg/day for 30 days (Norris et al. 1973, 1975b), although not in rats exposed to 
≤90 mg/kg/day for 90 days, rats exposed to ≤8,000 mg/kg/day for 13 weeks, or mice exposed to 
≤9,500 mg/kg/day for 13 weeks (IRDC 1976; NTP 1986).  The occurrence of thyroid hyperplasia in the 
rats exposed to ≥80 mg/kg/day for 30 days could be related to the low purity composition of the older 
commercial decaBDE mixture tested by Norris et al. (1973, 1975a, 1975b) (i.e., 77.4% decaBDE, 21.8% 
nonaBDE, and 0.8% octaBDE, compared to the ≥94% decaBDE composition used in the NTP studies).   
 
Thyroid function was not tested in any of the intermediate- and chronic-duration studies of decaBDE, 
although an acute study in rats (Zhou et al. 2001), summarized in the following paragraph, found that a 
>98% pure decaBDE product (DE-83R) caused no serum changes in thyroid hormones.  Studies of 
commercial octa- and pentaBDE mixtures and individual constituent congeners of these mixtures, also 
summarized below, indicate that the rat and mouse thyroid is particularly sensitive to the lower 
brominated BDEs.  The human relevance of the animal thyroid data is unclear due to evidence indicating 
that the main thyroid effect, decreased serum T4, occurs by a mechanism that is not clearly relevant to 
humans (see Section 5.5.2 Mechanisms of Toxicity). 
 
Thyroid hormone levels were determined in weanling (28-day-old) female Long-Evans that were treated 
by gavage for 4 days with commercial mixtures of decaBDE (DE-83R) or octaBDE (DE-79) in doses of 
0.3, 1, 3, 10, 30, 60, or 100 mg/kg/day, or pentaBDE (DE-71) in doses of 0.3, 1, 3, 10, 30, 100, or 
PBBs and PBDEs  187 
 








300 mg/kg/day (Zhou et al. 2001).  The animals were sacrificed on the day after the last exposure and 
evaluated for changes in serum levels of total T4, total T3, and TSH.  DecaBDE caused no changes in 
levels of any of the thyroid hormones.  OctaBDE induced a dose-related reduction in serum T4 levels with 
statistically significant (p<0.05) decreases occurring at ≥10 mg/kg/day and a 70% maximum decrease 
compared to controls at the highest dose of 100 mg/kg/day.  Serum total T3 levels were significantly 
reduced at ≥60 mg/kg/day with a maximum reduction of 25% at 100 mg/kg/day.  PentaBDE caused dose-
related reductions in serum T4 levels with significant decreases occurring at ≥30 mg/kg/day and an 80% 
maximum decrease compared to controls at the highest dose of 300 mg/kg/day.  Serum total T3 levels 
were significantly reduced at ≥100 mg/kg/day with a maximum reduction of 30% at 300 mg/kg/day.  
Neither octaBDE nor pentaBDE caused exposure-related changes in serum TSH concentrations.  
Benchmark dose (BMD) analysis of the octaBDE data found that the BMD and BMDL (95% lower 
confidence limit on the BMD) resulting in a 20% reduction in thyroid hormones (LED20) were 9.25 and 
5.29 mg/kg/day, respectively, for serum T4 and 53.38 and 11.98 mg/kg/day, respectively, for serum T3.  
For pentaBDE, the respective BMD and BMDL resulting in 20% reduced hormone levels were 12.74 and 
6.95 mg/kg/day for serum T4 and 32.94 and 8.56 mg/kg/day for serum T3. 
 
Serum levels of thyroid hormones were not evaluated in any other study of octaBDE.  Thyroid 
hyperplasia was equivocally increased in male CD rats that were exposed to 90 mg/kg/day of octaBDE 
(unspecified mixture) in the diet for 28 days (IRDC 1976); incidences of slight or moderate hyperplasia 
were 0/5, 0/5, and 3/5 at 0, 9, and 90 mg/kg/day, respectively.  CD rats that were exposed to octaBDE in 
estimated dietary doses of 5, 50, or 600 mg/kg/day (males) or 7, 70, or 750 mg/kg/day (females) for 
13 weeks had increased absolute and relative thyroid weights at ≥50/70 mg/kg/day (IRDC 1977).  The 
thyroid weight increases were still observed at 8 weeks postexposure in the 600/750 mg/kg/day groups 
and were concluded to be likely compound-related.  Most of the follicles in the thyroids of 4/35 males at 
600 mg/kg/day and 1/35 females at 750 mg/kg/day had epithelium that was tall columnar rather than the 
normal cuboidal type.  This effect was considered to be a very slight but probably compound-related 
histological change.  The thyroid glands were considered within the range of normal morphology at 
8 weeks postexposure in the 600/750 mg/kg/day rats as well as in the lower dose groups (IRDC 1977).   
 
The 4-day study in weanling rats summarized above (Zhou et al. 2001) is not the only study of the 
commercial pentaBDE mixture DE-71 that found reduced thyroid hormone levels in maternally-exposed 
rats and their offspring (Zhou et al. 2002).  Long-Evans rats were administered 1, 10, or 30 mg/kg/day of 
pentaBDE (DE-71) in corn oil by gavage from GD 6 through PND 21.  Total concentrations of serum T4 
and T3 were evaluated in dams on GD 20 and PND 22 and offspring were evaluated on GD 20 and PNDs 
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4, 14, 36, and 90.  Serum T4 was significantly (p<0.05) reduced compared to controls in dams at 
30 mg/kg/day on GD 20 and PND 22 (48 and 44% reduced, respectively), and in offspring at 
≥10 mg/kg/day on GD 20 (≥15% reduced) and PNDs 4 and 14 (50 and 64% reduced at 10 and 
30 mg/kg/day, respectively).  The effect on serum T4 concentrations in the offspring returned to control 
levels by PND 36.  The NOAEL for the effect on serum T4 levels (1 mg/kg/day) was used as the basis for 
the acute-duration MRL for oral exposure to tetra- to heptaBDEs as indicated in the footnote to Table 5-3 
and discussed in Chapter 4 and Appendix A.  The BMD and BMDL resulting in a 20% reduction in 
serum T4 levels were reported to be 2.36 and 0.94 mg/kg/day, respectively.  There were no exposure-
related changes in serum T3 levels in the dams or offspring, or any significant effects of treatment on litter 
size, sex ratio, or nonneurodevelopmental measures of offspring viability and growth as discussed in 
Section 5.2.2.6 (Developmental Effects).   
 
Reduced serum T4 levels additionally occurred in adult offspring of rats that were exposed to commercial 
pentaBDE mixture DE-71 during gestation and lactation in two studies incompletely reported as abstracts 
(Taylor et al. 2002, 2003).  In one study, rats were orally dosed with 0, 1, 10, or 30 mg/kg/day of DE-71 
in corn oil from GD 6 through PND 21 (Taylor et al. 2002).  Evaluation of the offspring at various ages 
(not specified) showed effects that included reduced serum T4 levels; specific data were not reported, 
although the BMD and BMDL for reduced T4 were 2.3 and 0.9 mg/kg/day, respectively.  In the other 
study, rats were similarly administered 1-100 mg/kg/day of DE-71 on GD 6 to PND 21 (Taylor et al. 
2003).  Measurement of serum levels of thyroid hormones in offspring showed dose-related decreases in 
T4 at 5, 30, and 100 mg/kg/day on PND 5 (73.3, 49.3, and 43.5% of controls) and PND 14 (75.6, 33.6, 
and 29.9% of controls).  The serum T4 decreases in both studies were accompanied by increases in 
hepatic metabolism (EROD, PROD, UDPGT, and glucuronidation).  Other effects included neuro-
behavioral and reproductive developmental changes as summarized in Sections 5.2.2.4 (Neurological 
Effects) and 5.2.2.5 (Reproductive Effects). 
 
Commercial pentaBDE mixture DE-71 was tested under EPA’s Endocrine Disruptor Screening Program 
(EDSP) using male and female rat pubertal protocols for detecting thyroid active agents (Laws et al. 
2003; Stoker et al. 2003).  These studies are incompletely reported as abstracts.  End points in both 
studies included pubertal development (time to preputial separation in males and vaginal opening in 
females), body and reproductive tissue weights, thyroid function (serum levels of T4, T3, and TSH), and 
liver microsomal enzyme induction (EROD, PROD, and UDPGT activity).  Both sexes showed delays in 
reproductive development that were accompanied by changes in thyroid hormone levels and hepatic 
metabolism.  In the study with males, Wistar rats were gavaged with 0, 3, 30, or 60 mg/kg/day doses in 
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corn oil for 5 days on PNDs 24–28, or for 31 days on PNDs 23–53 (Stoker et al. 2003).  Pubertal 
development was delayed as shown by significant increases in the age of preputial separation at 30 and 
60 mg/kg/day (2.0- and 2.3-day delay, respectively).  Seminal vesical and ventral prostate weights were 
reduced at 60 mg/kg/day with no significant changes in testis or epididymal weights or serum testosterone 
levels.  Thyroid hormone measurements showed reductions in serum T4 at 30 and 60 mg/kg/day (74 and 
81% lower than controls) after 5 days of exposure, serum T4 at 3, 30, and 60 mg/kg/day (20, 80, and 86% 
lower) after 31 days, and serum T3 at 30 and 60 mg/kg/day (25 and 20% lower) after 31 days, and 
increased serum TSH at 30 and 60 mg/kg/day (64 and 113% higher than controls) after 31 days.  Hepatic 
effects included increased relative liver weight and microsomal EROD, PROD, and UDPGT activity at 
30 and 60 mg/kg/day at both time points.  In the study with females, Wistar rats were gavaged with DE-
71 in corn oil in doses of 0, 3, 30, or 60 mg/kg/day for 5 days on PNDs 22–26, or for 20 days on 
PNDs 22–41 (Laws et al. 2003).  The 60 mg/kg/day dose caused a small but statistically significant delay 
in the age of vaginal opening (1.8-day delay compared to controls).  Other effects included a significant 
decrease in serum T4 at ≥30 mg/kg/day at both time points, a linear trend for increased TSH (1.6-fold 
increase at 60 mg/kg/day) after 20 days of exposure, and increased relative liver weight and microsomal 
EROD, PROD, and UDPGT activity at ≥30 mg/kg/day after at both time points.  The results of both 
studies indicate that the changes in thyroid hormone levels were related to induction of liver metabolic 
enzymes.   
 
End points assessed in a comprehensive 90-day feeding study of a commercial pentaBDE (DE-71) 
mixture in male and female Sprague-Dawley rats included serum T3 and T4 levels (TSH not measured) 
and thyroid histology (WIL Research Laboratories 1984).  Effects observed in both sexes included 
significantly reduced plasma T4 levels at ≥10 mg/kg/day and increased follicular cell hyperplasia at 
100 mg/kg/day.  Incidences of follicular cell hyperplasia in the 0, 2, 10, and 100 mg/kg/day dose groups 
of this study were 0/10, 2/10, 2/10, and 5/10 in males and 0/10, 0/10, 1/10, and 4/10 in females.  The 
thyroid hyperplasia was mild and transient as it was characterized as very slight in severity at all doses 
and was no longer observed at 24 weeks postexposure in any animals.  Thyroid hyperplasia was 
equivocally increased in male CD rats that were exposed to 90 mg/kg/day of pentaBDE (unspecified 
mixture) in the diet for 28 days (IRDC 1976).  Incidences of slight or moderate hyperplasia in the 0, 9, or 
90 mg/kg/day dose groups of this study were 0/5, 1/5, and 3/5 males, respectively; no increases were seen 
in females. 
 
Serum total T4 concentrations were significantly reduced in female C57BL/6J mice that were given a 
single gavage dose of commercial pentaBDE mixture DE-71 as low as 0.8 mg/kg (lowest tested dose) 
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(Fowles et al. 1994).  Reductions in serum T4 were found in four of five dose groups (i.e., 0.8, 4, 20, and 
500 mg/kg, but not 100 mg/kg), but did not occur in a dose-dependent manner.  This lack of dose-
dependency might be explained by the number of animals per group, which was relatively small (n=6).  
Another single-dose gavage study, this time in rats (Hakk et al. 2002), reported transient increases in total 
T4 plasma levels, but the small (n=3) number of animals per group and the lack of reported tests of 
statistical significance make the interpretation of the findings unclear.  Evaluation of mice exposed to 18, 
36, or 72 mg/kg/day of pentaBDE by daily gavage for 14 days showed significantly reduced total and free 
T4 levels at ≥18 mg/kg/day (Fowles et al. 1994).  Serum T3 and TSH levels and thyroid histology were not 
evaluated in these single-dose and 14-day mouse studies.  Serum levels of total and free T4 were also 
reduced in female Sprague-Dawley rats and female B6C3F1 mice that were exposed to ≥18 mg/kg/day of 
the commercial pentaBDE mixtures Bromkal 70 or Bromkal 70-5 DE, or the congener 2,2',4,4'-tetraBDE 
(BDE 47), by daily gavage for 14 days (Darnerud and Sinjari 1996; Hallgren and Darnerud 1998; 
Hallgren et al. 1998, 2001).  Exposure to the mixtures or congener did not cause decreases in serum T4 at 
doses ≤6 mg/kg/day, or any changes in serum TSH or thyroid histology at any tested level 
(≤36 mg/kg/day) in either species.  The decreases in serum T4 were associated with reduced ex vivo 
binding of T4 to the plasma thyroid hormone transporter protein transthyretin, as well as with induction of 
hepatic microsomal enzymes (EROD, MROD, PROD, and UDPGT) (Hallgren and Darnerud 1998).  A 
limited amount of information is available on hormonal effects of PBDEs other than thyroid.  There were 
no clear chemical-related changes in serum corticosterone levels in female mice that were exposed to a 
commercial pentaBDE mixture (DE-71) in doses of 18, 36, or 72 mg/kg/day by daily gavage for 14 days 
(Fowles et al. 1994).  As reported in a study abstract (Kuriyama and Chahoud 2003), serum levels of 
testosterone and LH were unchanged in adult male offspring of Wistar rats that were maternally exposed 
to a single 60 or 300 µg/kg oral dose of the penta congener BDE 99 on day 6 of gestation.  Although there 
were no effects on these male reproductive hormones, spermatid and sperm numbers were reduced as 
summarized in Section 5.2.2.6 Developmental Effects.   
 
Dermal Effects.     
 
Polybrominated Biphenyls.  Limited human data from an epidemiological study provide suggestive 
evidence that oral exposure to PBBs may produce skin disorders in humans, but do not provide 
information regarding dose-response relationships.  Symptoms of skin disorders (rashes, acne, increased 
sensitivity to the sun, darkening or thickening of the skin, discoloration or deformity of fingernails or 
toenails, slow healing of cuts) were reported with greater frequency in a group of 406 Michigan residents 
probably exposed to PBBs than in a group of 153 likely unexposed residents, but no association was 
evident between serum PBB levels and prevalence of skin disorders (Anderson et al. 1978c).  In a medical 
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history survey study conducted in 1976, symptoms of skin disorders (peeling and scaling, erythema, hair 
loss, increased nail growth, increased sweating) experienced during the previous 3 years were reported at 
higher prevalence rates in a group of 321 Michigan residents from quarantined farms and in a group of 
177 nonquarantined farm residents than in a group of 149 nonexposed Wisconsin residents (Chanda et al. 
1982).  Physical examination of the combined group of Michigan residents revealed alopecia in 4% of the 
subjects compared to no occurrence of alopecia in the control group. 
 
In animals, repeated exposures to PBBs produced characteristic dermal changes in certain species, 
particularly monkeys, but generally not in haired rodents.  No exposure-related histological changes were 
observed in the skin, salivary glands, or eyes of rats administered a single dose of 200 mg/kg FireMaster 
FF-1 and observed for 18–22 months (Kimbrough et al. 1981).  Rats and mice exposed to ≤30 mg/kg/day 
FireMaster FF-1 for 2 weeks showed no histological alterations in pinnae, ear canals, or salivary glands, 
but examination of skin was not performed (Gupta et al. 1981).  In intermediate- and chronic-duration 
studies, rats and/or mice exposed to FireMaster FF-1 or FireMaster BP-6 dosages of ≤30 mg/kg/day by 
gavage for 30 days (Gupta et al. 1981), ≤10 mg/kg/day in the diet for 30 days (Akoso et al. 1982a), 
≤10 mg/kg/day by gavage for 25 weeks (NTP 1983), or ≤3.9 mg/kg/day in the diet for up to 105 weeks 
(Chhabra et al. 1993; NTP 1992) showed no histopathological changes in skin, pinnae, ear canals, or 
salivary glands.  Xerophthalmia (extreme dryness of the conjunctiva, with keratinization of epithelium 
following chronic conjunctivitis) was observed in rats after 82 days of dietary exposure to 5 mg/kg/day 
FireMaster BP-6 (Darjono et al. 1983).  Alopecia, loss of eyelashes, generalized subcutaneous edema, dry 
scaly skin, and periorbital edema developed in monkeys exposed to FireMaster FF-1 in dosages of 
≥0.73 mg/kg/day for ≥25 weeks (two animals) or 18 mg/kg/day for 137 days (one animal) (Allen et al. 
1978; Lambrecht et al. 1978).  Histological examination, performed only in the monkey exposed to 
18 mg/kg/day, showed atrophy and squamous metaplasia of sebaceous glands and keratinization of hair 
follicles (Allen et al. 1978).  Dermatosis on the ventral surface was a clinical sign in two of four swine 
administered 8 mg/kg/day FireMaster FF-1 for 16 weeks (Ku et al. 1978).  No additional information was 
reported on the dermatosis (a nonspecific term used to denote any cutaneous lesion or group of lesions), 
and histologic examinations were not completed. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding dermal effects in humans after oral 
exposure to PBDEs. 
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Histopathological examinations showed no dermal changes in rats following dietary exposure to 
≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977) or ≤100 mg/kg/day of pentaBDE for 90 days 
(WIL Research Laboratories 1984).   
 
Ocular Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding ocular effects in humans after oral 
exposure to PBBs. 
 
Occasional eye discharge was observed in pregnant cows that were administered 67 mg/kg/day of 
FireMaster BP-6 in capsules for up to 60 days (Moorhead et al. 1977).  Necropsy following sacrifice 
between days 33 and 66 because of impending death due to poor health showed hyperkeratosis of the 
eyelids and squamous metaplasia with keratin cysts in the tarsal glands in five of six animals.  No ocular 
effects were observed in other cows treated with ≤0.65 mg/kg/day and examined 1 or 140 days following 
the end of treatment.  Histological changes were not observed in the eyes of rats exposed to FireMaster 
FF-1 for 2 weeks (Gupta et al. 1981), or in rats and mice treated by gavage (NTP 1983) or fed FireMaster 
FF-1 for up to 105 weeks (Chhabra et al. 1993; NTP 1992). 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding ocular effects in humans after oral 
exposure to PBDEs. 
 
Histopathological examinations showed no ocular effects in rats following dietary exposure to 
≤1.0 mg/kg/day of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8% octaDBE) for 2 years (Kociba 
et al. 1975; Norris et al. 1975b), ≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977), or 
≤100 mg/kg/day of pentaBDE for 90 days (WIL Research Laboratories 1984). 
 
Body Weight Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding body weight effects in humans after oral 
exposure to PBBs. 
 
Reduced body weight was observed in various species following acute oral administration of relatively 
high doses of PBBs; this effect is most evident with repeated exposure.  In general, decreases in food and 
water intake are not sufficient to account for decreases in body weight.  Effects on body weight can be 
quite pronounced following intermediate- and chronic-duration exposure, constituting a wasting 
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syndrome manifested by weight loss and depletion of body fat.  In acute-duration studies with rats, a 
single 1,000 mg/kg dose of FireMaster FF-1 caused decreased weight gain during the following 2 years 
(Kimbrough et al. 1981), and a single 800 mg/kg dose of FireMaster BP-6 during pregnancy caused 
maternal weight loss (Beaudoin 1977).  Single FireMaster doses of 400 (BP-6) or 500 (FF-1) mg/kg/day 
did not affect body weight in rats (Beaudoin 1977; Kimbrough et al. 1980).  Administration of 
1,000 mg/kg/day FireMaster FF-1 or 130 mg/kg/day FireMaster BP-6 for 2 weeks produced decreased 
weight gain or weight loss in rats and mice, respectively (Corbett et al. 1978; Fraker 1980; Fraker and 
Aust 1978; Gupta and Moore 1979), but 5 mg/kg/day FireMaster BP-6 for 10 days had no effect on body 
weight in rats (Raber and Carter 1986).  A single ≤2,000 mg/kg dose or two daily 3,000 mg/kg doses of 
octabromobiphenyl mixture had no effect on body weight gain in rats observed for the following 14–
28 days (Lee et al. 1975a; Norris et al. 1975a).  No changes in body weight were produced in rats exposed 
to ≤71 mg/kg/day octabromobiphenyl mixture for 2 weeks (Lee et al. 1975b; Waritz et al. 1977).  In 
intermediate-duration studies, decreased body weight gain and/or weight loss has been observed in rats at 
dosages as low as 3 mg/kg/day FireMaster FF-1 for 6 months (Luster et al. 1980; NTP 1983), 
5 mg/kg/day FireMaster BP-6 for 1–3 months (McCormack et al. 1978; Sleight et al. 1978), and 30–
50 mg/kg/day FireMaster FF-1 for 4.5–5 weeks (Gupta and Moore 1979; Sleight and Sanger 1976).  
FireMaster FF-1 dosages ≥100 mg/kg/day for 4.5 weeks (lethal doses) caused weight loss and emaciation 
in rats (Gupta and Moore 1979).  Final body weights were decreased ≥11–28% in rats exposed to 0.5 or 
1.5 mg/kg/day FireMaster FF-1 for up to 104 weeks (NTP 1992).  No body weight changes were 
observed in rats fed a decabromobiphenyl mixture at dosages as high as 100 mg/kg/day for 13 weeks 
(Millischer et al. 1980). 
 
In mice exposed to FireMaster FF-1, estimated dosages of 10 mg/kg/day for 25 weeks (NTP 1992) and 
21.7 mg/kg/day for 6 weeks (Loose et al. 1981) decreased the rate of weight gain.  Chronic exposure to 
≤3.9 mg/kg/day FireMaster FF-1 for up to 105 weeks, however, did not produce adverse effects on mouse 
body weight (NTP 1992).  Guinea pig, mink, and monkey seem to be particularly sensitive species, as 
indicated by pronounced weight loss in guinea pigs from ingestion of 4 mg/kg/day of unspecified PBBs 
for 30 days (Sleight and Sanger 1976), decreased weight gain in mink at FireMaster FF-1 dosages as low 
as 0.39 mg/kg/day with weight loss at 1.86 mg/kg/day (Aulerich and Ringer 1979; Ringer et al. 1981), 
and weight loss in monkeys at FireMaster FF-1 dosages as low as 0.73 mg/kg/day for 25–50 weeks (Allen 
et al. 1978; Lambrecht et al. 1978).  Monkeys that ingested an estimated FireMaster FF-1 dosage of 
0.012 mg/kg/day for 66 weeks lost weight (Lambrecht et al. 1978).  Food intake and body weight gain 
were reduced in pregnant cows after 4 and 20 days administration of 67 mg/kg/day FireMaster BP-6 in 
capsules (Moorhead et al. 1977).  This dosage was lethal because death was impending between days 33 
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and 66 (treatment duration was 60 days).  There were no effects on food intake or body weight in cows 
treated with ≤0.65 mg/kg/day and observed 1 or 140 days following the end of treatment. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding body weight effects in humans 
after oral exposure to PBDEs. 
 
DecaBDE had no effect on body weight gain in rats and mice that were exposed to dietary doses of 
≤16,000 and ≤19,000 mg/kg/day, respectively for 14 days, ≤8,000 and ≤9,500 mg/kg/day, respectively, 
for 13 weeks (NTP 1986), or ≤2,550 and ≤7,780 mg/kg/day, respectively, for 103 weeks (NTP 1986).  
Dietary ingestion of 77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaDBE) similarly 
caused no body weight changes in rats exposed to ≤800 mg/kg/day for 30 days or ≤1.0 mg/kg/day for 
2 years (Kociba et al. 1975; Norris et al. 1973, 1975a, 1975b). 
 
OctaBDE did not affect body weight in rats exposed to dietary doses of ≤90 mg/kg/day for 28 days 
(IRDC 1976), although exposure to ≥600 mg/kg/day for 13 weeks caused ≥12% decreases in weight gain 
(IRDC 1977).  There were no pentaBDE-related body weight changes in rats exposed to ≤90 mg/kg/day 
for 28 days (IRDC 1976) or mice exposed to ≤72 mg/kg/day pentaBDE for 14 days (Fowles et al. 1994), 
although the rate of weight gain was reduced in rats exposed to ≤100 mg/kg/day pentaBDE for 90 days 
(WIL Research Laboratories 1984). 
 
5.2.2.3  Immunological and Lymphoreticular Effects  
 
Polybrominated Biphenyls.  Numerous reports have been published regarding the immunological 
competence of individuals exposed to PBBs in the Michigan feed contamination episode.  Due to the 
relatively high number of published reports and to the fact that often different groups of investigators 
appear to have examined the same cohort, only representative studies are discussed below. 
 
Immunological parameters were compared between a group of 45 adult Michigan dairy farmers and their 
families who were exposed for periods ranging from 3 months to 4 years and two groups of control 
individuals not known to have been exposed to PBBs (Bekesi et al. 1978, 1979).  In 27 of the 
45 Michigan subjects, the peripheral blood lymphocytes responded within a normal range to 
phytohemagglutinin (PHA) and PWM mitogen-induced lymphoblastogenesis, but had reduced reactivity 
in mixed leukocyte cultures relative to controls.  In the remaining 18 Michigan subjects, the response to 
PHA and PWM and the reactivity to mixed leukocyte cultures was significantly reduced (p<0.00001) 
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relative to controls.  Assays for membrane markers of peripheral blood lymphocytes showed significant 
reductions in markers in the Michigan subpopulation with abnormal lymphoblastogenesis.  Both 
Michigan subpopulations had a significant increase in the number of lymphocytes without detectable 
surface markers, relative to controls.  The number of markers for monocytes was not significantly 
different among the groups studied.  There were no significant differences in serum PBB levels between 
the two Michigan subsets.  No consistent correlation could be demonstrated between lymphocyte function 
and PBB plasma concentration. 
 
Reexamination of a group of 40 Michigan farmers 5 years after the first examination (Bekesi et al. 1985; 
Roboz et al. 1985) showed that the number of T-lymphocytes and the lymphocyte response to stimulation 
with PHA were altered to the same extent reported 5 years earlier (Bekesi et al. 1978). 
 
In a similar study, Michigan subjects were classified into three groups according to their serum PBB 
levels: high (>300 ppb), low (<1–11 ppb), and unexposed (controls) (Silva et al. 1979).  The percentage 
of subjects that complained of recurrent infection was similar in the two exposed groups (about 20%).  
The total leukocyte count, percentage of lymphocytes, and percentage of subpopulations of T- and B-
lymphocytes were similar among the three groups.  Mean spontaneous lymphocyte transformation and 
lymphocyte mitogenic responsiveness to stimulation with three different mitogens were not significantly 
different among the three groups.  Furthermore, there was no correlation between a poor mitogenic 
response and low numbers of T-lymphocytes (Silver et al. 1979). 
 
It was also reported at this time that Michigan farm residents with the highest exposure to PBB had 
significantly elevated levels of IgM, IgA, and IgG relative to Wisconsin dairy farm residents (Bekesi et al. 
1985).  Cluster analysis of several immunological parameters performed for husbands and wives showed, 
according to the investigators, significant correlations for surface markers, lymphocyte functions, and IgG 
values (no correlation coefficient was >0.337).  This finding was interpreted as supporting a common 
dietary source for the immune dysfunction rather than a genetic predisposition (Bekesi et al. 1985). 
 
In yet another report, Michigan farmers reported a higher rate of infections (11%) than a group of 
chemical workers exposed to PBB (3%) (Stross et al. 1981), however, average PBB levels in serum, bile, 
and fat were higher in the chemical workers than in the farmers.  When the patients were divided 
according to their PBB fat level into high, moderate, and low, there was an equal distribution of abnormal 
physical, laboratory, and diagnostic findings among the groups. 
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The immunological effects of the commercial PBB mixtures FireMaster FF-1 and FireMaster BP-6 have 
been examined in rats, mice, guinea pigs, dogs, and pigs, but in many cases, the most sensitive 
immunological end points were not examined.  In all but two studies, the animals were exposed for an 
intermediate duration, and many studies administered the PBBs by gavage (exceptions noted below).  
Additionally, most studies were conducted in rats, a species that may be a poor model for investigating 
dioxin-like effects on the adult immune system.  Identification of the most sensitive species is further 
complicated by the fact that not all studies examined the same end points, although limited data suggest 
that guinea pigs may be particularly sensitive.  Immunological effects in animals, attributed to exposure to 
PBBs in utero or through lactation, are discussed in Section 5.2.2.6. 
 
Limited data exist regarding immunological effects of PBBs in animals following acute oral exposure.  
No histopathological alterations were observed in the spleen and thymus of rats treated with a single dose 
of 1,000 mg/kg FireMaster FF-1 and observed for 2 years (Kimbrough et al. 1978b).  A similar lack of 
effects in the thymus, spleen, and lymph nodes was reported in rats and mice treated for 2 weeks with up 
to 30 mg/kg/day FireMaster FF-1 (Gupta et al. 1981).  However, mice treated with ≈130 mg/kg 
FireMaster BP-6 in the diet for 14 days were incapable of mounting an antibody-mediated response 
following immunization with sheep red blood cells (SRBC) (Fraker 1980; Fraker and Aust 1978).  This 
treatment also reduced absolute thymus weight by 88% and caused high lethality in mice. 
 
Numerous intermediate-duration studies have examined the immunological effects of PBBs in rats.  For 
example, treatment of rats with FireMaster FF-1 for 25 weeks significantly increased absolute and relative 
spleen weight at ≥1 mg/kg/day and significantly decreased absolute and relative thymus weight at 
≥0.3 mg/kg/day (NTP 1983).  Nevertheless, no histopathological alterations were observed in these 
organs and in lymph nodes with doses of up to 10 mg/kg/day (NTP 1983).  Similar results were reported 
in rats treated with 30 mg/kg/day FireMaster FF-1 for 4–5 weeks (Gupta and Moore 1979; Gupta et al. 
1981), but a dose of 100 mg/kg/day caused thymic atrophy and necrosis of lymphoblasts (Gupta and 
Moore 1979).  A much smaller dose, 0.5 mg/kg/day FireMaster BP-6 in the diet for 150 days, reportedly 
caused moderate lymphoid depletion in thymus and spleen (Rezabek et al. 1989).  In the only chronic rat 
study, splenic fibrosis developed following exposure to 1.5 mg/kg/day, but not 0.5 mg/kg/day, FireMaster 
FF-1 in the diet for up to 104 weeks (NTP 1992).  Treatment of rats for 5 weeks with 30 mg/kg/day 
FireMaster FF-1 significantly reduced the in vitro lymphocytic response to stimulation with two out of 
three mitogens and thymus and spleen weight (Luster et al. 1978).  Relative thymus weight was reduced 
at 3 mg/kg/day; however, treatment with the test material did not alter the production of antibodies 4 days 
after immunization with SRBC.  The same group of investigators reported significantly decreased 
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lymphoproliferative responses to mitogens or allogenic cells in rats following treatment with 3 mg/kg/day 
FireMaster FF-1 for 6 months (Luster et al. 1980); a dose of 1 mg/kg/day was without effect.  It must be 
mentioned, however, that in the studies conducted by Luster and co-workers, doses ≥3 mg/kg/day 
FireMaster, reduced body weight by ≥15% in the animals, suggesting that PBBs can affect the immune 
system, but only at dose levels that produce overt toxicity. 
 
Mice treated for 30 days with FireMaster BP-6 in the diet at levels of approximately ≥1.3 mg/kg/day had 
a significantly reduced antibody-mediated response to SRBC (p<0.001) (Fraker 1980; Fraker and Aust 
1978).  Absolute thymus weight was significantly reduced (p<0.01) relative to controls with all dose 
levels tested (0.13, 1.3, 13 mg/kg/day).  Delayed-type hypersensitivity was not altered by PBB treatment.  
Corticosterone levels in plasma were elevated in treated mice relative to controls, but not elevated enough 
to be responsible for the immunological findings.  No histopathological effects were observed in the 
thymus, spleen, or lymph nodes of mice treated with 30 mg/kg/day FireMaster BP-6 for 4–5 weeks, but 
relative thymus weight was temporarily decreased (Gupta et al. 1981).  Other studies in mice reported 
increased lethality (p<0.05) after bacterial inoculation in groups treated with 10 mg/kg/day FireMaster 
FF-1 for 6 months (Luster et al. 1980) and increased lethality (p<0.05) due to challenge with Salmonella 
thyphosa lipopolysaccharide after 3 or 6 weeks of dietary exposure to ≈21.7 mg/kg/day FireMaster FF-1 
(Loose et al. 1981).  No histopathological changes were observed in the spleen, thymus, and lymph nodes 
of mice treated with up to 10 mg/kg/day FireMaster FF-1 for 25 weeks (NTP 1983), although 
3.9 mg/kg/day for up to 105 weeks caused increased splenic hematopoiesis (NTP 1992). 
 
Guinea pigs administered 0.4 mg/kg/day FireMaster BP-6 in the diet for 45 days exhibited a significant 
reduction (p<0.01) in tetanus-antitoxin titers following injection of tetanus toxoid (Vos and van Genderen 
1973, 1974).  A dose 5 times higher caused marked thymus atrophy, splenic effects (marked depletion of 
the follicles and periarteriolar lymphocyte sheaths), and lethality.  Pregnant sows fed a diet that provided 
approximately 2.5 mg/kg/day FireMaster BP-6 for a total of 12 weeks (including part of gestation and 
lactation) showed a significantly reduced (p<0.05) lymphocyte response to stimulation with PHA and 
PWM mitogens relative to controls (Howard et al. 1980); a dose of 1.25 mg/kg/day was without effect.  
However, PBB treatment did not affect bactericidal activity of whole blood towards Escherichia coli and 
Staphylococcus aureus. 
 
Two cows gavaged with daily doses of 67 mg/kg/day of an unspecified PBB mixture for 38 consecutive 
days showed minimal alterations in tests of humoral and cell immunity relative to a group of 
54 unexposed animals (Kateley et al. 1982).  The concentration of PBBs in tissues from these two cows 
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reached 1,000 mg/kg, and they became moribund and were later sacrificed.  A similar lack of significant 
immunological effects was reported in the same study for 58 cows from contaminated farms in Michigan 
that had PBB body burdens ranging from 0.02 to 24 mg/kg for at least 2 years (Kateley et al. 1982).  
Cows that received gavage doses of ≤0.65 mg/kg/day FireMaster PB-6 for 60 days showed no 
histopathologic alterations in the thymus or spleen (Moorhead et al. 1977).  However, doses of 67 mg/kg 
induced thymic involution and atrophy, and were nearly lethal. 
 
The highest NOAEL values and all LOAEL values from each reliable study for immunological effects in 
each species and duration category are recorded in Table 5-2 and plotted in Figure 5-2. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding immunological effects in humans 
after oral exposure to PBDEs.  No effects on pokeweed mitogen-stimulated DNA proliferation or IgG 
immunoglobulin synthesis were found in human lymphocytes exposed to 2,2',4,4'-tetraBDE (BDE 47) or 
2,2',3,4,4'-pentaBDE (BDE 85) in vitro (Fernlof et al. 1997). 
 
Limited information is available on effects of acute-duration exposure to pentaBDE on immunologic 
function in animals.  A single gavage dose of 0.8–500 mg/kg of pentaBDE (DE-71) did not effect the 
plaque-forming splenic cell (PFC) antibody response to injected SRBC in mice (Fowles et al. 1994).  
Mice that were given 18, 36, or 72 mg/kg/day doses of pentaBDE (DE-71) by gavage for 14 days had 
significantly reduced antibody response to SRBC (63% of control value, p<0.02) and decreased thymus 
weight at 72 mg/kg/day (Fowles et al. 1994).  There were no exposure-related effects of the 14-day 
exposure to ≤72 mg/kg/day on natural killer cell (NKC) activity to murine YAC-1 target cells; NKC 
activity was not evaluated in the single dose study.  A 14-day study of another pentaBDE mixture 
(Bromkal 70-5 DE) was conducted in which mice and rats were administered 18 or 36 mg/kg/day by 
gavage and were evaluated for spleen and thymus weights, numbers of splenic and thymic lymphocyte 
subsets (CD4+, CD8+, and CD45R+ cells), and in vitro IgG immunoglobulin production in pokeweed 
mitogen-stimulated splenocytes (Darnerud and Thuvander 1998).  The only exposure-related effect in 
either species was significantly reduced in vitro production of IgG in pokeweed-stimulated splenocyte 
cultures from the mice exposed to 36 mg/kg/day.  The effects in both 14-day studies of commercial 
pentaBDE mixtures occurred only at the highest dose and are possibly due to contamination with PBDDs 
and PBDFs.  Mice that were similarly tested with 18 mg/kg/day of the congener 2,2’,4,4’-tetraBDE 
(BDE 47) for 14 days had significantly reduced numbers of total splenocytes as well as CD4+, CD8+, and 
CD45R+ cells in spleen (Darnerud and Thuvander 1998).  This was the only dose level of a single 
congener used in the mice.  Rats were not evaluated. 
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Histopathological examinations of spleen, thymus, lymph node and/or bone marrow tissues showed no 
effects of repeated dietary administration in intermediate-duration studies in rats exposed to 
≤8,000 mg/kg/day decaBDE for 13 weeks (NTP 1986), in mice exposed to ≤9,500 mg/kg/day decaBDE 
for 13 weeks, in rats exposed to ≤750 mg/kg/day octaBDE for 13 weeks (IRDC 1977), or in rats exposed 
to ≤100 mg/kg/day pentaBDE for 90 days (WIL Research Laboratories 1984).  Chronic ingestion of 
decaBDE caused lesions in the spleen of rats exposed to ≥1,200 mg/kg/day (splenic hematopoiesis in 
males) or 2,240 mg/kg/day (splenic fibrosis and lymphoid hyperplasia in females) for 103 weeks (NTP 
1986). 
 
The highest NOAEL values and all LOAEL values from each reliable study for immunological effects in 
each species and duration category are recorded in Table 5-3 and plotted in Figure 5-3. 
 
5.2.2.4  Neurological Effects  
 
Polybrominated Biphenyls.  Neurological symptoms were reported frequently by Michigan residents 
during a 3–4-year period following the 1973 PBB contamination episode, but positive associations 
between serum PBB levels and frequency of neurological symptoms were not found in several studies.  In 
an epidemiological study conducted by the U.S. Center for Disease Control and the Michigan Department 
of Public Health, fatigue was reported more frequently by several putatively exposed groups including 
2,148 residents of farms quarantined for PBB contamination (36.4% prevalence rate), 1,421 recipients of 
food from contaminated farms (32.4%), 252 chemical workers involved in PBB manufacturing or 
distribution (22.0%), and 331 residents of farms with low levels of PBB contamination (41.4%), than by a 
small (60 persons) unexposed control group (15.8%); however, no positive association was apparent 
between serum levels of PBB and prevalence rates for any reported symptom (Landrigan et al. 1979).  
Neurological symptoms, including marked tiredness and decrements in the capacity for intellectual and 
physical work, also were reported with greater frequencies in groups of farmers and residents of Michigan 
likely to have consumed farm products contaminated with PBB, than in groups of unexposed Wisconsin 
farmers; however, serum PBB levels were not positively associated with prevalence rates for any 
symptom including neurological symptoms, nor with performance on neurobehavioral tests for a subset of 
this population (Anderson et al. 1978c, 1979; Valciukas et al. 1978, 1979).  In a 1976 medical history 
questionnaire study of 342 Michigan children likely to have been exposed to PBBs and 72 unexposed 
children from Wisconsin, the number of subjectively reported symptoms of ill health, including several 
symptoms of neurological effects, did not increase with increasing serum PBB levels (assayed in 1976), 
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but rather decreased; general neurological examinations did not reveal a pattern of abnormality among the 
Michigan children (Barr 1980).  Subjectively reported symptoms of neurological effects including 
weakness, fatigue, difficulty in concentrating, and irritability were prevalent in a group of 23 farmers 
involved in the Michigan PBB contamination episode, but tests of intelligence, memory, and nerve 
conduction velocity failed to demonstrate abnormalities.  In addition, a group of 28 workers involved in 
the manufacture or distribution of PBB displayed higher average serum PBB levels than the farmers 
(48 ppb versus 14 ppb), but did not report a prevalence of symptoms of neurological effects (Stross et al. 
1981).  In a study of 21 Michigan residents who consumed PBB-contaminated food and had lingering 
medical complaints and 21 volunteer control subjects with putative low-dose exposure to PBB, no 
positive association was observed between PBB levels in fat tissue and performance in a battery of 
neuropsychological tests (Brown and Nixon 1979).  In general, the findings of the epidemiological and 
clinical studies of people exposed to PBBs in Michigan are inconclusive; they do not clearly demonstrate 
or eliminate the possibility of an association between PBB oral exposure and the occurrence of 
neurological effects. 
 
Limited data indicate that orally (gavage) administered PBBs can produce neurological effects in rats.  
FireMaster FF-1 at 10 mg/kg/day (3 days/week) for 8 weeks did not alter the performance of rats in tests 
of operant behavior, but decreased motor activity, grip strength, and startle responsiveness observed in 
rats following administration of ≤10 mg/kg/day for 6 months or 30 mg/kg/day for 4 weeks (Tilson and 
Cabe 1979).  Motor activity changes were also observed in rats administered doses of FireMaster FF-1 as 
low as 1 mg/kg/day for 4 weeks (Geller et al. 1979).  In this experiment, neither learning nor performance 
of a simple discrimination task was affected by 1, 3, or 6 mg/kg/day dosage levels, but increased motor 
activity was observed at 1 mg/kg/day.  No changes were apparent at 3 mg/kg/day and decreased motor 
activity was apparent at 6 mg/kg/day, compared with controls.  Weakness of the hind limb was noted in 
rats treated with 10 mg/kg/day FireMaster FF-1 for 6 months compared with control rats (Cabe and 
Tilson 1978).  Histological examination of brain and/or spinal nerve tissue found no FireMaster FF-1-
related alterations in rats or mice administered up to 10 mg/kg/day for 25 weeks (NTP 1983) or 
3.9 mg/kg/day for up to 105 weeks (NTP 1992). 
 
Neurodevelopmental effects were assessed in offspring of mice that were treated with 3 or 10 mg/kg/day 
doses of FireMaster (FF-1) in corn oil by gavage on every other day during gestation and until weaning of 
the offspring at 21 days of age (Tilson 1992).  Acoustic startle response, negative geotaxis, motor activity, 
and body weight were measured in 8 pups/sex/dose at 30, 60, and 120 days of age.  Tests for avoidance 
learning and neurochemistry were performed on one pup/sex/dose at 30 days of age and on the remaining 
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animals at 120 days of age.  Reductions in acoustic startle responsiveness and negative geotaxis latency 
were observed at 10 and ≥3 mg/kg/day, respectively, in both sexes at 30 and 60 days of age.  Motor 
activity was decreased in 10 mg/kg/day females at 120 days of age.  The learning tests showed increased 
avoidance response latencies at 30 and 120 days of age in both sexes at ≥3 mg/kg/day, but no effect on 
acquisition or retention.  Neurochemical measurements included serotonin and metabolites, dopamine and 
metabolites, and norepinephrine in the cortex, hippocampus, and striation; the only effect observed was a 
decrease in dopamine concentration in the striation of both males and females at 120 days of age.  
 
Postnatal neurodevelopmental effects were also evaluated in offspring of rats that received 0.2 or 
2 mg/kg/day doses of FireMaster BP-6 dissolved in peanut butter from day 6 of gestation through day 24 
postpartum and observed until postnatal day 60 (Henck et al. 1994).  Multivariate analysis of variance of 
neurodevelopmental end points showed significant PBB-related effects for acquisition of forward 
locomotion, cliff avoidance, cage emergence, and open-field activity in male and female offspring of the 
rats exposed to 2 mg/kg/day.  The most prominent behavioral effects were delays in acquisition of 
forward locomotion and suppressed open-field activity.  Other effects in the offspring included reduced 
crown-rump length and body weight at birth and reduced postnatal body weight as summarized in 
Section 5.2.2.6 (Developmental Effects). 
 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 5-2 and plotted in Figure 5-2. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding neurological effects in humans 
after oral exposure to PBDEs.   
 
A limited amount of information is available on neurological effects of PBDE mixtures in animals.  None 
of the commercial decaBDE, octaBDE, and pentaBDE products have been screened for neurotoxicity 
using comprehensive test batteries that typically include functional observational, motor activity, and 
neuropathology evaluations.   
 
There were no indications of neurotoxicity for commercial decaBDE, as assessed by overt clinical signs 
and nervous system histopathology, in rats and mice in lifetime feeding studies of the 94–97% pure 
mixture (NTP 1986).  These animals were exposed to high dietary levels of the decaBDE product 
(estimated doses as high as 2,550 mg/kg/day in rats and 7,780 mg/kg/day in mice) for 103 weeks.  There 
also were no overt signs of neurotoxicity in rats and mice exposed to decaBDE in estimated dietary doses 
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of ≤16,000 and ≤19,000 mg/kg/day, respectively, for 14 days, or ≤8,000 and ≤9,500 mg/kg/day, 
respectively, for 13 weeks (NTP 1986).  Histological examinations of the nervous system were not 
performed in these 14-day and 13-week studies.  Although the high doses and extended exposure 
durations in the NTP (1986) studies provided opportunities for the induction and/or development of 
effects, neurotoxicity is incompletely evaluated due to the lack of testing for subtle behavioral and other 
sensitive neurological end points.  
 
Three studies, reported in limited detail as abstracts, assessed neurobehavioral development in offspring 
of rats that were perinatally exposed to commercial pentaBDE mixture DE-71 in corn oil by gavage on 
GD 6 through PND 21, in dose ranges of 1–30 mg/kg/day (Taylor et al. 2002), 1–100 mg/kg/day (Taylor 
et al. 2003), or 5–100 mg/kg/day (MacPhail et al. 2003).  Behavioral end points included motor activity 
(MacPhail et al. 2003; Taylor et al. 2002, 2003), auditory startle (Taylor et al. 2002, 2003), and fear 
conditioning (Taylor et al. 2003).  Evaluation of adult offspring showed no alterations in motor or sensory 
development as assessed by overall levels of motor activity, within-session habituation of activity, or 
auditory startle response, although tests of fear conditioning revealed decreases in cue-based (but not 
context-based) performance.  The lack of motor activity changes in the DE-71 mixture-exposed rats 
differs from attenuating effects on habituation of motor activity observed in mice exposed to individual 
PBDE congeners, as summarized below. 
 
Neurobehavioral effects of postnatal or perinatal exposure to individual PBDE congeners have been 
evaluated in a number of mouse studies.  As detailed below, these studies collectively indicate that the 
developing nervous system is a target of particular congeners, as shown by mild performance 
impairments in tests of spontaneous motor behavior and learning and memory in adult mice.  The 
aberrations in spontaneous behavior generally appeared to persist and worsen with age, and were induced 
during a defined critical phase of neonatal brain development. 
 
In a series of congener studies using similar experimental designs, single doses of 2,2',4,4'-tetraBDE 
(BDE 47), 2,2',4,4',5-pentaBDE (BDE 99), 2,2',4,4',5,5’-hexaBDE (BDE 153), or 2,2',3,3’,4,4',5,5’,6,6’-
decaBDE (BDE 209) were postnatally administered to male NMRI mice in a 20% fat emulsion vehicle by 
gavage (Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 2001a, 2001b, 2002a, 2002b, 2003a).  
Evaluations included spontaneous motor behavior at 2, 4, and/or 6 months of age (BDEs 47, 99, 153, and 
209), and Morris swim maze performance at 5 or 6 months of age (BDEs 47, 99, and 153).  The 
spontaneous behavior test measured open-field locomotion (horizontal movements), rearing (vertical 
movements), and total activity (all types of vibrations within a test cage).  The measurements were 
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performed during three consecutive 20-minute periods to assess habituation, defined as a decrease in the 
motor activities in response to diminishing novelty of the test chamber over 60 minutes.  The water maze 
test assessed spatial learning ability and memory by evaluating the ability to locate a submerged platform.  
Cognition was tested by providing visual cues to find and remember the location of a platform submerged 
in a pool of water.  The decrease in time needed to locate the platform over a total of 20 trials in a 4-day 
acquisition period was used as a measure of learning ability.  On day 5, the platform was relocated and 
the decrease in time needed to find the relocated platform over five trials was used to assess relearning 
ability. 
 
In the study with 2,2',3,3’,4,4',5,5’,6,6’-decaBDE (BDE 209), the mice were dosed once with 0, 2.22, or 
20.1 mg/kg on PNDs 3 or 19, or 0, 1.34, 13.4 or 20.1 mg/kg on PND 10, and evaluated for spontaneous 
behavior at 2, 4, and 6 months of age (Viberg et al. 2001b, 2003a).  A non-habituating behavior profile 
was observed in the mice exposed on PND 3, but not in those exposed on PND 10 or 19.  In particular, 
following exposure on PND 3, aberrations in spontaneous motor behavior were manifested at 6 months of 
age in the mice exposed to 2.22 mg/kg, and at 2, 4, and 6 months of age in those exposed to 20.1 mg/kg.  
The aberrations were more pronounced in the older animals, indicating that the effects worsened with age.  
The findings are consistent with tissue distribution data in this study, suggesting that brain uptake of 
14C-BDE 209 was more efficient in the younger animals and that the amount of radioactivity reaching the 
brain increased with time (see Section 5.4.2).  Additional information on the behavioral results of this 
study, including quantitative data, was not reported. 
 
In the study with 2,2',4,4',5,5’-hexaBDE (BDE 153), mice were dosed once with 0, 0.45, 0.9, or 
9.0 mg/kg on PND 10, and evaluated for spontaneous behavior at 2, 4, and 6 months of age, and swim 
maze performance at 6 months of age (Viberg et al. 2001b, 2002a).  Non-habituating behavior occurred in 
mice exposed to 0.45 mg/kg at 6 months of age, and 0.9 and 9.0 mg/kg at 2, 4, and 6 months of age.  The 
effect worsened with age and was most pronounced at 9.0 mg/kg.  The swim maze test found that all mice 
improved their ability to locate the platform during the acquisition period, although those exposed to 
≥0.9 mg/kg had significantly longer latencies to locate the platform on days 2 and 3 during the acquisition 
period.  Additional information on the behavioral results of this study, including quantitative data, was 
not reported. 
 
Mice were also exposed once to 2,2',4,4'-tetraBDE (BDE 47) in doses of 0, 0.7, or 10.5 mg/kg, or 
2,2',4,4',5-pentaBDE (BDE 99) in doses of 0, 0.8, or 12.0 mg/kg, on PND 10 (Eriksson et al. 1998, 
2002b).  Spontaneous behavior was tested at 2 and 4 months of age in all dose groups, and swim maze 
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performance was tested at 5 months of age in the groups given the high dose of each congener.  A 
disruption of habituation was observed in mice exposed to both congeners.  During the first of the three 
consecutive 20-minute test periods, at both 2 and 4 months, animals treated with 10.5 mg/kg BDE 47 and 
≥0.8 mg/kg BDE 99 were significantly less active than controls as shown by dose-related decreases in all 
three activity measures.  During the second period, the activities in all treated groups were comparable to 
controls at 2 and 4 months.  During the third period, exposure to 10.5 mg/kg BDE 47 and ≥0.8 mg/kg 
BDE 99 caused significantly more activity than controls at 2 and 4 months as shown by dose-related 
increases in the test measures.  The investigators noted that this nonhabituating behavior profile (i.e., 
decreased activity early in the test period and increased activity late in the test period) has also been 
reported in adult mice neonatally exposed to certain PCB congeners.  The same non-habituating behavior 
at 2 and 4 months of age (hypoactivity followed by hyperactivity) seen in mice exposed to an 8 mg/kg 
dose of BDE 99 on PND 10 (Viberg et al. 2002b).  The only exposure-related effect in the Morris water 
maze test was found in the mice exposed to BDE 99 at 12.0 mg/kg; performance in finding a new 
platform location did not improve as it did in controls and mice exposed to BDE 47(Eriksson et al. 1998, 
2001a). 
 
Other reports further characterized effects of postnatal exposure to 2,2’,4,4’,5-pentaBDE (BDE 99) on 
spontaneous motor behavior in mice.  In a study designed to ascertain if NMRI male mice are susceptible 
during a critical phase of neonatal brain development (i.e., during the period of rapid brain growth), 
spontaneous behavior was evaluated in adult mice that were administered a single 8 mg/kg dose of BDE 
992 on PNDs 3, 10, or 19 and tested at 4 months of age (Eriksson et al. 1999, 2002b).  A non-habituating 
behavioral pattern similar to that observed in the studies summarized above (i.e., decreased locomotion, 
rearing, and total activity over time in response to diminished novelty of the test chambers) was seen in 
the mice treated at either 3 or 10 days of age.  There were no significant changes in the three spontaneous 
activity measures in the mice exposed at 19 days of age, suggesting that there was a critical window for 
the induction of the behavioral disturbances.  In an assessment of sex and/or strain dependency (i.e., 
whether mice other than NMRI males were affected), male and female C57 Bl/J mice were exposed to 
BDE 99 as a single gavage dose of 0.4, 0.8, 4.0, 8.0, or 16.0 mg/kg on PND 10, and tested at 2, 5, and 
8 months of age (Viberg et al. 2003a).  Spontaneous motor behavior was significantly impaired at 
≥0.8 mg/kg in both sexes at all three ages.  The effect was dose-related and appeared to worsen with age, 
showing a pattern of response similar to that observed for BDE 99 and other congeners in the various 
studies with NMRI male mice.   
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In a study of perinatal exposure to 2,2’,4,4’,5-pentaBDE (BDE 99), groups of two male and two female 
CD-1 Swiss female mice were gavaged with 0, 0.6, 6, or 30 mg/kg/day in corn oil from GD 6 to PND 21 
(Branchi et al. 2001, 2002).  Somatic development (body weight gain, hair growth, day of eyelid and ear 
opening, day of incisor eruption) and neurobehavioral development (righting reflex, forelimb stick 
grasping reflex, forelimb placing reflexes, negative geotaxis, screen grasping and climbing, pole grasping, 
ultrasonic vocalizations, homing test) were assessed during PNDs 2–20.  Spontaneous activity, including 
locomotion (horizontal movement), rearing (vertical movement), and thigmotaxis (time and distance 
traveled close to walls, an index of emotionality), was assessed on PNDs 22, 34, 60, and 120.  There were 
no clear exposure-related indications of prenatal toxicity as shown by maternal weight gain and 
pregnancy and litter indices.  The testing during PNDs 2–22 suggested a delay in sensorimotor 
development at 30 mg/kg/day, as indicated by approximately 2 days delayed maturation in screen 
climbing response.  The spontaneous behavior testing showed changes suggestive of an age-dependent 
alteration in activity at ≥6 mg/kg/day; effects included hyperactivity (increased locomotion and rearing) 
and impaired habituation at PNDs 34 and 60, altered thigmotaxis (reduced time near walls) at PND 60, 
and a tendency to hypoactivity (reduced locomotion) at PND 120.  
 
5.2.2.5  Reproductive Effects  
 
Polybrominated Biphenyls.  Analysis of semen from 41 male residents of Michigan who lived on PBB-
contaminated farms or who had bought food directly from such farms and 11 males who were employed 
in a PBB manufacturing company revealed no abnormalities in the distribution of sperm counts, sperm 
motility, or sperm morphology, compared with an analysis of semen from 52 unexposed men (Rosenman 
et al. 1979).  This study was conducted in 1977, ≈4 years after initial contamination of Michigan's food 
supply, and would not have detected an earlier response that was subsequently reversed.  PBBs were 
detected (detection limit of 0.2 ppb) in the serum of 1 of the 52 unexposed men and in all of the exposed 
men; however, individual or mean values for PBB levels were not reported. 
 
No relationship was found between serum levels of PBBs and frequency and duration of lactation in a 
retrospective study of women exposed to PBBs during the Michigan contamination episode (Thomas et 
al. 2001).  A group of 1,020 women with available initial serum PBB levels was identified from the 
Michigan Department of Community Health PBB registry.  Among these participants, 446 had a live-
born infant after their initial serum PBB level; characteristics of this cohort included mean age of 
25.6±5.0 years, initial serum PBB level of 17.5±99.7 ppb, estimated serum PBB level at delivery of 
9.4±61.9 ppb, estimated serum PCB level at delivery of 5.5±5.2 ppb, duration of breast-feeding as main 
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source of nutrition of 2.6±3.3 months, and total duration of breast feeding of 4.1±5.3 months.  The 
numbers of women who breast fed their first infant after the initial serum PBB level and had previously 
breast-fed were 293 (65.7%) and 49 (11.0%), respectively.  Exposure was treated as a categorical variable 
by dividing the women into groups of low (reference) exposure (≤1 ppb, n=260, serum levels at or below 
the detection limit), moderate exposure (>1–≤7 ppb, n=141), and high exposure (>7 ppb, n=45, levels 
above the 90th percentile).  Three outcomes of interest were analyzed:  (1) the decision to breast feed 
(yes/no), (2) the duration (months) of breast-feeding as the main source of nutrition, and (3) the total 
duration (months) of breast-feeding.  None of the three outcomes was significantly associated with serum 
PBB levels, even after controlling for maternal age, previous history of breast-feeding, body mass index, 
maternal education, household income, history of smoking in the year before pregnancy, consumption of 
alcohol during the first trimester of pregnancy, history of thyroid disorder, gestational age of the infant, 
time to pregnancy, and year of birth.   
 
Effects on reproductive organs and reproductive function have been observed in animals following oral 
exposure to PBBs.  An increased incidence of uterine endometrial polyps was observed in rats, 2 years 
after they were administered a single gavage of 1,000 mg/kg dose FireMaster FF-1 (Kimbrough et al. 
1981).  Following weaning and two consecutive normal menstrual cycles in 6 months, serum 
progesterone was decreased in the same four females that showed this effect prebreeding.  In a multiple-
generation study in which only F0 rats were fed ≥5 mg/kg/day FireMaster BP-6 in the diet from 
GD 8 through postpartum day 28 (weaning), reproductive performance with respect to length of gestation 
or litter size was not affected in the F1 or F2 generations (McCormack et al. 1981).  Implantation was 
completely blocked in two of five and two of three female rats that survived gavage administration of 
28.6 or 57.1 mg/kg/day FireMaster BP-6, respectively, on alternate days between GDs 0 and 
14 (Beaudoin 1979).  Histological examination of reproductive organs in male and female rats and mice 
revealed no abnormalities following gavage treatment with doses up to 10 mg/kg/day FireMaster FF-1 for 
25 weeks or 30 mg/kg/day for 4–5 weeks (Gupta and Moore 1979; Gupta et al. 1981; NTP 1983).  
Necrosis, hyperplasia, and metaplasia in the epithelial lining of the ductus deferens were observed in male 
rats that died following 100 mg/kg/day FireMaster FF-1 for 4–5 weeks (Gupta and Moore 1979).  
Treatment of male and female mink with diets providing up to 0.39 mg/kg/day FireMaster FF-1 for 6–
7 months before breeding did not affect reproductive performance with respect to fertility or litter size 
(Aulerich and Ringer 1979; Ringer et al. 1981).  In the only chronic study, histological examination of 
male and female reproductive organs showed increased cystic endometrial hyperplasia in rats exposed to 
1.5 mg/kg/day FireMaster FF-1 for up to 104 weeks, but no changes were observed in mice exposed to 
≤3.9 mg/kg/day for up to 105 weeks (NTP 1992).  Following 6–7 months of exposure to 0.012 mg/kg/day 
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FireMaster FF-1 in the diet, four of seven female monkeys displayed a lengthening of the menstrual cycle 
from 28 to 31 days and decreased serum progesterone; prior to the treatment, they had at least 2 years of 
normal cycles (Allen et al. 1979; Lambrecht et al. 1978).  All seven of these monkeys conceived after one 
to four matings with control males (controls required one to three breedings), but two displayed prolonged 
implantation bleeding and another two had fetuses that were aborted or stillborn (see Developmental 
Effects).  Reduced spermatogenesis was observed in a male monkey that died after 25 weeks on a diet 
providing 0.73 mg/kg/day FireMaster FF-1 (Allen et al. 1978). 
 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 5-2 and plotted in Figure 5-2. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding reproductive effects in humans 
after oral exposure to PBDEs.   
 
Information on effects of PBDEs on reproductive function is limited to negative findings in a one-
generation study of decaBDE (FR-300 BA) in rats (Dow Chemical Co. 1975; Norris et al. 1975b).  This 
commercial mixture was comprised of 77.4% decaBDE, 21.8% nonaBDE, and 0.8% octaBDE and differs 
from current decaBDE formulations that contain ≥97% decaBDE.  Male and female rats were exposed to 
3, 30, or 100 mg/kg/day doses in the diet for 60 days before mating and subsequently during a 15-day 
period during which they were mated.  Both sexes continued to receive the test diet throughout gestation 
and until the end of the 21-day lactation period.  Parameters monitored included length of time between 
first day of cohabitation and parturition, numbers of live and dead newborn, number of live pups (PNDs 
1, 7, 14, and 21), litter weight (PNDs 1, 7, and 14), and weanling weight (PND 21).  Comprehensive 
histological examinations (adults and weanlings), skeletal examinations (weanlings), and cytogenetic 
evaluation of bone marrow (adults and weanlings) were also performed on PND 21.  There were no 
exposure-related effects on reproductive parameters or any indications of maternal or neonatal toxicity. 
 
No histopathological changes were observed in male or female reproductive tissues from rats that were 
exposed to decaBDE in dietary doses of ≤800 mg/kg/day for 30 days (Norris et al. 1973, 1975b), 
≤8,000 mg/kg/day for 13 weeks (NTP 1986), ≤1.0 mg/kg/day (77.4% containing 21.8% nonaBDE and 
0.8% octaDBE) for 2 years (Kociba et al. 1975; Norris et al. 1975b), or ≤2,550 mg/kg/day for 103 weeks 
(NTP 1986), or in mice exposed to ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day for 103 weeks 
(NTP 1986); octaBDE in doses of ≤750 mg/kg/day for 13 weeks (IRDC 1977); or pentaBDE in doses of 
≤100 mg/kg/day for 90 days (WIL Research Laboratories 1984). 
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Exposure to lower brominated PBDEs has been reported to cause reproductive effects in developing rats.  
As summarized in Section 5.2.2.6 Developmental Effects, postnatal exposure to the commercial 
pentaBDE mixture DE-71 caused delayed onset of puberty in male and female rats (Laws et al. 2003; 
Stoker et al. 2003).  Additionally, testicular and ovarian effects occurred in male and female adult 
offspring of rats that were gestationally exposed the pentaBDE congener BDE 99 (Kuriyama and 
Chahoud 2003; Talsness et al. 2003). 
 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 5-3 and plotted in Figure 5-3. 
 
5.2.2.6  Developmental Effects  
 
Polybrominated Biphenyls.  Examination of children (≈100 were identified) presumably exposed in utero 
or in early infancy during the peak of the Michigan PBB contamination episode and whose families lived 
on farms known to be contaminated with PBBs has not revealed any consistent or marked abnormalities 
in the children's physical and neuropsychological development.  No significant abnormalities were found 
by physical and neurological examination of 33 of these exposed children when they had a mean age of 
37.2 months, compared with a group of 20 age-matched, nonexposed control children (Weil et al. 1981).  
However, subjective interviews with parents suggested that more exposed children than control children 
had frequent upper respiratory illnesses such as colds, runny noses, and sore throats (Weil et al. 1981).  
PBBs were measured in the fat of the infants and in the blood of the mothers.  Fat levels of PBBs in 27 of 
the children ranged from 0.01 to 20.96 ppm; half of the values were below 0.120 ppm, and five of the 
values were above 1.0 ppm.  Maternal blood levels ranged from 0.001 to 0.845 ppm and seven mothers 
had levels that were not detectable (<0.001 ppm).  Seagull (1983) administered 5 of 18 tests in a battery 
of childhood developmental tests (McCarthy Scales of Children's Abilities) to 19 of these exposed 
children when their ages ranged from ≈2.5–4 years old and concluded that there was a statistically 
significant negative correlation for four of the five tests between PBB levels in fat tissue and 
developmental abilities.  Mean fat concentrations of PBBs were 0.50 ppm (range, 0.10–0.74 ppm) and 
4.218 ppm (range, 0.116–20.960 ppm) in the low and high exposure groups of this study.  Schwartz and 
Rae (1983) later administered the full battery of neuropsychological developmental tests, as well as I.Q. 
tests, to the same group of children (minus one child whose family refused to participate in the follow-up 
study) when their ages ranged from approximately 4 to 6 years old.  The exposed children's performances 
were within the normal range in all areas assessed.  There were statistically significant negative 
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correlations between PBB levels in adipose tissue (measured in the earlier study) and performance on 
some of the developmental tasks, but the tasks with significant correlations were not the same as those 
noted in the earlier study by Seagull (1983).  The available studies, primarily due to the small data set and 
the inconsistency of the results, do not conclusively establish or eliminate the possibility that in utero and 
early infancy exposure to PBBs might adversely affect the development of human children.  The 
information suggests that if the Michigan PBB contamination episode produced any effects on child 
development, they were subtle. 
 
A comparison of 1966–1981 fetal mortality rates for Michigan counties with a high percentage of 
quarantined farms (6.8–20.4%) with those of Michigan counties with no quarantined farms did not 
conclusively establish differences in rates or trends after the 1973 contamination episode (Humble and 
Speizer 1984).  This study is difficult to interpret because the exposure status method was imprecise, the 
collected data included only spontaneous abortions occurring after 20 weeks of gestation (early trimester 
abortions were not counted), and the two populations displayed different pre-1973 trends for fetal 
mortality rates. 
 
Results from animal studies indicate that in utero exposure to PBBs and exposure to PBBs through 
mothers' milk can produce embryolethal effects, structural abnormalities, growth retardation, liver effects, 
and neurological effects in offspring.  Developmental toxicity has been observed in studies with 
hexabromobiphenyl and octabromobiphenyl commercial mixtures, but not with commercial 
decabromobiphenyl PBBs.  Rats have been studied most extensively, but data are also available for mice, 
swine, minks, and monkeys. 
 
Following gavage administration of 200 mg/kg FireMaster FF-1 to rats on gestation days 7 and 14, 
decreased pup survival to weaning, decreased body weight throughout the lives of offspring, and 
increased mortality in offspring after 2 years were observed (Groce and Kimbrough 1984).  Single doses 
of 200 mg/kg FireMaster BP-6 administered to rats on one of several days during pregnancy caused 
increased fetal resorptions, and 400 or 800 mg/kg produced maternal toxicity (expressed as a decrease in 
body weight gain) and fetal malformations including cleft palate and diaphragmatic hernia (Beaudoin 
1977).  Increased fetal resorptions also were observed in rats receiving total doses of ≈14.3 mg/kg/day 
FireMaster BP-6 by gavage on alternate days from days 0 through 14 of pregnancy (Beaudoin 1979).  
Body weight gain and levels of vitamin A in the liver were reduced in offspring of rats administered 
5 mg/kg/day FireMaster BP-6 in the diet on gestation day 8 until weaning at 4 weeks postpartum 
(McCormack et al. 1982c).  Additional effects in pups weaned onto the same treated diets as the dams 
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included increased hepatic ALA synthetase activity (the rate-limiting enzyme in porphyrin synthesis) and 
increased urinary excretion of uro- and coproporphyrins at age 16 weeks.  Dietary administration of 
FireMaster BP-6 in dosages of 42.9 mg/kg/day on GDs 7–15 or 50 mg/kg/day on GDs 7–20 produced 
decreased body weight, but no other developmental effects, in rat fetuses and pups monitored up to 
60 days postpartum (Corbett et al. 1975; Harris et al. 1978b).  Increased incidences of fetuses with extra 
ribs were found in rats fed diets providing ≥86 mg/kg/day of octabromobiphenyl mixture from gestation 
days 6 through 15 (Waritz et al. 1977); however, no embryotoxic, fetotoxic, or teratogenic effects 
occurred in rats following gavage administration of ≤1,000 mg/kg/day decabromobiphenyl mixture on 
GDs 6–15 (Millischer et al. 1980). 
 
Effects in offspring of rats exposed to 0.5 mg/kg/day FireMaster FF-1 for 60 days before breeding until 
8 weeks postpartum (4 weeks postweaning) and observed for up to the following 2 years included 
vacuolization and altered foci in the liver (Chhabra et al. 1993; NTP 1992).  Pups of mice that were 
similarly perinatally exposed to 1.5 mg/kg/day FireMaster FF-1 developed liver cytomegaly and altered 
foci (Chhabra et al. 1993; NTP 1992).  As discussed in Section 5.2.2.8 (Carcinogenic Effects), these mice 
also developed hepatocellular adenoma and carcinoma; combined perinatal and adult exposure induced 
higher incidences of liver tumors in mice than adult exposure alone (Chhabra et al. 1993; NTP 1992). 
 
In a multiple-generation study, decreased pup survival to weaning, decreased body weight gain, delayed 
fur development, delayed eye and vaginal opening, and increased liver weight associated with hepatocyte 
swelling, vacuolization, and focal necrosis were observed in F1 generation rats whose only exposure was 
from the mothers fed a diet providing 5 mg/kg/day FireMaster FF-1 from day 8 of pregnancy until 
weaning at 28 days postpartum; less severe liver responses were observed in the F1 offspring of dams 
treated with 0.5 mg/kg/day (McCormack et al. 1981).  Although survival of F2 and F3 generations was not 
affected by the 5 mg/kg/day treatment of the F0 rat dams, F2 offspring, but not F3 offspring, displayed 
increased liver weights, liver enzyme induction, and hepatic histological alterations compared with 
controls (McCormack et al. 1981).  Dietary administration of 2.5 mg/kg/day FireMaster BP-6 to rats from 
gestation day 0 through postpartum day 15 produced increased relative liver weights, decreased body 
weights, and decreased serum levels of the thyroid hormone, T4, in 15-day-old offspring (Meserve et al. 
1992).  The pups had received direct stimulation of the pituitary by an injection of corticotropin-releasing 
factor or direct stimulation of the adrenals by an injection of adrenocorticotropic hormone.  Provision of a 
diet containing 0.5 mg/kg/day FireMaster FF-1 to lactating rats for the 18 days following parturition 
increased liver weights and elevated levels of hepatic cytochrome P-450 and associated enzymic activities 
in both dams and pups; a diet providing 0.05 mg/kg/day produced no hepatic effects in dams, but induced 
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hepatic enzymes in the pups (Moore et al. 1978).  According to the investigators (Moore et al. 1978), the 
results could indicate that nursing pups are more sensitive than their dams to liver enzyme induction, or 
that due to the different kinetic parameters among the PBB congeners, the pups received a more potent 
PBB mixture than the dams.  Yet, a third possibility is that the suckling pups received a higher dose of 
PBBs relative to their body weights due to bioconcentration of PBBs in breast milk (Dent 1978).  
Performance deficits in tests of operant behavior were observed in the 6-month-old offspring of rat dams 
given gavage doses of 0.2 or 2 mg/kg/day FireMaster BP-6 from day 6 of gestation until weaning (Henck 
and Rech 1986), but not in 75-day-old offspring of rat dams given gavage doses of 0.5 or 5 mg/kg/day for 
4 weeks prior to mating (Geller et al. 1985).  Effects found in offspring of rats exposed to 0.2 or 
2 mg/kg/day doses of FireMaster BP-6 in the diet from day 6 of gestation through day 24 postpartum, and 
observed through postnatal day 60, included reduced crown-rump length at birth at ≥0.2 mg/kg/day, 
reduced birth weight and postnatal body weight gain at 2 mg/kg/day, and suppressed acquisition of 
forward locomotion, cliff avoidance, cage emergence, and open-field activity at 2 mg/kg/day (Henck et al. 
1994).   
 
Dietary administration of 50 mg/kg/day FireMaster BP-6 to mice from gestation days 7 through 
18 produced decreased fetal body weight and fetal abnormalities including exencephaly, cleft palate, and 
hydronephrosis; 5 mg/kg/day did not produce significant developmental effects in this study (Corbett et 
al. 1975).  Early postnatal deaths occurred among offspring of mice given 10 mg/kg/day FireMaster FF-1 
on alternate days from gestation day 0 until litters were weaned (Luster et al. 1980).  Immunological 
parameters were unaffected in surviving offspring whose mothers received up to 10 mg/kg/day doses, but 
decreased hematocrit levels were measured in offspring of mothers receiving doses ≥3 mg/kg/day (Luster 
et al. 1980).  Performance deficits in tests of learning behavior were measured in offspring of female mice 
that received gavage doses of 3 or 10 mg/kg/day FireMaster FF-1 on alternate days from gestation 
day 0 through weaning at 21 days of age (Tilson 1992). 
 
Decreased body weight at birth and at 4 weeks after birth were measured in mink kits whose parents were 
fed diets containing 0.155 mg/kg/day FireMaster FF-1 from 7–8 months prior to mating through 4 weeks 
postpartum (Aulerich and Ringer 1979; Ringer et al. 1981).  Increased relative liver weight, fatty and 
necrotic hepatic changes, slight hyperplasia in the thyroid, and decreased serum levels of thyroid T3 and 
T4 hormones were observed in 4-week-old offspring of swine fed 2.5 mg/kg/day FireMaster BP-6 in the 
diet during the second half of gestation and during lactation; 1.25 mg/kg/day produced similar effects on 
the thyroid, but no necrosis in the liver of 4-week-old nursing pigs (Werner and Sleight 1981).  
Examination of several parameters of immune function in 4-week-old offspring of sows fed 
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≤2.5 mg/kg/day FireMaster BP-6 during gestation and lactation provided no conclusive evidence for 
immunosuppressive effects (Howard et al. 1980).  An abortion and a stillbirth occurred among seven 
female monkeys that were fed 0.012 mg/kg/day FireMaster FF-1 in the diet for 7 months prior to 
conception and during pregnancy (Allen et al. 1979; Lambrecht et al. 1978).  The surviving five infants 
had reduced birth weight and postnatal body weight gain, but no gross abnormalities.  The incidence of 
dystocia (difficult birthing) was 50% increased among first- and second-generation offspring of cows 
treated with 0.65 mg/kg/day FireMaster BP-6 by gelatin capsule for 180 or 202 days during late 
pregnancy (Willett et al. 1982).  The same dosage for 60 days caused a 21.6% increased incidence of 
dystocia, but this increase was not statistically significant (p=0.08).  Stillbirths and preweaning deaths 
were not significantly increased, but all mortality was attributable to dystocia.  Incidences of dystocia and 
calf mortality appeared to be related to higher birth weight, which in turn were correlated with 
concentrations of PBBs in maternal blood and tissues.  Growth and development were not affected in the 
surviving calves.  Of six pregnant cows that were similarly treated with a maternolethal dosage 
(67 mg/kg/day) of FireMaster BP-6, three aborted after 30–38 days, and three retained dead fetuses 
(Moorhead et al. 1977). 
 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in 
each species and duration category are recorded in Table 5-2 and plotted in Figure 5-2. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding developmental effects in humans 
after oral exposure to PBDEs.   
 
Information on the developmental toxicity of PBDEs is available from studies of commercial mixtures of 
deca-, octa- and pentaBDE (Argus Research Laboratories 1985b; Breslin et al. 1989; Dow Chemical Co. 
1975, 1985; Hardy et al. 2001, 2002; Life Science Research Israel Ltd. 1987; Norris et al. 1975b; WIL 
Research Laboratories 1986).  None of the commercial BDE mixtures have been shown to be overtly 
teratogenic in animals, although neurobehavioral tests, summarized in Section 5.2.2.4 (Neurological 
Effects), indicate that the developing nervous system is a potential target of some individual lower 
brominated congeners, including 2,2’,4,4’-tetraBDE (BDE 47), 2,2’,4,4’,5-pentaBDE (BDE 99), and 
2,2’,4,4’,5,5’-hexaBDE (BDE 153). 
 
No prenatal developmental toxicity was found in a comprehensive study of  commercial decaBDE 
product (Hardy et al. 2001, 2002).  The test material was a composite of current commercial decaBDE 
mixtures produced by three manufacturers and had a composition of 97.34% decaBDE and 2.66% nona- 
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and octaBDE congeners.  The mixture was administered to groups of 25 mated female Sprague-Dawley 
rats by gavage in corn oil in daily doses of 0, 100, 300, or 1,000 mg/kg/day on GDs 0 through 19.  All 
females were necropsied following sacrifice on GD 20.  Maternal end points included clinical 
observations, body weight and food consumption, gravid uterine and liver weights, gross lesions, and 
uterine implantation indices (e.g., numbers of corpora lutea, implantations, and early and late resorptions).  
Fetal end points included viability, body weights, sex distribution, gross malformations (all fetuses), 
skeletal/cartilaginous malformations and ossification variations (approximately half of each litter), and 
visceral malformations (remaining fetuses).  There were no treatment-related effects on any of the 
maternal or fetal end points, indicating that 1,000 mg/kg/day was a NOAEL for developmental toxicity of 
decaDBE. 
 
A lower purity commercial decaBDE product (77% decaDBE, 22% nonaBDE, 0.8% octaBDE) used in 
the 1970s was fetotoxic in rats at high dose levels that were not maternally toxic.  Developmental effects 
were investigated in rats that were exposed to doses of 10, 100, or 1,000 mg/kg/day by gavage on GDs 6–
15 and examined on GD 21 (Dow Chemical Co. 1985; Norris et al. 1975b).  No treatment-related 
maternal toxicity was observed.  The numbers of fetuses with subcutaneous edema and delayed 
ossification of normally developed skull bones were significantly increased at 1,000 mg/kg/day.  
Resorptions were significantly (p<0.05) increased at ≥10 mg/kg/day compared to controls as indicated by 
resorption/implantation site percentages [1% (3/288), 9% (12/141), 10% (13/135), and 4% (9/203)] and 
percentages of litters with resorptions [12% (3/25), 64% (9/14), 57% (8/14), and 39% (7/18)].  The 
resorptions were considered secondary to unusually low control values and unrelated to treatment because 
(1) the data do not follow a dose-response relationship across the three dose levels, and (2) the rates in the 
high dose group are comparable to historical control values.  As discussed in Section 5.2.2.5 
(Reproductive Effects), a one-generation study of the 77% commercial decaBDE mixture in rats found no 
effects of parental exposure to ≤100 mg/kg/day from 60 days before mating through the end of the 
lactation on numbers of live pups at birth and during the lactation period, body weights of pups at birth or 
weaning, or skeletal development or soft-tissue histology of pups at weaning (Dow Chemical Co. 1975; 
Norris et al. 1975b). 
 
Developmental toxicity testing of another octaBDE mixture (DE-79) in rats used gavage doses of 2.5, 10, 
15, 25, or 50 mg/kg/day on GDs 6–15 (WIL Research Laboratories 1986).  No exposure-related maternal 
or overt developmental effects were observed at ≤15 mg/kg/day.  The only statistically significant 
(p<0.05) finding at 25 mg/kg/day was an increased serum bromide level.  Effects observed at 
50 mg/kg/day included significantly reduced mean maternal body weight gain during the posttreatment 
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period (GDs 16–20) and fetotoxicity as indicated by increased postimplantation loss due to late 
resorptions (not significantly increased compared to control group but exceeded historical control range), 
39% reduced mean fetal weight (p<0.01), skeletal variations (e.g., reduced ossification of the skull and 
various unossified bones) that were associated with the reduced fetal weights in this group, and single 
instances of malformations (fetal anasarca, bent limb bones, unilateral absence of 13th rib) commonly 
associated with maternal toxicity. 
 
The developmental toxicity of a fourth octaBDE commercial mixture (Saytex 111) was tested in rabbits 
exposed to doses of 2, 5, or 15 mg/kg/day on GDs 7–19 and examined on GD 28 (Breslin et al. 1989).  
The 15 mg/kg/day group showed evidence of slight maternal toxicity as indicated by decreased body 
weight gain during GDs 7–20 and 7–28 (not statistically identified), reduced body weight on GD 28 (7% 
less than controls, p≤0.05), and significantly increased absolute and relative liver weights on GD 28.  
Slight fetotoxicity accompanied the maternal toxicity at 15 mg/kg/day as indicated by a significantly 
(p≤0.05) increased incidence of delayed ossification of the sternebrae. 
 
A developmental toxicity study of pentaBDE (Saytex 115) is available in which rats were administered 
10, 100, or 200 mg/kg/day doses by gavage on GDs 6–15 and examined on GD 20 (Argus Research 
Laboratories 1985a).  The only exposure-related maternal effect was significantly (p≤0.01) reduced body 
weight gain at ≥100 mg/kg/day during the dosing period.  This effect was dose-dependent and increased 
in severity with continued dosing but recovered during the postdosage period when differences between 
exposed and control groups were no longer significant.  Maternal body weight gain was 2.8, 20.1, and 
29.9% less than controls during GDs 6–16 at 10, 100, and 200 mg/kg/day, respectively.  There were no 
exposure-related indications of developmental toxicity.  Average fetal body weight per litter was slightly 
but not significantly reduced at 200 mg/kg/day (2.6% less than controls, p>0.05). 
 
Developmental toxicity was also evaluated in rats that were treated with 1, 10, or 30 mg/kg/day of 
pentaBDE (DE-71) in corn oil by gavage from GD 6 through PND 21 (Zhou et al. 2002).  Dams were 
sacrificed on GD 20 and PND 22 and offspring were sacrificed on GD 20 and PNDs 4, 14, 36, and 90.  
There were no exposure-related effects on maternal body weight gain, litter size, sex ratio, or offspring 
viability and growth as assessed by numbers of pups at birth and on PNDs 4–21, body weight of pups on 
PNDs 4–90, and eye opening status on PNDs 11–18.  Serum measurements of thyroid T3 and T4 hormone 
levels showed that serum T4 was significantly reduced in the rat dams at 30 mg/kg/day (GD 20 and 
PND 22) and offspring at ≥10 mg/kg/day (GD 20 and PNDs 4 and 14), as detailed in Endocrine Effects in 
Section 5.2.2.2.  There were no clear effects on pregnancy and birth indices in mice that were gavaged 
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with the congener 2,2’,4,4’,5-pentaBDE (BDE 99) in oral doses of 0.6–30 mg/kg/day from GD 6 to 
PND 21 (Branchi et al. 2001, 2002).   
 
A limited amount of information is available on neurodevelopmental effects of commercial pentaDBE 
mixture DE-71 in mice in two studies incompletely reported as abstracts (Taylor et al. 2002, 2003).  
These studies assessed effects in adult offspring of rats that were orally exposed during gestation and 
lactation (GD 6 to PND 21).  In one study, the maternal rats were dosed with 0, 1, 10, or 30 mg/kg/day 
and offspring were evaluated at various ages (not specified) for end points that included motor activity 
development, auditory startle response, and age at eye opening.  There were no alterations in any of these 
indices.  The second study also found no changes in motor activity, auditory startle response, or eye 
opening in the offspring following exposure to 1–100 mg/kg/day, although fear conditioning performance 
was altered (Taylor et al. 2003).  Other effects of DE-71 in both studies included decreased serum T4 
levels in the offspring and dams (see Section 5.2.2.2 Endocrine Effects). 
 
Delays in reproductive development occurred in male and female Wistar rats that were exposed to the 
pentaBDE commercial mixture DE-71 in studies that are incompletely reported as abstracts (Laws et al. 
2003; Stoker et al. 2003).  Male rats were gavaged with 0, 3, 30, or 60 mg/kg/day doses of DE-71 in corn 
oil for 5 days on PNDs 24–28, or for 31 days on PNDs 23–53 (Stoker et al. 2003).  Pubertal development 
was delayed as indicated by significant increases in the age at preputial separation at 30 and 60 mg/kg/day 
(2.0 and 2.3 days delay, respectively).  Seminal vesical and ventral prostate weights were reduced at 
60 mg/kg/day, although there were no significant changes in testis or epididymal weights or serum 
testosterone levels.  Female rats were gavaged with DE-71 in corn oil in doses of 0, 3, 30, or 
60 mg/kg/day for 5 days on PNDs 22–26, or for 20 days on PNDs 22–41 (Laws et al. 2003).  Pubertal 
development was delayed as indicated by a small but statistically significant delay in the age of vaginal 
opening (1.8 days delay compared to controls) at 60 mg/kg/day.  There were no treatment-related changes 
in weights of female reproductive tissues, and information on levels of female reproductive hormones was 
not reported.  As summarized in Endocrine Effects in Section 5.2.2.2, the delays in male and female 
reproductive development were accompanied by changes in serum levels of thyroid hormones (decreased 
T3 and T4, increased TSH).  The onset of puberty was also delayed in female offspring (vaginal opening), 
but not in male offspring (preputial separation), of Long Evans rats that were subcutaneously exposed to 
1 or 10 mg/kg/day doses of the congener 2,2’,4,4’,5-pentaBDE (BDE 99) on days 10–18 of gestation 
(Lichtensteiger et al. 2003b).   
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Testicular and ovarian effects were observed in male and female adult offspring of Wistar rats that were 
maternally exposed to a single 60 or 300 µg/kg oral dose of the pentaBDE congener BDE 99 in peanut oil 
on day 6 of gestation (Kuriyama and Chahoud 2003; Talsness et al. 2003).  Evaluations of the male 
offspring were performed on PND 140 and included reproductive tissue weights (testis, epididymis, 
ventral prostate, and seminal vesicle), spermatid and sperm numbers, and serum levels of testosterone and 
LH (Kuriyama and Chahoud 2003).  Effects in the male offspring occurred at 60 and 300 µg/kg, including 
significantly decreased (p<0.05) spermatid number (31 and 34% less than controls), sperm number 
(29 and 18% less than controls), and daily sperm production (31 and 34% less than controls).  The female 
offspring were necropsied in estrus on approximately postnatal day 90, at which time, ovaries were 
examined by electron microscopy (Talsness et al. 2003).  Ultrastructural alterations were observed in 
ovaries at both dose levels, particularly degenerative changes that included vacuolization and 
accumulation of vesicules in the cytoplasm of the stromal cells and necrosis in the serosal epithelial cells.  
The single congener dose levels in this study are much lower than the LOAEL of 2 mg/kg/day for liver 
effects in rats exposed to a commercial mixture of pentaBDE in the 90-day study used to derive the 
intermediate oral MRL. 
 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in 
each species and duration category are recorded in Table 5-3 and plotted in Figure 5-3. 
 
5.2.2.7  Cancer  
 
Polybrominated Biphenyls.  No epidemiological studies were located that provided evidence for an 
association between exposure to PBBs and the occurrence of cancer in humans, although one case report 
is available concerning gastrointestinal cancer in a Michigan dairy farmer with known exposure to PBBs 
and other chemicals. 
 
The Michigan Department of Public Health, the U.S. Center for Disease Control, the National Institutes 
of Health, the Food and Drug Administration, and the EPA established a cohort of Michigan residents 
with varying levels of PBB exposure to determine the short- and long-term effects (especially cancer) of 
exposure to PBBs (Landrigan et al. 1979).  The epidemiological and clinical data collected during the first 
4 years after the Michigan PBB contamination episode indicated that cancer was not a prevalent 
"symptom" among the cohort at that time.  Prevalence rates for cancer in exposed groups ranged from 
0.4 to 0.6% compared with 0% in a small control group comprised of residents of farms with low PBB 
contamination (Landrigan et al. 1979).  When the cohort was divided into seven groups based on serum 
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PBB levels, no trend with concentration was apparent, but the incidence of cancer was the highest in the 
group with the highest serum PBB levels.  Subsequent follow-up examinations of this cohort have not 
been reported. 
 
In studies conducted by the Environmental Science Laboratory of the Mount Sinai School of Medicine, 
mean plasma levels of carcinoembryonic antigen (CEA), which has been used as a screening tool for 
tumor recurrence after cancer therapy, were found to be slightly higher in 1976 in a population of 
611 Michigan residents who likely ingested PBB-contaminated food than mean levels in a nonexposed 
population of Wisconsin farm residents, but the difference was not statistically significant (Anderson et 
al. 1978b).  Cancer was not listed as a condition in the report of results of a symptomatology survey 
completed by this cohort (Anderson et al. 1979).  Reports of follow-up examinations of this cohort have 
not been reported. 
 
A relationship between serum PBBs and risk of breast cancer was suggested in a nested case-control 
study of 1,925 women enrolled in the Michigan Department of Public Health registry for persons exposed 
to PBBs (Henderson et al. 1995).  Study participants had lived on or received food from a farm 
quarantined by the Michigan Department of Agriculture, were recruited from July 1976 to December 
1977, and followed up annually from 1978 through 1993.  Twenty women who developed breast cancer 
were age- and race-matched to 290 controls.  Median serum PBB concentrations were similar in the 
cancer cases (3 ppb, range 0.5–16 ppb) and controls (2 ppb, range 0.5–419 ppb).  Conditional logistic 
regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for increasing 
serum PBB levels categorized into tertiles (<2 ppb, 2–3 ppb, ≥4 ppb) and a dichotomous variable (<2 ppb, 
≥2 ppb).  The estimated risk for breast cancer was slightly elevated for women with serum PBB levels of 
2–3 ppb (OR=3.5, 95% CI=0.9–13) and ≥4 ppb (OR=3.1, 95% CI=0.8–12) when compared with the 
reference group (<2 ppb), or when the dichotomous variable was used in the analysis (OR=3.3, 95% 
CI=0.9-11.4).  The results were essentially the same when the data were adjusted for available risk factors 
(body mass index and family history of cancer), or when matched sets of cases and controls were 
stratified into two groups based on date of diagnosis (≥10 years after exposure).  The results of this study 
are inconclusive due to the small number of cases, apparent lack of statistically significant increases 
(p values were not reported, but confidence intervals were broad with lower limits less than unity, 
indicating that it is difficult to exclude chance as an explanation for the findings), and lack of information 
on important breast cancer risk factors (e.g., exposure to other organochlorine chemicals and estrogen 
receptor status).   
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Another study of the Michigan PBB registry evaluated associations between levels of serum PBBs and 
risks of various site-specific cancers (Hoque et al. 1998).  Primary cancers (195 malignancies) were 
identified in 187 persons among 3,899 registrants enrolled in 1976 and followed through 1993.  Controls 
were 696 randomly selected cancer-free individuals who were frequency matched to cases by age (in 
5-year strata) and sex in a 4:1 ratio (except above age 70 years when, due to lower numbers, all eligible 
controls were used).  PBB levels in the cases were measured at the time of registry enrollment.  Serum 
PBB concentration ranges was categorized into four groups (not detectable–3 ppb, 4–20 ppb, 21–50 ppb, 
>50 ppb) defined by the median and the 90th and 95th percentiles.  Conditional logistic regression was 
used to calculate univariate and multivariate (adjusted) ORs by cancer site for the three highest serum 
PBB categories compared to the reference (≤3 ppb) group.  The multivariate ORs were adjusted for 
family history of cancer, smoking status, alcohol use, age, serum PCB level, and sex.  Digestive system 
cancer (12 cases) and lymphoma (not otherwise specified) (8 cases) showed increasing dose-response 
relationships for risk as PBB concentrations increased.  Digestive system cancer was a grouping that 
comprised of the following sites: liver (five cases), stomach (five cases), esophagus (one case) and 
pancreas (one case).  Adjusted ORs for digestive system cancer were 1.00 (reference), 8.23 (95% 
CI=1.27–53.3), 12.3 (0.80–191), and 22.9 (1.34–392) for the ≤3, 4–20, 21–50, and >50 ppb categories, 
respectively.  The corresponding adjusted ORs for PBB level and lymphoma risk were 1.00, 3.85 (0.32–
46.2), 19.6 (1.52–253), and 48.9 (4.09–585).  The lymphoma ORs were incompletely adjusted due to 
missing data for serum PCB level and family cancer history in the reference category.  Increased risks 
were also observed for breast cancer in the 4–20 ppb category (nine cases, adjusted OR=2.41, 95% 
CI=0.92–6.30), cancer at an unknown site in the 4–20 ppb category (four cases, adjusted OR=31.0, 95% 
CI=1.40–685), and leukemia in the 21–50 ppb category (one case, adjusted OR=4.49, 95% CI=0.92–
6.30).  The associations found in this study should be viewed as suggestive and preliminary due to the 
small numbers of cases.  The 2.4-fold increased risk of breast cancer for PBB levels between 4 and 
20 ppb is consistent with the 3-fold increased risk for breast cancer observed for PBB levels >2 ppb in the 
Henderson et al. (1995) study of the same cohort summarized above.  
 
A Michigan dairy farmer, who had a history of health complaints after 1976, developed malignant cancer 
of the esophageal and stomach wall in 1986; the man subsequently died in 1988 (Sherman 1991).  
Samples of adipose tissue, collected in 1976 and 1987, revealed PBB concentrations of 0.83 and 
0.85 ppm, respectively.  Also detected in the fat tissue collected in 1987 were polychlorinated biphenyls 
(PCBs) at 3.57 ppm and chlordane residues at concentrations ranging from 0.018 to 0.039 ppm. 
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FireMaster FF-1 has induced liver tumors and/or neoplastic nodules in rats and mice following single or 
repeated administration by gavage in oil vehicle, as well as following chronic dietary administration.  In 
female Sherman rats given a single 1,000 mg/kg dose and observed for 2 years, incidences of 
hepatocellular carcinomas and liver neoplastic nodules were 41.4% (24/58) and 72.4% (42/58), 
respectively (Kimbrough et al. 1981).  In an earlier study using the same treatment (single 1,000 mg/kg 
dose), groups of five Sherman rats of each sex were examined at 2, 6, 10, and 14 months following 
treatment (Kimbrough et al. 1978b).  Neoplastic nodules were found in the livers of 22.5% (9/40) of the 
treated rats observed for at least 10 months (4/5, 2/5, and 3/5 in the 10-month females, 14-month males, 
and 14-month females, respectively).  Liver tumors were not found, but this could be related to the 
relatively small number of animals (20/sex) and/or short duration of observation (≤14 months).  Liver 
neoplastic nodules without tumors also developed in 31.2% (5/16) of Sherman rats treated with a lower 
single dose (200 mg/kg) and observed for 18–22 months (Kimbrough et al. 1981).  No liver tumors or 
neoplastic nodules developed in untreated control groups in any of these single dose studies, and 
treatment-related tumors in sites other than liver were not observed.  When administered to pregnant rats 
once on gestation day 7, a dose of 200 mg/kg induced both hepatocellular carcinomas and liver neoplastic 
nodules in offspring that were observed for 2 years (Groce and Kimbrough 1984).  The incidences of 
tumors in male offspring (9.6% [4/41] versus 0% [0/42] in controls) and nodules in female offspring 
(17.6% [9/51) versus 4.2% [2/48]) increased significantly (p≤0.055).  Treatment-related tumors were not 
observed in nonhepatic tissues of the offspring. 
 
Hepatocellular carcinomas and liver neoplastic nodules also increased in female Sherman rats gavaged 
with 100 mg/kg FireMaster FF-1 twice a week for two 3-week periods (12 total doses) separated by 
≈10 weeks (Kimbrough et al. 1981).  Following observation for 2 years, the incidence of carcinomas was 
60.7% (17/28 versus 0/25 in controls) and incidence of nodules was 85.7% (24/28 versus 1/25).  In 
repeated dose studies performed by NTP (1983), FireMaster FF-1 was administered via gavage to 
Fischer-344/N rats and B6C3F1 mice of both sexes at dosages of 0, 0.1, 0.3, 1, 3, or 10 mg/kg/day on 
5 consecutive days per week for 25 weeks.  Both rats and mice were observed for life (up to 23 and 
24 months posttreatment, respectively).  Incidences of hepatocellular carcinoma were dose-related and 
significantly (p<0.01) increased in male rats at ≥3 mg/kg/day (0/33 [controls], 2/39, 0/40, 1/33, 7/33, and 
7/31 [high-dose]) and female rats at 10 mg/kg/day (7/20 versus 0/20 in controls).  The incidence of 
cholangiocarcinoma was significantly (p<0.01) increased in female rats at 10 mg/kg/day (7/20 versus 
0/20) and almost significant (p=0.06) in males at 10 mg/kg/day (2/31 versus 0/33).  Liver neoplastic 
nodules were dose-related and significantly (p<0.01) increased in female rats at ≥3 mg/kg/day.  No clear 
treatment-related effects on incidences of hepatic neoplastic nodules in males, or bile duct hyperplasia, 
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myelomonocytic (mononuclear cell) leukemia, or foci of pancreas-like tissue in the liver in either sex 
were observed.  In mice, incidences of hepatocellular carcinoma significantly (p<0.01) increased at 
10 mg/kg/day in males (21/22 versus 12/25 in controls) and females (7/8 versus 0/13).  Metastasis to lung 
also significantly (p<0.05) increased in female mice at 10 mg/kg/day.  No treatment-related effects on 
hepatocellular adenomas or hepatoblastomas were observed.  Thyroid follicular cell adenoma tended to 
increase in treated female mice, but data are inconclusive due to low incidences and small numbers of 
animals.  
 
The carcinogenicity of FireMaster FF-1 was additionally evaluated in Fischer-344/N rats and B6C3F1 
mice of both sexes that received adult exposure only, perinatal exposure only, or combined perinatal and 
adult exposure (NTP 1992).  The adult-only exposure involved dietary administration of PBBs (F1 diets) 
to ≈8-week-old animals for up to 104 weeks (rats) or 105 weeks (mice).  Perinatal-only exposure involved 
dietary treatment of dams (F0 diets) for 60 days prior to breeding and throughout gestation and lactation 
until pups were 8 weeks old.  The pups were administered the same treatment as the dams from weaning 
at week 4 until age 8 weeks, and were subsequently administered the same or different dietary treatments 
(F1 diets) for up to 104 weeks (rats) or 105 weeks (mice).  This study was designed to compare the 
carcinogenicity of PBBs given in a conventional bioassay protocol (i.e., the adult-only exposure) with that 
of PBBs given in a combined perinatal and adult exposure regimen. 
 
Eight F0:F1 doses (estimated) were tested in rats among one unexposed control group (0:0 mg/kg/day), 
two adult-only exposure groups (0:0.5 and 0:1.5 mg/kg/day), one perinatal-only exposure group 
(0.5:0 mg/kg/day), and four combined perinatal and adult exposure groups (0.05:0.15, 0.15:0.5, 0.5:0.5, 
and 0.5:1.5 mg/kg/day) (Chhabra et al. 1993; NTP 1992).  Incidences of hepatocellular tumors were 
increased in adult-only exposed rats of both sexes.  In males ingesting 0:0, 0:0.5, and 0:1.5 mg/kg/day, 
incidences of adenoma were 1 of 50, 10 of 49, and 38 of 50; of carcinoma, 0 of 50, 2 of 49, and 19 of 50; 
and of adenoma or carcinoma (combined), 1 of 50, 12 of 49, and 41 of 50, respectively.  In females, 
incidences of adenoma were 0 of 50, 10 of 50, and 38 of 50; of carcinoma, 0 of 50, 2 of 50, and 4 of 50; 
and of adenoma or carcinoma (combined), 0 of 50, 12 of 50, and 39 of 50, respectively.  These increases 
in liver tumor incidences were statistically significant (p≤0.002) except for carcinoma in 0:0.5 mg/kg/day 
males and females and 0:1.5 mg/kg/day females (p>0.05).  Combined perinatal and adult exposure 
significantly enhanced the development of liver tumors in female rats, as shown by comparisons with 
females receiving adult exposure only.  Compared to the 0:0.5 mg/kg/day female adult-only exposed 
group, incidences of hepatocellular adenoma were 22 of 50 (p=0.01) and 35 of 50 (p<0.001); of 
carcinoma, 1 of 50 (p=0.05) and 8 of 50 (p=0.048); and of hepatocellular adenoma or carcinoma 
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(combined), 22 of 50 (p=0.03) and 39 of 50 (p<0.001) in the 0.15:0.5 and 0.5:0.5 mg/kg/day groups, 
respectively.  Compared to the 0:1.5 mg/kg/day female adult-only exposed group, incidences of 
hepatocellular adenoma, carcinoma, and hepatocellular adenoma or carcinoma (combined) were 45 of 
50 (p=0.049), 22 of 50 (p<0.001), and 47 of 50 (p=0.016), respectively, in the 0.5:1.5 mg/kg/day group.  
This enhancing influence of perinatal exposure did not occur in the males.  Perinatal-only exposure did 
not cause significantly increased incidences of liver or other tumors in rats of either sex. 
 
Increased incidences of mononuclear cell leukemia occurred in adult-only exposed rats but were not 
clearly related to treatment (Chhabra et al. 1993; NTP 1992).  The incidences of this leukemia in the 0:0, 
0:0.5, and 0:1.5 mg/kg/day groups were 25 of 50, 33 of 50, and 31 of 50, respectively, in males and 14 of 
50, 22 of 50, and 23 of 50, respectively, in females; the incidences in the 0:0.5 mg/kg/day males and 
0:1.5 mg/kg/day females were significantly (p≤0.05) increased.  Comparison of the combined perinatal 
and adult exposure groups with the adult-only exposed groups showed no significant enhancement; 
however, comparison with the unexposed control (0:0 mg/kg/day) incidences showed a consistent 
increase in the incidence of this neoplasm at higher doses.  In the 0.15:0.5 and 0.5:0.5 mg/kg/day groups, 
the incidences of leukemia were 41 of 50 (p≤0.01) and 37 of 50 (p≤0.01) in males and 17 of 50 (p>0.05) 
and 27 of 50 (p≤0.01) in females.  In the 0.5:1.5 mg/kg/day groups, the incidences were 37 of 50 (p≤0.01) 
in males and 25 of 50 (p≤0.05) in females.  The incidences in some of these groups fall outside the NTP 
historical control range.  The incidences in males were as high as 82% and exceeded the upper historical 
control range of 62%.  In females, the incidences were as high as 54% and exceeded the overall upper 
historical control range of 52% and the laboratory upper historical control range of 28%.  A combined 
(life table) analysis of data from all eight experimental groups indicates that significant increases in the 
incidence of the leukemia are associated with increasing F1 concentrations (p≤0.05 in males; p≤0.01 in 
females).  For males, there was also a marginally significant (p≤0.05) increase associated with F0 
exposure. 
 
Eight F0:F1 doses were also tested in the mice among one unexposed control group (0:0 mg/kg/day), two 
adult-only exposure groups (0:1.3 and 0:3.9 mg/kg/day), one perinatal-only exposure group 
(3.9:0 mg/kg/day), and four combined perinatal and adult exposure groups (0.39:0.39, 1.3:1.3, 3.9:1.3, 
and 3.9:3.9 mg/kg/day) (NTP 1992).  As in the rats, hepatocellular tumors were significantly (p<0.001) 
increased in adult-only exposed mice of both sexes.  In males ingesting 0:0, 0:1.3, and 0:3.9 mg/kg/day, 
incidences of adenoma were 9 of 50, 48 of 49, and 42 of 50; of carcinoma, 8 of 50, 30 of 49, and 36 of 50; 
and of adenoma or carcinoma (combined), 16 of 50, 48 of 49, and 48 of 50, respectively.  In adult-only 
exposed females, incidences of adenoma were 4 of 50, 39 of 50, and 46 of 48, carcinoma were 1 of 50, 
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28 of 50, and 41 of 48, and adenoma or carcinoma (combined) were 5 of 50, 42 of 50, and 47 of 48, 
respectively.  Combined perinatal and adult exposure resulted in increased incidences of liver neoplasms 
in some treated groups.  However, because adult-only exposure to 1.3 or 3.9 mg/kg/day resulted in such 
high incidences of liver neoplasms (84–98%), the possible enhancing effect of combined perinatal and 
adult exposure could not be adequately assessed in either sex.  Compared to 0:1.3 mg/kg/day adult-only 
exposure, combined perinatal and adult exposure to 3.9:1.3 mg/kg/day caused significantly increased 
incidences of carcinoma in males (40 of 50, p=0.01) and females (44 of 50; p<0.001), adenoma in females 
(47 of 50, p=0.005) and adenoma or carcinoma (combined) in females (50 of 50, p<0.001).  Compared to 
0:3.9 mg/kg/day adult-only exposure, combined perinatal and adult exposure to 3.9:3.9 mg/kg/day caused 
significantly increased adenoma incidence in males (48 of 50; p=0.007) and decreased adenoma incidence 
in females (41 of 47; p=0.022).  Perinatal-only exposure also caused significantly increased incidences of 
liver neoplasms in mice of both sexes.  Comparison of the 0:0 and 3.0:0 mg/kg/day groups showed 
hepatocellular adenoma, carcinoma, and adenoma or carcinoma (combined) incidences of 31 of 
50 (p<0.001), 17 of 50 (p=0.033), and 40 of 50 (p<0.001) in males and 19 of 50 (p<0.001), 7 of 
50 (p=0.213), and 21 of 50 (p<0.001) in females.  Combined perinatal and adult exposure to 
3.9:1.3 mg/kg/day also caused a significant (p=0.029) increase in the incidence of thyroid follicular cell 
adenoma in male mice (5 of 48) compared to adult-only exposure to 0:1.3 mg/kg/day (0 of 49).  This 
incidence of thyroid adenoma exceeds the historical control range of 0–4% in untreated males in NTP 
studies, but the effect was not seen in the higher dose groups (0:3.9 or 3.9:3.9 mg/kg/day).  Perinatal-only 
exposure did not induce thyroid or other nonhepatic tumors in mice of either sex. 
 
The existing evidence conclusively demonstrates that the liver is the main target of PBB carcinogenicity 
in animals.  Results of a chronic study (Chhabra et al. 1993; NTP 1992) suggest that male rats are more 
sensitive than female rats (based on a higher carcinoma/adenoma ratio), and that mice are more sensitive 
than rats (based on earlier occurrence of hepatocellular adenomas, higher combined incidence of all liver 
neoplasms, and higher liver concentrations of PBBs).  Based on findings in male rats and mice of both 
sexes in this study, there is some evidence that combined perinatal and adult dietary exposure to 
FireMaster FF-1 enhanced the susceptibility of hepatocellular neoplasms in animals receiving adult 
exposure. 
 
The Cancer Effect Levels (CELs) for FireMaster FF-1 reported in Kimbrough et al. (1981), Groce and 
Kimbrough (1984), and NTP (1983, 1992) are recorded in Table 5-2 and plotted in Figure 5-2. 
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There are data indicating that FireMaster BP-6 has tumor promoting activity in rats and hamsters.  In 
standardized liver tumor promotion assays, development of enzyme-altered hepatic foci (putative 
preneoplastic lesions) was assessed in rats that were 70% hepatectomized, initiated with a 
subcarcinogenic intraperitoneal dose of diethylnitrosamine 24 hours after the partial hepatectomy, and 
promoted with orally administered FireMaster BP-6 beginning 30 days later.  Various promotion 
protocols caused significantly increased numbers of enzyme-altered hepatic foci with gamma-glutamyl 
transpeptidase (GGT) activity, including two gavage doses of 65 mg/kg on adjacent days (6.5 mg/kg was 
not effective) (Rezabek et al. 1987), estimated dietary dosages of 0.5 or 5 mg/kg for 180 days (Jensen et 
al. 1982), and estimated dietary dosages of 0.5 mg/kg/day for 140 days or 5 mg/kg for 15 days (Jensen et 
al. 1984).  In a similar assay with rats that were not hepatectomized, a single gavage dose of 100 mg/kg 
FireMaster BP-6 administered 7–10 days after initiation with dimethylnitrosamine (NDMA) or N-nitroso-
pyrrolidine (NPYR) promoted development of hepatic enzyme-altered foci (Rangga-Tabbu and Sleight 
1992).  A statistically significant increased number of tracheal papillomas (but not number of animals 
with papillomas) developed in a group of hamsters given a single subcutaneous initiating dose of diethyl-
nitrosamine and fed an estimated dietary dosage of 8.3 mg/kg/day FireMaster BP-6 for 140 days (Wasito 
and Sleight 1989). 
 
Individual PBB congeners have been examined for tumor promoting activity in rats that were partially 
hepatectomized and initiated with diethylnitrosamine (DENA).  Numbers of hepatic GGT-altered foci 
and/or neoplastic nodules were increased following promotion with 3,3',4,4'-tetrabromobiphenyl (BB 77) 
(≈0.25 mg/kg/day in the diet for 180 days or 8 weekly intraperitoneal injections of ≈7 mg/kg), 
2,2',4,4',5,5'-hexabromobiphenyl (BB 153) (≈0.5 mg/kg/day in the diet for 180 days) or 3,3',4,4',5,5'-hexa-
bromobiphenyl (BB 169) (≈0.05 mg/kg/day in the diet for 140 days) (Buchmann et al. 1991; Dixon et al. 
1988; Jensen et al. 1982, 1983).  Dietary exposure to ≈5 mg/kg/day of BB 153 for 480 days similarly 
promoted hepatic development of altered foci and neoplastic nodules in rats, whereas ≈0.05 mg/kg/day of 
BB 169 did not, although an apparent synergistic effect was observed when these two congeners were fed 
together (Jensen and Sleight 1986).  Additional information on structure-promotion relationships for 
PBBs is discussed in Section 5.5.2. 
 
The tumor initiating potential of PBBs is not well characterized.  Numbers of GGT-altered foci were 
significantly increased in partially hepatectomized rats that were administered a single 1–10 mg/kg oral 
dose of 3,3',4,4'-tetrabromobiphenyl (BB 77) followed by phenobarbital in the diet for 180 days (Dixon et 
al. 1988), indicating that PBBs may have initiating activity in hepatocarcinogenesis.  The potential for 
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liver tumor initiation by PBBs appears to be weak compared to their potent promoting activity 
(Buchmann et al. 1991; Dixon et al. 1988; Jensen et al. 1984). 
 
Polybrominated Diphenyl Ethers.  There was no clear association between risk of non-Hodgkin’s 
lymphoma (NHL) and exposure to 2,2'4,4'-tetraBDE in a case-control study of 77 Swedish men and 
women who were recruited in 1995–1997 and ranged in age from 28 to 85 years (Hardell et al. 1998; 
Lindstrom et al. 1998).  Adipose tissue levels of 2,2',4,4'-tetraBDE (BDE 47) (used as a marker for total 
PBDE exposure) were compared in 19 patients with NHL, 23 patients with malignant melanoma, 
8 patients with other cancers or in situ changes, and 27 persons with no cancer diagnosis.  The highest 
concentrations were seen in the patients with NHL.  The mean concentration of BDE 47 was 13.0 ng/g 
(ppb) lipid (range 1.0–98.2 ppb) in the 19 NHL patients and 5.1 ppb (range 0.6–27.5 ppb) in the 
27 persons without known malignancies.  Logistic regression, adjusted for age, gender, sum of PCBs, and 
sum of chlordanes, was performed on cases and controls in three concentration groups (<2.05, 2.05–
<5.43, and ≥5.43 ppb).  A nonsignificantly elevated risk with a suggestive dose-response was found for 
NHL in the two highest concentration groups compared with the lowest group; the ORs and 95% CIs 
were 1.9 (0.3–14) and 3.8 (0.7–26) in the middle and high groups, respectively.  Although the risk was 
highest in the group with the highest concentration of 2,2'4,4'-tetraBDE (p=0.09 for trend), there was no 
significant difference between cases and controls (p=0.14).  The results for patients with malignant 
melanoma did not differ from controls. 
 
Information on carcinogenic effects of PBDEs in animals is limited to results of chronic bioassays of 
decaBDE mixtures in rats and mice (Kociba et al. 1975; Norris et al. 1975b; NTP 1986).  As summarized 
below, these studies provide limited evidence for the carcinogenicity of decaBDE in animals.  No 
carcinogenicity studies of octaBDE or pentaBDE were located in the available literature. 
 
The National Toxicology Program evaluated the carcinogenicity of commercial grade decaBDE (94-97% 
pure, no detected brominated dioxins or furans) in Sprague-Dawley rats (50/sex/dose) and B6C3F1 mice 
(50/sex/dose) that were exposed in the diet for 103 weeks and observed for an additional 0–1 weeks (NTP 
1986).  Comprehensive gross and histological examinations were performed on all animals in all dose 
groups including those that were moribund or died during the study.  Reported estimated dose levels in 
the rats were 1,120 and 2,240 mg/kg/day in males and 1,200 and 2,550 mg/kg/day in females.  Incidences 
of liver neoplastic nodules in low- and high-dose male rats (7/50 and 15/49, respectively) and high-dose 
female rats (9/50) were significantly greater than in controls (1/50 in both males and females) (p≤0.03, 
Fisher Exact test) and showed positive dose-related trends (p<0.001, Cochran-Armitage trend test).  
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Incidences of hepatocellular carcinoma alone (1/50, control males; 1/50, low-dose males; 1/49, high-dose 
males; 0/50, control females; 2/49, low-dose females; and 0/50, high-dose females) were not significantly 
increased in the treated rat groups compared to controls.  The increased incidences of neoplastic nodules 
were considered as “some evidence of carcinogenicity” in both sexes.  However, although it was 
concluded that there was some evidence of carcinogenicity in male and female rats based on “neoplastic 
nodules”, this is a poorly defined and understood term that is no longer used by NTP to characterize 
hepatoproliferative lesions in rats.  A dose-related trend for mononuclear cell leukemia was observed in 
treated male rats but was not considered to be biologically significant because of a high incidence in 
control animals. 
 
Reported estimated doses in the mice were 3,200 and 6,650 mg/kg/day in males and 3,760 and 
7,780 mg/kg/day in females (NTP 1986).  Hepatocellular adenoma or carcinoma (combined) occurred at 
significantly increased incidences in low-dose male mice (22/50, p=0.002) and high-dose male mice 
(18/50, p=0.019) in comparison to controls (8/50) and showed a positive dose-related trend (p=0.021).  
Incidences of hepatocellular carcinoma alone were not significantly increased in either the low- or high-
dose male mice.  Slightly elevated incidences of thyroid gland follicular cell adenoma or carcinoma 
(combined) were additionally observed in exposed male mice but the increases were not statistically 
significant (control, 0/50; low dose, 4/50; high dose, 3/50).  Incidences of follicular cell hyperplasia were 
significantly increased in male mice as summarized in the subsection on Endocrine Effects in 
Section 5.2.2.2.  No significantly increased incidences of neoplastic lesions were observed in the female 
mice.  NTP (1986) concluded that the significant increase in liver tumors and equivocal increase in 
thyroid tumors represented equivocal evidence of carcinogenicity in male mice.  The evidence of 
carcinogenicity in the male mice was considered limited by an early loss of control animals.  Losses of 
control male mice were significant during the first year of the study but were subsequently comparable to 
the dosed mice; the early losses were presumed to be due to fighting among animals in both control and 
treatment groups. 
 
The carcinogenicity of decaBDE was also evaluated in Sprague-Dawley rats (25/sex/dose) that were 
exposed to dietary doses of 0, 0.01, 0.1, or 1.0 mg/kg/day for approximately 2 years (702 days for males, 
735 days for females) (Kociba et al. 1975; Norris et al. 1975b).  The commercial mixture was comprised 
of 77.4% decaBDE, 21.8% nonaBDE, and 0.8% octaBDE and therefore differs from typical decaBDE 
formulations containing ≥97% decaBDE.  Comprehensive histological examinations showed no 
exposure-related neoplastic effects.  The ability of this study to detect carcinogenic changes is limited by 
the very low dose levels in comparison to those tested in the NTP (1986) bioassay. 
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The Cancer Effect Levels (CELs) for decaBDE in the NTP (1986) study are recorded in Table 5-3 and 
plotted in Figure 5-2. 
 
5.2.3  Dermal Exposure  
 
A few studies have examined groups of chemical workers involved in the manufacture and distribution of 
PBBs and/or PBDEs (Bahn et al. 1980; Brown et al. 1981; Chanda et al. 1982; Landrigan et al. 1979; 
Rosenman et al. 1979; Stross et al. 1981).  Although the route of exposure (inhalation relative to dermal) 
of these workers has not been well defined, they appear to have had a high potential for dermal exposure 
(Anderson et al. 1978d).  Results from these studies are discussed in this section, as well as in 
Section 5.2.1.  Dermal exposure may not be an important route of concern for PBDEs because dermal 
absorption is likely to be low, particularly for the highly brominated congeners. 
 
5.2.3.1  Death  
 
Polybrominated Biphenyls.  No reports of death in humans after dermal exposure to PBBs were located 
in the available literature. 
 
No deaths were observed over a 14-day period among a group of four rabbits exposed to up to 
10,000 mg/kg of body weight of a commercial octabromobiphenyl mixture by application to abraded and 
occluded dorsal trunk skin (Waritz et al. 1977).  The bromobiphenyl was applied as a 35% (w/v) paste in 
corn oil.  The same group of investigators reported that four of four rabbits died over a 14-day period after 
application of 5,000 mg/kg of a commercial hexabromobiphenyl mixture in the same vehicle as the 
octabromobiphenyl mixture.  A dose of 10,000 mg/kg applied for 24 hours killed two of four rabbits.  The 
cause of death was not reported.  A commercial mixture of decabromobiphenyl in corn oil was not lethal 
in rats that were observed for 14 days following application of a single dose as high as 5,000 mg/kg to 
covered intact skin (Millischer et al. 1980).  The octabromobiphenyl LOAEL of 5,000 mg/kg is reported 
in Table 5-5.  It is unclear whether the different lethality rates observed among the hexa-, octa-, and 
decabromobiphenyl mixtures reflect differences in lethal potency or in absorption rates or both. 
 
Polybrominated Diphenyl Ethers.  No reports of death in humans after dermal exposure to PBDEs were 
located in the available literature. 
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Gn Pig Dermal M62
mg/kg/day
mg/kg/day
Bd Wt = body weight; d = days; DBB = deca-brominated biphenyl; Derm = dermal; FF-1 = FireMaster FF-1; HBB = hexa-brominated biphenyl; hr = hour(s); M = male; OBB =
octa-brominated biphenyl; wk = week(s); x = time(s)
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No deaths occurred in rabbits that were observed for 14 days following a single ≤2,000 mg/kg dermal 
dose of decaBDE, octaBDE or pentaBDE (IRDC 1974, 1975a, 1975b).  The PBDEs were applied to 
clipped intact skin, covered with an occlusive barrier, and washed from the treatment site 24 hours later.  
 
5.2.3.2  Systemic Effects  
 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, or renal effects in humans or animals after dermal exposure to PBBs. 
 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, or renal effects in humans or animals after dermal exposure to PBDEs. 
 
Systemic effects that have been observed in humans and animals following dermal exposure to PBBs and 
PBDEs are described below.  The highest NOAEL and all LOAEL values from each reliable study for 
systemic end points in each species and duration category are recorded in Tables 5-5 and 5-6. 
 
Hepatic Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding hepatic effects in humans after dermal 
exposure to PBBs. 
 
No significant changes in relative or absolute liver weight or gross pathological effects were reported in 
groups of four rabbits after application of a single dose of up to 10,000 mg/kg of octabromobiphenyl 
mixture in corn oil to abraded and occluded dorsal skin over a 24-hour period (Waritz et al. 1977).  It was 
unclear if histopathological examinations were performed.  Using the same protocol in rabbits, these 
investigators reported a significant increase (p<0.01) in relative and absolute liver weight, distinct lobular 
markings, and necrotic foci with doses ≥1,000 mg/kg of a commercial hexachlorobiphenyl mixture.  A 
dose of 100 mg/kg was without effect.  A significant increase (p<0.01) in relative liver weight was 
reported in rabbits after application of 1 mg/kg/day of a commercial mixture of octabromobiphenyl in 
corn oil to the intact and occluded shaved dorsal skin on 5 days/week for 2 weeks (Waritz et al. 1977).  
Histopathological examinations were not performed.  A relatively low dose (0.0013 mg/kg) of FireMaster 
BP-6 dissolved in benzene/decame (1:9) applied once a day for 5 days to the ear of three rabbits caused 
no histopathological effects in the liver (Hass et al. 1978).   
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No studies were located regarding hepatic effects following intermediate or chronic dermal exposure to 
PBBs. 
 
Endocrine Effects.     
 
Polybrominated Biphenyls.  Hypothyroidism was diagnosed in 4 of 35 men who were occupationally 
exposed to unspecified PBBs and/or decaBDE (Bahn et al. 1980).  The cohort consisted of workers (mean 
age 35.9 years) who had been employed at a production plant for at least 6 weeks during a 52-month 
period during which PBBs and decaBDE were the only chemicals manufactured and who had volunteered 
for a comprehensive medical evaluation performed 3 months after the end of the 52-month period.  There 
was no further description of exposure, and it was assumed to have occurred by both inhalation and 
dermal routes.  As detailed in Section 5.2.1.2, the results of this study suggest that occupational exposure 
to PBBs, decaBDE, and/or bromine affected the thyroid, but the mixed chemical exposure and a lack of 
data on serum or tissue levels of the chemicals preclude attributing effects solely to any particular 
congener or mixture of congeners. 
 
No studies were located regarding endocrine effects in animals after dermal exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  There is suggestive evidence of hypothyroidism in a small group of 
workers who were occupationally exposed to decaBDE as well as PBBs (Bahn et al. 1980) as summarized 
above and detailed in Section 5.2.1.2. 
 
No studies were located regarding endocrine effects in animals after dermal exposure to PBDEs. 
 
Dermal Effects.     
 
Polybrominated Biphenyls.  As discussed in Section 5.2.1.2, results from a medical history survey study 
of workers in a PBB manufacturing plant and a nonexposed group of Wisconsin farm residents indicated 
an association between occupational exposure to PBBs and the occurrence of acne (Chanda et al. 1982).  
The survey covered a period of 3 years of potential exposure, but exposure levels were not reported.  No 
adverse dermal effects were observed on the arms or legs of subjects after a 6-day application of polymer 
fibers containing commercial octabromobiphenyl mixture under an occlusive covering; no additional 
information was reported (Waritz et al. 1977). 
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Several studies examined the acute dermal effects of commercial PBB mixtures in rabbits.  Application of 
0.19 mg/kg FireMaster FF-1 for 5 days, in toluene vehicle, to the inner surface of the left ear of two 
rabbits (right ear served as control) induced moderate hyperkeratosis, which included marked dilation of 
the hair follicles, with moderate proliferation of the epithelium and partial atrophy of the sebaceous 
glands (Needham et al. 1982).  There was also evidence of excess keratin and debris in the subjacent hair 
follicles.  Application of either a dry or water-moistened formulation of octabromobiphenyl mixture 
(amount not reported) for 24 hours did not adversely affect intact skin in rabbits, but slight erythema and 
edema were observed in abraded skin (Norris et al. 1975a).  Repeated applications over a 2-week period 
of the dry octabromobiphenyl mixture formulation (amount not reported) to occluded intact or abraded 
skin caused no skin response, but the water-moistened formulation caused slight and transient erythema 
(Norris et al. 1975a).  None of these studies reported the number of animals used.  Rough skin with mild 
erythema was observed in occluded intact shaved dorsal skin of a group of rabbits after repeated 
applications of a dose of 1 mg/kg/day octabromobiphenyl mixture in corn oil over a 2-week period 
(Waritz et al. 1977).  Application of a commercial decabromobiphenyl mixture in olive oil to covered 
intact or abraded skin for 4 hours, in an amount equivalent to 658 mg/kg, caused very slight erythema 
with or without edema in rabbits (Millischer et al. 1980). 
 
Limited information is available regarding intermediate-duration dermal effects of PBBs in animals.  A 
10% chloroform solution of an unspecified commercial formulation of octabromobiphenyl did not induce 
bromacne when applied to the ear of rabbits for 30 days (Norris et al. 1975a).  Only slight erythema and 
exfoliation was observed.  Doses of 62 mg/kg of octabromobiphenyl mixture were not sensitizing when 
applied to the intact or abraded skin of guinea pigs over a 3-week period (Waritz et al. 1977). 
 
No studies were located regarding dermal effects in animals after chronic application of PBBs. 
 
Polybrominated Diphenyl Ethers.  A human sensitization study was conducted in which 77.4% decaBDE  
(containing 21.8% nonaBDE and 0.8% octaBDE ) as a 5% suspension in petrolatum was applied via 
patch, 3 times a week for 3 weeks, to 50 subjects (Norris et al. 1975a).  No skin sensitization responses 
occurred during the sensitizing period or on challenge 2 weeks following the last application.  No 
additional information was reported regarding the design and results of this study. 
 
There was no evidence of primary irritation in intact skin of rabbits that were dermally exposed to a 
former commercial decaBDE mixture (500 mg as dry solid was applied to clipped skin and occluded for 
24 hours) (IRCD 1974).  A similar application of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8% 
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octaBDE) (dry solid, amount not reported), octaBDE (500 mg as dry solid), or pentaBDE (0.5 mL as a 
viscous liquid) was also non-irritating to intact rabbit skin (IRCD 1975a, 1975b; Norris et al. 1975a).  A 
similar single application of solid 77.4% decaBDE (21.8% nonaBDE and 0.8% octaBDE) to abraded skin 
caused a slight erythematous and edematous response in rabbits, although repeated applications of the 
same decaBDE mixture to intact skin (5 days/week for 2 weeks) or abraded skin (3 days) was non-
irritating to rabbits (Norris et al. 1975a).  All skin sites returned to normal appearance following cessation 
of exposure. (Norris et al. 1975a).   
 
OctaBDE and pentaBDE were non-sensitizing in maximization tests in guinea pigs (Microbiological 
Associates Inc. 1996).  The induction doses consisted of three pairs of interscapular region intradermal 
injections of (1) a 50:50 solution of Freund’s adjuvant and corn oil, (2) 2.5% octaBDE or 5% pentaBDE 
solutions in corn oil, and (3) 2.5% octaBDE or 5% pentaBDE in the 50:50 corn oil/Freund’s adjuvant 
solution.  Control groups received the same regimen without PBDEs.  After 7 days, the PBDE-treated 
animals received topical applications of neat octaBDE or pentaBDE on the previously treated 
interscapular sites.  Two weeks later, the animals were challenged with topical doses of neat octaBDE or 
pentaBDE on the left flank.  Subsequent examination of the test sites at 24, 48, 72, 96, or 120 hours after 
the challenge dose showed no erythema or edema responses in any of the animals, indicating that the 
PBDEs did not cause delayed contact hypersensitivity. 
 
A 10% chloroform solution of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8% octaBDE) did not 
induce bromacne when applied to the ear of rabbits for 30 days (Norris et al. 1975b).  A slight 
erythematous response and slight exfoliation were the only observed effects.  No additional information 
was reported on the design and results of this acnegenesis study.  
 
Ocular Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding ocular effects in animals after dermal 
exposure to PBBs. 
 
Transient irritation of the conjunctival membranes was observed after a single instillation of an 
unreported amount of dry solid octabromobiphenyl mixture to the eye in rabbits, but the cornea, iris, and 
lens were unaffected (Norris et al. 1975a).  Commercial grade decabromobiphenyl did not cause eye 
irritation in rabbits when 0.05 mg in olive oil was instilled for 30 seconds followed by rinsing, but 
application of an unspecified amount of dry powder without rinsing was slightly irritating (Millischer et 
al. 1980).  Mild conjunctival redness and swelling and a copious discharge was reported after application 
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of 100 mg of an unspecified commercial PBB powder mixture (either hexa- or octabromobiphenyl) for 
20 seconds into the conjunctival sac of two rabbits (Waritz et al. 1977).  These effects disappeared within 
4 hours in both washed (with tap water) and unwashed eyes.  The iris and cornea were unaffected. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding ocular effects in animals after 
dermal exposure to PBDEs. 
 
Ocular effects were investigated in rats that had 100 mg decaBDE (solid), 100 mg octaBDE (solid), or 
0.1 mL pentaBDE (viscous liquid) instilled into the conjunctival sac (ICRD 1974, 1975a, 1975b).  The 
eyes were examined for irritation after 24, 48, and 72 hours and 7 days and corneal injury after 72 hours.  
There were no exposure-related effects with decaBDE or octaBDE, although pentaBDE caused slight 
evidence of corneal damage in one of six rats (IRDC 1975b). 
 
Body Weight Effects.     
 
Polybrominated Biphenyls.  No studies were located regarding body weight effects in humans after 
dermal exposure to PBBs. 
 
No treatment-related effects on body weight were reported in rabbits given a dose of 1 mg/kg/day of a 
commercial mixture of octabromobiphenyl in corn oil via application to the intact shaved dorsal skin for 
2 weeks (Waritz et al. 1977).  No significant effect on final body weight was reported in groups of four 
rabbits after application of a single dose of up to 10,000 mg/kg of octabromobiphenyl mixture in corn oil 
to the abraded and occluded dorsal skin over a 24-hour period (Waritz et al. 1977).  The observation 
period was 14 days.  In a similar study with a commercial mixture of hexabromobiphenyl, rabbits treated 
with 1,000 mg/kg showed no weight gain over 14 days.  Doses of 5,000 and 10,000 mg/kg induced an 
11% and 20% weight loss, respectively, whereas, a dose of 100 mg/kg was without effect (Waritz et al. 
1977). 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding body weight effects in humans 
after dermal exposure to PBDEs. 
 
There were no adverse effects on body weight in rabbits that were observed for 14 days following a single 
≤2,000 mg/kg dermal dose of decaBDE, octaBDE, or pentaBDE (IRDC 1974, 1975a, 1975b).  The 
PBDEs were applied to clipped intact skin, covered with an occlusive barrier, and washed from the 
treatment site after 24 hours. 
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5.2.3.3  Immunological and Lymphoreticular Effects  
 
Polybrominated Biphenyls.  Several immunological parameters were evaluated in a group of 28 workers 
from the Michigan Chemical Company who were involved in the manufacturing and distribution of PBBs 
including FireMaster FF-1 (Stross et al. 1981).  It is assumed that the main route of exposure was dermal, 
but inhalation and/or oral exposure cannot be ruled out.  The subjects had worked directly with PBBs 
during the previous 5 years.  Immunological studies included determination of immunoglobulin levels, 
skin testing, and lymphocyte transformation studies.  No abnormalities in lymphocyte number or function 
could be determined when compared to an unexposed group.  One of three blastogenic responses (PWM) 
was significantly reduced (p<0.01) relative to controls, but was within the normal range for the 
laboratory.  No specific information was provided regarding the skin testing and immunoglobulin levels. 
 
No studies were located regarding immunological effects in animals after dermal exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding immunological effects in humans 
or animals after dermal exposure to PBDEs. 
 
5.2.3.4  Neurological Effects  
 
Polybrominated Biphenyls.  Twenty-five workers at a PBB manufacturing plant displayed mean scores 
on tests of memory and learning that were typical for people of their age, educational, occupational, and 
cultural backgrounds, even though they displayed an elevated mean PBB concentration in adipose tissue 
(9.33 ppm compared with 3.94 ppm for farm residents) (Brown et al. 1981).  Workers with the highest 
concentrations of PBB in adipose tissue showed no evidence of memory dysfunction in these tests.  
Because 15/25 "directly handled PBBs or performed maintenance work in the area where PBBs were 
manufactured," it is likely that at least part of the exposure was by the dermal route. 
 
No studies were located regarding neurological effects in animals after dermal exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding neurological effects in humans or 
animals after dermal exposure to PBDEs. 
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5.2.3.5  Reproductive Effects  
 
Polybrominated Biphenyls.  Eleven workers in a PBB manufacturing company in Michigan displayed no 
differences in the distribution of sperm counts, motility, or morphology compared with a control group of 
52 unexposed men (Rosenman et al. 1979).  PBBs were detected in the serum of all exposed subjects and 
in only one unexposed subject, but mean or individual serum PBB values were not reported. 
 
No studies were located regarding reproductive effects in animals after dermal exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding reproductive effects in humans or 
animals after dermal exposure to PBDEs. 
 
5.2.3.6  Developmental Effects  
 
Polybrominated Biphenyls.  No studies were located regarding developmental effects in humans or 
animals after dermal exposure to PBBs. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding developmental effects in humans or 
animals after dermal exposure to PBDEs. 
 
5.2.3.7  Cancer  
 
Polybrominated Biphenyls.  No studies were located regarding cancer in humans after dermal exposure 
to PBBs. 
 
An unspecified PBB mixture (purity not reported) was not tumorigenic when applied to the shaved dorsal 
skin of female CD-1 mice at a dose of 3.3 mg/kg twice weekly for 30 weeks; no tissues other than skin 
were examined (Berry et al. 1978, 1979).  This same treatment did not promote the development of skin 
tumors in mice pretreated with a single application of a tumor initiator, dimethylbenzanthracene 
(DMBA), 1 week prior to PBB exposure (Berry et al. 1978, 1979).  The results of these studies must be 
interpreted with caution, since a dose-response study was not done (i.e., only one dose level was tested, 
and the doses may have been too low).  Toxic doses of FireMaster FF-1 promoted development of skin 
tumors in female HRS/J hairless mice (Poland et al. 1982).  A single dermal application of N-methyl-N'-
nitro-N-nitrosoguanidine (MNNG) initiator, followed by twice weekly applications of FireMaster FF-1 at 
PBBs and PBDEs  237 
 








66.7 mg/kg for 5 weeks and then 33.3 mg/kg for 15 weeks, resulted in a 60% (9/15) incidence of 
papillomas compared to 0% (0/23) in MNNG-only controls.  Toxic effects included mortality, which 
caused the dose reduction after 5 weeks, and severe hepatomegaly and hepatic porphyria. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding cancer in humans or animals after 
dermal exposure to PBDEs. 
 
5.3  GENOTOXICITY  
 
Polybrominated Biphenyls.  No studies were located regarding genotoxic effects in humans following 
inhalation, oral, or dermal exposure to PBBs. 
 
In vivo genotoxicity studies of PBBs in animals are summarized in Table 5-7.  Administration of single 
oral doses between 50 and 1,000 mg of FireMaster FF-1/kg (purity not reported) by gavage in corn oil to 
male and female B6C3F1 mice and male Fischer-344 rats did not induce unscheduled deoxyribonucleic 
acid (DNA) synthesis in hepatocytes (Mirsalis et al. 1985, 1989).  However, doses ≥200 mg/kg 
significantly increased hepatic cell proliferation in mice, but not in rats.  The increase in cell proliferation 
without a change in unscheduled DNA synthesis suggests that PBBs acted as a promoter rather than 
directly causing DNA damage (initiator).  A commercial mixture of decabromobiphenyl did not induce 
gene mutation in Salmonella typhimurium bacteria that were intraperitoneally injected into male CFLP 
mice in a host-mediated assay (Millischer et al. 1980).  This decabromobiphenyl mixture also did not 
induce micronuclei in bone marrow erythrocytes of mice (Millischer et al. 1980).  The mice in the host-
mediated assay and micronucleus test were orally treated (method not specified) with total doses of 5,000, 
10,000, or 20,000 mg/kg, administered in two equal doses 24 hours apart.   
 
In vitro studies indicate that PBBs are not directly genotoxic.  As summarized in Table 5-8, PBBs did not 
exhibit mutagenic activity when tested in the prokaryotic organisms S. typhimurium (Haworth et al. 1983; 
Millischer et al. 1980; NTP 1983) and E. coli (Rossman et al. 1991) with or without activation systems in 
the limited number of studies available.  In vitro testing in eukaryotic cells resulted in negative genotoxic 
responses in hamster cells (Galloway et al. 1987; Kavanagh et al. 1985; Williams et al. 1984), rat liver 
cells (Kavanagh et al. 1985; Williams et al. 1984), mouse liver and lymphoma cells (Myhr and Caspary 
1991; Williams et al. 1984), and human fibroblasts (Williams et al. 1984). 
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Table 5-7.  Genotoxicity of PBBs and PBDEs In Vivo 
 
Species (test system) End point Results Reference 
PBBs    
Mammalian cells    
 Rat hepatocytes Unscheduled DNA 
synthesis 
– Mirsalis et al. 1989 (FF-1) 
 Mouse hepatocytes Unscheduled DNA 
synthesis 
– Mirsalis et al. 1985, 1989 (FF-1) 
Host-mediated assays:    
 Salmonella typhimurium (mouse 
hosted-mediated) 
Gene mutation – Millischer et al. 1980 (DBB) 
Micronucleus test:    




– Millischer et al. 1980 (DBB) 
PBDEs    
Cytogenicity    
 Rat bone marrow cells (one-
generation reproduction study) 
Chromosome aberration – Norris et al. 1973, 1975 (77.4% 
decaBDE, 21.8% nonaBDE) 
 
– = negative result; DBB = decabromobiphenyl commercial mixture; decaBDE = decabromodiphenyl ether; 
DNA = deoxyribonucleic acid; FF-1 = FireMaster FF-1; nonaBDE = nonabromodiphenyl ether; 
PBBs = polybrominated biphenyls; PBDEs = polybrominated diphenyl ethers 
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Table 5-8.  Genotoxicity of PBBs and PBDEs In Vitro 
 
Results 





PBBs     
Prokaryotic organisms:     
 Salmonella typhimurium 
(plate incorporation) 
Gene mutation – – NTP 1983 (FF-1) 
 Salmonella typhimurium 
(plate incorporation) 
Gene mutation – – Haworth et al. 1983 (HBB) 
 Salmonella typhimurium 
(plate incorporation) 
Gene mutation – – Millischer et al. 1980 (DBB) 
 Escherichia coli (culture) Gene mutation – – Rossman et al. 1991 (PBB) 
Eukaryotic organisms     
Mammalian cells     
 Chinese hamster CHO 
cells (cell culture) 
Chromosomal 
aberration 
– – Galloway et al. 1987 (HBB) 
 Chinese hamster CHO 
cells (cell culture) 
Sister chromatid 
exchange 
– – Galloway et al. 1987 (HBB) 
 Chinese hamster V79 
cells (cell culture) 
Gene mutation – – Kavanagh et al. 1985 (BP-6) 
 Chinese hamster V79 
cells (cell culture) 
Gene mutation No data – Kavanagh et al. 1985 
(2,4,5-HBB) 
 Chinese hamster V79 
cells (cell culture) 
Gene mutation No data – Kavanagh et al. 1985 
(3,4,5-HBB) 
 Chinese hamster V79 
cells (cell culture) 
Gene mutation – – Kavanagh et al. 1985 
(3,4-TBB) 
 Rat liver cells WB (cell 
culture) 
Gene mutation No data – Kavanagh et al. 1985 
(2,4,5-HBB) 
 Rat liver cells WB (cell 
culture) 
Gene mutation No data – Kavanagh et al. 1985 
(3,4,5-HBB) 
 Mouse lymphoma cells 
L5178Y (cell culture) 
Gene mutation – – Myhr and Caspary 1991 
(FF-1) 
 Rat liver cells (cell 
culture) 
DNA repair No data – Williams et al. 1984 (FF-1) 
 Mouse liver cells (cell 
culture) 
DNA repair No data – Williams et al. 1984 (FF-1) 
 Hamster liver cells (cell 
culture) 
DNA repair No data – Williams et al. 1984 (FF-1) 
 Rat liver cells (cell 
culture) 
Gene mutation No data – Williams et al. 1984 (FF-1) 
 Human fibroblast D-550 
(cell culture) 
Gene mutation – No data Williams et al. 1984 (FF-1) 
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Table 5-8.  Genotoxicity of PBBs and PBDEs In Vitro 
 
Results 





PBDEs     
Prokaryotic organisms:     
 Salmonella typhimurium 
(plate incorporation) 
Gene mutation – – NTP 1986 (decaBDE) 
Mammalian cells:     
 Mouse lymphoma 
L5178Y cells (cell 
culture) 
Gene mutation – – NTP 1986 (decaBDE) 
 Chinese hamster 
Sp5/V79cells (cell 
culture) 
Gene recombination No data – Helleday et al. 1999 
(2,2',4,4'-tetraBDE) 
 Chinese hamster 
SPD8/V79cells (cell 
culture) 
Gene recombination No data + Helleday et al. 1999 
(2,2',4,4'-tetraBDE) 
 Chinese hamster 
Sp5/V79 cells (cell 
culture) 
Gene recombination No data + Helleday et al. 1999 
(3,4-diBDE) 
 Chinese hamster 
SPD8/V79 cells (cell 
culture) 
Gene recombination No data + Helleday et al. 1999 
(3,4-diBDE) 
 Chinese hamster 
Sp5/V79 cells (cell 
culture) 
Gene recombination No data + Helleday et al. 1999 
(2-monoBDE) 
 Chinese hamster 
SPD8/V79 cells (cell 
culture) 
Gene recombination No data + Helleday et al. 1999 
(2-monoBDE) 
 Chinese hamster ovary 
cells (cell culture) 
Sister chromatid 
exchange 
– – NTP 1986 (decaBDE) 
 Chinese hamster ovary 
cells (cell culture) 
Chromosomal 
aberrations 
– – NTP 1986 (decaBDE) 
 
– = negative result; 2,2',4,4'-tetraBDE = 2,2',4,4'-tetrabromodiphenyl ether; 2,4,5-HBB = 2,2',4,4',5,5'-hexabromobi-
phenyl; 2-monoBDE = 2-bromodiphenyl ether; 3,4,5-HBB = 3,3',4,4',5,5'-hexabromobiphenyl; 3,4-diBDE = 3,4-di-
bromodiphenyl ether; 3,4-TBB = 3,3',4,4'-tetrabromobiphenyl; BDE = brominated diphenyl ethers; BP-6 = FireMaster 
BP-6; DBB = decabromobiphenyl commercial mixture; decaBDE = decabromobiphenyl ether; DNA = deoxyribo-
nucleic acid; FF-1 = FireMaster FF-1; HBB = hexabromobiphenyl (unspecified); PBB = unspecified mixture; 
PBBs = polybrominated biphenyls; PBDEs = polybrominatedd diphenyl ethers   
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An in vitro study with a 14C-PBB mixture containing 12 major components found only traces of 
radioactivity bound to rat liver microsomal macromolecules (Dannan et al. 1978a).  Binding, however, 
was dependent upon the type of microsomes used to activate the PBB mixture.  Microsomes isolated from 
animals pretreated with methylcholanthrene (MC) bound twice the amount of radioactivity compared with 
controls, whereas activation with phenobarbital (PB) or PBB bound 5 times more radioactivity than 
control microsomes.  Also, the authors showed that no radioactivity was covalently bound to DNA 
following incubation with 14C-PBB.  The type of microsomes used or the presence or bsence of 
nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) in the incubation mixture made 
no difference. 
 
Although it appears that PBBs are not mutagenic, due to their enzyme induction properties, they may 
potentiate the genotoxic activity of other compounds by activation to reactive intermediates. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding genotoxic effects in humans 
following inhalation, oral, or dermal exposure to PBDEs. 
 
A limited amount of information has been published on the genotoxicity of PBDEs in animals in vivo or 
in prokaryotic and eukaryotic cells in vitro as summarized in Tables 5-7 and 5-8, respectively.  
Cytogenetic examination of bone marrow cells showed no increase in aberrations in maternal and 
neonatal rats following maternal oral exposure to ≤100 mg/kg/day of a 77.4% decaBDE mixture 
(containing 21.8% nonaBDE and 0.8% octaBDE) for 90 days prior to mating and during mating, 
gestation, and lactation (Norris et al. 1973, 1975a).  In vitro assays found that decaBDE did not induce 
gene mutations in bacterial cells (S. typhimurium TA98, TA100, TA1535, or TA1537) or mammalian 
cells (mouse lymphoma L5178Y cells), and did not induce sister chromatid exchange or chromosomal 
aberrations in Chinese hamster ovary cells (NTP 1986).  In vitro exposure to the congeners 
2,2',4,4'-tetraBDE (BDE 47), 3,4-diBDE (BDE 12), and 2-monoBDE (BDE 1) caused increased 
recombinogenic activity at the HGPRT locus in Chinese hamster SPD8 and Sp5 V79 cells (Helleday et al. 
1999).  
 
5.4  TOXICOKINETICS  
 
Data regarding the toxicokinetics of PBBs in humans are limited to information derived from cases of 
accidental ingestion of food contaminated with PBBs and cases of occupational exposure by the 
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inhalation and dermal routes.  These data provide qualitative evidence that PBBs are absorbed in humans 
by the inhalation, oral, and dermal routes.  Limited quantitative data in animals indicate that some PBB 
congeners are well absorbed after oral exposure.  Dermal absorption data for animals are insufficient for 
estimating absorption rates, and no inhalation absorption data were located.  In blood, 80% of PBBs, are 
bound to protein and 20% are associated with lipids.  The distribution pattern of PBBs did not differ 
significantly between humans and animals and among animal species.  Due to their lipophilic nature, 
PBBs, especially the highly brominated congeners, tend to accumulate in lipid-rich tissues.  Greater 
relative amounts of PBBs are usually found in the liver, adipose, skin, and breast milk.  Certain 
components of PBB mixtures are metabolized by the microsomal monooxygenase system catalyzed by 
cytochrome P-450 of the type induced by phenobarbital.  The rate of metabolism of some PBB congeners 
depends on the bromine substitution pattern.  PBB congeners of low bromine content are transformed into 
hydroxylated derivatives that are predominately eliminated in the urine.  Highly brominated congeners are 
either retained or excreted unchanged in the feces.  As discussed in Section 5.3.2, the exact mechanism of 
PBB toxicity is not known.  It has been suggested, however, that the mechanism for some congeners is 
related to the enhancement of gene expression triggered by initial binding to the same cytosolic receptor 
(Ah) involved in some effects of PCBs and PCDDs. 
 
5.4.1  Absorption  
5.4.1.1  Inhalation Exposure  
 
Polybrominated Biphenyls.  No studies were located regarding absorption of PBBs in humans after 
inhalation exposure.  However, absorption of PBBs by inhalation (and by dermal contact) in humans can 
be inferred by the relatively high levels of PBB residues detected in adipose tissue and serum of workers 
involved in PBB manufacturing (Brown et al. 1981; Landrigan et al. 1979; Stross et al. 1981). 
 
No studies were located regarding quantitative absorption of PBBs in animals after inhalation exposure to 
PBBs.  However, increased bromine concentrations were found in the liver and adipose tissue of rats 
exposed continuously to a commercial mixture of octabromobiphenyl for 15 weeks, suggesting that 
absorption had occurred (Waritz et al. 1977). 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding absorption of PBDEs in humans 
after inhalation exposure.  Evidence for the inhalation absorption of lower-brominated PBDEs in animals 
was provided by observations of systemic toxicity in rats that were intermittently exposed to a  
commercial octaBDE product (bromine content 78.7%) as dust aerosol for 13 weeks (Great Lakes 
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Chemical Corporation 2001a, 2001b).  The absorption of the lower brominated BDE congeners was 
indicated by the occurrence of hepatic, thyroid, and ovarian effects in rats following exposure to 16 or 
202 mg/m3 for 6 hours/day, 5 days/week, for 13 weeks. 
 
5.4.1.2  Oral Exposure  
 
Polybrominated Biphenyls.  Quantitative oral absorption data in humans were not located, but reports of 
increased levels of PBB residues in tissues and serum of individuals accidentally exposed to contaminated 
food indicate that gastrointestinal absorption of PBBs had occurred (Eyster et al. 1983; Humphrey and 
Hayner 1975; Landrigan et al. 1979; Miceli et al. 1985; Wolff et al. 1982). 
 
Absorption of PBBs from the gastrointestinal tract in animals can be inferred from the numerous reports 
of adverse effects (Section 5.2.2) and increased residue levels in tissues following oral administration of 
these compounds (Section 5.4.2.2); however, few quantitative data exist.  By comparing the amount of 
radioactivity in the feces of rats administered a single 1 mg/kg oral dose of 14C-2,2',4,4',5,5'-hexabromo-
biphenyl (BB-155) with that monitored after a single intravenous injection of the compound, it was 
estimated that ≈93% of the oral dose was absorbed over a 24-hour period (Matthews et al. 1977).  Data 
obtained from similar experiments with PBB-155 later confirmed these results (Tuey and Matthews 
1980).  It was also demonstrated that absorption of this hexabromobiphenyl congener was independent of 
the dose, since ≥90% was absorbed over a dose range of 1–30 mg/kg (Matthews et al. 1977).  In contrast 
with the high absorption rate for the hexabromobiphenyl congener, a commercial octabromobiphenyl 
mixture (45.2% octa, 47% nona, 5.7% deca, 1.8% hepta) appeared to be less well absorbed by rats after 
administration of a single dose of 1 mg/kg (Norris et al. 1975a).  Within the first 24 hours after dosing, 
61.9% of the dose was found in the feces.  This indicates that at least 38.1% of the dose was absorbed, but 
absorption may have been higher, since biliary excretion may have occurred. 
 
Polybrominated Diphenyl Ethers.  No information was located regarding absorption of PBDEs in 
humans following oral exposure.  Information regarding oral absorption in animals is available from 
studies of commerical PBDE mixtures and individual PBDE congeners.  As summarized below, 
absorption of decaBDE is poor, whereas the lower brominated PBDEs are readily absorbed . 
 
Studies with 14C-labeled decaBDE (BDE 209) in rats consistently indicate that gastrointestinal absorption 
of this congener is low at 10% or less in rats (El Dareer et al. 1987; Klasson Wehler et al. 2001; Morck 
and Klasson Wehler 2001; Morck et al. 2003; Norris et al. 1973, 1975c).  Following treatment with a 
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single 1 mg/kg dose of 14C-decaBDE, administered as a former low purity commercial mixture (77.4% 
decaBDE, 21.8% nonaBDE, 0.8% octaBDE) by gavage, 90.6 and >99% of the dose was eliminated in the 
feces within 24 and 72 hours post-dosing, respectively (Norris et al. 1973, 1975b).  Two feeding studies 
were conducted in which rats were exposed to a higher purity commercial mixture as unlabeled decaBDE 
(92% pure) on days 1–7 and 14C-decaBDE (98.9% pure) on day 8, followed by unlabelled decaBDE on 
days 9, 9–10 or 9–11 (El Dareer et al. 1987; NTP 1986).  In the first study, dietary concentrations ranged 
from 238 to 51,100 ppm (six levels) (≈20–4,500 mg/kg/day).  Recovery of radioactivity in the feces 
ranged from 91.3±4.0% to 101±4% of the amount ingested in the 72 hours following 14C-decaBDE intake 
and was not related to dose level.  In the second study, rats were exposed to dietary concentrations of 277 
or 48,000 ppm (≈20 or 4,300 mg/kg/day).  Recovery of radioactivity in the feces ranged from 82.5±4.7% 
to 86.4±8.5% of the dose and was not related to dose level or time of sacrifice (24, 48, or 72 hours after 
14C-decaBDE intake).  For both dose levels, the percent of 14C dose remaining in the gut contents (<4%) 
and gut contents (<0.04%) decreased with time.  Of the radioactivity recovered, >99% was in the feces 
and gut contents.  Based on a comparison of average tissue concentrations following intravenous and oral 
administration, NTP (1986) estimated that oral absorption was 0.33±0.19% at the highest dietary level 
(50,000 ppm). 
 
A study of laboratory synthesized 14C-decaBDE (>98% pure) was conducted in which a single 3 µmol/kg 
(≈3 mg/kg) dose was administered to normal or bile duct-cannulated male Sprague-Dawley rats by 
gavage (Klasson Wehler et al. 2001; Morck and Klasson Wehler 2001; Morck et al. 2003).  The 
compound was suspended in a novel vehicle, Lutrol F127/soya phospholipone (34:16, w/w)/water, that 
was formulated to enhance solubility and improve absorption in comparison with previous studies of 
decaBDE, including those summarized above.  In the normal rats, approximately 90% (86–93%, n=8) of 
the dose was found in the feces after 3 days; cumulative recovery after 7 days was 91% (87–95%, n=4).  
For the two bile duct-cannulated rats, an average of 88 and 9.5% of the dose was recovered in the feces 
and bile, respectively, within 3 days.  There was a large variation in the fecal excretion of the two 
cannulated rats, which might have been due to the fact that no bile salts were added to compensate for the 
collected bile; the investigators concluded that this likely affected absorption.  Because the biliary 
excretion of decaBDE was approximately 10% of the dose, it appears that at least this much of the 
decaBDE was absorbed.  The investigators could not exclude that more than 10% of the dose had been 
absorbed because 65% of the radioactivity excreted in the feces was metabolites. 
 
Information on oral absorption of the commercial pentaBDE mixture DE-71 and the commercial 
octaBDE mixture DE-79 is available from studies in which male Sprague-Dawley rats were fed diets 
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containing 0 or 32-33 ng/day (≈120 ng/kg/day) of either mixture in peanut oil for 21 days (Hakk et al. 
2001; Huwe et al. 2002b).  The doses were designed to mimic environmental exposure levels.  Liver, 
carcass, and feces were analyzed for major congeners in the penta- and octaBDE formulations 24 hours 
after the final feeding; urine was not evaluated.  The study of the pentaBDE mixture assessed the 
following six congeners:  2,2’,4,4’-tetraBDE (BDE 47), 2,2’,3,4,4’-pentaBDE (BDE 85), 
2,2’,4,4’,5-pentaBDE (BDE 99), 2,2’,4,4’,6-pentaBDE (BDE 100), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), 
and 2,2’,4,4’,5,6’-hexaBDE (BDE 154) (Hakk et al. 2001).  Based on liver, carcass, and unrecovered 
levels of congeners, and assuming that excretion in the urine was negligible, absorption is estimated to 
have been 44.3% for penta congener BDE 85 and 84.3–92.4% for the other tetra- to hexaBDE congeners.  
The study of the octaBDE mixture assessed the following eight congeners:  2,2’,4,4’,5,5’-hexaBDE (BDE 
153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), 2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), 2,3,3’,4,4’,5,6-hepta-
BDE (BDE 190), an unknown heptaBDE, and three unknown octaBDEs (Huwe et al. 2002b).  Based on 
liver, carcass, and unrecovered levels of congeners, and assuming that excretion in the urine was 
negligible, absorption is estimated to have been 84.2–95.1% for the hexaBDEs, 68.5–79.1% for the 
heptaBDEs, and 55.7–83.3% for the octaBDEs.   
 
A single 14.5 mg/kg (30 µmol/kg) gavage dose of 14C-2,2',4,4'-tetraBDE (BDE 47) in corn oil was well 
absorbed by rats and mice (Örn and Klasson-Wehler 1998).  Approximately 5% of the dose in rats and 
7% of the dose in mice was excreted as parent congener in the feces in 24 hours.  The investigators 
concluded that these values represented the non-absorbed doses, indicating that absorption was 93–95%. 
 
5.4.1.3  Dermal Exposure  
 
Polybrominated Biphenyls.  No studies were located regarding absorption of PBBs in humans or animals 
after dermal exposure to PBBs.  However, absorption of PBBs through the skin in humans can be inferred 
by the relatively high levels of PBB residues detected in the adipose tissue and serum of workers involved 
in the manufacturing of these chemicals (Brown et al. 1981; Landrigan et al. 1979; Stross et al. 1981).  It 
is assumed that dermal route predominates, but inhalation and/or oral exposure cannot be ruled out. 
 
Similarly, dermal absorption in rabbits can be inferred from reports of lethality and liver effects observed 
after application of a commercial mixture of hexabromobiphenyl to abraded and occluded dorsal skin 
(Waritz et al. 1977). 
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Polybrominated Diphenyl Ethers.  No information was located regarding dermal absorption of PBDEs in 
humans.  The only information regarding dermal absorption in animals is that from a study of absorption 
in an in vitro preparation (Hughes et al. 2001).  In that study, 14C-decaBDE dissolved in tetrahydrofuran 
was applied to dorsal skin (three dose levels) excised from adult hairless female mice and fractions of 
receptor fluid were collected over a 24-hour period.  Transfer of radioactivity to the receptor fluid was 
minimal, only 0.07 to 0.34% of the applied radioactivity.  Two to 20% of the radioactivity was found in 
the skin, and the lowest dose applied had the highest percentage of the dose in the skin.  Washing the skin 
with solvent 24 hours after application removed 77–92% of the applied dose. 
 
5.4.2  Distribution  
5.4.2.1  Inhalation Exposure  
 
Polybrominated Biphenyls.  No studies were located regarding distribution of PBBs in humans after 
inhalation exposure. 
 
Limited information was located regarding distribution of PBBs in animals after inhalation exposure.  
Increased bromide concentrations were observed in the liver and adipose tissue of rats exposed 
continuously to vapors of a commercial octabromobiphenyl mixture (33% octa, 60% nona, 6% deca, 1% 
hepta) (3.5 pg octabromobiphenyl/L air at equilibrium) for 15 weeks (Waritz et al. 1977).  Relative to 
controls, the concentration of bromide in liver and fat was increased by 39 and 100%, respectively; 
bromide concentration in skeletal muscle was not affected by treatment.  No further details were 
provided. 
 
Polybrominated Diphenyl Ethers.  No information was located regarding distribution of PBDEs in 
humans following inhalation exposure.  
 
The distribution of bromine was examined in tissues of rats after inhalation exposure octaBDE (Great 
Lakes Chemical Corporation 1978).  Groups of rats were exposed to 0, 1.2, 12, 120, or 1,200 mg/m3 of 
dusts of octaBDE 8 hours/day for 14 days.  At necropsy, sections of the lungs, adipose tissue, and liver 
were collected for bromine analysis using a neutron activation technique.  The results showed 
concentrations of bromine in the lungs and adipose tissue significantly higher in all groups relative to 
controls; the amounts of bromine detected were concentration-related.  In the liver, the concentration of 
bromine was also elevated in all groups relative to controls except in the 1.2 mg/m3 exposure group; the 
increases in the liver were not as marked as in the lungs or in adipose tissue.  
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5.4.2.2  Oral Exposure  
 
Polybrominated Biphenyls.  Numerous reports have been published regarding levels of PBBs in serum, 
adipose tissue, breast milk, placenta, and cord serum of humans exposed to PBBs via the diet (Anderson 
et al. 1978d; Eyster et al. 1983; Landrigan et al. 1979; Stross et al. 1979, 1981; Wolff et al. 1979a, 1982).  
By using paired sampling, several significant correlations were determined (Eyster et al. 1983).  For 
example, in parturient women from Michigan, statistically significant correlations were found between 
PBB levels in maternal serum and placenta, cord serum, breast milk, and adipose; and between PBB 
levels in adipose tissue and breast milk.  In addition, there was a significant correlation between PBB 
levels in serum and feces and between serum and biliary fluid samples in farmers and chemical workers 
in Michigan.  In groups of pregnant, nonpregnant, and male chemical workers the serum to adipose tissue 
PBB concentration ratios ranged from 1:140 to 1:160, but in male farmers, this ratio was 1:325–
329 (Eyster et al. 1983).  The latter value is consistent with other reports regarding Michigan populations 
(Landrigan et al. 1979; Wolff et al. 1982).  It is unclear why the partitioning ratios between male chemical 
workers and farmers should differ.  The investigators noted that the group of farmers was much larger and 
might represent a better sample, as well as the possibilities that the farmers may have been more 
physically active or, for a variety of reasons, may have had lower total serum lipids (the amount of serum 
lipid might have affected the serum concentration of PBBs).  PBB levels in body tissues and fluids are 
further discussed in Section 8.4. 
 
Analysis of postmortem tissue samples from 15 subjects in the Grand Rapids, Michigan area indicated 
that renal fat had the highest single PBB concentration (1.65 µg/g wet weight) and the highest mean 
concentration (0.475 µg/g) (Miceli et al. 1985).  In regards to adipose, PBB concentrations in different 
tissues, could be divided into three range groups: high (ratios of 0.45–0.56, adrenal, atheromatous aorta, 
and thymus), medium (ratios of 0.1–0.28, pancreas, liver, and left ventricle), and low (ratios of 0.02–0.09, 
kidney, lung, brain, skeletal muscle, thyroid, and nonatheromatous aorta). 
 
As with the structurally related PCBs (Agency for Toxic Substances and Disease Registry 2000), PBBs 
are rapidly (minutes to hours) cleared from the blood and initially accumulate mainly in the liver, lungs, 
and muscle (Domino et al. 1982; Matthews et al. 1977).  Due to their high affinity for lipid-rich tissues, 
PBBs are subsequently redistributed to adipose and skin for storage or metabolism in the liver, and a 
dynamic equilibrium of PBB concentrations is established among all tissues for each PBB homolog (Tuey 
and Matthews 1980).  
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In rats treated by gavage with one or four daily doses of 14C-2,2',4,4',5,5'-hexabromobiphenyl (BB 153), 
initial concentrations of radioactivity were highest in muscle, liver, and adipose tissue, but later 
redistribution to adipose tissue (4–7 days after the last dosing) resulted in lower concentrations in liver 
and muscle (Matthews et al. 1977).  In rats dosed daily with 14C-BB 153 over a 30-day period, tissue 
concentrations on day 31 were (in increasing order):  blood, muscle, liver, skin, and adipose and were in 
general agreement with those predicted by a physiological compartment model (Tuey and Matthews 
1980).  When the model was scaled to nonlactating humans as discussed in Section 5.4.5 (Physiologically 
Based Pharmacokinetic/Pharmacodynamic Models), human intake of 9.8 g of the congener over a 
230-day period would result in peak concentrations of 720 and 2.1 ppm in fat and blood, respectively, 
5 years after the onset of exposure.  The model also predicted that the body burden after 5 years would be 
5.2 g and the half-life 6.5 years.  This half-life is shorter than the 12 years (median, range 4–97 years) 
calculated for hexabromobiphenyl in a Michigan cohort (Lambert et al. 1990) (see Section 5.8.1). 
 
In rats fed diets containing octabromobiphenyl mixture for several weeks, adipose tissue and liver 
accumulated much more bromine than did skeletal muscle (Lee et al. 1975b).  For example, after 2 weeks 
of treatment, adipose of rats dosed with 50 mg/kg/day had 200 times more bromine than did adipose of 
control rats; the liver of these rats had 100 times more bromine than the livers of controls.  Feeding a 
PBB-free diet for 2 weeks decreased PBB levels in liver and muscle, but not in fat.  Eighteen weeks after 
exposure, the concentration of bromine in the adipose tissue of rats dosed with 50 mg/kg/day continued to 
increase to ≈840 times that of controls.  Similar results were reported by Norris et al. (1975a, 1975b).  
These investigators also reported that 16 days after a single dose of octabromobiphenyl mixture in rats, 
PBB residues were present in the adrenals, adipose tissue, heart, and skin at levels ranging from 0.14 to 
0.25% of the administered dose; the liver, pancreas, and spleen contained lesser amounts. 
 
The distribution and elimination of PBBs from tissues were examined in rats over a period of 112 days 
after a single oral dose of FireMaster FF-1 (Domino et al. 1982).  Elimination from blood was best 
described by a three-compartment model, and an elimination half-life from whole blood of 145 days was 
estimated.  Relative to the three compartments (C1, C2, and C3):  C1 consisted of heart, kidney, spleen, 
and whole blood; C2 included liver, lung, cerebrum, cerebellum, and testes; and C3 included 
subcutaneous fat.  PBB residues in C1 rose quickly, peaked within 5 hours of dosing and then fell rapidly; 
a half-life of 3.62 hours was estimated.  PBB peaked in C2 at 12 hours and then decreased; the half-life 
was 17.6 hours.  In C3, levels of PBB peaked only after 1 week and remained elevated for several weeks; 
the estimated half-life was 31.1 days.  Tissues with PBBs in order of increasing concentration were:  
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blood, spleen, kidney, and heart in C1, and testes, cerebrum, cerebellum, lung, and liver in C2.  
Simulations of different body fat proportions showed that reduction in body fat decreased the half-life of 
the chemical considerably.  According to the investigators (Domino et al. 1982), tissues within C1 and C2 
may be at greater risk of toxicity during the subacute phase of PBB ingestion.  In their view, this could 
explain the fact that blood PBB levels in Michigan families were not positively correlated with toxic 
symptoms of exposure to PBBs (see Section 5.2). 
 
In mink treated with FireMaster FF-1 in the diet for up to 11 months, the concentration of PBB residues 
in adipose tissue were higher than in brain and skeletal muscle at all times (Aulerich and Ringer 1979; 
Ringer et al. 1981).  The source of the PBBs (FireMaster FF-1 versus food contaminated with PBBs) did 
not seem to have a significant influence on the qualitative or quantitative distribution of residues in 
tissues.  Sows fed FireMaster BP-6 in the diet for 12 weeks also accumulated PBBs in adipose tissue; on a 
fat basis, the highest concentration of PBBs was found in the liver, followed by adipose, kidney, and brain 
(Werner and Sleight 1981).  Distribution studies in guinea pigs after a single dose of FireMaster FF-1 
showed preferential accumulation of residues in liver, kidneys, and lungs 2 days after dosing (Ecobichon 
et al. 1983).  This was followed by a slow decrease in these organs, but levels in adipose tissue reached a 
maximum between 7 and 14 days after dosing and then decreased. 
 
Several studies have examined the distribution of PBB residues in offspring after maternal exposure to 
PBBs during gestation and/or lactation.  In 4-week-old pigs exposed in utero and via lactation to 
FireMaster BP-6, PBBs accumulated preferentially in adipose tissue and liver on a wet tissue basis.  Over 
a wide range of doses, however, adipose had at least two times the PBB concentration compared to the 
liver (Werner and Sleight 1981).  PBB levels in tissues of sows were comparable to those measured in 
tissues of 4-week-old pigs.  On a fat basis, the liver had the highest concentration of PBBs in both sows 
and the young.  In pigs exposed only in utero, PBB levels in liver and adipose were similar and 
considerably lower than in tissues of sows or 4-week-old pigs, suggesting that far more PBBs are 
transferred through lactation than through the placenta.  A similar conclusion was reached in rat studies 
(McCormack and Hook 1982; Rickert et al. 1978).  In contrast, PBB levels in liver and body fat of guinea 
pigs exposed briefly through lactation were considerably lower than the tissue levels acquired 
transplacentally in a 2-day period (Ecobichon et al. 1983).  A biological half-life of 22 days in tissues of 
dams and pups was estimated in that study (Ecobichon et al. 1983). 
 
Polybrominated Diphenyl Ethers.  Results of tissue distribution studies of decaBDE are consistent with 
the poor absorption and rapid fecal elimination of this congener.  In male rats administered a single 
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gavage dose of 1 mg/kg of a 14C-labeled former commercial decaBDE mixture (77.4% pure containing 
21.8% nonaBDE and 0.8% octaDBE), radioactivity could be detected on day 1 in all sampled tissues 
(adipose, skin, liver, heart, adrenals, spleen, pancreas) (Norris et al. 1975b).  On day 16 after dosing 
radioactivity was only detected in adrenals and spleen (0.01 and 0.06% of the administered dose per gram 
of tissue, respectively).  Norris et al. (1975b) also examined the bromine content of tissues from rats 
administered 1 mg/kg/day doses of the 77.4% decaBDE mixture in the diet for 90 days, followed by an 
additional 90-day period on a control diet.  During the recovery period, interim sacrifices were conducted 
on days 0, 10, 30, and 60.  On recovery day 0, serum and kidneys had the same amounts of bromine as the 
controls, although adipose levels were increased approximately 4-fold and remained essentially 
unchanged over the 90-day recovery period.  In the liver, the bromine content was elevated on day 0 of 
the recovery period, but decreased and stabilized near control values after recovery day 10.  Tissue 
analyses in rats that were similarly exposed to 0.01-1 mg/kg/day of 77% decaBDE for 12 months showed 
adipose bromine levels that were slightly increased during the first 180 days and not significantly 
different than controls at the end of the year; no significant bromine accumulation occurred in serum, 
liver, kidneys, skeletal muscle, or testes (Norris et al. 1975b).  Pregnant rats that were administered the 
77% commercial decaBDE mixture by gavage on GDs 6–15 showed no significant increase in bromine 
content in the liver of fetuses on gestation day 21 compared to controls (Norris et al. 1975b).  Placental 
transfer cannot be totally ruled out since no other fetal tissues were examined. 
 
Two feeding studies were conducted in which rats were exposed to a higher purity commercial mixture as 
unlabeled decaBDE (92% pure) on days 1–7 and 14C-decaBDE (98.9% pure) on day 8, followed by 
unlabelled decaBDE on days 9, or 9–10, or 9–11 (El Dareer et al. 1987; NTP 1986).  The compound was 
poorly absorbed in both studies.  In the first study, dietary concentrations ranged from 238 to 51,100 ppm 
(≈20–4,500 mg/kg/day), and ≈91–100% of the 14C was recovered in the feces dose in 72 hours.  In the 
second study, rats were exposed to dietary concentrations of 277 or 48,000 ppm (≈20 or 
4,300 mg/kg/day), and fecal recovery of 14C ranged from ≈83 to 86% of the dose.  Both studies found 
only trace levels of radioactivity in any organ or tissue at any time point, and the maximum total 14C 
activity detected in the body at any time was only ≈1% of the dose.  In general, the highest amounts of 14C 
were found in the liver, and there was a tendency for rats fed the lower amounts of decaBDE to retain 
more radiolabel in tissues than rats fed higher amounts.  Analysis of all major organs and tissues in the 
second study found the highest levels of 14C in the gastrointestinal tract, followed by liver, kidney, lung, 
skin, and adipose. 
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A study of laboratory synthesized 14C-decaBDE (>98% pure) was conducted in which a single 3 µmol/kg 
(≈3 mg/kg) dose was administered to male Sprague-Dawley rats by gavage (Klasson Wehler et al. 2001; 
Morck and Klasson Wehler 2001; Morck et al. 2003).  The compound was suspended in a novel vehicle, 
Lutrol F127/soya phospholipone (34:16, w/w)/water, that was formulated to enhance solubility and 
optimize absorption.  The amount of the 14C dose remaining in the body after 3 and 7 days was 
approximately 9% (calculated by subtracting total urine and feces output from 100%).  The highest 
concentrations of radioactivity on a fresh weight basis were in adrenals, kidneys, heart, and liver after 
both 3 and 7 days.  Based on lipid weight, plasma and liver had the highest concentrations and adipose 
tissue had the lowest concentrations at both time points.  The data indicate that the highest concentrations 
were in plasma and blood-rich tissues and that decaBDE is not readily distributed to adipose.  The 
investigators speculated that decaDBD does not partition into lipids and is transported through aqueous 
compartments (e.g., serum and bile) due to binding to transport proteins.  As discussed below, PBDEs 
with fewer numbers of bromine preferentially accumulate in adipose.  The accumulation of lower 
brominated congeners appears to be due to their partitioning and retention in lipid-rich tissues, as well as 
rates of metabolism and elimination that are likely lower than for decaBDE. 
 
The tissue half-life of a commercial pentaBDE product (Bromkal 70) was investigated in male and female 
Wistar rats following gavage administration of a single high dose (300 mg/kg) in corn oil (von Meyerinck 
et al. 1990).  Groups of four rats/sex were sacrificed at weekly intervals until 10 weeks post-dosing for 
congeneric analysis of unspecified organs and perirenal fat.  Distribution from extra-adipose tissues into 
the fat was essentially complete after 4 days.  Five congeners were detected in the fat and incompletely 
characterized as a tetraBDE, two pentaBDEs, and two hexaBDEs.  The half-life of the congeners 
generally increased with increasing bromination.  The mean half-life of the tetraBDE congener was 
19.1 days in males and 29.9 days in females and significantly (p=0.01) different between the sexes.  The 
mean half-lives of the penta- and hexaBDE congeners did not significantly differ between the sexes, 
ranging from 36.8–47.4 days for pentaBDE congener 1, 24.9–25.2 days for pentaBDE congener 2, 44.6–
55.1 days for hexaBDE congener 1, and 90.9–119.1 days for hexaBDE congener 2.  Although the 
congeners were not fully identified (likely due to a  lack of analytical standards), it is relevant to note that 
the predominant congeners in Bromkal 70 are 2,2’,4,4’-tetra BDE (BDE 47) and 2,2’,4,4’,5-penta BDE 
(BDE 99). 
 
Information on the tissue distribution of the commercial pentaBDE mixture DE-71 and the commercial 
octaBDE mixture DE-79 is available from studies in which male Sprague-Dawley rats were fed diets 
containing 0 or 32–33 ng/day (≈120 ng/kg/day) of either mixture in peanut oil for 21 days (Hakk et al. 
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2001; Huwe et al. 2002b).  The doses were designed to mimic environmental exposure levels.  Liver, 
carcass, and feces were analyzed for major congeners in the penta- and octaBDE formulations 24 hours 
after the final feeding.  The study of the pentaBDE mixture assessed the following six congeners:  
2,2’,4,4’-tetraBDE (BDE 47), 2,2’,3,4,4’-pentaBDE (BDE 85), 2,2’,4,4’,5-pentaBDE (BDE 99), 
2,2’,4,4’,6-pentaBDE (BDE 100), .2,2’,4,4’,5,5’-hexaBDE (BDE 153), and 2,2’,4,4’,5,6’-hexaBDE (BDE 
154) (Hakk et al. 2001).  An average of 0.4–1.2 and 27.4–45.2% of the dosed congeners occurred in the 
liver and carcass, respectively, and 11.7–59.1% of the doses were not recovered.  The congener 
distribution patterns in the liver and carcass resembled that of the commercial pentaBDE mixture, 
suggesting that there was no preferential tissue accumulation of the tested congeners.  The study of the 
octaBDE mixture assessed the following eight congeners:  2,2’,4,4’,5,5’-hexaBDE (BDE 153), 
2,2’,4,4’,5,6’-hexaBDE (BDE 154), 2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), 2,3,3’,4,4’,5,6-heptaBDE 
(BDE 190), an unknown heptaBDE, and three unknown octaBDEs (Huwe et al. 2002b).  Four of 
congeners (BDE 90, the unknown heptaBDE, and two of the unknown octaBDEs) were not detected in 
the liver, and one congener (an unknown octaBDE) was not detected in the carcass.  Of the detected 
congeners, an average of 1.1–1.7% and 16.2–62.9% of the dose occurred in the liver and carcass, 
respectively.  Unlike the lower brominated congeners (tetra- to hexaBDEs) in the study of the pentaBDE 
mixture, tissue accumulation generally decreased with increasing bromination; total retentions in the liver 
and carcass were 64.4% for one of the hexaBDEs (BDE 153), 27.0–37.1% for the three heptaBDEs, and 
16.2–22.8% for two of the octaBDEs.  An average of 19.6–83.3% of the congener doses were not 
recovered.  The brain uptake and retention of PBDE congeners was studied in neonatal NMRI male mice 
that were given a single 1.5 mg/kg dose of 14C-2,2’,3,3’,4,4’,5,5’,6,6’-decaDBE (BDE 209), or 0.8 mg/kg 
of 14C-2,2’,4,4’,5-pentaDBE (BDE 99), by gavage in a 20% fat emulsion vehicle, on PNDs 3, 10, or 19 
and killed 24 hours or 7 days after exposure (Eriksson et al. 2002b, Viberg et al. 2001b, 2003a).  In the 
study with BDE 209, after 24 hours, the mice exposed on PND 3 or 10 had 4.8 or 4.0% of the total 
administered radioactivity in the brain, respectively, whereas the brain of those exposed on PND 19 had 
only 0.6% of administered amount (Viberg et al. 2001b, 2003a).  Seven days after exposure, the amount 
of radioactivity in the brain had increased approximately 2-fold in the mice exposed on PND 3 or 10 (to 
7.4 or 10.5% of the administered amount), whereas those exposed on PND 19 showed the same amount 
as at 24 hours post-exposure.  These findings suggest that brain uptake of 14C-BDE 209 was more 
efficient in the younger animals and that the amount of radioactivity reaching the brain increased with 
time.  The pattern of brain retention for BDE 209 was different than that for BDE 99, which showed a 
decrease over the 7-day period (Eriksson et al. 2002a).  In particular, 24 hours after exposure to 
14C-BDE 209, the amount of radioactivity in the brain was between 3.7 and 5.1% of the total administered 
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amount in the three different age categories, whereas the amount declined to 1.3–2.8% of the 
administered dose after 7 days.  
 
Rats that were administered a single 2.2 mg (≈10 mg/kg) gavage dose of 14C-2,2',4,4'-5-pentaBDE 
(BDE 99) in corn oil  and examined after 72 hours had the largest amounts of radioactivityin the carcass, 
adipose (epididymal), and gastrointestinal tract (38.8, 3.8, and 6.1% of the dose, respectively (Hakk et al. 
1999, 2002).  No other tissues contained contained >1% of the radioactivity.  Fractionation of the carcass 
into skin, bone, brain, eyes, and muscle showed that the majority of the 14C was in the skin.  When 
deposition was expressed on a concentration basis, the highest levels of radioactivity.occurred in the most 
lipid-rich tissues, i.e., adipose, adrenals, gastrointestinal tract, and skin.   
 
A single 14.5 mg/kg dose of 14C-2,2',4,4'-tetraBDE (BDE 47) in corn oil was administered by gavage to 
rats and mice (Örn and Klasson-Wehler 1998).  Approximately 86% of the absorbed dose in rats and 80% 
of the dose in mice remained in tissues (liver, lung, kidney, brain) at 5 days, mainly in the adipose.  In 
rats, adipose tissue had an approximately 70 times higher concentration of label than the other tissues on a 
fresh weight basis and 3.5-fold higher on a lipid weight basis.  The lungs had the second highest 
concentration of radiolabel with approximately twice that in the liver and kidneys.  In mice, adipose 
tissues had an approximately 10-fold higher level of label than other tissues on a fresh weight basis.  On a 
lipid weight basis, adipose tissue had a concentration of 14C similar to liver and twice that in lung and 
kidney. 
 
5.4.2.3  Dermal Exposure  
 
Polybrominated Biphenyls.  No studies were located regarding distribution of PBBs in humans after 
dermal exposure. 
 
Increased liver weight and necrosis were observed in rabbits after application of an unspecified 
hexabromobiphenyl mixture to the skin, suggesting that PBBs or metabolites reached that organ (Waritz 
et al. 1977).  No further information was available. 
 
Polybrominated Diphenyl Ethers.   No studies were located regarding distribution of PBDEs in humans 
or animals after dermal exposure. 
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5.4.2.4  Other Routes of Exposure  
 
Polybrominated Biphenyls.  In general, the distribution pattern of PBBs after parenteral administration is 
similar to that obtained after oral exposure.  In rats, immediately after intravenous injection of 
14C-2,2',4,4',5,5'-hexabromobiphenyl (BB-153) adipose, skin, muscle, liver, and blood contained ≈29, 20, 
40, 10, and 1.5% of the dose, respectively (Matthews et al. 1977).  Seven to 42 days postdosing, most of 
the residue in liver and muscle was redistributed to adipose tissue.  The percent of the dose remaining in 
liver and muscle on day 42 was 0.8 and 3.5%, respectively.  The concentration of radioactivity in skin 
remained relatively constant over a 42-day period.  In a similar study in rats, the adipose/blood 
equilibrium distribution rate was found to be much higher than for any other tissue examined, and 4 days 
after dosing, adipose tissue contained ≥60% of the body burden (Tuey and Matthews 1980). 
 
The elimination half-times from blood and several tissues were determined in rats administered a single 
intraperitoneal dose of 10 mg/kg FireMaster BP-6 (Miceli and Marks 1981).  Elimination from serum 
followed first-order kinetics, and a half-time of 23.1 weeks was calculated over a 36-week period after 
dosing.  Adrenal and adipose tissue had the highest PBB concentrations at week 6, and these levels were 
maintained throughout the 36-week observation period.  Concentrations of PBBs were also elevated in the 
liver, lungs, and pituitary at week 6, whereas PBB levels in brain, kidney, and spleen were several-fold 
lower.  Elimination half-times from adrenal, brain, fat, liver, lung, and spleen were 43.3, 63.0, 69.3, 11.5, 
11.2, and 9.0 weeks, respectively.  Elimination from heart, kidney, and pituitary did not appear to follow 
first-order kinetics; thus, elimination half-times from these tissues were not calculated.  The concentration 
of PBB in adipose tissue was at least 4 times higher than in any other tissue, and unlike other tissues, 
continued to increase, reaching a maximum at week 12 postdosing.  The adipose/serum ratio of PBB 
concentration increased from 222 at 6 weeks to 722 at 36 weeks, reflecting the much more rapid 
elimination of PBB from serum than from adipose tissue.  The investigators estimated that, given the 
elimination half-time from fat of 69 weeks, >1 µg/g of PBB would remain in fat by the time the rats 
reached 2 years of age, the end of their lifespans. 
 
The distribution of PBB residues was also examined in pregnant mink and ferrets after injection of a 
mixture of 2,2',4,4',5,5'-hexabromobiphenyl (BB 153) and 2,2',3,4,4',5,5'-heptabromobiphenyl (BB 180) 
(Bleavins et al. 1980).  Two hours after a single injection in the jugular vein on gestation day 37, the liver, 
kidney, and adipose tissue of ferret dams had 1.625, 0.108, and 0.124% of the dose/g tissue, respectively.  
PBB levels in fetal tissues did not exceed 0.013% of the dose (liver).  In mink, PBB levels in maternal 
liver, kidney, and adipose tissue were 1.622, 0.087, and 0.031% of the dose/g tissue, respectively.  Fetal 
liver had the highest amount of PBBs, 0.005% of the dose.  In a different experimental series, the 
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investigators (Bleavins et al. 1980) also showed that the dam's milk was the major route of offspring 
exposure since PBB levels, on a per gram or per kit basis, were significantly higher in 2-week-old kits 
than in newborn kits.  The ratio of the 2-week PBB concentration to the birth concentration was 3.94/g 
and 36.66/kit.  On a per kit basis, treated newborn kits accumulated 0.80% of the maternal dose through 
in utero exposure. 
 
Polybrominated Diphenyl Ethers.  No relevant information was located regarding distribution of PBDEs 
following exposure by non-natural routes of administration. 
 
5.4.3  Metabolism  
 
Polybrominated Biphenyls.  Information regarding the metabolism of PBBs in humans is limited.  
Chromatographic analysis of serum samples from Michigan dairy farmers and from Michigan Chemical 
Corporation employees revealed some differences in peak profile between these two groups and between 
these two groups and the peak profile of FireMaster BP-6 (Wolff and Aubrey 1978; Wolff et al. 1979a).  
The concentration of two pentabromobiphenyls was lower in the farmers than in the chemical workers.  
Both farmers and workers had a significantly lower amount of 2,2',3,4,4',5,5'-heptabromobiphenyl than 
FireMaster BP-6.  Other minor differences between the groups were also apparent.  The differences in 
peak profiles between farmers and chemical workers were attributed to different routes of exposure.  
Farmers had predominantly dietary exposure to PBBs which, according to the authors (Wolff and Aubrey 
1978), could have undergone partial metabolism in the animal food source (see below).  It should be 
noted that chemical transformation of the PBBs due to cooking of meat or pasteurization of milk whould 
not be expected since the temperatures reached during these processes is probably not high enough.  As 
discussed in Chapter 6, temperatures must exceed ≈500 °C for structural alterations of PBBs to occur.  
Nevertheless, a significant reduction (36–52%) in the concentration of PBBs in pressure-cooked meat 
relative to raw meat (due to loss of fat) has been reported (Zabik et al. 1978).  The decreased heptabromo-
biphenyl peak in farmers and workers relative to FireMaster BP-6 may reflect poor absorption of this 
congener since it is not expected to be metabolized readily (Wolff and Aubrey 1978; Wolff et al. 1979a). 
 
Human exposure to PBBs in the Michigan contamination episode occurred primarily through 
consumption of contaminated meat and dairy products.  The limited information available regarding the 
metabolism of PBBs in dairy cattle is insufficient to ascertain whether humans ingested PBBs or 
metabolic products of PBBs.  In a controlled study, cows fed single or repeated doses of FireMaster BP-6 
excreted 50% of the dose in the feces as parent compound (Willet and Durst 1978).  Tissues, feces, or 
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urine were not analyzed for metabolites.  Results of studies in rats, and also in vitro studies (see below), 
have shown that highly brominated PBB congeners, such as the major components of FireMaster BP-6, 
undergo little or no metabolic transformation.  Based on the existing information, it seems reasonable to 
assume that in the Michigan contamination episode, humans consumed mainly unchanged penta-, hexa-, 
and heptabromobiphenyls. 
 
The in vivo metabolism of some PBB congeners and of commercial PBB mixtures has been investigated 
in a limited number of animal studies.  For example, in pigs, intraperitoneal injection of 4-bromobiphenyl 
yielded three urinary metabolites:  4'-bromo-4-biphenylol (3% of the dose), bromobiphenylol (traces), and 
4'-bromobiphenylol (0.5% of the dose) (Kohli and Safe 1976).  4,4'-Dibromobiphenyl (BB 15) yielded 
four urinary metabolites:  4,4'-dibromo-3-biphenylol (5% of the dose), 3,4'-dibromo-4-biphenylol (1% of 
the dose), 4'-bromo-3-methoxy-4-biphenylol (1% of the dose), and traces of a dibromomethoxybiphenyl.  
The authors suggested these results indicate that metabolism of BB 15 occurs through the formation of an 
arene oxide.  The major urinary metabolite of FireMaster BP-6 was a pentabromobiphenylol (1% of the 
dose), which could have resulted from direct hydroxylation of the minor pentabromobiphenylol isomers 
in FireMaster BP-6 or by debromination/hydroxylation of the major congener, 2,2',4,4',5,5'-hexabromo-
biphenyl (BB 153). 
 
In rabbits, metabolism of 2-bromobiphenyl yielded two polar metabolites, one metabolite was identified 
as 2'-bromo-4-biphenylol (1% of the dose), and the other metabolite (traces) was also a mono-
hydroxylated derivative, but the position of the hydroxyl group was not determined (Kohli et al. 1978).  
3-Bromobiphenyl produced a major metabolite (4% of the dose) identified as either 3-bromo-4-biphenylol 
or 5-bromo-2-biphenylol; a minor dihydroxylated metabolite was also detected.  4-Bromobiphenyl 
yielded two metabolites:  4'-bromo-4-biphenylol (2% of the dose) and 4'-bromo-3,4-biphenyldiol (1.5% 
of the dose).  Experiments with tritiated 4-bromobiphenyl suggest that the metabolism of this congener 
involves the formation of an arene oxide. 
 
Similar results have been reported in rats (Sparling et al. 1980).  4'-Bromo-4-biphenylol was the major 
metabolite of 4-bromobiphenyl (BB 3).  2-Bromobiphenyl (BB 1) was metabolized to 2-bromo-4,4'-bi-
phenyldiol and 2-bromo-4',5-biphenyldiol; 2-bromo-5-biphenylol was a minor metabolite.  
3-Bromobiphenyl (BB 2) also yielded diols as major metabolites:  3-bromo-4,4'-biphenyldiol and an 
unknown diol.  The main conclusions of this experiment were:  the major site of hydroxylation is at the 
para position of the unsubstituted phenyl ring, and also at the para position of the ring for BB 1 and 
BB 2; substitutions in positions 2 and 3 tend to direct hydroxylation to position para and ortho (minor) to 
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the substituents; and the 2- and 3-hydroxylated products are subsequently dehydroxylated, whereas the 
4'-hydroxy congener is not. 
 
In contrast to the lower brominated congeners, no major metabolites were identified in the urine or feces 
of rats treated with a single intraperitoneal dose of 2,2'4,4'5,5'-hexabromobiphenyl, suggesting that this 
congener is stable and persistent (Safe et al. 1978).  Analyses of the feces of dogs administered 
FireMaster BP-6 orally revealed the presence of a metabolite identified as 6-hydroxy-2,2',4,4',5,5'-hexa-
bromobiphenyl (Gardner et al. 1979).  This metabolite was not found in the liver, but the parent 
compound was identified.  Since hydroxylation in position 6 of highly substituted congeners is unlikely, it 
was postulated that the metabolite found in the feces was formed by microbial metabolism of the PBB in 
the intestinal tract.  The in vitro metabolism of 2,2',4,4',5,5'-hexabromobiphenyl (BB 153) with liver 
microsomes of rats induced with either BB 153 or FireMaster BP-6 produced three major metabolic 
fractions:  lipophilic ether soluble polar metabolites, trichloroacetic acid (TCA) soluble conjugates, and 
macromolecular adducts (Purdy and Safe 1980). 
 
The NADPH-dependent metabolism of a PBB mixture was studied in vitro with liver microsomes of rats 
induced with PB, PBB, or 3-MC (Dannan et al. 1978a).  Of the 12 major components of the mixture, only 
2,2',4,5,5'-pentabromobiphenyl (BB 101) and a hexabromobiphenyl were metabolized by microsomes 
from PB- or PBB-treated rats.  Of seven structurally identified PBB components, only BB 101 had a 
bromine-free para position.  Although BB 101, 2,3',4,4',5-pentabromobiphenyl (BB 118), and 
2,2',3,4,4',5'-hexabromobiphenyl (BB 138) have two adjacent unsubstituted carbons, only BB 101 was 
metabolized.  No significant metabolism occurred when the PBB mixture was incubated with microsomes 
of control rats or MC-induced rats.  When 2,2'-dibromobiphenyl (BB 4) and 4,4'-dibromobiphenyl 
(BB 15) were incubated with liver microsomes of PB-treated rats, only BB 4 was metabolized.  These 
results suggest that the presence of a free para position is required for the metabolism of brominated 
biphenyls and that the bromine content of the molecule is less important in determining metabolism than 
the position of bromines on the biphenyl nucleus. 
 
A more recent study with hepatic microsomes of induced rats showed that MC pretreatment increased the 
NADPH-dependent metabolism of PBB congeners (di-, tri-, and tetrabrominated), which had adjacent 
unsubstituted ortho and meta positions on at least one ring (Mills et al. 1985).  Some penta- and 
hexabromobiphenyls that have adjacent unsubstituted ortho and meta positions were not metabolized, 
suggesting that further bromination prevents metabolism.  Pretreatment with PB increased the microsomal 
metabolism of congeners that have adjacent unsubstituted meta and para positions on at least one ring.  It 
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was concluded that the rates of metabolism of PBB congeners depends on the position of the bromines 
and the form of the cytochrome P-450 induced.  The ability to metabolize PBBs also depends on the 
species.  For example, hepatic microsomes isolated from rats have a greater potential to metabolize PBBs 
than hepatic microsomes isolated from pigeons (Borlakoglu and Wilkins 1993). 
 
Polybrominated Diphenyl Ethers.  DecaBDE (BDE 209) is predominantly excreted in the feces as 
unabsorbed parent molecule.  Data are available indicating that the small amount of decaBDE that is 
absorbed can be metabolized (El Dareer et al. 1987; Morck et al. 2003; NTP 1986).  A feeding study was 
conducted in which rats were exposed to a high purity mixture as unlabeled decaBDE (92% pure) on days 
1–7 and 14C-decaBDE (98.9% pure) on day 8, followed by unlabelled decaBDE on days 9, or 9–10, or 9–
11, at dietary concentrations of 277 or 48,000 ppm (El Dareer et al. 1987; NTP 1986).  Recovery of 
radioactivity in the feces ranged from 82.5±4.7 to 86.4±8.5% of the dose, and was not related to decaBDE 
dose level or time of sacrifice (24, 48, or 72 hours after consumption of 14C-decaBDE).  For both dose 
levels, the percent of 14C dose remaining in the gut contents (<4%) and gut contents (<0.04%) decreased 
with time.  Of the radioactivity recovered, >99% was in the feces and gut contents.  HPLC and UV 
spectral analyses of extracts of feces collected on days 9–11 indicated the presence of decaBDE (81% of 
recovered radioactivity) and three main unidentified metabolites.  The total radioactivity present as the 
metabolites tended to increase with increasing dietary level of decaBDE (1.5 and 27.9% of total recovery 
at the low and high dose, respectively).  Since absorption of decaBDE was minimal, El Dareer et al. 
(1987) speculated that the greater extent of metabolism in the high dose rats may be due to induction of 
hepatic metabolizing enzymes, or gastrointestinal tract bacteria, during the period of feeding unlabeled 
decaBDE.  Analysis of feces from rats following a single 1.07 mg/kg intravenous dose of 14C-decaBDE 
similarly indicated that the excreted material was predominantly unchanged compound and three main 
unidentified metabolites (El Dareer et al. 1987; NTP 1986).  Unchanged decaBDE comprised 36.5 and 
40.4% of the totals for the 0–48-hour and 48–72-hour collection periods, respectively.  The HPLC 
retention times of the metabolites were similar in the oral and intravenous studies.  A single metabolite 
was detected in the bile of rats following a single 0.9 mg/kg intravenous dose of 14C-decaBDE (El Dareer 
et al. 1987).  Approximately 7% of the administered dose appeared in the bile in 4 hours, and <1% of this 
amount was unchanged decaBDE. 
 
A study of laboratory synthesized 14C-decaBDE (>98% pure) was conducted in which a single 3 µmol/kg 
(≈3 mg/kg) dose was administered to normal or bile duct-cannulated male Sprague-Dawley rats by 
gavage (Morck and Klasson Wehler 2001; Morck et al. 2003).  The compound was emulsified in a novel 
vehicle, Lutrol F127/soya phospholipone (34:16, w/w) in water, that was formulated to enhance solubility 
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and optimize absorption.  Feces, bile, and several tissues (liver, kidney, lung, small intestine wall, and 
adipose) were qualitatively analyzed for metabolites using gel permeation chromatography (GPC) and gas 
chromatography-mass spectrometry (GC-MS).  In the normal rats, approximately 90% of the dose was 
excreted in the feces in 3 days, mainly as metabolites (65% of dose).  In the the two bile duct-cannulated 
rats, an average of 9.5% of the dose was excreted via the bile in 3 days, almost all of which represented 
metabolites.  Metabolites were characterized as nonextractable, water-soluble, lipid-bound, phenolic 
metabolites, and parent compound/neutral metabolites.  Feces from normal rats showed formation of 
phenolic and neutral metabolites.  Metabolites in the nonconjugated phenolic fraction included six penta- 
to heptaBDEs containing a guaiacol structure (a hydroxy and a methoxy group) on one of the rings 
(proposed to be on vicinal carbons), as well as traces of monohydroxylated diphenyl ethers with at least 
six bromine atoms and uncharacterized metabolites having eight bromine atoms.  DecaBDE was the main 
component in the neutral fraction of the feces, but trace amounts (<0.5% of the decaBDE) of three 
nonaBDEs also formed.  The mechanism by which decaBDE was debrominated to the methoxy-
hydroxylated penta- to hepatBDEs was not clear, but was inferred to include a catechol (dihydroxy 
compound) and/or other reactive intermediates.  Analysis of bile showed metabolites that were mainly 
lipid-bound on day 1 and subsequently water soluble.  Neutral compounds in the bile consisted mainly of 
parent decaBDE and traces of the three nonaBDEs that were found in the feces.  Phenolic metabolites in 
the bile included eight compounds that were the same as those found in the feces.  The tissue evaluations 
showed a high concentration of radioactivity in the liver and small intestine wall (27 and 61%, 
respectively) that was largely nonextractable, and therefore was assumed to be bound covalently to 
macromolecules and indicative of adducts formed by metabolism via reactive metabolites.  The 
metabolites identified in the feces of the rats were probably due to debromination of decaBDE, followed 
by metabolic substitution of vicinal carbons by methoxy or hydroxy groups.  The authors did not rule out 
that the intestinal endoderm or gut microflora could play a role in some of this metabolism.  PBDEs with 
fewer bromines probably have lower rates of metabolism (and elimination) than decaBDE because lower 
brominated PBDEs partition into, and are retained in, lipid-rich tissues, whereas decaBDE does not 
partition into lipids. 
 
Information on the metabolism of the commercial pentaBDE mixture DE-71 and the commercial 
octaBDE mixture DE-79 is available from studies in which male Sprague-Dawley rats were fed diets 
containing 0 or 32–33 ng/day (≈120 ng/kg/day) of either mixture in peanut oil for 21 days (Hakk et al. 
2001; Huwe et al. 2002b).  The doses were designed to mimic environmental exposure levels.  The 
predominant congeners in the pentaBDE formulation were 2,2’,4,4’-tetraBDE (BDE 47) and 
2,2’,4,4’,5-pentaBDE (BDE 99).  The octaBDE formulation was mainly comprised of hexaBDE through 
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nonaBDE congeners and only contained tetra- and pentaBDEs as minor components.  Liver, carcass, and 
feces were analyzed for major congeners in the penta- and octaBDE formulations 24 hours after the final 
feeding.  Urine was not analyzed because the lipophilic nature of the compounds and previous studies 
indicated that PBDEs are not excreted in the urine.   
 
The study of the pentaBDE mixture assessed the following six congeners:  2,2’,4,4’-tetraBDE (BDE 47), 
2,2’,3,4,4’-pentaBDE (BDE 85), 2,2’,4,4’,5-pentaBDE (BDE 99), 2,2’,4,4’,6-pentaBDE (BDE 100), 
2,2’,4,4’,5,5’-hexaBDE (BDE 153), and 2,2’,4,4’,5,6’-hexaBDE (BDE 154) (Hakk et al. 2001).  An 
average of 0.4–1.2 and 27.4–45.2% of the dosed congeners occurred in the liver and carcass, respectively.  
The congener distribution patterns in the liver and carcass resembled that of the commercial pentaBDE 
mixture, suggesting that there was no preferential tissue accumulation of the tested congeners.  An 
average of 11.7–59.1% of the congener doses was not recovered, suggesting that significant metabolism  
of some of the congeners occurred.  The study of the octaBDE mixture assessed the following eight 
congeners:  2,2’,4,4’,5,5’-hexaBDE (BDE 153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), 2,2’,3,4,4’,5’,6-
heptaBDE (BDE 183), 2,3,3’,4,4’,5,6-heptaBDE (BDE 190), an unknown heptaBDE, and three unknown 
octaBDEs (Huwe et al. 2002b).  Four of congeners (BDE 90, the unknown heptaBDE, and two of the 
unknown octaBDEs) were not detected in the liver, and one congener (an unknown octaBDE) was not 
detected in the carcass.  Of the detected congeners, an average of 1.1–1.7% and 16.2–62.9% of the dose 
occurred in the liver and carcass, respectively.  Unlike the lower brominated congeners (tetra- to 
hexaBDEs) in the study of the pentaBDE mixture, tissue accumulation generally decreased with 
increasing bromination; total retentions in the liver and carcass were 64.4% for one of the hexaBDEs 
(BDE 153), 27.0–37.1% for the three heptaBDEs, and 16.2–22.8% for two of the octaBDEs.  An average 
of 19.6–83.3% of the congener doses were not recovered, indicating that most of the congeners were 
metabolized to some extent  
 
The metabolism of 14C-2,2',4,4'-5-pentaBDE (BDE 99) was investigated in normal and bile duct-
cannulated rats that were administered a single 2.2 mg (≈10 mg/kg) dose in corn oil by gavage (Hakk et 
al. 1999, 2002).  The feces was the major route of elimination as shown by fecal recovery of 43 and 86% 
of the administered 14C in 72 hours in the normal and bile-duct cannulated rats, respectively.  The feces 
from the normal rats contained predominantly parent compound and minor amounts of metabolites 
(>90 and <10% of the extracted radioactivity, respectively).  The fecal metabolites were incompletely 
identified as two mono-OH-pentaBDEs and two mono-OH-tetraBDEs, indicating that some 
debromination occurred.  Metabolites found in the bile included two mono-OH-pentaBDEs, three di-OH-
pentaBDEs, and two possible thiol-substituted pentaBDEs.  The possible thiol-substituted pentaBDEs 
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could have been formed through the mercapturic acid pathway, but no glucuronide or sulfate conjugates 
were found in the bile.  Evidence for reactive intermediates in the feces of normal rats was indicated by 
high nonextractable fractions ranging from 18–52%.  Cumulative excretion of radiolabel in the urine at 
72 hours, consisting exclusively of uncharacterized metabolites, was 1 and 0.3% of the dose in the normal 
and bile duct-cannulated rats, respectively.  Absorbed BDE 99 was preferentially distributed to lipophilic 
tissues, in which it accumulated as parent compound; the only tissue in which metabolites were detected 
was the liver, which contained only trace amounts of OH-metabolites.   
 
Rats given a single gavage dose of 14.5 mg/kg dose of 14C-2,2',4,4'-tetraBDE (BDE 47) in corn oil 
excreted 14% of the dose in the feces and <0.5% in the urine over a 5-day period (Örn and Klasson-
Wehler 1998).  The majority of the fecal 14C (≈85% of the parent compound/metabolite fraction) was 
parent compound.  Six metabolites were detected in the feces, but were not precisely identified; the 
metabolites were tentatively characterized as hydroxlated derivatives (two ortho-, one meta-, and two 
para-OH-tetraBDEs) and a trace amount of a thiol-tetraBDE.  Mice treated in the same manner excreted 
20% of the dose in the feces and 33% in the urine over 5 days, indicating that the mouse is more capable 
of metabolizing BDE 47 than rats.  The majority of the fecal 14C in mice (≈70% of the parent 
compound/metabolite fraction) was the metabolite fraction, which contained the same six metabolites 
characterized in the rat feces.  Approximately 20% of the mouse urinary 14C was characterized as parent 
compound; the remainder could not be identified, but was speculated to arise from decomposition of a 
labile metabolite(s).  Unchanged tetraBDE was the major compound in all tissues analyzed in both 
species; minor amounts of hydroxylated tetraBDE metabolites were also detected.  A water-soluble 
metabolite was detected in urine from mice, but could not be isolated.   
 
Following oral exposure of male Sprague-Dawley rats to decaBDE (BDE-209), 13 phenolic metabolites 
were determined in the plasma (Sandholm et al. 2003).  The major metabolites were characterized as a 
hydroxyl-octaBDE, a hydroxyl-nonaBDE, and a hydroxyl-methoxy-hexaBDE.  In addition to the 
debromination reactions, the presence of a methoxy group is suggestive of methylation, and possibly 
other metabolic processes, by bacteria of the gut. 
 
5.4.4  Elimination and Excretion  
5.4.4.1  Inhalation Exposure  
 
No studies were located regarding excretion of PBBs or PBDEs in humans or animals after inhalation 
exposure. 
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5.4.4.2  Oral Exposure  
 
Polybrominated Biphenyls.  No studies were located that provide information on percentage of ingested 
PBBs excreted by humans.  However, PBBs in biliary fluid of a group of farmers and chemical workers 
ranged from undetected to 70 µg/L, and the correlation between serum PBB levels and levels in bile was 
statistically significant (Eyster et al. 1983).  Similarly, PBB levels in feces ranged from undetected to 
862 µg/kg, and the correlation between serum PBB levels and fecal levels was also statistically significant 
(Eyster et al. 1983). 
 
Serum half-life values have been estimated using human data from the Michigan PBB cohort (Blanck et 
al. 2000b; Lambert et al. 1990; Rosen et al. 1995).  A median half-life of 12.0 years (95% CI 4–97 years) 
was estimated based on two serum measurements from 15 women (≥20 years of age) with an initial serum 
PBB level of ≥5 ppb (Lambert et al. 1990).  An analysis of 51 women (≥18.8 years of age) and 112 men 
(≥18.1 years of age) with at least two measurements 1 year apart and an initial PBB level of ≥20 ppb 
found a median half-life of 13.0 years (95% CI 6.3–infinite years) and 10.0 years (95% CI 6.7–
20.0 years), respectively (Rosen et al. 1995).  Based on a median half-life of 10.8 years (95% CI 9.2–
14.7 years) for the entire group (163 persons, median PBB level 45.5 ppb), it was estimated that it will 
take more than 60 years for their PBB levels to fall below a detection limit of 1 ppb. 
 
Determinants of PBB serum decay were investigated in 380 Michigan women (≥16 years of age) who had 
an initial PBB level of at least 2 ppb and at least two measurements taken when they were not pregnant 
(Blanck et al. 2000b).  The mean initial PBB level was 20.9 ppb (standard deviation 78.7), and the mean 
time between the first and last measurement was 4.2 years (range 16.0–75.2 years).  A total of 109 women 
(29%) did not have a reduction in serum PBBs over time.  Assuming that PBBs reached equilibrium in 
the body before substantial amounts were eliminated and before the first serum measurements were taken, 
the entire body was modeled as a single compartment for PBBs with exponential decay.  The median 
PBB half-life in the entire group was 13.5 years (95% CI 10.5–23.2 years).  Subject-specific decay rate 
estimates were regressed on predictor variables including initial age, body mass index (BMI), smoking 
history, breast-feeding duration, and parity.  The serum PBB decay rate was slower, resulting in a longer 
half-life, with higher initial PBB levels; women with initial PBB levels of <10 and >10 ppb had median 
half-lives of 12.9 and 28.7 years, respectively.  The PBB decay rate was also slower (p=0.03) in women 
with an initial BMI above the median (BMI≥23).  Increasing number of pregnancies between the first and 
last measurement was also associated with slower decay, but the effect was of borderline statistical 
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significance (p=0.06).  Breast feeding as either a continuous variable or as categorized by tertiles of 
duration (<3, 3–9, or >9 months), age, and smoking were not associated with serum PBB decay. 
 
Lactation constitutes the most important route of excretion of PBB in lactating women.  Numerous 
studies reported PBB levels in breast milk from Michigan women (Brilliant et al. 1978; Eyster et al. 1983; 
Humphrey and Hayner 1975; Jacobson et al. 1984; Landrigan et al. 1979).  PBB levels in breast milk on a 
lipid basis ranged from undetected to 92,667 µg/kg, with a median of 250 µg/kg, in a group of parturient 
women from Michigan (Eyster et al. 1983).  Regression analysis of the data revealed that on a lipid basis, 
PBBs are 107–119 times more concentrated in milk than in serum.  Also, adipose PBB levels are 1.1–
1.5 times higher than the breast milk levels when milk levels were ≥100 µg/kg. 
 
The importance of PBB transfer through lactation in experimental animals is discussed in Section 5.4.2.2. 
 
There is limited information regarding excretion of PBBs in experimental animals.  Rats dosed once with 
14C-2,2',4,4',5,5'-hexabromobiphenyl (BB 153) excreted 7.9% of the dose in the feces within the first 
24 hours; urinary excretion data were not provided (Matthews et al. 1977).  It was estimated that <10% of 
the administered dose would ever be excreted.  These results are consistent with those of other 
investigators who report that this congener is stable and persistent (Safe et al. 1978).  In rats gavaged with 
14C-2,2',4,4',5,5'-hexabromobiphenyl for 22 days, between 10 and 20% of the daily dose was excreted 
daily in the feces; this value was predominantly due to elimination of unabsorbed PBB (Tuey and 
Matthews 1980).  In monkeys, the main route of excretion of hexabromobiphenyl residues was also in the 
feces (Rozman et al. 1982).  Between 60 and 70% of the administered dose was excreted in the feces in 
the first 11 days after dosing; urinary excretion was minimal.  The difference between the absorption rate 
reported by Matthews et al. (1977) and that reported by Rozman et al. (1982) can probably be accounted 
for by differences in the experimental designs. 
 
Rats treated with a single gavage dose of 14C-octabromobiphenyl excreted <1% of the administered dose 
in urine and expired air over a 16-day period (Norris et al. 1975a).  Within the first 24 hours after dosing, 
61.9% of the dose was present in the feces.  The proportion that represents unabsorbed PBB is not known.  
By day 16, 74% of the administered dose had been recovered in the feces. 
 
Polybrominated Diphenyl Ethers.  Oral studies with 14C-labeled decaBDE consistently show that this 
PBDE is rapidly and predominantly eliminated in the feces (El Dareer et al. 1987; Klasson Wehler et al. 
2001, Morck and Klasson Wehler 2001; Morck et al. 2003; Norris et al. 1973, 1975c).  In rats treated by 
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gavage with a single 1 mg/kg dose of a low purity former commercial mixture (77.4% 14C-decaBDE, 
21.8% nonaBDE, 0.8% octaBDE) in corn oil, most of the excreted radioactivity measured over a 16-day 
period was in the feces and <1% of the label was detected in the urine and expired air (Norris et al. 1973, 
1975c).  No significant differences in excretion patterns were observed between males and females.  
Approximately 91% of the decaBDE-derived radioactivity was found in the feces in the first 24 hours and 
almost all radioactivity (>99%) was accounted for by day 2 after dosing.  Two feeding studies were 
conducted in which rats were exposed to a higher purity commercial mixture as unlabeled decaBDE (92% 
pure) on days 1–7 and 14C-decaBDE (98.9% pure) on day 8, followed by unlabelled decaBDE on days 9, 
or 9–10, or 9–11 (El Dareer et al. 1987; NTP 1986).  In the first study, dietary concentrations ranged from 
238–51,100 ppm (six levels) (≈20–4600 mg/kg/day).  Recovery of radioactivity in the feces ranged from 
91.3±4.0 to 101±4% of the amount ingested in the 72 hours following 14C-decaBDE intake and was not 
related to dose level.  In the second study, rats were exposed to dietary concentrations of 277 or 
48,000 ppm (≈25 or 4,300 mg/kg/day).  Recovery of radioactivity in the feces ranged from 82.5±4.7 to 
86.4±8.5% of the dose and was not related to dose level or time of sacrifice (24, 48, or 72 hours after 
14C-decaBDE intake).  For both dose levels, the percent of 14C dose remaining in the gut contents (<4%) 
and gut contents (<0.04%) decreased with time.  Of the radioactivity recovered, >99% was in the feces 
and gut contents.  Urinary excretion of 14C accounted for ≤0.01% of the dose. 
 
In a study of laboratory synthesized 14C-decaBDE (>98% pure), a single 3 µmol/kg (≈3 mg/kg) dose was 
administered to normal or bile duct-cannulated male Sprague-Dawley rats by gavage (Klasson Wehler et 
al. 2001; Morck and Klasson Wehler 2001; Morck et al. 2003).  The compound was suspended in a novel 
vehicle, Lutrol F127/soya phospholipone (34:16, w/w)/water, that was formulated to enhance solubility 
and optimize absorption.  In the normal rats, approximately 90% (86–93%, n=8) of the dose was found in 
the feces after 3 days; cumulative recovery after 7 days was 91% (87-95%, n=4).  For the two bile duct-
cannulated rats, an average of 88 and 9.5% of the dose was recovered in the feces and bile, respectively, 
within 3 days.  There was a large variation in the fecal excretion of the two cannulated rats that might 
have been due to the fact that no bile salts were added to compensate for the collected bile.  Urinary 
excretion of 14C was negligible for all groups at <0.1% of the dose.  DecaBDE was speculated to have 
higher rates of metabolism and elimination than PBDEs with fewer numbers of bromines because it is 
unlikely to partition into lipids and is transported through aqueous compartments (e.g., serum and bile), 
whereas lower brominated congeners preferentially accumulate in the body due to their partitioning and 
retention in lipid-rich tissues. 
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Information on oral absorption of the commercial pentaBDE mixture DE-71 and the commercial 
octaBDE mixture DE-79 is available from studies in which male Sprague-Dawley rats were fed diets 
containing 0 or 32–33 ng/day (≈120 ng/kg/day) of either mixture in peanut oil for 21 days (Hakk et al. 
2001; Huwe et al. 2002b).  The doses were designed to mimic environmental exposure levels.  Liver, 
carcass, and feces were analyzed for major congeners in the penta- and octaBDE formulations 24 hours 
after the final feeding; urine was not evaluated.  The study of the pentaBDE mixture assessed the 
following six congeners:  2,2’,4,4’-tetraBDE (BDE 47), 2,2’,3,4,4’-pentaBDE (BDE 85), 
2,2’,4,4’,5-pentaBDE (BDE 99), 2,2’,4,4’,6-pentaBDE (BDE 100), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), 
and 2,2’,4,4’,5,6’-hexaBDE (BDE 154) (Hakk et al. 2001).  One of the penta congeners, BDE 85, 
occurred at a relatively high level in the feces (55.8% of the adminstered amount).  Fecal excretion of the 
five other tetra- to hexaBDE congeners ranged from 7.6 to 15.8% of the dose.  The study of the octaBDE 
mixture assessed the following eight congeners:  2,2’,4,4’,5,5’-hexaBDE (BDE 153), 
2,2’,4,4’,5,6’-hexaBDE (BDE 154), 2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), 2,3,3’,4,4’,5,6-heptaBDE 
(BDE 190), an unknown heptaBDE, and three unknown octaBDEs (Huwe et al. 2002b).  Fecal excretion 
ranged from 4.9 to 15.9% of the dose for the hexaBDE congeners, 20.9–31.5% of the dose for the 
heptaBDE congeners, and 16.7–44.3% of the dose for the octaBDE congeners. 
 
The elimination of 14C-2,2',4,4'-5-pentaBDE (BDE 99) was investigated in normal and bile duct-
cannulated rats that were administered a single 2.2 mg (≈10 mg/kg) dose in corn oil by gavage (Hakk et 
al. 1999, 2002).  The main route of elimination was via the feces as shown by cumulative fecal recovery 
of 43 and 86% of the administered radiolabel in 72 hours in the normal and bile-duct cannulated rats, 
respectively.  The difference in the excreted amounts of radioactivity suggests that bile salts are needed 
for the intestinal uptake of BDE 99.  Cumulative urinary excretion of radiolabel over 72 hours was ≈1% 
and ≈0.3% of the dose in the normal and bile duct-cannulated rats, respectively.  The cumulative biliary 
excretion of radiolabel in cannulated rats was ≈4%.  
 
Rats given a single gavage dose of 14.5 mg/kg dose of 14C-2,2',4,4'-tetraBDE (BDE 47) in corn oil 
excreted 14% of the dose in the feces and <0.5% in the urine over a five day period (Örn and Klasson-
Wehler 1998).  Mice treated in the same manner excreted 20% of the dose in the feces and 33% in the 
urine over the same time period.  The amount of non-absorbed material in the feces on day 1 was 
approximately 5 and 7% of the dose in rats and mice, respectively, suggesting efficient absorption in both 
species (Örn and Klasson-Wehler 1998).   
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5.4.4.3  Dermal Exposure  
 
No studies were located regarding excretion of PBBs or PBDEs in humans or animals after dermal 
exposure. 
 
5.4.4.4  Other Routes of Exposure 
 
Polybrominated Biphenyls.  Rats given a single intravenous dose of 14C-2,2',4,4',5,5'-hexabromobiphenyl 
(BDE 153) excreted a cumulative 0.96, 3.3, and 6.6% of the dose in the feces 1, 7, and 42 days after 
dosing, respectively (Matthews et al. 1977).  Only traces (0.1% of the dose) were excreted in the urine.  
Two decay components were calculated from excretion data; an initial decay rate of 1.05% of the 
dose/day and a later rate of 0.15% of the dose/day.  Biliary excretion accounted for 0.68% of the dose 
between 0 and 4 hours after dosing.  Analysis of bile and feces showed that at least 95% of the 
radioactivity corresponded to the parent compound.  Moreover, in rats, ≈35% of the radioactivity excreted 
in the bile during the first week after a single dosing was reabsorbed (Tuey and Matthews 1980). 
 
Parenteral administration of mono- and dibromobiphenyls to rats, rabbits, and pigs suggests that the urine 
is an important route of excretion for polar metabolites (Kohli and Safe 1976; Kohli et al. 1978; Sparling 
et al. 1980).  However, cumulative urinary excretion did not account for more than 5% of the 
administered doses.  Data regarding fecal excretion were not provided. 
 
Polybrominated Diphenyl Ethers.  No relevant information was located regarding elimination of PBDEs 
following exposure by non-natural routes of administration. 
 
5.4.5  Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
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PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.   
 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions.   
 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 5-5 shows a conceptualized representation of a PBPK model. 
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Figure 5-5.  Conceptual Representation of a Physiologically Based Pharma 














































Source: adapted from Krishnan et al. 1994 
 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical 
chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, 
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Polybrominated Biphenyls.  A PBPK model that incorporates tissue volume, affinity for PBBs, and rate 
of perfusion was developed to describe the distribution and body burden of the major component of 
FireMaster PBB mixtures, 2,2',4,4',5,5'-hexabromobiphenyl (BB 153), in the rat (Tuey and Matthews 
1980).  The modeling methods are an extension of those used to predict the disposition of PCBs 
(Matthews et al. 1977).  The model predicts that at equilibrium, changes in the PBB concentration or 
changes in tissue volume of any tissue will lead to a corresponding change in all tissues.  For example, if 
the concentration of a PBB congener in the liver is reduced by metabolism or excretion, then the 
concentration of that PBB congener in all tissues will be reduced proportionally.  Congeners that cannot 
be readily metabolized (as is the case for BB 153) or excreted will concentrate in adipose tissue, but will 
still circulate to other tissues.  Exposure to other tissues will be proportional to the respective tissue/blood 
ratios and the concentration in main storage tissues.  This dynamic distribution results in accumulation of 
persistent congeners in all tissues and depletion from all tissues of those congeners that can be cleared.  In 
rats orally dosed daily with 14C-2,2',4,4',5,5'-hexabromobiphenyl over a 30-day period, tissue 
concentrations on day 31 were (in increasing order):  blood, muscle, liver, skin, and adipose, and were in 
general agreement with those predicted by the PBPK model.  When the model was scaled to nonlactating 
humans by adjusting for tissue volume, blood flow, and clearance and rate constant parameters, human 
intake of 9.8 g of the congener from milk consumption over a 230-day period would result in peak 
concentrations of 720 and 2.1 ppm in fat and blood, respectively.  The model also predicted that the body 
burden after 5 years would be 5.2 g and the half-life 6.5 would be years.  The half-life of 6.5 years 
predicted using the rat-based PBPK model is shorter than mean half-life values of ≈10-15 years estimated 
using human sera data from the Michigan PBB cohort (Blanck et al. 2000b; Lambert et al. 1990; Rosen et 
al. 1995), as discussed in Section 5.4.4 (Elimination and Excretion).  The shorter predicted half-life from 
the rat model compared to estimated values based on human sera might be due to differences in adipose 
content between rats and man; fat acts as a depot for these chemicals, and most rat studies use young 
animals with a fat content less than in many people. 
 
Polybrominated Diphenyl Ethers.  No PBPK/PD models were located for PBDEs. 
 
5.5  MECHANISMS OF ACTION  
5.5.1  Pharmacokinetic Mechanisms  
 
Polybrominated Biphenyls.  The mechanism by which PBBs enter the blood stream from the lungs, skin, 
or gastrointestinal tract is not known and little information is available on how PBBs are distributed in the 
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body.  The available data indicate that the absorption mechanism is likely passive diffusion.  Results from 
studies of Michigan subjects showed that in the blood stream, 80% of the PBBs were bound to protein 
and 20% was associated with lipids (Greaves et al. 1984).  Of the fraction bound to protein, 73% was 
bound to apolipoprotein B and the remaining percent was bound to apolipoprotein A.  In an in vitro 
model, shown to be representative of environmentally contaminated blood, the distribution of PBBs 
among plasma, erythrocytes, mononucleocytes, and polymorphonucleocytes was 89:9:<1:<1, respectively 
(Roboz et al. 1985).   
 
In an in vitro study in an adipocyte cell line (3T3L1 cells), >75% of the 2,2',4,4',5,5'-hexabromobiphenyl 
(BB 153) taken up by the cells was associated with subcellular fractions that contained 85% of the 
cellular triglyceride, with only 20% of the compound found in the microsomal plasma-membrane fraction 
(Kraus and Bernstein 1986).  This study also found that inhibition of respiration by cyanide at a 
concentration that completely inhibited oxygen consumption did not affect uptake of BB 153, supporting 
the assumption that because of their lipophilic nature, PBBs penetrate membranes by passive diffusion. 
 
Polybrominated Diphenyl Ethers.  No studies were located regarding pharmacokinetic mechanisms for 
PBDEs. 
 
5.5.2  Mechanisms of Toxicity  
 
PBBs and PBDEs share some toxicological properties with other structurally similar polyhalogenated 
aromatic compounds, particularly PCBs, chlorinated dibenzo-p-dioxins (CDDs), and chlorinated 
dibenzofurans (CDFs) (Agency for Toxic Substances and Disease Registry 1994, 1998, 2000).  However, 
although these chemicals are structurally similar in two dimensions, PBDEs (and PCDEs) differ from the 
other classes on a three dimensional basis.  In particular, the oxygen bridge of the ether linkage in the 
diphenyl oxide molecule increases the distance between the biphenyl rings.  This apparently reduces 
steric interactions between ortho substituents on the adjacent rings, such that the presence of ortho 
bromines is unlikely to present a barrier to rotation that would prevent the two aromatic rings from 
assuming a fully coplanar configuration (Chen et al. 2001; Hardy 2002; Howie et al. 1990).  In other 
words, the ether bridge makes PBDEs more non-coplanar in nature, and introducing ortho substitutions 
into PBDEs does not create a spatial impediment for the two phenyl rings to assume a semi-flat position 
with respect to each other, as it does for PBBs or PCBs.  Therefore, for PBDEs, the influences of the ether 
bridge and bromine position preclude clearly classifying the congeners as either dioxin-like (coplanar) or 
non-dioxin-like (non-coplanar).  This has implications not only for dioxin-type toxicities, which are 
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mediated by the Ah (aryl hydrocarbon) receptor (AhR) pathway, but also for non-dioxin-type effects.  For 
example, Chen et al. (2001) found that the induction of CYP1A1 by PBDEs is AhR-mediated, as it is for 
numerous organochlorines, even though PBDEs do not readily adopt the planar conformation usually 
considered characteristic of AhR ligands.  Structure-activity relationships have been incompletely 
examined for non-dioxin-like effects of PBDEs such as neurotoxicity.  However, based on limited 
available data, it can be speculated that di-ortho-substituted PBDEs might follow the neurotoxic potency 
of ortho-PCBs (Eriksson et al. 2002b; Kodavanti and Derr-Yellin 2002a; Mariussen and Fonnum 2002, 
2003). 
 
There are also geometrical differences in PCBs, PBBs, and PBDEs due to the higher atomic weight and 
considerably larger molecular volume of bromine compared to chorine (Hardy 2000, 2002).  These 
differences contribute to dissimilar physical/chemical properties that can influence the relative 
bioavailability, absorption, tissue accumulation, receptor interactions, and toxicities of the chemicals.  For 
example, a comparison of a series of isosteric 3,3',4,4'-tetrahalobiphenyls in rats showed that relative 
toxicity (growth rate and thymic atrophy), AhR binding affinity, and AHH and EROD induction 
potencies increased with increasing bromine substitution (Andres et al. 1983).  Possible explanations for 
this effect included the increased polarizability of bromine versus chlorine and differences in the 
electronic, hydrophobic, and hydrogen bonding characteristics of bromine and chlorine (Andres et al. 
1983).  The geometrical differences in bromine and chlorine also have implications for understanding the 
mechanism(s) of effects for nondioxin-like PBB congeners, which are not as well characterized as for 
PCBs.  In particular, it cannot necessarily be assumed, on the basis of two-dimensional structure, that the 
mechanisms and effects for nondioxin-like PBBs and PCBs are similar. 
 
Polybrominated Biphenyls.  The mechanism of toxicity for PBBs has been extensively studied, but is not 
completely understood (Akoso et al. 1982a, 1982b; Andres et al. 1983; Dannan et al. 1982a, 1982b; 
Goldstein et al. 1979; Parkinson et al. 1983; Render et al. 1982; Robertson et al. 1982; Safe 1984).  Many 
PBBs, PCBs, chlorinated dibenzo-p-dioxins (CDDs), chlorinated dibenzofurans (CDFs), and other 
structurally related halogenated aromatic hydrocarbons are believed to share a common mechanism of 
action strongly related to similarities in their structural configuration.  Most of what is known regarding 
the mechanism of action of these compounds is based on structure-receptor binding relationships, 
structure-induction relationships, and structure-toxicity relationships (Goldstein and Safe 1989; Safe 
1990).  Most of the studies providing this information used parenteral routes of exposure and/or in vitro 
test systems, as explained below.  It is beyond the scope of this profile to discuss these studies in detail. 
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A limited number of studies have shown that some PBB congeners bind to the cellular AhR, which 
regulates the synthesis of a variety of proteins.  This receptor was identified in the cytosol of mouse liver 
cells (Poland et al. 1976) and, subsequently, in extrahepatic tissues of laboratory animals, mammalian cell 
cultures, and human organs and cell cultures (Goldstein and Safe 1989).  The structure-binding 
relationships for the coplanar 3,3',4,4',5-pentabromobiphenyl (BB 126), the monoortho substituted 
congener 2,3,3',4,4',5-hexabromobiphenyl (BB 156), and the diortho substituted analog 2,2’,5,5'-tetra-
bromobiphenyl (BB 52) were examined in rat liver cytosol (Safe et al. 1985).  At PBB concentrations 
1,000-fold (10 µM) greater than tetrachlorordibenzo-p-dioxin (TCDD) concentrations (10 nM), the 
coplanar congener completely displaced radiolabeled 2,3,7,8-TCDD from the cytosolic AhR protein, the 
monoortho analog partially displaced the radiolabel, and 2,2',5,5'-tetrabromobiphenyl (BB 52) was the 
least active competitor.  The latter congener is relatively nontoxic and does not induce AHH.  The Ah-
binding characteristics of 3,3',4,4'-tetrabromobiphenyl (BB 77) and 3,3'4,4'5,5'-hexabromobiphenyl, both 
coplanar, were also examined in rat and mice liver cytosol (Millis et al. 1985).  The results showed than 
the tetrabromobiphenyl was 10 times more effective than the hexabromobiphenyl in displacing 
radiolabeled 2,3,7,8-TCDD from the receptor.  The stereospecific nature of the binding (high affinity seen 
with congeners substituted in both para and two or more meta positions) strongly suggests that a 
biological receptor mediates the responses caused by some PBBs. 
 
The ability of PBBs to induce hepatic Phase I xenobiotic metabolizing enzymes (cytochrome P-450-
dependent monooxygenases) is well documented (Dannan et al. 1978b, 1982a, 1982b, 1983; Ecobichon et 
al. 1979; Moore et al. 1978, 1979; Parkinson et al. 1983; Robertson et al. 1982; Schramm et al. 1985).  
PBB mixtures were classified as "mixed-type" inducers of hepatic microsomal monooxygenases and 
resembled a mixture of phenobarbital (PB)-like plus 3-methylcholanthrene (MC) as inducers of P-450 
isozymes from CYP1A and CYP2B families.  The CYP1A1 and CYP1A2 genes are induced by AhR 
agonists, such as 2,3,7,8-TCDD and MC, and the structure-induction relationships for PBBs as inducers 
of these P-450 isozymes and their related activities have also been determined (Dannan et al. 1983; 
Parkinson et al. 1983; Robertson et al. 1982).  For example, when injected intraperitoneally to immature 
male Wistar rats, the coplanar derivatives, 3,4,4'-tribromobiphenyl (BB 37), 3,4,4',5-tetrabromobiphenyl 
(BB 81), 3,3',4,4'-tetrabromobiphenyl (BB 77), 3,3',4,4'5-pentabromobiphenyl (BB 126), and 
3,3',4,4',5,5'-hexabromobiphenyl (BB 169) had a pattern of induction resembling that of MC (Robertson 
et al. 1982).  Similar type experiments have shown that monoortho-bromo-substituted analogs of the 
coplanar PBBs, such as 2,3',4,4'-tetrabromobiphenyl (BB 66), 2,3',4,4',5-pentabromobiphenyl (BB 118), 
and 2,3',4,4',5,5'-hexabromobiphenyl (BB 167), exhibit a mixed-type induction activity and resemble 
FireMaster BP-6 in their mode of induction (Dannan et al. 1978b; Parkinson et al. 1983).  Yet a third 
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group of PBB congeners, the diortho-bromo analogs of the coplanar PBBs, resemble PB in their mode of 
induction (PB induces the CYP2B1 and CYP2B2 genes).  Among the diortho-bromo-substituted PBBs 
studied are 2,2’,5,5'-tetrabromobiphenyl (BB 52), 2,2',4,5,5'-pentabromobiphenyl (BB 101), 
2,2',4,4',5,5'-hexabromobiphenyl (BB 153), and 2,2',3,4,4',5,5'-heptabromobiphenyl (Moore et al. 1979; 
Parkinson et al. 1983).  Results from studies with some dibromobiphenyls revealed that 4,4'-dibromo-
biphenyl (BB 15) resembled PB in its mode of induction (Robertson et al. 1982), whereas 2,2'-dibromo-
biphenyl (BB 4) had no significant effect on hepatic microsomal drug-metabolizing enzymes (Moore et 
al. 1979).  The results of these experiments indicated that coplanar PBB congeners substituted in both 
para and one or more meta positions are MC-type inducers, diortho substituted congeners are PB-type 
inducers, and monoortho analogs of the coplanar PBBs are mixed-type inducers.  These results were 
qualitatively similar to those obtained with PCBs and support the idea of a common receptor-mediated 
mechanism of action for PBBs.  PBBs are also efficacious inducers of hepatic phase II metabolizing 
enzymes such as glutathione transferases, UDP glucuronyl transferases, and epoxide hydrolase (Parkinson 
et al. 1983; Schramm et al. 1985).  For example, when intraperitoneally injected in rats, FireMaster BP-6 
efficaciously induced hepatic glutathione transferases while concomitantly depressing selenium-
dependent glutathione perioxidase activity, an important antioxidant enzyme in the liver (Schramm et al. 
1985). 
 
Many studies that examined structure-induction relationships for several PBB congeners also studied 
structure-toxicity relationships.  Thymus and spleen weight were significantly reduced in rats by a series 
of MC-type inducers (Robertson et al. 1982).  Further experiments in rats revealed that of a series of PBB 
congeners, only MC-type inducers significantly decreased thymus weight and body weight; PB-type, 
mixed-type, and MC-type inducers increased relative liver weight (Parkinson et al. 1983).  Results from 
feeding studies in rats indicate that 3,3',4,4',5,5'-hexabromobiphenyl (BB 169) (MC-type) and 
2,2',4,4',5,5'-hexabromobiphenyl (BB 153) (PB-type) increased liver weight; however, only the MC-type 
inducer decreased body weight and thymic and splenic weight, and caused lymphocytic depletion in the 
thymus (Render et al. 1982).  Similar results were obtained when the toxicities of 3,3',4,4'-tetrabromo-
biphenyl (BB 77) (MC-type) and 2,2'5,5'-tetrabromobiphenyl (weak PB-type) were compared in rats 
(Robertson et al. 1983a).  Only BB 77 caused significant reductions in growth rate and thymus size and 
marked depletion of lymphocytes from the thymic cortex.  Results from studies with FireMaster BP-6 
revealed that the pattern of toxic responses and the magnitude of the responses attributed to this mixture 
are consistent with it being composed of both MC-type and PB-type congeners; the most toxic responses 
being attributed to the MC-type congeners (Akoso et al. 1982a, 1982b; Dannan et al. 1982a, 1982b; 
Ecobichon et al. 1979; Parkinson et al. 1983; Render et al. 1982).  These results suggest a correlation 
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between immunological and hepatic effects and the ability to induce AHH activity and that the most toxic 
congeners are those that resemble the structural configuration of 2,3,7,8-TCDD.  This relationship further 
supports the idea of a common receptor-mediated mechanism of action.  Other PBB congeners (ortho- 
substituted) induce other types of effects, such as neurotoxicity, by yet unknown but AhR independent 
mechanisms. 
 
Some information on structure-promotion relationships for PBBs is available from studies that used two-
stage liver and skin carcinogenesis models.  In the liver promotion studies, development of enzyme-
altered hepatic foci (putative preneoplastic lesions) was assessed in rats that were partially 
hepatectomized, initiated with diethylnitrosamine and promoted with PBBs (Buchmann et al. 1991; 
Dixon et al. 1988; Evans and Sleight 1989; Jensen and Sleight 1986; Jensen et al. 1982, 1983; Sleight 
1985).  Both MC-type (3,3',4,4',5,5'-hexabromobiphenyl [BB 169] and 3,3',4,4'-tetrabromobiphenyl 
[BB 77]) and PB-type (2,2',4,4',5,5'-hexabromobiphenyl [BB 153]) congeners showed hepatic promoting 
activity with varying potencies.  FireMaster BP-6 was a more effective promoter than its major 
constituent congener BB 153 (Jensen et al. 1982), which also indicates that other congeners are very 
effective as promoters, or possibly that the combination of congeners with mixed- or PB-type activity 
have a synergistic or additive effect.  Although both MC- and PB-type congeners promote two-stage 
hepatic tumor activity, it appears that the MC-type congeners may exert their effects indirectly by causing 
hepatotoxic (cytotoxic effects and necrosis), whereas the PB-type congeners may act as mitogens 
(stimulate cellular growth and division).  In a skin tumor assay, HRS/J hairless mice were initiated with 
MNNG and promoted with PBBs (Poland et al. 1982).  FireMaster FF-1 and BB 169 were effective skin 
tumor promoters, but BB 153 showed no activity, suggesting that, unlike rat liver tumor promotion, 
promoter activity in the mouse skin tumor model is AhR-dependent.  Another indication that promotion 
of tumors by PBBs is not solely an Ah-receptor mediated process is provided by the results of an in vitro 
gap junctional intercellular intercommunication assay (Kang et al. 1996).  Gap junctional intercellular 
intercommunication in normal human breast epithelial cells was inhibited by 2,2',4,4',5,5'-hexaCB 
(CB 153) in a dose-dependent manner, but not by the coplanar congener 3,3',4,4',5,5'-hexaCB (CB 169).  
Inhibition of gap junctional intercellular communication is generally regarded as a mechanistic marker for 
tumor promotion (as well as several other toxicological end points). 
 
Expression of the dioxin-type toxic response, which is species and strain dependent, is initiated by the 
binding of individual congeners with the AhR.  The responsiveness of a particular organ or cell depends 
on the affinity of the receptor for the ligand molecule (Goldstein and Safe 1989).  For example, certain 
inbred strains of mice, typified by C57BL/6J, have a cytosolic AhR protein with a relatively high binding 
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affinity for inducers of benzo[a]pyrene hydroxylase such as 3-MC, ß-naphthoflavone, 2,3,7,8-TCDD, and 
other isostereomers of 2,3,7,8-TCDD.  In contrast, other inbred mouse strains, such as DBA/2J, have 
reduced AhR binding affinity.  Responsiveness to aromatic hydrocarbons is inherited in a simple 
autosomal dominant mode.  Nonresponsiveness has been attributed to a mutation resulting in a receptor 
with a diminished affinity (Okey et al. 1989).  This defective receptor is almost completely unresponsive 
to weak inducers such as 3-MC and has reduced sensitivity to more potent inducers such as 
2,3,7,8-TCDD.  Studies with PBBs have shown that treatment of C57BL/6J and DBA/2J with FireMaster 
BP-6 resulted in the induction of hepatic microsomal benzo[a]pyrene hydroxylase only in the C57BL/6J 
strain and aminopyrine N-demethylase (PB inducible) in both strains of mice (Robertson et al. 1984a).  
However, 3,3',4,4'-tetrabromobiphenyl (BB 77), a more potent MC-type inducer than the BP-mixture, 
induced benzo[a]pyrene hydroxylase in both strains of mice but did not induce aminopyrine 
N-demethylase in either strain of mice.  Also, after treatment with the dioxin-like congener BB 77, thymic 
atrophy was only observed in the responsive strain (Robertson et al. 1984a).  In general, studies 
summarized in Section 5.2 in which more than one strain was tested (mice or other species) do not 
address the possible strain-dependency of the toxic responses observed.  It must be mentioned, however, 
that differences in the response between tissues, strains, or species, do not exclusively indicate differences 
in receptor affinities, but most likely reflect the fact that the battery of enzyme activities (see below) 
controlled by the Ah locus varies within the tissue, strain, and animal species. 
 
Initial binding of a PBB congener to the AhR is followed by an activation or transcription step and 
subsequent accumulation of occupied nuclear receptor complexes.  These complexes interact with a 
specific DNA sequence in the CYP1A1 gene (which regulates the expression of cytochrome P-450IA1 
isozymes), changing its secondary or supersecondary structure (Elferinck and Whitlock 1990), which 
leads to enhancement of the CYP1A1 gene expression.  Newly synthesized enzymes and macromolecules 
resulting from the pleiotropic response to the ligand-receptor complex are believed to be responsible for 
many of the effects caused by PBBs and other halogenated aromatic hydrocarbons.  In other words, the 
binding of a congener to the AhR initiates a transcriptional upregulation of a battery of genes that 
modulates biochemical and endocrine pathways, cell cycle regulation (e.g., apoptosis, proliferation, and 
differentiation), morphogenesis, oxidative stress response, and other processes, and is ultimately 
expressed as a diverse spectrum of well characterized toxic responses. 
 
No studies were located regarding the mechanism of endocrine effects (thyroid toxicity, estrogenicity) of 
PBBs. 
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Polybrominated Diphenyl Ethers.  As discussed in the introduction to this section, bromination at the 
ortho position does not appear to significantly change the planarity of PBDE molecules or their biological 
effects.  Structure-activity studies have shown that some PBDE congeners can bind to the AhR, although 
binding affinities and induction of AhR-mediated responses are very weak or negligible, particularly for 
commercial PBDE mixtures and environmentally relevant congeners. 
 
For example, Meerts et al. (1998) indirectly examined the AhR-mediated (dioxin-like) properties of 
17 PBDE congeners in a recombinant H4II rat hepatoma cell line showing AhR mediated expression of a 
luciferase reporter gene.  The tested congeners varied from dibromo-substituted to heptabromo-
substituted, and with the exception of 4,4'-diBDE (BDE 15)and 3,3',4,4'-tetraBDE (BDE 77), all had at 
least one ortho substitution.  Seven of the congeners showed luciferase expression, indicating their ability 
to activate the AhR.  The only discernable pattern of receptor activation that appeared to emerge from 
these results was that greater receptor activation was obtained with the penta- and hexaBDEs than with 
tri- and tetraBDEs.  Another study also examined the AhR induction potency of PBDE congeners using 
the in vitro luciferase assay with H4IIE-luc recombinant rat hepatoma cells (Villeneuve et al. 2002).  Only 
1 of 10 tested congeners, 3,3’,4,4’,5-pentaBDE (BDE 126), induced a significant AhR-mediated gene 
expression response in the H4IIE-luc cells, but the magnitude of induction was only 13% of that caused 
by TCDD.  With the exception of 2,3,3’,4,4’-pentaBDE (BDE 105), which induced a response of 1.7% of 
the TCDD maximum, no other congener, including the environmentally prominent congeners 
2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE (BDE 99), and 2,2',4,4',5,5’-hexaBDE (BDE 153), 
yielded a response greater than 1% of TCDD.  Overall, the tested PBDE congeners were at least 
200,000 times less potent than TCDD for inducing AhR-mediated gene expression in this test system. 
 
Chen et al. (2001) studied the affinities of a series of 18 PBDE congeners and 3 commercial PBDE 
mixtures for rat hepatic AhR by using competitive AhR-ligand and EROD induction assays.  The analysis 
showed that both the congeners and octa- and pentaBDE commercial mixtures had binding affinities 10-2–
10-5 times that of 2,3,7,8-TCDD.  The congener with the highest affinity among the tested congeners was 
2,2',3,4,4'-pentaBDE (BDE 85), although its relative binding affinity was only 2% that of 2,3,7,8-TCDD.  
No binding activity could be determined for the decaBDE mixture.  In contrast with PCBs, the binding 
affinities did not appear to relate to the planarity of the molecule, which according to Chen et al. (2001), 
was possibly due to the fact that the large size of bromine atoms expands the receptor binding site.  The 
dioxin-like activity of the PBDE congeners and commercial mixtures was subsequently more completely 
characterized, by determining whether they act as AhR agonists or antagonists at sequential stages of the 
AhR signal transduction pathway leading to CYP1A1 in rat hepatocytes (Chen and Bunce 2001).  
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Congeners 3,3’,4,4’-tetraBDE (BDE 77), 2,3’,4,4’,6-pentaBDE (BDE 119), and 3,3’,4,4’,5-pentaBDE 
(BDE 126) were moderately active towards DRE (dioxin response element) binding and induced 
responses of both CYP1A1 mRNA and CYP1A1 protein equivalent to the maximal response of TCDD, 
although at concentrations 3–5 orders of magnitude greater than TCDD.  These congeners showed 
additive behavior towards DRE binding with TCDD (i.e., an increased response compared to TCDD 
alone), whereas most of the other congeners antagonized the action of TCDD.  Congeners 
2,2’,4,4’,6-pentaBDE (BDE 100), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), and 2,2’,3,4,4’,5’,6-heptaBDE 
(BDE 183) were very weak activators of DRE binding, and other congeners and the three commercial 
BDE mixtures were inactive.  In particular, the environmentally prominent congeners 2,2’,4,4’-tetraBDE 
(BDE 47) and 2,2’,4,4’,5-pentaBDE (BDE 99) were among the least active with respect to dioxin-like 
behavior (i.e., were inactive at all stages of signal transduction), and the commercial pentaBDE mixture 
had negligible EROD induction activity.  The PBDE congeners that bound most strongly to the AhR were 
also the strongest inducers of CYP1A1 mRNA and CYP1A1 protein, indicating that the induction of 
CYP1A1 was AhR-mediated.  Considering all end points evaluated in the Chen et al. (2001) and Chen 
and Bunce (2003) studies, it was concluded that the relative induction potencies (REPs) of the most active 
PBDEs toward CYP1A1 are ≈10-4 that of TCDD (similar to some mono-ortho-PCBs and two orders of 
magnitude less than those of coplanar PCBs), and the REPs for the environmentally prominent congeners 
are essentially zero. 
 
The enzyme induction properties of PBDEs have been less studied than for other structurally similar 
chemicals.  Existing information suggests that PBDEs can be classified as mixed-type inducers of hepatic 
microsomal monooxygenases, although the mixed induction properties of the commercial mixtures are 
likely due to contamination with PBDDs/PBDFs (Darnerud et al. 2001; de Wit 2002; Hardy 2002b).  Few 
studies have examined the structure-induction relationships for PBDEs.  Chen et al. (2001) examined the 
ability of 12 PBDE congeners and 3 commercial mixtures to induce EROD activity in chick and rat 
hepatocytes, in liver cell lines from rainbow trout, rat, and human, and in a human intestinal cell line.  The 
number of bromine substitutions in the congeners tested ranged from 3 to 7.  In all cell types, 
3,3',4,4'-tetraBDE (BDE 77), 2,2',4,4',6-pentaBDE, 2,3',4,4'-tetraBDE (BDE 66), and 3,3',4,4',5-penta-
BDE (BDE 126) were the strongest inducers.  Congeners 2,2',4,4',5,5'-hexaBDE (BDE 153) and 
2,2',3,4,4',5',6-heptaBDE were weak inducers in all cell types, whereas BDE 66 and 2,2',3,4,4'-pentaBDE 
(BDE 85) were very weak inducers in rat hepatocytes and inactive in the other cells.  Congeners 
2,2',4,4'-tetraBDE (BDE 47) and 2,2'4,4',5-pentaBDE, which are prominent in the environment, were not 
inducers in any cell line, and neither were 2,4,4'-triBDE (BDE 28), 2,2',4,4',5,6'-hexaBDE, or the penta-, 
octa-, or decaBDE mixtures.  For those congeners that had measurable EROD induction activity, their 
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relative potencies were 10-3–10-6 that of 2,3,7,8-TCDD.  In general, the EROD induction activity 
paralleled the strength of the AhR binding with the notable exception of 2,2',3,4,4'-pentaBDE (BDE 85), 
which despite its relatively strong AhR binding affinity (see above), showed no evidence of activating the 
AhR to its dioxin-response element (DRE) binding form and was only a weak EROD inducer.  
 
Relevant information on structure-toxicity relationships is available for PCDEs.  Howie et al. (1990) 
examined the immunotoxic potencies of various PCDE congeners on the inhibition of the splenic PFC 
response to SRBC antigen and found the following potency order:  2,3,3',4,4',5-hexaCDE > 
3,3',4,4',5-pentaCDE > 2, 3',4,4',5-pentaCDE > 3,3',4,4'-tetraCDE > 2,2',4,4',5,5'-hexaCDE > 
2,2',4,5,5'-pentaCDE > 2,2',4,4',5,6'-hexaCDE.  In general, this potency order paralleled their potencies as 
inducers of hepatic microsomal AHH and EROD.  Worth noticing is the fact that the resulting ranking 
order of potency did not follow the order that would have been expected for a response known to be AhR-
mediated, such as the inhibition of the PFC response to challenge with SRBC antigen.  For example, the 
laterally substituted congeners 3,3',4,4'-tetraCDE and 3,3',4,4',5-pentaCDE were less immunotoxic than 
their respective monoortho-substituted analogs; this was true also for their enzyme induction potencies.  
These findings showed that increasing ortho-substitution is less effective in reducing the “dioxin-like” 
activity of these compounds.  Howie et al. (1990) suggested that the ether bridge in the polyCDE 
molecules increases the bond length between the two phenyl rings, thus diminishing the effects of ortho 
substituents on the biochemical and toxic potencies of these compounds. 
 
Evidence for thyroid hormone involvement in PBDE toxicity includes observations in rats and mice that 
were orally exposed to commercial mixtures of deca-, octa-, or pentaBDE (see Section 5.2.2.2, Endocrine 
Effects).  DecaBDE appears to be much less potent than the lower brominated mixtures and the main 
effects include (1) histological changes in the thyroid indicative of glandular stimulation (e.g., follicular 
cell hyperplasia similar to that induced by a hypothyroid state) (IRDC 1976; Norris et al. 1973, 1975b; 
NTP 1986; WIL Research Laboratories 1984), and (2) decreased serum thyroxine (T4) levels with no 
accompanying changes in serum TSH (Darnerud and Sinjari 1996; Fowles et al. 1994; Hallgren and 
Darnerud 1998;WIL Research Laboratories 1984; Zhou et al. 2001, 2002).  Considering these data, the 
structural resemblance of PBDEs to T4, and information from studies of individual congeners as 
summarized below, it is hypothesized that, depending on dose, duration, and mixture/congener, PBDEs 
can disrupt the production, transport, and disposition of thyroid hormones.  
 
The mechanism(s) by which PBDEs decrease serum T4 levels is is unclear.  The apparent lack of effect of 
PBDEs on serum TSH suggests that direct effects on the thyroid leading to inhibition of T4 synthesis are 
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unlikely.  PBDEs are hepatic microsomal enzyme inducers, but there is little evidence that increased 
enzyme activity leads to greater clearance of thyroid hormones.  The induction of hepatic UDPGT by 
PBDEs has been demonstrated in several studies (Fowles et al. 1994; Hallgren et al. 2001; Zhou et al. 
2001, 2002) and this could increase the UDPGT-catalyzed deactivation and excretion of T4 (i.e., the 
conjugation of T4 with glucuronic acid).  An indication that increased UDPGT activity may not be the 
main mechanism for the reduced T4 levels is provided by Hallgren et al. (2001), who found that exposure 
to ≥18 mg/kg/day pentaBDE for 14 days caused serum T4 reductions in both mice and rats with no effect 
on UDPGT activity in the mice, and increased UDPGT in the rats only at higher dose levels.  In contrast, 
the decreases in serum T4 correlated with the induction of microsomal phase I enzymes (EROD and 
MROD). As discussed below, increased microsomal enzyme activity could also increase the formation of 
hydroxylated PBDE metabolites that can bind to T4 plasma transport proteins.  This would serve to 
increase the number of occupied sites on T4-binding proteins and subsequently result in decreased serum 
levels of T4; however, this mechanism is not fully elucidated.   
 
The possible interaction of PBDEs with T4 binding to human transthyretin (TTR) was investigated in an 
in vitro competitive binding assay (Meerts et al. 1998, 2000).  Testing of 17 congeners, ranging from di- 
to heptaBDEs, showed that none of the parent compounds competed with T4 for binding to human TTR.  
Incubation of the congeners with rat liver microsomes induced by PB (CYP2B enriched), β-naptho-
flavone (CYPIA enriched), or clofibrate (CYP4A3 enriched) indicated that metabolism is necessary to 
compete with T4-TTR binding and that potency is likely to be both congener and metabolic enzyme-
specific.  The CYP2B-enriched liver microsomes were the most potent, causing 9 of the 17 congeners to 
generate metabolites (not identified) that were effective in displacing T4 from TTR (60% inhibition):  
4,4'-diBDE (BDE 15), 2,4,4'-triBDE (BDE 28), 2,4,6-triBDE (BDE 30), 2,2',4,4’-tetraBDE (BDE 47), 
2,2',4,6'-tetraBDE (BDE 51), 2,4,4',6-tetraBDE (BDE 75), 3,3,4,4'-tetraBDE, 2,2',4,4',6-pentaBDE, and 
2,3',4,4',6-pentaBDE (BDE 119).  No T4-TTR inhibition occurred with the higher brominated diphenyl 
ethers (i.e., 2,2',3,4,4',5'-hexaBDE (BDE 138), 2,2',4,4',5,5'-hexaBDE (BDE 153), 2,3,4,4',5,6-hexaBDE 
(BDE 166), and 2,3,3',4,4',5,6-heptaBDE), although it was not verified that these PBDEs were 
metabolized during the in vitro microsomal incubations.  Three pure hydroxylated PBDEs, synthesized 
for their structural resemblance with the thyroid hormones 3,5-diiodothyronine (3,5-T2), 3,3',5-triiodo-
thyronine (T3), and 3,3',5,5'-tetraiodothyronine (T4), were also tested in the T4-TTR competition binding 
assay.  The relative potencies showed that the T4-like (2,6-dibromo-4-[2,4,6-tribromophenoxy]phenol) 
and T3-like (2-bromo-4-[2,4,6-tribromophenoxy]phenol) hydroxylated PBDEs were 1.42- and 1.22-fold 
more potent, respectively, than T4, and the percentage competition at 500 nM exceeded that of the natural 
ligand; the T2-like hydroxylated PBDE (4-[2,4,6-tribromophenoxy]phenol) showed low affinity for TTR 
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(0.41-fold less potent than T4).  Because the PBDEs were able to compete with T4-TTR binding only after 
metabolic conversion by induced rat liver microsomes, and considering that thyroid hormones are also 
hydroxy-halogenated diphenyl ethers.  Studies with PCBs and hydroxylated derivatives similarly showed 
that the congener patterns most closely resembling the diiodophenolic ring of thyroxine had the highest 
TTR binding activity (Chauhan et al. 2000; McKinney et al. 1987; Rickenbacher et al. 1986). 
 
Although the findings discussed above suggest that hydroxylation of PBDEs could be involved in the 
mechanism of thyroid toxicity, there are indications that hydroxylated metabolites might not play a large 
role for commercial penta- and octaBDE products.  For example, of the in vitro-generated metabolites 
displacing T4 from TTR (Meerts et al. 1998, 2000), only two (2,2’,4,4’-tetraBDE [BDE 47] and 
2,2’,4,4’,6-pentaBDE [BDE 100]) are known to be present in a commercial product (pentaBDE).  An in 
vivo study in rats (Om and Klasson-Wehler 1998) showed that BDE 47 is well absorbed (~95%), but 
poorly metabolized, because (1) only 3% of the amount excreted in feces over a 5-day period was in the 
form of metabolites, (2) the parent molecule was the major compound detected in all tissues analyzed 
(and the only brominated compound detectable in kidney, brain, and adipose tissue), and (3) plasma levels 
were low and mainly due to the parent molecule.  Additionally, the three pure hydroxylated PBDEs 
synthesized by Meerts et al. (1998, 2000) for their structural similarity to thyroid hormones are not based 
on congeners known to be present in commercial penta- or octaBDE mixture; this suggests that the 
congeners in these mixtures do not share close structural relationships with thyroid hormones.  It is 
relevant to note that high concentrations of hydroxy and methoxy metabolites of PBDEs have been 
detected in fish from the Baltic Sea (Asplund et al. 1999), indicating that these compounds can potentially 
directly impact thyroid function in humans consuming fish. 
 
Three hydroxylated PBDEs, the 4'-hydroxyl derivatives of 1,3,5-triBDE, 1,3,3',5'-tetraBDE, and 
1,3,3',5,5'-pentaBDE, were tested for affinity to the human thyroid hormone receptor proteins THR-α and 
THR-β in vitro (Marsh et al. 1998).  These congeners were tested because they theoretically show the 
highest structural similarity to T4 and T3.  None of the hydroxylated derivatives effectively competed with 
the thyroid hormones for binding to either receptor (affinities were 4–>1,000 times less than for T4 and 
T3).  Because the tested congeners were the most likely to have affinity for the thyroid hormone receptor, 
it was speculated that other hydroxylated PBDE congeners will have even lower potential for receptor 
binding.  DecaBDE (not hydroxylated) had no effect on thyroid hormone receptor-mediated 
transcriptional activation by T3 in HeLaTRDR4-luc human cells; no other congeners were tested in this 
assay (Sakai et al. 2003). 
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The extent that PBDEs affect circulating levels of T4 or T3 is likely to vary with species and rats are 
generally regarded as more sensitive than humans.  As discussed in Section 5.5.3, this is thought to be 
related to a smaller and more rapid turnover of the hormone pool in the rat thyroid, and to a more rapid 
clearance of secreted hormone in the rat; that latter being, in part, related to the absence of thyroid binding 
globulin (TBG) in rats (Capen 1997).  Transthyretin (TTR) is the major thyroid hormone binding protein 
in rats, whereas TBG is the main binding protein in man and most other mammals.  However, although 
TTR is a minor thyroid hormone binding protein in humans, it is the principal protein involved in T4 
transport to the brain in both rats and man (Blay et al. 1993; Sinjari et al. 1998).  TTR does not transport 
T4 from the bloodstream to the brain, but rather is the main T4 binding protein in cerebrospinal fluid 
(CSF) in both rats and humans.  In the rat, T4 is transported to the brain primarily through the blood-brain 
barrier, and not via the choroid plexus and CSF (Blay et al. 1993).  2,2',4,4'-TetraBDE (BDE 47) 
competitively inhibited binding of T4 to sites in rat choroid plexus following in vivo (but not in vitro) 
exposure (Sinjari et al. 1998).  Choroid plexus homogenate from rats that were orally treated with 6 or 
18 mg/kg/day for 14 days showed T4 binding that was 80 and 63%, respectively, of that in controls.  At 
least one group of mammals is known to exist without TTR (Palha et al. 1997; Schussler 2000).  The 
TTR-nul mouse has decreased protein-bound and total T4, normal free T4, and has apparent good health 
(Palha et al. 1997, 2000).  Interference with the blood-choroid-plexus-CSF-TTR-mediated route of T4 to 
the brain caused by the absence of TTR did not produce measurable features of hypothyroidism (Palha et 
al. 2000). 
 
Neurobehavioral developmental alterations have been induced in mice that were neonatally or perinatally 
exposed to individual PBDE congeners, including 2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE 
(BDE 99), 2,2',4,4',5,5’-hexaBDE (BDE 153), and 2,2',3,3’,4,4',5,5’,6,6’-decaBDE (BDE 209) (Branchi 
et al. 2001, 2002; Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 2001a, 2001b, 2002a, 2002b, 2003).  
As detailed in Section 5.2.2.4 Neurological Effects, the main effects were observed at adulthood and 
included reduced spontaneous motor activity, impaired habituation capability, and learning impairment in 
a maze task.  The mechanisms for these behavioral and cognitive effects have not been elucidated.  One 
possibility involves the well-documented key role of thyroid hormones in brain development.  As 
discussed above, in vivo and in vitro exposure to PBDEs has caused changes in hormone levels and other 
thyroid end points in animal models.  Some studies suggest that the effects might be related to alterations 
in cholinergic functions.  For example, neonatal exposure to a single 8 mg/kg oral dose of BDE 99 on 
PND 10 altered the behavioral response to nicotine, a cholinergic agent, in adult mice (Viberg et al. 
2002b).  Neonatal exposure to nicotine and adult exposure to BDE 99 (single 8 mg/kg oral dose at age 
5 months) also affected behavior in mice; the change was not seen in mice only exposed to BDE 99 as 
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adults or mice only exposed to nicotine as neonates (Ankarberg et al. 2001).  Adult mice that were 
exposed to single 9 mg/kg oral dose of BDE 153 on PND 10 had a decrease in specific α-Bungarotoxin 
binding sites (cholinergic nicotinic receptors) in the brain hippocampus (Viberg et al. 2001b, 2002a).   
 
Effects of PBDEs on intracellular signaling processes in rat neuronal cultures and cerebellar fractions 
have been reported.  In vitro exposure to commercial pentaBDE mixture DE-71 or tetra congener BDE 47 
stimulated arachidonic acid release in rat cerebellar granule neurons; this effect was not seen with the 
commercial octaBDE product DE-79 (Kodavanti 2003; Kodavanti and Derr-Yellin 2002).  The release of 
arachidonic acid appeared to be mediated by the activation of both Ca+2-dependent and Ca+2-independent 
cytosolic phospholipase A2.  In vitro exposure to penta mixture DE-71and tetra congener BDE 47 also 
caused translocation of protein kinase C, as indicated by increased phorbol ester binding; octaBDE 
mixture DE-79 did not induce this effect (Kodavanti and Derr-Yellin 2002; Rao et al. 2003).  Other 
effects of penta mixture DE-71 and tetra congener BDE 47 included decreases in intracellular calcium 
buffering by microsomes and mitochondria (Kodavanti and Derr-Yellin 2002).  The tetra congener BDE 
47 was generally more potent than the DE-71 mixture (mainly comprised of tetra and penta congeners) in 
these tests.  Another study found that DE-71 was more toxic than octa and deca congeners in inducing 
cell death and free radical formation in cerebellar granule cells (Reistad et al. 2002).  The in vitro uptake 
of the neurotransmitter dopamine into rat brain synaptic vesicles was inhibited by penta mixture DE-71 
mainly tetra and penta congeners), but not by commercial mixtures of octaBDE (DE-79) or decaBDE 
(DE-83R) (Mariussen and Fonnum 2002, 2003).   
 
The ability of PBDE congeners to induce estrogen receptor (ER)-mediated gene expression in MVLN 
recombinant human breast carcinoma cells, or displace steroid hormones (3H-testosterone or 3H-estradiol) 
from carp serum proteins, was assessed by Villeneuve et al. (2002).  Of 10 tested congeners, including the 
environmentally prominent congeners 2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE (BDE 99), and 
2,2',4,4',5,5’-hexaBDE (BDE 153), induced a significant response in either in vitro assay.  Another study 
found that a hydroxylated metabolite of BDE 47, 6-OH-2,2’,4,4’-tetraBDE, did not inhibit aromatase 
(CYP 19) enzyme activity in human H295R adrenocortical cells (Canton et al. 2003).  Aromatase is a 
steroidogenic enzyme that mediates the conversion of androgens to estrogens.  No other PBDEs were 
tested in this in vitro study.   
 
The estrogenic and antiestrogenic activities of several PBDE congeners and three hydroxylated PBDEs 
were also assessed in vitro using human breast cell line assays based on ER-dependent luciferase reporter 
gene expression (Meerts et al. 2001).  The hydroxylated PBDEs, tribromophenoxy)phenol, 2-bromo-
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4-(2,4,6-tribromophenoxy)phenol, and 2,6-dibromo-4-(2,4,6-tribromophenoxy)phenol, have bromine 
substitution patterns similar to those of the thyroid hormones T2 (3,5-diiodothyronine), T3 (3,3’,5-triiodo-
thyronine), and T4 (3,3’,5,5’-tetraiodothyronine), respectively.  Eleven of 17 PBDE congeners showed 
estrogenic activity (dose-dependent luciferase induction) in the ER-CALUX assay with T47D.Luc cells, 
although the most potent PBDE congeners (2,2',4,4',6-pentaBDE [BDE 100] > 2,4,4',6-tetraBDE 
[BDE 75] > 2,2',4,6'-tetraBDE [BDE 51] > 2,4,6-triBDE [BDE 30] > 2,3',4,4',6-pentaBDE [BDE 119]) 
had EC50 values that were 250,000–390,000 times less potent than 17β-estradiol (E2).  In contrast, the T3- 
and T2-like hydroxylated PBDEs showed estrogenic potencies exceeding that of E2 (no estrogenic activity 
was induced by the T4-like hydroxylated PBDE).  Antiestrogenic potencies were determined in the ER-
CALUX assay by treating T47D.Luc cells with the PBDEs and hydroxylated PBDEs in the presence of 
E2.  Only 2,2',4,4',5,5'-hexaBDE (BDE 153), 2,3,4,4',5,6-hexaBDE (BDE 166), and 2,3,3',4,4',5,6-hepta-
BDE, which did not induce luciferase activity alone, caused reductions in E2-induced luciferase activity.  
Three of the compounds with potent estrogenic activity in the ER-CALUX assay, 2,4,6-triBDE (BDE 30), 
2,2',4,4',6-pentaBDE (BDE 100), and 4-(2,4,6-tribromophenoxy)phenol, were also tested for estrogenicity 
in ERα-specific and ERβ-specific human embryonic kidney cell lines (293-ERα-Luc and ERβs-Luc cells, 
respectively).  The hydroxylated PBDE was potent in the ERα-specific cells (maximum luciferase 
induction similar to E2) and also showed activity in the ERβ-specific cells (maximum 50% induction 
compared to E2), whereas the ERα- and ERβ-specific cell lines were less responsive to 2,4,6-triBDE 
(BDE 30) (34.2 and 7.8% induction compared to E2) and 2,2',4,4',6-pentaBDE (≈20 and <2% relative 
induction).  These results indicate that pure and hydroxylated congeners of PBDEs can be agonists of 
both ERα and ERβ receptors and that metabolism of PBDEs may produce more potent pseudoestrogens.  
The common structural features among the estrogenic PBDEs in this study are two ortho (2,6)-bromine 
atoms on one phenyl ring, at least one para-bromine atom (preferably on the same phenyl ring as the 
ortho bromines), and nonbrominated ortho-meta or meta carbons on the other phenyl ring (Meerts et al. 
2001).   
 
The predominant congeners in biological samples, 2,2’,4,4’-tetraBDE (BDE 47) and 2,2’,4,4’,5-penta-
BDE (BDE 99), did not demonstrate estrogenic activity in the Meerts et al. (2001) study.  The hydroxy-
PBDE derivatives that showed minimal activity were para-substituted with a hydroxyl group, whereas the 
para position of the predominant isomers in biological samples is occupied by bromine atom, suggesting 
that the relevance of the results to commercial BDE mixtures is unclear.  Additionally, all of the available 
estrogenicity studies were in vitro, and there is, as yet, no evidence either for estrogenicity or anti-
estrogenicity of PBDEs and/or PBDE metabolites in vivo. 
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5.5.3  Animal-to-Human Extrapolations  
 
Residue levels of PBBs and PBDEs in humans reflect multiple exposure pathways and congener-specific 
elimination and thus, in general, represent steady state body burdens that do not match the congener 
profiles in the original exposure sources.  For example, profiles of PBB and PBDE congeners in human 
milk do not resemble the pattern of any of the commercial mixtures, as illustrated by the finding that the 
major PBDE congener in milk from Swedish mothers was 2,2',4,4'-tetraBDE (BDE 47), which comprised 
approximately 55% of the total PBDEs (Darnerud et al. 1998).  As discussed in Chapter 8, residue 
analyses indicate that tetra- to hexa-congeners predominate in humans, aquatic mammals, birds, fish, and 
other biota, indicating that the biological fate of PBB and PBDE congeners is qualitatively similar in 
various animal species.  The wildlife residue data also indicate that different species have different tissue 
ratios of congeners, possibly reflective of interspecies differences in metabolic capabilities as well as 
potential differences in exposure.  The likelihood of interspecies differences in the quantitative disposition 
of PBBs and PBDEs is illustrated by the observation that metabolism and urinary excretion of a single 
oral dose of BDE 47 was significantly slower in rats than in mice (Orn and Klasson-Wehler 1998). 
 
Humans are  possibly less sensitive than rats to effects of PBDEs on circulating levels of thyroid 
hormones.  This difference is thought to derive from the rat thyroid having a smaller store of iodinated 
thyroglobulin that is more easily depleted when the availability of iodide is limited, and from a more rapid 
clearance of T4 from the rat circulation; the latter resulting from rats not having a high affinity binding 
protein for T4 in serum analogous to thyroid-binding globulin (TBG) in humans (Capen 1997).  If the 
production of T4 and T3 is impaired sufficiently to deplete the thyroid of stored iodinated thyroglobulin, 
the thyroid cannot produce or secrete amounts of T4 and T3 needed to support physiological demands, 
circulating levels of T4 (free T4) and T3 decrease, and a state of thyroid hormone insufficiency ensues.  
Transthyretin (TTR) is the major thyroid hormone binding protein in rats, but not in man.  In most 
mammals, including humans, thyroxin binding globulin (TGB) is the principal thyroid hormone binding 
protein; 74% of the total bound-T4 is bound to TGB, and TTR and albumin bind only 11 and 15%, 
respectively, of the total (Schussler 2000).  In contrast to most mammals, the rat utilizes TTR as the major 
T4 plasma binding protein; approximately 75% of T4 in rat serum is bound to TTR and only 25% to 
albumin.  Both circulating T3 and T4 are highly protein bound with only a small fraction of their total 
present as free hormone, and this high degree of protein binding serves to maintain equilibrium between 
the extracellular and intracellular pools of these hormones (O’Connor et al. 1999).  The increased 
metabolic clearance of serum T4 is thought to involve the induction of hepatic microsomal enzymes.  
Although it is well documented that PBDEs are microsomal enzyme inducers, there is little evidence that 
induction of hepatic enzymes leads to greater clearance of thyroid hormones, indicating that it is 
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misleading to assume that PBDEs are unlikely to affect thyroid function in humans, or that humans are 
less sensitive to these effects than rats. 
 
Less is known about the relative sensitivities of humans and experimental animals to developmental 
effects of PBDEs.  Outstanding uncertainties include potential differences in kinetics of maternal-fetal 
and maternal-infant transfer of PBDEs, as well as potential differences in the degree to which the fetus of 
the human, in comparison to experimental animals, is dependent on maternal thyroid hormone for 
development, particularly during the period of gestation prior to the onset of fetal hormone production. 
 
5.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the EPA 
to develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997a).  As a result, these chemicals may play a role in altering, for 
example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought to 
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be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
 
Concern has been raised that many industrial chemicals, including PBBs and PDBEs, are endocrine-
active compounds capable of having widespread effects on humans and wildlife (Colborn et al. 1993; 
Crisp et al. 1998; Daston et al. 1997; Safe and Zacharewski 1997).  Particular attention has been paid to 
the possibility of these compounds mimicking or antagonizing the action of estrogen.  Estrogen influences 
the growth, differentiation, and functioning of many target tissues, including female and male 
reproductive systems, such as mammary gland, uterus, vagina, ovary, testes, epididymis, and prostate.  In 
addition, there is evidence that some of these environmentally-persistent chemicals alter the thyroid 
hormone system, which is a very important system for normal structural and functional development of 
sexual organs and the brain. 
 
Polybrominated Biphenyls.  PBBs have the potential to interact with the endocrine system based on 
effects that mainly include changes in levels of thyroid and female reproductive hormones.  No studies 
were located that investigated the estrogenic and antiestrogenic activity of PBBs in vitro or in vivo at the 
level of the estrogen receptor. 
 
The thyroid gland is an unequivocal target of PBBs in animals, and evidence in humans is suggestive of a 
similar relationship.  A spectrum of effects has been observed in rats exposed for acute and intermediate 
durations, ranging from decreases in serum levels of T4 and T3 to histological and ultrastructural changes 
in the follicles (Akoso et al. 1982b; Allen-Rowlands et al. 1981; Byrne et al. 1987; Gupta and Moore 
1979; Kasza et al. 1978a; Norris et al. 1975a, 1975b; NTP 1983; Sepkovic and Byrne 1984; Sleight et al. 
1978).  The preponderance of these studies tested FireMaster FF-1 or FireMaster BP-6 in rats, although 
chronic exposure to FireMaster FF-1 induced thyroid follicular hyperplasia in mice (NTP 1992).  Thyroid 
effects also occurred in offspring of treated rats and pigs (Meserve et al. 1992; Werner and Sleight 1981).  
Effects in workers exposed to unspecified PBBs and/or decabromobiphenyl included increased serum 
FSH, low or borderline low serum T4, and increased thyroid antimicrosomal antibody titers (Bahn et al. 
1980). 
 
Serum levels of the adrenal hormones corticosterone B, dehydroepiandrosterone, and dehydro-
epiandrosterone sulfate were decreased in rats fed ≥0.25 mg/kg/day FireMaster BP-6 for 5–7 months 
(Byrne et al. 1988).  Serum corticosterone levels and adrenal weight did not change in rats exposed to 
≤6 mg/kg/day of an unspecified PBB mixture for a shorter duration of 20 days (Castracane et al. 1982).   
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Increased menstrual cycle duration and prolonged implantation bleeding were observed in female 
monkeys fed FireMaster FF-1 in approximate daily dose levels of 0.012 mg/kg for 7 months before 
breeding and during pregnancy (Allen et al. 1979; Lambrecht et al. 1978).  A corresponding decrease in 
serum levels of progesterone suggests that the reproductive effects in the monkeys are related to PBB-
induced endocrine imbalance.  Implantation was completely blocked in 40–67% of female rats treated 
with FireMaster BP-6 by gavage in dose levels ≥28.6 mg/kg on alternate days between gestation 
days 0 and 14 (Beaudoin 1979). 
 
Delayed vaginal opening, an effect suggesting retarded sexual maturation, was observed in F1 generation 
rats whose only PBB exposure was from the mothers fed a diet providing 5 mg/kg/day FireMaster FF-1 
from day 8 of pregnancy until weaning at 28 days postpartum (McCormack et al. 1981). 
 
Two studies of women exposed during the Michigan contamination episode found no associations 
between serum levels of PBBs and breast feeding (Blanck et al. 2000b; Thomas et al. 2001).  
Determinants of PBB serum decay were investigated in women who had a mean initial PBB level of 
20.9 ppb, a mean time between the first and last measurement of 4.2 years, and at least two measurements 
taken when they were not pregnant (Blanck et al. 2000b).  The median PBB half-life was estimated to be 
13.5 years.  Subject-specific decay rates were regressed on various predictor variables.  Results included 
the finding that breast feeding, as either a continuous variable or as categorized by duration (<3, 3–9, or 
>9 months), was not associated with serum PBB decay, although increasing number of pregnancies was 
weakly associated with a slower rate of serum PBB decay (the effect had borderline statistical 
significance).  Additional information on the design and results of this study is provided in Section 5.8.1.  
Thomas et al. (2001) found no relationship between serum levels of PBBs and the frequency and duration 
of lactation in Michigan women.  Characteristics of the study cohort included a mean initial serum PBB 
level of 17.5 ppb, an estimated mean serum PBB level at delivery of 9.4 ppb, mean duration of breast-
feeding as main source of nutrition of 2.6 months, and mean total duration of breast feeding of 
4.1 months.  Exposure was treated as a categorical variable by dividing the women into groups of low 
(reference) exposure (≤1 ppb), moderate exposure (>1–≤7 ppb), and high exposure (>7 ppb), and three 
outcomes of interest were analyzed: (1) the decision to breast feed (yes/no), (2) the duration (months) of 
breast-feeding as the main source of nutrition, and (3) the total duration (months) of breast-feeding.  None 
of the three outcomes was significantly associated with serum PBB levels.  Additional information on the 
design and results of this study is provided in Section 5.2.2.5. 
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The issue of breast cancer has received attention following reports of high levels of organochlorine 
compounds in breast cancer patients.  A relationship between increasing serum levels of PBBs and 
increasing risk of breast cancer was indicated in case-control studies of women exposed during the 
Michigan contamination episode (Henderson et al. 1995; Hoque et al. 1998), but the results are only 
suggestive due to factors such as small number of cases, insufficient information on known breast cancer 
risk factors, and confounding exposures to other organochlorine chemicals.  The evidence for an 
association between breast cancer and PCBs is also not conclusive (Agency for Toxic Substances and 
Disease Registry 2000), and the hypothesis that environmental exposure to PCBs can cause breast cancer 
in humans is controversial (Safe and Zacharewski 1997; Wolff and Toniolo 1995).  Overall, the evidence 
for an association between breast cancer and PBBs is inconclusive and needs further study. 
 
Polybrominated Diphenyl Ethers.  Results of in vitro estrogen receptor and thyroid hormone transport 
protein binding assays, as well as in vivo thyroid hormone homeostasis studies in animals, suggest that 
there is a potential for some PBDEs to disrupt thyroid and other endocrine system functions in humans. 
 
The estrogenic and antiestrogenic activities of 17 PBDE congeners and 3 hydroxylated PBDEs were 
tested in vitro using human breast cell line assays based on ER-dependent luciferase reporter gene 
expression (Meerts et al. 2001).  Eleven of 17 PBDE congeners showed estrogenic activity (dose-
dependent luciferase induction) in the ER-CALUX assay with T47D.Luc cells, although the most potent 
PBDE congeners (2,2',4,4',6-pentaBDE > 2,4,4',6-tetraBDE [BDE 75] > 2,2',4,6'-tetraBDE [BDE 51] > 
2,4,6-triBDE [BDE 30] > 2,3',4,4',6-pentaBDE [BDE 119]) had EC50 values that were 250,000–
390,000 times less potent than that of the natural ligand, 17β-estradiol (E2).  In contrast, two of the 
hydroxylated PBDEs, 4-(2,4,6-tribromophenoxy)phenol, 2-bromo-4-(2,4,6-tribromophenoxy)phenol 
(which have bromine substitution patterns similar to the thyroid hormones T2  [3,5-diiodothyronine] and 
T3 [3,3’,5-triiodothyronine], respectively) had estrogenic potencies exceeding that of E2.  Three of the 
compounds with potent estrogenic activity in the ER-CALUX assay, 2,4,6-triBDE (BDE 30), 2,2',4,4',6-
pentaBDE, and 4-(2,4,6-tribromophenoxy)phenol, were also tested for estrogenicity in ERα-specific and 
ERβ-specific human embryonic kidney cell lines (293-ERα-Luc and ERβs-Luc cells, respectively).  The 
hydroxylated PBDE was potent in the ERα-specific cells (maximum luciferase induction similar to E2) 
and also showed activity in the ERβ-specific cells (maximum 50% induction compared to E2), whereas 
the ERα- and ERβ-specific cell lines were less responsive to BDE 30 and 2,2',4,4',6-pentaBDE.  These 
results indicate that pure congeners of PBDEs can be agonists of both ERα and ERβ receptors and that 
metabolism to hydroxylated PBDEs may increase estrogenic potency.  However, no estrogenic activity 
was demonstrated by the predominant congeners in biological samples, 2,2’,4,4’-tetraBDE (BDE 47) and 
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2,2’,4,4’,5-pentaBDE (BDE 99).  The hydroxy-PBDE derivatives that showed minimal activity were 
para-substituted with a hydroxyl group, whereas the para position of the predominant isomers in 
biological samples is occupied by bromine atom, suggesting that the relevance of the results to 
commercial PBDE mixtures is unclear.  Additionally, because all of the available estrogenicity data are in 
vitro, there is, as yet, no evidence either for estrogenicity or anti-estrogenicity of PBDEs and/or PBDE 
metabolites in vivo. 
 
The same 17 PBDE congeners and three hydroxylated PBDEs were also tested for possible interaction 
with T4 binding to human TTR, a plasma transport protein of thyroid hormones, in an in vitro competitive 
binding assay (Meerts et al. 1998, 2000).  None of the pure congeners competed with T4 for binding to 
human TTR.  Incubation of the congeners with rat liver microsomes induced by PB (CYP2B enriched), 
β-napthoflavone (CYPIA enriched), or clofibrate (CYP4A3 enriched) indicated that 9 of the 17 pure 
congeners generated metabolites (not identified) that were able to displace T4 from TTR:  4,4'-diBDE 
(BDE 15), 2,4,4'-triBDE (BDE 28), 2,4,6-triBDE (BDE 30), 2,2',4,4’-tetraBDE (BDE 47), 2,2',4,6'-tetra-
BDE (BDE 51), 2,4,4',6-tetraBDE (BDE 75), 3,3,4,4'-tetraBDE, 2,2',4,4',6-pentaBDE, and 
2,3',4,4',6-pentaBDE (BDE 119).  Testing of the three known hydroxylated PBDEs, used for their 
structural resemblance with the thyroid hormones 3,5-diiodothyronine (3,5-T2), 3,3',5-triiodothyronine 
(T3), and 3,3',5,5'-tetraiodothyronine (T4) showed that the T4-like (2,6-dibromo-4-[2,4,6-tribromophen-
oxy]phenol) and T3-like (2-bromo-4-[2,4,6-tribromophenoxy]phenol) hydroxylated PBDEs were 
1.42- and 1.22-fold more potent, respectively, than T4; the T2-like hydroxylated PBDE (4-[2,4,6-tribromo-
phenoxy]phenol) showed low affinity for TTR (0.41-fold less potent than T4).  Studies with hydroxylated 
derivatives of PBBs similarly showed that the congener patterns most closely resembling the diiodo-
phenolic ring of thyroxine had the highest TTR binding activity (Chauhan et al. 2000; McKinney et al. 
1987; Rickenbacher et al. 1986). 
 
Because PBDEs were able to compete with T4-TTR binding only after metabolic conversion, and 
considering that thyroid hormones are also hydroxy-halogenated diphenyl ethers, the results of the Meerts 
et al. (1998, 2000) study suggest that hydroxylation of PBDEs could be involved in the mechanism of 
thyroid toxicity.  However, there are indications that hydroxylated metabolites might not play a large role 
for thyroid effects of commercial penta- and octaBDE mixtures.  For example, of the in vitro-generated 
metabolites displacing T4 from TTR (Meerts et al. 1998, 2000), only two (2,2’,4,4’-tetraBDE (BDE 47) 
and 2,2’,4,4’,6-pentaBDE) are known to be present in a commercial mixture (pentaBDE).  An in vivo 
study in rats (Om and Klasson-Wehler 1998) showed that BDE 47 is well absorbed (~95%), poorly 
metabolized (only 3% of the amount excreted in feces was in the form of metabolites), and occurs in 
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blood and other tissues mainly as the parent compound.  Additionally, the three pure hydroxylated PBDEs 
synthesized by Meerts et al. (1998, 2000) for their structural similarity to thyroid hormones are not based 
on congeners known to be present in commercial penta- or octaBDE mixtures; this suggests that the 
congeners in these mixtures do not share close structural relationships with thyroid hormones.  In another 
study, 4'-hydroxyl derivatives of 1,3,5-triBDE, 1,3,3',5'-tetraBDE, and 1,3,3',5,5'-pentaBDE were tested 
for affinity to the human thyroid hormone receptor proteins THR-α and THR-β in vitro (Marsh et al. 
1998).  These congeners were tested because they theoretically show the highest structural similarity to T4 
and T3.  None of the hydroxylated derivatives effectively competed with the thyroid hormones for binding 
to either receptor (affinities were 4–>1,000 times less than for T4 and T3).  Because the tested congeners 
were the most likely to have affinity for the thyroid hormone receptor, it is likely that other hydroxylated 
PBDE congeners will have even lower potential for receptor binding. 
 
Studies of serum hormone levels and organ histology indicate that the thyroid is a sensitive target for 
some PBDEs.  Reduced serum T4 levels and follicular cell hyperplasia have been consistently observed in 
rats and mice orally exposed to PBDEs.  Acute-duration studies showed decreases in serum T4 in rats 
exposed to ≥10 mg/kg/day octaBDE or ≥30 mg/kg/day pentaBDE for 4 days and in rats and mice exposed 
to ≥18 mg/kg/day pentaBDE for 14 days (Darnerud and Sinjari 1996; Hallgren et al. 2001; Zhou et al. 
2001).  Effects observed in intermediate-duration studies include thyroid hyperplasia in rats exposed to 
≥8 mg/kg/day octaBDE for 30 days (Norris et al. 1973, 1975a, 1975b) and reduced serum T4 in rats 
exposed to ≥10 mg/kg/day pentaBDE for 90 days (WIL Research Laboratories 1984).  Exposure to 
pentaBDE on gestation day 6 through postnatal day 21 caused serum T4 reductions at 30 mg/kg/day in 
maternal rats and at ≥10 mg/kg/day in their offspring (Zhou et al. 2002).  Intermediate-duration exposure 
to a 77% decaBDE/22% nonaBDE commercial mixture caused thyroid hyperplasia in rats at doses of 
≥80 mg/kg/day for 30 days (Norris et al. 1973, 1975a, 1975b).  Chronic (103-week) exposure to high-
purity commercial decaBDE (≥97%) did not induce thyroid histopathological changes in rats at 
≤2,550 mg/kg/day, although follicular cell hyperplasia developed in mice exposed to 2,240 mg/kg/day 
(NTP 1986). 
 
As summarized above, evidence for thyroid hormone involvement in PBDE toxicity includes 
observations in rats and mice that were orally exposed to commercial mixtures of deca-, octa- or 
pentaBDE.  The main effects include (1) histological changes in the thyroid indicative of glandular 
stimulation (e.g., follicular cell hyperplasia similar to that induced by a hypothyroid state) (IRDC 1976; 
Norris et al. 1973, 1975b; NTP 1986; WIL Research Laboratories 1984), and (2) decreased serum 
thyroxine (T4) levels with no accompanying changes in serum TSH (Darnerud and Sinjari 1996; Fowles 
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et al. 1994; Hallgren and Darnerud 1998;WIL Research Laboratories 1984; Zhou et al. 2001, 2002), and 
decaBDE appears to be much less potent than the lower brominated mixtures.  Considering these data, the 
structural resemblance of some PBDEs to T4, and information from binding studies of individual 
congeners as summarized above, it is hypothesized that, depending on dose, duration, and 
mixture/congener, PBDEs can disrupt the production, transport, and disposition of thyroid hormones. 
 
The extent that PBDEs affect circulating levels of T4 or T3 is likely to vary with species, and rats are 
generally regarded as more sensitive than humans.  This is thought to be related to a smaller and more 
rapid turnover of the hormone pool in the rat thyroid, and to a more rapid clearance of secreted hormone 
in the rat; that latter being, in part, related to the absence of thyroid binding globulin (TBG) in rats (Capen 
1997).  Transthyretin (TTR) is the major thyroid hormone binding protein in rats, whereas TBG is the 
main binding protein in man and most other mammals.  However, although TTR is a minor thyroid 
hormone binding protein in humans, it is the principal protein involved in T4 transport to the brain in both 
rats and man (Blay et al. 1993; Sinjari et al. 1998).  TTR does not transport T4 from the bloodstream to 
the brain, but rather is the main T4 binding protein in cerebrospinal fluid (CSF) in rats and humans.  In the 
rat, T4 is transported to the brain primarily through the blood-brain barrier, and not via the choroid plexus 
and CSF (Blay et al. 1993).  2,2',4,4'-TetraBDE (BDE 47) competitively inhibited binding of T4 to sites in 
rat choroid plexus homogenates following in vivo exposure (Sinjari et al. 1998). 
 
5.7  CHILDREN’S SUSCEPTIBILITY  
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 8.6 Exposures of Children. 
 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
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(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
 
Children are exposed to PBBs and PBDEs in the same manner as the general population, primarily via 
consumption of contaminated foods.  Exposure also may occur by transfer of PBBs and PBDEs that have 
accumulated in women’s bodies to the fetus across the placenta.  Because PBBs and PBDEs are lipophilic 
substances, they can additionally accumulate in breast milk and be transferred to nursing infants.  
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Placental transfer, although it may be limited in absolute amounts, is a concern because of possible effects 
of PBBs and PBDEs on sensitive immature tissues, organs, and systems, with potentially serious long-
lasting consequences.  Transfer of PBBs and PBDEs via breast milk could be relatively considerable and, 
like prenatal exposure, has the potential to contribute to altered development. 
 
Although embryos, fetuses, and nursing infants may be exposed to relatively high amounts of PBBs and 
PBDEs during sensitive periods of development, it is not known if the susceptibility of children to the 
health effects of these chemicals differs from that of adults.  Younger children may be particularly 
vulnerable to PBBs and PBDEs because, compared to adults, they are growing more rapidly and are 
generally expected to have lower and distinct profiles of biotransformation enzymes, as well as much 
smaller fat depots for sequestering these lipophilic chemicals.  No specific information was located 
regarding the pharmacokinetics of PBBs in children or nutritional factors that may influence the 
absorption of PBBs. 
 
No biomarkers of exposure or effects for PBBs or PBDEs have been validated in children or in adults 
exposed as children.  There also are no biomarkers in adults that identify previous childhood exposure.  
No studies were located regarding interactions of PBBs or PBDEs with other chemicals in children or 
adults.  No information was located regarding pediatric-specific methods for reducing peak absorption 
following exposure to PBBs or PBDEs, reducing body burden, or interfering with the mechanism of 
action for toxic effects.  In addition, no data were located regarding whether methods for reducing toxic 
effects in adults might be contraindicated in children. 
 
Polybrominated Biphenyls.  Information on health effects of PBBs in children is available from several 
studies of the Michigan contamination episode.  A 1976 medical history questionnaire study of 
342 Michigan children likely to have been exposed to PBBs found that the number of subjectively 
reported symptoms of ill health, including several symptoms of neurological effects, did not increase with 
increasing serum PBB levels (assayed in 1976), but rather decreased; general neurological examinations 
did not reveal a pattern of abnormality among the Michigan children (Barr 1980).  Studies of fetal 
mortality rates in Michigan (Humble and Speizer 1984) and of physical and neuropsychological 
development in Michigan children exposed during the contamination episode (Schwartz and Rae 1983; 
Seagull 1983; Weil et al. 1981) did not conclusively correlate the ingestion of PBBs with effects, as 
summarized below.   
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Examination of approximately 100 children presumably exposed in utero or in early infancy during the 
peak of the Michigan contamination episode and whose families lived on farms known to be 
contaminated with PBBs has not revealed any consistent or marked abnormalities.  No significant 
abnormalities were found by physical and neuropsychological examination of 33 of these exposed 
children when they had a mean age of 37.2 months, compared with a group of 20 age-matched, non-
exposed control children (Weil et al. 1981).  However, subjective interviews with parents suggested that 
more exposed children than control children had frequent upper respiratory illnesses such as colds, runny 
noses, and sore throats (Weil et al. 1981).  Administration of 5 of 18 possible neuropsychological 
development tests from the McCarthy Scales of Children's Abilities to 19 of these exposed children at 
≈2.5–4 years of age showed a statistically significant negative correlation between PBB levels in fat tissue 
and developmental abilities in four of the five tests (Seagull 1983).  Subsequent administration of the full 
battery of 18 neuropsychological tests, as well as I.Q. tests, to the same group of children when ≈4–
6 years old, found that the exposed children's performances were within the normal range in all areas 
assessed (Schwartz and Rae 1983).  Due mainly to the small data set and the inconsistency of the results, 
the available data do not conclusively establish or eliminate the possibility that in utero and early infancy 
exposure to PBBs might adversely affect the development of human children. 
 
Neurobehavioral alterations have been observed in animals following gestational and lactational exposure 
to PBBs.  Performance deficits in tests of operant behavior were seen in 6-month-old offspring of rats that 
were exposed to ≥0.2 mg/kg/day of FireMaster BP-6 by gavage from day 6 of gestation until weaning 
(Henck and Rech 1986), but not in 75-day-old offspring of rats exposed to ≥0.5 mg/kg/day for 4 weeks 
prior to mating (Geller et al. 1985).  Effects on acquisition of forward locomotion, cliff avoidance, cage 
emergence, and open-field activity were found in offspring of rats exposed to ≥0.2 mg/kg/day of 
FireMaster BP-6 in the diet from day 6 of gestation through PND 24 and tested through PND 60 (Henck 
et al. 1994).  Testing of mouse offspring at 30–120 days of age following maternal exposure to 
FireMaster FF-1 by gavage on every other day during gestation and through weaning showed altered 
negative geotaxis and avoidance response latencies at ≥3 mg/kg/day and reduced acoustic startle 
responsiveness and motor activity at 10 mg/kg/day (Tilson 1992).   
 
Animal studies of FireMaster FF-1 and FireMaster BP-6 have also shown that hexabromobiphenyl PBB 
mixtures can induce non-neurological developmental toxicity.  Embryolethal effects or increased 
mortality among nursing young were observed in rats (Beaudoin 1977, 1979; Groce and Kimbrough 
1984) and mice (Luster et al. 1980) after oral exposure during gestation and in monkeys after exposure 
before conception and during pregnancy (Allen et al. 1979; Lambrecht et al. 1978).  Structural 
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malformations in fetuses, including cleft palate, were also observed in rats (Beaudoin 1977) and mice 
(Corbett et al. 1975) after exposure to these PBBs during gestation.  Increased incidences of fetuses with 
extra ribs were found in a study of rats orally exposed to a commercial octabromobiphenyl mixture during 
gestation (Waritz et al. 1977), although decabromobiphenyl was not embryotoxic, fetotoxic, or 
teratogenic in rats (Millischer et al. 1980).  Other studies with FireMaster FF-1 and FireMaster BP-6 
found that body weight gain was reduced in the offspring of rats and mice after exposure during gestation 
and/or lactation (Corbett et al. 1975; Groce and Kimbrough 1984; McCormack et al. 1981, 1982c; 
Meserve et al. 1992).  Liver effects, including increased liver weight and hepatic cytochrome P-450 
enzymic activity, hepatocyte enlargement, vacuolization, and/or other degenerative changes, occurred in 
the offspring of rats, mice, and swine fed FireMaster FF-1 or FireMaster BP-6 during gestation and/or 
lactation (Chhabra et al. 1993; Moore et al. 1978; NTP 1992; Werner and Sleight 1981). 
 
Other effects in offspring of animals exposed to PBBs during gestation and lactation include altered 
thyroid hormone levels.  Serum T4 levels were reduced in 15-day-old offspring of rats that were exposed 
to 2.5 mg/kg/day FireMaster BP-6 in the diet from GD 0 through PND 15 (Meserve et al. 1992).  The 
pups had received pituitary stimulation by an injection of corticotropin-releasing factor or adrenal 
stimulation by an injection of adrenocorticotropic hormone.  Serum concentrations of T3 and T4 were 
significantly reduced in 4-week-old nursing offspring of swine that were fed ≥1.25 mg/kg/day dietary 
doses of FireMaster BP-6 during the second half of gestation and throughout lactation (Werner and 
Sleight 1981).  These effects in offspring are consistent with evidence that the thyroid gland is an 
unequivocal target of PBBs in adult animals.  A spectrum of thyroid effects, ranging from decreases in 
serum T4 and T3 levels to histological and ultrastructural changes in the follicles, has been documented in 
adult rats orally exposed to PBBs (mainly FireMaster BP-6 and FF-1) for acute and intermediate 
durations (Akoso et al. 1982b; Allen-Rowlands et al. 1981; Byrne et al. 1987; Gupta and Moore 1979; 
Kasza et al. 1978a; Norris et al. 1975a, 1975b; NTP 1983; Sepkovic and Byrne 1984; Sleight et al. 1978).  
Additionally, there is suggestive limited evidence of thyroid effects in adult humans; effects in workers 
exposed to unspecified PBBs and/or decaBDE included increased serum FSH, low or borderline low 
serum T4, and increased thyroid antimicrosomal antibody titers (Bahn et al. 1980). 
 
No information was located on possible immunological effects of PBBs in children, and data in adult 
humans are limited and largely inconclusive.  Altered lymphocyte transformation responses among 
populations exposed to PBBs during the Michigan contamination episode have been reported in some 
studies (Bekesi et al. 1978; Roboz et al. 1985), but other investigations were not able to confirm these 
findings (Landrigan et al. 1979; Silva et al. 1979; Stross et al. 1981).  No correlation can be established 
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between altered immune parameters and serum PBB levels based on the available data.  Exposure to 
PBBs caused altered immune responses in a variety of animal species, which suggests that humans may 
also be affected.  Studies in animals, mostly intermediate-duration studies in rodents, showed that a 
variety of immunological parameters such as spleen and thymus weights (Gupta and Moore 1979; Gupta 
et al. 1981; NTP 1983), antibody production (Loose et al. 1981), and lymphoproliferative responses 
(Howard et al. 1980; Luster et al. 1978, 1980) can be affected by treatment with commercial PBB 
mixtures, although some of these effects were only seen at PBB levels that cause overt toxicity (Luster et 
al. 1978, 1980).   
 
Levels of PBBs in breast milk have been measured in women exposed as a result of the Michigan 
contamination episode.  The milk concentrations of PBBs in women from the lower peninsula of 
Michigan (exposed area) were generally higher than in breast milk of females from the upper peninsula 
(farthest from the sources) (Brilliant et al. 1978).  PBB levels in breast milk of five women from exposed 
farms ranged from 0.21–92.7 ppm (Cordle et al. 1978; Humphrey and Hayner 1976).  On a lipid basis, the 
ratio of PBBs in breast milk to maternal serum was 107–122 to 1 and in adipose tissue to breast milk was 
1.1–1.5 to 1 in a cohort of Michigan residents (Eyster et al. 1983; Landrigan et al. 1979).  No monitoring 
information was located on PBBs in breast milk for U.S. populations outside of Michigan. 
 
Determinants of PBB serum decay were investigated in Michigan women who had a mean initial PBB 
level of 20.9 ppb, a mean time between the first and last measurement of 4.2 years, and at least two 
measurements taken when they were not pregnant (Blanck et al. 2000b).  Assuming that PBBs reached 
equilibrium in the body before substantial amounts were eliminated and before the first serum 
measurements were taken, the authors estimated the median PBB half-life to be 13.5 years.  Subject-
specific decay rates were regressed on various predictor variables.  Results of the analysis included the 
finding that an increasing number of pregnancies between the first and last measurement was associated 
with a slower rate of serum PBB decay (the effect had borderline statistical significance).  Breast feeding 
as either a continuous variable or as categorized by duration (<3, 3–9, or >9 months) was not associated 
with serum PBB decay.  Additional information on the design and results of this study is provided in 
Section 5.8.1.  Another study of women exposed to PBBs during the Michigan contamination episode 
similarly found no relationship between serum levels of PBBs and the frequency and duration of lactation 
(Thomas et al. 2001).  Characteristics of the study cohort included a mean initial serum PBB level of 
17.5 ppb, an estimated mean serum PBB level at delivery of 9.4 ppb, a mean duration of breast-feeding as 
the main source of nutrition for 2.6 months, and a mean total duration of breast-feeding of 4.1 months.  
Exposure was treated as a categorical variable by dividing the women into groups of low (reference) 
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exposure (≤1 ppb), moderate exposure (>1–≤7 ppb), and high exposure (>7 ppb).  Three outcomes of 
interest were analyzed: (1) the decision to breast feed (yes/no), (2) the duration (months) of breast-feeding 
as the main source of nutrition, and (3) the total duration (months) of breast-feeding.  None of the three 
outcomes was significantly associated with serum PBB levels, even after controlling for various 
confounding determinants, including histories of previous breast-feeding and thyroid disorders.  
Additional information on the design and results of this study is provided in Section 5.2.2.5. 
 
Polybrominated Diphenyl Ethers.  No specific information was located on health effects of PBDEs in 
newborn or older children.  Thyroid and neurobehavioral alterations have been observed in developing 
animals following pre- and/or postnatal exposure to lower brominated BDEs, indicating that infants and 
children might be particularly susceptible to these effects.  The potential for thyroid and 
neurodevelopmental effects of decaBDE is expected to be relatively low due to differences in the 
toxicokinetics and toxicity of decaBDE compared to lower brominated BDEs.   
 
Thyroid hormones regulate cell proliferation, migration, and differentiation during development, and 
maintenance of normal levels is essential to normal growth and development.  Disruption of circulating 
hormone levels can have markedly different effects, depending on the stage of development, and even 
transient disruptions can produce permanent effects.  Effects can include mental retardation, impaired 
motor skills, and hearing and speech impediments (Boyages 2000; Fisher and Brown 2000).  Several 
factors might contribute to a high vulnerability of the fetus and neonate to lower brominated PBDEs.  
Relatively brief periods of thyroid hormone insufficiency (e.g., 14 days) can produce measurable 
neurological deficits in newborn infants (van Vliet 1999).  Furthermore, unlike the adult thyroid gland, 
which contains a relatively large store of T4 that is sufficient to support circulating levels of hormone for 
several months, the neonatal thyroid contains only enough hormone to support circulating levels of 
hormone for ≥1 day (van den Hove et al. 1999; Vulsma et al. 1989).  Thus, even acute exposures to a dose 
of lower brominated PBDEs sufficient to suppress thyroid hormone production could potentially result in 
thyroid insufficiency in the neonate.  The absorbed dose of lower brominated PBDEs per unit of body 
mass is also likely to be higher in infants compared to adults exposed to similar levels of PBDEs because 
of higher intakes per unit of body mass and exposure from breast milk.  It should be noted that screening 
of all newborn children for hypothyroidism is already a widely accepted and legislatively mandated 
practice (LaFranchi 1999; Landenson et al. 2000); newborns are tested for thyroid hormone levels within 
the first few days of life in the United States and most other developed countries; and treatment is started 
immediately if indicated (LaFranchi 1999; Landenson et al. 2000). 
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Although there is no evidence that exposure to PBDEs causes thyroid effects in humans, the thyroid is a 
well-documented target of lower brominated commercial mixtures and single congeners in adult and 
neonatal rats and mice.  The main effects in animals are reduced serum T4 hormone levels and follicular 
cell hyperplasia, with no accompanying changes in serum T3 or TSH levels.  In adult animals, acute-
duration oral exposure caused decreases in serum T4 in rats exposed to ≥10 mg/kg/day octaBDE or 
≥30 mg/kg/day pentaBDE for 4 days, and in rats and mice exposed to ≥18 mg/kg/day pentaBDE for 
14 days (Darnerud and Sinjari 1996; Hallgren and Darnerud 1998; Hallgren et al. 2001; Zhou et al. 2001).  
Effects observed in intermediate-duration oral studies included thyroid hyperplasia in rats exposed to 
≥8 mg/kg/day octaBDE for 30 days (Norris et al. 1973, 1975a, 1975b) and reduced serum T4 in rats 
exposed to ≥10 mg/kg/day pentaBDE for 90 days (WIL Research Laboratories 1984). 
 
Other animal studies have shown reduced serum levels of thyroid hormones in offspring of rats exposed 
to lower brominated PBDEs during gestation and lactation, as well as in rats orally exposed as weanlings.  
Exposure to pentaBDE from GD 6 through the end of lactation caused serum T4 decreases in maternal 
rats (on GD 20 and PND 22) at 30 mg/kg/day and in their offspring (on PNDs 4 and 14) at ≥10 mg/kg/day 
(Zhou et al. 2002).  Assessment of weanling (28-day-old) rats that were orally exposed to PBDEs for 
4 days and evaluated for thyroid hormone changes on the day after the last exposure showed that 
octaBDE caused significantly reduced serum T4 and T3 levels at ≥10 and ≥60 mg/kg/day, respectively 
(Zhou et al. 2001).  Similar exposure to pentaBDE caused serum T4 and T3 decreases at higher dose levels 
of ≥30 and ≥100 mg/kg/day, respectively.  The results of these studies are consistent with findings of 
reduced serum T4 hormone levels and follicular cell hyperplasia in adult rats and mice confirming that the 
thyroid is a sensitive target of octaBDE and pentaBDE at doses as low as 10 mg/kg/day (Darnerud and 
Sinjari 1996; Hallgren et al. 2001; WIL Research Laboratories 1984). 
 
Although alterations in thyroid hormone homeostasis can cause neurodevelopmental effects, little specific 
information is currently available on the potential neurotoxic effects of PBDEs.  Data are mainly limited 
to the results of three behavioral tests in animals showing some alterations in spontaneous locomotion 
behavior and learning and memory ability in mice that were tested at 2 months of age and as adults 
(4 months), following neonatal exposure (PNDs 3, 10, or 19) to single low oral doses of the congeners 
2,2',4,4'-tetraBDE (BDE 47) or 2,2',4,4',5-pentaBDE (BDE 99) (Eriksson et al. 1998, 1999, 2001, 2002a).  
Effects on spontaneous activity were observed in adult mice treated at either 3 or 10 days of age, but not 
at 19 days of age, suggesting that there is a critical phase of neonatal brain development for the induction 
of behavioral disturbances (Eriksson et al. 1999, 2002a).  No studies were located that sufficiently 
evaluated neurological effects of PBDEs in animals exposed as adults. None of the commercial decaBDE, 
PBBs and PBDEs  299 
 








octaBDE, and pentaBDE products have been screened for neurotoxicity using comprehensive test 
batteries that typically include functional observational, motor activity, and neuropathology evaluations.  
There were no indications of neurotoxicity in rats and mice fed high dietary dose levels of a 94–97% pure 
commercial decaBDE mixture for 14 days (≤19,000 mg/kg/day), 13 weeks (≤9,500 mg/kg/day), or 
103 weeks (≤7,780 mg/kg/day), as assessed by overt clinical signs (all exposures) and nervous system 
histopathology (chronic exposure only) (NTP 1986).  Although the high doses and extended exposure 
durations in the NTP (1986) studies provided opportunities for the development of effects, neurotoxicity 
is only incompletely evaluated due to the lack of testing for subtle behavioral and other sensitive 
neurological end points.  
 
The human relevance of the thyroid and neurodevelopmental effects of lower brominated BDEs in 
animals is unclear.  Humans are generally regarded as being less sensitive than rats to effects of PBDEs 
on circulating thyroid hormones.  This is thought to be related to a smaller and more rapid turnover of the 
hormone pool in the rat thyroid, and to a more rapid clearance of secreted hormone in the rat; the latter 
being, in part, related to the absence of thyroid binding globulin (TBG) in rats (Capen 1997).  
Transthyretin (TTR) is the major thyroid hormone binding protein in rats, whereas TBG is the main 
binding protein in man and most other mammals.  However, although TTR is a minor thyroid hormone 
binding protein in humans, it is the principal protein involved in T4 transport to the brain in both rats and 
man (Blay et al. 1993; Sinjari et al. 1998).  TTR does not transport T4 from the bloodstream to the brain, 
but rather is the main T4 binding protein in cerebrospinal fluid (CSF) in rats and humans.  In the rat, T4 is 
transported to the brain primarily through the blood-brain barrier, and not via the choroid plexus and CSF 
(Blay et al. 1993).  Also, mechanism by which lower brominated BDEs cause decreased serum T4 might 
involve hepatic microsomal enzyme induction and consequent increased metabolic formation of hydroxy-
metabolites, but humans are not particularly sensitive to this effect.  Additionally, the animal studies in 
which neurobehavioral alterations were observed were performed using an atypical design that has not 
been validated, and used exposure levels much higher than those likely to be experienced by humans.   
 
The potential for induction of thyroid and neurodevelopmental effects by decaBDE is low in comparison 
to commercial penta- and octaBDE mixtures due to toxicokinetic and toxicity differences.  The lower 
brominated BDEs preferentially accumulate in the body due to their partitioning and retention in lipid-
rich tissues and lower rates of metabolism and elimination relative to decaBDE (Hardy 2002b; Morck et 
al. 2001, 2003).  These characteristics seem to be a function of the number and location of bromines on 
the diphenyl oxide molecule .  The tetra- and pentaBDEs appear to be relatively well absorbed, whereas 
the fully brominated decaBDE, a large poorly soluble molecule, is very poorly absorbed (≈1% or less of 
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an oral dose) and rapidly eliminated (≈99% of the dose within 72 hours).  Further, decaBDE is 
significantly less toxic than lower brominated BDE mixtures.  For example, a study in weanling rats 
showed that acute oral exposure to commercial decaBDE had no effect on thyroid hormones, while 
similar exposures to commercial octaBDE or pentaBDE mixtures caused decreases in serum T4 and T3 
levels (Zhou et al. 2001).  Similarly, acute postnatal oral exposure to pure decaBDE congener (BDE 99) 
was less potent than BDE 47, BDE 99, and 2,2',4,4',5,5’-hexaBDE (BDE 153) in inducing behavioral 
effects in adult mice (Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 2001a, 2001b, 2002a, 2002b, 
2003).  Chronic (103-week) exposure to a high-purity (≥97%) commercial decaBDE mixture induced 
thyroid follicular cell hyperplasia in mice, but the dose levelwas very high (2,240 mg/kg/day) and no 
thyroid histological changes occurred in similarly exposed rats (NTP 1986).   
 
No information is available regarding the immunosuppressive potential of PBDEs in young animals, and 
data on immune function in adult animals are mainly limited to findings in acute-duration oral studies of 
relatively high doses of pentaBDE.  The plaque-forming splenic cell antibody response to injected sheep 
red blood cells was significantly reduced in mice exposed to 72 mg/kg/day pentaBDE for 14 days 
(Fowles et al. 1994), and in vitro production of IgG immunoglobulin from mitogen-stimulated 
splenocytes was reduced in mice exposed to 36 mg/kg/day pentaBDE for 14 days (Darnerud and 
Thuvander 1998).  Other 14-day studies in mice found no changes in natural killer cell activity at dosages 
≤72 mg/kg/day (Fowles et al. 1994) or numbers of splenic and thymic lymphocyte subsets at dosages 
≤36 mg/kg/day (Darnerud and Thuvander 1998), although 18 mg/kg/day of the single congener 
2,2’,4,4’-tetraBDE (BDE 47) caused significantly reduced numbers of total lymphocytes and CD4+, 
CD8+, and CD45R+ subtypes in spleen (Darnerud and Thuvander 1998). Histological examinations of 
spleen, thymus, lymph node, and/or bone marrow tissues in systemic toxicity studies showed no effects of 
repeated dietary administration in intermediate-duration studies in rats exposed to ≤8,000 mg/kg/day 
decaBDE for 13 weeks (NTP 1986), in mice exposed to ≤9,500 mg/kg/day decaBDE for 13 weeks, in rats 
exposed to ≤750 mg/kg/day octaBDE for 13 weeks (IRDC 1977), or in rats exposed to ≤100 mg/kg/day 
pentaBDE for 90 days (WIL Research Laboratories 1984).  Chronic ingestion of decaBDE caused lesions 
in the spleen of rats exposed to ≥1,200 mg/kg/day (splenic hematopoiesis in males) or 2,240 mg/kg/day 
(splenic fibrosis and lymphoid hyperplasia in females) for 103 weeks (NTP 1986).  None of these studies 
reported changes in clinical condition that could be indicative of reduced immunocompetence.  Although 
the high doses and extended exposure durations provided opportunities for the development of 
histopathology in immune system tissues and relevant clinical signs, no comprehensive immunotoxicity 
evaluations of PBDEs have been performed. 
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Information on the reproductive toxicity of PBDEs mainly consists of a one-generation study of decaBDE 
in rats that found no exposure-related functional effects (Dow Chemical Co. 1975; Norris et al. 1975a, 
1975b).  No histopathological changes were observed in male or female reproductive tissues from rats 
that were exposed to PBDEs in dietary systemic toxicity studies, including decaBDE in rats at doses 
≤8,000 mg/kg/day for 13 weeks or ≤2,550 mg/kg/day for 103 weeks (NTP 1986), decaBDE in mice at 
doses ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day for 103 weeks (NTP 1986); octaBDE in rats 
at ≤750 mg/kg/day for 13 weeks (IRDC 1977); or pentaBDE in rats at doses ≤100 mg/kg/day for 90 days 
(WIL Research Laboratories 1984).  Developmental toxicity studies showed no evidence of teratogenicity 
of deca-, octa-, and pentaBDE in rats and rabbits, although fetotoxic effects, including skeletal 
ossification variations at maternally toxic doses have been observed (Argus Research Laboratories 1985b; 
Breslin et al. 1989; Dow Chemical Co. 1975, 1985; Life Science Research Israel Ltd. 1987; Norris et al. 
1975a, 1975b; WIL Research Laboratories 1986). 
 
Results of in vitro estrogen receptor assays suggest that there is a potential for some PBDEs to disrupt 
endocrine system functions in humans.  The estrogenic and antiestrogenic activities of 17 PBDE 
congeners and 3 hydroxylated PBDEs were tested in vitro using human breast cell line assays based on 
ER-dependent luciferase reporter gene expression (Meerts et al. 2001).  Eleven of 17 PBDE congeners 
showed estrogenic activity (dose-dependent luciferase induction) in the ER-CALUX assay with 
T47D.Luc cells, although the most potent PBDE congeners (2,2',4,4',6-pentaBDE > 2,4,4',6-tetraBDE 
[BDE 75] > 2,2',4,6'-tetraBDE [BDE 51] > 2,4,6-triBDE [BDE 30] > 2,3',4,4',6-pentaBDE [BDE 119]) 
had EC50 values that were 250,000–390,000 times less potent than that of the natural ligand, 17β-estradiol 
(E2).  In contrast, two of the hydroxylated PBDEs, 4-(2,4,6-tribromophenoxy)phenol, 
2-bromo-4-(2,4,6-tribromophenoxy)phenol (which have bromine substitution patterns similar to the 
thyroid hormones T2  [3,5-diiodothyronine] and T3 [3,3’,5-triiodothyronine], respectively) had estrogenic 
potencies exceeding that of E2.  Three of the compounds with potent estrogenic activity in the ER-
CALUX assay, 2,4,6-triBDE (BDE 30), 2,2',4,4',6-pentaBDE, and 4-(2,4,6-tribromophenoxy)phenol, 
were also tested for estrogenicity in ERα-specific and ERβ-specific human embryonic kidney cell lines 
(293-ERα-Luc and ERβs-Luc cells, respectively).  The hydroxylated PBDE was potent in the ERα-
specific cells (maximum luciferase induction similar to E2) and also showed activity in the ERβ-specific 
cells (maximum 50% induction compared to E2), whereas the ERα- and ERβ-specific cell lines were less 
responsive to BDE 30 and 2,2',4,4',6-pentaBDE.  These results indicate that pure congeners of PBDEs can 
be agonists of both ERα and ERβ receptors and that metabolism to hydroxylated PBDEs may increase 
estrogenic potency.  However, no estrogenic activity was demonstrated by the predominant congeners in 
biological samples, 2,2’,4,4’-tetraBDE (BDE 47) and 2,2’,4,4’,5-pentaBDE (BDE 99).  The hydroxy-
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PBDE derivatives that showed minimal activity were para-substituted with a hydroxyl group, whereas the 
para position of the predominant isomers in biological samples is occupied by bromine atom, suggesting 
that the relevance of the results to commercial PBDE mixtures is unclear.  Additionally, because all of the 
available estrogenicity data are in vitro, there is no evidence for estrogenicity or anti-estrogenicity of 
PBDEs or PBDE metabolites in vivo, including possible effects on reproductive development in children. 
 
Lower brominated PBDEs are pervasive environmental contaminants that bioaccumulate in the mother’s 
body and can be transferred to infants through the placenta and breast milk.  Considering the continued 
widespread production and use of PBDEs, particularly commercial pentaBDE mixtures whose constituent 
tetra- to hexaBDE congeners are highly bioaccumulative, as well as the time lag from current-year usage 
to exposure via the food chain, it is probable that tissue concentrations among the general population will 
continue to rise.  The accumulation of decaBDE in breast milk does not appear to be appreciable, in large 
part because the amount in the maternal bloodstream and available for transfer to breast milk is low due to 
poor gastrointestinal absorption and rapid elimination in the feces (Hardy 2002b).  The increasing 
temporal trend for PBDEs in human tissues is illustrated by findings of an exponential increase of PBDEs 
in Swedish human breast milk from 1972 to 1997 with a doubling rate of 5 years (Norén and Meironyté 
1998, 2000).  The milk concentrations of PBDEs (sum of eight congeners) on a lipid basis were 0.07 ppb 
in 1972 and 4 ppb in 1997 (Meironyté et al. 1999).  Analysis of samples from 11 Finnish women showed 
that PBDE concentrations (sum of four congeners, lipid basis) were similar in breast milk and placenta, 
with ranges of 0.99–5.89 and 1.00–4.40 ppb, respectively (Strandman et al. 2000).  The four highest sum 
concentrations were from women following their first childbirth.  No PBPK models have been developed 
for PBDEs that could be used to quantitatively predict transfer of PBDEs via breast milk or across the 
placenta. 
 
Assessments of potential health risks to children were performed for commercial pentaBDE, octaBDE, 
and decaBDE products by industry as part of the EPA Voluntary Children’s Chemical Evaluation 
Program (VCCEPP) (BFRIP 2002; ENVIRON 2003a, 2003b).  Based on evaluations of toxicity and 
potential exposure data, the reports concluded that none of the three commercial mixtures were expected 
to be harmful to children.  These assessment documents have been independently reviewed as part of the 
VCCEP Peer Consultation process, but final reports reflecting peer review findings and EPA conclusions 
are not yet available (EPA 2004a, 2004b, 2004c). 
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5.8  BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The substance being measured may be a metabolite of another 
xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different 
aromatic compounds).  Depending on the properties of the substance (e.g., biologic half-life) and 
environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites 
may have left the body by the time samples can be taken.  It may be difficult to identify individuals 
exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential 
mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to PBBS and PBDEs are 
discussed in Section 5.8.1. 
 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by PBBS and PBDEs are discussed in Section 5.8.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 5.10 “Populations That Are Unusually Susceptible”. 
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5.8.1  Biomarkers Used to Identify or Quantify Exposure to PBBs and PBDEs 
 
Polybrominated Biphenyls.  PBBs are environmental contaminants found mainly, but not exclusively, in 
body tissues and fluids of populations with known exposure to PBBs.  Because they are lipophilic and 
have long half-lives, certain PBB congeners preferentially accumulate in lipid-rich tissues, especially 
adipose, and are present in serum and human milk.  Both serum and adipose PBB levels are indicators of 
exposure, but monitoring PBBs simultaneously in samples of both types is more reliable than in serum 
only.  The serum/adipose partition ratios for groups of pregnant and nonpregnant Michigan women and 
chemical workers ranged between 1:140 and 1:260; the value for Michigan male farmers was 1:325–
329 (Eyster et al. 1983).  These values agree with those reported by other investigators for similar 
populations (Landrigan et al. 1979; Wolff et al. 1982).  The importance of a dual determination of PBBs 
in serum and adipose can be illustrated with the following example.  In a Michigan cohort, 70% of 
839 subjects were identified as having had exposure by their serum PBB levels.  When adipose tissue 
results were added, an additional 24% indicated exposure (Wolff et al. 1982).  The larger number of 
people with measured exposure when adipose tissue results were included reflects the higher fat content 
of adipose compared to serum and the lipophilicity of the chemicals.  The partition ratio of ≈1:300 made 
the adipose limit of detection a more sensitive indicator of exposure, even though the limit of detection in 
adipose was one order of magnitude higher than in serum.  Partition ratios below those reported from 
groups expected to be in equilibrium may indicate current or recent exposure (Anderson 1985). 
 
Using an animal physiological compartment model scaled to humans by adjusting tissue volume, blood 
flow, and clearance and rate constant parameters, it was predicted that human intake of 9.8 g of 
2,2',4,4',5,5'-hexabromobiphenyl (BB 153) from milk consumption over a 230-day period would result in 
peak tissue concentrations of 720 and 2.1 ppm in adipose and blood, respectively, at 8 months, and 
443 and 1.3 ppm, respectively (Tuey and Matthews 1980).  The elimination rate after 5 years would be 
1.63 mg/day, the body burden would be 5.2 g, and the half-life would be 6.5 years.  When a dose of 
0.1 mg/day for 10 months was simulated, the excretion rate in a lean individual was estimated at 
10.2 µg/day; overweight individuals had an excretion rate of 4.1 µg/day.  PBB in adipose tissue from the 
lean and overweight subjects were predicted to be 2,769 and 1,103 ppb, respectively.  PBB in serum 
would be 8.1 ppb in lean subjects and 3.2 ppb in overweight subjects, indicating that t1/2 increases with 
increasing fat content.  These predictions point to the importance of the percentage of body fat in the 
equilibrium dynamics of PBBs and indicate that because lean individuals have a smaller fat compartment, 
all of their body tissues will have higher concentrations of PBB than those in fatter individuals of the 
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same exposure (Tuey and Matthews 1980).  The assumptions on which the predictions are based do not 
reflect possible differences in fat and lean subjects due to the way that PBBs are compartmentalized 
and/or excreted as a percent of the total body burden, or in decay rates due to differential partitioning. 
 
As indicated above, PBBs are persistent chemicals due to their lipophilicity.  Some studies have reported 
practically no change in serum PBB levels over a 12–18-month period (Wolff et al. 1979b) or over a 
3-year period (Landrigan et al. 1979).  The half-life of 6.5 years predicted by Tuey and Matthews (1980) 
is shorter than half-life values determined using sera data from the Michigan PBB cohort (Blanck et al. 
2000b; Lambert et al. 1990; Rosen et al. 1995).  A median half-life of 12.0 years (95% CI 4–97 years) 
was estimated based on two serum measurements from 15 women (≥20 years of age) with an initial serum 
PBB level of ≥5 ppb (Lambert et al. 1990).  An analysis of 51 women (≥18.8 years of age) and 112 men 
(≥18.1 years of age) with at least two measurements 1 year apart and an initial PBB level of ≥20 ppb 
found a median half-life of 13.0 years (95% CI 6.3–infinite years) and 10.0 years (95% CI 6.7–
20.0 years), respectively (Rosen et al. 1995).  Based on a median half-life of 10.8 years (95% CI 9.2–
14.7 years) for the entire group (163 persons, median PBB level 45.5 ppb), it was estimated that it will 
take more than 60 years for their PBB levels to fall below a detection limit of 1 ppb. 
 
Determinants of PBB serum decay were investigated in a group of 380 Michigan women (≥16 years of 
age) who had an initial PBB level of at least 2 ppb and at least two measurements taken when they were 
not pregnant (Blanck et al. 2000b).  The mean initial PBB level was 20.9 ppb (standard deviation 78.7), 
and the mean time between the first and last measurement was 4.2 years (range 16.0–75.2 years).  A total 
of 109 women (29%) did not have a reduction in serum PBB over time.  Assuming that PBBs reached 
equilibrium in the body before substantial amounts were eliminated and before the first serum 
measurements were taken, the entire body was modeled as a single compartment for PBBs with 
exponential decay.  The median PBB half-life in the entire group was 13.5 years (95% CI 10.5–
23.2 years).  Subject-specific decay rate estimates were regressed on predictor variables including initial 
age, body mass index (BMI), smoking history, breast-feeding duration, and parity.  The serum PBB decay 
rate was slower, resulting in a longer half-life, with higher initial PBB levels; women with initial PBB 
levels of <10 and >10 ppb had median half-lives of 12.9 and 28.7 years, respectively.  The PBB decay 
rate was also slower (p=0.03) in women with an initial BMI above the median (BMI≥23).  Increasing 
number of pregnancies between the first and last measurement was also associated with slower decay, but 
the effect was of borderline statistical significance (p=0.06).  Breast feeding as either a continuous 
variable or as categorized by tertiles of duration (<3, 3–9, or >9 months), age, and smoking were not 
associated with serum PBB decay.  
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The average concentration of PBBs (on an adipose basis and as hexabromobiphenyl) in pooled extracts of 
several hundred individual tissue samples collected in a statistically valid manner from all nine regions of 
the continental United States was 1–2 ppb (Lewis and Sovocool 1982).  Chemical workers involved in the 
PBB manufacturing process had a median adipose PBB concentration of 6,000 ppb (range 400–350, 
500 ppb); Michigan male farmers and chemical workers not involved in the PBB manufacturing process 
had a median of 1,050 ppb (range 70,000–350,000 ppb) (Eyster et al. 1983). 
 
Polybrominated Diphenyl Ethers.  Lower brominated PBDEs are persistent environmental contaminants 
that accumulate in adipose tissue, serum, and breast milk serum of the general population, whereas 
decaBDE does not appear to be bioaccumulative.  The accumulation of lower brominated congeners is 
likely due to ease of absorption, metabolism, and elimination compared to decaDBE (i.e., related to each 
molecule’s specific structure and not solely due to lipophilicity).  Serum, adipose, and breast milk levels 
are indicators of exposure for lower brominated PBDEs.  Lower brominated congeners in breast milk are 
useful as markers of maternal body burdens as well as lactational and in utero exposures.  The 
predominant congeners identified in milk and other human tissues are 2,2',4,4'-tetraBDE (BDE 47), 
2,2'4,4',5-pentaBDE (BDE 99), and 2,2'4,4',5,5'-hexaBDE (BDE 153) (all ortho-para substituted 
congeners).  Considering the continued widespread production and use of PBDEs, particularly 
commercial pentaBDE mixtures whose tetra- to hexaBDE congeners are highly bioaccumulative, as well 
as the time lag from current-year usage to exposure via the food chain, it is highly likely that tissue 
concentrations among the general population will continue to rise.  The increasing temporal trend for 
PBDEs in human tissues is suggested by findings of an exponential increase of PBDEs in Swedish human 
breast milk from 1972 to 1997 with a doubling rate of 5 years (Norén and Meironyté 1998, 2000).  In the 
1997 sample, the concentration of PBDE (sum of eight congeners) was 4 ppb on a lipid basis, whereas the 
1972 sample contained 0.07 ppb (Meironyté et al. 1999).  PBDEs have been detected in human placenta 
at concentrations similar to those in breast milk from the same women; concentrations (sum of four 
congeners, lipid basis) ranged from 0.99 to 5.89 ppb in milk and from 1.00 to 4.40 ppb in placenta 
(Strandman et al. 2000). 
 
Estimates of PBDE serum concentrations among electronics-dismantling workers before and after 
exposure-free vacation (median duration 28 days, range 21–35 days) indicate that the higher brominated 
congeners have shorter half-lives than lower brominated congeners (Sjödin et al. 1999b).  The median 
percentage decrease in serum concentrations, based on 5–11 measurements per congener, were 14 (range 
3.5–39), 14 (2.1–38), 14 (6.7–42), 30 (7.9–52), and 66 (47–100) for 2,2',4,4'-tetraBDE (BDE 47), 
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2,2',4,4',5,5'-hexaBDE (BDE 153), 2,2',4,4',5,6'-hexaBDE (BDE 154), 2,2',3,4,4',5',6-heptaBDE 
(BDE 183), and 2,2',3,3',4,4',5,5',6,6'-decaBDE (BDE 209), respectively.  Although actual half-lives were 
not calculated, the data suggest that the half-lives of the lower brominated congeners were <1 year. 
 
Congener patterns in humans may provide information on the nature or pathway of PBDE exposures 
(Hooper and McDonald 2000).  Low tetra:deca congener ratios are suggestive of direct, recent, or 
occupational exposures to the parent PBDE mixture, whereas higher ratios may indicate an environmental 
pathway where exposures result from PBDEs that have leached from the parent mixtures and have been 
degraded in the environment. 
 
5.8.2  Biomarkers Used to Characterize Effects Caused by PBBs and PBDEs 
 
Polybrominated Biphenyls.  Biomarkers of effects for PBBs are likely to be common to the general class 
of halogenated aromatic hydrocarbons, rather than specific for PBBs, because PCBs, PBDEs, and other 
structurally similar chemicals cause generally similar effects.  A potential biomarker for PBBs is related 
to their effect on the thyroid gland.  As discussed in Sections 5.2.2.2, Endocrine Effects, the thyroid gland 
is a sensitive and unequivocal target of PBBs in animals, and evidence in humans is suggestive of a 
similar relationship.  Effects in workers exposed to unspecified PBBs and/or decabromobiphenyl included 
increased serum thyrotropin, low or borderline low serum T4, and increased thyroid antimicrosomal 
antibody titers (Bahn et al. 1980).  A spectrum of thyroid effects has been observed in exposed rats, 
ranging from decreases in serum levels of serum T4 and T3 to histological and ultrastructural changes 
(Akoso et al. 1982b; Allen-Rowlands et al. 1981; Byrne et al. 1987; Gupta and Moore 1979; Kasza et al. 
1978a; Meserve et al. 1992; Norris et al. 1975a, 1975b; NTP 1983; Sepkovic and Byrne 1984; Sleight et 
al. 1978; Werner and Sleight 1981).  Therefore, serum levels of T4 and/or other thyroid hormones are 
potential biomarkers of effects for PBBs.  Additional studies could better characterize thyroid effects of 
PBBs in humans and develop specific correlations between levels and duration of exposure and 
alterations in serum T4 and T3 levels, including information on the specific amount of change in the 
biomarkers associated with a demonstrably adverse effect.  These potential biomarkers are not specific to 
PBBs because PBDEs and other antithyroid agents can have similar effects. 
 
Caffeine has been used as a potential tool to characterize exposure and/or effect of PBBs (Lambert et al. 
1990).  In this test, caffeine is used as a metabolic probe of cytochrome P-450 isozymes activity from the 
CYP1A family, which is significantly induced by PBBs in animals (Safe 1984).  The caffeine breath test 
(CBT) is primarily useful for detecting induction of CYP1A2 activity in human liver.  Because the 
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induction of CYP1A enzymes is AhR mediated, the test has been used as a marker for exposure to PCBs, 
CDDs, and CDFs (Lambert et al. 1992).  A volunteer population of 50 Michigan subjects with previously 
high serum PBB levels and 50 with undetectable or low serum levels was compared to a control 
population not exposed to PBBs (Lambert et al. 1992).  Two tests were conducted, the CYP1A2-
dependent caffeine 3-N-demethylase activity was monitored by the CBT, and 7-N-demethylase activity 
was monitored by the caffeine urinary metabolite ratio (CMR).  PBB-exposed subjects had higher CBT 
values (p<0.02) than urban nonsmokers, but the values were comparable to those of urban smokers.  The 
correlation between serum PBB levels and the CBT value was poor (r2=0.2).  The CMR value in PBB-
exposed subjects was also higher than that of urban nonsmokers (p<0.05); there was no correlation 
between serum PBB levels and CMR values.  Generally, smokers have higher CBT values than 
nonsmokers due to the presence of polycyclic aromatic hydrocarbons (PAH) in tobacco smoke, which 
induce CYP1A (Kotake et al. 1982). 
 
Many reports have been published regarding possible associations between PBB exposure and adverse 
health effects in populations from the state of Michigan.  An early study compared the health status of 
people on quarantined farms with people in nonquarantined farms in the same area (Humphrey and 
Hayner 1975).  The results showed no pattern of differences between the groups.  Moreover, no 
abnormalities of heart, liver, spleen, or nervous system that could be related to PBB exposure were found 
in physical examinations.  A follow-up study examined the prevalence of selected symptoms in groups of 
varying potential exposure 4 years after exposure (Landrigan et al. 1979).  In general, symptoms were 
more prevalent in two self-selected groups and were least prevalent in the group composed of chemical 
workers.  No positive associations were found between serum PBB concentrations and symptom 
frequencies; yet a third group of studies reported an increased incidence of symptoms in Michigan 
farmers relative to a group of control Wisconsin farmers (Anderson et al. 1978a, 1978b, 1978c, 1979).  As 
observed in other epidemiology studies, self-selected groups, which had lower PBB concentrations in 
serum, reported a high incidence of symptoms, compared to randomly selected groups.  No specific 
biomarker of effect could be identified in the Michigan contamination episode.  Furthermore, the 
prevalence of the reported symptoms had no consistent relationship to the extent or types of exposure, and 
most objective clinical measurements have failed to show a significant relationship to PBB exposure 
(Fries 1985a).  Additional information regarding biomarkers for effects can be found in OTA (1990) and 
CDC/ATSDR (1990).  For a more detailed discussion of the health effects caused by PBBs see 
Section 5.2. 
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Polybrominated Diphenyl Ethers.  Biomarkers of effects for PBDEs are likely to be common to the 
general class of halogenated aromatic hydrocarbons, rather than specific for PBDEs, because PBBs, 
PCBs, and other structurally similar chemicals cause generally similar effects.  The thyroid is a critical 
target for lower brominated PBDEs in animals.  As discussed in Sections 5.2.2.2, Endocrine Effects, 
exposure to commerical penta- and octaBDE products caused thyroid changes in rats and mice, 
particularly reduced serum T4 levels (Darnerud and Sinjari 1996; Fowles et al. 1994; Hallgren and 
Darnerud 1998; WIL Research Laboratories 1984; Zhou et al. 2001, 2002).  The potential for induction of 
thyroid effects by decaBDE appears to be low in comparison to penta- and octaBDE mixtures due to 
toxicokinetic and toxicity differences.  In particular, lower brominated BDE congeners preferentially 
accumulate in the body compared to decaBDE, apparently due to their greater partitioning and retention 
in lipid-rich tissues and lower rates of metabolism and elimination (Hardy 2002b; Morck et al. 2001, 
2003), and decaBDE only affected the thyroid in animals following lifetime exposure to dose levels 
several orders of magnitude higher than effect levels of penta- and octaBDE in acute-duration studies 
(NTP 1986; Zhou et al. 2001).   
 
Serum T4 may not be a reliable biomarker in humans because the extent that PBDEs affect circulating 
levels of T4 (or T3) possibly varies with species.  As discussed in  Section 5.5.3, Animal-to-Human 
Extrapolations, humans are generally regarded as less sensitive than rats to thyroid effects of PBDEs due 
to differences in the binding of T4  to serum transport proteins.  In particular, in humans, the binding of 
T4  to thyroxine binding globule (TBG) protects the hormones from metabolism and excretion, resulting 
in relatively long serum half-lives.  Rats lack a high-affinity binding protein (i.e., TBG) and consequently 
have lower serum levels of T4  due to increased availability of the hormone for metabolism and 
elimination.  The clearance of T4  in rats is enhanced by the induction hepatic microsomal enzymes, 
particularly UDP-glucuronyl transferase, which catalyzes the conjugation of free T4 and enhances its 
excretion in the bile.  Effects of PBDEs on thyroid status via induction of hepatic enzymes are therefore 
unlikely to occur in humans.  However, because PBDE-induced decreases in T4 appear to involve 
multiple mechanisms in addition to increased thyroid hormone metabolism (Zhou et al. 2001), serum T4 
level is a potential biomarker of effects for lower brominated PBDEs in humans.  Additional studies 
would be useful to characterize the applicability of the biomarker to humans and develop possible 
correlations between levels and duration of exposure and changes in serum T4.  This biomarker is not 
specific to PBDEs because other antithyroid agents can have similar effects.  Additionally, screening of 
newborn children for hypothyroidism is a widely accepted and legislatively mandated practice (LaFranchi 
1999; Landenson et al. 2000).   
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5.9  INTERACTIONS WITH OTHER CHEMICALS  
 
Polybrominated Biphenyls.  PBBs are potent inducers of liver and kidney P-450 enzymes (MFO) (Haake 
et al. 1985; Halvorson et al. 1985; Shepherd et al. 1984), and as such, they could potentially enhance or 
decrease the toxicity of any substance that is metabolized by the P-450 system.  PBBs are thought to 
potentiate the hepatotoxicity and nephrotoxicity of halogenated hydrocarbons and other substances by 
inducing P-450s that biotransform them to more toxic metabolites (Ahmadizadeh et al. 1984; Kluwe and 
Hook 1978; Kluwe et al. 1978, 1979, 1982; Kuo and Hook 1982; Roes et al. 1977).  In these studies, rats 
and/or mice were given diets containing FireMaster BP-6 that provided doses of 0.13–13 mg/kg/day for 
periods of 10–28 days prior to intraperitoneal challenge with the halogenated hydrocarbons.  
Nephrotoxicity was assessed by measuring kidney weights and the levels of blood urea nitrogen, and by 
the accumulation of p-aminohippurate and/or tetraethylammonium (TEA) in renal cortical slices.  
Hepatotoxicity was assessed by relative liver weights and by levels of SGPT and/or SGOT.  In most 
cases, exposure to PBBs alone did not affect the parameters of nephrotoxicity in animals.  However, 
exposure to PBBs alone usually caused increased relative liver weights and elevated levels of SGOT and 
SGPT.  Pre-exposure to PBBs increased the hepatotoxicity and nephrotoxicity of chloroform 
(Ahmadizadeh et al. 1984; Kluwe and Hook 1978; Kluwe et al. 1978) and carbon tetrachloride (Kluwe et 
al. 1979, 1982) and the nephrotoxicity of trichloroethene and 1,1,2-trichloroethane (Kluwe et al. 1978, 
1979).  PBB pretreatment in dietary studies also potentiated the nephrotoxicity of the antibiotic, 
cephaloridine, in rats (Kuo and Hook 1982). 
 
Pretreatment with PBBs also potentiated the lethality of chloroform, carbon tetrachloride, and 1,1,2-tri-
chloroethane by decreasing the LD50 values (Kluwe et al. 1978, 1979) and the lethality of bromobenzene 
by decreasing the time to death (Roes et al. 1977) in mice after challenge with the halogenated hydro-
carbon.  In contrast, pretreatment of mice with PBBs in dietary studies increased the LD50 value of 1,2-di-
bromo-3-chloropropane (DBCP) but had no effect on the LD50 value of 1,2-dibromoethane (EDB) (Kluwe 
et al. 1981).  Also, PBBs were found to reverse the depletion of nonprotein sulfhydryls (e.g., glutathione) 
caused by DBCP and EDB in the livers and kidneys of mice, suggesting that PBB exposure protected the 
mice from the lethality of DBCP by making glutathione more available for conjugation with the toxic 
metabolites. 
 
No potentiation of toxicity was found when rats were co-exposed to diets containing PBB and mirex, 
photomirex, or kepone, compared with toxicity elicited by each of these substances alone (Chu et al. 
1980). 
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Polybrominated Diphenyl Ethers.  No specific information was located regarding interactions between 
PBDEs and other chemicals.  PBDEs are a group of 209 congeners that display biological activity 
involving different potential mechanisms, and share some toxicological properties with structurally 
similar polyhalogenated aromatic compounds, particularly PBBs, PCBs, polychlorinated- and poly-
brominated dibenzo-p-dioxins (PCDDs and PCBDs), and chlorinated and brominated dibenzofurans 
(PCDFs and PBDFs).  However, although these chemicals are structurally similar in two dimensions, 
PBDEs differ from the other classes on a three-dimensional basis.  In particular, as discussed 
Section 5.5.2 Mechanisms of Toxicity, the influences of the ether bridge in the PBDE molecule preclude 
clearly classifying the congeners as either dioxin-like (coplanar) or non-dioxin-like (non-coplanar).  This 
has implications for both dioxin-type toxicities (mediated by the AhR pathway) and non-dioxin-type 
effects.  For example, structure-activity studies of PBDEs have shown that binding affinities and 
induction of AhR-mediated responses are very weak or negligible (Chen et al. 2000; Meerts et al. 1998), 
suggesting that there is a low potential for effects and interactions involving Ah-receptor-mediated 
mechanisms (e.g., induction of hepatic CYP1A oxygenases and Phase II enzymes, body wasting, thymic 
atrophy, and porphyria).  Because of the diversity of PBDE activities involving Ah-receptor-independent 
mechanisms (e.g., induction of CYP2B and CYP3A oxygenases, induction of changes in brain dopamine 
levels, and disruption of calcium homeostasis), or possibly both Ah-receptor-dependent and -independent 
mechanisms (e.g., liver hypertrophy, disruption of steroid hormone homeostasis, thyroid hormone 
homeostasis, disruption of immune functions), there is a large potential for PBDEs to alter the toxicity of 
other chemicals, or other chemicals to alter the toxicity of PBDEs.  For example, lower brominated PBDE 
mixtures and congeners are inducers of hepatic microsomal enzymes (Carlson 1980a, 1980b; Fowles et al. 
1994; Hallgren et al. 2001; Zhou et al. 2001, 2002) and therefore could potentially enhance or decrease 
the toxicity of any substance that is metabolized by the P-450 system.   
 
5.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE  
 
A susceptible population will exhibit a different or enhanced response to PBBs and PBDEs than will most 
persons exposed to the same level of PBBs and PBDEs in the environment.  Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of PBBs and PBDEs, or compromised 
function of organs affected by PBBs and PBDEs.  Populations who are at greater risk due to their 
unusually high exposure to PBBs and PBDEs are discussed in Section 8.7, Populations with Potentially 
High Exposures. 
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Information was located on a small part of the U.S. population that might be unusually susceptible to 
PBBs and PBDEs.  As indicated in Section 5.4.4.2, breast milk constitutes the most important route of 
excretion of PBBs in lactating females, and this is likely to be the case for lower brominated PBDEs as 
well.  DecaBDE has not been reported in breast milk and is unlikely to accumulate in the milk due to poor 
absorption and rapid elimination in the feces (Hardy 2002b).  Therefore, women with high body burdens 
of PBBs and/or lower brominated PBDEs who breast-feed may be placing their infants at a higher risk of 
potential health effects.  However, in most cases, the benefits of breast-feeding are expected to outweigh 
any risk to infants from exposure to these chemicals in the maternal milk. 
 
Experiments in animals and model simulations in humans have shown that reduction in body fat markedly 
decreases the elimination half-life of PBBs (Domino et al. 1982; Tuey and Matthews 1980).  For 
example, when a dose of 0.1 mg/day for 10 months was simulated in humans, the excretion rate in a lean 
individual was estimated at 10.2 µg/day; overweight individuals had an excretion rate of 4.1 µg/day.  The 
cumulative excretion was 51% of the dose in lean subjects compared to 20.7% in overweight subjects.  
These data indicate that overweight individuals may be at higher risk because they store PBBs for a 
longer time than lean subjects.  On the other hand, because lean individuals have a smaller fat 
compartment, their body tissues will contain higher concentrations of PBB than those in subjects with 
more fat who received the same exposure (Tuey and Matthews 1980); thus, leaner individuals may be 
more vulnerable to short-term effects than fatter individuals.  Because of this phenomenon, a sudden 
reduction in body fat, such as that which could occur during dieting, may cause a redistribution of PBBs 
to potential target organs, which would also increase the potential for adverse health effects to such 
individuals. 
 
Pregnant women and developing infants and fetuses should be viewed as possibly sensitive populations 
for exposure to PBBs and lower brominated PBDEs as they are for other thyroid hormone disrupting 
chemicals (Glinoer 1990; McDonald 2002; Morreale de Escobar et al. 2002).  The condition of pregnancy 
normally puts a significant strain on the maternal thyroid system, which can be exacerbated by iodine 
deficiency; according to data from 1988 to 1994, iodine deficiency is prevalent in approximately 12% of 
the general population and 15% of women of child-bearing age in the United States (Hollowell et al. 
1998).  Thyroid hormones are essential for normal development of the nervous system, lung, skeletal 
muscle, and possibly other organ systems, and the fetus is dependent on maternal thyroid hormones at 
least until the fetal thyroid begins to produce T4 and T3, which occurs in humans at approximately 16–
20 weeks of gestation (Zoeller and Crofton 2000).  The potential of lower brominated PBDEs to disrupt 
maternal, fetal, and newborn thyroid hormone levels is demonstrated by the Zhou et al. (2001, 2002) 
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studies of pentaBDE (technical mixture) in rats, as discussed in Section 5.2.2.2 (Endocrine Effects 
subsection).  The potential for induction of thyroid and neurodevelopmental effects by decaBDE is low in 
comparison to commercial penta- and octaBDE mixtures due to toxicokinetic and toxicity differences, as 
discussed in .Section 5.7 (Children’s Susceptibility). 
 
People with exposure to anti-thyroid drugs (e.g., lithium), thyroid disease, or otherwise compromised 
thyroid function might have a more pronounced response to PBBs and PBDEs because of their underlying 
limitations in thyroid hormone production.  Similarly, people with compromised function of other organs, 
such as those with liver or kidney diseases (e.g., liver cirrhosis or hepatitis B), could be considered more 
susceptible to health effects of PBBs and PBDEs.  However, the potential for induction of thyroid effects 
by PBDEs in humans appears to be low, based on mechanistic data as discussed Section 5.5.3 (Animal-to-
Human Extrapolations). 
 
5.11  METHODS FOR REDUCING TOXIC EFFECTS  
 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to PBBs and PBDEs.  However, because some of the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment of exposures to PBBs and PBDEs.  
When specific exposures have occurred, poison control centers and medical toxicologists should be 
consulted for medical advice. Specific treatment methods have not been developed for exposures to PBBs 
or PBDEs.   
 
The treatment methods discussed below are general methods that would apply to any persistent, lipophilic 
chemical, and have not been tested for efficacy, indicating that they might not be effective in reducing the 
toxic effects of PBBs and PBDEs.  There is no indication of hazards associated with the treatments.  The 
methods are particularly appropriate for trying under conditions of acute exposure, but PBBs and PBDEs 
are not acutely toxic chemicals.  Scenarios where life-threatening acute exposure would occur are 
unlikely, although accidental or intentional ingestion of the commercial products is a conceivable 
concern.  The relevance of the methods to common background environmental exposures to these 
chemicals is unclear, and it is questionable whether current exposure and tissue levels in the general 
population are a health concern.  
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5.11.1  Reducing Peak Absorption Following Exposure  
 
Ingested PBBs and PBDEs are absorbed by the gastrointestinal tract of humans and animals (see 
Section 5.4).  Although there are no specific recommendations for clinical treatment of acute intoxication 
from ingested PBBs and PBDEs, recommendations based on experiences with PCBs are relevant.  
Treatments for acute poisonings from PCBs and related substances include the induction of emesis or 
gastric lavage and stomach pumping to decrease gastrointestinal absorption of the chemicals (Lemesh 
1992).  These procedures would not be beneficial if performed too long after exposure occurred.  
Administration of activated charcoal as a slurry, either aqueous or mixed with a saline cathartic or 
sorbitol, is frequently recommended to decrease the gastrointestinal absorption of PCBs, but the value of 
this treatment for reducing absorption of PCBs, PBBs, and PBDEs is unknown (HSDB 1992).  Repetitive 
administration of activated charcoal might be useful in preventing reabsorption of metabolites.  Rice bran 
fiber decreased absorption of PCBs in the gastrointestinal tract and had a stimulatory effect on fecal 
excretion of PCBs in rats (Takenaka et al. 1991), but it is unclear if rice bran would be of benefit in 
poisoned humans. 
 
The detection of PBBs and PBDEs in the serum and fat of people who were occupationally exposed to 
these chemicals indicates that PBBs and PBDEs can be absorbed by the lungs,skin, and/or orally by hand-
to-mouth contact.  Although no specific methods to reduce absorption of dermally applied or inhaled 
PBBs or PBDEs were located, multiple washings of contaminated skin with soap and water immediately 
following exposure have been suggested to reduce the dermal absorption of PCBs (HSDB 1992).  Studies 
with monkeys showed that soap and water was as effective as or better than such solvents as ethanol, 
mineral oil, or trichlorobenzene in removing PCBs from skin (Wester et al. 1990).  Personal protective 
equipment (e.g., long sleeves, gloves, safety glasses, respiratory protection) and industrial hygiene 
programs generally help to limit occupational exposures.  
 
5.11.2  Reducing Body Burden  
 
PBBs and lower brominated PBDEs tend to accumulate in lipid-rich tissues and are slowly metabolized 
and eliminated from the body (see Section 5.4).  DecaBDE differs from the lower brominated PBDEs in 
that it is unlikely to preferentially accumulate in body tissues due to poor oral absorption and metabolism 
and rapid elimination in the feces (Hardy 2002b).  Several methods to enhance the elimination of PBBs 
from the body have been examined in animals and are applicable to PBDEs, although the relevance of the 
methods is questionable because it is unclear whether current tissue levels are a health concern for the 
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general population.  Methods for increasing the elimination of these chemicals include the restriction of 
caloric intake (to reduce total body fat), and the administration of various agents that interact with bile 
acids including activated charcoal, mineral oil and bile-binding resins such as cholestyramine 
(Kimbrough et al. 1980; McConnell et al. 1980; Polin and Leavitt 1984; Polin et al. 1985, 1991; Rozman 
et al. 1982).  It should be mentioned, however, that based on the pharmacokinetic considerations 
discussed in Section 5.8.1, a rapid breakdown of fat, as might occur in dieting, might lead to a transient 
increase in PBB and PBDE levels in serum and other body tissues, possibly posing a significant re-
exposure problem.  Although some of the studies observed no enhanced elimination (Kimbrough et al. 
1980; McConnell et al. 1980), others identified treatments that were effective in enhancing the biliary and 
intestinal elimination of PBB residues (Polin et al. 1991; Rozman et al. 1982).  Polin et al. (1991) found 
that dietary intervention to reduce PBBs was dose dependent; treatment with 10% mineral oil and a 45% 
reduction in food intake resulted in a 69 and 23% reduction in body burden in rats fed PBBs at dietary 
concentrations of 0.1 and 100 ppm, respectively (Polin et al. 1991).  A combination of mineral oil, 
colestipol, and dietary restriction was successful in reducing the PBB body burdens in chickens (Polin 
and Leavitt 1984; Polin et al. 1985), while each treatment alone had no effect in reducing PBB body 
burden.  A 3-week treatment regimen that included dietary supplements of polyunsaturated oil, vitamins, 
and minerals, and heat stress has been applied in a pilot study to seven human subjects that were known to 
have been exposed to PBBs; following treatment, statistically significant reductions were measured in 
PBB concentrations in fat (Schnare et al. 1984).  Although the lack of a separate control group 
complicates interpretation of the results of this study (each subject served as his/her own control), this 
treatment was developed for the purpose of reducing body burdens of fat-soluble psychoactive drugs 
(Schnare et al. 1984).  A liquid diet was used for 16 individuals who developed symptoms following 
exposure to PCBs and polychlorinated dibenzofurans (Imamura and Tung 1984).  Symptoms were 
reduced several months after the fasting period.  This study is limited in that a control group was not used, 
and body burdens were not measured.  Based on information for PCBs, mobilization of PBBs or PBDEs 
from adipose tissue is not recommended in individuals with hepatic or renal disease (Lemesh 1992). 
 
5.11.3  Interfering with the Mechanism of Action for Toxic Effects  
 
There are no known methods for interfering with the mechanism of action of PBBs or PBDEs.  Although 
the mechanism of action of PBBs and PBDEs is not completely understood, experimental evidence 
accumulated in recent years indicates that some PBB congeners exert toxic actions by a process involving 
several steps (Safe 1984).  This process begins with the binding of particular congeners to the AhR and 
leads ultimately to enhancement of the CYP1A1 gene expression (see Section 5.5).  It appears, therefore, 
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that interfering with the initial step, binding to the receptor, or with any of the subsequent steps, would 
possibly prevent the expression of the toxic effects.  Several compounds have been identified that 
partially antagonize one or more AhR-mediated responses (Bannister et al. 1989); their use, however, has 
been limited to experimental studies in animals.  These compounds were successful antagonists when 
given before or at the same time as an AhR activator (2,3,7,8-tetrachlorodibenzo-p-dioxin) (Bannister et 
al. 1989).  Therefore, the potential for interfering with the mechanism of AhR-mediated effects of PBBs 
after exposure has occurred is largely untested.  For PBDEs, the ether bridge precludes congeners from 
readily adopting the coplanar (dioxin-like) conformation characteristic of AhR ligands (see Section 5.5.2 
Mechanisms of Toxicity).  Because PBDE congeners are not clearly classifiable as either dioxin-like 
(coplanar) or non-dioxin-like (non-coplanar), AhR antagonists might not effectively antagonize effects of 
PBDEs. 
 
PBBs and PBDEs may also cause toxicity by other mechanisms of action.  For example, some PBB 
congeners can be metabolized to reactive arene oxides (Kohli and Safe 1976; Kohli et al. 1978) that may 
alkylate critical cellular macromolecules and result in injury.  PBDE-induced decreases in thyroid T4 
hormone, which can affect neurobehavioral development, are likely to involve multiple mechanisms (see 
Section 5.5.3).  These include induction of hepatic microsomal enzymes, particularly UDPGT, which can 
increase the rate of T4 conjugation and excretion, and metabolic formation of hydroxy-metabolites of 
PBDEs.  PBDEs and their hydroxy metabolites can bind with high affinity to thyroid transport proteins 
because they are structurally similar to T4 hormone  (i.e., are also hydroxy-halogenated diphenyl ethers) 
(see Section 5.5.2).  Effects of PBDEs on thyroid status via induction of hepatic enzymes, however, are 
unlikely to occur in humans, and the impact of hydroxy-metabolites on serum T4 needs further 
clarification.  Effects of PBDEs on the function and development of the nervous system could also 
involve disruption of calcium homeostatic mechanisms and intracellular signalling events (Kodavanti 
2003; Kodavanti and Derr-Yellin 2001, 2002; Smolnikar et al. 2001; Wiegand et al. 2001), effects on 
dopamine uptake into synaptic vesicles and synaptosomes (Mariussen and Fonnum 2002, 2003; 
Mariussen et al. 2003a) and cholinergic functions (Viberg et al. 2001b, 2002a, 2002b), and/or free radical-
induced neuronal death (Reistad et al. 2002).  Clinical interventions designed to interfere with the 
aforementioned mechanisms have yet to be developed.   
 
5.12  ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
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adequate information on the health effects of PBBs and PBDEs is available.  Where adequate information 
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of PBBs and PBDEs. 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
5.12.1  Existing Information on Health Effects of PBBs and PBDEs 
 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
PBBs and PBDEs are summarized in Figures 5-6 and 5-7.  The purpose of this figure is to illustrate the 
existing information concerning the health effects of PBBs and PBDEs.  Each dot in the figure indicates 
that one or more studies provide information associated with that particular effect.  The dot does not 
necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for 
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. 
 
As indicated in Figure 5-6, information is available regarding systemic, immunological, neurological, 
developmental, reproductive, and carcinogenic effects of PBBs in humans.  The information on effects in 
humans is derived from the Michigan contamination episode that involved chronic-duration oral exposure 
to contaminated food and from occupational exposure data in which it was assumed that exposure was 
predominantly through skin contact, although inhalation exposure cannot be ruled out.   
 
Information on health effects in animals is extensive and available for all effect categories, but is nearly 
completely limited to oral exposure studies, which appears to reflect experimental practicality and 
concern for what is thought to be the most prevalent and likely route of environmental exposure. 
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A limited amount of information is available on the systemic and carcinogenic effects of PBDEs in 
humans (Figure 5-7).  Information on health effects of PBDEs in animals is available for all effect 
categories but, like PBBs, is mainly limited to oral exposure studies in animals.  In general, the health 
effects of PBDEs are less adequately studied than for PBBs (and PCBs), and a prominent limitation of the 
PBDE database is a lack of adequate human studies.  
 
5.12.2  Identification of Data Needs  
 
Acute-Duration Exposure.     
 
Polybrominated Biphenyls.  The hepatotoxicity of PBBs in rats and mice is reasonably well characterized 
for acute-duration oral exposure (Bernert et al. 1983; Corbett et al. 1975; Gupta and Moore 1979; Gupta 
et al. 1981; Kimbrough et al. 1978b, 1980, 1981; Lee et al. 1975a, 1975b; Norris et al. 1975a; Raber and 
Carter 1986; Waritz et al. 1977).  Effects on body weight in rats and mice and on the thyroid in rats are 
also well documented (Allen-Rowlands et al. 1981; Corbett et al. 1978; Fraker 1980; Gupta and Moore 
1979; Kimbrough et al. 1981), and thyroid effects occurred at doses as low as those causing liver effects.  
Insufficient acute data exist to definitely establish if the thyroid effects are more critical than effects in the 
liver, but extensive data on thyroid effects from longer term studies and the functional nature of the 
changes suggest that this is the case and justify using a thyroid effect as the basis for an acute oral MRL.  
Acute oral studies in other species would clearly establish the most sensitive target and species for acute 
exposure.  Tests with monkeys, guinea pigs, and mink would be informative because intermediate- and 
chronic-duration studies indicate that these species are more sensitive than the rat and that 
endocrinological effects are particularly sensitive end points. 
 
Information on toxic effects of acute-duration exposure to PBBs by routes other than oral are limited to 
data on hepatic, renal, dermal, and ocular effects of inhalation and dermal exposure in rats or rabbits 
(Millischer et al. 1980; Needham et al. 1982; Norris et al. 1975a; Waritz et al. 1977), but these data may 
not be reliable due to study limitations and possible delayed lethality.  Limitations in the animal database 
include inadequate reporting (e.g., numbers of animals not reported), limited number of exposure levels, 
and lack of studies of PBB mixtures likely to be most toxic (i.e., Firemaster PBBs).  Quantitative data for 
inhalation and dermal absorption of PBBs are lacking.  Studies of inhalation and dermal absorption 
following exposure to soil containing PBBs (i.e., bioavailability studies) would be useful for assessing 
risk at a hazardous waste site.  Further studies identifying target organs and examining the dose-response 
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relationship following acute inhalation and dermal exposure to PBBs would also be informative, although 
exposure via soil and acute toxicosis is not likely to ever be a concern. 
 
Polybrominated Diphenyl Ethers.  Acute-duration studies have documented effects of PBDEs mainly on 
the liver and thyroid of orally exposed rats and mice (Argus Research Laboratories 1985a; Carlson 1980a, 
1980b; Darnerud and Sinjari 1996; Fowles et al. 1994; Hallgren et al. 2001; IRCD 1974, 1975a, 1975b; 
Life Science Research Israel Ltd. 1987; NTP 1986; WIL Research Laboratories 1986; Zhou et al. 2001, 
2002).  The available data on lower brominated PBDEs indicate that the thyroid is a particularly sensitive 
target of acute oral exposure and justify using thyroid effects as the basis for an acute oral MRL, but acute 
effects of lower brominated PBDEs on the liver are not as well characterized as thyroid effects.  Other 
studies indicate that immunosuppression and neurobehavior are important and potentially critical health 
end points for acute exposure to lower brominated PBDEs that need to be further investigated (see 
discussions of data needs for Immunotoxicity and Neurotoxicity).  Studies in other species would help to 
clearly establish the most sensitive target and species for acute exposure, as well as which animal toxicity 
data are the most relevant to humans and useful for assessing acute health risks of lower brominated 
PBDEs.. 
 
Data on decaBDE are insufficient for derivation of an acute-duration oral MRL.  Information is available 
on effects of acute oral exposure to decaBDE on body and liver weights, microsomal enzyme induction in 
the liver, and serum thyroid levels in weanling rats (Carlson 1980b; NTP 1986; Zhou et al. 2001), but the 
database is limited by lack of LOAELs and/or sufficiently sensitive end points for estimation of an MRL. 
 
Acute-duration inhalation exposure toxicity studies of decaBDE were not located.  The inhalation 
database for acute-duration exposure to lower brominated PBDEs is essentially limited to two 14-day 
unpublished industry-sponsored studies of octaBDE in rats (Great Lakes Chemical Corporation 1978, 
2000).  Liver and nasal effect levels were identified in these studies, but MRL estimation is precluded by 
inconsistencies between the studies and a lack of information on thyroid hormone levels.  Additional 
dose-response studies are needed to provide an adequate basis for derivation of an acute inhalation MRL 
for lower brominated PBDEs.   
 
Intermediate-Duration Exposure.     
 
Polybrominated Biphenyls.  The preponderance of toxicity data for PBBs are available from animals 
exposed to FireMaster FF-1 or FireMaster BP-6 in the diet or by gavage in intermediate-duration studies 
(Akoso et al. 1982a, 1982b; Allen et al. 1978; Allen-Rowlands et al. 1981; Aulerich and Ringer 1979; 
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Byrne et al. 1987, 1988; Castracane et al. 1982; Darjono et al. 1983; Gupta and Moore 1979; Gupta et al. 
1981; Kasza et al. 1978a, 1978b; Ku et al. 1978; Lambrecht et al. 1978; Lee et al. 1975a, 1975b; Loose et 
al. 1981; McCormack et al. 1978; Norris et al. 1975a; NTP 1983; Ringer et al. 1981; Sepkovic and Byrne 
1984; Sleight and Sanger 1976; Sleight et al. 1978; Waritz et al. 1977; Werner and Sleight 1981).  Studies 
have been performed with various species (rats have been tested most extensively), and there is evidence 
indicating that monkeys, guinea pigs, and mink may be the most sensitive.  The liver, skin, stomach, and 
thyroid are unequivocal targets, but existing studies do not identify NOAELs for toxic effects in these 
organs in rats and/or more sensitive species.  Hematologic changes indicative of anemia are consistently 
reported effects in various species, but the relative importance of these effects is not known.  Evidence 
suggests that the LOAELs for thyroid effects in rats and hepatic effects in guinea pigs are similar (Akoso 
et al. 1982b; Sleight and Sanger 1976), but reproductive and developmental effects occurred in monkeys 
at a lower dosage.  The serious nature of the developmental toxicity (fetal death) precludes derivation of 
an intermediate-duration oral MRL.  Additional intermediate-duration dose-response studies determining 
NOAELs for the most sensitive end points, as well as the most sensitive species, would be useful for 
possible MRL derivation.  Studies addressing interspecies differences could help to better characterize the 
relative sensitivity of monkeys and humans, particularly the possibility that monkeys are more sensitive 
than humans, as indicated by the high reproductive/developmental toxicity of PBBs in this species that 
has not been noted in PBB-exposed workers or the Michigan cohort.  These studies could also help 
elucidate the toxicological significance of effects in the thyroid and other endocrine organs, particularly 
since the reproductive effects may be related to endocrine imbalance. 
 
Limited information is available on effects of PBBs in animals by inhalation or dermal exposure for 
intermediate durations (Millischer et al. 1980; Norris et al. 1975a; Waritz et al. 1977).  Some inhalation 
data are available for octabromobiphenyl and decabromobiphenyl mixtures and some dermal data are 
available for octabromobiphenyl mixture, but intermediate-duration inhalation and dermal studies of 
FireMaster PBBs have not been performed.  Studies of FireMaster FF-1 or FireMaster BP-6 would be 
particularly useful because these are likely to be the most toxic PBBs based on oral data and due to their 
higher content of potentially toxic congeners.  Although the octabromobiphenyl mixture inhalation data 
are limited by numbers of animals, dose levels, and end points, and only one species (rat) was tested in 
the octabromobiphenyl mixture and decabromobiphenyl inhalation studies, it appears that these PBB 
mixtures are not highly toxic.  Due to the inadequacies of the octabromobiphenyl mixture data and lack of 
any information on inhalation toxicity of the likely more potent FireMaster mixtures, there is insufficient 
basis for deriving an intermediate inhalation MRL.  Although intermediate-duration inhalation studies of 
FireMaster PBBs would be particularly relevant to MRL derivation, they may not be practical due to the 
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low volatilization potential of PBBs.  The intermediate-duration dermal studies of octabromobiphenyl 
mixtures revealed some skin irritation in rabbits but no sensitization in guinea pigs.  Additional studies 
could corroborate the potential for dermal irritation by PBBs and are relevant because the skin is a route 
of concern for exposure at or near hazardous waste sites.  Intermediate-duration inhalation and dermal 
exposure studies of PBB-contaminated soil (e.g., bioavailability studies) that identify thresholds would be 
especially useful for risk assessment at a hazardous waste site. 
 
Polybrominated Diphenyl Ethers.  Available intermediate-duration oral studies in animals indicate that 
the liver and thyroid are the main systemic targets of repeated exposures to lower brominated PBDEs as 
shown by effects that mainly include enlargement and histological alterations in both organs and changes 
in serum levels of thyroid hormones, particularly decreases in serum T4 (Carlson 1980a; IRDC 1976, 
1977; WIL Research Laboratories 1984; Zhou et al. 2001, 2002).  Hepatic effects occurred at the lowest 
LOAEL and were used as the basis for an intermediate oral MRL, but thyroid effects occurred at doses as 
nearly as low as those causing liver effects and the data are insufficient to clearly characterize liver effects 
as more critical than effects in the thyroid.  Studies designed to identify NOAELs for octa-, and 
pentaBDE could provide a better basis for an intermediate duration MRL, as well as help to ascertain the 
most appropriate PBDE mixture on which to base a chronic MRL for lower brominated PBDEs.   
Essentially all of the available data on thyroid effects of lower brominated PBDEs have been obtained 
from oral studies in rats.  It is speculated that the extent that PBDEs affect circulating levels of thyroid 
T4 or T3 might vary with species, and rats are often regarded as more sensitive than humans.  As indicated 
in the Comparative Toxicokinetics section below, specific evidence is needed to determine whether 
PBDEs are likely to affect thyroid function in humans, or if humans are less sensitive to these effects than 
rats.  Studies designed to elucidate the mechanism(s) of action for thyroid and other effects of lower 
brominated PBDEs would help to better understand how the animal toxicity data can best be used to 
identify target end points and assess health risks in humans. 
 
A commercial decaBDPE product (97.34% DBDPO, 2.66% nonaBDE and octaBDE) was administered to 
groups of 25 mated female Sprague-Dawley rats by gavage in corn oil in daily doses of 0, 100, 300, or 
1,000 mg/kg/day on gestation days 0 through 19 in a GLP-compliant study (Hardy et al. 2002).  Each 
female was sacrificed on gestation day 20 and necropsied.  End points included maternal clinical 
observations, maternal body weight/weight gain and food consumption, maternal gravid uterine and liver 
weights, maternal gross lesions, total number of corpora lutea, uterine implantations, early and late 
resorptions, viable and nonviable fetuses, and fetal weight and sex.  Fetuses were examined grossly (all 
fetuses), evaluated for skeletal/cartilaginous malformations and ossification variations (approximately 
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half of each litter), and evaluated for visceral malformations (remaining fetuses).  No treatment-related 
effects on any maternal or fetal endpoints were observed, indicating that 1,000 mg/kg/day was the 
NOAEL for maternal and developmental toxicity. 
 
One intermediate-duration oral toxicity study has been conducted for high purity decaBDE.  In this study, 
multiple dose levels of a commercial decaBDE product (94B97% pure) was fed to rats and mice for 
13 weeks (NTP 1986).  Comprehensive histological examinations were performed, but were limited to the 
control and high-dose groups, and no hematology, clinical chemistry, or urine indices, or thyroid hormone 
levels were evaluated.  There were no compound-related clinical signs, deaths, body weight or food 
consumption changes, gross pathology, or histopathology, indicating that the highest tested doses in rats 
and mice (8,000 and 9,500 mg/kg/day, respectively) were intermediate-duration NOAELs for systemic 
toxicity.  A developmental toxicity study in rats identified a NOAEL of 1,000 mg/kg/day (Hardy et al. 
2002).  Because doses of decaBDE higher than 1,000 mg/kg/day have not been tested for developmental 
toxicity, and the NTP (1986) study indicates that this dose is also a NOAEL for systemic toxicity, the 
1,000 mg/kg/day developmental toxicity NOAEL was used to derive the MRL.  Additional systemic and 
developmental toxicity studies could provide an indication of NOAEL/LOAEL thresholds and possibly 
provide a better basis for an intermediate-duration oral MRL for decaBDE.  
 
The inhalation database for intermediate-duration exposure to PBDEs consists of one well-conducted 
13-week unpublished industry study of octaBDE in rats (Great Lakes Chemical Corporation 2001).  
Hepatic, nasal, lung, thyroid, and ovarian effects were observed, and a NOAEL for changes in thyroid 
hormone levels was used as the basis for estimation of an intermediate-duration inhalation MRL.  
 
Chronic-Duration Exposure and Cancer.     
 
Polybrominated Biphenyls.  Information on chronic systemic toxicity of PBBs in animals is limited to an 
oral bioassay showing hepatic, gastric, hematologic, and/or thyroid effects in rats and mice (NTP 1992), 
and a study showing effects on skin, stomach, and body weight in two monkeys (Allen et al. 1979; 
Lambrecht et al. 1978).  Although limited by the number of studies and species, the available chronic 
animal data corroborate the results of intermediate-duration studies with respect to the observed effects.  
Additional studies would be necessary to determine the most sensitive animal target organ and species for 
chronic exposure and to provide a basis for an MRL, as serious hepatic changes as well as weight loss, 
decreased survival, and developmental effects occurred at the lowest tested dosages.  Because PBBs are 
no longer being produced, exposure is most likely to occur at a contaminated waste site.  Therefore, 
chronic studies examining the effects of PBB-contaminated soil following oral, inhalation, and dermal 
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exposure (i.e., bioavailability studies) would be particularly useful.  Evaluations of the thyroid would be 
particularly informative because intermediate-duration animal studies indicate that the thyroid may be a 
particularly sensitive target organ. 
 
There is sufficient evidence that commercial hexabromobiphenyl mixtures (FireMaster FF-1) are 
hepatocarcinogenic in rats and mice following acute, intermediate, and/or chronic exposure (Groce and 
Kimbrough 1984; Kimbrough et al. 1978b; NTP 1983, 1992).  Additional animal studies could provide 
useful information on interspecies differences and carcinogenesis of other PBB mixtures. 
 
Polybrominated Diphenyl Ethers.  One chronic study of high purity decaBDE has been conducted.  In 
this study, a commercial decaBDE product (94B97% pure) was fed to rats and mice for 103 weeks (NTP 
1986).  Comprehensive gross and histological examinations were performed on all animals, but no 
hematology, clinical chemistry, or urine indices, or thyroid hormone levels, were evaluated.  The lowest 
tested dose in the study, 1,120 mg/kg/day in male rats, was a LOAEL for a liver lesion (neoplastic 
nodules) that is precancerous and associated with thrombosis in the same tissue, precluding estimation of 
an MRL.  Additional chronic dose-response information is needed to provide information on the 
NOAEL/LOAEL threshold and an appropriate basis for derivation of a chronic MRL for decaBDE.  
Neoplastic effects in this study included increased incidences of neoplastic nodules in the liver in the male 
and female rats and hepatocellular adenoma or carcinoma (combined) in the male mice.  Slightly elevated 
incidences of thyroid gland follicular cell tumors were additionally observed in exposed male mice, 
although the increases were equivocal.   
 
Information on the chronic oral toxicity data of lower brominated PBDEs is available from a study in 
which rats were fed a 77.4% pure commercial decaBDE mixture (containing 21.8% nonaBDE and 0.8% 
octaBDE) for approximately 2 years (Kociba et al. 1975; Norris et al. 1975b).  Evaluations that included 
clinical signs, body weight, food consumption, hematology, clinical chemistry, urine indices, and 
comprehensive histological examinations showed no exposure-related effects.  The highest tested dose 
(1 mg/kg/day) was a NOAEL, but this effect level is not an appropriate basis for MRL estimation due to 
insufficient sensitivity of the study.  In particular, a chronic oral MRL based on this study would be 
higher than the intermediate MRL.  No exposure-related neoplastic changes were found, but the power of 
this study to detect carcinogenic effects is limited by the low dose levels.  Considering the limitations of 
the available data, well-designed chronic toxicity studies of pentaBDE and/or octaBDE are needed to 
provide adequate bases for MRL derivation and cancer assessment for lower brominated PBDEs.  
Evaluations that include the thyroid and neurobehavioral end points would be particularly informative 
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because acute and intermediate-duration oral studies indicate that the thyroid and developing central 
nervous system are particularly sensitive targets for lower brominated PBDEs. 
 
Genotoxicity.     
 
Polybrominated Biphenyls.  No information is available regarding potential genotoxic effects of PBBs in 
exposed humans.  PBB mixtures or congeners were not genotoxic in any of the prokaryotic or eukaryotic 
animal systems tested.  These include in vitro assays with S. typhimurium and E. coli bacteria (Haworth et 
al. 1983; Millischer et al. 1980; NTP 1983; Rossman et al. 1991), a host-mediated assay with 
S. typhimurium (Millischer et al. 1980), and in vitro assays with hamster cells (Galloway et al. 1987; 
Kavanagh et al. 1985; Williams et al. 1984), rat liver cells (Kavanagh et al. 1985; Williams et al. 1984), 
mouse liver and lymphoma cells (Myhr and Caspary 1991; Williams et al. 1984), and human fibroblasts 
(Williams et al. 1984).  PBBs also were inactive in in vivo unscheduled DNA synthesis assays with rat 
and mouse hepatocytes (Mirsalis et al. 1985, 1989) and in a micronucleus test with mice (Millischer et al. 
1980).  However, only some of these studies tested commercial PBB mixtures (Kavanagh et al. 1985; 
Millischer et al. 1980; Myhr and Caspary 1991; NTP 1983; Rossman et al. 1991; Williams et al. 1984).  
Additional studies of commercial mixtures could more fully characterize the genotoxic potential of PBBs, 
and provide information regarding differences in potencies of different mixtures and the sensitivities of 
different organisms.  Cytogenic analysis of human populations exposed to PBBs in occupational settings, 
or exposed by consumption of food contaminated with PBBs, might make it possible to more adequately 
assess the genotoxic potential of these compounds in humans. 
 
Polybrominated Diphenyl Ethers.  A limited amount of information has been published on the 
genotoxicity of PBDEs.  Cytogenetic examination of bone marrow cells showed no increase in 
aberrations in maternal and neonatal rats following maternal oral exposure to a 77.4% decaBDE mixture 
(containing 21.8% nonaBDE and 0.8% octaBDE) for 90 days prior to mating and during mating, 
gestation, and lactation (Norris et al. 1973, 1975a).  In vitro assays found that decaBDE did not induce 
gene mutations in bacteria (S. typhimurium) or mammalian cells (mouse lymphoma L5178Y cells), and 
did not induce sister chromatid exchange or chromosomal aberrations in Chinese hamster ovary cells 
(NTP 1986).  In vitro exposure to the single congeners 2,2',4,4'-tetraBDE (BDE 47), 3,4-diBDE 
(BDE 12), and 2-monoBDE (BDE 1) caused increased recombinogenic activity in Chinese hamster SPD8 
and Sp5V79 cells (Helleday et al. 1999).  Although the weight of available evidence indicates that 
decaBDE is not genotoxic, studies using lower brominated mixtures and a wider variety of assay types 
would help to better characterize the genotoxic potential of PBDEs. 
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Reproductive Toxicity.     
 
Polybrominated Biphenyls.  A limited amount of information is available regarding reproductive effects 
in humans after exposure to PBBs.  No evidence for PBBs-related effects on sperm counts, motility, or 
sperm morphology was found in a group of male Michigan workers exposed to PBBs by inhalation or 
dermal contact (Rosenman et al. 1979).  No relationship was found between serum levels of PBBs and the 
frequency and duration of lactation in women exposed during the Michigan contamination episode 
(Thomas et al. 2001). 
 
Although no alterations in fertility or litter size were observed in mink fed PBB-containing diets prior to 
breeding and during pregnancy (Aulerich and Ringer 1979; Ringer et al. 1981) or in the F1 or F2 
generations of female F0 rats fed PBB-containing diets during postimplantation gestation through weaning 
(McCormack et al. 1981), implantation was completely blocked in 40–67% of female rats exposed by 
gavage to PBBs between GDs 0 and 14 (Beaudoin 1979).  Additionally, a lengthening of the menstrual 
cycle and prolonged implantation bleeding with decreased serum progesterone were observed in two of 
seven female monkeys fed a PBB-containing diet prior to and during pregnancy (Allen et al. 1979; 
Lambrecht et al. 1978).  The dosage causing these reproductive effects in monkeys was the lowest tested 
in any intermediate-duration study of PBBs.  In addition, alterations of male reproductive organs in rats 
(Gupta and Moore 1979) and in a monkey (Allen et al. 1978) have been observed after intermediate-
duration exposure to lethal oral doses of PBBs.  Histopathological alterations were not observed in male 
or female reproductive organs after intermediate- or chronic-duration, oral exposure of rats or mice to 
nonlethal doses of PBBs (NTP 1983, 1992).  The animal data suggest that PBBs may cause adverse 
effects on reproductive organs and their function(s) and that reproductive organ functions during the early 
phases of pregnancy may be particularly sensitive to PBBs.  Additional studies in animals exposed by oral 
and other routes, including multi-generation studies with pre-breeding exposure to assess effects on 
fertility in both males and females, might help to further identify the reproductive processes affected by 
PBBs and to determine the dose-response relationships.  Studies elucidating the NOAEL region and 
relative susceptibility of sensitive species (e.g., monkeys) to reproductive and developmental effects 
would be particularly useful, as these data could enable derivation of an intermediate oral MRL. 
 
Polybrominated Diphenyl Ethers.  Information on the reproductive toxicity of PBDEs is limited to a 
single one-generation oral study of decaBDE in rats that found no exposure-related functional effects 
(Dow Chemical Co. 1975; Norris et al. 1975a, 1975b).  Evaluation for histologic effects on reproductive 
organs in the available studies of PBDEs has generally reported no detectable effects.  Tests of octaBDE 
and/or pentaBDE, particularly second-generation studies designed to assess effects on fertility in both 
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sexes, would better characterize the reproductive toxic potential of PBDEs and assure the adequacy of the 
intermediate oral MRL. 
 
Developmental Toxicity.     
 
Polybrominated Biphenyls.  No studies were located regarding developmental effects in humans or 
animals after inhalation or dermal exposure to PBBs.  Studies of fetal mortality rates in Michigan 
(Humble and Speizer 1984) and of physical and neuropsychological development in Michigan children 
exposed in utero or in early infancy during the peak of the 1973 contamination episode (Schwartz and 
Rae 1983; Seagull 1983; Weil et al. 1981) did not conclusively correlate the ingestion of PBBs with 
developmental effects.  Oral acute-, intermediate-, and chronic-duration studies of FireMaster FF-1 or 
FireMaster BP-6 in several species have reported fetotoxic and developmental effects, including 
embryolethality or increased mortality among nursing young (Allen et al. 1979; Beaudoin 1977, 1979; 
Groce and Kimbrough 1984; Lambrecht et al. 1978; Luster et al. 1980), fetal malformations (Beaudoin 
1977; Corbett et al. 1975; Waritz et al. 1977), growth retardation in offspring (Allen et al. 1979; Aulerich 
and Ringer 1979; Corbett et al. 1975; Groce and Kimbrough 1984; Lambrecht et al. 1978; McCormack et 
al. 1981; Meserve et al. 1992; Ringer et al. 1981), liver effects in offspring (Moore et al. 1978; Werner 
and Sleight 1981), and performance deficits in tests of operant behavior in offspring (Henck and Rech 
1986; Tilson 1992).  A limited amount of data is available for octabromobiphenyl and 
decabromobiphenyl mixtures, which indicates that these PBBs are less developmentally toxic than 
FireMaster FF-1 or FireMaster BP-6 (Millischer et al. 1980; Waritz et al. 1977).  Because FireMaster 
FF-1 caused developmental effects in monkeys at the lowest dosage tested in any study of PBBs, a 
chronic oral MRL could not be calculated; studies determining developmental NOAELs in sensitive 
species, therefore, would be particularly relevant.  Additional studies regarding inhalation or dermal 
exposure to PBBs might help to determine whether or not the developmental toxicity of PBBs is route-
specific.  Studies on the mechanism(s) of action of PBBs in different animal species may provide a better 
understanding of the physiological and biochemical basis for the developmental toxicity of PBBs and a 
better basis for extrapolating from animal data in the evaluation of the hazard presented by PBBs to the 
development of human fetuses and children. 
 
Polybrominated Diphenyl Ethers.  Oral developmental toxicity studies have shown no evidence of 
teratogenicity of deca-, octa-, and pentaBDE in rats and rabbits, although fetotoxic effects, including 
skeletal ossification variations at maternally toxic doses, have occurred with lower brominated mixtures 
(Argus Research Laboratories 1985b; Breslin et al. 1989; Dow Chemical Co. 1975, 1985; Hardy et al. 
2002; Life Science Research Israel Ltd. 1987; Norris et al. 1975a, 1975b; WIL Research Laboratories 
PBBs and PBDEs  329 
 








1986).  Effects of gestational exposure to lower brominated PBDEs included minimally increased post-
implantation loss in rats and increased skeletal variations in rabbits at octaBDE doses as low as 10 and 
15 mg/kg/day, respectively (Argus Research Laboratories 1985b; Breslin et al. 1989; Life Science 
Research Israel Ltd. 1987).  Exposure to decaBDE at level as high as 1,000 mg/kg/day (highest tested 
dose) caused no fetal or maternal effects in rats (Hardy et al. 2002).   The available evidence appears to 
adequately show that teratogenicity and fetal toxicity is not a critical effect of concern for either lower 
brominated PBDEs or decaBDE.  However, there is increasing evidence that the developing nervous 
system is a sensitive target of particular PBDE congeners, including decaBDE, as shown by impairments 
in tests of spontaneous motor behavior and learning and memory in adult mice exposed early in life 
(Branchi et al. 2001, 2002; Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 2001a, 2001b, 2002a, 2002b, 
2003a) (see neurotoxicity data needs section). 
 
Immunotoxicity.     
 
Polybrominated Biphenyls.  Information regarding immunological effects of PBBs in humans is 
equivocal.  Some groups of investigators reported altered lymphocyte transformation responses in 
subjects accidentally exposed to PBBs through contaminated food (Bekesi et al. 1978, 1985; Roboz et al. 
1985).  Other investigators could not confirm this in the same populations (Landrigan et al. 1979; Silva et 
al. 1979).  Carefully designed follow-up studies of these populations would provide valuable information 
regarding possible immunological effects of PBBs.  Additional research on the binding of PBBs with 
different plasma fractions could be fruitful, since it appears that on a per cell basis in exposed subjects, 
there is ≈100-fold excess of PBB in white cell fractions, compared to the erythrocyte fraction (Roboz et 
al. 1980, 1985).  Acute oral data in rats and mice provided information regarding histopathology of the 
thymus, spleen, and lymph nodes (Fraker 1980; Fraker and Aust 1978; Gupta et al. 1981).  Data from oral 
intermediate-duration studies in experimental animals suggest that the immune system may be one of the 
most sensitive targets for PBBs (Farber et al. 1978; Fraker 1980; Vos and van Genderen 1973, 1974).  
PBBs decreased the resistance of mice to infection by reducing antibody production (Loose et al. 1981), 
decreased the responsiveness of lymphocytes to mitogenic stimulation in rats and mice (Luster 1978, 
1980) and pigs (Howard et al. 1980), altered thymus weight in rats (NTP 1983), and caused thymus 
atrophy in dogs (Farber et al. 1978), guinea pigs (Vos and van Genderen 1973), and cattle (Moorhead et 
al. 1977).  No studies were located regarding the immunological effects of PBBs in animals after 
inhalation or dermal exposure.  Due to the relatively low vapor pressure of PBBs, inhalation is not a 
predominant route of exposure.  Additional oral studies using a battery of immunological tests would be 
useful to further define the immunological effects of PBBs. 
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Polybrominated Diphenyl Ethers.  Information regarding the immunosuppressive potential of PBDE 
mixtures is essentially limited to evidence from acute-duration oral studies in animals exposed to 
relatively high doses of pentaBDE.  The plaque-forming splenic cell antibody response to injected sheep 
red blood cells was significantly reduced in mice exposed to 72 mg/kg/day pentaBDE for 14 days 
(Fowles et al. 1994), and in vitro production of IgG immunoglobulin from pokeweed mitogen-stimulated 
splenocytes was reduced in mice exposed to 36 mg/kg/day pentaBDE for 14 days (Darnerud and 
Thuvander 1998).  Other 14-day studies in mice found no changes in natural killer cell activity at 
≤72 mg/kg/day (Fowles et al. 1994) or numbers of splenic and thymic lymphocyte subsets at 
≤36 mg/kg/day (Darnerud and Thuvander 1998), although 18 mg/kg/day of the single congener 
2,2’,4,4’-tetraBDE (BDE 47) caused significantly reduced numbers of total lymphocytes and CD4+, 
CD8+, and CD45R+ subtypes in the spleen (Darnerud and Thuvander 1998).  In a 2-year study, NTP 
(1986) reported that exposure to 2,240 mg/kg/day of decaBDE in the diet resulted in a significant increase 
in splenic fibrosis; while not a measure of effects on immune function, it does indicate a treatment-related 
effect on an immune tissue.  Additional oral studies using a battery of immunological tests and a lower 
range of doses would serve to better characterize the immunotoxic potential of PBDEs. 
 
Neurotoxicity.     
 
Polybrominated Biphenyls.  One study was located regarding neurological effects in humans after 
inhalation and/or dermal exposure to PBBs (Brown et al. 1981).  No studies were located regarding 
neurological effects in animals after inhalation or dermal exposure to PBBs.  Although neurological 
symptoms were reported with some frequency by certain residents of Michigan who were likely to have 
consumed PBB-contaminated food, several studies of Michigan residents (including workers in PBB 
manufacturing who presumably were exposed predominately by inhalation and dermal contact) found no 
statistically significant associations between levels of PBBs in serum or fat (from oral or dermal exposure 
to PBBs) and frequencies of subjectively reported neurological symptoms or performance on neuro-
psychological tests (Anderson et al. 1978c, 1979; Barr 1980; Brown and Nixon 1979; Brown et al. 1981; 
Landrigan et al. 1979; Stross et al. 1981; Valciukas et al. 1978, 1979).  Studies of the neuropsychological 
development of children exposed in utero or in early infancy, likewise, were inconclusive in establishing 
an association with PBB exposure (Schwartz and Rae 1983; Seagull 1983; Weil et al. 1981).  Subtle 
effects in neurobehavioral tests were found in rodents, including decreased motor activity (Geller et al. 
1979; Tilson and Cabe 1979) and hind limb weakness (Cabe and Tilson 1978) after intermediate-duration, 
oral exposure and performance deficits in tests of learning behavior in the offspring of female mice and 
female rats exposed during gestation and lactation (Henck and Rech 1986; Henck et al. 1994; Tilson 
1992).  Histopathological alterations of brain or spinal nerve tissue revealed no abnormalities in rats or 
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mice after intermediate- or chronic-duration oral exposure (NTP 1983, 1992).  Periodic neurobehavioral 
testing of animals exposed to PBBs at multiple doses for chronic durations would be useful for 
determining if longer-term exposure leads to more severe neurological effects than those observed with 
intermediate-duration exposures. 
 
Polybrominated Diphenyl Ethers.  A limited amount of information is available on neurological effects 
of commercial PBDE mixtures.  No clinical signs of neurotoxicity or neurohistopathology were observed 
in rats or mice exposed to commercial decaBDE in dietary doses as high as 16,000–19,000 mg/kg/day for 
14 days, 8,000–9,000 mg/kg/day for 13 weeks, or 2,550–7,780 mg/kg/day for 103 weeks (NTP 1986).  
Although the high doses and extended exposure durations provided opportunities for the induction and/or 
development of clinical signs, the study is limited by lack of testing for subtle behavioral changes and 
neurodevelopmental effects.  A commercial pentaBDE mixture was evaluated for several behavioral end 
points in offspring of rats that were perinatally exposed to 1–100 mg/kg/day by gavage on GD 6 through 
PND 21 (MacPhail et al. 2003; Taylor et al. 2002, 2003).  Evaluation of the offspring as adults showed no 
alterations in motor or sensory development as assessed by motor activity, habituation, and auditory 
startle response, although suggestive decreases in fear conditioning were observed.   
 
Neurobehavioral effects of individual PBDE congeners were evaluated in mice that were exposed during 
perinatal and/or early postnatal periods to 2,2',4,4'-tetraBDE (BDE 47), 2,2',4,4',5-pentaBDE (BDE 99), 
2,2',4,4',5,5’-hexaBDE (BDE 153), or 2,2',3,3’,4,4',5,5’,6,6’-decaBDE (BDE 209) (Branchi et al. 2001, 
2002; Eriksson et al. 1999, 2001a, 2002a; Viberg et al. 2001a, 2001b, 2002a, 2002b, 2003a).  Most of 
these studies used similar single oral dose experimental designs and evaluated spontaneous motor 
behavior and swim maze performance at 2–6 months of age.  The findings collectively indicate that the 
nervous system is a target of particular PBDE congeners during a defined critical phase of neonatal brain 
development, as shown by mild impairments in spontaneous motor behavior and learning and memory in 
older mice.  One study used a different experimental design in which mice were exposed to BDE 99 from 
GD 6 to PND 21, and were evaluated using a variety of somatic (body weight gain, hair growth, day of 
eyelid and ear opening, day of incisor eruption) and neurobehavioral (righting reflex, forelimb stick 
grasping reflex, forelimb placing reflexes, negative geotaxis, screen grasping and climbing, pole grasping, 
ultrasonic vocalizations, homing test) end points during PNDs 2–22, as well as spontaneous activity 
endpoints on PNDs 22–120 (Branchi et al. 2001, 2002).  Findings were suggestive of delayed 
sensorimotor development and altered spontaneous behavior. 
 
PBBs and PBDEs  332 
 








Additional oral studies using comprehensive neurobehavioral test batteries are needed to better 
characterize the potential for PBDEs to cause neurotoxic effects in humans.  Based on the limited 
available information (predominantly study abstracts), studies evaluating effects of exposure to lower-
brominated PBDEs and decaBDE commercial mixtures during critical postnatal periods of brain 
development would be particularly useful.,  
 
Epidemiological and Human Dosimetry Studies.     
 
Polybrominated Biphenyls.  Epidemiology studies of people exposed by ingesting PBB-contaminated 
food as a result of the 1973 Michigan PBB contamination episode or who were exposed occupationally in 
the manufacture or distribution of PBBs have not provided conclusive evidence that detectable effects 
have occurred as a result of exposure to PBBs (Anderson et al. 1978c, 1979; Barr 1980; Henderson et al. 
1995; Hoque et al. 1998; Humble and Speizer 1984; Landrigan et al. 1979; Thomas et al. 2001; Valciukas 
et al. 1978, 1979).  Clinical examinations, including neuropsychological, liver function, and sperm count 
testing, of people who may have experienced the highest exposures did not conclusively identify 
particular effects or clinical signs associated with exposure (Brown and Nixon 1979; Brown et al. 1981; 
Rosenman et al. 1979; Schwartz and Rae 1983; Seagull 1983; Stross et al. 1981; Weil et al. 1981).  No 
relationship was found between serum levels of PBBs and the frequency and duration of lactation in 
women exposed during the Michigan contamination episode (Thomas et al. 2001).  A relationship 
between increasing serum levels of PBBs and increasing risk of breast cancer was indicated in case-
control studies of women exposed during the Michigan episode (Henderson et al. 1995; Hoque et al. 
1998), but the results are only suggestive due to factors such as small number of cases, insufficient 
information on known breast cancer risk factors, and confounding exposures to other organochlorine 
chemicals.  The evidence for an association between breast cancer and PBBs is inconclusive and warrants 
further study.  Continued monitoring of the Michigan cohort for prevalence of other types of cancer as the 
cohort ages are also of interest, because lifetime and short-term exposure to PBBs are known to cause 
cancer in animals, and the residence time of PBBs in the body is expected to be long.  If human exposure 
to PBBs is found to be occurring at a hazardous waste site, the nearby population should be studied for 
both exposure and effect data. 
 
Polybrominated Diphenyl Ethers.  A limited amount of epidemiological information is available for 
PBDEs.  Plasma levels of various organohalogen compounds, including the congener 2,2',4,4-tetraBDE, 
as well as serum hormone levels (free and total T3 and T4, TSH, free testosterone, follicle-stimulating 
hormone, lutenizing hormone, and prolactin), were analyzed in 110 men who consumed fatty fish from 
the Baltic Sea (Hagmar et al. 2001).  There was a weak negative correlation between 2,2',4,4'-tetraBDE 
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(BDE 47) and plasma TSH after age adjustment, but BDE 47 could not explain more than 10% of the 
variance in TSH.  No clear association was found between risk of non-Hodgkin’s lymphoma and adipose 
tissue levels of 2,2'4,4'-tetraBDE in a case-control study of 77 Swedish men and women (Hardell et al. 
1998; Lindstrom et al. 1998).  2,2'4,4'-TetraBDE was used as a marker for total PBDE exposure in both of 
these studies.  No epidemiological data on PBDEs are available for non-oral exposure routes. 
 
Animal data raise particular concern for effects of PBDEs on the thyroid as well as possible 
immunological, neurodevelopmental, and carcinogenic effects of exposure.  Epidemiological 
investigations are needed to better characterize the potential for PBDEs, both the lower PBDEs and 
decaBDE, to induce these and other kinds of effects as well as the relationship between PDBE body 
burden and the observed effects.  Considering the possibility that PBDEs can be transferred to the fetus 
across the placenta and that greater amounts might be transferred to nursing infants via breast milk, as 
well as evidence that perinatal exposure to PCBs and other similar chemicals may induce subtle 
neurological damage and immunological and thyroid effects in children, transgenerational studies would 
be particularly informative.  Limitations that are likely to constrain the epidemiological investigations, 
such as unmeasured PBDE exposure concentrations and lack of controls for confounding co-exposures, 
should be addressed. 
 




Polybrominated Biphenyls.  PBBs are stored primarily in adipose tissue and are present in serum and 
human milk of exposed populations.  Several studies have shown that serum and adipose PBB levels are 
biomarkers of exposure (Blanck et al. 2000b; Brilliant et al. 1978; Humphrey and Hayner 1975; Lambert 
et al. 1990; Landrigan et al. 1979; Rosen et al. 1995; Wolff et al. 1982).  It has been proposed that 
measurement of PBB levels in adipose tissue may be a more reliable prediction of body burden than 
serum levels because of the high adipose/serum PBB partition ratio (Anderson 1985).  However, once a 
stable correlation between adipose/serum levels has been characterized, serum levels are a better choice 
for surveillance and monitoring (Anderson 1985).  Further studies on the predictive value of levels of 
PBB (particularly congeners) in serum and adipose tissue in individuals exposed to PBBs for acute, 
intermediate, and chronic durations would provide valuable information that could lead to early detection 
of PBB exposure. 
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A potential biomarker of exposure to PBBs is related to their effect on the thyroid gland.  Effects in 
exposed workers included increased serum thyrotropin, low or borderline low serum T4, and increased 
thyroid antimicrosomal antibody titers (Bahn et al. 1980), and effects in exposed rats included reduced 
levels of serum T4 and T3 (Akoso et al. 1982b; Allen-Rowlands et al. 1981; Byrne et al. 1987; Gupta and 
Moore 1979; Kasza et al. 1978a; Meserve et al. 1992; Norris et al. 1975a, 1975b; NTP 1983; Sepkovic 
and Byrne 1984; Sleight et al. 1978; Werner and Sleight 1981).  Additional studies could better 
characterize thyroid effects of PBBs in humans and develop specific correlations between levels and 
duration of exposure and alterations in serum hormone levels. 
 
Polybrominated Diphenyl Ethers.  PBDEs also accumulate in adipose tissue, serum, and breast milk of 
the general population due to their lipophilic characteristics.  Concentrations of PBDEs in breast milk are 
useful, non-invasive markers of maternal body burdens and of in utero and lactational exposures, but 
body burden assessments are limited by a lack of time-trend data for PBDEs in the milk of U.S. 
populations (Hooper and McDonald 2000).  Breast milk monitoring programs are needed to provide time-
trend data and to verify findings that PBDE levels have been exponentially increasing in breast milk 
during the past 25 years (Norén and Meironyté 1998, 2000).  Studies on the predictive value of levels of 
PBDEs in serum and adipose tissue could provide useful information for detection and monitoring of 
exposure.  It should be noted, however, that solubilities in adipose and breast milk are likely to vary with 
the congener; for example, decaBDE is much less soluble in adipose than pentaBDE.  These differences 
must be kept carefully in mind when designing studies evaluating PBDE exposure. 
 
A potential biomarker of exposure to PBDEs relates to their effect on the thyroid gland.  Thyroid changes 
in rats and mice include reduced serum T4 levels with no changes in serum TSH (Darnerud and Sinjari 
1996; Fowles et al. 1994; Hallgren and Darnerud 1998; WIL Research Laboratories 1984; Zhou et al. 
2001, 2002).  However, using thyroid changes as a biomarker may not be reliable, as thyroid changes are 
not specific to exposure to PBDEs and the effects associated with the thyroid in non-clinical studies are 
likely specific to the rodent and may or may not be directly relevant to the human.  Additional studies 
could characterize thyroid effects of PBDEs in humans and develop specific correlations between levels 




Polybrominated Biphenyls.  There are no specific biomarkers of effects for PBBs.  Numerous studies 
have attempted to correlate serum and adipose PBB levels with an array of symptoms and health 
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complaints in PBB exposed subjects from the state of Michigan (Anderson et al. 1978a, 1978b, 1978c, 
1979; Bekesi et al. 1978; Humphrey and Hayner 1975; Landrigan et al. 1979; Stross et al. 1979).  Thus 
far, no significant correlation has been found.  Continued follow-up studies on the Michigan cohort would 
provide information on effects that may have a long latency, such as cancer.  Elevated levels of two 
cytochrome P-450I-dependent enzymes were observed among PBB exposed subjects, relative to controls 
(Lambert et al. 1990).  The thyroid is a sensitive target for PBBs and characteristic changes include 
reduced serum levels of T4 and other thyroid hormones (Akoso et al. 1982b; Allen-Rowlands et al. 1981; 
Byrne et al. 1987; Gupta and Moore 1979; Kasza et al. 1978a; Meserve et al. 1992; Norris et al. 1975a, 
1975b; NTP 1983; Sepkovic and Byrne 1984; Sleight et al. 1978; Werner and Sleight 1981), indicating 
that they are potential biomarkers of effect.  Levels of CYP enzymes and thyroid hormones, however, are 
not specific for PBB exposure.  Further studies designed to identify specific biomarkers of effects of 
PBBs would facilitate medical surveillance leading to early detection of potentially adverse health effects 
and possible treatment.  Congener-specific analysis may be useful for characterizing dioxin-like health 
effects. 
 
Polybrominated Diphenyl Ethers.  Biomarkers that could be used to characterize health effects caused 
specifically by PBDEs have not been identified.  The thyroid is a critical target for PBDEs in animals, as 
discussed in Section 3.2.2.2, Endocrine Effects, and serum T4 is a potential biomarker of effect for these 
chemicals in humans.  Although this biomarker is not specific to PBDEs because other antithyroid agents 
can have similar effects, changes in T4 could be considered to indicate potential impairment of health.  
 
Absorption, Distribution, Metabolism, and Excretion.     
 
Polybrominated Biphenyls.  There are no quantitative data regarding absorption in humans via the 
inhalation route, but data from occupationally exposed individuals and individuals who ingested food 
contaminated with PBBs suggest that exposure by the oral or dermal route may lead to considerable 
accumulation of PBBs in tissues (Anderson et al. 1978c; Eyster et al. 1983; Landrigan et al. 1979).  The 
animal data indicate that the main component of a commercial PBB mixture (2,2,'4,4',5,5'-hexa-
bromobiphenyl) is efficiently absorbed by the oral route (Matthews et al. 1977; Tuey and Matthews 
1980).  Data regarding absorption after inhalation exposure was limited to a single study (Waritz et al. 
1977).  There are no data regarding absorption via the dermal route.  No studies were located in which 
several doses of different PBB congeners were administered by the inhalation, oral, and dermal routes, 
and for various exposure periods.  Such studies could provide information on the relationship between 
bromination patterns and absorption efficiency and rates of absorption by the different routes of exposure.  
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In addition, studies with different PBB mixtures could help determine possible interaction effects among 
congeners that could affect absorption. 
 
Distribution data are limited to qualitative information derived from cases of accidental ingestion of food 
contaminated with PBBs, cases of occupational exposure via dermal contact (Eyster et al. 1983; 
Landrigan et al. 1979) and autopsy reports (Miceli et al. 1985).  These data suggest that PBBs distribute 
preferentially to tissues with high fat content regardless of the route of exposure.  Data derived from oral 
administration of PBBs to animals indicate that PBBs are distributed first to liver and muscle and then to 
adipose tissue where they are stored (Domino et al. 1982; Lee et al. 1975; Matthews et al. 1977).  Little 
information regarding distribution of PBBs could be drawn from the limited number of studies in animals 
administered PBBs by the inhalation or dermal routes.  Additional well-conducted studies by these routes 
of exposure would provide useful information regarding possible route-dependent distribution patterns.  
Studies regarding distribution through the placenta after inhalation and dermal exposure were not 
available. 
 
Data regarding biotransformation of PBBs in humans are limited to individuals who accidentally 
consumed food contaminated with PBBs or who were exposed to PBBs in the workplace (Wolff and 
Aubrey 1978; Wolff et al. 1979a).  The use of human cell systems in culture might be considered a useful 
addition to whole animal studies for studying the metabolic fate of PBBs.  There are studies regarding the 
metabolism of some PBB congeners after oral administration to rats (Sparling et al. 1980), rabbits (Kohli 
et al. 1978), and pigs (Kohli and Safe 1976).  However, the PBBs mainly studied were monobromo-
biphenyls and dibromobiphenyls, which are only trace components of FireMaster mixtures.  Therefore, 
studies on the in vivo metabolism of the main components of commercial PBB mixtures would provide 
valuable information regarding the metabolic disposition of highly brominated congeners.  A limited 
amount of information is available on the metabolism of PBBs in farm animals (e.g., dairy cows, 
chickens).  This is a data gap because people exposed to PBBs during the Michigan PBB contamination 
episode were predominately exposed by consuming products of farm animals.  Although information 
regarding metabolism after inhalation or dermal exposure is lacking, there is no evidence to suggest that 
other pathways would operate after exposure by these routes. 
 
Studies regarding urinary or fecal excretion of PBBs in humans were not located; however, elimination of 
PBBs through maternal milk is well documented (Brilliant et al. 1978; Eyster et al. 1983; Jacobson et al. 
1984; Landrigan et al. 1979).  Fecal excretion of unabsorbed PBBs appears to be the main route of 
elimination of highly brominated congeners after oral exposure (Matthews et al. 1977; Norris et al. 1975a; 
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Rozman et al. 1982), whereas polar derivatives formed by lower brominated congeners appeared to be 
excreted mainly in the urine (Kohli and Safe 1976; Kohli et al. 1978; Sparling et al. 1980).  Although data 
regarding excretion in animals after inhalation and dermal exposure were not located, there is no reason to 
believe that results from additional studies would reveal different patterns of excretion. 
 
Polybrominated Diphenyl Ethers.  A limited amount of data is available on the toxicokinetics of PBDEs.  
There are data gaps in a number of areas, particularly for octaBDE and pentaBDE commercial mixtures 
and the tetra and hexa congeners that are most prevalent in the environment.  Quantitative absorption 
studies could corroborate the conclusions on oral uptake in animals that are based on elimination and 
excretion data.  Metabolism studies would help to characterize the enzymes involved as well as the 
transformation of some congeners to biologically active hydroxylated BDEs.  There are still data gaps in 
the toxicokinetics of decaBDE, including an incomplete understanding of the debromination of decaBDE 
to lower brominated BDEs. 
 
Comparative Toxicokinetics.     
 
Polybrominated Biphenyls.  The data suggest that there are qualitative differences in the toxicokinetic 
disposition of PBBs among humans and among animal species (Wolff and Aubrey 1978; Wolff et al. 
1979a).  However, these differences appear to be highly dependent on the specific congener or mixture 
studied.  In general, all species absorb PBBs, with varying efficiency, and accumulate PBBs in tissues 
rich in fat.  Once absorbed, PBBs are distributed in a biphasic manner in all examined animal species 
(Domino et al. 1982; Ecobichon et al. 1983; Matthews et al. 1977).  No studies were located that provide 
information regarding differences or similarities in metabolic disposition of PBBs between humans and 
animals.  Limited data in humans indicate that fecal excretion of PBB residues occur (Eyster et al. 1983).  
Experimental data in animals suggest that the rate and extent of PBB elimination in the urine and feces 
are dependent on the degree and pattern of bromination (Kohli et al. 1978; Matthews et al. 1977; Sparling 
et al. 1980).  Analysis of the excreta of humans exposed in the workplace and near hazardous waste sites 
would provide information regarding biotransformation and elimination kinetics in humans.  In addition, 
similar target organs have been identified across animal species, but the database is not complete enough 
for identifying a most sensitive species.  Although the toxicological data in humans are limited and 
inconclusive, adverse immune effects observed in humans (Bekesi et al. 1978) have also been observed in 
rats, mice, and pigs (Howard et al. 1980; Luster et al. 1978, 1980) suggesting that any of these species 
may represent a suitable animal model for humans.  The only reported PBPK model for PBBs describes 
the distribution and body burden of the major component of FireMaster mixtures, 2,2',4,4',5,5'-hexa-
bromobiphenyl (BB 153), in the rat (Tuey and Matthews 1980).  The serum mean half-life of 6.5 years 
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predicted using this model is shorter than half-life values of approximately 12–29 years estimated using 
human sera data from the Michigan PBB cohort (Blanck et al. 2000b; Lambert et al. 1990; Rosen et al. 
1995); one possible reason for this difference is differences in body fat between humans and laboratory 
rodents resulting in a different distribution of the administered compound.  This indicates a need for an 
improved PBPK model for extrapolating animal data to humans and/or for studies designed to produce 
data for improving the performance of PBPK analyses. 
 
Polybrominated Diphenyl Ethers.  Insufficient data are available to determine whether qualitative 
differences in the toxicokinetic disposition of PBDEs exist between humans and animals and among 
animal species.  Differences are likely to be dependent on the specific congener or mixture studied, and 
pharmacokinetic modeling studies could help to determine the validity of extrapolating data.  Most of the 
available toxicokinetic studies of PBDEs have been performed in rats, and studies in other species could 
help to ascertain the most relevant animal model. 
 
The extent that PBDEs affect circulating levels of thyroid T4 or T3 might vary with species and rats are 
often regarded as  more sensitive than humans.  The main basis for this opinion seems to be studies 
showing that PBDEs affect binding of thyroid hormones to transthyretin (TTR), the primary transport 
protein in rats.  Because TTR is not the major transport protein in humans, the findings have been 
interpreted as evidence that humans will be less sensitive than rats to thryoid effects of PBDEs.  As 
discussed in Section 5.5.3, the greater sensitivity of rats is thought to be related to a smaller and more 
rapid turnover of the hormone pool in the rat thyroid, and to a more rapid clearance of secreted hormone 
in the rat; the latter being, in part, related to the absence of thyroid binding globulin (TBG) in rats.  
Whereas TTR is the major thyroid hormone binding protein in rats, TBG is the main binding protein in 
humans and most other mammals.  Specific evidence is needed to determine whether PBDEs are likely to 
affect thyroid function in humans, or if humans are less sensitive to these effects than rats. 
 
Methods for Reducing Toxic Effects.     
 
Polybrominated Biphenyls.  The mechanism by which PBBs enter the blood stream in humans is not 
known; consequently, there are no established methods for reducing absorption.  Studies in experimental 
animals that could identify substances that prevent or delay absorption and that do not represent a toxic 
risk per se would be valuable.  There are no established methods for reducing body burden in humans, but 
studies in animals and model simulations in humans indicate that reducing body fat markedly increases 
elimination of PBBs (Domino et al. 1982; Tuey and Matthews 1980).  The effect of reduction of body fat 
(e.g., by dieting and exercising) in PBB-exposed humans has not been fully researched. 
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The mechanism of toxic action of PBBs is not completely understood and no methods exist to block the 
toxic response due to exposure to PBBs.  A more complete characterization of the cytosolic AhR protein, 
to which some PBB congeners are thought to bind, and understanding of physiological effects of receptor 
blockage would be useful for the possible identification of blockers of AhR-mediated toxic effects.  
Further studies aimed at elucidating the nonreceptor-mediated mechanism of action of some PBBs would 
also be valuable. 
 
Polybrominated Diphenyl Ethers.  The mechanism by which PBDEs enter the blood stream is not 
known, there are no established methods for reducing body burden of PBDEs, and the mechanisms of 
toxic action of PBDEs are incompletely understood.  Types of studies that could address these data gaps 
and possibly provide information on reducing toxic effects of PBDEs are discussed in the preceding 
subsection on PBBs.  
 
Children’s Susceptibility.     
 
Polybrominated Biphenyls.  Information on health effects of PBBs in children is available from several 
studies of the Michigan feed contamination episode.  A 1976 study of Michigan children likely to have 
been exposed to PBBs found that the number of subjectively reported symptoms of ill health, including 
several symptoms of neurological effects, did not increase with increasing serum PBB levels, but rather 
decreased; general neurological examinations did not reveal a pattern of abnormality among the Michigan 
children (Barr 1980).  Studies of fetal mortality rates in Michigan (Humble and Speizer 1984) and of 
physical and neuropsychological development in Michigan children exposed during the contamination 
episode (Schwartz and Rae 1983; Seagull 1983; Weil et al. 1981) did not conclusively correlate the 
ingestion of PBBs with effects.  Neurobehavioral alterations have been observed in rats following 
gestational and lactational exposure to PBBs (Henck and Rech 1986; Henck et al. 1994; Tilson 1992).  
Other effects in offspring of rats exposed to PBBs during gestation and lactation include decreased serum 
levels of thyroid hormone levels (Meserve et al. 1992; Werner and Sleight 1981).  These effects in 
offspring are consistent with evidence that the thyroid gland is an unequivocal target of PBBs in adult 
animals.  No information was located on possible immunological effects of PBBs in children, and data in 
adult humans are limited and largely inconclusive (Bekesi et al. 1978; Landrigan et al. 1979; Roboz et al. 
1985; Silva et al. 1979; Stross et al. 1981), but exposure to PBBs caused altered immune responses in a 
variety of animal species, which suggests that children may also be affected.  Continued assessment of 
children exposed to PBBs during the Michigan contamination episode, with particular emphasis on 
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evaluation of cognitive abilities, thyroid function, and immune competence, would help to better assess 
the susceptibility of children to PBBs. 
 
Polybrominated Diphenyl Ethers.  No information was located on health effects of PBDEs in newborn or 
older children.  Thyroid and neurobehavioral alterations have been observed in animals following pre- 
and/or postnatal exposure to commercial PBDE mixtures and single PBDE congeners, indicating that 
these are potential effects of concern in exposed children.  Serum levels of thyroid T4 and T3 hormones 
were reduced in offspring of rats that were orally exposed to pentaBDE during gestation and lactation and 
in rats exposed as weanlings (Zhou et al. 2002).  Alterations in spontaneous locomotion behavior and 
learning and memory ability were observed in mice that were tested at 2 months of age and as adults 
(4 months) following neonatal exposure to single low oral doses of the congeners  2,2',4,4'-tetraBDE 
(BDE 47) and 2,2',4,4',5-pentaBDE (BDE 99) (Eriksson et al. 1998, 1999, 2001a, 2002a).  Effects were 
observed in adult mice treated at either 3 or 10 days of age, but not at 19 days of age, suggesting that there 
was a critical window for the induction of behavioral disturbances (Eriksson et al. 1999, 2002a).  
Additional studies are needed to better characterize the potential susceptibility of children to the effects of 
PBDEs on the thyroid and neurodevelopment, particularly considering the possibility that these effects are 
related to the dependence of central nervous system development on thyroid hormones.  No information is 
available regarding the immunosuppressive potential of PBDEs in children or young animals, indicating 
that studies of immune competence in developing animals would also help to more fully assess children’s 
susceptibility to PBDEs. 
 
Child health data needs relating to exposure are discussed in Section 8.8.1 Identification of Data Needs:  
Exposures of Children. 
 
5.12.3  Ongoing Studies  
 
Ongoing studies that are relevant to health effects of PBBs and PBDEs, as identified in the Federal 
Research in Progress database (FEDRIP 2002) and the websites of various U.S. government agencies, are 
listed in Table 5-9. 
 
The Great Lakes Chemical Corporation is collaboratively working with Health Canada to assess potential 
effects of pentaBDE using a three-tier study approach (Biesemeier 2004).  The first tier study, a 28-day 
repeated oral (gavage) toxicity study in rats, has been completed, but the draft report was not available as 
of June 2004.  The basis of this study was mainly to serve in selecting gavage dose levels for the second  
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Table 5-9.  Ongoing Studies on the Health Effects of PBBs and PBDEs 
 
Investigator Affiliation Research description Sponsor Source 
Anderson HA Wisconsin Department 
of Health and Family 
Services, Madison, 
Wisconsin 
To characterize human exposures to 
PCBs, PBDEs, and DDT from Great 
Lakes fish consumption and to 
determine mechanisms by which 
PBDEs in Great Lakes fish may act 
separately or synergistically with PCB 




Hammock B University of California, 
Davis, California 
Support for testing hypotheses 
regarding the association of PBBs, 
PBDEs, and other known xenobiotic 








Compare the concentration of PBDEs 
in infants and analyze sediments and 
fish in the Great Lakes 
EPA EPA 
2004d 
Huwe JK Agricultural Research 
Service, Fargo, North 
Dakota 
Development of effective remediation 
procedures for PBDEs and other 
persistent organic pollutants in animal 






University, East Lansing, 
Michigan 
An effort to determine if exposure to 
halogenated organic compounds 
(including PBBs and PBDEs) via 
breastfeeding creates a risk to the 
immune system of the child 
EPA EPA 
2004d 
Ludewig G University of Kentucky, 
Lexington, Kentucky 
A multispecies approach to analyze 




Marcus M Emory University, 
Atlanta, Georgia 
Investigation of the effect PBBs have 
on pubertal development, reproductive 
health, and ovarian function 
NIEHS FEDRIP 
2003 
Omann GM Department of Veterans 
Affairs, Washington, DC 
The immunotoxicological potential of 
PBDEs found in the environment will 
be assessed using fish immune cells 










investigation of end points and 
mechanisms of action for PBDEs and 
PCDEs, including structure-activity 







Triangle Park, North 
Carolina 
Development of a PBPK animal model 
for PBDEs to estimate fetal exposure 
in humans and to determine the 
validity of the model by creating/using 
new analytical methods using cord 
blood and meconium  
EPA EPA 
2004d 
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Table 5-9.  Ongoing Studies on the Health Effects of PBBs and PBDEs 
 
Investigator Affiliation Research description Sponsor Source 
Robertson L University of Kentucky 
Medical Center, 
Lexington, Kentucky 
Laboratory synthesis of pure PBDE 




Sikka HC State University of New 
York College at Buffalo, 
Buffalo, New York 




Trosko JE Michigan State 
University, East Lansing, 
Michigan 
Epigenic effects of PBBs and other 
environmental toxicants on cellular 
communication  pathways 
NIEHS/EPAa FEDRIP 
2002 
Vos J Bilthoven, Netherlands Risk assessment of brominated flame 
retardants for human health and 
wildlife 
EU EU 2004 
Willett LB Ohio State Universities, 
Wooster, Ohio 
Develop methods to monitor the 
occurrence of PBBs and other 
xenobiotics in the environment of 
cattle; create methods that will reduce 
or eliminate exposure of cattle and the 
food products they produce to these 
xenobiotics; determine mechanisms 
by which xenobiotics are transported, 
bound, and mobilized in vivo; describe 
the pharmacokinetics; and to study 
target organ modifications in cattle 
caused by xenobiotic chemicals that 







aNIEHS/EPA Superfund Basic Research Program 
bNational Sea Grant College Program 
 
DDT = dichlorodiphenyltrichloroethane; EPA = U.S. Environmental Protection Agency; EU = European Union; 
NIEHS = National Institute of Environmental Health Sciences; NOAA = National Oceanic and Atmospheric 
Administration; PCB = polychlorinated biphenyls; PBPK = physiologically based pharmacokinetic; USDA = U.S. 
Department of Agriculture  
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tier study, a one-generation reproductive study in rats, of which the draft protocol is currently being 
written (as of June 2004).  This protocol is being drafted with a pharmacokinetic segment, but it has not 
yet been confirmed whether it will be retained in the final study design.  The results of the one-generation 
study will be used to select gavage dose levels for the third tier study, a two-generation reproductive study 
in rats with endocrine, developmental neurobehavioral, and other end point segments.  The entire program 
is not expected to be completed until near the end of 2005. 
 
NTP is in the process of designing a study to assess the toxicity of tetraBDE (NTP 2004). 
 











6.  CHEMICAL AND PHYSICAL INFORMATION 
 
6.1   CHEMICAL IDENTITY  
 
Polybrominated Biphenyls.  PBBs are a class of structurally similar brominated hydrocarbons in which 
2–10 bromine atoms are attached to the biphenyl molecule.  Monobrominated structures (i.e., one 
bromine atom attached to the molecule) are often included when describing PBBs.  The general chemical 












where m + n = 1–10 
 
It can be seen from the structure that a large number of brominated compounds are possible.  The 
209 possible compounds for PBBs are called “congeners”.  However, the number of PBB congeners that 
actually exist in commercial PBB mixtures is much less compared to polychlorinated biphenyls (PCBs).  
Typically, only a subset of the 209 possible congeners is observed for PBBs.  PBBs can be categorized by 
degree of bromination.  The term “homolog” is used to refer to all PBBs with the same number of 
bromines (e.g., tribromobiphenyls).  Based on the number of bromine substituents, there are 
10 homologous groups of PBBs (monobrominated through decabrominated).  Each homologous group 
contains one or more congeners.  The mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, and 
decabromo congeners can exist in 3, 12, 24, 42, 46, 42, 24, 12, 3, and 1 forms, respectively.  Homologs 
with different substitution patterns are referred to as isomers.  For example, the group of dibromobiphenyl 
homologs contains 12 isomers.  The numbering system for PBBs is also shown above.  Positions 2, 2', 6, 
and 6' are called ortho positions, positions 3, 3', 5, and 5' are called meta positions, and positions 4 and 
4' are called para positions.  In a PBB molecule, the benzene rings can rotate around the bond connecting 
them; the two extreme configurations are planar (the two benzene rings are in the same plane; dihedral 
angle=0°) and nonplanar (the two benzene rings are in perpendicular planes to each other; dihedral 
angle=90°).  The degree of planarity is largely determined by the number of substitutions in the ortho 
positions.  The replacement of hydrogen atoms in the ortho positions with larger bromine atoms forces 
the benzene rings to adopt a configuration with a larger dihedral angle or a nonplanar configuration.  The 
benzene rings of non-ortho substituted PBBs, as well as mono-ortho substituted PBBs, may assume a 
small dihedral angle (in which the dihedral angle is small, but >0°) or “near” planar configuration.  These 
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molecules are referred to as planar or coplanar congeners.  The benzene rings of other congeners cannot 
assume a planar or coplanar configuration and are referred to as nonplanar congeners (Hardy 2002). 
 
Like PCBs, the 209 congeners for PBBs are arranged in ascending numerical order using a numbering 
system developed by Ballschmiter and Zell (1980) that follows the IUPAC rules of substituent 
characterization of biphenyls.  The resulting numbers assigned by Ballschmiter and Zell (which are also 
referred to as congener, IUPAC, or BZ numbers) are widely used for identifying individual congeners of 
PBBs.  For example, the PBB congener, 2,2',4,4',5,5'-hexabromobiphenyl, may be referred to as BB 153 
in this document.  The identities of several PBB congeners are shown in Table 6-1 (WHO 1994a, 1994b). 
 
Michigan Chemical Corporation, the major producer of PBBs from 1970 to 1976, marketed mixtures of 
PBBs under the trade name FireMaster (e.g., BP-6 and FF-1).  However, the FireMaster trade name has 
also been used for other brominated flame retardants using different numerical designations.  Other 
former producers of PBBs in the United States included White Chemical Corporation (Bayonne, New 
Jersey) and Hexcel Corporation (Sayreville, New Jersey), which both produced technical mixtures of 
octabromobiphenyl and decabromobiphenyl until 1979.  The trade names of some commercial PBB 
mixtures formerly produced in other countries are: Berk Corporation, Great Britain (e.g., BerkFlam, 
Flammex); Chemische Fabrik Kalk, Germany (e.g., Bromkal); and Ugine Kuhlmann (now Atofina in 
France) (e.g., Adine).   
 
The chemical identities of hexabromobiphenyl, octabromobiphenyl, decabromobiphenyl (BB 209), and 
BB 153, the most abundant congener in commercial FireMaster FF-1 and FireMaster BP-6, are listed in 
Table 6-2.   
 
Polybrominated Diphenyl Ethers.  PBDEs are a class of structurally similar brominated hydrocarbons, in 
which 2–10 bromine atoms are attached to the diphenyl ether molecule.  Monobrominated structures (i.e., 
one bromine atom attached to the molecule) are often included when describing PBDEs.  The general 

















where m + n = 1–10 
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Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
 Biphenyl 92-52-4 92-52-4 
 Monobromo- 26264-10-8 101-55-3 
1 2 2052-07-7  
2 3 2113-57-7  
3 4 92-66-0  
 Dibromo- 27479-65-8 2050-47-7 
4 2,2’ 13029-09-9  
5 2,3 115245-06-2  
6 2,3’ 49602-90-6  
7 2,4 53592-10-2  
8 2,4’ 49602-91-7  
9 2,5 57422-77-2  
10 2,6 59080-32-9  
11 3,3’ 16400-51-4  
12 3,4 60108-72-7  
13 3,4’ 57186-90-0  
14 3,5 16372-96-6  
15 4,4’ 92-86-4  
 Tribromobiphenyl 51202-79-0 49690-94-0 
16 2,2’,3   
17 2,2’,4   
18 2,2’,5 59080-34-1  
19 2,2’,6   
20 2,3,3’   
21 2,3,4   
22 2,3,4’   
23 2,3,5   
24 2,3,6   
25 2,3’,4   
26 2,3’,5 59080-35-2  
27 2,3’,6   
28 2,4,4’ 6430-90-6  
29 2,4,5 115245-07-3  
30 2,4,6 59080-33-0  
31 2,4’,5 59080-36-3  
32 2,4’,6 64258-03-3  
33 2’,3,4   
34 2’,3,5   
35 3,3’,4   
PBBs and PBDEs  348 
 








Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
36 3,3’,5   
37 3,4,4’ 6683-35-8  
38 3,4,5 115245-08-4  
39 3,4’,5 72416-87-6  
 Tetrabromobiphenyl 40088-45-7 40088-47-9 
40 2,2’,3,3’   
41 2,2’,3,4   
42 2,2’,3,4’   
43 2,2’,3,5   
44 2,2’,4,5’   
45 2,2’,3,6   
46 2,2’,3,6’   
47 2,2’,4,4' 66115-57-9  
48 2,2’,4,5   
49 2,2’,4,5' 60044-24-8  
50 2,2’,4,6   
51 2,2’,4,6' 97038-95-4  
52 2,2’,5,5' 59080-37-4  
53 2,2’,5,6' 60044-25-9  
54 2,2’,6,6' 97038-96-5  
55 2,3,3’,4 97038-99-8  
56 2,3,3’,4’   
57 2,3,3’,5   
58 2,3,3’,5’   
59 2,3,3’,6   
60 2,3,4,4’   
61 2,3,4,5 115245-09-5  
62 2,3,4,6 115245-10-8  
63 2,3,4’,5   
64 2,3,4’,6   
65 2,3,5,6   
66 2,3’,4,4’ 84303-45-7  
67 2,3’,4,5   
68 2,3’,4,5’   
69 2,3’,4,6   
70 2,3’,4’,5 59080-38-5  
71 2,3’,4’,6   
72 2,3’,5,5’   
73 2,3’,5’,6   
74 2,4,4’,5   
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Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
75 2,4,4’,6 64258-02-2  
76 2’,3,4,5   
77 3,3’,4,4’ 77102-82-0  
78 3,3’,4,5   
79 3,3’,4,5’ 97038-98-7  
80 3,3’,5,5’ 16400-50-3  
81 3,4,4’,5 59589-92-3  
 Pentabromobiphenyl 56307-79-0 32534-81-9 
82 2,2’,3,3’,4   
83 2,2’,3,3’,5   
84 2,2’,3,3’,6   
85 2,2’,3,4,4’   
86 2,2’,3,4,5   
87 2,2’,3,4,5’   
88 2,2’,3,4,6 77910-04-4  
89 2,2’,3,4,6’   
90 2,2’,3,4’,5   
91 2,2’,3,4’,6   
92 2,2’,3,5,5’   
93 2,2’,3,5,6   
94 2,2’,3,5,6’   
95 2,2’,3,5’,6 88700-05-4  
96 2,2’,3,6,6’   
97 2,2’,3’,4,5   
98 2,2’,3’,4,6   
99 2,2’,4,4’,5 81397-99-1  
100 2,2’,4,4’,6 97038-97-6  
101 2,2’,4,5,5’ 67888-96-4  
102 2,2’,4,5,6’ 80274-92-6  
103 2,2’,4,5’,6 59080-39-6  
104 2,2’,4,6,6’ 97063-75-7  
105 2,3,3’,4,4’   
106 2,3,3’,4,5   
107 2,3,3’,4’,5   
108 2,3,3’,4,5’   
109 2,3,3’,4,6   
110 2,3,3’,4’,6   
111 2,3,3’,5,5’   
112 2,3,3’,5,6   
113 2,3,3’,5’,6   
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Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
114 2,3,4,4’,5 96551-70-1  
115 2,3,4,4’,6   
116 2,3,4,5,6 38421-62-4  
117 2,3,4’,5,6   
118 2,3’,4,4’,5 6788-97-5  
119 2,3’,4,4’,6 86029-64-3  
120 2,3’,4,5,5’ 80407-70-1  
121 2,3’,4,5’,6   
122 2’,3,3’,4,5   
123 2’,3,4,4’,5 74114-77-5  
124 2’,3,4,5,5’   
125 2’,3,4,5,6’   
126 3,3’,4,4’,5 84303-46-8  
127 3,3’,4,5,5’ 81902-33-2  
 Hexabromobiphenyl 36355-01-8 36483-60-0 
128 2,2’,3,3’,4,4’ 82865-89-2  
129 2,2’3,3’,4,5   
130 2,2’,3,3’,4,5’ 82865-90-5  
131 2,2’,3,3’,4,6   
132 2,2’,3,3’,4,6’ 119264-50-5  
133 2,2’,3,3’,5,5’ 55066-76-7  
134 2,2’,3,3’,5,6   
135 2,2’,3,3’,5,6’ 119264-51-6  
136 2,2’,3,3’,6,6’   
137 2,2’,3,4,4’,5 81381-52-4  
138 2,2’,3,4,4’,5’ 67888-98-6  
139 2,2’,3,4,4’,6   
140 2,2’,3,4,4’,6’   
141 2,2’,3,4,5,5’ 120991-47-1  
142 2,2’,3,4,5,6   
143 2,2’,3,4,5,6’   
144 2,2’,3,4,5’,6 119264-52-7  
145 2,2’,3,4,6,6’   
146 2,2’,3,4’,5,5’   
147 2,2’,3,4’,5,6   
148 2,2’,3,4’,5,6’   
149 2,2’,3,4’,5’,6 69278-59-7  
150 2,2’,3,4’,5,6’ 93261-83-7  
151 2,2’,3,5,5’,6 119264-53-8  
152 2,2’,3,5,6,6’   
PBBs and PBDEs  351 
 








Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
153 2,2’,4,4’,5,5’ 59080-40-9  
154 2,2’,4,4’,5,6’ 36402-15-0  
155 2,2’,4,4’,6,6’ 59261-08-4  
156 2,3,3’,4,4’,5 77607-09-1  
157 2,3,3’,4,4’,5’ 84303-47-9  
158 2,3,3’,4,4’,6   
159 2,3,3’,4,5,5’ 120991-48-2  
160 2,3,3’,4,5,6   
161 2,3,3’,4,5’,6   
162 2,3,3’,4’,5,5’   
163 2,3,3’,4’,5,6   
164 2,3,3’,4’,5’,6 82865-91-5  
165 2,3,3’,5,5’,6   
166 2,3,4,4’,5,6   
167 2,3’,4,4’,5,5’ 67888-99-7  
168 2,3’,4,4’,5’,6 84303-48-0  
169 3,3’,4,4’,5,5’ 60044-26-0  
 Heptabromobiphenyl 35194-78-6 68928-80-3 
170 2,2’,3,3’,4,4’,5 69278-60-0  
171 2,2’,3,3’,4,4’,6   
172 2,2’,3,3’,4,5,5’ 82865-92-7  
173 2,2’,3,3’,4,5,6   
174 2,2’,3,3’,4,5,6’ 88700-04-3  
175 2,2’,3,3’,4,5’,6   
176 2,2’,3,3’,4,6,6’   
177 2,2’,3,3’,4’,5,6   
178 2,2’,3,3’,5,5’,6 119264-54-9  
179 2,2’,3,3’,5,6,6’   
180 2,2’,3,4,4’,5,5’ 67733-52-2  
181 2,2’,3,4,4’,5,6   
182 2,2’,3,4,4’,5,6’ 119264-55-0  
183 2,2’,3,4,4’,5’,6   
184 2,2’,3,4,4’,6,6’ 119264-56-1  
185 2,2’,3,4,5,5’,6   
186 2,2’,3,4,5,6,6’ 119264-57-2  
187 2,2’,3,4’,5,5’,6 84303-49-1  
188 2,2’,3,4’,5,6,6’ 119264-58-3  
189 2,3,3’,4,4’,5,5’ 88700-06-5  
190 2,3,3’,4,4’,5,6 79682-25-0  
191 2,3,3’,4,4’,5’,6   
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Table 6-1.  Chemical Identity of Polybrominated Biphenyl (PBB) and 
Polybrominated Diphenyl Ether (PBDE) Congeners  
 
CAS No.b IUPAC 
No.a 
Compound/ 
substituents Brominated biphenyls (BB)c Brominated diphenyl ethers (BDE)d
192 2,3,3’,4,5,5’,6   
193 2,3,3’,4’,5,5’,6   
 Octabromobiphenyl 27858-07-7 32536-52-0 
194 2,2’,3,3’,4,4’,5,5’ 67889-00-3  
195 2,2’,3,3’,4,4’,5,6   
196 2,2’,3,3’,4,4’,5’,6   
197 2,2’,3,3’,4,4’,6,6’ 119264-59-4  
198 2,2’,3,3’,4,5,5’,6   
199 2,2’,3,3’,4,5,6,6’   
200 2,2’,3,3’,4,5,6,6’ 119264-60-7  
201 2,2’,3,3’,4,5’,6,6’ 69887-11-2  
202 2,2’,3,3’,5,5’,6,6’ 59080-41-0  
203 2,2’,3,4,4’,5,5’,6   
204 2,2’,3,4,4’,5,6,6’ 119264-61-8  
205 2,3,3’,4,4’,5,5’,6   
 Nonabromobiphenyl 27753-52-2 63936-56-1 
206 2,2’,3,3’,4,4’,5,5’,6 69278-62-2  
207 2,2’,3,3’,4,4’,5,6,6’ 119264-62-9  
208 2,2’,3,3’,4,5,5’,6,6’ 119264-63-0  
 Decabromobiphenyl 13654-09-6 1163-19-5 
209 2,2’,3,3’,4,4’,5,5’,6,6’ 13654-09-6 1163-19-5 
 
aBallschmiter and Zell 1980 
bNot all PBBs have been assigned CAS numbers; with the exception of BDE 209, no CAS numbers were identified 
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Synonym(s) FireMaster BP-6b; 
FireMaster FF-1b 
Bromkal 80b Flammex B 10b; 
Adine 0102b; 







Bromkal 80 Flammex B 10; 
Adine 0102; 
Berkflam B 10 
None 
Chemical formula C12H4Br6 C12H2Br8 C12Br10 C12H4Br6 
Chemical structure     
Identification 
numbers: 
    
CAS registry 59536-65-1 (BP-6); 
67774-32-7 (FF-1); 
36355-01-8 (hexa-








NIOSH RTECS LK 5060000 (BP-6); 
LK 5065000 (FF-1) 
DV 570000 (octa-
bromo mixture) 
No data No data 
EPA hazardous 
waste 
No data No data No data No data 
OHM/TADS No data No data No data No data 
DOT/UN/NA/IMCO 
shipping 
No data No data No data No data 
HSDB No data No data No data 2913 
NCI No data No data No data No data 
 
aAll information obtained from IARC 1986 except where noted. 
bThese are mixtures of compounds, and their compositions are given in the text. 
 
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
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It can be seen from the structure that a large number of brominated compounds are possible.  The 
209 possible compounds for PBDEs are called “congeners”.  However, the number of PBDE congeners 
that actually exist in commercial PBDE mixtures are much less compared to PCBs.  Typically, only a 
subset of the 209 possible congeners is observed for PBDEs.  PBDEs can also be categorized by degree of 
bromination.  The term “homolog” is used to refer to all PBDEs with the same number of bromines (e.g., 
tribromodiphenyl ether refers to PBDEs containing only three bromine atoms).  Based on the number of 
bromine substituents, there are 10 homologous groups of PBDEs (monobrominated through 
decabrominated).  Each homologous group contains one or more congeners.  The mono-, di-, tri-, tetra-, 
penta-, hexa-, hepta-, octa-, nona-, and decabromo-congeners can exist in 3, 12, 24, 42, 46, 42, 24, 12, 3, 
and 1 forms, respectively.  Homologs with different substitution patterns are referred to as isomers.  For 
example, the group of dibromodiphenyl ether homologs contains 12 isomers.  The numbering system for 
PBDEs is also shown above.  The structures of representative PBB and PBDE molecules appear similar 
when drawn in one dimension.  However, there are important three-dimensional differences in their 
structures due to the ether linkage and location/number of halogen atoms.  The ortho positions of the 
aromatic rings must be nonhalogen-substituted for a diphenyl ether molecule to assume a planar or near 
planar configuration.  Halogen substitution of the diphenyl ether molecule in the ortho position (2,2’,6,6’) 
will force the aromatic rings orthogonal to one another (e.g., the phenyl rings will be positioned in space 
with a dihedral angle >0°).  This is particularly evident for decabromodiphenyl ether, which is predicted 
to have a dihedral angle of ca. 90° and a high barrier to rotation around the ether linkage preventing this 
molecule from assuming a planar configuration.  The benzene rings of non-ortho substituted PBDEs may 
assume a small dihedral angle (in which the dihedral angle is small, but >0°) or “near” planar 
configuration.  These molecules are referred to as planar or coplanar congeners (Hardy 2002).   
 
Like PCBs, the 209 congeners for PBDEs are arranged in ascending numerical order using a numbering 
system developed by Ballschmiter and Zell (1980) that follow the IUPAC rules of substituent 
characterization in biphenyls.  The resulting numbers assigned by Ballschmiter and Zell (which are also 
referred to as congener, IUPAC, or BZ numbers) are widely used for identifying individual congeners of 
PBDEs.  For example, the PBDE congener, 2,2',4,4'-tetrabromodiphenyl ether may be referred to as BDE 
47 in this document.  The identities of several PBDE congeners are shown in Table 6-1 (WHO 1994a, 
1994b). 
 
In the United States, Albemarle Corporation and Great Lakes Chemical Corporation market mixtures of 
PBDEs under trade names (e.g., DE-60F, DE-61, DE-62, and DE-71 for pentaBDE mixtures; DE-79 for 
octaBDE mixtures; and DE 83R, Saytex 102E for decaBDE mixtures).  There are also several trade 
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names used by producers from Europe and Japan for the BDE mixtures.  The chemical identities of 
commercial mixtures of penta-, octa-, and decabromodiphenyl ethers are listed in Table 6-3 (WHO 
1994a).  
 
Various synonyms and abbreviations for PBDEs exist in the literature and are shown below: 
 
polybrominated biphenyl ethers = Polybromobiphenyl ethers = PBBE 
polybrominated biphenyl oxides = Polybromobiphenyl oxides = PBBEs 
polybrominated diphenyl ethers = Polybromodiphenyl ethers = PBDEs or PBDPEs 
polybrominated diphenyl oxides = Polybromodiphenyl oxides = PBDOs or PBDPOs 
 
For consistency in this document, polybrominated diphenyl ethers or PBDEs will be used to identify this 
class of chemicals.  The PBDE homologs are abbreviated as follows in this document: 
 
dibromodiphenyl ether = DiBDE = diBDE 
tribromodiphenyl ether = TrBDE = triBDE 
tetrabromodiphenyl ether = TeBDE = tetraBDE 
pentabromodiphenyl ether = PeBDE = pentaBDE 
hexabromodiphenyl ether = HxBDE = hexaBDE 
heptabromodiphenyl ether = HpBDE = heptaBDE 
octabromodiphenyl ether = OBDE = octaBDE 
nonabromodiphenyl ether = NoBDE = nonaBDE 
decabromodiphenyl ether = DeBDE = decaBDE 
 
6.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
Polybrominated Biphenyls.  Information found in the literature regarding the physical and chemical 
properties of hexabromobiphenyl, octabromobiphenyl, decabromobiphenyl, and BB 153 is presented in 
Table 6-4.  The data for the properties listed in Table 6-4 may not be reliable because products of 
questionable purity were used by earlier investigators to derive them.  For example, the water solubility of 
hexabromobiphenyl (Neufeld et al. 1977) was reported to be the same as that of FireMaster FF-1 (Getty et 
al. 1977), although FireMaster FF-1 contained only 84.4% (Robertson et al. 1983b) hexabrominated 
biphenyls.  However, recent physical and chemical property data have been reported for 
hexabromobiphenyl in Tittlemier et al. (2002). 
 
Of the 209 possible congeners of PBBs, only about 42 have been synthesized in pure form even on a 
laboratory scale (Sundstrom et al. 1976b).  The PBBs produced for commercial use were mixtures of 
PBBs with other non-PBB impurities.  The technical products were FireMaster BP-6, FireMaster FF-1, 
Bromkal 80, and Flammex B 10 (or Adine 0102 or Berkflam B 10) (IARC 1986).  FireMaster FF-1, a  
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DE 71; Bromkal 70-5 
DE; FR 1205/1215; 
Bromkal 70; Bromkal 
G1; Pentabromprop; 
Tardex 50; Tardex 50 L; 
Saytex 115 
Bromkal 7908DE; DE 
79; FR 143; Tardex 80; 
FR 1208; Adine 404; 
Saytex 111 
FR-300 BA; DE-83-RTM; Saytex 
102; Saytex 102E; FR-1210; Adine 
505; AFR 1021; Berkflam B10E; 
BR55N; Bromkal 81; Bromkal 
82-ODE; Bromkal 83-10 DE; Caliban 
F/R-P 39P; Caliban F/R-P 44; 
Chemflam 011; DE 83; DP 10F; EB 
10FP; EBR 700; Flame Cut BR 100; 
FR P-39; BR 100; FR 330BA; FR 
P-39; FRP 53; FR-PE; FR-PE(H); 
Planelon DB 100; Tardex 100; 




C12H10-yBryO   
where y=4–6  
C12H10-yBryO   




   
Identification numbers:   
 CAS registry 32534-81-9 32536-52-0 1163-19-5 
 NIOSH RTECS No data No data No data 
 EPA hazardous 
waste 
No data  No data No data 
 OHM/TADS No data No data No data 
 DOT/UN/IMCO 
shipping 
No data No data No data 
 HSDB 7109 7110 2911 
 NCI No data No data No data 
 
Source: WHO 1994a 
 
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
PBB = polybrominated biphenyl; RTECS = Registry of Toxic Effects of Chemical Substances 
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Molecular weight 627.4 785.2 943.1 627.4 
Color White White White White 
Physical state Solid Solid Solid Solid 
Melting point 72 °C 200–250 °C; 367–
367 °Cb (for 
industrial product)
380–386 °C No data 
Boiling point No data No data No data No data 
Density No data No data No data No data 
Odor No data No data No data No data 
Odor threshold:     
 Water No data No data No data No data 
 Air No data No data No data No data 
Solubility:     
 Water 11 µg/L; 3 µg/Lc 20–30 µg/L Insoluble 11 µg/Ld 
 Organic 
solvent(s) 








Acetone (6 weight 
percent); benzene 
(75 weight percent)c 
Partition coefficients:    
 Log Kow 6.39e 5.53 8.58f 9.10 (estimated)d 
 Log Koc 3.33–3.87g No data No data 5.088d 
Vapor pressure 5.2x10-8 mmHg at 
25 °Ch; 5.6x10-6 mm 
Hg (liquid sub-
cooled)c 
7x10-11 mmHg at 
28 °Ci 






No data No data 5.7x10-3 atm-m3/mold 
Autoignition 
temperature 
No data No data No data No data 
Flashpoint No data No data No data No data 
Flammability limits No data No data No data No data 
Conversion 
factors 
Since these compounds exist in the particle phase in the ambient atmosphere, the 
concentrations in air are expressed in weight per unit volume of the air. 
Explosive limits No data No data No data No data 
 
aAll information obtained from IARC (1978) and Norris et al. (1973) unless otherwise noted. 
bSundstrom et al. 1976  
cTittlemier et al. 2002 
dHardy (2002) 
eDoucette and Andren 1988 
fThe values for 2,2'4,4'6,6'- and 2,2',3,3',4,4'-hexabromobiphenyl are given as 7.20 (Chessells et al. 1992) and 
8.09 (Anliker et al. 1988), respectively. 
gEstimated from the Freundlich adsorption constants given by Jacobs et al. (1978). 
hJacobs et al. 1976 
iWaritz et al. 1977 
jEstimated from the ratio of vapor pressure and water solubility. 
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white powder, was made by grinding brown flakes of FireMaster BP-6 and adding 2% calcium silicate as 
an anticaking agent (Fries 1985b).  The exact composition of FireMaster BP-6 or FireMaster FF-1 seems 
to have varied between and within batches (Sundstrom et al. 1976a).  Table 6-5 provides the 
concentrations of the PBB congeners in FireMaster FF-1 and FireMaster BP-6. 
 
An interesting feature of commercial FireMaster FF-1 and FireMaster BP-6 is that they contain >50% of 
the congener BB 153.  The second most abundant congener is 2,2',3,4,4',5,5'-heptabromobiphenyl 
(BB 180).  A detailed analysis of FireMaster BP-6 (lot 7062) was able to separate 22 congeners of PBBs 
that included four tri, five tetra, three penta, seven hexa, and three hepta congeners of PBBs (Robertson et 
al. 1983b, 1984b).  The coplanar and toxic congeners 3,3',4,4'-tetra-, 3,3',4,4',5-penta-, and 3,3',4,4',5,5'-
hexabrominated biphenyls were found at abundances of 0.159, 0.079, and 0.294%, respectively (Orti et 
al. 1983; Robertson et al. 1983b).  In addition to the 22 congeners, other investigators have identified 
2,2',3,3',4,4',5,6'-octa-, 2,2',3,3',4,4',5,5'-octa-, 2,2',3,3',4,4',5,5',6-nona-, and decabromobiphenyl in 
commercial PBBs (Moore et al. 1978).  Other impurities detected in FireMaster FF-1 and FireMaster 
BP-6 were tetra-, penta-, and hexabromonaphthalene (Di Carlo et al. 1978); however, at a detection limit 
of 0.5 ppm, brominated dioxins and dibenzofurans were not detected in commercial FireMaster FF-1 or 
FireMaster BP-6 (Hass et al. 1978). 
 
Commercial octabromobiphenyl (Bromkal 80) contained at least four compounds.  Assays of two 
commercial octabromobiphenyls showed the following compositions: 1.0–1.8% heptabromobiphenyl, 
33.0–45.2% octabromobiphenyl, 47.4–60.0% nonabromobiphenyl, and 5.7–6.0% decabromobiphenyl 
(Norris et al. 1973; Waritz et al. 1977).  Notably, the major component of commercial octabromobiphenyl 
was nonabromobiphenyl, and not octabromobiphenyl.  Commercial decabromobiphenyl (Flammex B 10) 
contained 96.8% decabromobiphenyl, 2.9% nonabromobiphenyl, and 0.3% octabromobiphenyl (Di Carlo 
et al. 1978). 
 
Pyrolysis of FireMaster BP-6 in the temperature range of 600–900 °C in the absence of oxygen produced 
bromobenzenes and brominated biphenyls as key products, but no brominated dioxins and dibenzofurans 
(Thoma and Hutzinger 1987; Thoma et al. 1987).  Thermolysis of FireMaster BP-6 between 400 and 
600 °C in the presence of air produced 2,3,7,8-tetrabromodibenzofuran in the percent (1%=10 g/kg) range 
(Rappe and Buser 1980).  Pyrolysis of FireMaster BP-6 in an open quartz tube at 800 °C produced 0.48–
1.49 g/kg 2,3,7,8-TCDD equivalent levels of polybrominated dibenzofurans (Zacharewski et al. 1988).  
FireMaster BP-6 hydrolyzed when refluxed with 2% potassium hydroxide in ethanol, but the possible rate  
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Table 6-5.  Identified PBB Congeners in FireMaster® BP-6 and FireMaster® FF-1 
 
Percent composition of 
IUPAC No.a Structure FireMaster BP-6 FireMaster FF-1 References 
Dibromobiphenyls    
4 2,2’- 0.020  Moore et al. 1979 
Tribromobiphenyls    
18 2,2’,5- 0.050  Robertson et al. 1984 
26 2,3’,5- 0.024   
31 2,4’,5- 0.015   
37 3,4,4’- 0.021   
Tetrabromobiphenyls    
49 2,2’,4,5’- 0.025   
52 2,2’,5,5’- 0.052   
66 2,3’,4,4’- 0.028   
70 2,3’,4’,5- 0.017   
77 3,3’,4,4’-  <0.080 Orti et al. 1983 
  0.159  Robertson et al. 1984 
Pentabromobiphenyls    
95 2,2’,3,5’,6- 0.020  Orti et al. 1983 
99 2,2’,4,4’,5-  <0.08  
101 2,2’,4,5,5’- 2.69  Robertson et al. 1984 
  4.50 3.70 Aust et al. 1981 
   1.54 Orti et al. 1983 
  2.60  Krüger 1988 
118 2,3’,4,4’,5- 2.94  Robertson et al. 1984 
   0.70 Robertson et al. 1984 
  3.20  Krüger 1988 
126 3,3’,4,4’,5-  <0.01  
  0.079  Robertson et al. 1984 
Hexabromobiphenyls    
132 2,2’3,3’,4,6’- 1  Krüger 1988 
138 2,2’,3,4,4’,5’- 12.3  Robertson et al. 1984 
  12 8.6 Aust et al. 1981 
   5.23 Orti et al. 1983 
  10.6  Krüger 1988 
149 2,2’,3,4’,5’,6- 2.24  Robertson et al. 1984 
  1.40 1.30 Aust et al. 1981 
   0.78 Orti et al. 1983 
153 2,2’,4,4’,5,5’- 53.9  Robertson et al. 1984 
  47.8 47.1 Aust et al. 1981 
  55.2  Orti et al. 1983 
  58.5  Krüger 1988 
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Table 6-5.  Identified PBB Congeners in FireMaster® BP-6 and FireMaster® FF-1 
 
Percent composition of 
IUPAC No.a Structure FireMaster BP-6 FireMaster FF-1 References 
155 2,2’4,4’,6,6’- 0.5   
156 2,3,3’,4,4’,5- 0.980  Robertson et al. 1984 
  5.0  Aust et al. 1981 
  0.37  Orti et al. 1983 
  1.0  Krüger 1988 
157 2,3,3’,4,4’,5’- 0.05  Orti et al. 1983 
  0.526  Robertson et al. 1984 
  0.5`  Krüger 1988 
167 2,3’,4,4’,5,5’- 5.5 3.3 Aust et al. 1981 
  3.37  Orti et al. 1983 
  <0.3   
  7.95  Robertson et al. 1984 
  5.5  Krüger 1988 
169 3,3’,4,4’,5,5’- 0.294  Robertson et al. 1984 
Heptabromobiphenyls    
170 2,2’,3,3’,4,4’,5- 0.256   
  1.1 1.5 Aust et al. 1981 
  1.66  Orti et al. 1983 
  2.4  Krüger 1988 
172 2,2’,3,3’,4,5,5’- <0.30  Orti et al. 1983 
174 2,2’,3,3’,4,5,6’- 0.24   
178 2,2’,3,3’,5,5’,6- 0.3  Krüger 1988 
180 2,2’,3,4,4’,5,5’ 6.97  Robertson et al. 1984 
   24.7 Aust et al. 1981 
   23.5 Orti et al. 1983 
187 2,2’,3,4’,5,5’,6- 0.392  Robertson et al. 1984 
   1.0 Krüger 1988 
189 2,3,3’,4,4’,5,5’-  0.51 Orti et al. 1983 
Octabromobiphenyls    
194 2,2’,3,3’,4,4’,5,5’- 0.9 2.4 Aust et al. 1981 
   1.65 Orti et al. 1983 
196 2,2’,3,3’,4,4’,5,6’-   Moore et al. 1980 
201 2,2’,3,3’,4,5,5’,6’-   Orti et al. 1983 
203 2,2’,3,4,4’,5,5’,6-    
 
Source: WHO 1994b 
 
aBallschmiter and Zell 1980 
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of PBB hydrolysis under much milder environmental conditions remains unknown (Pomerantz et al. 
1978). 
 
Hexabromonapthalene has been identified as a toxic contaminant of Firemaster BP-6 or FF-1 at 
concentration levels of approximately 150 ppm (Birnbaum et al. 1983).  Previously reported to be a single 
compound, hexabromonapthalene was shown to be a 60:40 mixture of 1,2,3,4,6,7-hexabromonaphthalene 
and 2,3,4,5,6,7-hexabromonaphthalene.  
 
Polybrominated Diphenyl Ethers.  Information found in the literature regarding the physical and 
chemical properties of selected technical PBDE mixtures is presented in Table 6-6.  Recent information 
regarding the vapor pressure, water solubility, Henry’s Law constant, and log Kow of some PBDE 
congeners is presented in Table 6-7.   
 
Commercially available product mixtures of PBDEs (see Table 6-3) are not pure substances, but instead 
are mixtures of congeners.  For example, the commercial mixture pentabromodiphenyl ether denotes the 
main component of the mixture contains the pentabromodiphenyl ether homolog.  However, the 
commercial pentaBDE mixture actually contains tetrabromodiphenyl ether (24–38%) and 
pentabromodiphenyl ether (50–62%) homologs with small amounts of hexabromodiphenyl ether (4–8%) 
and trace amounts of tribromodiphenyl ether (0–1%) homologs.  In this document, the commercial 
mixture of pentaBDE may be called “the commercial pentaBDE mixture,” “technical pentaBDE,” or 
“technical PeBDE” to distinguish this mixture of homologs from the pentaBDE homolog which refers to 
polybrominated diphenyl ethers with only five bromine atoms (see Section 6.1).  Commercial 
octabromodiphenyl ether is a mixture of hexa-, hepta-, octa-, and nonabrominated diphenyl ether 
homologs with trace amounts of decabromodiphenyl ether (i.e., BDE 209).  In this document, the 
commercial mixture of octaBDE may be called “the commercial octaBDE mixture,” “technical 
octaBDE,” or “technical OBDE” to distinguish this mixture of different homologs from the octaBDE 
homolog, which refers to polybrominated diphenyl ethers with only eight bromine atoms (see 
Section 6.1).  The composition of commercial decabromodiphenyl ether is 97% of the 
decabromodiphenyl ether (i.e., BDE 209); the remainder is nonabromodiphenyl ether homologs and trace 
amounts of octabromodiphenyl ether homologs (WHO 1994a).  In this document, commercial 
decabromodiphenyl ether may be called “the commercial decaBDE mixture,” “technical decaBDE,” or 
“technical DeBDE” which represents 97% BDE 209 congener with 3% nona- and octaBDE homolog 
impurities.  The composition of commercial octaBDE (e.g., DE-79) is <10% of nonaBDE, <33% of 
octaBDE, <45% of heptaBDE, and <12% of hexaBDE (i.e., 2% of BDE 154 and 14% of BDE 153)  
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Molecular weight Mixture Mixture 959.22a 
Color Clear, amber to pale 
yellowa 
Off-whitea Off-whitea 
Physical state Highly viscous liquid  Powder  Powdera 
Melting point -7 to -3 °C (commercial)b  85–89 °C (commercial)c; 
200 °C (range, 167–
257)a; 79–87 °Ca; 170–
220 °Ca 
290–306 °Ca 
Boiling point >300 °C (decomposition 
starts above 200 °C)a,b 
Decomposes at >330 °C 
(commercial)c 
Decomposes at >320, >400, 
and 425 °Ca 
Density (g/mL) 2.28 at 25 °Ca; 2.25–2.28b 2.76a; 2.8 (commercial)c 3.0a; 3.25a 
Odor No data Fainta Odorlessa 
Odor threshold:    
 Water No data No data Not applicable 
 Air No data No data Not applicable 
Solubility:    
 Water 13.3 µg/L (commercial)b,d; 
2.4 µg/L (pentabromodi-
phenyl ether component)b; 
10.9 µg/L (tetrabromodi-
phenyl ether component)b 
<1 ppb at 25 °C (com-




 Organic solvent(s) 10 g/kg methanol; miscible 
in toluened 
acetone (20 g/L); 
benzene (200 g/L); 
methanol (2 g/L) all at 
25 °Ca 
acetone (0.05%), benzene 
(0.48%), methylene bromide 
(0.42%), xylene (0.87%), 
and toluene (0.2%)e 
Partition coefficients:   
 Log Kow 6.64–6.97d; 6.57 
(commercial)b 
6.29 (commercial)c 6.265e 
 Log Koc 4.89-5.10f 5.92-6.22f 6.80f 
Vapor pressure 2.2x10-7–5.5x10-7 mm Hg 
at 25 °Cd; 3.5x10-7 mm Hg 
(commercial)b 
9.0x10-10–1.7x10-9 mm 
Hg at 25 °Cd; 4.9x10-8 
mm Hg at 21 °C 
(commercial)c 
3.2x10-8 mm Hgg; 
3.47x10-8 mm Hge 











330 °C (commercial)c 
Not applicablea 
Flashpoint No data No data None 
Flammability limits Not applicable (flame 
retardant)b,d 
Not applicable (flame 
retardant)c 
Non-flammablea 
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Conversion factors 1 ppm=23.48 mg/m3 at 
20 °Cd 
No data No data 
Explosive limits Noneb,g Nonec No data 
 
a WHO 1994a  
bENVIRON 2003a  
cENVIRON 2003b 
dEU 2001  
eAmerican Chemistry Council 2002 
fEstimated values were calculated using EPIWIN v3.10 (EPA 2001). 
gHardy 2002 
hEstimate value was calculated using vapor pressure and water solubility values in table.  
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Henry’s Law constant 
(atm m3/mol)a Log Kowb 
BDE-3 1.94x10-3 – – – 
BDE-15 1.30x10-4 130 2.07254x10-4 – 
BDE-17 – – – 5.74 
BDE-28 1.64x10-5 70 5.03331x10-5 5.94 
BDE-47 1.40x10-6 15 1.48038x10-5 6.81 
BDE-66 9.15x10-7 18 4.93461x10-6 – 
BDE-77 5.09x10-7 6 1.18431x10-5 – 
BDE-85 7.40x10-8 6 1.08562x10-6 – 
BDE-99 1.32x10-7 9 2.26992x10-6 7.32 
BDE-100 2.15x10-7 40 6.80977x10-7 7.24 
BDE-138 1.19x10-8 – – – 
BDE-153 1.57x10-8 1 6.61238x10-7 7.90 
BDE-154 2.85x10-8 1 2.36862x10-6 7.82 
BDE-183 3.51x10-9 2 7.30323x10-8 8.27 
BDE-190 2.12x10-9 – – – 
 
aTittlemier et al. 2002 
bBraekvelt et al. 2003 
cliquid sub-cooled vapor pressures 
 
– = No data reported; BDE = brominated diphenyl ether 
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(ENVIRON 2003b).  The composition of commercial pentaBDE (e.g., DE-71) is 4–12% of hexaBDE 
(i.e., 4% BDE 154 and 6% BDE 153), 50–62% of pentaBDE (i.e., 8% of BDE 100, 43% of BDE 99), 24–
38% of tetraBDE (i.e., <1% of BDE 66, <1% of BDE 49, 28% of BDE 47), and 0–1% of triBDE (i.e., 
>1% of BDE 28/33) (ENVIRON 2003b).  The compositions of commercial product mixtures of PBDEs 
(e.g., technical penta-, octa-, and decaBDE) are given in Table 6-8.  The chemical composition of 
commercial pentaBDE product has been shown to vary over the past 10–20 years and between different 
commercial products (ENVIRON 2003a).  
 
Trace analysis of these commercial mixtures for 15-different 2,3,7,8-substituted brominate dibenzo-
p-dioxins and dibenzofurans revealed no detectable amounts of these substances (Hardy 2002).  The 
commercial decaBDE product has been analyzed for trace quantities of 15 2,3,7,8-substituted 
polybrominated-p-dibenzodioxins (PBDDs) and polybrominated dibenzofurans (PBDFs).  None of the 
analytes were present at or above the quantization limits established under an EPA test rule (BFRIP 
2002).  While in today’s commercial PBDE samples, there are not measurable quantities of 
PBDDs/PBDFs, there are some materials that have reported quantifiable levels of these contaminants.  
For example, hexabromodibenzofurans have been detected in commercial decaBDE mixtures at 
concentrations as high as 200 µg/kg.  In other PBDE mixtures (e.g., tetra- to hexaBDEs), the sum of 
tetra-, penta-, and hexabromodibenzofurans were reported at a concentrations of 8,000 µg/kg.  In addition, 
tetra- and pentabromo- p-dibenzodioxins have been measured in commercial decaBDE at concentrations 
of 0.05 and 0.35 µg/kg, respectively (WHO 1998).  
 
When pyrolyzed up to 900 °C, PBDEs may produce PBDFs and PBDDs (Buser 1986; EU 2001).  The 
amount of PCDFs and PBDDs formed depends upon the conditions of pyrolysis.  For example, 
2,3,7,8-tetrabromodibenzofuran in ppm concentrations can be generated during pyrolysis of 
decabromodiphenyl ether (decaBDE) in the temperature range of 400–700 °C (Bieniek et al. 1989).  
PBDFs may also be produced during the pyrolysis of polymers containing PBDEs as flame retardants 
(Brenner and Knies 1993; Dumler et al. 1989a, 1990; Lenoir et al. 1994).  However, studies performed in 
the late 1980’s may have suffered from analytical methods that could not differentiate between PBDD/Fs 
formed (e.g., 2,3,7,8-substituted congeners) and decaBDE which might have artificially elevate levels of 
PBDFs detected (Ranken et al. 1994).   
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early 1980s 2002 
Late 1970s – 






a DE-71b Product DE-79b Product DE-83R and DE-83b
DecaBDE 
(1 congener) 
BDE-209 – 0.8 <0.70% 1.6% >98% 
NonaBDE 
(3 congeners) 
– – 0.2 <10% 13.0% – 
OctaBDE 
(12 congeners) 
– – 0.3 <33% 30.7% – 
HeptaBDE 
(24 congeners) 
– – 2.6 <45% 45.1% – 
 4–12% 13.3 <12% 8.5% – 
BDE-154 (4%)  (2%)   
HexaBDE 
(42 congeners) 
BDE-153 (6%)  (14%)   
 50–62% 58.1 <0.50% 1.1% – 
BDE-100 (8%)  (ND)   
BDE-99 (43%)  (<1%)   
PentaBDE 
(46 congeners) 
BDE-85 (–)  (–)   
 24–38% 24.6 – – – 
BDE-66 (<1%)  (ND)   
BDE-49 (<1%)  (ND)   
TetraBDE 
(42 congeners) 
BDE-47 (28%)  (<1%)   
 0–1% – – – – TriBDE 
(24 congeners) BDE-28/33 (>1%)  (ND)   
 
Source:  ENVIRON 2003b 
 
aIUPAC numbering system 
bAs currently produced 
 















7.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
7.1   PRODUCTION  
 
Polybrominated Biphenyls.  The commercial production of polybrominated biphenyls (PBBs) generally 
involves bromination of biphenyl, a process involving a much more specific reaction and that produces a 
smaller number of product mixtures than chlorination (Sundstrom et al. 1976a).  In one process, biphenyl 
is brominated with 0–20% stoichiometric excess of bromine chloride (e.g., slightly more than 10 mol of 
bromine chloride may be reacted with 1 mol of biphenyl to obtain decabromobiphenyl) in the presence of 
iron or a Friedel-Crafts catalyst (e.g., aluminum chloride).  In another process, biphenyl is dissolved in 
ethylene bromide solvent and reacted with bromine in the presence of a catalyst (either aluminum 
chloride or bromide) (Neufeld et al. 1977).  Research quantities of PBBs can be synthesized by the diazo 
coupling of brominated aniline with an excess of the corresponding bromobenzene.  For example, 
2,3,3',4,4',5'-hexabromobiphenyl can be synthesized by the diazo coupling of 3,4,5-tribromoaniline with 
1,2,3-tribromobenzene (Kubiczak et al. 1989; Robertson et al. 1983b).  Methods for laboratory scale 
synthesis of 42 congeners of brominated biphenyls are also available (Sundstrom et al. 1976b). 
 
The commercial production of PBBs began in 1970.  Approximately 13.3 million pounds of PBBs were 
produced in the United States from 1970 to 1976.  Only three commercial PBB products were 
manufactured (i.e., hexabromobiphenyl, octabromobiphenyl, and decabromobiphenyl) and these three 
products were based on a limited number of congeners (Hardy 2002b).  Hexabromobiphenyl constituted 
about 11.8 million pounds (ca 88%) and octa- and decabromobiphenyl constituted ≈1.5 million pounds 
together of this total (Neufeld et al. 1977).  Over 98% of the hexabromobiphenyl was produced as 
FireMaster BP-6 and the residual as FireMaster FF-1 (Hesse and Powers 1978).  Michigan Chemical 
Corporation, St. Louis, Michigan, the sole producer of hexabromobiphenyl in the United States, stopped 
producing this PBB in 1975.  White Chemical Co., Bayonne, New Jersey, and Hexcel Corporation, 
Sayreville, New Jersey, manufactured octa- and decabromobiphenyl in the United States until 1979 
(IARC 1986; Neufeld et al. 1977).  Shortly after the 1973–1974 agriculture contamination episode in 
Michigan (see Section 5.2), PBB production in the United States was voluntarily discontinued (Hardy 
2000); PBBs are no longer produced in the United States (SRI 2001).  Re-initiation of manufacture of 
PBBs requires approval from the EPA.  Production of decaPBB in Great Britain was discontinued in 1977 
and highly brominated PBBs were produced in Germany until mid-1985.  Until the year 2000, the only 
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PBB in commercial production was decabromobiphenyl, which was manufactured by one company 
(Atochem) in France (Hardy 2000). 
 
Polybrominated Diphenyl Ethers.  The commercial production of PBDEs generally involves bromination 
of diphenyl oxide to varying degrees.  The degree of bromination is controlled either through stiochio-
metry or through control of reaction kinetics (Pettigrew 1993).  Technical decabromodiphenyl ether is 
manufactured by bromination of diphenyl oxide in the presence of a Friedel-Crafts catalyst (e.g., 
aluminum bromide) and excess bromine.  Technical decabromodiphenyl ether may also be produced at 
atmospheric pressure by dissolving diphenyl oxide and bromine in ethylene dibromide in the presence of 
a Friedel-Crafts catalyst (e.g., aluminum bromide).  The use of bromine in an organic solvent requires 
long reaction times, results in low productivity per volume, and necessitates recycling of the solvent.  
These limitations have led to the use of bromine as both the reactant and the solvent for this process 
(Dagani and Sanders 1985).   
 
The commercial production of PBDEs began in late 1970s (WHO 1994a).  As of 2003, in the United 
States, penta- and octabromodiphenyl ethers (pentaBDE and octaBDE) are produced by the Great Lakes 
Chemical Corporation in El Dorado, Arkansas (SRI 2002).  According to SRI (2002), as of 2003, 
technical decabromodiphenyl ether (decaBDE) is produced by Albemarle Corporation in Magnolia, 
Arkansas.  Technical PentaBDE is produced commercially in the United States as Great Lakes DE-60F, 
DE-61, DE-62, and DE-71.  Technical octaBDE is produced commercially in the United States as DE-79.  
Technical decaBDE (BDE 209) is produced commercially in the United States as DE-83R and Saytex 
102E.  Dead Sea Bromines/Eurobrome and Tosoh are currently producing PBDEs in the Netherlands and 
Japan, respectively (WHO 1994a).  No current estimates of PBDE production quantities were located 
(SRI 2002).   
 
In 2001, the total market demand for PBDEs in the Americas was 33,100 metric tons (see Table 7-1).  
Technical decaBDE constituted about 24,500 metric tons (74%), while technical mixtures of octaBDEs 
and pentaBDEs were 1,500 and 7,100 metric tons (4 and 22 %) of this total, respectively (BSEF 2003).  
In 2001, the total market demand for PBDEs in the world was 67,390 metric tons.  Technical decaBDE 
constituted about 56,100 metric tons (83%), while technical mixtures of octaBDEs and pentaBDEs were 
3,790 and 7,500 metric tons (6 and 11%) of this total, respectively (BSEF 2003).  About 98% of the 
global demand for the technical pentaBDE mixture resides in North America (Hale et al. 2003).  The 
Great Lakes Chemical Corporation recently announced that it is voluntarily phasing out production of 
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Table 7-1.  Total Market Demand of PBDEs by Regions of the World in 2001a 
 
 Americas Europe Asia Rest of world Total 
PentaBDE 7,100 150 150 100 7,500 
OctaBDE 1,500 610 1,500 180 3,790 
DecaBDE 24,500 7,600 23,000 1,050 56,100 
 
Source:  BSEF 2003 
 
aData in metric tons  
 
decaBDE = commercial decabrominated diphenyl ether mixture; octaBDE = commercial octabrominated diphenyl 
ether mixture; pentaBDE = commercial pentabrominated diphenyl ether mixture 
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pentaDBEs and octaDBEs by the end of 2004.  Since there are no other pentaDBE manufacturers in the 
United States, this decision functionally eliminated U.S. production of this compound (Tullo 2003). 
 
Table 7-2 lists the facilities in each state that manufacture or process technical decaBDE, the intended 
use, and the range of maximum amounts of technical decaBDE that are stored on-site.  There are 
141 facilities that produce or process technical decaBDE in the United States (TRI01 2003).  The data 
from the Toxics Release Inventory (TRI) listed in Table 7-2 should be used with caution, however, since 
only certain types of facilities were required to report.  The TRI is not an exhaustive list.  Facilities are 
only required to report to the TRI if they manufacture or process more than 25,000 pounds of a TRI listed 
chemical during the year, or otherwise use more than 10,000 pounds, and have the equivalent of more 
than 10 full-time employees.  According to the EPA, TRI data have certain limitations.  TRI data reflect 
releases and other waste management of chemicals, and not exposures of the public to those chemicals.  
TRI data alone are not sufficient to determine exposure or calculate potential adverse effects on human 
health and the environment. 
 
7.2   IMPORT/EXPORT  
 
Polybrominated Biphenyls.  PBBs are no longer being imported or exported except possibly in small 
quantities for laboratory uses.  PBBs have not been imported from other countries into the United States, 
except in finished products (Neufeld et al. 1977).  The two companies that manufactured octa- and deca-
bromobiphenyl in the United States between 1976 (0.805 million pounds) and 1978 exported all of their 
products to Europe (Neufeld et al. 1977). 
 
Polybrominated Diphenyl Ethers.  No U.S. import or export data were located in the literature for 
PBDEs.  In 2001, worldwide demands for technical penta-, octa-, and decabromodiphenyl ethers were 
7,500, 3,790, and 56,100 metric tons, respectively (see Table 7-1; BSEF 2003).   
 
7.3   USE  
 
Polybrominated Biphenyls.  PBBs are no longer used in the United States.  In the past, PBBs were used 
as additive flame retardants to suppress or delay combustion.  Additive flame retardants are added to the 
polymer material, but are not chemically incorporated into the polymer matrix.  Because PBBs are not  
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Minimum amount on 
site in poundsb 
Maximum amount on site in 
poundsb Activities and usesc 
AL 1 10,000 99,999 7, 8 
AR 5 1,000 9,999,999 1, 4, 7, 8 
CA 5 1,000 999,999 7, 8 
CT 3 1,000 99,999 7, 8, 9, 14 
FL 2 100 999,999 7 
GA 5 100 99,999 2, 3, 5, 7, 8, 11, 12 
IL 2 10,000 999,999 7, 8 
IN 6 0 99,999 7, 8 
KY 2 10,000 99,999 7 
LA 1 100,000 999,999 12 
MA 12 1,000 99,999 7, 8 
MD 1 10,000 99,999 8 
MI 5 1,000 9,999,999 7, 8 
MN 3 10,000 99,999 7, 8 
MO 1 1,000 9,999 7 
MS 2 10,000 99,999 7, 8 
NC 13 1,000 99,999 7, 8 
NE 1 10,000 99,999 8 
NH 1 1,000 9,999 7 
NJ 4 10,000 999,999 7, 8 
NY 3 10,000 99,999 6, 7, 8 
OH 10 1,000 999,999 2, 3, 7, 8, 10 
PA 7 1,000 9,999,999 7, 8 
RI 1 1,000 9,999 7 
SC 9 1,000 999,999 7, 8 
TN 7 1,000 99,999 7 
TX 8 1,000 99,999 1, 2, 3, 7, 8, 12 
VA 5 10,000 999,999 7, 8 
VT 1 10,000 99,999 2, 5, 7, 12 
WA 1 10,000 99,999 8 
WI 2 1,000 9,999 7, 8 
 
Source: TRI01 2004 
 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Onsite use/processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Impurity 
7.  Reactant 
8.  Formulation Component 
9.  Article Component 
10.  Repackaging 
11.  Chemical Processing Aid 
12.  Manufacturing Aid  
13.  Ancillary/Other Uses 
14.  Process Impurity 
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chemically bound to the polymer matrix, they may migrate out of the matrix with time (WHO 1994b).  
PBB applications were almost exclusively limited to a particular thermoplastic (arylonitrile-butadiene-
styrene, ABS) used in electronic equipment housings (Hardy 2002b).  Prior to termination of production, 
hexabromobiphenyl was used as a fire retardant mainly in thermoplastics for constructing business 
machine housings and in industrial (e.g., motor housing), and electrical (e.g., radio and TV parts) 
products.  Smaller amounts were used as a fire retardant in coating and lacquers, and in polyurethane 
foam for auto upholstery (Neufeld et al. 1977).  PBDEs and other flame retardants replaced hexabromo-
biphenyl after its voluntary ban in the late 1970s.  Octabromobiphenyl and decabromobiphenyl were 
never used in the United States, probably because the hexabromobiphenyl was less expensive and equally 
effective as a fire retardant (Neufeld et al. 1977). 
 
Polybrominated Diphenyl Ethers.  PBDEs are used as additive flame retardants in thermoplastics.  
Additive flame retardants are physically combined with the polymer material being treated rather than 
chemically combined (as in reactive flame retardants).  This means that there is a possibility that the 
flame retardant may diffuse out of the treated material to some extent.  PBDEs are used in different resins, 
polymers, and substrates at levels ranging from 5 to 30% by weight (EU 2001).  As of August 15, 2004, 
no products containing more than 0.1% penta- or octoBDE by mass can be sold in the European Union 
(EU 2003b). 
 
The commercial pentaBDE product is used predominantly (95–98%) for flame retardant purposes as an 
additive in consumer products manufactured by the furniture industry (ENVIRON 2003a).  It is used 
almost exclusively for flame retard flexible polyurethane foam (FPUF), which is used in bed mattresses 
and cushioning in upholstered products.  The commercial pentaBDE is typically used in FPUF as an 
additive mixture with aromatic phosphate esters (e.g., mixture of 75% pentaBDE and 25% aromatic 
phosphate esters).  Mattress FPUF contains approximately 2–3% flame retardant mixture and cushion 
FPUF contains 3–5% flame retardant mixture (ENVIRON 2003a).  Scrap materials from both industries 
have been used as padding beneath carpets, and as a result, carpet padding likely contains 3–5% flame 
retardant mixture.  However, not all of the FPUF found in cushion, mattress, and carpet padding products 
are treated with commercial pentaBDE.  Approximately 7.5% of the more than 2.1 billion pounds of 
FPUF produced annually in the United States uses the commercial pentaBDE product as a flame retardant 
additive (ENVIRON 2003a).  The majority of FPUF products treated with the commercial pentaBDE 
product are sold in California, the only state requiring by law that upholstered products achieve a 
prescribed level of ignition resistance (ENVIRON 2003a).  A small percentage of pentaBDE is used in 
commercial adhesive products.  Historical uses of commercial pentaBDE included coatings for specialty 
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textiles, printed circuit board components, hydraulic and oilfield completion fluids, and rubber products.  
However, all of these uses have been discontinued in recent years.  In the past, automotive and airplane 
seating cushions contained FPUF with commercial pentaBDE.  However, this use was discontinued in the 
early 1990s.  Prior to approximately 1990, the commercial pentaBDE product may have been used in 
small quantities as a flame retardant in specialty fire-resistant clothing using polyurethane treatment and 
in polyurethane coatings in carpets (ENVIRON 2003a).  With the exception of small quantities used in 
rigid polyurethane elastomers for instrument casings, the commercial pentaBDE product is not used in 
electronic equipment.  However, it is possible that electronic equipment containing pentaBDE produced 
in other countries (principally Asian) could find its way into the United States (EU 2001).  The 
commercial pentaBDE product is not used in acrylonitrile-butadiene-styrene plastics or electronics 
equipment (ENVIRON 2003a).  Other applications of pentaBDE may include use as an additive flame 
retardant for flexible polyester polyurethane foam, rigid polyurethane, rigid polyurethane foams, epoxies, 
laminates, adhesives, coatings, unsaturated polyesters, and flexible polyvinyl chloride (PVC) compounds 
(Great Lakes Chemical Corporation 2004a).   
 
The commercial octaBDE is used by the plastics industry as an additive flame retardant for manufactured 
products.  It is used almost exclusively to flame retard acrylonitrile-butadiene-styrene (ABS) terpolymers 
used in computer casings and monitors (ENVIRON 2003b).  In the European Union, approximately 95% 
of the total commercial octaBDE product sold to the electronics and plastics industries is used in ABS 
(EU 2003a).  Although data are not available in the United States, similar volumes are expected 
(ENVIRON 2003b).  The commercial octaBDE product is used in ABS products at 12–18% weight 
loadings of flame retardant.  OctaBDE is always used as a flame retardant in conjunction with antimony 
trioxide.  Other minor uses for octaBDE, accounting for the remaining 5% use, include high impact 
polystyrene (HIPS), polybutylene terephthalate (PBT), and polyamide polymers (EU 2003a).  Other 
possible applications of octaBDE include use as additive flame retardant in polycarbonate, phenol-
formaldehyde resins, unsaturated polyesters (EU 2003a), nylon, thermoplastic elastomers, polyolefins, 
adhesives, and coatings (Great Lakes Chemical Corporation 2004b).   
 
The commercial decaBDE product is an additive flame retardant used in a variety of polymer 
applications.  Industry information indicates that decaBDE is used at loadings of 10–15% weight in 
polymers and is always used in conjunction with antimony trioxide (EU 2002).  The major application for 
decaBDE is in high impact polystyrene (HIPS), which is used in the television industry for cabinet backs.  
It is also used for a large number of other polymers with end-uses in electrical and electronic equipment 
(e.g., computers, connectors, electrical boxes, wire and cable, etc.).  Examples include polypropylene (for 
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electronics), acetate copolymers (ethylene-vinyl acetate [EVA] and other copolymers for wire and cable), 
ethyelene-propylene-diene terpolymer (EPDM) and thermoplastic elastomers (for wire and cable), and 
polyester resins (for electronics).  Other minor uses include styrenic rubbers, polycarbonates, polyamides, 
and terphthalates, and small amounts are reported to be used in hot-melt adhesives (EU 2002).  Other 
possible applications of decaBDE are as an additive flame retardant for low-density polyethylene (LDPE), 
unsaturated polyester, epoxy, coatings, adhesive systems, and backcoatings for fabrics (Great Lakes 
Chemical Corporation 2004c).  Upholstered furniture in commercial settings in the United States is 
required to meet federal flammability standards and may utilize upholstery textiles that are flame retarded 
with a backcoating containing decaBDE at 5 mg/m2 (BFRIP 2002). 
 
Currently, technical decaBDE is the most widely used PBDE flame retardant worldwide, followed by 
technical pentaDBE.  About 95% of technical pentaBDE is used in the manufacture of flexible 
polyurethane foam used as cushioning in upholstery.  Flexible polyurethane foam is also used in foam-
based laminated automotive applications, for domestic furniture, and in foam-based packaging (EU 
2001).  Technical octaBDE is mainly used in the preparation of acrylonitrile-butadiene-styrene 
terpolymer (ABS), which is used in the manufacture of computer and business equipment housings.  
Technical octaBDE is also used in adhesives and coatings applications (WHO 1994a).  Technical 
decaBDE is primarily used in combination with antimony trioxide in high impact polystyrene (HIPS) 
applications, such as electronic enclosures (e.g., television cabinets).  Other minor uses of technical 
decaBDE are in textile applications to flame retard upholstery fabric (e.g., polyester fiber additives and 
coatings for automobile fabric, tarpaulins, and tents) (WHO 1994a).   
 
7.4   DISPOSAL  
 
Polybrominated Biphenyls.  PBBs are no longer commercially produced in the United States.  In the past, 
an estimated 0.0046 pounds have been lost to sewers for every 1,000,000 pounds of PBBs produced at 
manufacturing sites (Neufeld et al. 1977).  The Michigan Chemical Corporation discharged an estimated 
0.25 pounds of PBBs/day to the Pine River as effluent (Di Carlo et al. 1978).  The Michigan Chemical 
Corporation estimated that the solid waste generated during the manufacture of FireMaster BP-6 was 5% 
of the FireMaster BP-6 and FireMaster FF-1 produced (Di Carlo et al. 1978).  Since Michigan Chemical 
Corporation produced ≈11.8 million pounds of FireMaster BP-6 and FireMaster FF-1 from 1970 to 1974 
(Di Carlo et al. 1978), solid wastes containing a total of 590,000 pounds of PBBs would have been sent to 
disposal.  About one-half of this waste was deposited in the Gratiot County landfill in St. Louis, Michigan 
(Di Carlo et al. 1978), and the rest was possibly landfilled at other locations.  Contaminated animal 
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carcasses, poultry and eggs, animal feed, butter, cheese, and other milk products following the Michigan 
agriculture contamination episode were disposed of in a sanitary landfill in Cadillac, Michigan (Dunckel 
1975). 
 
Approximately 11.8 million pounds of hexabromobiphenyl were used in commercial and consumer 
products in the United States, most in the production of plastic products with an estimated use life of 5–
10 years (Neufeld et al. 1977).  Since the cessation of production, all of these products, such as TV 
cabinet and business machine housings, must have been disposed of by land filling or incineration 
(Neufeld et al. 1977).  The formation of polybrominated dioxins (PBDDs) and polybrominated dibenzo-
furans (PBDFs) during the incineration of plastics containing PBBs remains a distinct possibility (Luijk 
and Govers 1992; O'Keefe 1978). 
 
Polybrominated Diphenyl Ethers.  PBDEs are currently used as flame retardants in a wide range of 
consumer products (see Section 7.3).  In the United States, waste disposal of PBDE-containing consumer 
products is described as transfers to disposal (landfill), recycling, energy recovery (incineration), or 
publicly owned treatment works (POTWs) (Darnerud et al. 2001).  No other information was located on 
the past or present volumes of PBDE-containing consumer products disposed of by each method of waste 
transfer. 
 
Landfill disposal of plastic consumables containing pentaBDE (e.g., polyurethane foams), octaBDE (e.g., 
computer monitors) and decaBDE (e.g., televisions) to landfills is likely to increase in the United States 
due to their limited useful lifespan.  Given that all PBDEs have low water solubilities (see Table 6-6), the 
potential for leaching of PBDE from landfills appears to be small (EU 2002).  Well-designed landfills will 
include measures to minimize leaching and those measures would also be effective in minimizing the 
leaching of any PBDE particulates present (EU 2002).   
 
PBDEs in sewage are disposed of in publicly owned treatment works (POTWs), as indicated by analysis 
of sewage sludge from various countries.  Tetra- and penta-BDEs have been detected in sewage sludge 
from POTWs in the United States with the composition of PBDEs in these biosolids closely resembling 
the DE-71 (i.e., pentaBDE) commercial formulation (La Guardia et al. 2000).  Hale et al. (2001b) 
reported that the practice of land application of sewage sludges may introduce significant amounts of the 
pentaBDE commercial mixture into the environment, although levels have not yet been quantified.   
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Incineration of waste materials containing PBDEs is thought to be a potential source of PBDFs and/or 
PBDDs.  The formation of PBDFs/PBDDs as a result of uncontrolled landfill fires is also a possibility, 
although no data are available on the scale of this source.  The results of pyrolysis experiments showed 
that PBDEs can form PBDFs and PBDDs (in much smaller quantities) under a wide range of heating 
conditions.  If chlorine is present, mixed halogenated furans/dioxins can be formed (Oberg et al. 1987; 
Zier et al. 1991).  Unless sufficiently high temperatures and long residence times are maintained, 
PBDFs/PBDDs can be generated during the incineration of products containing PBDEs.  When heavy 
metals are present, the concentration of PBDDs and PBDFs are higher than when no metals are present.  
Sakai et al. (2001a) measured residues of PBDFs/PBDDs in effluents from a municipal incineration plant 
burning domestic waste materials.  Flue gases, fly ash, and bottom ash reportedly contained 
PBDFs/PBDDs at concentration ranges of 0.28–3.3 ng/N m3, 0.082–13 ng/g, and 0.0058–27 ng/g, 
respectively.  However, modern, properly operated municipal waste incineration should not emit 
significant quantities of PBDFs/PBDDs, regardless of the composition of municipal waste (WHO 1994a).   
 
In the United States, waste disposal of industrial by-products containing PBDEs may also be described as 
transfers to disposal (landfill), recycling, energy recovery (incineration), industrial treatment works, or 
POTWs.  The types of waste transfer may be different for manufacturing versus processing sectors, and 
also from within different types of processing.  Waste disposal from manufacturing processes is 
predominantly to secure chemical landfills (e.g., those built with liners and leachate collection).  For 
example, solid wastes (e.g., filter cakes) from the commercial production of technical octaBDE are 
disposed of in hazardous waste landfills as these wastes may contain toluene from the production process 
(EPA 1995).  Plastic processors typically transfer most waste to disposal (landfill), recycling, energy 
recovery (incineration), and industrial treatment works, while minimal releases are to POTWs.  In 
contrast, textile processors typically transfer most waste to POTWs.  This difference in waste transfers 
between the plastic and textile sectors is because textile processors use water in their processing operation 
and other processors (e.g., processors of plastic) do not.  
 
Recycling of plastic materials containing PBDEs is a common practice in industry.  It has been 
demonstrated that decaBDE-containing resins can be successively recycled without generation of 
PBDDs/PBDFs (Brenner and Knies 1990; Donnelly et al. 1987); McAllister et al. 1990).  For example, 
virgin high impact polystyrene (HIPS) resins (containing antimony trioxide [Sb2O3] and decaBDE) and 
repeatedly ground and injected molded (e.g., “recycled”) HIPS/decaBDE/Sb2O3 resins both met the 
requirements of the German Chemicals Banning Ordinance with respect to 2,3,7,8-substituted 
PBDD/PCDF congeners.  These resins were at least 1 order of magnitude below the regulated limit values 
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for PBDDs/PCDFs (1 ppb for the sum of four congeners, 5 ppb for the sum of all eight regulated 
congeners). 











8.  POTENTIAL FOR HUMAN EXPOSURE 
 
8.1   OVERVIEW  
 
Polybrominated Biphenyls.  PBBs have been identified in at least 9 of the 1,647 hazardous waste sites 
that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2004).  
However, the number of sites evaluated for PBBs is not known.  The frequency of these sites can be seen 
in Figure 8-1.  Of these sites, all are located within the United States and none are located in the 
Commonwealth of Puerto Rico (not shown). 
 
The production of PBBs in the United States ceased in 1979 (IARC 1986).  In the past, PBBs were 
released to the environment during the manufacture of these compounds and disposal of commercial and 
consumer products containing these compounds (Hesse and Powers 1978; Neufeld et al. 1977).  One of 
the significant sources of environmental contamination occurred as a result of the accidental mixup of 
FireMaster BP-6 with cattle feed in a number of farms in the lower peninsula in Michigan (see 
Section 5.2 for additional details concerning this incident).  By June 1975, 412 farms had been 
quarantined.  Disposal of contaminated feed, animal carcasses (poultry, dairy cattle, swine), and animal 
products (dairy, meat, eggs) contributed to environmental contamination (Dunckel 1975; Kay 1977).  No 
information was located on the current levels of contamination at these locations.   
 
PBBs can exist as 209 different congeners, but only about 42 have been synthesized (Sundstrom et al. 
1976b).  Environmental contamination of PBBs is likely to have occurred mainly from the two 
commercial products, FireMaster BP-6 and FireMaster FF-1.  The principal component in both of these 
commercial products was 2,2',4,4',5,5'-hexabromobiphenyl or BB-153 (Robertson et al. 1983b). 
 
PBBs are strongly adsorbed to soil and sediment (Filonow et al. 1976; Hesse and Powers 1978) and 
usually persist in the environment (Jacobs et al. 1978).  Adsorption of PBBs generally increases as 
bromination of the PBBs and organic carbon content of soil and sediment increase (Filonow et al. 1976; 
Griffin and Chou 1981a, 1981b).  As a result, the leaching of commercial mixtures of PBBs from soil is 
slow.  Leaching studies with four Michigan soils mixed with 100 mg/kg 2,2',4,4',5,5'-hexabromobiphenyl 
showed that <0.6% of the compound leached through soils after a 19-day period.  Leachate quantities in 
this study were equivalent to 20 times the average annual rainfall in Michigan (Filonow et al. 1976).  The 
PBBs in commercial mixtures resist both chemical and biological degradation (Jacobs et al. 1978;  
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Kawasaki 1980; Shelton and Tiedje 1981), although biotic debromination to lower brominated products 
may occur in anaerobic zones of contaminated sediment and soil (Morris et al. 1992). 
 
PBBs with six or fewer bromine substitutions bioconcentrate in aquatic organisms such as fish, but the 
octabromo- and decabromobiphenyls do not bioconcentrate significantly in fish (Gobas et al. 1989; Norris 
et al. 1973; Opperhuizen et al. 1985; Veith et al. 1979; Zitko 1979; Zitko and Hutzinger 1976).  Orchard 
grass, alfalfa, corn, and tops of carrots grown in soil contaminated with PBBs showed no uptake of PBBs, 
and only minor uptake occurred on carrot roots (Jacobs et al. 1976, 1978).  Although PBBs were detected 
in fish-eating birds and predatory animals that had consumed PBB-contaminated food (Heinz et al. 1983, 
1985), the biomagnification potential of PBBs in predators resulting from such consumption remains 
unknown. 
 
PBBs were detected in air, water, sediment, and soil in the vicinity of the manufacturing plants and in 
groundwater from a landfill site (DeCarlo 1979; Hesse and Powers 1978; Shah 1978).  PBBs were also 
detected in soil near the contaminated farms in Lower Michigan (Fries and Jacobs 1980).  The 
distribution of PBBs was limited to the environment in the vicinity of production sites and the 
contaminated farm sites.  Recent studies have identified PBBs in marine mammals from coastal seas and 
the Atlantic Ocean (de Boer et al. 1998).  Data regarding the current levels of PBBs in ambient air, 
drinking water, or food were not located. 
 
No estimate on PBB intake by the general population from air, water, and food was located in the 
literature.  Current intake of PBBs for the general population is expected to be zero or very small.  
Populations near the contaminated farms in Lower Michigan may still have low exposures from air, 
water, and food.  The level of PBBs in human tissue and body fluids in the exposed population of 
Michigan has been extensively studied (Brilliant et al. 1978; Cordle et al. 1978; Eyster et al. 1983; 
Humphrey and Hayner 1975; Lambert et al. 1990; Landrigan et al. 1979; Wolff et al. 1979a, 1982).  The 
finding that PBBs are stored in fatty tissues of the human body and are very slowly excreted (Eyster et al. 
1983) indicates a slow decline in the body burden for exposed individuals. 
 
Polybrominated Biphenyl Ethers.  The widespread use of PBDEs over the past 30 years has resulted in 
the presence of some lower-brominated congeners in the environment (e.g., 2,2’,4,4’-tetrabromodiphenyl 
ether [BDE 47]).  However, highly brominated congeners (e.g., decaBDE) are typically detected only 
near point sources.  PBDEs are released into the environment from their manufacture and use as additive 
flame retardants in thermoplastics in a wide range of products (WHO 1994a).  PBDEs containing waste 
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may be incinerated as municipal waste, deposited in landfills, discharged to municipal sewage-treatment 
plants, or emitted directly to the atmosphere as particulates (Darnerud et al. 2001).  In the future, the 
disposal of plastic consumables containing PBDEs is likely to increase in the United States (NSC 1999).  
 
PBDEs are strongly adsorbed to soil and sediment and persist in the environment.  Adsorption of PBDEs 
generally increases as bromination of PBDEs and organic carbon content of soil and sediment increase.  
As a result, most PDBEs have little or no mobility in soil and are not expected to leach (e.g., into 
groundwater).  Lower BDE homologs (e.g., tri- and tetraBDE), which may exist partially in the vapor 
phase, have the potential for long-range transport in the atmosphere.  The detection of lower brominated 
PBDEs (e.g., 2,2’,4,4’-tetraBDE [BDE 47]) in remote regions of the world suggests that long-range 
transport of these congeners is occurring.  Higher BDE homologs (e.g., decaBDE) will primarily exist 
near point sources.  Biodegradation will not be significant for PBDEs, but under certain conditions, some 
PBDEs compounds (e.g., decaBDE) may degrade by direct photolysis to form lower-brominated 
congeners.  However, determining the rate and extent of degradation processes (e.g., biodegradation and 
photolysis) for PBDEs, such as decaBDE and pentaBDE commercial mixtures, is still an active area of 
research.  
 
Monitoring studies indicate that lower brominated PBDEs, for example, 2,2’,4,4’-tetrabromodiphenyl 
ether (BDE 47) and 2,2’4,4’,5-pentabromodiphenyl ether (BDE 99), are transported globally.  
Atmospheric, water, and biota levels of PBDEs also tend to be dominated by lower brominated congeners 
(e.g., BDE 47, BDE 99).  Environmental concentrations of lower brominated PBDEs (i.e., tetraBDE and 
pentaBDE) appear to be leveling off in Europe, but appear to be increasing in certain areas in Canada and 
the United States, although data are too sparse to make broad statements regarding trends.  In the 
environment, higher brominated commercial mixtures (e.g., decaBDE) are concentrated in soils and 
sediment near industrial point sources. 
 
Studies of the biota indicate that lower brominated congeners (e.g., 2,2’,4,4’-tetraBDE [BDE 47]) are 
being preferentially bioconcentrated.  Lower brominated diphenyl ether (e.g., tetra- and penta-) 
concentrations increase with respect to trophic level; thus, organisms that reside higher on food chains 
tend to have higher concentrations of these brominated diphenyl ethers.  Body-burden data indicate that 
the general population is exposed to low levels of lower brominated (e.g., tetra- and penta-) BDEs.  In 
general, decaBDE is not found in body burden data.  
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Humans are primarily exposed to lower brominated (e.g., tetra- and pentaBDEs) BDEs by inhalation of 
ambient or contaminated air and ingestion of contaminated food.  Levels of PBDEs in body tissues and 
fluids from individuals living in the United States have recently been determined.  Most studies indicate 
that levels of lower brominated BDEs (e.g., 2,2’,4,4’-tetraBDE [BDE 47]) in body fluids and tissues are a 
factor of 10–100-fold higher for individuals living in the United States compared to individuals living in 
other regions of the world (e.g., Europe).  In general, decaBDE is not detectable in body fluids and 
tissues.  Occupational exposure to PBDEs occurs primarily by inhalation of air containing PBDEs.  
 
PBDEs have not been identified in any of the 1,647 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2004).  However, the number of sites 
evaluated for PBDEs is not known.  
 
8.2   RELEASES TO THE ENVIRONMENT  
 
Polybrominated Biphenyls.  The production of PBBs in the United States ceased in 1979 (IARC 1986).  
In the past, PBBs were released to the environment during the manufacture of these compounds and 
disposal of commercial and consumer products containing these compounds (Hesse and Powers 1978; 
Neufeld et al. 1977).  One of the significant sources of environmental contamination occurred as a result 
of the accidental mixup of FireMaster BP-6 with cattle feed in a number of farms in the lower peninsula 
in Michigan (see Section 5.2 for additional details concerning this incident).  By June 1975, 412 farms 
had been quarantined.  Disposal of contaminated feed, animal carcasses (poultry, cattle, swine), and 
animal products (meat, milk, eggs) contributed to environmental contamination (Dunckel 1975; Kay 
1977).  
 
Polybrominated Diphenyl Ethers.  The widespread use of PBDEs over the past 30 years has resulted in 
the presence of lower brominated diphenyl ether congeners, for example, 2,2’,4,4’-tetrabromodiphenyl 
ether (BDE 47) and 2,2’4,4’,5-pentabromodiphenyl ether (BDE 99), in the environment.  Higher 
brominated congeners (e.g., octabromodiphenyl ether and decabromodiphenyl) tend to concentrate near 
point sources (Wania and Dugani 2002).  The commercial production of PBDEs began in late 1970s 
(WHO 1994a).  In 2001, the total market demand for PBDEs in the Americas was 33,100 metric tons 
(BSEF 2003).  Technical decabromodiphenyl ether constituted about 24,500 metric tons (74%), while 
technical mixtures of octa- and pentabromodiphenyl ethers were 1,500 and 7,100 metric tons (4 and 22% 
of this total), respectively (BSEF 2003).  PBDEs may be released into the environment from their 
manufacture and use in a wide range of consumer products (WHO 1994a).  PBDEs are used as additive 
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flame retardants in thermoplastics.  Additive flame retardants are physically, rather than chemically, 
combined with polymers.  Thus, there is a possibility that some PBDEs congeners (e.g., lower brominated 
congeners) may diffuse out of the treated materials to some extent (EU 2001).  Waste from products 
containing PBDEs may be either incinerated as municipal waste, deposited in landfills, or discharged to 
municipal sewage-treatment plants (Darnerud et al. 2001).  In the future, the disposal of plastic 
consumables containing PBDEs to landfills is likely to increase in the United States and elsewhere in the 
world.  
 
The widespread use of pentaBDE over the past 30 years has resulted in the rapid increase in 
concentrations of lower brominated congeners, for example, 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47) 
and 2,2’4,4’,5-pentabromodiphenyl ether (BDE 99), and their presence in the environment.  No 
quantitative information was located on the releases of the commercial pentaBDE product from its 
production and use in the United States.  The commercial pentaBDE product is used predominantly (95–
98%) as an additive flame retardant in flexible polyurethane foam (FPUF), which has applications as 
cushioning in bed mattresses and upholstered products (see Section 7.3).  No quantitative information was 
located on the releases of pentaBDE from the production of flexible polyurethane foams.  However, the 
main source of release for liquid flame retardant additives (e.g., pentaBDE) is associated with the handing 
of the raw material (e.g., splashes and spills) prior to the foaming process, where releases are to waste 
water (EU 2001).  There is a potential release to air during the curing phase since the polyurethane foam 
is heated at elevated temperatures (e.g., up to 160 °C) for several hours.  Foam scrap will be disposed of 
to a landfill or possibility incinerated (EU 2001).  Since pentaBDE is an additive flame retardant, it may 
be subject to volatilization or leaching from the polymer matrix during the lifetime of the use of an article.  
Losses of foam particles containing the substance (e.g., due to abrasion) may also occur.  However, 
pentaBDE has a very low vapor pressure (see Table 6-6) and volatilization losses from polyurethane foam 
would be expected to be low.  Given that the major use of pentaBDE is as a component of polyurethane 
foam for furniture/seating/automobile use, the potential for leaching of pentaBDE during use will be 
minimal.  This is because, although it is likely that foam coverings may be washed during the lifetime of 
use, it is very unlikely that the foam cushioning containing pentaBDE will be washed as well (EU 2001).  
Residual ‘waste’ pentaBDE in the environment will be particles of polymer (foam) products that contain 
pentaBDE (e.g., 2,2’4,4’-tetraBDE).  Polyurethane foam has an open cell structure, which presents a large 
surface area to the environment and therefore, the potential for release is likely to be greater than the hard 
dense plastics where octaBDE and decaBDE are used.  In addition, this foam may become friable and 
crumble with age.  Thus, small particles thereby released could move into the environment and disperse 
its components (i.e., commercial pentaBDE mixture) (BFRIP 2002).  These form particles are released to 
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the urban/industrial soil compartment, but may also end up in sediment or air (EU 2001).  Movement of 
polymer (foam) particles containing pentaBDE within the landfill could provide a transport mechanism 
leading to entry into leachate water or groundwater.  However, well-designed landfills, in general, already 
include measures to minimize leaching and these measures would also be effective in preventing any 
leaching of pentaBDE as well (EU 2001).  
 
Commercial octaBDE is used almost exclusively to flame retard acrylonitrile-butadiene-styrene (ABS) 
terpolymers used in computer casings and monitors (ENVIRON 2003b).  No quantitative information was 
available on emissions of octaBDE from production operations.  The major sources of air emissions are 
thought to be as a result of grinding and bagging operations.  The emission to air of octaBDE vapor from 
production can be considered to be negligible (EU 2003a).  The most likely way in which octaBDE may 
reach water from its production is due to washing out of equipment.  The major source of octaBDE waste 
is from filter waste and reject material (EU 2003a).  Much of the loss from polymer applications (e.g., 
acrylonitrile-butadiene-styrene) is likely to be in the form of dust.  It is expected that much of this dust 
will be collected for reuse or disposed of to landfill/incineration.  Some of this may end up in waste water 
as a result of cleaning floors and equipment (EU 2003a).  Given that the major use of plastics containing 
octaBDE appears to be in electrical applications and that the substance has very low water solubility, the 
potential for leaching of octaBDE from the products during uses appears to be small.  Waste remaining in 
the environment can be considered to be particles (or dust) of polymer product, or dust generated from 
polymer products, that contain octaBDE.  These particles are primarily released to urban/industrial soil, 
but may also end up in sediment or air.  Plastics containing octaBDE will usually be disposed of either to 
landfills or by incineration.  No experiments have been carried out on the leachability of octaBDE from 
polymers in landfills.  However, octaBDE is not expected to leach to a significant extent from polymers, 
unless the polymer itself undergoes some form of degradation, thus releasing octaBDE.  It is expected that 
emissions of octaBDE from incineration processes will be near zero (EU 2003a).  
 
Commercial decaBDE product is an additive flame retardant used in a variety of polymer applications 
(EU 2002).  The major application for decaBDE is in high-impact polystyrene (HIPS), which is used in 
the television industry for cabinet backs.  No quantitative information is available on emissions of 
decaBDE from production operations.  Since the major use of plastics containing decaBDE is in 
electrical/electronic applications and the substance has very low water solubility, the potential for 
leaching of decaBDE from plastic products during use appears to be small (EU 2003a).  A study of the 
leaching of decaBDE (DOW FR-300-BA; 77.4% deca-, 21.8% nona-, and 0.8% octaBDE) from pellets of 
acrylonitrile-butadiene-styrene (ABS) polymer and polystyrene (both containing 10% decaBDE) was 
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undertaken.  The lack of increase in bromine concentration with time was observed.  In static extractions 
of ABS containing 4.25% decaBDE (Dow FR-300-BA) with water, acetic acid, and cottonseed oil at 
elevated temperatures, little or no leaching of the decaBDE was evident.  No decaBDE was detected in 
the water and acetic acid and only 0.03% of the total decaBDE was extracted by cottonseed oil over 
7 days at elevated temperatures (EU 2002).  
 
Releases of decaBDEs are required to be reported under the Superfund Amendments and Reauthorization 
Act (SARA) Section 313; consequently, data are available for this compound in the Toxics Release 
Inventory (TRI) (EPA 1995).  According to the TRI, a total of 649,541 pounds (294,627 kg) of decaBDE 
were released to the environment in 2001.  In addition, an estimated 787,927 pounds (357,398 kg) were 
transferred off-site, including to publicly-owned treatment works (POTWs) (TRI01 2004).  The TRI data 
should be used with caution because only certain types of facilities are required to report.  This is not an 
exhaustive list.  Facilities are only required to report to the TRI if they manufacture or process more than 
25,000 pounds of a TRI listed chemical during the year, or otherwise use more than 10,000 pounds, and 
have the equivalent of more than 10 full-time employees.  According to the EPA, TRI data have certain 
limitations.  TRI data reflect releases and other waste management of chemicals and not exposures of the 
public to those chemicals.  TRI data alone are not sufficient to determine exposure or calculate potential 
adverse effects on human health and the environment. 
 
On-site land releases dominate decaBDE releases on-site from its manufacture and use, and are 
predominantly associated with disposal of decaBDE in either a manufacturer’s on-site landfill in 
Arkansas or in a commercial chemical landfill in Louisiana.  On-site air and water releases make up only 
a small fraction of total on-site releases.  For example, on-site air emissions in 2000 were ~6.6% of the 
total; on-site surface water discharges also make up only a small fraction of the total (~0.2% of the 
2000 total) and are nearly all associated with operations that apply decaBDE to upholstery textiles.  
DecaBDE releases off-site for disposal from its manufacture and use are typically larger than those on-
site to land; decaBDE-waste transfers for further waste management are dominated by transfers to 
POTWs from the textile industry, although a significant rise in recycling has occurred in recent years.  
The plastics industry released minimal amounts to POTWs.  The largest releases of decaBDE or 
decaBDE-waste to water occur in Maryland, North Carolina, and South Carolina and result from its use in 
textiles (TRI01 2004). 
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8.2.1   Air  
 
Polybrominated Biphenyls.  In the past, PBBs were released into the air during the manufacture of these 
compounds in three areas: through the vents of the hydrogen bromide recovery system, from the 
centrifugation area for recovering PBBs from slurries produced by bromination, and from the drying, 
pulverizing, and bagging area of the finished product (Di Carlo et al. 1978).  An estimated 
0.07 pounds/million pounds of the PBBs produced were lost from the hydrogen bromide-recovery vent 
(Di Carlo et al. 1978).  No data are available for the air pollution factor (amount released/million pounds 
produced) at the centrifugation site.  The concentrations of FireMaster BP-6 in the Michigan Chemical 
Corporation bagging area were 0.016–0.032 mg/L of air during the bagging operation and 0.003 mg/L of 
air after the completion of bagging (Di Carlo et al. 1978).  In 1977, the maximum air losses of PBBs at 
production sites were estimated to total 1,125 pounds of PBBs for every 1 million pounds of PBBs 
produced (Di Carlo et al. 1978). 
 
Another process that could release lower levels of brominated biphenyls in the air is the incineration of 
PBBs.  Pyrolysis of hexabromobiphenyl in the absence and presence of air has produced small amounts of 
lower brominated biphenyls (Thoma and Hutzinger 1987).  No data are available on the importance of 
this source for the release of PBBs in the air during the incineration of PBBs.  However, since the vast 
majority of products containing PBBs are expected to be out of circulation after more than 25 years since 
the voluntary ban, incineration will not be a significant source of PBBs to air.  
 
PBBs have been identified in 1 air sample, collected from 1,647 NPL hazardous waste sites, where they 
were detected in some environmental media (HazDat 2004). 
 
Polybrominated Diphenyl Ethers.  The widespread use of pentaBDE technical mixtures over the past 
30 years has resulted in the increasing concentrations of lower brominated congeners in air, e.g., 
2,2’,4,4’-tetrabromodiphenyl ether (BDE 47) and 2,2’4,4’,5-pentabromodiphenyl ether (BDE 99).  No 
quantitative information was located on the releases of the pentaBPE technical mixtures to the atmosphere 
from its production and use.  However, the release of pentaBDE technical mixtures to air has the potential 
to occur during the curing phase, since the polyurethane foam is at elevated temperatures (e.g., up to 
160 °C) for several hours during this phase.  Since pentaBDE technical mixtures are additive flame 
retardants, they may be subject to volatilization or leaching from the polymer matrix during the lifetime 
of the use of the foam article.  Losses of foam particles containing the substance (e.g., due to abrasion) 
may also occur.  However, most congeners in pentaBDE technical mixtures have very low vapor 
pressures (see Table 6-6) and therefore, losses from polyurethane foam due to volatilization would be 
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expected to be low.  Migration of pentaBDE technical mixtures from consumer products may be a 
significant diffuse source of lower brominated congeners of pentaBDE technical mixtures to the 
atmosphere.  Although no studies were found that determined the migration rate of pentaBDE technical 
mixtures from polymers into the air, estimates have been made.  The estimated migration rate for 
pentaBDE technical mixtures is 0.39% per year (Danish EPA 1999). 
 
In the regions surrounding metal-recycling plants in Taiwan and Japan, a variety of tri-, tetra-, and 
hexabromodiphenyl ethers (BDEs) were measured in air (Watanabe et al. 1992).  The concentrations in 
Taiwan and Japan were 23–53 and 7.1–21 pg/m3, respectively. 
 
No quantitative information is available on emissions of octaBDE technical mixtures to the atmosphere 
from production operations.  The major sources of air emissions of octaBDE technical mixtures are 
thought to be a result of grinding and bagging operations.  However, the emission to air of vapors from 
production of octaBDE technical mixtures may be considered to be negligible (EU 2003a).  OctaBDE 
technical mixtures are used almost exclusively to flame retard ABS terpolymers used in computer casings 
and monitors (ENVIRON 2003b).  No quantitative information was available on emissions of octaBDE 
technical mixtures to the atmosphere from ABS applications.  However, much of the loss from polymer 
applications is likely to be in the form of dust.  Losses of octaBDE technical mixture powders (particle 
sizes >40 µm) have been estimated as 0.21% during handling of raw materials.  These losses will initially 
be to the atmosphere, but it is expected that this dust will rapidly settle and may be disposed of to 
landfills.  OctaBDE technical mixtures in the compounding stage are also susceptible to dust generation.  
However, losses at this stage are thought to be lower than during the handling of raw materials (EU 
2003a).  Plastics containing octaBDE technical mixtures will usually be disposed of either to landfill or 
by incineration.  It is expected that emissions of PBDE congeners resulting from incineration of plastics 
containing octaBDE technical mixtures will be negligible (EU 2003a).  
 
No quantitative information is available on emissions of decaBDE technical mixtures to the atmosphere 
from production operations.  In 1979, decaBDE was found in the atmosphere as particulate matter in the 
vicinity of plants manufacturing brominated flame retardants (Zweidinger et al. 1979); the concentration 
of decaBDE ranged from not detected to 72 ng/m3.  The estimated releases of decaBDE vapor to air 
during production are low, typically 1.1x10-5 mg/metric tons of production (EU 2002).  The major source 
of air emissions is thought to be a result of grinding and bagging operations.  Losses of powders during 
the handling of raw materials will initially be to the atmosphere, but it is expected that this dust will 
rapidly settle within the production facility and therefore, these losses will be mainly to solid waste (EU 
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2002).  The compounding stage is also susceptible to dust generation, but losses are thought to be lower 
than during handling of raw materials (i.e., an order of magnitude lower).  Releases will again be initially 
to the atmosphere, but the particles would be expected to settle within the compounding facility and will 
ultimately be to solid waste or waste water.  In addition to particulates, emissions to the atmosphere due 
to the volatility of the flame retardant at the elevated processing temperatures may be possible.  However, 
due to the high vapor pressure of decaBDE (see Table 6-6), volatilization is expected to be negligible. 
 
The commercial decaBDE product is an additive flame retardant used in a variety of polymer applications 
(EU 2002).  The major application for decaBDE is in high-impact polystyrene (HIPS), which is used in 
the television industry for cabinet backs.  Thus, decaBDE made be released during the polymer 
processing of HIPS.  Waste remaining in the environment can be considered to be small particles of 
polymer product or dust generated from polymer products containing decaBDE (EU 2002).  These 
particles are primarily released to soil, but may also end up in air.  End products with outdoor uses are 
most likely to be atmospheric sources of decaBDE dust.  Releases from these products occur over the 
lifetime of the product due to weathering and wear.  Waste of this type may also be generated during 
disposal of a variety of plastic articles, in particular, where these articles are dismantled or subject to other 
mechanical processes.  Ultimately, plastic articles containing technical decaBDE will be disposed of 
either to landfill or by incineration.  Emissions of decaBDE from controlled incineration processes will be 
near zero (EU 2002).  The concentration of decaBDE was determined in bottom ash from two municipal 
incinerators in Finland.  With a method detection limit of 0.02–0.06 µg/kg, decaBDE was not detected in 
either ash sample (EU 2002).  The low vapor pressure of decaBDE (see Table 6-6) limits its volatility to 
the atmosphere when disposed of in a landfill (EU 2002).  
 
The estimated release of 97,198 pounds (44,088 kg) of decaBDE to the atmosphere from 
54 manufacturing, processing, and waste disposal facilities in 2001 accounted for about 15.0% of the 
estimated total on-site environmental releases (TRI01 2004).  These releases are summarized in 
Table 8-1.  The data from the TRI listed in Table 8-1 should be used with caution, however, since only 
certain types of facilities are required to report (EPA 1995).  This is not a comprehensive list.   
 
DecaBDE was not identified in air samples collected from 1,647 NPL hazardous waste sites (HazDat 
2004). 
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Table 8-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Decabromodiphenyl Ethera 
 












Total on and 
off-site 
release 
AL 1 10 5 0 0 15 0 15 
AR 5 81,717 0 0 130,000 211,717 9,902 221,619 
CA 5 750 0 0 0 750 100,023 100,773 
CT 3 1,024 No data 0 0 1,024 24,149 25,173 
FL 2 0 No data 0 0 0 19,040 19,040 
GA 7 755 0 0 0 755 11,225 11,980 
IL 2 32 No data 0 0 32 13,700 13,732 
IN 6 20 0 0 0 20 3,987 4,007 
KY 2 555 No data 0 0 555 17,478 18,033 
LA 1 0 No data 0 270,000 270,000 0 270,000 
MA 13 292 8 0 0 300 30,658 30,958 
MD 1 0 No data 0 0 0 0 0 
MI 6 3,741 0 0 23,600 27,341 26,503 53,844 
MN 3 0 No data 0 0 0 8,507 8,507 
MO 1 500 No data 0 0 500 1,189 1,689 
MS 2 106 No data 0 0 106 30,933 31,039 
NC 14 2,818 4,237 0 99,090 106,145 73,151 179,296 
NE 2 0 No data 0 0 0 0 0 
NH 1 2 5 0 0 7 285 292 
NJ 5 97 No data 0 0 97 84,846 84,943 
NV 1 No data No data No data No data No data No data 0 
NY 4 0 5 0 990 995 36,837 37,832 
OH 9 322 0 0 750 1,072 77,277 78,349 
PA 7 1,996 109 0 0 2,105 156,439 158,544 
RI 1 13 No data 0 0 13 1,766 1,779 
SC 12 0 2,055 0 40 2,095 20,758 22,853 
TN 7 786 42 0 18,137 18,965 13,644 32,609 
TX 8 1,390 5 0 3,265 4,660 5,712 10,372 
VA 5 270 No data 0 0 270 15,087 15,357 
VT 1 0 No data 0 0 0 0 0 
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Table 8-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Decabromodiphenyl Ethera 
 












Total on and 
off-site 
release 
WA 1 0 No data 0 0 0 0 0 
WI 3 2 No data 0 0 2 4,831 4,833 
Total 141 97,198 6,471 0 545,872 649,541 787,927 1,437,468 
 
Source:  TRI01 2004 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dThe sum of fugitive and stack releases are included in releases to air by a given facility. 
eThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
fTotal amount of chemical transferred off-site, including to publicly owned treatment works (POTW). 
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8.2.2   Water  
 
Polybrominated Biphenyls.  In the past, PBBs were released to water during the manufacturing process.  
An estimated 0.0046 pounds were lost to sewers for every 1,000,000 pounds of PBBs produced at 
manufacturing sites (Neufeld et al. 1977).  To manufacture PBBs, water was added to the reaction 
mixture when the desired extent of bromination was achieved.  Ultimately, this water was discharged as 
effluent into surface water.  Samples of effluents from the Michigan Chemical Corporation contained 
PBB concentrations 503 ppm (Di Carlo et al. 1978).  Runoff water from the manufacturing plants 
containing PBBs also contaminated surface water (Di Carlo et al. 1978).  Landfill sites used to dispose of 
wastes from PBB production can also be a source of PBBs in water.  Concentrations of PBBs in 
groundwater from one such landfill in St. Louis, Michigan were low (0.1–0.2 ppb), but those in water 
from a drainage ditch and catch basin were much higher (0.35–1.2 ppm) (Di Carlo et al. 1978). 
 
PBBs have been identified in 2 and 5 surface water and groundwater samples, respectively, collected 
from 1,647 NPL hazardous waste sites (HazDat 2004). 
 
Polybrominated Diphenyl Ethers.  Industrial and urban effluents are significant sources of PBDEs to 
surface waters and sediments.  Limited data on industrial and urban effluents were located for the United 
States.  Hale et al. (2002) measured the concentration of soil and stream sediments collected near a 
polyurethane manufacturing plant (near the Dan River, Virginia).  Summed concentrations of 
2,2’,4,4’-tetraBDE (BDE 47), 2,2’,4,4’,5-pentaBDE (BDE 99), and 2,2’,4,4’,6-pentaBDE (BDE 100), the 
dominant congeners in these samples, ranged from <1 to 132 µg/kg (ng/g) dry weight.  In 1995, sediment 
samples were collected up- and downstream near an area where the Swedish plastics industry uses 
brominated flame retardants (Sellström and Jansson 1995; Sellström et al. 1998a).  Samples were 
analyzed for tetraBDEs (50 ng/g dry weight) and pentaBDEs (sum of three congeners, 2,300 ng/g dry 
weight).  These PBDEs were found in higher concentrations downstream of the plant than upstream, 
which indicates that the plastics industry was the most likely source of these compounds.  Surficial 
sediment samples were collected at eight locations along River Viskan near several textile manufacturing 
facilities that used various brominated flame retardants in the production of textiles.  The concentrations 
of BDE 47, BDE 99, BDE 100, and BDE 209 in sediments increased as samples were collected further 
downstream where additional industries were located (Sellström et al. 1998a).  The lowest levels of 
PBDEs were found upstream of the textile industries.  The combined concentration of BDE 47, BDE 99, 
and BDE 100 ranged from not detected to 120 ng/g (µg/kg) dry weight; the concentration of BDE 209 
ranged from not detected to 16,000 ng/g (µg/kg) dry weight.  Allchin et al. (1999) surveyed the 
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concentrations of PBDEs in sediments from several rivers and estuaries in Great Britain.  Sediments were 
collected upstream and downstream of suspected sources of pentaBDE and octaBDE, including a 
manufacturer, several industries, landfills, and a reference site.  The highest concentrations of BDE 47, 
BDE 99, pentaBDE (as 2,3’,4’,6-tetrabromodiphenyl ether or BDE 71), and octaBDE (as 3,3’,4,5’-tetra-
bromodiphenyl ether or BDE 79) were in sediments near or downstream from a manufacturing site at 
Newton Aycliffe in River Skerne.  The highest concentrations of decaBDE (as 2,2’,3,3’,5-pentabromo-
diphenyl ether or BDE 83) were found downstream of a sewage-treatment plant on River Calder.  High 
concentrations were also detected on River Skerne downstream of a manufacturing site.  BDE 99 
concentrations were identical or slightly higher than BDE 47 in most sediments (Allchin et al. 1999).  The 
sum of five pentaBDE congeners (BDE 47, BDE 99, BDE 100, BDE 153 [i.e., 2,2’,4,4’,5,5’-hexabromo-
diphenyl ether], and BDE 209) ranged from 0.07 to 10.6 ng/g (µg/kg) dry weight in freshwater sediments 
from Denmark (Christensen and Platz 2001).  The highest concentrations were found in sediment close to 
populated areas.  
 
Although the available information indicates that leaching of PBDEs from landfills is minimal, movement 
of polymer particles containing pentaBDE, octaBDE, and decaBDE commercial mixtures within the 
landfill could lead to entry into leachate water of groundwater.  However, it is not currently possible to 
assess the significance of this type of process.  Well designed landfills already include measures to 
minimize leaching in general, and these measures would also be effective in minimizing leaching of any 
PBDEs present (EU 2002, 2003). 
 
The estimated release of 6,471 pounds (2,935 kg) of decaBDE to water from nine domestic 
manufacturing and processing facilities in 2001 accounted for about 0.45% of the estimated total 
environmental releases (TRI01 2004).  An additional 787,927 pounds (357,398 kg) were transferred off-
site, including to POTWs (TRI01 2004).  These releases are summarized in Table 8-1.  The data from the 
TRI listed in Table 8-1 should be used with caution, however, since only certain types of facilities are 
required to report (EPA 1995).  This is not a comprehensive list. 
 
PBDEs were not identified in water samples collected from 1,647 NPL hazardous waste sites (HazDat 
2004). 
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8.2.3   Soil  
 
Polybrominated Biphenyls.  The important former sources of PBBs in soil are manufacturing operations, 
disposal of PBB-containing finished products, and agricultural operations contaminated in the original 
episode in 1973–1974.  The concentrations of PBBs in soils from bagging and loading areas of the 
Michigan Chemical Corporation were 3,500 and 2,500 mg/kg, respectively (Di Carlo et al. 1978).  
Similarly, soil from sites adjacent to the Hexcel Corp and the White Chemical Company, the 
manufacturers of octabromo- and decabromobiphenyl, contained decabromobiphenyl and other lower 
brominated biphenyls down to hexabromobiphenyl (Di Carlo et al. 1978).  The disposal into landfills of 
solid wastes generated during the production of PBBs was another important source of PBBs in soil 
(Neufeld et al. 1977).  Photodecomposition of FireMaster BP-6 in soil could also be a source of lower 
brominated biphenyls (Ruzo and Zabik 1975; Trotter 1977) in soil. 
 
Approximately 11.8 million pounds (5,350,000 kg) of hexabromobiphenyl was used in commercial and 
consumer products in the United States, mostly in the production of plastic products.  Since the cessation 
of production of hexabromobiphenyl, all of these products, such as TV cabinet and business-machine 
housings, with a usable life of 5–10 years must have been disposed of by landfilling or incineration 
(Neufeld et al. 1977).  Disposal of these plastic materials in waste-disposal sites is an important source of 
PBBs in soil.  The migration of plastic-incorporated PBBs to soil would be very low since PBBs would be 
tightly bound into the plastic (Neufeld et al. 1977). 
 
The indirect source of PBBs in soil was the contaminated farms in Michigan.  Approximately 650 pounds 
(290 kg) of PBBs was mixed in cattle feeds that were delivered to Michigan farms during 1973–1974 
(Fries 1985b).  About 50% of this amount was excreted in the feces of the exposed animals and remained 
on the farms in places of fecal deposition and manure disposal (Fries 1985b).  Soil in fields that received 
contaminated manure contained as high as 300 µg/kg PBBs, whereas soil in resurfaced cattle-exercise lots 
contained as high as 1,000–2,000 µg/kg of PBBs (Fries 1985b). 
 
PBBs have been identified in 5 soil and 3 sediment samples collected from 1,647 NPL hazardous waste 
sites (HazDat 2004). 
 
Polybrominated Diphenyl Ethers.  PBDEs are released to land (i.e., landfills) as waste from their 
manufacture (both raw material and polymer) and as municipal wastes with the disposal of consumer 
products.  Solid waste from commercial production of octaBDE is typically disposed in landfills (EPA 
1995).  The disposal of consumer products containing PBDEs is likely to increase worldwide due to rapid 
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obsolescence of plastic products.  For example, between 1997 and 2004, the number of obsolete 
computers containing flame retardants is projected to be 315 million (NSC 1999).  Based on a monitor 
weight of 30 pounds (14 kg), an estimated 350 million pounds (160,000,000 kg) of brominated flame 
retardants will be released to landfills (NSC 1999).  Although PBDEs will only be a fraction of this total, 
the amount of PBDEs released to the environment by disposal will still be significant. 
 
PBDEs are released to farmland with their disposal as biosolids (i.e., sewage sludge).  PBDEs were 
detected in biosolids destined for land applications in four different regions of the United States (Pardini 
et al. 2001).  The total concentrations of pentaBDE in biosolids ranged from 1,100 to 2,290 µg/kg dry 
weight; the levels of pentaBDE were high and consistent, regardless of the region of origin.  The 
concentration of decaBDE (BDE 209) varied widely among biosolids from different regions; the 
concentration of BDE 209 ranged from 84.8 to 4,890 µg/kg dry weight in the biosolid samples.   
 
In 2001, 545,872 pounds (247,603 kg) of decaBDE was released to land from 8 domestic manufacturing, 
processing, and waste-disposal facilities reporting releases of the compound to the environment (TRI01 
2004).  No releases (0 pounds) of decaBDE occurred via underground injection (TRI01 2004).  Releases 
to the environment from facilities that produce, process, or use decaBDE are summarized in Table 8-1.  
The data from the TRI should be used with caution since only certain types of facilities are required to 
report (EPA 1995).  This is not a comprehensive list.   
 
PBDEs were not identified in soil and sediment samples collected from 1,647 NPL hazardous waste sites 
(HazDat 2004). 
 
8.3   ENVIRONMENTAL FATE  
8.3.1   Transport and Partitioning  
 
Polybrominated Biphenyls.  PBBs exist predominantly in the particulate phase in the atmosphere.  
Particulate phase PBBs are removed from the atmosphere by wet and dry deposition and should not travel 
long distances in the environment.  In water, PBBs are expected to absorb strongly to suspended solids 
and sediment, and may bioconcentrate in aquatic organisms.  The volatilization of PBBs from water to air 
is not expected to be important due to attenuation by adsorption in the water column.  In soil, PBBs are 
adsorbed strongly and will be immobile.  Volatilization of PBBs from soil to air is not important due to 
the low volatility of PBBs and strong adsorption of PBBs to soil.  
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Organic compounds with vapor pressures >10-4 mm Hg should exist almost entirely in the vapor phase in 
the atmosphere, while organic compounds with vapor pressures <10-8 mmHg should exist almost entirely 
in the particulate phase (Eisenreich et al. 1981).  The estimated vapor pressure of FireMaster BP-6 is 
5.2x10-8 mm Hg at 25 °C (Jacobs et al. 1976).  The vapor pressure of octabromobiphenyl is 7.0x10-11 mm 
Hg at 28 °C (Waritz et al. 1977).  Although no data are available, the vapor pressures of 
decabromobiphenyl at ambient temperatures should be lower than octabromobiphenyl.  Thus, PBBs 
produced in the 1970s should exist predominantly in the particulate phase in the atmosphere.  Since the 
particulate phase PBBs would precipitate out by dry deposition and wet deposition due to washout (Atlas 
and Giam 1987), PBBs would not be expected to be transported long distances in the atmosphere. 
 
There are limited data regarding the transport and partitioning of PBBs in water.  Based on an estimated 
Henry's law constant of 3.9x10-6 atm-m3/mol (where Henry’s law constant = vapor pressure/water 
solubility) and an estimation method (Thomas 1990), the estimated volatilization half-life of 
hexabromobiphenyl is 23 days.  Therefore, the transport of PBBs from water to the atmosphere by 
volatilization is not expected to be important.  This is consistent with a fish bioconcentration study in 
which losses of octabromobiphenyl and decabromobiphenyl from water to air were found to be 
insignificant (Norris et al. 1973).  Soil-mobility studies have shown that PBBs are strongly adsorbed by 
soil materials (Filonow et al. 1976; Griffin and Chou 1981a, 1981b).  Therefore, sorption of water-bound 
PBBs to particulate matter and sediment is a major transport process for PBBs in water.  The detection of 
at least a 1,000-fold higher concentration of PBBs in Pine River sediment (where effluent from Michigan 
Chemical Corporation was discharged) compared with the level of PBBs in the river water confirms the 
importance of this transport process (Hesse and Powers 1978). 
 
PBBs may also be transported from water to aquatic organisms in which bioconcentration may take place.  
Data from different laboratories on the bioconcentration of PBBs in fish show wide variation.  The 
experimentally determined bioconcentration factor (BCF; the BCF is the concentration of the chemical in 
fish tissues over concentration of chemical in water) for hexabromobiphenyl (mixtures of unspecified 
congeners) in the whole body of fathead minnows (Pimephales promelas) was 18,100 in a 32-day 
exposure (Veith et al. 1979).  In fillet of fathead minnow, the estimated BCF was >10,000 (Hesse and 
Powers 1978).  The lipid weight-based BCF values of 4,4'-dibromobiphenyl, 2,4,6-tribromobiphenyl, 
2,2',5,5'-tetrabromobiphenyl, and 2,2',4,4',6,6'-hexabromobiphenyl in guppies (Poecilia reticulata) were 
269,000; 115,000; 1,440,000; and 708,000; respectively (Gobas et al. 1989).  BCF values for mono- to 
tetra- bromobiphenyl congeners tend to increase with higher degrees of bromination while BCF values for 
tetra- and higher congeners tend to decrease with higher degrees of bromination.  A similar trend in BCF 
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values for various PBBs was also observed in juvenile Atlantic salmon (Salmo salar).  For example, the 
whole body BCF values determined for 2,6-dibromobiphenyl, 2,4-dibromobiphenyl, 3,4-dibromo-
biphenyl, 2,5,4'-tribromobiphenyl, 2,2',4,5'-tetrabromobiphenyl, 2,3',4',5-tetrabromobiphenyl, 
hexabromobiphenyl (unspecified congener), and octabromobiphenyl were 1,267, 1,343, 63, 425, 314, 
111, 2–48, and 0.02, respectively (Zitko 1979; Zitko and Hutzinger 1976).  The BCF values determined 
for 2,2',3,3',4,4'-hexabromobiphenyl and decabromobiphenyl in whole body guppies (P. reticulata) were 
10 and 0, respectively (Opperhuizen et al. 1985).  The BCF value for octabromobiphenyl in filleted 
rainbow trout (Salmo gairdneri) was 0 (Norris et al. 1973).  The lack of accumulation for the higher 
brominated compounds is most likely because they have very limited water solubility and are therefore 
not available to penetrate membranes (Zitko 1979). 
 
PBBs are adsorbed strongly to soil, and the adsorption increases with an increase in the organic carbon 
content of soil (Filonow et al. 1976; Griffin and Chou 1981a, 1981b).  Neither clay content nor pH of soil 
correlated with adsorption of hexabromobiphenyl to soil (Filonow et al. 1976).  PBBs present in soil-
water solution will partition to the soil solids by adsorption.  The presence of certain types of dissolved 
organic carbon in natural water (e.g., leachate from a landfill) may decrease the adsorption of PBBs in 
sediments (Simmons and Kotz 1982).  Because of the strong adsorption, PBBs will have low mobility in 
soil, and the leaching of PBBs from soil to groundwater will generally be insignificant (Filonow et al. 
1976; Griffin and Chou 1981a, 1981b).  However, the mobility of PBBs may greatly increase if methanol 
or other organic solvents (capable of solubilizing PBBs) are present at significant concentrations in soil as 
would happen at some contaminated sites (Griffin and Chou 1981b).  This phenomenon is commonly 
called “co-solvency.”  The transport of PBBs from soil to the atmosphere by volatilization is not 
important due to the low volatility and strong adsoprtion of PBBs (Jacobs et al. 1976).  The transport of 
PBBs from soil to surface water or another land area via eroded soil contained in runoff water is possible 
(Jacobs et al. 1976).  Orchard grass and tops of carrots grown in soil contaminated with PBBs showed no 
uptake, and carrot roots showed only minor uptake of PBBs (Jacobs et al. 1976, 1978).  Therefore, the 
transport of PBBs from soil to plants via translocation is insignificant. 
 
Polybrominated Diphenyl Ethers.  In air, PBDE commercial mixtures, which have low vapor pressures 
and exist in the particulate phase, will be removed from the atmosphere by wet and dry deposition.  Thus, 
in general, PBDEs are not expected to travel long distances in the environment.  However, some 
congeners in pentaBDE commercial mixtures, 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47) and 
2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99), have been found in Arctic regions.  It has not been 
definitively explained how these lower brominated congeners have been transported such long distances 
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from areas of emission.  However, it is likely that they have been transported to remote regions as dust 
particles rather than in the vapor phase.  In water, PBDEs are expected to adsorb strongly to suspended 
solids and sediment, and bioconcentrate in aquatic organisms.  The volatilization of PBDEs from water to 
air is not expected to be important due to attenuation by adsorption in the water column.  In soil, PBDEs 
are adsorbed strongly and will be immobile.  They are not likely to leach into groundwater.  Volatilization 
of PBDEs from soil to air is not important due to the low volatility of PBDEs and strong adsorption of 
PBDEs to soil. 
 
PBDEs with vapor pressures between 10-4 and 10-8 mm Hg (di- to hexa- bromodiphenyl ether) should 
exist in both the vapor and particulate phase in the atmosphere, while PBDEs with vapor pressures 
<10-8 mm Hg (hexa- to decaBDE) should exist almost entirely in the particulate phase in the atmosphere 
(Bidleman 1988; Eisenreich et al. 1981).  PBDEs have low vapor pressures, with vapor pressure tending 
to decrease with increasing bromination.  Watanabe and Tatsukawa (1990) determined the vapor 
pressures for a range of brominated PBDEs as follows (mm Hg at 25 °C): di- (9.8x10-5–1.4x10-4); tri- 
(1.2x10-5–2.0x10-5); tetra- (1.8x10-6–2.5x10-6); penta- (2.2x10-7–5.5x10-7); hexa- (3.2x10-8–7.1x10-8); and 
octa- (9.0x10-10–1.7x10-9).  Vapor pressures have also been determined for commercial PBDE mixtures, 
such as pentaBDE (2.2x10-7–5.5x10-7 mm Hg) and decaBDE (3.2x10-8 mm Hg at 25 °C) (EU 2001; NRC 
2000).  Since particulate phase PBDEs will precipitate out by wet and dry deposition, these PBDEs would 
not be expected to be transported long distances in the atmosphere (Atlas and Giam 1987).  Thus, highly 
brominated PBDEs (e.g., octa- through decaBDEs), which have low vapor pressures and exist solely in 
the particulate phase, will not be transported long distances.  Although no information was located in the 
literature, moderately brominated PBDEs (e.g., pentaBDEs and hexaBDEs) may have the potential to be 
transported and would likely be found at higher concentration close to PBDE point sources.  Lower BDE 
homologs (e.g., tetraBDE), which exist partially in the vapor phase, have the potential for long-range 
transport in the atmosphere (Dodder et al. 2000a).  For example, 2,2’,4,4’-tetrabromodiphenyl ether 
(BDE47), 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99), and 2,2’,4,4’,5,5’-hexabromodiphenyl ether 
(BDE 153) were detected in air samples from urban, rural, and remote areas of the Great Lakes region in 
the United States (Dodder et al. 2000a).  
 
Concentrations of PBDEs in water are expected to be low due to the low water solubility of PBDEs.  For 
example, the solubilities of the commercial mixtures of pentaBDE and decaBDE are 13.3 and <0.1 µg/L, 
respectively (EU 2001; Hardy 2002b).  As consequence of their low water solubility, they have not 
detected PBDEs in environmental waters (see Section 8.4.2).  
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PBDEs adsorb strongly onto suspended solids and sediments in the water column.  Volatilization of 
PBDEs from water surfaces will be attenuated by adsorption, and thus is not an important fate process.  
Sediment-water partition coefficients (Kp) have been measured for several components of commercial 
pentaBDEs (Watanabe 1988).  Kp values for tetra-, penta-, and hexaBDEs are 28,300, 49,200, and 
62,700 L/kg, respectively, which suggest strong partitioning to sediment.  High log Kow values have been 
measured for PBDEs as follows (Watanabe and Tatsukawa 1990):  di- (5.03); tri- (5.47–5.58); tetra- 
(5.87–6.16); penta- (6.46–6.97); hexa- (6.86–7.92); octa- (8.35–8.90); and deca- (9.97).  Using these log 
Kow values, log organic carbon-water partition coefficients (Koc) were estimated for PBDEs:  di- (4.11); 
tri- (4.35–4.41); tetra- (4.57–4.73); penta- (4.89–5.17); hexa- (5.11–5.69); octa- (5.92–6.22); and deca- 
(6.80) (Lyman et al. 1990). 
 
DecaBDE and octaBDE commercial products do not bioconcentrate in fish.  The reported BCFs for these 
commercial mixtures are typically less than 50 (Hardy 2002b).  A single study on a mixed range of 
PBDEs, between hexaBDE and decaBDE, indicated little bioconcentration in carp (e.g., Cyprinus carpio) 
with a bioconcentration factor of <4 after 8 weeks of exposure (WHO 1994a).  A bioconcentration study 
was carried out with rainbow trout under static conditions.  The concentration in the water was 20 µg 
14C-decaBDE per liter.  Fish were exposed to decaBDE for 0, 0.5, 1, 2, 4, 6, 12, 24, or 48 hours.  For each 
of the exposure periods, there was no measurable accumulation of decaBDE in flesh, skin, or viscera 
(WHO 1994a).  
 
An abundance of monitoring data illustrates the uptake of lower brominated diphenyl ethers by aquatic 
organisms, which results in bioconcentration (see Section 8.4.4).  The commercial pentaBDE product 
undergoes bioconcentration with a BCF of approximately 14,000 (Hardy 2002b).  Congener components 
of the pentaBDE commercial product bioconcentrate to different extents.  For example, approximately 
50–70% of PBDEs detected in fish is a single isomer (2,2’,4,4’-tetrabromodiphenyl ether [BDE 47]).  The 
next most prominent isomer is typically 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99) followed by 
2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100).  In a laboratory study of Baltic blue mussels (Mytilus 
edulis L), BCFs from water absorption were found to be 1,300,000 for BDE 47, 1,400,000 for BDE 99, 
and 1,300,000 for 2,2’,4,4’,5,5’-hexabromodiphenyl ether (BDE 153) (Gustafsson et al. 1999).  At several 
sites along the coast and in the Schelde estuary (the Netherlands), BCFs for blue mussels were determined 
(Booij et al. 2000).  The maximum BCFs were 1x109 for BDE 99 and BDE 100, and ≈2.5x107 for 
BDE 28, ≈2.5x108 for BDE 47, and ≈1.6x108 for BDE 153.  
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Bioaccumulation of PBDEs in the aquatic food web is inversely related to the degree of bromination 
(Burreau et al. 2000; Jansson et al. 1993).  Higher brominated congeners (e.g., decaBDE) are rarely 
detected in biota.  This is a result of their low solubility, high log Kow values, and sorption to soil and 
sediment (Hardy 2000).  In contrast, tetraBDE to hexaBDE homologs are more frequently detected in 
biota (Burreau et al. 1997; Hale et al. 2003), which would be expected due to their greater water solubility 
and relatively high Kow values.  
 
Concentrations of lower brominated diphenyl ethers in biota are related to the trophic level of the species.  
For example, Haglund et al. (1997) examined the concentrations of tetra- to hexa- bromodiphenyl ethers 
in herring, salmon muscle, and gray and ringed seals collected along the Swedish coast of the Baltic Sea 
between 1981 and 1988.  The concentrations of tetrabromodiphenyl ethers (e.g., 2,2’,4,4’-tetrabromo-
diphenyl ether, BDE 47) were found to increase with trophic level.  Concentrations of PBDEs in herring 
and their predators, grey seal and guillemot, all collected at the same location of the Baltic Sea, have been 
compared to estimate potential biomagnification (de Wit 2002).  The herring were caught in the autumn 
of the same year as guillemot egg collection (1987).  Biomagnification factors for guillemot egg versus 
herring were 19, 17, and 7.1 for BDE 47, 2,2’4,4’,5-pentabromodiphenyl ether (BDE 99), and 
2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100), respectively.  Burreau et al. (2000) analyzed small 
herring and salmon from the Atlantic Ocean (near Iceland) for several PBDEs.  The calculated 
biomagnification factors for Atlantic salmon versus small herring were 3.5, 3.8, and 6.0 for BDE 47, 
BDE 99, and BDE 100, respectively.  These authors concluded that biomagnification was occurring for 
the lower brominated congeners. 
 
PBDEs will be strongly adsorbed to soils based on log Kow values ranging from 5.03 to 9.97 (Watanabe 
and Tatsukawa 1990).  Thus, PBDEs present in soil-pore water will bind to soil organic matter.  Because 
PBDEs adsorb strongly to soil, they will have very low mobility (Swann et al. 1983), and leaching of 
PBDEs from soil to groundwater will be insignificant.  Like PBBs, the presence of dissolved organic 
carbon in natural water may increase the mobility of PBDEs.  The transport of PBDEs from soil to 
surface water via eroded soil contained in runoff water is also possible.  Volatilization of PBDEs from 
moist soil surfaces will be attenuated by adsorption and is not expected to be an important fate process.  
Volatilization of PBDEs from dry soil will not be important due to the low volatility of PBDEs (see 
Table 6-6).  
 
PBBs and PBDEs  401 
 








8.3.2   Transformation and Degradation  
 
Photolysis appears to be the dominant transformation process for PBBs and PBDEs.  However, the 
importance of photochemical transformation reactions in the environment cannot be determined due to 
lack of information.  Based on a very limited number of studies, biodegradation does not appear to be 
significant for either PBBs or PBDEs. 
 
8.3.2.1   Air  
 
Polybrominated Biphenyls.  In air, the two processes that may result in significant degradation or 
transformation of PBBs are photooxidation by hydroxyl (OH) radicals and direct photolysis.  The 
estimated half-life of pentachlorobiphenyl in air due to reaction with hydroxyl radicals is 41.6–83.2 days 
(Atkinson 1987a).  Based on a structure-activity relationship for the estimation of half-lives for the gas-
phase reactions of hydroxyl radicals with organic compounds (Atkinson 1987b), the estimated half-lives 
of hexabromobiphenyl and decabromobiphenyl due to reaction with OH radicals are 182 and 2,448 days, 
respectively.  These half-lives are consistent with the half-life of pentachlorobiphenyl due to reaction with 
OH radicals.  However, the half-lives of brominated biphenyls expected to be present in the particulate 
phase in the air may be even longer than the estimated half-lives due to gas phase reaction.  Therefore, the 
transformation of the hexa- and other higher brominated PBBs in the atmosphere due to reaction with OH 
radicals are probably not important. 
 
Hexa- and other higher brominated biphenyls are expected to be present in the particle-adsorbed state in 
the atmosphere.  These PBBs photolyze in solution and in soil (Hill et al. 1982; Ruzo and Zabik 1975; 
Trotter 1977).  Since PBBs present in surface soil are known to photolyze, particle-sorbed PBBs present 
in the atmosphere may also undergo photolysis.  The importance of the photochemical reaction under 
sunlight illumination conditions for the degradation/transformation of PBBs in air cannot be evaluated 
due the lack of information. 
 
Polybrominated Diphenyl Ethers.  In air, PBDEs may undergo indirect photolysis with hydroxyl radicals 
or direct photolysis with sunlight.  Vapor-phase PBDEs may be degraded in the atmosphere by reaction 
with photochemically produced hydroxyl radicals.  The half-lives for this reaction in air are estimated to 
be 29, 140, and 476 days, respectively, for penta-, octa-, and deca- bromodiphenyl ether homologs, 
calculated using a structure estimation method (Meylan and Howard 1993).  This estimation is calculated 
using an atmospheric concentration of 5x105 hydroxyl radicals per cm3 and is based on a 24-hour day of 
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sunlight.  The half-lives of PBDEs that are expected to be present in the particulate phase in the air will be 
longer than the estimated half-lives calculated for the gas-phase reaction.  Thus, for the higher brominated 
PBDEs (e.g., octa- and decaBDEs), indirect photolysis with hydroxyl radicals will not be important.   
 
In water, some PBDEs have been reported to undergo direct photolysis (Hua et al. 2003).  Likewise, 
PBDEs present in the vapor phase (e.g., tetraBDE) or as particulates (e.g., decabromodiphenyl ether) may 
also undergo photolysis in the atmosphere.  However, the rate and extent of the photolysis of PBDEs in 
air cannot be evaluated due the lack of information. 
 
8.3.2.2   Water  
 
Polybrominated Biphenyls.  The photolytic degradation of PBBs in solution has been the subject of 
several studies.  Available data in the literature indicate that brominated biphenyls photodegrade by 
reduction in solvents capable of proton transfer with the formation of lower brominated biphenyls.  For 
example, the irradiation of FireMaster BP-6 and 2,2',4,4',5,5'-hexabromobiphenyl in methanol at 
wavelengths >286 nm produced mainly penta- and tetrabromobiphenyl (Ruzo and Zabik 1975).  
FireMaster BP-6 photolyzed 7 times faster than its chlorinated counterpart, 2,2',4,4',5,5'-hexachloro-
biphenyl (Ruzo and Zabik 1975).  Although an earlier study tentatively identified dimethoxy tetrabromo-
biphenyl as a photolysis product of FireMaster BP-6 (Ruzo and Zabik 1975), later work did not detect this 
compound (Ruzo et al. 1976).  Earlier studies indicated that the debromination usually occurs with the 
stepwise preferential loss of bromine from the ortho and para positions of the biphenyl ring (i.e., 2, 2', 6, 
and 6' positions) (De Kok et al. 1977; Ruzo and Zabik 1975; Ruzo et al. 1976; Trotter 1977).  Thus, the 
photolysis of 2,2',4,4',5,5'-hexachlorobiphenyl, the major component of FireMaster BP-6, would be 
expected to produce 2,3',4,4',5-pentabromobiphenyl and subsequently 3,3',4,4'-tetrabromobiphenyl.  More 
recent work indicates that although photolysis mainly produces debromination products, unlike in the case 
of an individual PBB congener, reductive debromination of ortho substituents is not the predominant 
photolytic degradation pathway for FireMaster BP-6 (Robertson et al. 1983b).  
 
The study of photolysis of PBBs in the aqueous phase is more relevant to natural environmental situations 
than photolysis in proton-donating organic solvents.  It was suggested that the photolysis of PBBs in 
aqueous solution would proceed by oxidative process of photohydroxylation, leading to the formation of 
phenolic compounds (Norris et al. 1973).  However, photolysis of 2,4-dibromo- and 2,3',4',5-tetrabromo-
biphenyl in acetonitrile-water solution showed that debromination was the major reaction (Ruzo et al. 
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1976).  No evidence of the formation of hydroxylated species (phenolic products) was found (Ruzo et al. 
1976). 
 
PBBs are not expected to undergo abiotic hydrolysis under environmental conditions due to the lack of 
hydrolysable functional groups (Boethling and Mackay 2000). 
 
Several investigators assessed the biodegradation potential of PBBs under aerobic conditions, with 
activated sludge or pure cultures of microorganisms as microbial inoculum, and concluded that although 
the lower substituted biphenyls might biodegrade in aerobic water and sediment (Kong and Sayler 1983; 
Sugiura 1992; Yagi and Sudo 1980), the higher substituted biphenyls are resistant to aerobic 
biodegradation (Kawasaki 1980; Sasaki 1978; Shelton and Tiedje 1981).  This is consistent with 
biodegradation studies in soil (see Section 8.3.2.3).  It has been proposed that complete mineralization of 
4-bromobiphenyl to carbon dioxide occurs via a 4-bromobenzoate intermediate by mixed bacterial 
cultures obtained from PBB-contaminated river sediment (Kong and Sayler 1983).  However, complete 
mineralization was not observed for 2- and 3-bromobenzoate (Kong and Sayler 1984). 
 
Although higher brominated biphenyls do not biodegrade in water or sediment under aerobic conditions, 
it has been shown that anaerobic microorganisms in river sediments obtained from populated areas can 
biodegrade higher substituted PBBs, including FireMaster mixtures (Morris et al. 1992).  The 
biodegradation involved debromination at the meta and para positions, and no ortho bromine removal 
was observed (Morris et al. 1992).  However, the possibility of ortho bromine removal from higher 
brominated biphenyls with certain inoculations (e.g., microorganisms from polluted river sediment 
repeatedly transferred on a pyruvate medium amended with Aroclor 1242) has been suggested (Morris et 
al. 1992). 
 
Polybrominated Diphenyl Ethers.  PBDEs absorb light in the environmental spectrum.  Hua et al. (2003) 
found that decaBDE and the commercial octaBDE absorbed light up to 325 nm, which indicates that these 
compounds may be susceptible to photodegradation at environmental wavelengths (Hua et al. 2003).  Di- 
and tetrabromodiphenyl ethers were reported to absorb minimal light at wavelengths >300 nm.  This trend 
suggests that the lower brominated diphenyl ethers (e.g., pentaBDE commercial mixtures) will be less 
susceptible to photolysis compared to octaBDE and decaBDE commercial mixtures. 
 
PBDEs undergo debromination by direct photolysis in organic solvents and organic solvent:water 
mixtures.  Laboratory studies of the photolytic breakdown of decaBDE in toluene have shown that it is 
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successively debrominated by UV light to hexaBDE and that photolysis occurs very rapidly (Sellström et 
al. 1998b).  The photolysis half-life in toluene was <15 minutes.  However, the amounts of lower 
brominated congeners appear to be small (EU 2002).  The photolysis of decaBDE (and tetra-, penta-, 
hexa-, hepta-, and octabromodiphenyl ethers) was recently reported in a 80:20 mixture of methanol:water 
at wavelengths >290 nm (EU 2002).  The rate of photodegradation was found to increase with increasing 
degree of bromination.  DecaBDE was found to degrade with a half-life of around 30 minutes while half-
lives for tetra-, penta-, hexa-, hepta-, and octabromodiphenyl ethers were 12–16 days, 2.4 days, 1.2 days, 
1.2 days, and 5 hours, respectively.  The decomposition products of decaBDE were identified to be 
PBDEs (with >6 bromine atoms per molecule) and polybrominated furans (with <6 bromine atoms per 
molecule).  Results of this study indicate that the photochemical stability of PBDEs increases with 
decreasing bromination (EU 2002).  Rayne et al. (2003b) recently reported that 4,4’-dibromodiphenyl 
(BDE 15) photodegraded in organic (acetonitrile-methanol) and aqueous (H2O:acetonitrile; 1:1 v/v) 
solvent systems at a wavelength of 300 nm.  Reductive bromination was reported to be much slower in 
the aqueous system (e.g., 73% remained after 300 minutes) compared to the organic system (where 51% 
and 41% remained after 30 minutes).  However, these studies were conducted in the presence of organic 
solvents, which are not representative of conditions found in the environment.  Organic solvents can act 
as hydrogen donors in photolysis reactions, which will potentially affect the distribution of products 
formed. 
 
In a recent study, the photolysis of PBDEs was examined under environmentally relevant conditions.  
Hua et al. (2003) studied the degradation of decaBDE in several different experiments:  (1) on humic 
acid-coated silica particles, (2) on glass surfaces in contact with aqueous humic acid solutions, and (3) on 
glass surfaces in contact with water.  DecaBDE dissolved in toluene was deposited on the solid substrate 
under a stream of nitrogen (to evaporate the solvent) and then desiccated to remove any residual toluene.  
The adsorbed decaBDE on the solid substrate was then inundated with the aqueous test solution, followed 
by irradiation for the duration of the test period.  In all experiments, natural sunlight (location, 40° 26’ N, 
86° 55’ W) was used.  The extent of degradation was determined using high-performance liquid 
chromatography (HPLC) with ultraviolet detection (UV) detection or by gas chromatography-mass 
spectrometry (GC-MS).  In the first experiment, solar irradiation of decaBDE adsorbed onto humic acid-
sand indicated that the photolysis of decaBDE was slow.  After 96 hours of exposure to sunlight, 88% of 
initial decaBDE remained on the coated sand.  There is some evidence that lower brominated congeners 
(e.g., 2,2’,4,4’,6,6’-hexabromodiphenyl ether [BDE 155]) were formed in the experiment (EU 2002).  In 
the second experiment, decaBDE was adsorbed on glass tubes containing a humic acid.  In this study, the 
concentration of decaBDE decreased relatively quickly over the first 24 hours of exposure, after which, 
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the concentration remained stable.  Bromide ion accumulated at an almost linear rate from start to end of 
the 72-hour exposure period.  Approximately 70% of the initial decaBDE remained after the 72-hour 
exposure.  The difference in kinetics (for the disappearance of decaBDE vs. the appearance of bromide 
ion) suggests that after the initial degradation of decaBDE, bromide ion was generated by the degradation 
of lower brominated diphenyl ether congener products (possibly octa- and nonabromodiphenyl ethers).  
Bromide ion mass balance for the system indicated that 70% of the total bromine present was accounted 
for by decaBDE or bromide, with the remaining 30% present as unidentified compounds.  In the third 
experiment, Hua et al. (2003) investigated the photodegradation of decaBDE adsorbed on glass tubes, 
which were filled with aqueous solutions (without humic acid).  The result of this test showed a much 
more rapid loss of decaBDE than found in the analogous test using humic acid solutions.  Approximately 
29% of the initial decaBDE present remained after 72 hours.  The rate of decaBDE loss and bromide ion 
accumulation was relatively constant over the entire 72-hour test period.  Mass balance indicated that 
approximately 50% of the total bromine was present as either decaBDE or bromide ion, while the 
remaining 50% was possibly unidentified nona- and octabromodiphenyl ether congeners.  The difference 
between the tests using glass tubes with and without humic acid solution is possibly due to the absorption 
of light by humic acids, which may attenuate the degradation process.  These studies indicate that 
adsorbed decaBDE may undergo photolysis forming octa- and nonabromodiphenyl ethers under 
somewhat environmentally relevant conditions.  Lower brominated diphenyl ether congeners are also 
formed although only to a minor extent.  These tests do not provide evidence that lower brominated 
diphenyl ethers (e.g., tetra- and pentabromodiphenyl ethers) are a major degradation product of decaBDE 
(EU 2002).  There is also insufficient information from these studies to estimate the rate of photolysis or 
if intermediate degradation products build up after long-term exposures (EU 2002).  
 
Söderström et al. (2004) examined the time course of photolysis of decaBDE (BDE 209) in toluene, on 
silica gel, sand, sediment, and soil using artificial sunlight and on the natural matrices (e.g., sediment, 
soil, and sand) using natural sunlight.  On natural samples, BDE 209 was first dissolved in toluene and 
then deposited on the natural matrix.  The toluene was allowed to evaporate, and then the sample was 
reconstituted with water to resemble natural conditions.  BDE 209 was photolytically labile and formed 
debromination products in all matrixes studied.  Nona- to tetra- BDEs were formed as well as some 
PBDFs.  The half-lives in toluene and on silica gel were less than 15 minutes, and half-lives on other 
matrices ranged from 40 to 200 hours.  No differences were observed in the debromination patterns under 
different matrices or light conditions.  These experiments show that photolytic debromination of BDE 209 
is a possible pathway for the formation of more bioavailable, lower brominated PBDEs.  However, the 
mostt commonly found BDEs in environmental samples (e.g., 2,2’,4,4’-tetrabromodiphenyl ether 
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[BDE 47], 2,2’4,4’,5-pentabromodiphenyl ether [BDE 99], and 2,2’,4,4’,6-pentabromodiphenyl ether 
[BDE 100]) were only formed to a minor degree (Söderström et al. 2004).  
 
Following the methodology described for decaBDE, photolysis experiments were conducted on 
2,2’,4,4’-tetraBDE (BDE 47) (EU 2002).  BDE 47 was adsorbed on glass tubes filled with an aqueous 
solution and exposed to natural sunlight.  After 72-hours of exposure, 30% of the initial BDE 47 
remained.  The rate of disappearance of BDE 47 was comparable to that found for decaBDE under similar 
test conditions.  Accumulation of bromide was initially slow with the rate increasing after 24 hours while 
the disappearance of BDE 47 was initial rapid over the first 24 hours.  Using GC-MS, the authors 
concluded that 2,4,4’-tribromodiphenyl ether was being formed during this reaction and that removal of 
bromine atoms ortho to the ether functionality may be a significant reaction pathway for removal of 
bromine atoms under the conditions of this study.  This study suggests that adsorbed pentabromodiphenyl 
ether congeners, like decaBDE, may undergo photolysis under somewhat environmentally relevant 
conditions (EU 2002). 
 
PBDEs are not expected to undergo abiotic hydrolysis under environmental conditions due to the lack of 
hydrolysable functional groups (Boethling and Mackay 2000). 
 
PBDEs are unlikely to biodegrade rapidly in the environment under aerobic conditions.  PentaBDE did 
not undergo biodegradation (determined by CO2 evolution) after 29 days in an OECD 301B ready 
biodegradation test (EU 2001).  The substance tested was a composite sample from two producers with 
the following composition: 33.7% tetraBDE, 54.6% pentaBDE, and 11.7% hexaBDE.  The test was 
extended to 93 days to allow sufficient opportunity for adaptation to occur.  At the end of 93 days, 2.4% 
of the theoretical amount of CO2 had been evolved.  Thus, pentaBDE was determined to be not readily 
biodegradable.  No degradation (as oxygen uptake) was seen for octaBDE after 28 days in an OECD 
301D ready biodegradation test (EU 2003a).  Thus, octaBDE was determined to be not readily 
biodegradable.  The biodegradability of decaBDE has been studied under aerobic conditions using an 
activated sludge inoculum (EU 2002).  DecaBDE at 100 mg/L was incubated with activated sludge (at 
30 mg/L) over a 2-week period using a method similar to an OCED 301C MITI test.  No degradation (as 
measured by biochemical oxygen demand) was observed.  Thus, decaBDE was determined to be not 
readily biodegradable.  
 
No data on biodegradation of pentaBDE and octaBDE commercial mixtures under anaerobic conditions 
are available.  An anaerobic degradation study was carried out with 2,2’,4,4’-tetrabromodiphenyl ether 
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(BDE 47) using a mixture of 14C labeled and unlabeled compound (EU 2003a).  The test was carried out 
using a sediment-water (Schuykill River, PA) inoculum.  After 32 weeks, it appeared that no significant 
degradation of BDE 47 had occurred.  However, the analytical method (i.e., HPLC using radiometric 
detection) used in this test indicated that some unidentified products had been formed in samples taken 
after 32 weeks.  From these results, it is clear that BDE 47 has the potential to degrade slowly under 
anaerobic conditions (EU 2003a).  Rayne et al. (2003b) recently reported that 4,4’-dibromodiphenyl 
undergoes reductive debromination under anaerobic conditions.  Debromination proceeds with 
replacement of a bromine (Br) atom by a hydrogen (H) atom.  The authors suggest that anaerobic 
debromination may sequentially debrominate BDE 15 to the parent diphenyl ether.  
 
The anaerobic biodegradability of 14C-labeled decaBDE was studied over a period of 32 weeks (EU 
2002).  The test chambers consisted of 500 mL bottles containing 300 mL of sediment (Schuykill River, 
Pennsylvania) prepared under anaerobic conditions.  The test chambers were incubated at 25 °C and in 
the dark during the test.  After the 32-week period, <1% of the total radioactivity added was found as 
14CO2 and 14CH4 indicating that essentially no mineralization had occurred.  GC-MS results showed no 
evidence for the formation of lower brominated congeners from deceBDE under the conditions of this test 
(EU 2002).  
 
8.3.2.3   Sediment and Soil  
 
Polybrominated Biphenyls.  Information on the fate of PBBs in soil is limited.  A pure culture of 
microorganism isolated from soil biodegraded 2-bromobiphenyl via the 2-bromobenzoic acid pathway 
(Takase et al. 1986).  There is little evidence that the higher brominated biphenyls biodegrade in soil 
under aerobic conditions during an incubation period of ≤1 year (Griffin and Chou 1981a, 1981b; Jacobs 
et al. 1976).  Some degradation of an undefined congener of pentabromobiphenyl was observed when 
incubated in soil, but this degradation could not be definitely attributed to biodegradation (Jacobs et al. 
1976).  As discussed in Section 8.3.2.2, higher brominated PBBs may biodegrade in an anaerobic region 
of river sediment and possibly soil polluted with PCBs and PBBs to form lower brominated products.  
Biodegradation of the photolysis products of hexa- and heptabromobiphenyl in soil (which produces 
lower brominated products) was only minor (≈3% in 1 year) since the photodegradation products were 
bound to soil and light does not penetrate far into soil (Jacobs et al. 1978) 
 
Degradation of PBBs present in a contaminated soil from a manufacturing site in Michigan was 
significant (Hill et al. 1982).  For example, 2,2',4,4',5,5'-hexabromobiphenyl, the principal component of 
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FireMaster (54–68% in FireMaster) was reduced to 26% of the total PBBs when exposed to a field soil 
for several years.  In two other soils, in which the original concentrations of PBBs were much lower, the 
rate of degradation was much lower.  Principal degradation products were 2,3',4,4',5-pentabromobiphenyl, 
2,2',4,4',5-pentabromobiphenyl, and two unidentified tetrabromobiphenyls.  The degradation was 
attributed to photochemical reactions.  On the other hand, no significant photodegradation of FireMaster 
was observed after 1 year in contaminated manure spread in field soil from Michigan (Jacobs et al. 1978).  
The authors provided no explanation for the difference in photoreactivity of PBBs in soils with and 
without manure.  It is important to point out that, due to attenuation and scattering of light, sunlight will 
not penetrate most soil beyond the surface layer.  Therefore, it can be concluded from these studies that 
although photolysis may be the only viable degradative process for PBBs in soil, photolysis will be 
limited to the surface layer of soil, and the rate of photolysis will be very slow.  PBBs incorporated into 
thermoplastics which were eventually buried at waste sites are not likely to absorb much light and 
undergo photolytic degradation. 
 
Analysis (Morris et al. 1993) of sediments from a PBB-contaminated river in Michigan (Pine River) 
indicates that little degradation of PBBs has occurred since the 1970s.  Although microorganisms capable 
of debrominating PBBs were not present in regions of highest contamination, they were found in 
sediments downstream from the area of highest contamination.  The investigators (Morris et al. 1993) 
suggest that high levels of contaminants including PBBs may be inhibiting the microbial degradation of 
PBBs in this river. 
 
Polybrominated Diphenyl Ethers.  Information on the transformation and degradation of PBDEs in soil is 
limited.  The extent to which PBDEs undergo direct photolysis in soils and sediment is unknown.  
However, sunlight would only penetrate the uppermost few millimeters of soil and will not impact 
sediment.  Photolysis of PBDEs is possibily important for land-applied sewage sludge contaminated with 
PBDEs.  However, no information was available on this possibility.  Based on studies in water, most 
PBDEs are unlikely to biodegrade in soils or sediment under aerobic or anaerobic conditions.  Lower 
brominated diphenyl ether congeners (e.g., 2,2’4,4’-tetrabromodiphenyl ether [BDE 47]) may slowly 
biodegrade under anaerobic conditions in sediment (EU 2003a).  However, information on the rate or 
extent of anaerobic biodegradation of BDE 47 has not been found.  No other information was found in the 
literature about the transformation and degradation processes for PBDEs in soils and sediment.  
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8.3.2.4   Other Media  
 
No other information was found in the literature about the transformation and degradation processes for 
PBBs or PBDEs in other media.  
 
8.4   LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
 
Evaluation of the potential for human exposure to PBBs or PBDEs depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Comparisons among 
various studies are complicated by the fact that authors may report PBB or PBDE concentrations as 
technical mixtures, as homologs, or as congeners.  For PBDEs, it is common to determine the 
concentration of individual congeners.  However, only a limited number of standards are available.  Total 
PBDEs, the definition of what constitutes total PDBEs (i.e., how many and which congeners are 
summed), is often not the same in the various studies.  Chemical analysis procedures are discussed in 
greater detail in Chapter 9.  Recent monitoring data for PBBs are very limited.  Historical monitoring data 
indicate that environmental PBB concentrations are confined to areas near former manufacturing facilities 
and regions of Michigan effected by the farm catastrophe of the early 1970's (see Section 8.1).  
Monitoring studies indicate that PBDEs are transported globally.  Atmospheric, water, and biota levels of 
PBDEs tend to be dominated by lower brominated congeners (e.g., BDE 47).  Sediments tend to be 
dominated by higher brominated congeners (e.g., BDE 209).  Biota monitoring studies indicate that 
PBDE concentrations have increased since the late 1970s, with lower brominated congeners (e.g., 
BDE 47) being preferentially bioconcentrated.  Studies indicate that PBDE concentrations increase with 
respect to trophic level; organisms that reside higher on the food chain tend to have higher concentrations 
of PBDEs.  
 
8.4.1   Air  
 
Polybrominated Biphenyls.  Historically, PBBs were released to the atmosphere during three stages of 
the manufacturing process, and an estimate of the maximum amount of PBBs expected to be lost to the air 
during the manufacture of PBBs in the United States is available (see Section 8.2.1) (Neufeld et al. 1977).  
Monitoring data on the ambient air levels of PBBs are very limited.  The concentration of 
hexabromobiphenyl in air samples collected downwind and crosswind from the White Chemical 
Company plant in Bayonne, New Jersey was 0.06 ng/m3 (DeCarlo 1979). 
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Polybrominated Diphenyl Ethers.  In general, limited information is available in the literature reporting 
the levels of PBDEs in ambient air.  The concentrations of PBDEs in air samples are summarized in 
Table 8-2.  Atmospheric concentrations of PBDEs tend to be dominated by lower brominated congeners 
(e.g., 2,2’,4,4’-tetrabromodiphenyl ether [BDE 47], 2,2’,4,4’,5-pentabromodiphenyl ether [BDE 99], 
2,2’,4,4’,6-pentabromodiphenyl ether [BDE 100], 2,2’,4,4’,5,5’-hexabromodiphenyl ether [BDE 153], 
and 2,2’,4,4’,5,6’-hexabromodiphenyl ether  [BDE 154]).  DecaBDE (BDE 209) has only been detected 
in the particulate phase in air near point sources.  Air samples sampled from urban (Chicago, Illinois), 
rural (Sleeping Bear Dunes, Michigan and Sturgeon Point, New York), and remote (Eagle Harbor, 
Michigan) shorelines of the U.S. Great Lakes all contained quantifiable levels of BDE 47, BDE 99, 
BDE 100, BDE 153, and BDE 154 (Dodder et al. 2000a; Strandberg et al. 2001).  The most significant 
congeners were BDE 47 and BDE 99.  Air measurements were averaged over a 3-year period between 
1997 and 1999.  The concentration of total PBDEs ranged from 5.5 pg/m3 in rural environments to 
52 pg/m3 in urban air from Chicago, Illinois.  The concentration of BDE 47 was 48 pg/m3 observed near 
Chicago, Illinois.  The average concentration of decaBDE at the remote and rural locations was 
<0.10 pg/m3 for each of the years investigated.  The average concentration of decaBDE in the particulate 
phase at the urban location ranged from 0.20 to 0.35 pg/m3 (Strandberg et al. 2001).  
 
Throughout the year of 1997, air samples were taken from a rural site in southwestern England called 
Stokes Ferry and a semirural site in northwestern England called Hazelrigg and analyzed for PBDEs 
(Peters et al. 1999).  Tri- and heptabromodiphenyl ethers were detected; the combined concentrations of 
2,2’,4,4’-tetrabromodiphenyl ether (BDE 47), 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99), and 
2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100) ranged from 7 to 69 pg/m3 at Hazelrigg and from 6 to 
58 pg/m3 at Stoke Ferry (de Wit 2002).  PBDEs have also been measured in air samples taken from 
remote stations in the Arctic (e.g., Alert, Northwest Territories, Canada; Dunai Island, eastern Siberia, 
Russia) between January 1994 and January 1995 (de Wit 2002).  The total concentration of several di- to 
hexabromodiphenyl ethers ranged from 1 to 4 pg/m3 at Alert for the majority of the year; however, in July 
1994, the concentration was 28 pg/m3.  At Dunai, the major congeners found were BDE 47 and BDE 99.  
In Sweden during 1990–1991, air samples collected from Ammarnäs in the northern mountains and 
Hoburgen on the southern tip of Gotland in the Baltic Sea, had measurable amounts of BDE 47, BDE 99, 
and BDE 100 (de Wit 2002).  Total PBDE levels were approximately 1 and 8 pg/m3, respectively.  The 
concentration of BDE 47 was found to be highest in the gas phase, while BDE 99 and BDE 100 were 
highest in the particulate phase.  No decaBDE was found, although the limit of detection limit for 
decaBDE is much higher than for the lower brominated diphenyl ethers. 
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Table 8-2.  Concentrations (pg/m3) of Several PBDEs in Air Samples 
 
Location BDE 47 BDE 99 BDE 100 ΣPBDEsa Reference 
Urban, United States 48 25 3.0 77* Dodder et al. 2000 
Rural, United States 6.2–9.2 4.3–5.0 0.6–0.9 2–4.8* Dodder et al. 2000 
Remote, United 
States 
3.7 2.6 0.33 6.9* Dodder et al. 2000 
Alert, Northwest 
Territories Canada 
No data No data No data 1–28 Alaee et al. 1999 
Eagle Harbor, 
Wisconsin 
2.9 2.1 0.28 5.5* Strandberg et al. 2001 
Sturgeon Point, New 
York 
3.8 2.8 0.39 7.2* Strandberg et al. 2001 
Sleeping Bear 
Dunes, Michigan 
8.4 5.3 0.80 15* Strandberg et al. 2001 
Chicago, Illinois 33 16 2.0 52* Strandberg et al. 2001 
Ammarnäs, Sweden 6.3  1.6 0.4 8.3 de Wit 2000, 2002 
Hoburgen, Sweden 0.7 0.35 0.07 1.1 de Wit 2000, 2002 
Stoke Ferry, United 
Kingdom 
4.7–50 5.5–13 1.1–3.9 6.7–58 Peters et al. 1999 
Hazelrigg, United 
Kingdom 
3.2–61 3.1–22 0.62–5.4 4.1–69 Peters et al. 1999 
Dunai Island, Russia No data No data No data 1–8* Alaee et al. 1999 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Sources: de Wit 2002; Lee et al. 2002; Strandberg et al. 2001  
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8.4.2   Water  
 
Polybrominated Biphenyls.  Recent information on the concentrations of PBBs is not available.  The 
concentrations of PBBs in effluents discharged from the Michigan Chemical Corporation plant in St. 
Louis, Michigan, to the Pine River during 1974–1977 ranged from <0.01 to 150 µg/L (Hesse and Powers 
1978).  The concentrations of PBBs in effluents from White Chemical Company, Bayonne, New Jersey, 
and Hexcel Chemical Corporation, Sayerville, New Jersey, ranged from <0.2 to 210 µg/L (DeCarlo 
1979).  The concentrations of PBBs in the Pine River ≤12 miles downstream from the Michigan Chemical 
Corporation plant in 1974 were 0.01–3.2 µg/L (Hesse and Powers 1978; Neufeld et al. 1977).  
2,2',5,5'-Tetrabromobiphenyl and 3,3',5,5'-tetrabromobiphenyl were qualitatively detected in water from 
Lake Ontario, and hexabromobiphenyl (unspecified congeners) was qualitatively detected in water from 
Lakes Ontario and Huron (Great Lakes Water Quality Board 1983).  The concentrations of PBBs in test 
wells within a PBB landfill site in Michigan ranged from 0.4 to 26.0 µg/L, although the concentrations of 
PBBs in test wells outside the landfill ranged from <0.1 to 4.4 µg/L (Shah 1978).  No other information 
was located about the concentrations of PBBs in water.  
 
Polybrominated Diphenyl Ethers.  Due to the hydrophobic nature of PBDEs, this class of compounds has 
not been detected in water to any significant extent.  In 1999, the concentration of PBDEs in Lake Ontario 
surface waters ranged between 4 and 13 pg/L with ~90% in the dissolved phase (Luckey et al. 2001).  
2,2’,4,4’-Tetrabromodiphenyl ether (BDE 47) and 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99) were 
the most abundant congeners, together making up >70% of the total PBDEs.  In Japan, nondetectable 
levels of PBDEs were reported in 75–200 water samples (ENVIRON 2003a).  No other information was 
located about the concentrations of PBDEs in water.  
 
8.4.3   Sediment and Soil  
 
Polybrominated Biphenyls.  Soil samples from the bagging and loading areas of the Michigan Chemical 
Corporation plant in St. Louis, Michigan, contained PBBs at concentrations of 3,500 and 2,500 mg/kg, 
respectively (Di Carlo et al. 1978).  PBBs (mostly decabromobiphenyl, but some lower brominated 
biphenyls down to hexabromobiphenyl) in soil near the Hexcel Chemical Corporation plant in New Jersey 
and the White Chemical Company plant in New Jersey ranged from 40 to 4.6 mg/kg and from 1.14 to 
4.25 mg/kg, respectively (DeCarlo 1979).  PBB levels in surface soil samples from seven dairy farms in 
Michigan that spread contaminated manure on the fields ranged from 35 to 1,260 µg/kg, while the 
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concentrations in surface soil of control farms (that did not use contaminated manure) were <25 µg/kg 
(Fries and Jacobs 1980). 
 
Concentrations of PBBs in sediments upstream from the Michigan Chemical Corporation plant were 
below the detection limit (100 µg/kg) with the exception of one sample (Hesse and Powers 1978).  The 
concentration of PBBs in sediment from one upstream sample was 350 µg/kg.  Hesse and Powers (1978) 
explained that this higher value was due to contamination by upstream currents during periods of water-
level regulation at the St. Louis dam.  The concentrations of PBBs in near shore sediment near the 
Michigan Chemical Corporation plant sewer outfall were ≤77.0 mg/kg.  PBB concentrations in Pine River 
sediments downstream from the plant showed a gradual decrease from a maximum value of 9.2 mg/kg to 
a value of 0.1 mg/kg at a location 29 miles downstream from the plant outfall (Hesse and Powers 1978).  
Similarly, PBB concentrations in sediment samples from swamps and marshes adjacent to the White 
Chemical Company and Hexcel Chemical Corporation plants in New Jersey ranged from <10 µg/kg to 
4.6 mg/kg (DeCarlo 1979).  A sludge sample from the discharge treatment plant of the White Chemical 
Company contained 431 mg/kg of PBBs (DeCarlo 1979). 
 
Polybrominated Diphenyl Ethers.  No information was located on the ambient environmental 
concentrations of PBDEs in soils in the United States or other parts of the world.  Hale et al. (2002) 
reported the concentration of PBDEs in soil samples collected in the vicinity of a polyurethane foam-
manufacturing facility.  Levels in these soils are likely to be higher than to be expected in rural and 
potentially urban areas of the United States.  Total PBDE levels in these samples ranged from not 
detected to 76 µg/kg dry weight.  2,2’,4,4’,5-Pentabromodiphenyl ether (BDE 99) was the predominant 
congener in soil followed by 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47), and 2,2’,4,4’,6-pentabromo-
diphenyl ether (BDE 100).  
 
Sediment concentrations of PBDEs tend to be dominated by higher brominated congeners (e.g., 
BDE 209) (deWit 2002).  Temporal trends suggest that concentrations of PBDEs in sediments are 
increasing.  Burdens of PBDEs in sediment appear to be a function of distance from the source and their 
organic carbon content (Hale et al. 2003).  The concentrations of PBDEs in sediment samples are 
summarized in Table 8-3.   
 
In the United States, Dodder et al. (2002) analyzed four surficial sediments from Hadley Lake (Indiana).  
This lake is in the vicinity of a production point source.  DecaBDE (BDE 209) was the major congener 
detected at concentration ranging from 19 to 36 µg/kg (ng/g) dry weight.  Other congeners detected (in 
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type Location BDE 47 BDE 99 BDE 100 ΣPBDEs BDE 209 Reference 
Sediment Hadley Lake, 
Indiana 




584 (dw)a 480±170 
(dw) 
Dodder et al. 
2002 
Sediment Japan No data No data No data 21–59 
(dw) 
<25–11,600 Watananbe et 
al. 1986, 1987, 
1995 
Sediment Baltic Sea ND–3.4 ND–2.4 ND–1.3 ND–5.4 ND Nylund et al. 
1992 
Sediment Upstream plastics 
plant, Sweden 





780 1,200 270 2,250 No data Sellström and 
Jansson 1995 





<2–50 <1–53 <0.4–19 ND–120 ND–16,000 Sellström et al. 
1998a 






No data No data <0.51–1,800 de Wit 2002 




















<2–9 (dw) <0.1–23 
(dw) 
No data No data <9–4,600 
(dw) 
de Boer et al. 
2000b 
 
aincludes sum of BDE 47, BDE 99, BDE 100, BDE 209, and other congeners (not specified) 
 
dw = dry weight; ND = not detected 
 
Sources: de Wit 2002; Hale et al. 2003 
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decreasing order: 2,2’,4,4’,5-tetrabromodiphenyl ether [BDE 99]; 2,2’,4,4’,5,5’-hexabromodiphenyl ether 
[BDE 153]; 2,2’,4,4’,5,6’-hexabromodiphenyl ether [BDE 154]; 2,2’,4,4’-tetrabromodiphenyl ether 
[BDE 47]; and 2,2’,4,4’,6-pentabromodiphenyl ether [BDE 100]) were less than 5 µg/kg (ng/g) dry 
weight.  PBDEs were above the detection limit (i.e., 0.5 µg/kg [ng/g] dry weight) in 22% of surficial 
sediment samples (from 133 sites) in freshwater tributaries of Virginia (Hale et al. 2001b).  BDE 47 was 
the predominant congener followed by BDE 99 and BDE 100.  The maximum concentration detected in 
sediment was 52.3 µg/kg (ng/g) dry weight.  Hale et al. (2002) reported that stream sediment adjacent to a 
former polyurethane foam production facility in North Carolina contained up to 132 µg/kg (ng/g) dry 
weight of pentaBDE.  
 
In Japan, tetra-, penta-, hexa-, and decabromodiphenyl ethers have been observed in river sediments 
(Watanabe et al. 1986, 1987, 1995).  The combined concentrations of tetra- and pentabromodiphenyl 
ethers ranged from 21–59 ng/g (µg/kg) dry weight.  The concentration of decaBDE (BDE 209) ranged 
from <25 to 11,600 ng/g (µg/kg) dry weight (deWit 2002).  In 1999, sediment samples from several 
locations in the Netherlands contained BDE 47, BDE 99, and BDE 209 (de Boer et al. 2000).  
Concentrations ranged from 0.3 to 7.1 ng/g (µg/kg) dry weight for BDE 47, not detected to 5.5 ng/g 
(µg/kg) dry weight for BDE 99, and not detected to 510 ng/g (µg/kg) dry weight for BDE 209.  The 
concentration of PBDEs in suspended particulate matter ranged from not detected to 9 ng/g (µg/kg) dry 
weight for BDE 47, not detected to 23 ng/g (µg/kg) dry weight for BDE 99, and not detected to 
4,600 ng/g (µg/kg) dry weight for BDE 209 (de Boer et al. 2000).  The concentration of several 
brominated flame retardants was measured in sediments collected from the mouths of major European 
rivers (de Wit 2002).  Elevated levels of BDE 47 and BDE 99 were found in Humber and Mersey rivers 
(Great Britain).  In two rivers of the Netherlands, the sum of BDE 47 and BDE 99 ranged 1.61 to 
13.1 ng/g (µg/kg) dry weight.  The highest hexaBDE levels (as BDE 153) were found in the river Seine 
(France), three rivers in the Netherlands, and the rivers Schelde (Belgium), Forth (Great Britain) and Ems 
(Germany); the concentration of BDE 153 ranged from 0.013 to 0.056 ng/g (µg/kg) dry weight in these 
sediments.  The concentrations of decaBDE were highest in sediment from the Seine, ranging from 2.4 to 
3.9 ng/g (µg/kg) dry weight.  The concentrations of decaBDE in River Mersey (Great Britain), Schelde 
and River Liffey (Ireland) ranged from 34 to 1,800 ng/g (µg/kg) dry weight.  In the southern Baltic Sea 
(Bornholm Deep), the upper layer of sediment was analyzed for BDE 47, BDE 99, and BDE 100; the 
combined concentration of these three congeners was 0.52 ng/g (µg/kg) dry weight (Nylund et al. 1992).  
 
A well-studied sediment core collected from the southern part of the Baltic Sea proper was analyzed for 
PBDEs and a number of organochlorine contaminants (Nylund et al. 1992).  The retrospective temporal 
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trend from 1939 to 1987 showed that the PBDE levels (i.e., sum of BDE 47, BDE 99, and BDE 100) have 
increased with a sharp increase after 1980.  The PBDE level in the sample from 1989 was 2.9 ng/g 
(Nylund et al. 1992).  Measurable amounts of BDE 28, BDE 47, BDE 66, BDE 99, and BDE 100 were 
found in sediment cores from a freshwater lake in Germany, the Wadden Sea (the Netherlands), and 
Drammenfjord (Oslo Fjord, Norway) (Zegers et al. 2000).  Samples from the Drammenfjord and 
freshwater lake also contained BDE 153 and BDE 154, and the Wadden Sea and freshwater lake samples 
contained BDE 209.  The lower brominated PBDEs appear in the 1960s, and BDE 209 appears about 
10 years later.  The Drammenfjord sediment core shows increasing levels of BDE 47 starting in the 1940s 
(range, 0.02–0.18 ng/g dry weight) and increasing levels of BDE 99 (range, 0.5–0.28 ng/g dry weight), 
BDE 100 (range, not detected–0.07 ng/g dry weight), and BDE 154 (range, not detected–0.06 ng/g dry 
weight) beginning in the 1950s up to 1999.  In the sediment core from Lake Woserin, lower brominated 
BDE congeners are detected beginning in the late 1950s, increase until the late 1970s, and then level off 
when BDE 209 first appears.  A similar leveling-off trend is also observed in the Wadden Sea core 
(Zegers et al. 2000).  It is important to note that this study identified the presence of PBDEs compounds 
in sediments from the late 1950s and early 1960s.  This is nearly a decade prior to any significant 
commercial production of these substances.  The existence of PBDEs at these early dates lends some 
credibility to the likelihood that either the substances identified in the environment as PBDEs are not 
necessarily PBDEs or that there are yet unknown sources of PBDEs produced in nature.   
 
8.4.4   Other Environmental Media  
 
Polybrominated Biphenyls.   
 
Food.  Although the agriculture episode in Michigan involving contaminated feed occurred in May 1973, 
PBBs were not identified as the causative factor until April 1974 (Fries 1985b).  PBB-containing meats, 
milk, butter, eggs, and cheese entered the human food chain for almost a year before the PBBs were 
identified.  Concentrations of PBBs (on a fat basis) in milk samples collected from contaminated farms 
soon after PBB was identified ranged from 2.8 to 595 mg/kg (Cordle et al. 1978; Kay 1977).  
Concentrations of PBBs in other products processed from the contaminated milk were as follows:  butter, 
1–2 mg/kg; cheese, 1.4–15.0 mg/kg; and canned milk, 1.2–1.6 mg/kg (Cordle et al. 1978).  In 1974, the 
levels of PBBs in eggs from contaminated farm premises were as high as 59.7 mg/kg (Kay 1977).  The 
levels of PBBs in poultry and cattle tissues from the contaminated farm collected in 1974 were 
4,600 mg/kg and up to 2,700 mg/kg, respectively (Kay 1977).  With the seizure and destruction of the 
contaminated farm animals and products, the levels of PBBs in consumer products showed a steady 
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decline.  For example, in 1975, among 18 milk samples, 13 cheese samples, and 14 butter samples taken 
in Michigan, only 3 butter samples exceeded the FDA guidelines of 0.3 mg/kg fat (Di Carlo et al. 1978).  
In 1975, PBBs were detected in 245/2,040 meat samples collected in Michigan, with only 24 samples 
containing levels >0.3 mg/kg fat (Di Carlo et al. 1978).  Although 95% of 1,430 meat samples collected 
in Michigan in 1976 contained detectable PBBs, only 1 sample contained >0.6 mg/kg, and a market 
basket survey in Michigan showed detectable PBBs in only 1/102 meat samples (Di Carlo et al. 1978). 
 
Fish.  No PBBs were detected in several varieties of fish (carp, white sucker, Northern pike, bullhead, 
and bass) from the Alma Reservoir, which is upstream from the Michigan Chemical Corporation plant 
and above a dam that prevents fish from moving upstream (Hesse and Powers 1978).  On the other hand, 
tissue samples from fish collected from the Pine River, ≤29 miles downstream from the plant, contained 
up to 1.33 mg PBBs/kg (wet weight in skinless fillets).  There was no apparent change in PBB 
concentrations in fish between 1974 and 1976 (Hesse and Powers 1978).  PBBs could be detected in fish 
from Pine River and other embayments and tributaries of Lake Huron in 1983.  PBB concentrations in 
carp and other sedentary fish from embayments and tributaries of Lake Huron (including Pine River) and 
Lake Superior were determined (Great Lakes Water Quality Board 1989; Jaffe et al. 1985).  PBBs were 
detected in the concentration range of 15–15,000 µg/kg (fat basis) in fish from embayments and 
tributaries of Lake Huron, but not from Lake Superior.  Recently, Luross et al. (2002) determined the 
concentrations of several PBB congeners in lake trout from Lakes Huron, Superior, Erie, and Ontario. 
2,2’,4,4’,5,5’-Hexabromobiphenyl (BB-153) and 2,2’,4,5,5’-pentabromobiphenyl (BB-101) were found at 
the highest levels at concentrations ranging from 189 to 2,083 pg/g wet weight and from 42 to 633 pg/g 
wet weight, respectively.  Several other congeners were also detected in these lake trout samples (see 
Table 8-4).   
 
In German rivers, elevated levels of nona- and octaBBs were present in fish.  HexaBB was predominant 
in fish from the North Sea and Baltic Sea.  3,3’,4,4’,5,5’-Hexabromobiphenyl (BB-169) was found at a 
maximum concentration of 36 mg/kg (µg/g) fat in samples from the Baltic Sea.  However, BB-169 was 
not found in waters from the North Sea or rivers.  In Baltic marine fish, the concentrations of 
2,2’,4,4’,5,5’-hexabromobiphenyl (BB-153) ranged from 0.2 to 4.2 mg/kg (µg/g) lipid (de Boer et al. 
2000a).   
 
Animals.  PBB concentrations in whole (with skin) and skinless ducks collected within 2 miles of the 
Michigan Chemical Corporation plant in 1974–1977 ranged from not detected to 2.70 mg/kg (µg/g) and 
not detected to 1.8 mg/kg (µg/g), respectively (Hesse and Powers 1978).  Three bottlenose dolphins  
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Table 8-4.  Mean Concentrations of Nine PBB Congeners in Lake Trout from the 
Great Lakes (pg/g Wet Weight) 
 
Congener Lake Superior Lake Huron Lake Erie Lake Ontario 
BB-26/29 <1.3 5.2±2.3 <1.3 <1.3 
BB-31 <1.8 5.2±1.8 <1.8 <1.8 
BB-49 6.8±1.7 125±43 20±7.6 14±4.9 
BB-52 8.4±3.6 191±77 24±9.5 11±4.5 
BB-80 <3.8 <3.8 <3.8 <3.8 
BB-101 42±18 633±359 71±20 109±50 
BB-103 <1.5 4.4±1.9 <1.5 <1.5 
BB-153 189±105 2,083±1,282 220±47 1,008±513 
BB-155 1.0±0.78 5.8±3.4 <0.98 1.1±0.43 
 
Source: Luross et al. 2002 
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(Tursiops truncatus) collected during 1987–1988 from the U.S. mid-Atlantic contained PBBs at 
concentrations of 14–20 µg/kg (ng/g) lipid basis (Kuehl et al. 1991).  The source of the PBBs in the 
dolphins was not given.  The median concentrations of PBBs in 10 specimens of carcass and brain of bald 
eagles (Haliaeetus leucocephalus) collected from 29 states in 1977 were 0.07 and 0.05 mg/kg (µg/g), 
respectively (Kaiser et al. 1980).  Twenty-two other specimens did not contain detectable levels 
(<0.03 mg/kg [µg/g]) of PBBs.  The concentrations of PBBs in eggs of fish-eating birds (common tern, 
little gull, herring gull, and red-breasted mergansers) collected during 1975–1980 from nesting islands in 
northwestern Lake Michigan and Green Bay contained PBBs in the concentration range of 0.02–
0.25 mg/kg (µg/g) wet weight (Heinz et al. 1983, 1985).   
 
White-tailed sea eagles collected from the Baltic Sea contained 280 ng PBBs/g lipid weight (Jansson et al. 
1987).  The concentration of PBBs in common guillemots (Uria aalge) collected in 1979–1981 from the 
Baltic Sea was 160 ng/g lipid (Jansson et al. 1987).  Brunnich’s guillemot (Uria lomvia), collected from 
Svalbard in the Arctic, contained 50 ng PBBs/g lipid (Jansson et al. 1987). 
 
In 1981, female ringed seals from Svalbard in the Swedish Arctic contained 4 ng PBBs/g lipid (Jansson et 
al. 1987).  The level of PBBs in Baltic Sea harbor seal (Phoca vitulina) was 20 ng/g lipid; North Sea 
harbor seal contained 3 ng PBBs/g lipid (Jansson et al. 1987).  The concentration of hexaBB ranged from 
13–61 µg/kg (ng/g) wet weight from harbor seals collected from the North Sea (decaBB <1 µg/kg [ng/g] 
wet weight).  In whitebeaked dolphins from the North Sea, the concentration of hexa-, penta-, and deca-
BBs were 13, 8.3, and <0.9 µg/kg (ng/g) wet weight, respectively.  Tetra-, penta-, and deca-BBs 
concentration ranges were 1.1–1.9, 0.4–0.9, and <0.5 µg/kg (ng/g) wet weight, respectively, in sperm 
whales from the Atlantic Ocean (de Boer et al. 1999). 
 
Human Tissues and Body Fluids.  The quantitative determination of the concentrations of PBBs in 
blood, serum, adipose tissue, milk, and other body tissues or fluids is important in determining the human 
body burden of these chemicals.  Fat is the largest repository of PBBs in the body, and concentrations in 
fat can provide an index of body burdens and exposure.  It is simpler and less invasive to collect samples 
of serum or breast milk than body fat.  However, the collection of milk and serum for the estimation of 
possible body burden has limitations.  Breast milk can be obtained from limited segments of the 
population.  Also the concentration of PBBs in breast milk can show considerable fluctuations because 
the breast is emptied only periodically (Brilliant et al. 1978; Willett et al. 1988).  Serum, however, has 
lower PBB concentrations than body fat (see Section 5.5.1). 
 
PBBs and PBDEs  420 
 








Hexabromobiphenyl was detected (detection limit 6.6 µg/kg [ng/g]) at a frequency of 8–57% in human 
adipose tissue samples from six Canadian Great Lakes municipalities in 1984 (Williams et al. 1988).  The 
concentration of 2,2',4,4',5,5'-hexabromobiphenyl in adipose tissue samples pooled from tissues of the 
general population of the conterminous Unites States ranged from 1 to 2 µg/kg (ng/g) (Lewis and 
Sovocool 1982).  PBB levels in the adipose tissues of 15 quarantined dairy farm residents in mid-
Michigan (where the mix-up involving FireMaster BP-6 occurred) ranged from 0.104 to 174 mg/kg 
(µg/g) (Humphrey and Hayner 1975).   
 
In the fall of 1993, the serum levels of BB-167 (2,2’,4,4’,5,5’-hexabromobiphenyl) in 32 subjects, 
approximately 10 of whom consumed sport fish from the Great Lakes, were measured (Anderson et al. 
1998).  When the data were stratified by lake, on average, the Lake Huron fish consumers had the highest 
levels of PBBs (0.6 ppb [ng/g]) and Lake Erie fish consumers had the lowest (0.2 ppb [ng/g]).  When the 
data were then stratified by state of residence, on average, Great Lakes sport fish consumers who live in 
Michigan had the highest PBB level (0.7 ppb [ng/g]) and residents of Wisconsin had the lowest level 
(0.05 ppb [ng/g]).  
 
In Michigan after the agriculture contamination episode in 1973–1974, the median PBB concentrations in 
blood of exposed adults and children in farms were 0.014 and 0.035 mg/kg (14 and 35 ppb [ng/g]), 
respectively, compared to corresponding median concentrations of 0.003 and 0.006 mg/kg (3 and 6 ppb 
[ng/g]) in a control group (Humphrey and Hayner 1975).  PBB levels in the blood of quarantined farm 
workers in Michigan were also higher than in nonquarantined farm residents and the general population 
of Michigan (Cordle et al. 1978; Kimbrough 1987; Lambert et al. 1990; Landrigan et al. 1979).  The 
concentration ratio of PBBs in adipose tissue over blood plasma for 13 paired specimens was 175 to 
1 (Humphrey and Hayner 1975).   
 
A cross-section of the population of Michigan was studied in 1978, 5 years following the agriculture 
episode involving FireMaster BP-6, to determine the levels of PBBs in human tissues.  Levels of PBBs 
were highest in the part of state in which the episode occurred (median: adipose tissue, 500 µg/kg (ng/g); 
serum, 1.7 µg/L) and were lowest in the upper peninsula (median: adipose tissue, 15 µg/kg (ng/g); serum, 
0.2 µg/L), farthest from the source of contamination.  Levels in the rest of the state were in between 
(median: adipose tissue, 240 µg/kg [ng/g]; serum, 0.9 µg/L) (Wolff et al. 1982).  The estimated 
concentration ratio of PBBs in adipose tissue over serum was near 300 among 31 Michigan dairy farm 
residents (Wolff et al. 1979a).  The ratio of adipose tissue to serum PBB concentration was 363 to 1 for 
the general population and 100 to 1 in lactating women (Brilliant et al. 1978).  The kinetics of fat 
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metabolism in lactating women seems to alter PBB partitioning.  The ratios of adipose tissue to serum 
PBB concentration for nonpregnant females and male chemical workers, farm workers and other males, 
and pregnant females in 3,683 Michigan residents with varying degrees of exposure were 190–260 to 1, 
325–329 to 1, and 107–119 to 1, respectively (Eyster et al. 1983).  The PBB ratios for cord to serum and 
placenta to serum in pregnant females were 0.10–0.14 to 1 and 0.10–0.17 to 1, respectively (Eyster et al. 
1983).  The PBB ratios for feces to serum and bile to serum in farm and chemical workers were 0.53–
0.71 to 1 and 0.45–0.63 to 1, respectively (Eyster et al. 1983).  The detection of PBBs in bile and feces 
indicates transfer into the intestinal tract.  However, the concentration of PBBs in feces represented a 
minor proportion of the total body burden, indicating a slow rate of excretion (Eyster et al. 1983).  Serum 
PBBs were determined in a nested case-control study of 1,925 women enrolled in the Michigan 
Department of Public Health registry for persons exposed to PBBs (Henderson et al. 1995).  Study 
participants had lived on or received food from a farm quarantined by the Michigan Department of 
Agriculture, were recruited from July 1976 to December 1977, and were followed up annually from 1978 
through 1993.  Median serum PBB concentrations were 2 ppb (n=290; range=0.5–419 ppb [µg/L]).   
 
The concentrations of PBBs in the breast milk of females from the lower peninsula of Michigan (exposed 
area) were generally higher than in breast milk of females from the upper peninsula (farthest from the 
sources) (Brilliant et al. 1978).  PBB levels in breast milk of five females from the exposed farms were 
0.21–92.7 mg/kg (Cordle et al. 1978; Humphrey and Hayner 1976).  In a cohort of Michigan residents, 
the ratio of PBBs in breast milk to maternal serum was 107–122 to 1 and in adipose tissue to breast milk 
was 1.1–1.5 to 1 (Eyster et al. 1983; Landrigan et al. 1979).  The concentrations of PBBs found in human 
tissues and body fluids are given in Table 8-5.  Recent levels of PBBs in human breast milk (i.e., 1990 to 
present) were not located (WHO 1994b).   
 
Cow’s Milk.  In an attempt to determine the metabolites of PBBs, whole milk of lactating cows from 
contaminated areas of Michigan was analyzed for monohydroxy metabolites, but none were found 
(Gardner et al. 1976).  In a later study, the feces of dogs fed FireMaster BP-6 in corn oil was found to 
contain a metabolite identified as 6-hydroxy-2,2',4,4',5,5'-hexabromobiphenyl (Gardner et al. 1979).   
 
The effects of processing cow's milk containing PBBs also has been studied (Murata et al. 1977; Zabik et 
al. 1978).  Spray-drying reduced PBB levels in whole and skim milk, whereas pasteurization, freeze-
drying, aging of cheese, and condensation were not effective in reducing the level of PBBs in milk 
products.  Pressure-cooking meat containing PBBs reduced the level of PBBs in the cooked meat (Zabik 
et al. 1978). 
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concentrationa Year Reference 
Serum Exposed farm workers 14 µg/L 1976 Stross et al. 1979 
 Chemical workers 48 µg/L No data Stross et al. 1981 
 Chemical workers 1.1–1,000 µg/L 1976 Anderson et al. 1978d
 Exposed farm workers BDL to 
1,000 µg/L 
1976 Anderson et al. 1978d
 Residents from quarantined farms 26.9 µg/L 1976–1977 Landrigan et al. 1979 
 Residents from non-quarantined 
farms 
3.5 µg/L 1976–1977 Landrigan et al. 1979 
 Farm product consumers 17.1 µg/L 1976–1977 Landrigan et al. 1979 
 Chemical workers and families 43.0 µg/L 1976–1977 Landrigan et al. 1979 
 Control group 3.5 µg/L 1976–1977 Landrigan et al. 1979 
 General population (lower peninsula) 1.9 µg/L 1978 Wolff et al. 1982 
 General population (upper 
peninsula) 
0.2 µg/L 1978 Wolff et al. 1982 
 General population (remainder of 
state) 
0.9 µg/L 1978 Wolff et al. 1982 
 Chemical workers 25.4 µg/L No data Eyster et al. 1983 
 Farm and other workers 5.4 µg/L No data Eyster et al. 1983 
 Mothers from lower peninsula 26.2 µg/L 1976–1977 Landrigan et al. 1979 
 Exposed mothers from farms 3.4 µg/L No data Eyster et al. 1983 
 Non-pregnant women from exposed 
farms 
3.1 µg/L No data Eyster et al. 1983 
 Exposed women enrolled in the 
Michigan Department of Public 
Health registry 
2 µg/L 1993 Henderson et al. 1995
Cord serum Exposed mothers from lower 
peninsula 
3.2 µg/L 1976–1977 Landrigan et al. 1979 
 Mothers from lower peninsula <1.0 µg/L No data Eyster et al. 1983 
Blood plasma Workers from quarantined farms 14 µg/L 1974 Humphrey and 
Hayner 1975 
 Children from quarantined farms 35 µg/L 1974 Humphrey and 
Hayner 1975 
 Adults from non-quarantined farms 3 µg/L 1974 Humphrey and 
Hayner 1975 
 Children from non-quarantined farms 6 µg/L 1974 Humphrey and 
Hayner 1975 
Placenta Exposed mothers <1 µg/L No data Eyster et al. 1983 
Breast milk Exposed mothers 370 µg/kg (fat 
basis) 
No data Eyster et al. 1983 
 Exposed mothers from lower 
peninsula 
3,614 µg/kg (fat 
basis) 
1976–1977 Landrigan et al. 1979 
 Mothers from lower peninsula  68 µg/kg (fat 
basis) 
1976 Brilliant et al. 1978 
 Mothers from upper peninsula  <44 µg/kg (fat 
basis) 
1976 Brilliant et al. 1978 
PBBs and PBDEs  423 
 












concentrationa Year Reference 
Adipose 
tissue 
Population of lower peninsula 500 µg/kg 1978 Wolff et al. 1982 
 Population of upper peninsula 15 µg/kg 1978 Wolff et al. 1982 
 Population of rest of the state 240 µg/kg 1978 Wolff et al. 1982 
 Chemical workers 9,330 µg/kg No data Brown et al. 1981 
 Farm residents from lower peninsula 3,940 µg/kg No data Brown et al. 1981 
 Farm residents from lower peninsula 3,260 µg/kg 1976 Stross et al. 1979 
 Chemical workers 12,820 µg/kg No data Stross et al. 1981 
 Workers from quarantined dairy 
farms 
12,500 µg/kg 1974 Humphrey and 
Hayner 1975 
 Pregnant females from lower 
peninsula 
400 µg/kg No data Eyster et al. 1983 
 Chemical workers 5,290 µg/kg No data Eyster et al. 1983 
 Farm and other workers from lower 
peninsula 
1,650 µg/kg No data Eyster et al. 1983 
 
aWhen both mean and median values are available, the former values have been used in the table.  In some cases, 
when neither value is available, the range is given in the table. 
 
BDL = below detection limit 
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Polybrominated Diphenyl Ethers.   
 
Food.  Information about the concentrations of PBDEs in food-stuff is very limited.  Huwe et al. (2002a) 
reported total PBDE levels in farm chickens raised in two different regions of the United States.  The total 
PBDE level of discrete samples of chickens raised in Arkansas was 39.4 ng/g whole weight, while one 
composite sample of chickens raised in North Dakota was 1.7 ng/g whole weight.  In the United States, 
chickens fed ball clay and chickens bought in the grocery store were analyzed for total PBDEs (Environ 
2003b).  2,2’,4,4’,5-Pentabromodiphenyl ether (BDE 99) was the dominant congener in all samples.  
Total PBDEs ranged between 4 and 35 ng/g lipid weight in chickens fed ball clay and 0.5 ng/g lipid 
weight in store-bought chicken.  Recently, Ohta et al. (2002a) determined the concentration of total 
PBDEs in vegetables and meat samples from Japan.  The concentrations of PBDEs in spinach, potato, and 
carrot were 134, 47.6, and 38.4 pg/g fresh weight, respectively.  The highest concentrations of total 
PBDEs and 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47) were found in spinach.  Interestingly, different 
congener patterns were found among the vegetables analyzed.  Compared to root vegetables, which had 
high concentrations of 2,2’,4,4’,5,5’-hexabromodiphenyl ether (BDE 153), spinach (representing a leafy 
vegetable) might be strongly influenced by PBDE contamination in air.  The concentration of PBDEs in 
pork, beef, and chicken were 63.6, 16.2, and 6.25 pg/g fresh weight, respectively.  PBDE concentrations 
were highest in pork samples; however, the reason for this is unknown (Ohta et al. 2002a).  Bocio et al. 
(2003) determined the concentrations of PBDEs in food samples from Catalonia, Spain during 2000.  The 
highest concentration of total PBDEs was found in oils and fats (587.7–569.3 pg/g), followed by fish and 
shellfish (333.9–325.3 pg/g), meat and meat products (109.2–102.4 pg/g), and eggs (64.5–58.3 pg/g).  In 
all these food groups, a predominance of the tetra- and pentaBDE homologs, followed by hexaBDE, was 
observed in the sum total PBDEs.  By contrast, PBDEs were not detected in the groups of fruits, cereals, 
and tubers.  Four types of commercial fish oils sold in Sweden were found to contain PBDEs (0.2–
28.1 ng/g lipid weight) (Haglund et al. 1997).  The highest concentration of PBDEs was found in the cod 
liver oil.  These oils were from products marketed as dietary supplements for humans.  The concentrations 
of PBDEs in seafoods from the Inland Sea of Japan were determined for samples collected in 1998 (Hori 
et al. 2000).  The congeners, 2,4,4’-tribromodiphenyl ether (BDE 28); BDE 47; 2,3’,4,4’-tetrabromodi-
phenyl ether (BDE 66); BDE 99; 2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100); BDE 153; and 
2,2’,4,4’,5,6’-hexabromodiphenyl ether (BDE 154) were detected in all analyzed seafood samples.  
BDE 47 was detected as the predominant congener with concentrations ranging from 58 to 2,100 pg/g wet 
weight.  Harrad et al. (2004) determined the concentrations of several PBDE concengers in omnivorous 
and vegetarian diet samples from the United Kingdom.  Median concentrations of BDE 47 
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(2,2’,4,4’-tetraBDE), 99 (2,2’,4,4’,5-pentaBDE), 100 (2,2’,4,4’,6-pentaBDE), 153 (2,2’,4,4’,5,5’-hexa-
BDE), and 154 (2,2’,4,4’,5,6’-hexaBDE) in omnivorous diet samples were 66.8, 63.8, 10, 20, and 20 pg/g 
dry weight, respectively.  In vegetarian samples, median concentrations of BDE 47 (2,2’,4,4’-tetraBDE), 
99 (2,2’,4,4’,5-pentaBDE), 100 (2,2’,4,4’,6-pentaBDE), 153 (2,2’,4,4’,5,5’-hexaBDE), and 
154 (2,2’,4,4’,5,6’-hexaBDE) were 47.2, 56.7, 10.0, 20, and 20 pg/g dry weight, respectively.  
Concentrations of BDE 47, 99, and total PBDE were found to be statistically higher in omnivorous diet 
samples compared to vegitarian diet samples.  
 
Biosolids and Effluents.  The concentrations of PBDEs in biosolids (sewage sludge) and effluents are 
summarized in Table 8-6.  PBDEs were detected in biosolids from four different regions of the United 
States (Pardini et al. 2001).  The total concentrations of pentaBDE in biosolids ranged from 1,100 to 
2,290 ng/g dry weight; the levels of pantaBDE were high and consistent, regardless of the region of 
origin.  The concentration of decaBDE (BDE 209) varied widely among biosolids from different regions; 
the concentration of BDE 209 ranged from 84.8 to 4,890 ng/g dry weight in the biosolid samples.  
Sewage sludges in the vicinity of the Dan River (Virginia) were collected and analyzed for PBDEs (Hale 
et al. 2002).  Congener patterns suggestive of both penta- and decaBDE commercial products were 
present at concentrations of 1,370 ng/g dry weight (sum of BDE 47 to BDE 154) and from 1,470 ng/g dry 
weight, respectively.  While no known industrial source of pentaBDE discharged to this plant, the 
distribution pattern for lower brominated congeners matched the pentaBDE commercial product.  
 
Sewage sludge samples from 13 waste water-treatment plants in Germany were sampled (Hagenmaier et 
al. 1992).  The mean concentration of tri- to hepta-BDEs was 8.37 ng/g with tri-, tetra-, penta-, hexa-, and 
heptaBDE at concentrations of 0.65, 3.06, 3.02, 0.49, and 0.22 ng/g, respectively.  Levels of penta- and 
hexaBDEs were highest in these samples.  de Boer et al. (2000b) determined the concentration of PBDEs 
in sewage treatment-plant effluents (STP) from the Netherlands.  The concentration of total PBDEs 
ranged from 11 to 35 ng/g dry weight, while the concentrations of 2,2’,4,4’-tetrabromodiphenyl ether 
(BDE 47) and BDE 209 were 11–35 and 310–920 ng/g dry weight, respectively.  Kohler et al. (2003) 
determined the levels of decaBDE in sewage sludge from Switzerland between 1993 and 2002.  These 
authors reported that the average concentration of decaBDE increased with time from 220 to 1,100 ng/g 
dry weight, corresponding to an average increase of 560%.  
 
World Trade Center Site.  In 2001, PBDEs were detected in dust and smoke samples taken near the 
World Trade Center (WTC) disaster site (Lioy et al. 2002).  The highest concentration was for decaBDE 
(i.e., BDE 209), which was present in thermoplastics (e.g., computers).  Concentrations of PBDE 
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Table 8-6.  Concentrations (ng/g Dry Weight) of Several PBDEs in Biosolids 
(Sewage Sludge) and Effluents 
 























53 53 13 119 No data Sellström 1999; 
Sellström and 

















11–35 <1 No data 11–35 310–920 de Boer et al. 
2000b 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Source: de Wit 2002; Hale et al. 2002  
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congeners were 107–174 µg/kg dry weight basis for 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47), 51.1–
74.1 µg/kg dry weight basis for 2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100), 155–293 µg/kg dry 
weight basis for 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99), 42.0–53.5 µg/kg dry weight basis for 
2,2’,4,4’,5,5’-hexabromodiphenyl ether (BDE 153), 219–305 µg/kg dry wt basis for 2,2’,4,4’,5,6’-hexa-
bromodiphenyl ether (BDE 154)/PBB-153, and 1,330–2,660 µg/kg dry wt basis for decaBDE (BDE 209).  
Levels of PBDEs were found to be similar to levels found in sewage sludge (Lioy et al. 2002).  No further 
information on levels of PBDEs in environmental was located for the WTC site.  
 
Freshwater Fish.  Monitoring data indicated that the levels of PBDEs are increasing in freshwater 
organisms with higher concentrations near point sources.  The congener profiles show the highest levels 
for 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47).  The presence of PBDEs in freshwater aquatic 
organisms taken from remote regions suggests that diffuse sources of PBDEs are also important.  The 
concentrations of PBDEs in freshwater fish samples in the United States are summarized in Table 8-7.  
Fish were sampled from two U.S. lakes, Hadley Lake, Indiana near a possible PBDE point source, and 
Lake of the Ozarks, Missouri, with no known sources (Dodder et al. 2000a).  Mean total PBDE 
concentrations (sum of BDE 47, 2,2’,4,4’,5-pentabromodiphenyl ether [BDE 99], 2,2’,4,4’,6-pentabromo-
diphenyl ether [BDE 100], 2,2’,4,4’,5,5’-hexabromodiphenyl ether [BDE 153], and 2,2’,4,4’,5,6’-hexa-
bromodiphenyl ether [BDE 154]) were higher in crappie (Poxomis annularis) and bluegill (Lepomis 
macrochiras) from Hadley Lake (1,500 and 1,900 ng/g lipid weight, respectively) than from Lake of the 
Ozarks (340 and 390 ng/g lipid, respectively).  BDE 47, BDE 99, BDE 153, and BDE 154 were primary 
congeners.  From the Lake of Ozarks, BDE 47 was the dominant congener in fish.  The total PBDE 
concentrations in smelt (Osmerus mordax) from Lakes Superior and Ontario were 150±9 and 
240±30 ng/g lipid, respectively (Dodder et al. 2002).  The dominate congeners in these fish were BDE 47 
and BDE 99.  An analysis of fish tissue samples from selected locations in Washington State showed that 
total PBDE concentrations ranged from 29 ng/g lipid in rainbow trout from a remote spring-fed stream 
(Douglas Creek, Washington) to 19,000 ng/g lipid in rainbow trout from the urbanized Spokane River, 
Washington (Johnson and Olson 2001).  The tetra- and pentaBDE isomers were the major compounds 
present.  TetraBDE to hexaBDE were found in carp (Cyprinus carpio) from the Buffalo River (New 
York), a polluted area around the Great Lakes (Loganathan et al. 1995).  TetraBDEs dominated the 
congener pattern with 94–96% of total PBDEs.  TetraBDE and pentaBDE concentrations ranged from 
13 to 22 ng/g fresh weight.  Asplund et al. (1999a) found tri- to hexaBDEs in steelhead trout 
(Oncorhynchus mykiss) sampled in 1995 from Lake Michigan.  The combined concentration of BDE 47, 
BDE 99, BDE 100, BDE 153, and BDE 154 was 3,000 ng/g lipid weight (Asplund et al. 1999b).  Lake 
trout (Salvelinus manaycush) from Lakes Ontario, Huron, and Superior were also found to have di- to 
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Table 8-7.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several PBDEs 
in Freshwater Fish Samples from the United States 
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference 
Alewife Grand Traverse 
Bay, Lake 
Michigan 







11 (fw) No data No data 23 (fw) No data Stapleton and 
Baker 2003 
Bluegill Hadley Lake, 
Indiana 
420 320 240 1,900 No data Dodder et al. 
2000 
Bluegill Lake of the 
Ozarks, Missouri 
200 91 59 390 No data Dodder et al. 
2000 
Burbot Grand Traverse 
Bay, Lake 
Michigan 
43 (fw) No data No data 86 (fw) No data Stapleton and 
Baker 2003 
Carp United States No data No data No data 13–22* (fw) No data Loganathan et 
al. 1995 
Carp Detroit River, 
Grosse Isle, 
Michigan 
3.0 (fw) 0.50 (fw) 0.48 (fw) 40.7* No data Rice et al. 2002 
Carp Des Plaines 
River, Joliet, 
Illinois 
2.54 (fw) 0.5 (fw) 0.44 (fw) 281* No data Rice et al. 2002 
Carp Des Plaines 
River, Joliet, 
Illinois 
1.34 (fw) 0.50 (fw) 0.49 (fw) 78.3* No data Rice et al. 2002 
Carp (fillet) Yakima River, 
Washington 
No data No data No data 22 (fw) No data Johnson and 
Olson 2001 
Crappie Hadley Lake, 
Indiana 
250 430 150 1,500* No data Dodder et al. 
2000 
Crappie Lake of the 
Ozarks, Missouri 







2.8 (fw) No data No data 3 (fw) No data Stapleton and 
Baker 2003 
Lake trout Grand Traverse 
Bay, Lake 
Michigan 
75 (fw) No data No data 126 (fw) No data Stapleton and 
Baker 2003 
Lake trout Lake Ontario, 
United States 
No data No data No data 540* No data Alaee et al. 1999
Lake trout Lake Ontario, 
United States 
58 (fw) 14 (fw) 5.7 (fw) No data No data Luross et al. 
2002 
Lake trout Lake Huron, 
United States 
No data No data No data 240* No data Alaee et al. 1999
Lake trout Lake Huron, 
United States 
27 (fw) 7.7 (fw) 3.8 (fw) No data No data Luross et al. 
2002 
Lake trout Lake Superior, 
United States 
No data No data No data 140* No data Alaee et al. 1999
Lake trout Lake Superior, 
United States 
29 (fw) 12 (fw) 4.1 (fw) No data No data Luross et al. 
2002 
Lake trout Lake Erie, 
United States 
No data No data No data 117* No data Alaee et al. 1999
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Table 8-7.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several PBDEs 
in Freshwater Fish Samples from the United States 
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference 
Lake trout Lake Erie, 
United States 







































No data Johnson and 
Olson 2001 
Salmon Grand Traverse 
Bay, Lake 
Michigan 
34 (fw) No data No data 95 (fw) No data Stapleton and 
Baker 2003 
Salmon Lake Michigan, 
United States 
52.1 (fw) 9.3 (fw) 9.7 (fw) 2,440 No data Manchester-
Neesvig et al. 
2001 
Smelt Lake Superior, 
United States 
5.7 (fw) 1.8 (fw) 0.98 (fw) 150 <1.5 (fw) Dodder et al. 
2002 
Smelt Lake Ontario, 
United States 













1,700 600 360 3,000* No data Asplund et al. 
1999b 
Whitefish Columbia River, 
United States 
No data No data No data 72 (fw) No data Rayne et al. 
2003a 
Whitefish Grand Traverse 
Bay, Lake 
Michigan 
9.8 (fw) No data No data 18 (fw) No data Stapleton and 
Baker 2003 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Sources: Luross et al. 2002; Manchester-Neesvig et al. 2001; Rayne et al. 2003; Stapleton and Baker 2003 
 
dw = dry weight; fw = fresh weight 
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heptaBDEs with combined concentrations of 545, 237, and 135 ng/g lipid weight, respectively (Alaee et 
al. 1999).  Lake trout from Lake Erie had 117 ng/g lipid weight (Luross et al. 2000).  Variations in local 
sources, combined with atmospheric transport, may explain differences that were seen in congener 
profiles for the different lakes.  A retrospective temporal study for the years 1978, 1983, 1988, 1993, and 
1998 using archived trout samples from Lake Ontario show a dramatic increase in total PBDE 
concentrations over time (Luross et al. 2000).  At 50 fresh water sites in Virginia, muscle samples from 
253 fish samples were collected and analyzed for PBDEs (Hale et al. 2000, 2001b).  Approximately 85% 
of the samples contained BDE 47, the predominant congener, at measurable concentrations.  
Concentrations were >1,000 ng/g lipid weight at 9 of 50 sites.  The highest combined PBDE 
concentrations (up to 57,000 ng/g lipid weight) were observed in carp downstream of textile and furniture 
facilities.  BDE 47 levels were greater than 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB 153) concentrations 
in 58% of the samples analyzed.  PBDEs were identified in fish collected from the Detroit River 
(Michigan) and Des Plaines Rivers (Illinois).  In Detroit River fish (carp and large mouth bass), the 
congener patterns were dominated by BDE 47; however, in the Des Plaines River carp, the dominant 
congeners were heptaBDE congeners (2,2’,3,4,4’,5,6-heptBDE [BDE 181] and 2,2’,3,4,4’,5’,6-heptaBDE 
[BDE 183]), lesser amounts of 2,3,3’,4,4’,5,6-heptaBDE (BDE 190), and two hexaBDEs (BDE 154 and 
BDE 153).  Possible sources for the heptaBDE congeners were not obvious since none of the commercial 
mixtures are known to contain these congeners.  Three possible explanations were proposed to explain the 
presence of the heptaBDE congeners found in Des Plaines River carp: waste discharge from an industrial 
facility; publicly-owned treatment works (POTW) effluents; or formation in situ by decaBDE deposits.  
 
The concentrations of PBDEs in freshwater fish samples from Europe are summarized in Table 8-8.  
Between 1986 and 1988, levels of 2,2’4,4’-tetrabromodiphenyl ether (BDE 47), 2,2’,4,4’,5-pentabromo-
diphenyl ether (BDE 99), and 2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100) were measured in 
whitefish (Coregonus spp.) from a remote mountain lake in Northern Sweden (Lake Storvindeln), Arctic 
char (Salvelinus alpinus) from a heavily populated lake (Lake Vättern) in south-central Sweden with 
numerous municipal and industrial point sources, and in trout (Salmo trutta) and pike (Esox lucius) from 
several sites along Dalslands Canal in west central Sweden (Jansson et al. 1993).  No point sources of 
PBDEs were identified from these sites.  Whitefish from the remote lake contained the lowest levels 
(26 ng/g lipid weight) of PBDEs, whereas the Arctic char, from a heavily populated lake, contained 
520 ng/g lipid weight PBDEs.  In both samples, BDE 47 was the predominant congener.  PBDE 
concentration levels in pike and trout from the Dalslands Canal ranged from 180 to 210 ng/g lipid weight 
and from 280 to 1,200 ng/g lipid weight, respectively.  The congener pattern in these samples was similar 
to the technical mixture, Bromkal 70-5DE, with equal quantities of both BDE 47 and BDE 99.  The levels 
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Table 8-8.  Concentrations (ng/g Lipid Weight Except as Noted) of Several PBDEs 
in Freshwater Fish Samples from Europe 
 
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference 
Arctic char Lake Vättern, 
Sweden 








No data No data No data de Boer et al. 
2000b 
Eels Netherlands <20–1,400 No data No data <50–1,700 No data de Boer 1990 
Osprey Sweden 1,800 140 200 2,140 No data Sellström et al. 
1993 
Pike Lake Bolmen, 
Sweden 
65 42 19 130 No data Kierkegaard et 
al. 1993 
Pike Dalslands canal, 
Sweden 
94–98 60–79 25–36 180–210 No data Sellström et al. 
1993 














Germany No data No data No data 19–983* No data Krüger 1988 
Trout Dalslands canal, 
Sweden 





15 7.2 3.9 26 No data Sellström et al. 
1993 
Whitefish Lake Geneva, 
Switzerland 
26 13 2.5 44* No data Zennegg et al. 
2003 
Whitefish Lake Greifen, 
Switzerland 
96 52 9.1 165* No data Zennegg et al. 
2003 
Whitefish Lake Biel, 
Switzerland 
75.9 39 7.1 128* No data Zennegg et al. 
2003 
Whitefish Lake Lucerne, 
Switzerland 
56 46 10 121* No data Zennegg et al. 
2003 
Whitefish Lake Zürich, 
Switzerland 
56 25 4.5 89* No data Zennegg et al. 
2003 
Whitefish Lake Nauchatel 
Switzerland 
41 20 4.0 68* No data Zennegg et al. 
2003 
Whitefish Lake Constance, 
Switzerland 
32 15 2.9 52* No data Zennegg et al. 
2003 
Whitefish Lake Thun, 
Switzerland 
19 12 2.5 36* No data Zennegg et al. 
2003 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Sources: de Wit 2002; Zennegg et al. 2003 
 
dw = dry weight; fw = fresh weight 
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in pike and trout are of the same order of magnitude as in the Arctic char, indicating the spread of PBDEs 
from diffuse sources (de Wit 2002).  In 1979 and 1980, high levels of tri- to hexaBDEs (range, 950–
27,000 ng/g lipid weight in muscle tissues) were measured in fish sampled along a river in Sweden 
(Viskan) where numerous textile industries are located (Andersson and Blomkvist 1981).  These textile 
industries have used PBDEs in the production of textiles.  BDE 47 was the predominant congener at 70–
80% of the total PBDEs.  In 1977, the PBDEs were not detected in fish sampled at the same sites.  The 
elevated levels of BDE 47, BDE 99, and BDE 100 were later confirmed in a follow-up study in which 
fish were caught from approximately the same locations (Sellström et al. 1993).  In the current study, 
BDE 47 was the predominant congener at 65–96% of total PBDEs.  Several fish species were sampled 
(pike, perch, bream, eel, tench, and sea trout) in these studies.  In 1995, fresh samples of pike and 
sediments were collected at four of eight sites along River Viskan in order to search for point sources of 
contaminants.  The combined concentrations of BDE 47, BDE 99, and BDE 100 ranged from not detected 
to 4,600 ng/g lipid weight, with BDE 47 being the predominant congener (50–90% of total).  DecaBDE 
(BDE 209) was found in a few fish at trace amounts.  The lowest levels of the PBDEs were found 
upstream of the industries.  The concentrations of PBDEs increased further downstream as more 
industries were passed (Sellström et al. 1998a).  Levels of BDE 47 ranged from <20 to 1,700 ng/g lipid in 
eels (Anguilla anguilla) from Dutch rivers and lakes (at 10 locations); BDE 47 comprised 70% of the total 
PBDEs (de Boer 1990).  Bream (Abramais brama) sampled from several sites in the Netherlands had 
concentrations of BDE 47 ranging from 0.2 to 130 ng/g dry weight (de Boer et al. 2000).  BDE 99 was 
below the detection limits.  BDE 153 ranged from <0.04 to 4.1 ng/g dry weight.  Allchin et al. (1999) 
conducted a study of PBDEs in plaice (Pleuronectes platessa), flounder (Platichys flesus), and dab 
(Limanada limanada) collected in the estuaries of rivers in the United Kingdom.  Suspected sources of 
PBDEs in the estuaries include a manufacturer of pentaBDE and octaBDE, several industries using 
pentaBDE, and several landfills receiving wastes suspected to contain PBDEs.  Levels of BDE 47, 
BDE 99, pentaBDE (as technical mixture DE-71), and octaBDE (as technical mixture DE-79) in fish 
ranged from not detected to 9,500 ng/g lipid weight, not detected to 370 ng/g lipid weight, 47 to 
1,200 ng/g lipid weight, and not detected to 1,200 ng/g lipid weight.  The highest levels were at Tees Bay 
downstream from a manufacturing plant on the River Tees.  These results are similar to the situation 
found in Sweden along the River Viskan (Andersson and Blomkvist 1981; Sellström et al. 1993).  
Freshwater mussels (Dreissena polymorpha) were collected at several locations in the Netherlands and 
analyzed for BDE 47, BDE 99, BDE 153, and BDE 209) (de Boer et al. 2000).  Concentration ranges for 
the congeners were 0.7–17, 0.4–11, and <0.1–1.5 ng/g dry weight for BDE 47, BDE 99, and BDE 153, 
respectively; BDE 209 was below the detection limit. 
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Saltwater Fish.  No identifiable temporal trends were found for PDBE levels in marine aquatic species.  
Spatial trends show higher levels of lower brominated BDE congeners found near human populated areas.  
The congener profiles show the highest levels for 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47).  The 
levels of several PBDEs in marine aquatic species are summarized in Table 8-9.  In the year 2000, sole 
liver collected from five sites along the Canadian west coast (Crofton, Bamfield, Kitimat, Trincomali, and 
Vancouver) were analyzed for 14 BDE congeners (Ikonomou et al. 2002b); the total PBDE 
concentrations were 64–340 ng/g lipid while the three highest congener concentrations were 27–160 ng/g 
lipid (BDE 47), 8.5–54 ng/g lipid (2,2’,4,4’,6-pentabromodiphenyl ether [BDE 100]), and 9.5–46 ng/g 
lipid (2,2’,4,4’,5-pentabromodiphenyl ether [BDE 99]), respectively.  The highest levels were found in 
sole samples collected near Vancouver, Canada.  DecaBDE was not detected in these samples at the level 
of procedural blank.  Farmed salmon collected at two locations in Canada were analyzed for PBDE 
congeners (Easton et al. 2002).  Forty-one congeners were detected with BDE 47 at the highest level 
(690 and 2,600 ng/g wet weight) followed by BDE 99 and BDE 100; total BDE congener levels were 
1,188 and 4,147 ng/g wet weight for the two samples.  Likewise, wild salmon from four locations in 
Canada were analyzed for BDE congeners.  Levels were a factor of 10 lower for these samples compared 
to farmed salmon samples.  The total PBDE concentration for the 41 detected congeners ranged from 
38.7 to 485.2 ng/g wet weight.  The concentration of the highest congener, BDE 47, ranged from 29 to 
280 ng/g wet weight (Easton et al. 2002).  PBDE concentrations in skipjack tuna from Asian offshore 
waters, off-Seychelles, off-Brazil, and open seas were determined for samples collected during 1996–
2001 (Ueno et al. 2003).  The concentration of total BDEs in muscles tissues ranged from not detected 
(<0.05 ng/g lipid) to 53 ng/g lipid.  The concentration of the highest congener in muscle tissues, BDE 47, 
ranged from <0.1 to 15 ng/g lipid.  BDE 99, BDE 100, BDE 153, and BDE 154 also were detected; 
BDE 209 was below the detection limit (<5.0 ng/g lipid) for these samples.  Samples collected off the 
coast of the Seychelles (relatively pristine area) did not have detectable levels of any PBDEs, while 
samples collected in industrial areas of southeast Asia had the highest.  Fall-caught herring (Clupea 
harengus) muscle from five sites along the Swedish coast was analyzed for BDE 47, BDE 99, and 
BDE 100; the combined concentration of these three congeners ranged from 17 to 61 ng/g lipid, with 
BDE 47 being the dominate congener (Sellström et al. 1993).  Likewise, the concentration of BDE 47 in 
Baltic herring ranged from 3.2 to 27 ng/g lipid in different age groups; the combined concentration of 
BDE 47, BDE 99, and BDE 100 ranged from 3.2 to 32 ng/g lipid (Haglund et al. 1997); 2-year-old 
herring had the lowest levels and 5-year-old herring had the highest levels.  Similarly, Strandman et al. 
(1999) observed increasing concentrations with age of BDE 47, BDE 99, and BDE 153 in Baltic sprat 
(Sprattus sprattus, age 3–13 years).  However, this trend was not evident for herring.  BDE 47 was the  
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No data Easton et al. 2002 
Sole liver West coast, 
Canada 

















2.9–7.9 0.18–3.0 0.56–2.1 5.8–21 <5.0 Ueno et al. 2003 
Herring Baltic Sea 19–38 7.8–17 3.4–6 30–61 No data de Wit 2002 
Sellström et al. 
1993 
Herring Baltic Sea 3.2–27 ND–2.9 1.3–1.9 3.2–32 No data Haglund et al. 1997
Herring Baltic Sea 7.6–24 4.3–3.9 No data 12.9–28.3* No data Strandman et al. 
1999 
Herring Baltic Sea 6.3 0.6 0.8 12* No data Burreau et al. 1999
Herring Kattegatt, 
Sweden 
12 3.4 1.6 17 No data de Wit 2002; 
Sellström et al. 
1993 






1.9–9.5 No data 21–149* No data Strandman et al. 
1999 
Sprat Baltic Sea 4.3 0.7 0.8 8.4* No data Burreau et al. 1999
Cod liver  North Sea 170 No data No data 1.9–360 No data de Boer 1989 
Salmon Baltic Sea 167 52 44 220 No data Haglund et al. 1997
Salmon Baltic Sea 190 52 46 290 No data Asplund et al. 
1999b 
Salmon Baltic Sea 46 7.3 6.4 86* No data Burreau et al. 1999
Several fish 
species 




Japan 0.5 0.4 0.25 1.9* No data Ohta et al. 2000 
Yellowtail Japan 17 4.5 4.0 30.5* No data Ohta et al. .2000 
Yellowtail 
(cultured) 
Japan 29 3.3 5.3 44* No data Ohta et al. 2000 
Salmon Japan 22 8.1 5.3 46* No data Ohta et al. 2000 
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<0.01–4.6 No data No data No data de Boer et al. 
2000b 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Source: Easton et al. 2002; de Wit 2002; Ikonomou et al. 2002; Ueno et al. 2003 
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primary congener with levels ranging from 7.6 to 24 ng/g lipid weight for 1–3-year-old sprat, 17–
140 ng/g lipid weight for 3- to 13-year-old sprat, and 7.6–24 ng/g lipid weight in herring.  The 
concentrations of BDE 47, BDE 99, and BDE 100 in whole-body composites of herring were 6.21, 0.62, 
and 0.81 ng/g lipid, respectively; in sprat, the concentrations were 4.32, 0.71, and 0.80 ng/g lipid, 
respectively (Burreau et al. 1999).  Baltic sea herring had similar levels of BDE 47 (46.3 ng/g lipid) 
compared to 8.4–100 ng/g lipid of BDE 47 found by de Boer (1990) for herring collected from three 
regions of the North Sea.  BDE 47, BDE 99, and BDE 153 concentrations in Baltic salmon (Salmo salar) 
muscle were 167, 52, and 4.2 ng/g lipid, respectively (Haglund et al. 1997).  BDE 47, BDE 99, and 
BDE 100 levels were 47, 7.2, and 6.3 ng/g lipid, respectively, in whole-body composites (Burreau et al. 
1999).  In another study, the levels of BDE 47, BDE 99, and BDE 100 were determined in muscle, ripe 
eggs, and blood plasma from Baltic salmon (Asplund et al. 1999a).  The mean concentrations of PBDEs 
in tissues from Baltic salmon (ng/g lipid weight) were as follows: BDE 47 (muscle, 190; ripe eggs, 64; 
blood, 190), BDE 99 (muscle, 52; ripe eggs, 16; blood, 55), and BDE 100 (muscle, 46; ripe eggs, 18; 
blood, 59).  Cod (Gadus morhua) liver samples at three locations of the North Sea had combined levels of 
BDE 47 and BDE 99 of 1.9–360 ng/g lipid (de Boer 1989).  BDE concentrations in flounder were 0.6–
20 ng/g dry weight for BDE 47 and <0.01–4.6 ng/g dry weight for BDE 99 from several sites in the 
Netherlands (de Boer et al. 2000).  Concentrations of BDE 153 and BDE 209 were below the detection 
limit.  In 1996, de Boer et al. (2001) measured the levels of two BDE congeners in flounder liver samples 
from the Amsterdam and Rotterdam harbors, and off the Dutch coast; BDE 47 and BDE 99 ranged from 
15 to 280 and from <2 to 24 ng/g lipid weight, respectively.  Olsson et al. (1999) detected BDE 47 in 
perch (Perca fluviatilis) from Latvia in a study examining environmental contamination in coastal areas 
of the former Soviet Union; the concentration of BDE 47 ranged from 6.4 to 10 ng/g lipid weight in the 
perch.   
 
Watanabe et al. (1987) detected PBDEs in numerous marine fish and shell fish in Japan.  TetraBDE and 
pentaBDE levels ranged from 0.1 and 17 ng/g fresh weight, with tetraBDE being the major congener.  
decaBDE was also detected in a mussel sample from Osaka Bay (at 1.4 µg/kg wet weight).  Recently, 
Japanese market fish were analyzed for PBDEs.  The highest combined PBDE levels (2,4,4’-triBDE 
[BDE 28], 2,2’,4,4’-tetraBDE [BDE 47], 2,3’,4,4’-tetraBDE [BDE 66], 2,2’,4,4’,5-pentaBDE [BDE 99], 
2,2’,4,4’,6-pentaBDE [BDE 100], 2,2’,4,4’,5,5’-hexaBDE [BDE 153], and 2,2’,4,4’,5,6’-hexaBDE 
[BDE 154]) were in salmon, cultured yellowtail, and wild yellowtail muscle (46, 44, and 30.5 ng/g lipid 
weight, respectively) and lowest levels in yellowfin tuna (1.9 ng/g lipid weight) (Ohta et al. 2000).  
BDE 47 was major congener in all samples.  In another study, several fish species from Japan were 
analyzed for 15 BDE congeners (Hori et al. 2000).  The PBDE levels ranged from 0.00136 to 2.1 ng/g 
PBBs and PBDEs  437 
 








fresh weight, with BDE 47 as the predominant congener.  Seven species of marine fish (conger eel, 
flounder, gray mullet, horse mackerel, red sea bream, sea bass, and yellowtail) were collected from the 
Inland Seas near Seto, Japan (Akutsu et al. 2001).  Seven PBDEs (BDE 28, BDE 47, 2,3’,4,4’-tetraBDE 
[BDE 66], BDE 99, BDE 100, BDE 153, and BDE 154) were detected in all samples with BDE 47 being 
the most abundant congener.  Levels of total PBDEs in gray mullets and yellowtails were 63 and 15 ng/g 
lipid weight, respectively. 
 
Marine Aquatic Organisms.  Marine mussels (Mytilus edulis) collected at several locations in the 
Netherlands and analyzed for 2,2’,4,4’-tetraBDE (BDE 47), 2,2’,4,4’,5-pentaBDE (BDE 99), 
2,2’,4,4’,5,5’-hexaBDE (BDE 153), and decaBDE (BDE 209) (de Boer et al. 2000).  Concentrations of 
BDE 47 and BDE 99 ranged from 0.9 to 4.3 ng/g dry weight and from 0.3 to 1.6 ng/g dry weight, 
respectively.  BDE 153 and BDE 209 were not detected.  Di- to heptaBDE were analyzed for in 
hepatopancreas samples from Dungenes crab from several sites on the Strait of Georgia, British 
Columbia, Canada (Ikonomou et al. 1999).  The primary congener detected was BDE 47.  The combined 
concentration of BDE 47 and BDE 99 was approximately 100–350 ng/g lipid weight.   
 
Marine Animals.  In marine animals, temporal trends show increasing levels of lower brominated BDE 
congeners with higher levels found near human-populated areas.  In all marine animal studies, the 
congeners profile show the highest levels for BDE 47.  The concentrations of several PBDEs in marine 
animals are summarized in Table 8-10.  PBDEs have been detected in several species of seal from several 
different sites.  In San Francisco Bay, California, the concentrations of PBDEs in harbor seals have 
increased dramatically over the past decade, with current levels among the highest reported for this 
species (She et al. 2002).  The concentration of total PBDEs (sum of BDE 47, 2,2’,4,4’,5-pentaBDE 
[BDE 99], 2,2’,4,4’,6-pentaBDE [BDE 100], 2,2’,4,4’,5,5’-hexaBDE [BDE 153], and 
2,2’,4,4’,5,6’-hexaBDE [BDE 154]) in harbor seal blubber increased by over a factor of 50 from a 
concentration of 88 ng/g lipid for species samples collected in 1988 to a concentration of 2,985–
8,325 ng/g lipid for species samples collected in 1998.  The highest concentrations reported were for 
BDE 47, which increased from 45.6 ng/g lipid for blubber samples in 1989 to 2,343–6,682 ng/g lipid for 
blubber samples collected in 1998.  The dominance of the tetraBDE congeners over other congeners may 
indicate that tetraBDEs bioaccumulate more than the higher brominated congners (She et al. 2002).  In the 
Baltic Sea, female grey seals (Halichoerus grypus) sampled in 1979–1985 contained 730 ng PBDE/g lipid 
in their blubber (sum of BDE 47, BDE 99, and BDE 100) (Jansson et al. 1993); male grey seals had 
280 ng PBDE/g lipid weight (Andersson and Wartanian 1992).  Male ringed seals (Pusa hispida) from the 
Baltic Sea had 320 ng PBDE/g lipid weight (Andersson and Wartanian 1992).  Baltic gray and ringed seal 
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type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference 
Bottlenose 
dolphin 
Gulf of Mexico No data No data No data 8,000 No data Kuehl and Haebler 
1995 



























































































220 (fw) 89.8 (fw) 56.6 (fw) 453 (fw)* No data Norstrom et al. 2002
Beluga 
whale 
































290–634 160 No data No data No data de Wit 2002 
Grey seal Baltic Sea 650 40 38 730 No data de Wit 2002; 
Sellström et al. 1993
Grey seal  Baltic Sea 308 54 57 419 No data Haglund et al. 1997 
Grey seal Baltic Sea No data No data No data 208 No data Andersson and 
Wartanian 1992 
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No data No data 440–7,670 No data Law et al. 2000 
Harbor seal Baltic Sea No data No data No data 90 No data Jansson et al. 1987 
Harbor seal Skagerrak, 
Norway and 
Sweden 
No data No data No data 230 No data Andersson and 
Wartanian 1992 
Harbor seal North Sea 390–
4,900 





160–600 87–280 843–3,160* No data Lindström et al. 1999
Long-finned 
pilot whale 
Faeroe Islands 66–860 24–170 12–98 126–1,250* No data van Bavel et al. 1999
Minke whale Netherlands 630 160 79 870 No data de Boer et al. 1998 
Ringed seal Baltic sea 256 33 61 350 No data Haglund et al. 1997 
Ringed seal Baltic sea No data No data No data 320 No data Andersson and 
Wartanian 1992 
Ringed seal Svalbard, 
Sweden 
47 1.7 2.3 51 No data de Wit 2002;  
Sellström et al. 1993
Ringed seal Canadian Arctic No data No data No data 25.8–50* No data Alaee et al. 1999 
Ringed seal Holman Island, 
Northwest Ter-
ritories, Canada 
2.8 No data No data 2.4–4.9* No data Ikonomou et al. 2000
Sperm whale Netherlands 130–250 32–64 21–35 187–349 No data de Boer et al. 1998 
Whitebeaked 
dolphin 
Netherlands 5,500 1,000 1,200 7,700 No data de Boer et al. 1998 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Sources: de Wit 2002; Norstrom et al. 2002; She et al. 2002 
 
fw = fresh weight 
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blubber sampled between 1981 and 1988 contained 419 and 350 ng PBDEs/g lipid (total of BDE 47, 
BDE 99, and BDE 100), respectively (Haglund et al. 1997).  In 1981, female ringed seals from Svalbard 
in the Swedish Arctic contained 40–51 ng PBDEs/g lipid in blubber (Jansson et al. 1987, 1993; Sellström 
et al. 1993).  Higher levels of PBDEs are generally evident in Baltic Sea ringed seals (320–350 ng/g lipid) 
(Andersson and Wartanian 1992; Haglund et al. 1997) compared to Arctic ringed seals (26–51 ng/g lipid) 
(Alaee et al. 1999; Jansson et al. 1987).  The level of PBDEs in harbor seals from Skagerrak on the 
Swedish west coast was 230 ng PBDE/g lipid (Andersson and Wartanian 1992).  She et al. (2000) 
analyzed the concentration of BDE 47, BDE 99, and BDE 153 in harbor seal from the San Francisco Bay 
area (She et al. 2000).  Mean concentrations for BDE 47, BDE 99, and BDE 153 were 1,124, 107, and 
50 ng/g lipid weight, respectively.  Alaee et al. (1999) found that ringed seal from the Canadian Arctic 
had mean PBDE concentrations (sum of di- to hexaBDEs) of 25.8 ng/g lipid weight (females) and 
50.0 ng/g lipid weight (males).  The lower levels in female seals suggest that PBDEs are transferred to 
young through breast milk.  On Holman Island, Northwest Territory, Canada (Arctic) in 1996, ringed seal 
had total PBDE concentrations of 2.4–4.9 ng/g lipid for males.  The levels of PBDEs were found to 
increase with age (Ikonomou et al. 2000).  In a temporal trend study, archived samples of blubber from 
ringed seals from Holman Island, Northwest Territory, Canada were analyzed for PBDE levels.  The 
concentration of PBDE in samples collected between 1981 and 1996 increased from approximately 
0.3 ng/g lipid weight in 1981 to 3.6 ng/g lipid weight in 1996 (Ikonomou et al. 2000).   
 
The levels of PBDEs have recently been determined in harbor porpoises (Phocaena phocaena) from 
British Columbia, Canada (Ikonomou et al. 2000) and from the coasts of England and Wales (Law et al. 
2000).  In British Colombia (Canada) samples, the total PBDE levels (sum of tri- to hepta-congeners) 
were 350–2,300 ng/g lipid weight; 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47) was found at the highest 
levels in these samples (range, 50–1,200 ng/g lipid weight) (Ikononmou et al. 2000).  Concentrations of 
total PBDEs (sum of 13 congeners) along the coast of England and Wales, ranged from 450 to 7,670 ng/g 
lipid weight, with BDE 47 levels ranging from 227 to 6,790 ng/g lipid weight (Law et al. 2000). 
 
During a mass mortality event on the south Atlantic coast in 1987–1988, blubber samples were collected 
from three bottlenose dolphins (Tursiops truncatus); these samples contained 180–220 ng PBDEs/g lipid 
(Kuehl et al. 1991).  Blubber samples, taken from stranded bottlenose dolphins from several locations 
around the Gulf of Mexico in 1990, contained 3,110 ng PBDEs/g lipid (Kuehl and Haebler 1995).  On the 
Dutch coast in early 1998, de Boer et al. (1998) found PBDEs in blubber of one whitebeaked dolphin 
(Lagenorhynchus albirostris); the levels of 2,2’4,4’-tetraBDE (BDE 47), 2,2’,4,4’,5-pentaBDE (BDE 99), 
and 2,2’,4,4’,6-pentaBDE (BDE 100) were 5,500, 1,000, and 1,200 ng/g lipid weight, respectively.  
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The concentration of 19 PBDEs was determined in long-finned pilot whale (Globicephala melas) from 
the Faeroe Islands in the north Atlantic (Lindström et al. 1999).  Young males and females had the highest 
levels, ranging from 3,000 to 3,160 ng/g lipid; lower levels were observed for both adult females (840–
1,050 ng/g lipid) and males (1,610 ng/g lipid).  The predominant isomers in all samples were BDE 47 and 
2,2’,4,4’,5-pentaBDE (BDE 99), accounting for 70% of the sum of 19 congeners.  van Bavel et al. (1999) 
also studied the levels of PBDEs in long-finned pilot whales.  They observed a similar trend with young 
animals having higher PBDE concentrations (740 ng/g lipid weight) and adult animals having lower 
levels (females, 230 ng/g lipid; males, 540 ng/g lipid).  In Beluga whales sampled in 1997 from southeast 
Baffin (Cumberland Sound), the levels of total PBDEs and BDE 47 were 15 and 10 ng/g lipid weight, 
respectively (Stern and Ikonomou 2000).  Between 1982 and 1997, total PBDE concentrations in archived 
blubber samples of beluga whales from southeast Baffin Canada increased significantly.  For this time 
period, BDE 47, BDE 99, 2,2’,4,4’,6-pentaBDE (BDE 100), and 2,2’,4,4’,5,6’-hexaBDE (BDE 154), and 
total PBDEs increased by factors of 6.5, 10.3, 7.9, 30.6, and 6.8, respectively (Stern and Ikonomou 2000).  
Three sperm whales (Pyseter macrocephalus) and one minke whale (Balaenaoptera acutorostrata) found 
stranded on the Dutch coast in early 1998 were analyzed for PBDEs (de Boer et al. 1998a, 1998b).  
Exposure to PBDEs for these animals occurred in the deep Atlantic through the food web.  The 
concentrations of PPBEs in these marine mammals were as follows: sperm whale (BDE 47, 130–250 ng/g 
lipid weight; BDE 99, 32–64 ng/g lipid weight; and BDE 100, 21–35 ng/g lipid weight) and minke whale 
(BDE 47, 630 ng/g lipid weight; BDE 99, 160 ng/g lipid weight; BDE 100, 79 ng/g lipid weight); 
BDE 209 (decaBDE) was below detection limits in all samples.  
 
Marine Birds.  Increasing levels of PBDEs have been found in marine birds and eggs, with 2,2’4,4’-tetra-
BDE (BDE 47) found at the highest levels.  Di- and triBDE have been detected, but not quantified, in 
black skimmer (Rynchops nigra) tissues and eggs in the United States (Stafford 1983).  In 2000, herring 
gull eggs collected from 15 locations around the Great Lakes (United States and Canada) were pooled and 
analyzed for PBDEs (Norstrom et al. 2002).  A total of 25 di- to hepta-BDE congeners were identified in 
herring gull throught the Great Lakes system.  No mono-, octa-, nona-, or decaBDEs were found at the 
detection limit of the analysis (0.01–0.05 ng/g wet weight).  Seven congeners, 2,4,4’-triBDE (BDE 28), 
BDE 47, 2,2’,4,4’,5-pentaBDE (BDE 99), 2,2’,4,4’,6-pentaBDE (BDE 100), 2,2’,4,4’,5,5’-hexaBDE 
(BDE 153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), and 2,2’,3,4,4’,6,6’-heptaBDE (BDE 184) constituted 
97.5% of total PBDEs (192–1,400 ng/g wet weight).  BDE 47 was the dominant congener (70–602 ng/g 
wet weight) followed by BDE 99 (52–459 ng/g wet weight).  The highest concentrations (1,003–
1,400 ng/g wet weight) were found in two Lake Michigan colonies and in Toronto Harbor, Lake Ontario 
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(Norstrom et al. 2002).  Muscle tissues from ospreys (Pandion haliaetus), found dead at various locations 
around Sweden, were pooled and analyzed for PBDEs (Jansson et al. 1993; Sellström et al. 1993).  The 
ospreys’ diet was freshwater fish.  The combined concentration of BDE 47, BDE 99, and BDE 100 was 
2,100 ng/g lipid in samples collected between 1982 and 1986; BDE 47 was the primary congener (86%) 
in these samples (n=35).  High concentrations of PBDEs may reflect biomagnification and/or fish 
consumption along their migratory routes.  The concentrations of PBDEs in common guillemots (Uria 
aalge) collected in 1979–1981 from the Baltic and North Seas were 370 and 80 ng/g lipid, respectively 
(Jansson et al. 1987).  As part of the Swedish National Environmental Monitoring Program, guillemot 
eggs (St. Karlsö, Baltic Sea) are collected yearly and placed in the Swedish Natural History Museum’s 
Environmental Specimens Bank.  The concentrations of BDE 47, BDE 99, and BDE 100 in pooled egg 
samples from the specimen bank showed a significant increase from 1969 to the beginning of the 1990s, 
with highs of 1,100 ng/g for BDE 47 in 1984 and 190 ng/g for BDE 99 in 1990 (Sellström 1999; 
Sellström et al. 1993).  Between 1992 and 1997, PBDE levels started to decrease statistically.  In 1997, 
the PBDE level (sum of BDE 47, BDE 99, and BDE 100) was 190 ng/g lipid, with BDE 47 as the 
predominant congener.  
 
Human Body Tissues and Fluids.  The quantitative determination of the concentrations of PBDEs in 
body tissues and fluids is important in determining the human body burden of these chemicals.  
Increasing levels of lower brominated PBDEs have been measured in blood and breast milk in temporal 
trend studies.  Individuals who consumed fish had a somewhat higher concentration of total PBDEs in 
body fluids compared to individuals who ate less fish.  
 
Tables 8-11, 8-12, and 8-13 summarize the concentrations of PBDEs found in blood (serum), adipose 
tissue, breast milk, and other body tissues or fluids, respectively.  Levels of PBDEs in body tissues and 
fluids from individuals living in the United States have recently been determined.  These studies indicate 
that levels of lower brominated BDEs in body fluids are a factor of 10–100-fold higher for individuals 
living in the United States compared to individuals living in other regions of the world (e.g., Europe).  
Serum samples collected from 12 U.S. blood donors in 1988 were analyzed for PBDEs, and BDE 47, 
BDE 153, BDE 183, and BDE 209 were detected (Patterson et al. 2000; Sjödin et al. 2001).  
Concentrations of these congeners were similar to those found in the Sjödin et al. (1999b) study for the 
control group.  The median concentrations and ranges of BDE 47, BDE 153, BDE 183, BDE 209, and 
total PBDEs (sum of four congeners) were 0.63 (<0.4–24); 0.35 (0.08–2.0); 0.17 (0.09–1.3); <1 (<1–34); 
and 2.2 ng/g lipid weight, respectively (Sjödin et al. 2001).  DecaBDE was found at levels above the limit 
of quantification (1 pmol/g lipid) in 5 of 12 serum samples (Patterson et al. 2000).  Serum samples were 
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16.5 No data No data No data No data Petreas et al. 2003
Human 
blood 






























No data Mazdai et al. 2003 
Human 
blood 



















No data No data 3.3–4.1* <0.7 
(median) 





2.1 No data No data No data No data Bergman et al. 




Sweden, no fish 
intake 
0.40 No data No data No data No data Bergman et al. 














No data Meironyte 







0.07 0.07 0.46–4.28 No data Meironyte 




Germany 3.9 No data No data 5.6* No data Schröter-Kermani 
et al. 2000 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Source: de Wit 2002; Sjödin et al. 2001 
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Table 8-12.  Concentrations (ng/g Lipid Weight) of Several PBDEs in Human 
Adipose Tissue Samples 
 
Sample 




















United States No data No data No data No data ND–0.7 Cramer et al. 1990; 












Sweden 2.2 1.6 0.1 5* No data Meironyté Guvenius 

















Japan 459 118 250 1,288 No data Choi et al. 2003 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  
 
Source: de Wit 2002; Petreas et al. 2003 
 
ND = not detected 
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Table 8-13.  Concentrations (ng/g Lipid Weight) of Several PBDEs in Human 
Breast Milk Samples 
 
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference 
Human 
breast milk 










2.35 0.62 0.38 4.01 No data  
Human 
breast milk 


















































Japan 0.18–0.57 0.09–0.13 0.07–0.18 0.65–1.48* No data Ohta et al. 2000 
 
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*). 
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collected from a group of 50 Laotian immigrants (aged 19–40) participating in a reproductive outcome 
study in the San Francisco Bay area (Petreas et al. 2002).  Participants were recruited and sampled in the 
late 1990s.  The mean level of BDE 47 in serum was approximately 95 ng/g lipid.  The contemporary 
samples were compared to serum samples taken from a group of over 400 women from the San Francisco 
Bay in the 1960s.  Levels of BDE 47 in all archived samples were below the limit of detection.  Recently, 
Petreas et al. (2003) expanded their investigation to include a diverse group of local women from the San 
Francisco Bay area sampled in the late 1990s.  Their results confirmed earlier findings reported in Petreas 
et al. (2002).  Mean concentrations of BDE 47 in serum samples taken from California women ranged 
from 5 to 510 ng/g lipid, with a median (16.5 ng/g lipid) 3–10 times higher than those reported from 
Europe (Petreas et al. 2003).  In 2001, Mazdai et al. (2003) determined the concentration of six PBDE 
congeners (BDE 47, 2,2’,4,4’,5-pentaBDE [BDE 99], 2,2’,4,4’,6-pentaBDE [BDE 100], BDE 153, 
2,2’,4,4’,5,6’-hexaBDE [BDE 154], and BDE 183) and total PBDEs in maternal and fetal blood samples 
taken from subjects in Indianapolis, Indiana.  Median levels of total PBDE (sum of six congeners) were 
39 and 37 ng/g lipid for fetal and maternal serum, respectively.  BDE 47 was the predominant congener 
reported at median concentrations of 25 and 28 ng/g lipid for fetal and maternal serum samples, 
respectively.  When compared with serum PBDE levels for a similar population of Swedish mothers and 
newborns, the levels for the Indiana population were 20- to 69-fold higher for maternal blood and 30- to 
106-fold higher for fetal blood.  In fact, the median blood levels for this study were comparable to 
Swedish workers considered to have direct work-related exposures.  These observations indicated that 
women in some areas of North America are exposed to much higher levels of lower brominated BDEs 
(i.e., BDE 47) than are European women.  In general, the PBDE congener profile found in human serum 
was similar to that detected in environmental samples, except that there was an apparent decrease in the 
proportion of BDE 99.  BDE 183 was detected in <17% of the samples even though it is the primary 
congener in octaBDE commercial mixtures (Mazdai et al. 2003).   
 
Six PBDE congeners (2,4,4’-triBDE [BDE 28], 2,2’,4,4’-tetraBDE [BDE 47], 2,3’,4,4’-tetraBDE 
[BDE 66], 2,2’,4,4’,5-pentaBDE [BDE 99], 2,2’,4,4’,6-pentaBDE [BDE 100], and 2,2’,4,4’,5,5’-hexa-
BDE [BDE 153]) were quantified in 40 human blood-plasma samples from Sweden.  The highest 
concentrations in plasma were for BDE 47 and BDE 99; these congeners made up 70% of the total PBDE 
concentration.  The mean concentration of total PBDEs were 2.1±1.4 ng/g lipid weight (Klasson Wehler 
et al. 1997).  Whole-blood samples from a German environmental specimen bank, collected in 1985, 
1990, 1995, and 1999, contained measurable quantities of BDE 28, BDE 47, BDE 66, 2,2’,3,4,4’-hexa-
BDE (BDE 85), BDE 99, BDE 100, BDE 153, and 2,2’,4,4’,5,6’-hexaBDE (BDE 154).  An increasing 
temporal trend was also observed; the mean total PBDE concentration (sum of eight congeners) increased 
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from 3.9 ng/g lipid weight in 1985 to 5.6 ng/g lipid weight in 1999.  For the 1999 sample, BDE 47 was 
the major congener found, with a mean concentration of 3.9 ng/g lipid weight.  The total PBDE 
concentrations were significantly lower in female blood samples (Schröter-Kermani et al. 2000).  In a 
study of the influence of diet on concentrations of PBDEs, BDE 47 was measured in blood serum from 
persons with high fish intake and no fish intake (Bergman et al. 1999; Sjödin et al. 2000).  High fish 
intake groups of Swedish and Latvian men had median BDE 47 concentrations of 2.2 and 2.4 ng/g lipid 
weight, respectively, whereas the no fish-intake groups had median concentrations of 0.4 and 0.26 ng/g 
lipid weight, respectively (Sjödin et al. 2000).  
 
2,2’,4,4’-TetraBDE (BDE 47), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), 
2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), and decaBDE (BDE 209) were measurable in blood plasma from 
three groups of workers (i.e., workers at a computer-disassembly plant, workers in a computerized office, 
and a control group) (Sjödin et al. 1999b).  The median concentrations (sum of five congeners) were 
highest for the computer-disassembly plant workers (26 ng/g lipid weight); the office workers had a 
median concentration of 4.1 ng/g lipid weight and the control group had a median concentration of 
3.3 ng/g lipid weight.  The congener patterns for the control group and office workers were similar, with 
BDE 47 having the highest levels.  For the computer disassembly plant workers, the median 
concentrations of BDE 183, BDE 153, BDE 154, BDE 47, and BDE 209 were 7.8, 4.5, 1.2, 2.9, and 
4.8 ng/g lipid weight, respectively.  Blood serum samples from 19 full-time computer technicians were 
analyzed (Hagmar et al. 2000).  The serum concentrations of BDE 153, BDE 183, and BDE 209 in these 
samples were found to be approximately 5 times higher than the control and office workers in the Sjödin 
et al. (1999b) study.  The median concentration for total PBDEs (for the sum of five congeners) was 
10.6 pmol/g (7.0 ng/g) lipid weight.  The highest concentrations were of BDE 153.  Two octaBDE 
congeners and one nonaBDE congener were also detected.  Connections were observed between fish 
consumption and serum concentrations for congeners BDE 47, BDE 153, and BDE 183, and between 
worktime at the computer and congeners BDE 153 and BDE 183.   
 
DecaBDE, as well as hexa- through nonaBDE, has been found in composite samples from the 1987 
National Human Adipose Tissue Survey repository (Cramer at al 1990; Stanley et al. 1991).  The 
concentrations ranged from not detected to 1 ng/g fat for hexaBDE, 0.001–2 ng/g fat for heptaBDE and 
not detected to 8 ng/g fat for octaBDE.  NonaBDE concentrations were estimated to be >1 ng/g fat; 
decaBDE was estimated to range between not detected and 0.7 ng/g fat.  In the late 1990s, breast adipose 
samples collected in northern California contained quantifiable amounts of 2,2’,4,4’-tetraBDE (BDE 47), 
2,2’,4,4’,5-pentaBDE (BDE 99), and 2,2’,4,4’,5,5’-hexaBDE (BDE 153) (She et al. 2000).  Mean 
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concentrations were 18 ng/g lipid weight for BDE 47, 4.9 ng/g lipid weight for BDE 99, and 2.2 ng/g 
lipid weight for BDE 153.  Average total PBDEs levels (86 ng/g lipid) were the highest human levels 
reported to date.  Recently, Petreas et al. (2003) expanded their investigation to include a diverse group of 
local women from the San Francisco Bay area sampled in the late 1990s.  Their results confirmed earlier 
findings reported in She et al. (2000).  Mean concentrations of BDE 47 in adipose tissues samples taken 
from California women were 28.9 ng/g lipid.  In the adipose tissue of a 74-year-old Swedish male, the 
BDE 47 concentration was 8.8 ng/g lipid weight (Haglund et al. 1997).   
 
Adipose and liver tissue from two Swedish males were examined for several PBDEs (2,4,4’-triBDE 
[BDE 28], 2,2’,4,4’-tetraBDE [BDE 47], 2,2’,3,4,4’-pentaBDE [BDE 85], 2,2’,4,4’,5-pentaBDE 
[BDE 99], 2,2’,4,4’,6-pentaBDE [BDE 100], 2,2’,4,4’,5,5’-hexaBDE [BDE 153], and 2,2’,4,4’,5,6’-hexa-
BDE [BDE 154]) (Meironyté Guvenius and Norén 1999).  The distribution of congener concentrations in 
the adipose and liver tissues for each individual were similar.  BDE 47, BDE 99, and BDE 153 were the 
predominant congeners with adipose BDE 47 concentrations ranging from 2 to 2.4 ng/g lipid weight, 
BDE 99 concentrations of 1.6 ng/g lipid weight, BDE 100 concentrations of 0.1 ng/g lipid weight, and 
BDE 153 concentrations ranging from 1 to 1.3 ng/g lipid weight.  The total PBDE concentration (i.e., the 
sum of the seven congeners) in adipose tissue was 5 ng/g lipid weight.  Human liver and adipose tissues 
from one woman and four men autopsied in Sweden in 1994 were analyzed for PBDEs containing 3–
6 bromine atoms (Meironyté Guvenius and Norén 2001).  PBDEs were found in all of the tissue samples.  
The sums of nine congeners (BDE 17, BDE 28, BDE 47, BDE 66, BDE 100, BDE 99, BDE 85, 
BDE 154, and BDE 153) were 5–18 and 4–8 ng/g lipids in liver and adipose tissue, respectively.  The 
PBDE congeners BDE 47, BDE 99, and BDE 153 occurred at the highest levels and constituted 87–
96 and 84–94% of the total sum in liver and adipose tissue, respectively.  Strandman et al. (1999) 
measured the concentration of BDE 47, BDE 99, and BDE 153 in adipose tissue samples from 
10 randomly selected individuals in Finland.  Mean concentrations were 7.3 ng/g fat for BDE 47, 2.2 ng/g 
fat for BDE 99, and 2.3 ng/g fat for BDE 153.  Levels of PBDEs were measured in adipose tissue samples 
from 13 individuals (3 women, 10 men) from Tarragona, Spain; the mean concentrations of BDE 47, 
BDE 99, and BDE 153 were 1.36, 0.42, and 1.83 ng/g lipid weight, respectively.  The mean 
concentrations of PeBDE and HexaBDE were 0.93 and 1.83 ng/g lipid weight, respectively (Meneses et 
al. 1999).  
 
Human Milk.  Recently, Schecter et al. (2003b) reported the first findings on levels of PBDEs congeners 
in human milk from individuals in the United States.  Forty-seven individual milk samples were analyzed 
from nursing mothers, 20–41 years age, from a milk bank in Austin, Texas, and a community health clinic 
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in Dallas, Texas, both in the year 2001.  The median concentration of the sum of PBDE congeners was 
34.0 ng/g lipid.  The predominant congener was BDE 47 (18.4 ng/g lipid); other congeners detected were 
2,2’,4-triBDE (BDE 17), 2,4,4’-triBDE (BDE 28), 2,3’,4,4’-tetraBDE (BDE 66), 2,2’,3,4,4’-pentaBDE 
(BDE 85), 2,2’,3,4,4’-pentaBDE (BDE 99), 2,2’,4,4’,6-pentaBDE (BDE 100), 2,2’,3,4,4’,5’-hexaBDE 
(BDE 138), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), and 
2,2’,3,4,4’,5’,6-heptaBDE (BDE 183) at median concentrations of 0.01, 1.2, 0.14, 0.41, 5.7, 2.9, 0.09, 2.0, 
0.22, and 0.07 ng/g lipd, respectively.  DecaBDE was detected in 7 out of 47 samples with a maximum 
concentration of 8.24 ng/g lipid.  PBDE levels in breast milk from this study were similar to levels found 
in U.S. blood and adipose tissue lipid from California and Indiana and are 10–100 times greater than 
human tissue levels in Europe (Schecter et al. 2003b).  
 
Norén and Meironyté (1998, 2000) examined the temporal trends of PBDE concentrations in pooled 
breast milk samples from mothers in Stockholm, Sweden.  Between 1972 and 1997, the concentration of 
PBDEs in human breast milk increased, with a doubling rate of 5 years.  In the 1997 sample, the 
concentration of PBDEs (sum of eight congeners) was 4 ng/g lipid, whereas the 1972 sample contained 
0.07 ng/g lipids (Meironyté et al. 1999).  The authors suggest that the current exposure of humans to 
PBDEs may not be only diet; other exposure routes may result from the presence of PBDE in both work 
and home environments.  PBDE levels were studied in breast milk obtained from mothers pregnant for 
the first time (n=39, ages 22–36 years old) from Uppsala County, Sweden (Darnerud et al. 1998).  The 
mean value of total PBDEs (sum of eight congeners) was 4.4 ng/g fat; the major congener was BDE 47, 
contains ca. 55% of the total PBDEs.  Recently, Lind et al. (2003) reported levels of PBDEs in human 
breast milk sampled from Uppsala County, Sweden.  Total PBDEs, 2,2’,4,4’-tetraBDE (BDE 47), 
2,2’,4,4’,5-pentaBDE (BDE 99), and 2,2’,4,4’,6-pentaBDE (BDE 100) levels were 4.01, 2.35, 0.62, and 
0.38 ng/g lipid, respectively.  In human breast milk from 25 German mothers, the levels of PBDEs ranged 
from 0.6 to 11 ng/g lipid (de Wit 2002).  In 1992, the mean concentration of total PBDEs (sum of 
2,4,4-triBDE [BDE 28], -47, -99, -100, 2,2’,4,4’,5,5’-hexaBDE [BDE 153], and 2,2’,3,4,4’,5’,6-hepta-
BDE [BDE 183]) was 5.8 ng/g lipid weight for samples (n=6) from mothers from Ontario and Quebec, 
Canada (Ryan and Patry 2000).  Combined samples from 1992 representing four regions of Canada and 
one representing all Canadian provinces had total PBDE concentrations ranging from 2.6 to 19 ng/g lipid 
weight; the highest concentrations were observed in the New Brunswick, Nova Scotia, and Prince Edward 
Island.  Breast milk samples from Finland, collected between 1994 and 1998, had concentrations of total 
PBDEs (sum of BDE 28, BDE 47, BDE 99, and BDE 153) ranging from 0.88 to 5.9 ng/g lipid weight 
(Strandman et al. 2000).  In Japan, breast milk samples had total PBDE concentrations (sum of BDE 28, 
BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154) ranging from 0.66 to 2.8 ng/g lipid weight (Ohta et 
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al. 2002a).  Women who consumed fish had a somewhat higher concentration of total PBDEs (range, 1.4–
2.8 ng/g lipid weight) compared to women who ate less fish (range, 0.67–0.87 ng/g lipid weight).  
BDE 47 was the major congener in most of the samples; BDE 153 levels were analogous to BDE 47 
levels in some samples (Ohta et al. 2002a).  
 
Hydroxy- and Methoxy- Derivatives in Biota.  Hydroxy- and methoxy- derivatives of PBDEs have been 
identified in biota.  However, their orgin in the environment has not yet been explained.  Anthropogenic 
sources of these compounds have not been found.  Tetra- and pentabrominated methoxy (MeO) BDEs 
were found in herring, salmon, grey seal, ringed seal, and white-tailed sea eagle from the Baltic region 
(Asplund et al. 1999a; Haglund et al. 1997; Olsson et al. 2000) as well as beluga whale from Svalbard and 
pilot whale from the Faroe Islands (van Bavel et al. 2001).  The concentrations of hydroxy- and methoxy- 
derivatives were of the same order of magnitude as PBDEs present in the samples.  Biogenic production 
via metabolism of PBDEs or natural production via biobromination have been suggested as the origin for 
these compounds.  Naturally produced methoxy-tetrabrominated diphenyl ethers have been reported in 
tropical marine sponges (sp. Dysidea) as well as in green algae (sp. Cladophora) collected in Japan 
(Kierkegaard et al. 2004).  Kierkegaard et al. (2004) found that the concentrations of 6-methoxy-
2,2’,4,4’-tetrabromodiphenyl etherin herring from five locations along the Swedish coast increased from 
south to north in the Baltic Sea.  No correlation between the concentrations of BDE congeners and 
methoxy-brominated diphenyl ethers was observed, indicating sources other than PBDEs for these 
compounds.  
 
8.5   GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
 
Polybrominated Biphenyls.  PBBs are no longer produced or used in the United States.  Thus, the general 
population exposure to PBBs will only be from historical releases.  For people residing in the lower 
peninsula of Michigan, especially in the immediate vicinity of the PBB contaminated areas of this region, 
exposure to PBBs may still be occurring today.  However, environmental levels have decreased since the 
1970s and current exposure, if any, will be at low levels.  For other regions of the United States, the levels 
of exposure will either be very low or none.   
 
In the past, the general population may have been exposed to PBBs by inhaling contaminated air, 
ingesting contaminated water and food, and using consumer products containing PBBs.  Other than in air 
in the vicinity of PBB production plants (see Section 8.1), no current or historical data exist that would 
indicate that PBBs might be present in ambient air.  There are no current or historical data on the direct 
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exposure of humans to PBBs from water.  The general population may have been exposed to low levels of 
PBBs from the consumption of contaminated foods, but no estimate is available that quantitated this 
exposure.  Historical monitoring and body burden data indicate that low level exposures to PBBs were 
limited to the population within the state of Michigan (see Section 8.4 and Table 8-5).  The level of 
exposure to PBBs was slightly higher for the people residing in the lower peninsula of Michigan and 
highest among people residing in the immediate vicinity of the contaminated dairy farms, where people 
consumed contaminated meat, eggs, and dairy products (see Section 8.4 and Table 8-5).  Consumer 
exposure in the past (plastics containing PBBs may not be in circulation anymore since PBB production 
ceased in the 1970s) from using PBB-containing plastics (e.g., typewriters, calculators, projector 
housings, and movie equipment cases) is expected to be very low since the PBBs were incorporated into 
the plastic and their mobilization could only have occurred under conditions such as combustion (Di 
Carlo et al. 1978). 
 
Workers involved in the historical production of PBBs, PBB-containing plastics, and PBB-containing 
plastic products could have been exposed to PBBs via inhalation of dust and vapor and/or dermal contact.  
Both workplace environmental monitoring and body burden monitoring data of workers (see Table 8-5) 
(Hesse and Powers 1978; Humphrey and Hayner 1975; Wolff et al. 1979b) indicated that workers in PBB 
industries were exposed to higher concentrations of PBBs than the general population.  Although no 
evidence has been reported, workers in facilities that combusted or incinerated PBB-containing plastics 
might have been exposed to higher levels of PBBs. 
 
Polybrominated Diphenyl Ethers.  Body burden data indicate that there are low-level exposures to 
PBDEs for the general population.  However, the current understanding of exactly how low levels of 
certain PBDE isomers/congeners (e.g., 2,2’,4,4’-tetraBDE [BDE 47]; 2,2’,4,4’,5-pentaBDE [BDE 99]; 
2,2’,4,4’,6-pentaBDE [BDE 100]) came to be present in human tissues is insufficient to reach definitive 
conclusions.  Humans appear to be exposed to lower brominated BDEs by ingestion of contaminated 
foods (e.g., fish) and possibly inhalation of ambient or contaminated air.  Dermal exposure to PBDEs 
could occur by contact with products containing PBDEs such as textiles or polymers.  Inhalation exposure 
could occur from outgassing of PBDEs from electrical appliances and furniture into indoor atmospheres.  
However, little information is known about the potential exposure from these routes.    
 
In the United States, exposure is evident by the levels of lower brominated PBDEs found in tissues from 
individuals (see Section 8.4.4).  For example, breast adipose samples collected in northern California in 
the late 1990s contained quantifiable amounts of 2,2’,4,4’-tetraBDE (BDE 47), 2,2’,4,4’,5-pentaBDE 
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(BDE 99), and 2,2’,4,4’,5,5’-hexaBDE (BDE 153) (She et al. 2000).  Mean concentrations were 18 ng/g 
lipid weight for BDE 47, 4.9 ng/g lipid weight for BDE 99, and 2.2 ng/g lipid weight for BDE 153.  In 
studies of the general populations of other countries, it has also been shown that exposure to lower 
brominated PBDE congeners by the general population is widespread (see Section 8.4.4; Haglund et al. 
1997; Meneses et al. 1999).  In general, levels of decaBDE in human tissues and body fluids are 
negligible which indicates that direct exposure to decaBDE congener appears to be low.  However, the 
level current information is insufficient to draw conclusions on whether decaBDE degrades in the 
environment and if possible degradation products of decaBDE may be important sources of human 
exposure.  
 
The concentration of total PBDEs in outdoor air ranges from 2 (rural) to 77 (urban) pg/m3 in the United 
States (Dodder et al. 2000a).  Typically, lower brominated congeners (e.g., 2,2’,4,4’-tetraBDE [BDE 47]) 
are predominant which indicates low levels of exposure to these congeners by the general population.  
Levels of higher brominated congeners (e.g., decaBDE) tend to be below the limit of quantitation.  In 
Sweden, indoor air concentrations of PBDEs in lecture halls, computerized indoor environments, and 
rooms with electronic devices (e.g., televisions) have low levels of PBDEs (Lindström 1999).  Point 
sources may result in increased concentrations of PBDEs in indoor air.  For example, octaBDE has been 
found in indoor areas that contain electronic products containing PBDEs (e.g., televisions and computers) 
(Bergman et al. 1997).  The release of PBDEs from polymers is dependant on the migration ability of the 
PBDE molecule through the polymer matrix to the polymer surface where emission is possible (Danish 
EPA 1999).  Because PBDEs are large molecules, migration is expected to occur slowly.  No 
experimental studies were located on the emission rate of PBDEs from plastics.  Based on worst case 
emission factors, the estimated emission of deca-, octa-, and pentaBDEs from plastics are 0.038, 0.054, 
and 0.39% per year, respectively (Danish EPA 1999).  
 
Harrad et al. (2004) found a significant possitive correlation between PBDE concentrations in indoor air 
and both the number of electrical appliances and the number of chairs containing polyurethane foam.  
Concentrations of tetra- and pentabrominated concengers (BDE 47, 99, and 100) in indoor air were 
always higher than those detected in outdoor air.  On average, indoor air concentrations were 150, 120, 
and 140 times higher than outdoor air for BDE 47 (1,700 pg/m3), 99 (852 pg/m3), and 100 (217 pg/m3), 
respectively.  In this study, the median lower bound estimates of inhalation exposure (i.e., where a 
congener is below the detection limit, the concentration is assumed to be zero) for BDE 47 
(2,2’,4,4’-tetraBDE), 99 (2,2’,4,4’,5-pentaBDE), 100 (2,2’,4,4’,6-pentaBDE), 153 (2,2’,4,4’,5,5’-hexa-
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BDE), 154 (2,2’,4,4’,5,6’-hexaBDE), and total PBDEs were 4.5, 1.2, 0.41, 0.016, 0.040, and 6.9 ng/day, 
respectively (Harrad et al. 2004). 
 
Consumption of food is expected to be the major route of exposure in humans (Lindström 1999).  
Consumption of fish has been associated with elevated levels of PBDEs in tissues from the Swedish 
population (Bergman et al. 1999).  In Sweden, fish consumption is about 30 g/day; this translates to an 
estimated 0.1 µg of pentaBDE and 0.3 µg of total PBDEs from fish that is ingested by humans daily 
(WHO 1994a).  The fish of greatest concern to humans are bottom feeders like carp and catfish.  Harrad 
et al. (2004) estimated the daily dietary intakes of PBDEs in omnivorous and vegetarian diet samples 
from the United Kingdom.  In this study, the median lower bound estimates of dietary exposure (i.e., 
where a congener is below the detection limit, the concentration is assumed to be zero) for BDE 47 
(2,2’,4,4’-tetraBDE), 99 (2,2’,4,4’,5-pentaBDE), 100 (2,2’,4,4’,6-pentaBDE), 153 (2,2’,4,4’,5,5’-hexa-
BDE), 154 (2,2’,4,4’,5,6’-hexaBDE), and total PBDEs were 46.4, 42.6, 0, 0, 0, and 90.5 ng/day, 
respectively (Harrad et al. 2004).  Like PCBs, there may be a higher risk of exposure to PBDEs in Native 
Americans who reside in the Arctic region and consume whale and seal blubber (Jaret 2000). 
 
Workers involved in the production and manufacture of PBDE-containing plastics and plastic products 
are exposed to PBDEs.  Body burden data indicate higher levels for workers exposed to PBDEs than for 
the general population.  Occupational exposure to PBDEs also occurs in workers at plants that dismantle 
electronic equipment, computer monitor repair technicians, and automobile drivers, as well as other 
professions (Lindström 1999).  Occupational exposure occurs primarily by inhalation.  Inhalation of 
vapor phase PBDEs is expected to be low due to the low vapor pressures of PBDEs (see Table 6-6); 
however, the inhalation of particulate phase PBDEs is possible during plastic reprocessing where grinding 
or shredding of polymers with PBDEs occurs.  Occupational exposure may also likely involve oral 
exposure to particulate PBDEs as a result of hand-to-mouth activity. 
 
Air samples were taken from an electronics dismantling plant, an office with computers, and outdoors and 
then analyzed for PBDEs (Sjödin et al. 1999a, 2001a).  The electronics dismantling plant had the highest 
concentrations of PBDEs, with mean concentrations of 2.5 pmol/m3 (1.25 ng/m3) for 2,2’,4,4’-tetraBDE 
(BDE 47), 4.6 pmol/m3 (2.6 ng/m3) for 2,2’,4,4’,5-pentaBDE (BDE 99), 6.1 pmol/m3 (3.93 ng/m3) for 
2,2’,4,4’,5,5’-hexaBDE (BDE 153), 26 pmol/m3 (18.8 ng/m3) for 2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), 
and 38 pmol/m3 (36.5 ng/m3) for decaBDE (BDE 209) (Sjödin et al. 1999a, 2001a).  Air samples were 
found to be 4–10 times higher in PBDE concentrations near a plastic shredder when compared to other 
locations in the plant (range, 0.42–200 ng/m3).  Concentrations of PBDEs in the office (range, <0.002–
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0.09 ng/m3) were 400–4,000 times lower than in the plant, and PBDEs were not detected in outside air 
(Sjödin et al. 1999a, 2001a).  
 
2,2’4,4’-TetraBDE (BDE 47), 2,2’,4,4’,5,5’-hexaBDE (BDE 153), 2,2’,4,4’,5,6’-hexaBDE (BDE 154), 
2,2’,3,4,4’,5’,6-heptaBDE (BDE 183), and decaBDE (BDE 209) were measurable in blood plasma from 
three groups of workers (i.e., workers at a computer disassembly plant, workers in a computerized office, 
and a control group) (Sjödin et al. 1999b).  The median concentrations (sum of five congeners) were 
highest for the computer disassembly plant workers (26 ng/g lipid weight); the office workers had a 
median concentration of 4.1 ng/g lipid weight and the control group had a median concentration of 
3.3 ng/g lipid weight.  The congener patterns for the control group and office workers were similar, with 
BDE 47 having the highest levels.  For the computer disassembly plant workers, the median 
concentrations of BDE 183, BDE 153, BDE 154, BDE 47, and BDE 209 were 7.8, 4.5, 1.2, 2.9, and 
4.8 ng/g lipid weight, respectively.  Blood serum samples from 19 full-time computer technicians were 
analyzed (Hagmar et al. 2000).  The serum concentrations of BDE 153, BDE 183, and BDE 209 in these 
samples were found to be approximately 5 times higher than the control and office workers in the Sjödin 
et al. (1999b) study.  The median concentration for total PBDEs (for the sum of five congeners) was 
10.6 pmol/g (7.0 ng/g) lipid weight.  The highest concentrations were for BDE 153.  Two octaBDE 
congeners and one nonaBDE congener were also detected.  
 
8.6   EXPOSURES OF CHILDREN  
 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 5.7 Children’s Susceptibility. 
 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
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Polybrominated Biphenyls.  Infants who consume breast milk may have had a higher exposure to PBBs 
than children who drink formula milk, especially children exposed during the Michigan episode (see 
Section 8.4.4).  No additional information was found in the literature about the exposure of children to 
PBBs (WHO 1994b). 
 
Polybrominated Diphenyl Ethers.  Infants who consume breast milk may have a higher exposure to 
lower brominated BDEs than children who drink formula milk (see Section 8.4.4).  Exposure of neonates 
is evident due to the presence of lower brominated BDEs (e.g., 2,2’,4,4’-tetraBDE [BDE 47]) in breast 
milk and placental tissue.  The PBDEs detected in breast milk are the tri- to hexaBDEs, but not the hepta- 
to decaBDEs (LaKind and Berlin 2000), which are the same congeners found in bioaccumulation studies 
with fish and other mammals.  Schecter et al. (2003b) reported the first findings on levels of PBDEs 
congeners in human milk from individuals in the United States.  The median concentration of the sum of 
PBDE congeners was 34.0 ng/g lipid with BDE 47 (18.4 ng/g lipid) as the predominant congener.  
DecaBDE was detected in 7 out of 47 samples with a maximum concentration of 8.24 ng/g lipid.  The 
levels of PBDEs in breast milk from this study were 10–100 times greater than human tissue levels in 
Europe (Schecter et al. 2003b).  Levels of lower brominated BDEs in the breast milk of Swedish women 
shows an exponentially increasing trend in exposure since the 1970s, with concentrations of lower 
brominated BDEs in breast milk doubling every fifth year (Lindström 1999).  The concentrations of lower 
brominated BDEs in breast milk are increasing exponentially from about 300 pg/g lipid in 1976 to about 
4,000 pg/g lipid in 1997 in Swedish women (Norön and Meironyté 2000).  The sum of four PBDE 
congeners (2,4,4’-triBDE [BDE 28], BDE 47, 2,2’,4,4’,5-pentaBDE [BDE 99], and decaBDE [BDE 209]) 
was between 0.88 and 5.89 ng/g lipid in breast milk and between 1.00 and 4.40 ng/g lipid in placental 
tissue of 11 Finnish women (Strandman et al. 2000).  The four highest concentrations of total PBDEs 
were found in nulliparous women.  In 2001, Mazdai et al. (2003) determined the concentration of six 
PBDE congeners (BDE 47, BDE 99, 2,2’,4,4’,6-pentaBDE [BDE 100], BDE 153, 2,2’,4,4’,5,6’-hexaBDE 
[BDE 154], and 2,2’,3,4,4’,5’,6-heptaBDE [BDE 183]) and total PBDEs in maternal and fetal blood 
samples taken from subjects in the United States.  Median levels of total PBDE (sum of six congeners) 
were 39 and 37 ng/g lipid for fetal and maternal serum, respectively.  BDE 47 was the predominant 
congener reported at median concentrations of 25 and 28 ng/g lipid for fetal and maternal serum samples, 
respectively.  Concentrations of PBDEs in fetal and maternal serum were comparable.  Thus, the authors 
concluded that measurement of maternal serum PBDE levels could be used to determine fetal exposure to 
PBDEs.  Concentrations of PBDEs were determined in children from Norway (Thomsen et al. 2002b).  
Samples were collected between the period of 1975–2002.  Children ages 0–4 years had congener levels 
of BDE 28, BDE 47, BDE 100, BDE 99, 2,2’,4,4’,5,5’-hexaBDE (BDE 153), and BDE 154 at 0.26, 6.2, 
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1.7, 1.6, 1.5, and 0.45 ng/g lipid, respectively; while children 4–14 years old had levels of BDE 28, 
BDE 47, BDE 100, BDE 99, BDE 153, and BDE 154 at 0.20, 2.0, 0.66, 0.37, 0.86, and 0.39 ng/g lipid, 
respectively.  No additional information was found in the literature about the exposure of children to 
PBDEs (WHO 1994a). 
 
8.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
Polybrominated Biphenyls.  The production of PBBs ceased in 1979, and the usable life of the plastics 
containing PBBs has expired.  Therefore, these plastics are probably no longer in circulation.  At the 
present time and in the near future, populations potentially exposed to low levels of PBBs are those living 
near hazardous waste sites in which the PBB-containing plastics have been disposed and the residents in 
and around the contaminated farms in Michigan.  The lifetime of PBBs in soil is on the order of years 
(Jacobs et al. 1978), and the levels of PBBs in fish caught in contaminated waters have declined slowly 
(Hesse and Powers 1978).  Therefore, concentrations of residual PBBs in soil and streams in the vicinity 
of PBB-containing hazardous waste sites, PBB production facilities, and contaminated farm areas are 
expected to remain above background levels for many years.  The sources of potential exposure to PBBs 
for residents in these areas are consumption of contaminated meat and dairy products obtained from herds 
grazing over contaminated soil and consumption of fish from nearby contaminated streams.  PBB 
contamination has triggered the issuance of one human health advisory in the state of Michigan.  As of 
September 30, 1993, recreational and subsistence fishermen who consume appreciably higher amounts of 
fish caught in the Pine River downstream from St. Louis in Gratiot and Midland Counties (RTI 1993) 
may be exposed to above-average levels of PBBs associated with dietary intake (EPA 1993).  The body 
burden for PBBs in residents of contaminated areas has been higher than in the general population 
(Brilliant et al. 1978; Cordle et al. 1978; Eyster et al. 1983; Humphrey and Hayner 1975; Kimbrough 
1987; Lambert et al. 1990; Landrigan et al. 1979; Wolff et al. 1982).  Therefore, babies breast fed by 
exposed mothers in the contaminated areas may also be at higher risk (Jacobson et al. 1989). 
 
Polybrominated Diphenyl Ethers.  Subsistence fishermen who consume PBDE-contaminated fish and 
Native Americans who reside in the Arctic region and consume whale and seal blubber may have a higher 
risk of exposure to lower brominated PBDEs (WHO 1994a).  Other populations with high exposure levels 
to PBDEs involve occupational exposures (see Section 8.6).  No other information was located that 
identified specific populations with higher exposure levels to PBDEs.  
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8.8   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of PBBs and PBDEs are available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of PBBs and PBDEs.  
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
 
8.8.1   Identification of Data Needs  
 
Physical and Chemical Properties.     
 
Polybrominated Biphenyls.  Many of the relevant physical and chemical properties of the PBBs are not 
available (see Table 6-3).  More data on the physical and chemical properties of hexabromobiphenyl are 
available relative to octabromo- and decabromobiphenyl.  Even in the case of hexabromobiphenyl, not all 
relevant data are available, and the quality of data is questionable because the properties of FireMaster 
BP-6 have been reported as the properties of hexabromobiphenyls.  More importantly, very limited data 
are available on the physical and chemical properties for the individual congeners of hexabromo-, octa-
bromo-, and decabromobiphenyl.  The absence of such important data as Koc, vapor pressure, and Henry’s 
law constant, is a major impediment in the prediction of the environmental fate and transport of PBBs. 
 
Polybrominated Diphenyl Ethers.  Many of the relevant physical and chemical properties of the PBDEs 
are available (see Table 6-4).  Very limited data are available on the physical and chemical properties for 
the individual congeners (Braekvelt et al. 2003; Tittlemier et al. 2002).  Important data, such as Koc, vapor 
pressure, and Henry’s law constant, are necessary for the prediction of the environmental fate and 
transport of PBDEs. 
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Production, Import/Export, Use, Release, and Disposal.     
 
Polybrominated Biphenyls.  The production of all PBBs in the United States stopped in 1979 (IARC 
1986).  Data on the past production, import/export, and use of PBBs are available (Neufeld et al. 1977).  
In the past, PBB-containing plastic was used in consumer products, but the useful life of these products 
may have ended (Di Carlo et al. 1978; Neufeld et al. 1977), and these products are probably no longer in 
circulation.  In the workplace, the environmental media contaminated by PBBs were air, water, and soil 
(DeCarlo 1979).  Outside of the workplace, soil is expected to be the medium with significant 
contamination due to disposal of solid waste from production plants and disposal of PBB-containing 
plastics in landfills (Neufeld et al. 1977).  Although it is known that PBB-containing plastics may have 
been disposed in landfills (Di Carlo et al. 1978), the amount that may have been incinerated is not known.  
No data were located from studies that determined the efficiency of incineration as a method of disposal 
of PBBs present in the neat form in industrial wastes or in plastics.  Environmental regulations regarding 
the manufacture and disposal of PBBs have been established (EPA 1988a).  According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit chemical release and off-site transfer information to the EPA.  The Toxics Release Inventory 
(TRI), which contains this information for 1999, became available in 2002.  This database will be updated 
yearly and should provide a list of industrial production facilities and emissions. 
 
Polybrominated Diphenyl Ethers.  Production and use data are available for PBDE commercial mixtures 
(BSEF 2003).  PBDEs are used as additive flame retardants in thermoplastics at levels ranging from 5 to 
30% by weight (EU 2001).  The commercial pentaBDE product is used predominantly (95–98%) for 
flame-retardant purposes as an additive in consumer products manufactured by the furniture industry 
(ENVIRON 2003a).  The commercial octaBDE is used by the plastics industry as an additive flame 
retardant for manufactured products.  It is used almost exclusively as a flame retardant for acrylonitrile-
butadiene-styrene (ABS) terpolymers used in computer casings and monitors (ENVIRON 2003b).  The 
commercial decaBDE product is an additive flame retardant used in a variety of polymer applications.  
Industry information indicates that decaBDE is used at loadings of 10–15% weight in polymers and is 
always used in conjunction with antimony trioxide (EU 2002).  The Great Lakes Chemical Corporation 
recently announced that it is voluntarily phasing out production of pentaDBEs and octaDBEs by the end 
of 2004 (Tullo 2003).  In the United States, waste disposal of PBDE-containing consumer products is 
described as transfers to disposal (landfill), recycling, energy recovery (incineration), or publicly owned 
treatment works (POTWs) (Darnerud et al. 2001).  More information for PBDEs is needed on 
import/export, release, and disposal.  In particular, the mechanism by which PBDEs are leaving the 
products in which they are used and entering the environment is not understood.  Possibilities include 
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disinigradtion of plastic products in particulates contaminated with PBDEs or volatilization of PBDEs 
from the plastic itself (Hites 2004).  In the United States, waste disposal of PBDE-containing consumer 
products is described as transfers to disposal (landfills), recycling, energy recovery (incineration), or 
POTWs (Darnerud et al. 2001).  Soil should be a medium of significant contamination due to disposal of 
PBDE-containing plastics in landfills.  The commercial decaBDE and octaBDE products are used in hard 
dense plastics from which migration would be very difficult (BFRIP 2002).  Although it is known that 
PBDE-containing plastics are disposed in landfills, information on the recycling of PBDE-containing 
plastics and the amounts of PBDE-containing plastics that are incinerated is not known.  Additional 
information of levels of PBDEs and PBDD/PBDF from incineration of PBDE-containing plastics would 
be useful in determining exposure to the general population.  
 
Environmental Fate.     
 
Polybrominated Biphenyls.  Information regarding the environmental fate of PBBs in air was not located 
in the literature.  The data about the fate of PBBs in air are important for the prediction of transport 
characteristics of these compounds in air.  Photolysis of the PBBs will produce debrominated products in 
proton-donating organic solvents (Ruzo and Zabik 1975; Ruzo et al. 1976), but there is less certainty 
about the importance of photolysis of PBBs in water (Norris et al. 1973; Ruzo et al. 1976).  PBBs will 
partition from the aquatic phase to sediment and suspended solids in water (Hesse and Powers 1978).  
PBBs will bioconcentrate in aquatic organisms, but the BCF may decrease as the bromine substitution 
exceeds six (Gobas et al. 1989; Opperhuizen et al. 1985; Zitko 1979; Zitko and Hutzinger 1976).  
However, the difference in the reported BCF values for hexabromobiphenyl among different investigators 
is vast (Gobas et al. 1989; Hesse and Powers 1978; Opperhuizen et al. 1985; Veith et al. 1979).  PBBs 
will remain strongly sorbed to soil (Filonow et al. 1976; Griffin and Chou 1981a, 1981b) and will persist 
in soil because of the lack of suitable degradation pathways (Jacobs et al. 1978).  The translocation of 
PBBs from soil to upper parts in plants was not observed, and the transfer of PBBs from soil to carrot 
roots was found to be minor (Jacobs et al. 1976, 1978).  A recent article by de Boer et al. (1998) found 
PBBs in deep ocean marine mammals, which suggests that PBBs may be transported globally.  More 
monitoring data for PBBs in the environment are needed to verify the possible global transport of PBBs.  
Since the toxicity and the environmental fate of PBBs depends on specific PBBs congeners, development 
of more data regarding congener-specific fate and transport of PBBs in the environment are needed. 
 
Polybrominated Diphenyl Ethers.  Based on limited data, photolysis appears to be the dominant 
transformation process for some PBDEs (e.g., decaBDE) (Hua et al. 2003).  PBDEs absorb light in the 
environmental spectrum.  Hua et al. (2003) found that decaBDE and the commercial octaBDE absorbed 
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light up to 325 nm, which indicates that these compounds may be susceptible to photodegradation at 
environmental wavelengths.  However, the importance of photochemical transformation reactions in the 
environment cannot be determined due to lack of quantitative rate information (EU 2002, 2003).  Based 
on a very limited number of studies, biodegradation does not appear to be significant for PBDEs 
commercial mixtures (EU 2002, 2003).  Limited studies have been done on biodegradation of PBDEs in 
the environment under both aerobic and anaerobic conditions, especially studies investigating de-
halogenation mechanisms (EU 2002, 2003).  More studies are needed to determine conclusively if 
commercial PBDE mixtures, such as decaBDE, are degraded to lower brominated congeners (e.g., 
2,2’4,4’-BDE [BDE 47]), which appear to bioaccumulate in fish, animals, and humans (see Sections 8.4).  
Since the toxicity and the environmental fate of PBDEs depend on specific PBDEs congeners, 
development of more data regarding congener-specific fate and transport of PBDEs in the environment 
are needed. 
 
Bioavailability from Environmental Media.     
 
Polybrominated Biphenyls.  Available information regarding the rate of absorption of PBBs following 
inhalation, oral, or dermal contact is discussed in the Toxicokinetics Section (Section 5.4).  Although no 
data on the bioavailability of PBBs from inhalation of contaminated air, or ingestion of or dermal contact 
with water, or inhalation of or dermal contact with soil are available, the bioavailabilities from these 
routes of exposure are expected to be far less than 100% because these compounds strongly sorb to 
particulate matter and soil.  The estimated bioavailability of higher brominated biphenyls is expected to 
be even lower than the less brominated biphenyls due to stronger sorption characteristics of the former 
compounds.  The estimated bioavailability of PBBs by farm animals from ingestion of contaminated soil 
was 56–65% (Fries 1985a).  Also, studies on many persistent halogenated aromatic compounds clearly 
show that they become progessively less bioavailable with time (Alexander 2000).  Often, three-fourths or 
more of the concentration of such compounds is not bioavailable.  Information on the possibility of the 
very low bioavailability of PBBs is needed. 
 
Polybrominated Diphenyl Ethers.  The absorption and distribution of PBDEs as a result of inhalation, 
ingestion, and dermal exposure are discussed in Sections 5.3.1, 5.3.2, and 5.3.3.  Studies that describe the 
bioavailability of PBDEs commercial mixtures and congeners from ambient air, surface water, and 
groundwater, or soil do not exist.  Essentially no good data exist on the adsorption of PBDEs commercial 
mixtures and congeners with the exception of decaBDE (BFRIP 2002).  Studies on many persistent 
halogenated aromatic compounds clearly show that they become progessively less bioavailable with time 
(Alexander 2000).  Often, three-fourths or more of the concentration of such compounds is not 
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bioavailable.  Information on the possibility of the very low bioavailability of PBDEs is needed.  Studies 
determining the effect of particle size and organic matter content on the bioavailability of PBDEs from 
soil and the role of microparticle-sorbed PBDEs on the bioavailability of PBDEs from drinking water are 
needed.  Such studies would be useful in assessing the health effects of PBDEs on people living near 
hazardous waste sites. 
 
Food Chain Bioaccumulation.     
 
Polybrominated Biphenyls.  PBBs do not readily translocate from soil to plants via root uptake (Jacobs et 
al. 1976, 1978).  Therefore, PBBs may not bioconcentrate in plants.  However, plant uptake data are 
limited, and it will be helpful to develop additional plant uptake data.  Brominated biphenyls with 
bromine substitution 6 or less will bioconcentrate in aquatic organisms (Gobas et al. 1989; Norris et al. 
1973; Opperhuizen et al. 1985; Zitko 1979; Zitko and Hutzinger 1976).  PBBs are preferentially stored in 
the adipose tissue of animals (Kimbrough 1987).  Although PBBs have been detected in fish-eating birds 
and predatory animals from the consumption of contaminated food (Heinz et al. 1983, 1985; Hesse and 
Powers 1978), no systematic study was located that analyzed the biomagnification potential in predators 
resulting from consumption of contaminated food. 
 
Polybrominated Diphenyl Ethers.  An abundance of monitoring data illustrate the uptake of lower 
brominated diphenyl ethers by aquatic organisms, which results in bioconcentration (see Section 8.4.4; 
Hardy 2002b).  Congener components of the pentaBDE commercial product tend to bioconcentrate to 
different extents.  DecaBDE and octaBDE commercial products appear to not bioconcentrate, 
bioaccumulate, or biomagnify (Hardy 2002b).  The limited existing data indicate that lower brominated 
BDE congeners (e.g., pentaBDE commercial mixtures) bioaccumulate in aquatic and terrestrial food 
chains and biomagnify in predators due to consumption of contaminated prey.  Bioaccumulation of 
PBDEs in the aquatic food web is inversely related to the degree of bromination (Burreau et al. 2000; 
Jansson et al. 1993).  More information on bioaccumulation and biomagnification of PBDE and its 
congeners is needed in assessing human health risks. 
 
Exposure Levels in Environmental Media.     
 
Polybrominated Biphenyls.  Only limited data on the levels of PBBs in ambient air are available 
(DeCarlo 1979).  Data are available on the levels of PBBs in effluent water from manufacturing plants, in 
river water, stream sediment, and soil in the vicinity of the plants, in sludge of a waste treatment plant, 
and in groundwater of a landfill site (Hesse and Powers 1978; Shah 1978).  No data on the level of PBBs 
PBBs and PBDEs  462 
 








in drinking water from the contaminated sites were located.  No estimate on the human intake of PBBs 
from any of the various environmental media was located in the literature. 
 
Reliable monitoring data for the levels of PBBs in contaminated media at hazardous waste sites are 
needed so that the information obtained on levels of PBBs in the environment can be used in combination 
with the known body burden of PBBs to assess the potential risk of adverse health effects in populations 
living in the vicinity of hazardous waste sites. 
 
Polybrominated Diphenyl Ethers.  Information on the relative importance of different routes of exposure 
to PBDEs is limited especially in the United States.  Atmospheric concentrations of PBDEs tend to be 
dominated by lower brominated congeners, e.g., 2,2’,4,4’-pentaBDE (BDE 47) (Dodder et al. 2000a; 
Strandberg et al. 2001).  More monitoring data on the concentrations of total PBDEs and PBDE 
congeners in air in remote, rural, and urban areas, as well as areas near hazardous waste sites and 
incinerators are needed.  Due to the hydrophobic nature of PBDEs, this class of compounds has not been 
detected in water to any significant extent.  BDE 47 was detected at low concentrations in Lake Ontario 
surface waters (Luckey et al. 2001).  Although levels are predicted to be low, monitoring data on PBDE 
concentrations in finished drinking water nationwide would be helpful.  No information was located on 
the ambient environmental concentrations of PBDEs in soils in the United States or other parts of the 
world.  Hale et al. (2002) reported the concentrations of PBDEs in soil samples collected in the vicinity of 
a polyurethane foam manufacturing facility, which are higher than expected in rural and potentially urban 
areas.  Sediment concentrations of PBDEs tend to be dominated by higher brominated congeners (e.g., 
decaBDE or BDE 209) (deWit 2002; Dodder et al. 2002; Hale et al. 2001b, 2002); temporal trends 
suggest that concentrations of PBDEs in sediments are increasing.  Information about the concentrations 
of PBDEs in food stuffs is very limited (Bocio et al. 2003; Huwe et al. 2002a; Ohta et al. 2002a), 
especially in the United States.  Data on the concentrations of PBDEs in foods, collected using a market-
basket approach, are needed to determine concentrations of PBDEs in foods consumed by the general 
population.  Data on the PBDE concentrations in foods grown in contaminated areas, particularly in the 
vicinity of hazardous waste sites, are also needed.  Data on congener-specific PBDE analysis of food, 
especially plant products, would be useful.  Monitoring data indicated that the levels of PBDEs are 
increasing in aquatic organisms with higher concentrations near point sources (Alaee et al. 1999; Dodder 
et al. 2000a; Johnson and Olson 2001; Loganathan et al. 1995; Luross et al. 2000).  Additional monitoring 
data on environmental levels of PBDEs would to useful to determine the extent of contamination in 
environmental media, and also the mechanisms of human exposure to this class of chemicals. 
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Exposure Levels in Humans.     
 
Polybrominated Biphenyls.  Body burden data indicate that low-level exposures to PBBs have occurred 
for people in the state of Michigan.  No recent information about average daily intake of PBBs was 
located.  The levels of PBBs in human tissue and body fluids, such as blood, serum, adipose tissue, breast 
milk, feces, cord blood, biliary fluid, and placenta, of people in the state of Michigan have been 
extensively studied (Brilliant et al. 1978; Cordle et al. 1978; Eyster et al. 1983; Humphrey and Hayner 
1975; Lambert et al. 1990; Landrigan et al. 1979; Wolff et al. 1982).  However, no recent data are 
available.  Data on the levels of PBBs in tissues and body fluids of residents in the vicinity of sites of 
industrial discharge of PBB wastes were not located.  Updated information would be useful to understand 
current exposure levels of people in the state of Michigan to PBBs.  This information is necessary for 
assessing the need to conduct health studies on these populations.   
 
Polybrominated Diphenyl Ethers.  Body-burden data indicate that there are low-level exposures to lower 
brominated PBDEs for the general population.  The absence of decaBDE (BDE 209) in the ambient 
population is likely the result of analytical bias since most studies of the ambient population did not 
include BDE 209 as one of the analytes of interest.  Thus, future studies that include the analysis of 
BDE 209 in body tissues and fluids would be useful (Hites 2004).  Information about the average daily 
intake of PBDEs is limited to populations living in Sweden (Bergman et al. 1999; Lindström 1999; WHO 
1994a).  PBDE levels are reported in the current literature for blood, breast milk, and adipose tissue of the 
general population and occupationally exposed individuals (WHO 1994a).  Limited information on the 
levels of PBDEs in body tissues and fluids from individuals living in the United States have been located 
(Mazdai et al. 2003; Patterson et al. 2000; Petreas et al. 2002, 2003; Schecter et al. 2003b; Sjödin et al. 
2001).  These studies indicate that levels of lower brominated BDEs in body fluids are a factor of 10–
100 higher for individuals living in the United States compared to individuals living in other regions of 
the world (e.g., Europe).  Limited surveys have ever been conducted in the United States to evaluate the 
trend of PBDE concentrations in human tissues over the years.  It would be helpful to develop a database 
of information on congener-specific PBDE levels in tissues of exposed and control cases for studying 
clinical and epidemiological outcomes.  In particular, a comprehensive study that monitors congener-
specific concentrations in fish species and relates them directly to congener levels in human tissue would 
be extremely useful.  Monitoring data indicate 2,2’,4,4’-tetraBDE (BDE 47) and 2,2’,4,4’,5,5’-hexaBDE 
(BDE 153) are relatively higher in human samples than in the commercial pentaBDE product and that  
2,2’,4,4’,5-pentaBDE (BDE 99) is relatively lower.  The cause of this difference is not known.  It may be 
due to its relatively higher vapor pressure of BDE 99, or it may be due to the selective environmental 
elimination of BDE 99, a process that has been observed in some biota (Hites 2004).  Additional studies 
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that examine these trends would be useful.  Additional data regarding the concentrations of PBDEs in 
body fluids or tissues of people who reside near hazardous waste sites are needed.  This information is 
necessary for assessing the need to conduct health studies on these populations. 
 
Exposures of Children.     
 
Polybrominated Biphenyls.  Children may be exposed to PBBs by a variety of exposure pathways.  
Levels will be highest for children living in the vicinity of the area affected by the Michigan 
contamination episode.  The most important pathway appears to be consumption of contaminated 
mother’s milk (see Section 8.4.4).  More data are needed on the levels of PBB exposure in nursing 
women from consumption of fish and from those of the general population.  Exposure and body burden 
studies related to consumption of fish in the U.S. population are needed to determine exposure levels, 
particularly in children of recreational and subsistence fishers.  Information related to the exposure of 
children living near hazardous waste sites is also needed.  In particular, information is needed that is 
related to the potential for children to be exposed to PBBs bound to soil and dust particles through pica or 
unintentional hand-to-mouth activity within homes located in these areas.  Quantitative information 
regarding the bioavailability and amount of PBBs that children are exposed to through contact with 
contaminated soils are unavailable.  Therefore, any information concerning this subject would be useful in 
evaluating children’s exposure.  Additional information on weight-adjusted intakes would be helpful for 
determining the health risks for young children.  Infants and young children consume a greater amount of 
food per kilogram of body weight and, therefore, may have a proportionately greater exposure to PBBs 
than adults. 
 
Polybrominated Diphenyl Ethers.  Children may be exposed to PBDEs by a variety of exposure 
pathways.  The most important pathway appears to be consumption of contaminated foods, particularly 
fish (Bergman et al. 1999; Lindström 1999; WHO 1994a).  Children can also be exposed to PBDEs from 
mother’s milk (LaKind and Berlin 2000; Lindström 1999; Norön and Meironyté 2000; Schecter et al. 
2003b; Strandman et al. 2000; WHO 1994a).  More data are needed on the levels of PBDEs exposure in 
nursing women, from occupational situations, from consumption of fish, and from those of the general 
population.  Exposure and body-burden studies related to consumption of fish in the U.S. population are 
needed to determine exposure levels, particularly in children of recreational and subsistence fishers.  
Exposure and body-burden studies are also needed in Native American communities that consume high 
levels of game and marine mammals.  Information related to the exposure of children living near 
hazardous waste sites is also needed.  In particular, information is needed that is related to the potential 
for children to be exposed to PBDEs bound to soil and dust particles through pica or unintentional hand-
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to-mouth activity within homes located in these areas.  Quantitative information regarding the 
bioavailability and amount of PBDEs that children are exposed to through contact with contaminated 
soils is unavailable.  Therefore, any information concerning this subject would be useful in evaluating 
children’s exposure.  Additional information on weight-adjusted intakes would be helpful for determining 
the health risks for young children, particularly those in Native American populations.  Infants and young 
children consume a greater amount of food per kilogram of body weight and, therefore, may have a 
proportionately greater exposure to PBDEs than adults. 
 
Child health data needs relating to susceptibility are discussed in Section 5.12.2 Identification of Data 
Needs: Children’s Susceptibility. 
 
Exposure Registries.     
 
Polybrominated Biphenyls.  The Michigan Department of Community Health (MDCH), together with the 
Centers for Disease Control and Prevention (CDC) and three other federal agencies, began a major study 
to assess the health effects of PBBs after the Michigan contamination episode.  A health questionnaire 
and blood samples were collected from people affected by the feed-contamination incident.  MDCH had 
the responsibility to analyze several thousand samples for PBB from 1975 to 1978.  MDCH continues 
contact with this cohort, updates health questionnaires, and collects blood samples to be analyzed (MDCH 
2002).  
 
Polybrominated Diphenyl Ethers.  No exposure registries for PBDEs were located.  This substance is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for 
subregistries to be established.  The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance. 
 
8.8.2   Ongoing Studies  
 
Polybrominated Biphenyls.  A search in Federal Research in Progress (FEDRIP 2002) did not identify 
ongoing research studies for PBBs. 
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Polybrominated Diphenyl Ethers.  A search of FEDRIP (2003) did not identify ongoing research studies 
for PBDEs.  However, EPA has funded work in the Science To Achieve Results (STAR) Research Grants 
program, as well as regional and intramural efforts (EPA 2004).  In addition, the National Toxicology 
Program (NTP) has committed to performing studies on the commercial pentaBDE and octaBDE 
products and their congener components (NTP 2004).    
 
 










9.  ANALYTICAL METHODS 
 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring polybrominated biphenyls (PBBs) and polybromintaed diphenyl ethers 
(PBDEs), its metabolites, and other biomarkers of exposure and effect to PBBs and PBDEs.  The intent is 
not to provide an exhaustive list of analytical methods.  Rather, the intention is to identify well-
established methods that are used as the standard methods of analysis.  Many of the analytical methods 
used for environmental samples are the methods approved by federal agencies and organizations such as 
EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other methods presented in 
this chapter are those that are approved by groups such as the Association of Official Analytical Chemists 
(AOAC) and the American Public Health Association (APHA).  Additionally, analytical methods are 
included that modify previously used methods to obtain lower detection limits and/or to improve accuracy 
and precision. 
 
PBBs and PBDEs are analyzed in environmental and biological samples by methods quite similar to those 
used for polychlorinated biphenyls (PCBs) (de Kok et al. 1977; Fries 1985b; Pomerantz et al. 1978).  The 
analytical methods for PBBs were developed primarily in the 1970s, whereas analytical methods for 
PBDEs were developed very recently.  In the 30 years between analytical efforts directed at PBBs and 
PBDEs, there have been many advances in the technology and costs of analytical instruments.  Thus, 
while gas chromatography-electron capture detection (GC-ECD) with packed columns (i.e., noncongener 
specific) was the primary analytical technique used in the 1970s for PBBs, gas chromatography-mass 
spectrometry (GC-MS) with capillary columns (i.e., congener specific) is the primary analytical technique 
now used for PBDEs.  These points should be considered when comparing the differences and quality of 
analysis for these two classes of compounds.   
 
Covaci et al. (2003) recently reviewed the determination of brominated flame retardants, with emphasis 
on PDBEs in environmental and human samples.  The analysis methodology for PBBs and PBDEs 
includes several steps:  sample collection and storage, sample pretreatment, extraction, cleanup and 
fractionation, and analytical determination.  Care must be taken to assure that the sample collection 
follows quality-assurance protocols and that equipment and containers are free from contamination.  It is 
important that laboratories utilize blanks when reporting trace levels of PBBs and PBDEs.  This practice 
will minimize the influence of trace contamination samples that can originate from a variety of sources.   
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Most sample collections are by grab sampling; however, PBBs and PBDEs may be concentrated from 
water onto sorbents.  Desiccation of solid samples (e.g., soil, sediment, and sewage sludge) is largely 
done for convenience.  Dry samples are more efficiently homogenized, allowing for parallel 
determination of other analytes (e.g., lipid content) (Covaci et al. 2003). 
 
PBBs and PBDEs are typically separated from the biological and environmental media by extraction with 
organic solvents.  Liquid-solid extraction (e.g., Soxhlet apparatus) remains a widely used technique for 
solid samples despite recent advances in other extraction techniques.  Typical solvents are hexane, 
toluene, hexane/acetone mixtures, or dichloromethane.  New extractions techniques, such as accelerated 
solvent extraction (ASE) or microwave-assisted extraction (MAE), are also currently used by a number of 
laboratories.  The advantage of these techniques is lower solvent consumption and reduced extraction 
time.  Supercritical fluid extraction (SFE) with solid-phase trapping has been used for the extraction 
brominated flame retardants from sediment with CO2 as the supercritical fluid.  Extraction with 
pressurized hot water (PHWE) has been used for the analysis of brominated analytes from sediment.  
Liquid-liquid extraction has been applied for river and seawater samples, using hexane/acetone mixtures.  
Solid-phase extraction (SPE) has been used for the analysis of acidic and neutral brominated flame 
retardants from human plasma (Covaci et al. 2003).  
 
Cleanup steps are necessary to remove compounds that may interfere with the determination (e.g., humic 
acids, lipids) of PBBs and PBDEs.  Lipids (e.g., oils and fats) may be destroyed with concentrated 
sulfuric acid treatment either directly to the extract or using impregnated silica columns.  
Chromatography (e.g., gel permeation, silica gel, Florisil) is used to remove other matrix interferences 
and to fractionate samples (Covaci et al. 2003). 
 
The identification and quantitation of PBBs and PBDEs are most often accomplished by GC techniques.  
Capillary or high-resolution gas chromatography (HRGC) columns capable of separating a substantial 
proportion of the congeners are indispensable, and GC detectors possessing high selectivity and 
sensitivity for the PBBs and PBDEs are required.  The more universal and less sensitive flame-ionization 
detector (FID) is used much less often than the electron-capture detector (ECD), which has exceptional 
sensitivity to highly brominated compounds.  The mass-spectrometer detectors have sensitivities 
somewhat lower than ECD, and they have even greater selectivity for PBBs and PBDEs and can 
distinguish and individually measure homologs that may co-elute on a particular HRGC column.  The use 
of MS is indispensable in the definitive identification of PBB and PBDE congeners.  A recent method of 
detection is electron-capture negative ionization (ECNI) as an ionization technique in combination with 
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GC-MS analysis (de Boer et al. 2000).  This method is advantageous because it offers a high sensitivity 
for compounds with four or more bromine atoms.  The sensitivity is approximately 10 times higher than 
with the use of the ECD.  However, ECNI, although generally more sensitive and less costly than other 
ionization methods for PBDE analysis, does not provide information on the molecular ion cluster (as 
required for qualitative identification).  It is also more subject to brominated interferences and does not 
allow the used of 13C-labeled standards for quantification (Ikonomou and Rayne 2002).  Conversely, 
electron ionization (EI) methods suffer from fragmentation of the molecular ions, creating difficulties in 
both identification and quantitation of congeners in full-scan and single ion monitoring (SIM) modes, 
respectively.  For example, loss of Br atoms from PBDE congeners during EI may lead to incorrect 
identification of the parent ion as a lower brominated congener.  In addition, the relatively unpredictable 
fragmentation during EI or ECD restricts the utility of applying relative response factors (RRFs) of one 
congener for which an analytical standard is available (e.g., 2,2,4,4’-tetrabromodiphenyl ether or BDE 47) 
for other members of its homolog group (e.g., tetrabromodiphenyl ether [tetraBDEs]).  This can result in 
either under- or overestimating concentrations of congeners for which analytical standards are not 
available (Ikonomou and Rayne 2002b).  In general, hepta- through deca-BDE congeners are difficult to 
determine accurately by GC analysis, especially in biological samples (Ikonomou and Rayne 2002b).   
 
The analysis of decaBDE (i.e., BDE 209) and 2,2’,4,4’,5,6’-hexabromodiphenyl ether (i.e., BDE 154) has 
some analytical difficulties.  For example, BDE 209 (1) is not stable at high temperatures in the GC 
injector and GC column; (2) is sensitive to degradation by UV light (i.e., both sunlight and fluorescent 
light); (3) behaves differently in the MS source from those of chlorinated and lower brominated 
compounds (de Boer and Cofino 2002); and (4) may easily adsorb to small dust particles in the 
laboratory, which may result in sample contamination (Covaci et al. 2003).  Thermal decomposition of 
BDE 209 can be avoided using a short GC column and a thermally inert GC injection port.  In contrast, 
BDE 154 usually coelutes from most gas chromatographic columns with 2,2’,4,4’,5,5’-hexabromo-
biphenyl (PBB-153).  In order to ensure the separation of BDE 154 and PBB 153, analysts need to use a 
sufficiently long GC column.  Thus, in order to accurately determine the levels of BDE 209 and BDE 154 
in analytical samples, analysts are required perform two separate GC measurements under different 
operating conditions.   
 
9.1   BIOLOGICAL MATERIALS  
 
Methods for the determination of organobromine compounds such as PBBs and PBDEs generally consist 
of the following steps:  extraction of the analyte from the sample matrix; cleanup to remove interfering 
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compounds; and analysis (separation and quantitation).  The primary method of analysis is GC coupled 
with ECD or MS.  Analytical methods have been developed for the determination of PBBs and PBDEs in 
blood or serum, urine, feces, adipose tissue, liver, and breast milk.  The methods for determining PBB and 
PBDE residues in biological samples are given in Tables 9-1 and 9-2, respectively.  
 
Polybrominated Biphenyls.  Residues in biological samples can be extracted using hexane/ether, 
petroleum ether/diethyl ether, toluene/ethyl acetate, or methylene chloride (Burse et al. 1980; Domino et 
al. 1980; Fawkes et al. 1982; Fehringer 1975b; Wolff et al. 1979b).  Elution of samples on a florisil 
column, which is used for the cleanup of extracts with petroleum ether, separates PBBs from interfering 
substances (Pomerantz et al. 1978).  As in the case of PCBs, the solvent(s) used for the extraction of a 
sample and the method used for the cleanup of an extract is dependent on the sample matrix (Pomerantz 
et al. 1978).  Quantitation is usually done by GC.  The major difference between the methods for the 
determination of PCBs and PBBs arises from the lower volatility of PBBs compared to PCBs.  Due to the 
lower volatility of PBBs, the GC method is performed at a higher temperature and low liquid-phase load 
of the stationary phase.  Capillary columns are required for the separation of the individual congeners in a 
mixture (Robertson et al. 1983b).  However, decabromobiphenyl is so nonvolatile that a very short 
capillary column and high carrier gas linear velocity are required, which reduces the advantage of the 
capillary column over the packed column (Farrell 1980).  Peaks from individual congeners of PBBs are 
detected and quantified with ECD (Robertson et al. 1983b).  In general, retention time in gas 
chromatographic columns and response of ECD increase with increasing bromination.  PBB residues in a 
sample can be confirmed by thin-layer chromatography, photochemical-alteration method, halogen-
specific gas-chromatographic detection, or MS (de Kok et al. 1977; Erney 1975; Pomerantz et al. 1978).  
High recoveries (80–90%) of PBB residues are obtained by the available analytical methods.  Typically, 
the limit of quantitation for PBB residues is about 1 µg/kg in blood serum, 1 µg/kg in human milk, and 
0.5 µg/kg in adipose tissue (Eyster et al. 1983; Wolff et al. 1979a).  An interlaboratory study is available 
that validates the precision and accuracy of PBB residue determination in human serum by a commonly 
used method (Burse et al. 1980). 
 
Polybrominated Diphenyl Ethers.  Residues in biological samples can be extracted using sulfuric acid, 
2-propanol/hexane, methylene chloride, n-hexane, formic acid/2-propanol/water, or hexane/methyl t-butyl 
ether (Cramer et al. 1990; Meironyté Guvenius et al. 2001; Ohta et al. 2002a; Sellström et al. 1993; 
Sjödin et al. 1999; Thomsen et al. 2001b).  Samples are cleaned up to remove interferences using Florisil, 
silica gel, alumina or activated-charcoal column chromatography, gel-permeation chromatography (GPC),  
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Table 9-1.  Analytical Methods for Determining PBBs in Biological Materials 
 
Sample 







Serum Extract denatured sample with 
hexane-ethyl ether; clean up by 
Florisil column chromatography 
GC-ECD 1 µg/L 100.6–106.8 
at 100 µg/L 
Burse et al. 
1980 
Serum Extract denatured sample with 
hexane-ether; clean up by Florisil 
column chromatography 
GC-ECD 1 ng/g 86–92 Wolff et al. 1979
Plasma Extract denatured sample with 
petroleum ether-ethyl ether; clean 
up by Florisil and silica gel column 
chromatography 




Willet et al. 1978
Whole 
blood 
Extract denatured sample with 
petroleum ether-ethyl ether; clean 
up by Florisil column chromato-
graphy 
GC-ECD 0.7 ng/g 90–96 Domino et al. 
1980 
Feces Extract sample with petroleum 
ether-ethyl ether; clean up by 
Florisil and silica gel column 
chromatography 
GC-ECD 1.4 ng/g (for 
hexa) 
61 (for hexa) Willet et al. 1978
Bile Extract denatured sample with 
petroleum ether-ethyl ether; clean 
up by Florisil and silica gel column 
chromatography 
GC-ECD 0.08 ng/g (for 
hexa) 
92 (for hexa) Willet et al. 1978
Milk Extract denatured sample with 
petroleum ether-ethyl ether; clean 
up by Florisil and silica column 
chromatography 




Willet et al. 1978
Milk, 
human 
Extract with potassium oxalate, 
ethanol/diethyl ether, or hexane 
GC-ECD 1 ng/g No data Eyster et al. 
1983 
Liver Extract sample with methanol-
chloroform; clean up by acidic 
silica column chromatography 




Extract sample with methylene 
chloride; clean up by acidic silica 
gel column chromatography 






Toluene/ethyl acetate (1+3); clean 
up using GPC/Bio beads 





Extract with hexane; clean up 
using Florisil column 
GC-ECD 0.5 ng/g No data Micelli et al. 
1985 
 
EC = electron capture detection; GC = gas chromatography; GPC = gel permeation chromatography; hexa = hexa-
brominated biphenyl; PBBs = polybrominated biphenyls; SIM = selected ion monitoring 
 
PBBs and PBDEs  472 
 









Table 9-2.  Analytical Methods for Determining PBDEs in Biological Materials 
 
Sample 











Extraction with sulfuric 










Soxhlet extraction; clean 












Extraction with methylene 
chloride; evaporate; clean 
up on silica gel followed by 
clean up on alumina and 











hexane; clean up with 










Human milk Extract with potassium 
oxalate/ethanol/diethyl 
ether/pentane; GPC; clean 




<0.6 ng/g fat No data WHO 1994a 
Human milk Extract by column 
chromatography using 
hexane/dichloromethane/




5 pg/g lipids 86–102 Meironyté et 
al. 1999a, 
1999b 
Human milk Extract with n-hexane; 











Extract with formic acid, 
2-propanol, and water on a 











MTBE (1:1); clean up silica 









Sjödin et al. 
1999a 
 
ECD = electron capture detection; EI = electron impact; EILR = electron impact low-resolution; GC = gas 
chromatography; GPC = gel permeation chromatography; HRGC = high resolution gas chromatography; 
HRMS = high resolution mass spectrometry; LRGC = low resolution gas chromatography; LRMS = low resolution 
mass spectrometry; MS = mass spectrometry; MTBE = methyl-tert-butyl either; NCI = negative chemical ionization; 
PBDEs = polybrominated diphenyl ethers; SIM = selected ion monitoring; SPE = solid phase extraction 
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and/or liquid chromatography (LC) (Sellström et al. 1993; Cramer et al. 1990; Meironyté Guvenius et al. 
2001; Sellström et al. 1993; Sjödin et al. 1999).  Most techniques are based on analysis by GC with ECD 
or coupled with MS (WHO 1994a).  Capillary columns and temperature programming allow the 
separation of the different PBDE congeners.  High recoveries (69–104%) of PBDE residues are obtained 
by the available analytical methods.  Typically, the limit of quantitation for PBDE residues is about 
0.7 ng/g lipid in blood serum, 5 pg/g lipid in human milk, and 0.3 ng/g lipid in adipose tissue (Covaci et 
al. 2002b; Meironyté Guvenius 1999a, 1999b; Sjödin et al. 1999). 
 
9.2   ENVIRONMENTAL SAMPLES  
 
Most environmental analyses have been performed using multiresidue methods involving solvent 
extraction of the analytes from the sample matrix, cleanup to remove interfering compounds, 
determination by GC with ECD, and confirmation using an ancillary method such as MS.  New methods 
and technologies are evolving, and this has resulted in lower detection limits.  For example, detection 
limits for PBBs are in the low parts-per-billion (ppb) to parts-per-trillion (ppt) range for water matrices 
and in the low parts-per-million (ppm) to ppb range for food; for PBDEs, detection limits are in the low 
ppb range for water matrices and in the low ppb to ppm range for fish tissues.  Analytical methods for the 
determination of PBBs and PBDEs in environmental samples are given in Tables 9-3 and 9-4, 
respectively.  
 
Polybrominated Biphenyls.  Residues in environmental samples can be extracted using hexane-ether, 
petroleum ether-ether, toluene-ethyl acetate, or methylene chloride (Burse et al. 1980; Domino et al. 
1980; Fawkes et al. 1982; Fehringer 1975b; Wolff et al. 1979b).  As for biological samples, quantitation 
of environmental samples is also usually done by GC.  Capillary columns are required for the separation 
of the individual congeners in a mixture (Robertson et al. 1983b).  High recoveries (74–98%) of PBB 
residues in environmental samples are obtained by the available analytical methods.  Typically, the limit 
of quantitation for PBB residues is about 0.1 µg/kg in soil and 0.7 µg/kg in sediment (Jacobs et al. 1976, 
1978; Kuosmanen et al. 2002).  
 
Polybrominated Diphenyl Ethers.  Like PCBs, air samples containing PBDEs are usually collected by 
pumping air through a sampler containing a glass-fiber filter and adsorbent trap to separate the particle-
bound and vapor-phase fractions, respectively (Dobber et al. 2000a; Hillery et al. 1997).  The filters and 
adsorbents are then Soxhlet extracted with acetone/hexane, and the extracts are cleaned up and analyzed 
by high-resolution GC techniques. 
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Table 9-3.  Analytical Methods for Determining PBBs in Environmental Samples 
 
Sample 







Commercial Sample dissolved in benzene 
FireMaster BP-6 
GC-ECD 1.6 ng (EC) 
GC-PED 
Not applic-
able 2.8 ng 
(PED) 
Mulligan et al. 
1980 
Soil Extract sample with hexane-
acetone; clean up by Florisil column 
chromatography 
GC-ECD 0.1 ng/g 74.2–83.2 
(for hexa) 
Jacobs et al. 
1976, 1978 
Soil Extraction using hexane/acetone; 
clean up using Florisil column 
GC-
FID/ECD 
No data No data Hill et al. 1982
Plant tissue Extract macerated sample with 
hexane-acetone; clean up by Florisil 
column chromatography 




Extract sample with hexane-ethyl 
ether 
GC-ECD 0.1 ng/g 90 Hesse and 
Powers 1978 
Sediment Extract sample with hexane-acetoneGC-ECD No data No data Hesse and 
Powers 1978 
Sediment Pressurized hot water extraction 
coupled with clean up by LC 
LC-GC-MS/
FID 
0.71 ng/g No data Kuosmanen et 
al. 2002 
Fish Extract homogenized sample with 
hexane-water; clean up by acidic 
and basic silica columns 
GC-ECD No data 98 (for 
hexa) 
Gobas et al. 
1989 
Fish Extract homogenized sample with 
hexane-methylene chloride; clean 




No data No data Kuehl et al. 
1991 
Fish Extract homogenized sample with 











Extraction with diethyl ether/hexane; 
hydrolysis with 98% sulfuric acid/bio 
beads/silica gel/activated charcoal 
MS (NCI) No data No data Jansson et al. 
1991, 1993 
Dolphin fat Soxhlet extraction using hexane-
methylene chloride; clean up using 
GPC, silica gel 
MS No data No data Kuehl et al. 
1991 
Animal feeds Elute ground sample containing 
celite with methylene chloride; clean 
up by Florisil column 
chromatography 








Fat extracted by methanol/ether; 
clean up by GPC, 25% toluene in 
ethyl acetate 
GC-ECD 7 ng/g No data Fehringer 
1975 
Plants Cut, extracted with hexane/acetone; 
clean up with Florisil column 
GC-ECD 0.3 ng/g wet 
basis 
No data Chou et al. 
1978 
 
EC = electron capture detection; FID = flame ionization detector; GC = gas chromatography; hexa = hexabrominated 
biphenyl; HRGC = high resolution gas chromatography; HRMS = high resolution mass spectrometry; LC = liquid 
chromatography; MS = mass spectrometry; NCI = negative chemical ionization; PED = plasma emission detection; 
PBBs = polybrominated biphenyls 
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Table 9-4.  Analytical Methods for Determining PBDEs in Environmental Samples
 
Sample 







Air Air pumped through glass 
fiber filter and adsorbent trap; 
filters and adsorbents are 
Soxhlet extracted with 
acetone/hexane; cleaned-up 
by column chromatography  
GC/MS No data No data Dodder et al. 
2000a 










Sewage Extract with chloroform; 
evaporate and dissolve 
residue in ethanol 
GC/MS 0.06 µg/g No data WHO 1994a  




9.7 ng/g 91±6.3 Yamamoto et 
al. 1997 
Sediment Pressurized hot water 
extraction coupled with clean 
up by LC 
LC-GC-
MS/FID 
0.71 ng/g No data Kuosmanen et 
al. 2002 
Sediment Extract with acetone; clean 





No data Watanabe et al. 
1987 
Fish Extract with acetone-hexane 
+ hexane-ethyl ether; treat-
ment with sulfuric acid or 
clean up on alumina; 
chromatography on silica gel 
GC/EC; 
GC/MS 
0.1 µg/g fat No data Anderson and 
Blomkvist 1981 
Fish Extract with dichloromethane 
on chromatography column; 
clean-up using GPC; 




5–93 pg/g No data Alaee et al. 
2001 











Homogenize; extract with 
n-hexane-acetone; treatment 
with sulfuric acid; GPC; 
chromatography or silica gel 




10 pg/g No data Jansson et al. 
1991 
 
ECD = electron capture detection; GC = gas chromatography; GPC = gel permeation chromatography; 
HRMS = high resolution mass spectrometry; LC = liquid chromatography; MS = mass spectrometry; NAA = neutron 
activation analysis; NCI = negative chemical ionization; PBDEs = polybrominated diphenyl ethers 
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Residues in environmental samples can be extracted using chloroform, acetone, acetone-hexane, hexane-
acetone, and hexane-ether (Anderson and Blomkvist 1981; Jansson et al. 1991; Watanabe et al. 1987; 
WHO 1994a).  Samples are cleaned up to remove interferences using Florisil, silica gel, alumina or 
activated charcoal column chromatography, gel permeation chromatography (GPC), and/or liquid 
chromatography (LC) (Akutsu et al. 2001; Alaee et al. 2001; Anderson and Blomkvist 1981; Jansson et 
al. 1991; Watanabe et al. 1987; Yamamoto et al. 1997).  As for biological samples, quantitation of 
environmental samples is also usually done by GC.  Capillary columns are required for the separation of 
the individual congeners in a mixture (WHO 1994a).  High recoveries (88–128%) of PBDE residues in 
environmental samples are obtained by the available analytical methods (Akutsu et al. 2001).  Typically, 
the limit of quantitation for PBDE residues is about 0.12 ng/mL in water, 9.7 µg/kg in sediment, and 
0.2 µg/kg lipid in fish (Akutsu et al. 2001; Yamamoto et al. 1997).  The first inter-laboratory study on 
PBDEs in environmental samples showed that there is good agreement for quantification of BDE 47 and 
2,2’,4,4’,6-pentabromodiphenyl ether (BDE 100) congeners.  However, improved methods are required 
for analysis of 2,2’,4,4’,5-pentabromodiphenyl ether (BDE 99), 2,2’,4,4’,5,5’-hexabromodiphenyl ether 
(BDE 153), 2,2’,4,4’,5,6’-hexabromodiphenyl ether (BDE 154), and BDE 209 congeners (de Boer 2000). 
 
9.3   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of PBBs and PBDEs is available.  Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of PBBs and PBDEs.  
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
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9.3.1   Identification of Data Needs  
 
Methods for Determining Biomarkers of Exposure and Effect.     
 
Exposure.  Methods used as biomarkers for exposure to PBBs and PBDEs are available (Brilliant et al. 
1978; Covaci et al. 2002b; Eyster et al. 1983; Landrigan et al. 1979; Meironyté Guvenius 1999a, 1999b; 
Sjödin et al. 1999; Wolff et al. 1982).  Analytical methods of sufficient precision and accuracy are 
presently available for the determination of PBBs and PBDEs in adipose tissue, serum, and breast milk 
(Burse et al. 1980; Covaci et al. 2002b; Domino et al. 1980; Fawkes et al. 1982; Fehringer 1975a; 
Meironyté Guvenius 1999a, 1999b; Sjödin et al. 1999; Willet et al. 1978; Wolff et al. 1979a, 1979b).  
Additional congener standards are needed for PBB and PBDEs analysis.  Only 30–40 congener standards 
are currently available for identification and quantification of PBDEs (Eljarrat et al. 2002; Sjödin et al. 
1998).  Metabolites are also important biomarkers for exposure to PBBs and PBDEs.  However, these 
compounds are mostly unknown, and standards are not available.  
 
Effect.  No studies have been conducted to determine if known effects of PBBs and PBDEs exposure can 
be quantitatively correlated with PBB or PBDE exposure.  
 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Analytical methods of sufficient sensitivity are presently available for the determination of 
PBBs and PBDEs in environmental samples (Akutsu et al. 2001; Anderson and Blomkvist 1981; Covaci 
et al. 2003; Fehringer 1975b; Hesse and Powers 1978; Jacobs et al. 1976, 1978; Yamamoto et al. 1997).   
 
It would be helpful to develop data determining the detection limit and accuracy of PBBs determinations 
in fish and other aquatic animals (e.g., seals) and in sediment (Gobas et al. 1989; Jaffe et al. 1985; Kuehl 
et al. 1991).  Analytical methods for determining lower brominated PBBs in environmental samples are 
available (Morris et al. 1992).  An analytical method to determine PBB metabolites in fish would be 
helpful.  A method for determining of 6-hydroxy-2,2',4,4',5,5'-hexabromobiphenyl, a metabolite of 
2,2',4,4',5,5'-hexabromobiphenyl, in dog feces is available (Gardner et al. 1979).  Photochemical 
degradation leads to the formation of lower brominated products, which are the only environmental 
degradation products identified for PBBs.  Analytical methods are presently available for the 
determination of these compounds in environmental samples (De Kok et al. 1977; Hill et al. 1982; 
Robertson et al. 1983b).  There is no evidence in the literature of detectable biodegradation of PBBs in the 
environment under aerobic conditions (Griffin and Chou 1981a, 1981b), but the compounds may 
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biodegrade to debrominated products under anaerobic conditions in polluted environments (Morris et al. 
1992). 
 
It would be helpful to develop data determining the accuracy of PBDE determinations (e.g., percent 
recovery) in environmental samples.  Methods for determining degradation products and metabolites of 
PBDE are needed.  There is no information in the literature of detectable biodegradation of PBDEs in the 
environment under aerobic or anaerobic conditions.  The analysis of PBDE pyrolysis degradation 
products, such as polybrominated dibenzo-p-dioxins and dibenzofurans (PBDD/Fs), is often disturbed by 
the presence of PBDEs.  Ebert et al. (1999) demonstrated that by using a Florisil column in a sample 
clean-up process, almost complete separation of PBDEs and PBDDs/PBDFs is achieved before analysis 
by GC-MS. 
 
9.3.2   Ongoing Studies  
 
No ongoing studies regarding analytical methods for determining PBBs and PBDEs residues or 














10.  REGULATIONS AND ADVISORIES 
 
Table 10-1 summarizes international, national, and state regulations and guidelines on human exposure to 
PBBs and PBDEs. 
 
ATSDR has derived an MRL of 0.01 mg/kg/day for acute-duration oral exposure to PBBs.  The MRL is 
based on a NOAEL for thyroid effects in rats (Allen-Rowland et al. 1981).  Intermediate- and chronic-
duration oral MRLs were not derived because serious developmental effects (fetal abortion and stillbirths) 
were observed in monkeys that had been exposed to PBBs for durations that spanned the intermediate and 
chronic categories at the lowest dose tested in the database.  This dose, 0.012 mg/kg/day, caused 
increased menstrual cycle duration and implantation bleeding after 6–7 months of exposure and fetal 
deaths after1 year of exposure in monkeys, with surviving infants having decreased birth weight and 
decreased postnatal weight gain and weight loss also occurring in maternal animals (Allen et al. 1978, 
1979; Lambrecht et al. 1978).  The reproductive effects are less serious, but concern for serious 
developmental toxicity following exposures of >1 year precludes deriving an MRL for intermediate-
duration exposure.  Derivation of an MRL for chronic oral exposure is precluded by the serious 
developmental effects that occurred following exposures exceeding 1 year in duration. 
 
ATSDR has derived an MRL of 0.03 mg/kg/day for acute-duration oral exposure to lower brominated 
diphenyl ethers (BDEs).  The acute oral MRL is based on a NOAEL of 1 mg/kg/day for reduced serum 
levels of thyroid T4 hormone in fetal rats that were exposed to a commercial pentaBDE mixture on 
days 4–20 of gestation (Zhou et al. 2002).  ATSDR also derived an MRL of 0.007 mg/kg/day for 
intermediate-duration oral exposure to lower brominated BDEs.  The intermediate oral MRL is based on a 
minimal LOAEL of 2 mg/kg/day for liver effects in rats that were exposed to a commercial pentaBDE 
mixture for 90 days (WIL Research Laboratories 1984).  A chronic-duration oral MRL was not derived 
for lower brominated BDEs due to insufficient data.   
 
ATSDR has derived an MRL of 10 mg/kg/day for intermediate-duration oral exposure to decaBDE.  This 
intermediate oral MRL is based on a NOAEL of 1000 mg/kg/day for developmental toxicity in rats 
exposed to decaBDE for 19 days during gestation (Hardy et al. 2002).  No acute- or chronic-duration oral 
MRLs were derived for decaBDE due to insufficient data.  
 
ATSDR has derived an MRL of 0.006 mg/m3 for intermediate-duration inhalation exposure to lower 
brominated BDEs.  The intermediate inhalation MRL is based on a NOAEL of 1.1 mg/m3 for thyroid  
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Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
INTERNATIONAL   
Guidelines:    
 IARC Carcinogenicity classification  IARC 1987 
   Decabromobiphenyl Group 2Bb  
   Decabromodiphenyl ether Group 3c  
   Hexabromobiphenyl Group 2Bb  
   Octabromobiphenyl Group 2Bb  
NATIONAL   
Regulations and Guidelines:   
a.  Air    
 ACGIH TLV (8-hour TWA) No data  
 NIOSH REL (10-hour TWA) No data  
 OSHA PEL (8-hour TWA) No data  
b.  Water    
 EPA Standards for owners and operators of 
hazardous waste TSD facilities; 
groundwater monitoring for p-bromodi-
phenyl ether 
 EPA 2002e 
   Suggested EPA method 8270 40CFR264, 
   PQL 10 µg/L Appendix IX 
d.  Food    
 FDA Indirect food additives; substances for 
use only as components of adhesives 
 FDA 2001 
21CFR175.105 
(c)(5) 
   Hexabromo-1,1'-biphenyl   
e.  Other    
 EPA Carcinogenicity classification  IRIS 2002 
   Decabromodiphenyl ether Group Cd  
   Nonabromodiphenyl ether Group De  
   Octabromodiphenyl ether Group De  
   Hexabromodiphenyl ether Group De  
   Pentabromodiphenyl ether Group De  
   Tetrabromodiphenyl ether Group De  
   Tribromodiphenyl ether Group De  
   p,p’-Dibromodiphenyl ether Group De  
   p-Bromodiphenyl ether Group De  
 EPA Oral reference dose (RfD)  IRIS 2002 
   Decabromodiphenyl ether 1x10-2 mg/kg/day  
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Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
   Octabromodiphenyl ether 3x10-3 mg/kg/day  
NATIONAL (cont.) 
 EPA  Pentabromodiphenyl ether 2x10-3 mg/kg/day  
  Chemical substances subject to 
proposed or final TSCA rules or orders 
Regulated under  
TSCA section(s) 
EPA 1998 
   Decabromobiphenyl 5(a)(2)  
   Decabromodiphenyl ether 4  
   Hexabromo-1,1'-biphenyl 5(a)(2)  
   Octabromobiphenyl 5(a)(2)  
   Octabromodiphenyl ether 4  
   p-Bromodiphenyl ether 5(a)(2)  
   Pentabromodiphenyl ether 4  
  EPCRA Section 313; toxic chemical  EPA 2001 
   Decabromodiphenyl ether   
  Identification and listing of hazardous 
waste; commercial chemical products, 
manufacturing chemical intermediates, 
or off-specification commercial 
chemical products are identified as 
toxic wastes; EPA hazardous waste 
number 
 EPA 2002b 
40CFR261.33(f) 
   p-Bromodiphenyl ether U030  
  Land disposal restrictions; universal 
treatment standards 
 EPA 2002c 
40CFR268.48(a) 
   p-Bromodiphenyl ether   
    Wastewater 
standard 
0.055 mg/L  
    Nonwastewater 
standard 
15 mg/kg  




PQL EPA 2002a 
40CFR258, 
Appendix II 
   p-Bromodiphenyl ether 8110 25 µg/L  
   8270 10 µg/L  
  Radiation protection; health and 
environmental protection standards for 
uranium and thorium mill tailings; listed 
constituent 
 EPA 2002d 
40CFR192, 
Appendix I 
   p-Bromodiphenyl ether   
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Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
NATIONAL (cont.) 
 EPA CERCLA hazardous substance under 
Section 307(a) of the Clean Water Act 
and RCRA Section 3001; reportable 
quantity 
 EPA 2002f 
40CFR302.4 
   p-Bromodiphenyl ether 100 pounds  
  Chemicals subject to the Prior Informed 
Consent Procedure: International right-
to-know 
 EPA 2002g 
   Decabromobiphenyl   
   Hexabromobiphenyl   
   Octabromobiphenyl   
  Toxic chemical release reporting; 
community right-to-know; effective date 
for reporting 
 EPA 2002h 
40CFR372.65(c) 
   Decabromodiphenyl ether 01/01/87  
   Polybrominated biphenyls 01/01/87  
  TSCA; chemical information rules; 
manufacturers and importers must 
submit a Preliminary Assessment 
Information Manufacturers’ Report for 
each site at which they manufacture or 
import each substance by the reporting 
date shown 
 EPA 2002i 
40CFR712.30(d) 
   Decabromodiphenyl ether 03/12/90  
   Octabromodiphenyl ether 03/12/90  
   Pentabromodiphenyl ether 03/12/90  
  TSCA; chemical substances required to 
be tested 
Chemical substances 
known to be manufact-
ured between 01/01/84 





   Decabromodiphenyl ether   
   Octabromodiphenyl ether   
   Pentabromodiphenyl ether   







   Decabromodiphenyl ether 01/11/90 06/30/98  
   Octabromodiphenyl ether 06/30/98 01/11/90  
   Pentabromodiphenyl ether 01/11/90 06/30/98  
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Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
NATIONAL (cont.) 
 EPA TSCA; reporting requirements including 
deadline for submitting the protocols 
 EPA 2002k 
40CFR766.35 
   Decabromodiphenyl ether 01/31/91  
   Octabromodiphenyl ether 01/31/91  
   Pentabromodiphenyl ether 02/06/95  
 EPA TSCA; significant new uses subject to 
reporting of p-bromodiphenyl ether 
Significant new use 
includes manufacturing, 
importing, or processing 
of 10,000 pounds or 
more per year per 
facility for any use 
EPA 2002m 
40CFR721.3430 
  TSCA; significant new uses subject to 
reporting of polybrominated biphenyl 
The significant new use 
is any use 
EPA 2002n 
40CFR721.1790 
   Decabromodiphenyl   
   Hexabromo-1,1'-biphenyl   
   Octabromobiphenyl   
  Voluntary children’s chemical 
evaluation program 
 EPA 2002o 
   Decabromodiphenyl ether   
   Octabromodiphenyl ether   
   Pentabromodiphenyl ether   
 NTP Carcinogenicity classification  NTP 2002 
   Decabromobiphenyl Reasonably anticipated 
to be human 
carcinogens 
 
   Octabromobiphenyl   
   Polybrominated biphenyl   
STATE    
Regulations and Guidelines:   
a.  Air  No data  
b.  Water    
 Florida Drinking water guideline 10 µg/L HSDB 2002 
   p-Bromodiphenyl ether   
c.  Food  No data  
d.  Other    
 Florida Toxic substance  BLR 2002 
  Polybrominated biphenyl   
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Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
STATE (cont.) 
 Massachusetts Hazardous substances requires the 
labeling of containers of toxic 
substances in the workplace 
 BLR 2002 
  Decabromobiphenyl Extraordinary 
hazardousg 
 
  Decabromdiphenyl ether   
  Hexabromobiphenyl Extraordinary 
hazardousg 
 
   Hexabromo-1,1'-biphenyl Extraordinary 
hazardousg 
 
  Octabromobdiphenyl Extraordinary 
hazardousg 
 
  p-Bromodiphenyl ether   
  Polybrominated biphenyl   
 Michigan Critical materials register; requires all 
businesses discharging waste products 
into the water or any sewer system to 
report the annual amount 
 BLR 2002 
  p-Bromodiphenyl ether   
 Minnesota Hazardous substance  BLR 2002 
  Decabromodiphenyl ether   
  Hexabromo-1,1'-biphenyl   
 New Jersey Hazardous substance; requires SIC 
employers to submit Community Right-
to-Know survey listing environmental 
hazardous substances present at their 
facilities in quantities that exceed 
500 pounds 
 BRL 2002 
  Decabromodiphenyl ether   
 New York Hazardous substance  BLR 2002 
  p-Bromodiphenyl ether   
   Reportable quantity (air) 100 pounds  
   Reportable quantity (land) 100 pounds  
PBBs and PBDEs  485 
 








Table 10-1.  Regulations and Guidelines Applicable to PBBs and PBDEsa 
 
Agency Description Information Reference 
STATE (cont.) 
 Pennsylvania Hazardous substance; requires 
employers to complete the Hazardous 
Substance Survey Form annually 
 BLR 2002 
  Decabromodiphenyl ether Environmental hazard  
  p-Bromodiphenyl ether Environmental hazard  
  Polybrominated biphenyl Special hazard  
aPolybrominated biphenyls category includes: decabromobiphenyl (CAS# 13654-09-6); decabromodiphenyl ether 
(CAS# 1163-19-5); hexabromobiphenyl (CAS# 59080-40-9); hexabromo-1,1'-biphenyl (CAS# 36355-01-8); 
hexabromodiphenyl ether (CAS# 36483-60-0); nonabromodiphenyl ether (CAS# 63936-56-1); octabromobiphenyl 
(CAS#  27858-07-7); octabromobiphenyl (CAS# 61288-13-9); octabromodiphenyl ether (CAS# 32536-52-0); 
p-bromodiphenyl ether (CAS# 101-55-3); p,p’-dibromodiphenyl ether (CAS# 2050-47-7); pentabromodiphenyl ether 
(CAS# 32534-81-9); polybrominated biphenyl (CAS# 59536-65-1); polybrominated biphenyl mixture (CAS# 67774-
32-7); tetrabromodiphenyl ether (CAS# 40088-47-9); and tribromodiphenyl ether (CAS# 49690-94-0). 
bGroup 2B: possibly carcinogenic to humans 
cGroup 3: not classifiable as to its carcinogenicity to humans 
dGroup C: possible human carcinogen 
eGroup D: not classifiable as to human carcinogenicity 
fHealth and safety data reporting: the listed chemical substances are subject to all provisions of 40CFR716.  
Manufacturers, importers, and processors of a listed substance are subject to the reporting requirements of 
Subpart A for that substance. 
gExtraordinary hazardous and designated carcinogen 
 
ACGIH = American Conference of Governmental Industrial Hygienists; BRL = Business & Legal Reports, Inc.; 
CERCLA = Comprehensive Environmental Response Compensation and Liability Act; CFR = Code of Federal 
Regulations; EPA = Environmental Protection Agency; EPCRA = Emergency Planning and Community Right-to-
Know Act; FDA = Food and Drug Administration; HSDB = Hazardous Substances Data Bank; IARC = International 
Agency for Research on Cancer; IRIS = Integrated Risk Information System; NIOSH = National Institute for 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 
Administration; PEL = permissible exposure limit; PQL = practical quantitation limits; RCRA = Resource 
Conservation Recovery Act; REL = recommended exposure limit; RfD = oral reference dose; SIC = Standard 
Industrial Classification; TLV = threshold limit value; TSCA = Toxic Substances Control Act; TSD = treatment, 
storage, and disposal; TWA = time-weighted average 
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effects in rats that were exposed to a commercial octaBDE mixture for 13 weeks (Great Lakes Chemical 
Corporation 2001a, 2001b).  
 
EPA derived reference doses (RfDs) for octaBDE and pentaBDE of  3x10-3 and 2x10-3 mg/kg/day, 
respectively (IRIS 2002).  The current RfD for decaBDE is 1x10-2 mg/kg/day, but this is based on a study 
using a preparation that contained only 77% decaBDE; the RfD for decaBDE is currently under review by 
the IRIS program. 
 
The National Academy of Sciences (NRC 2000) derived a RfD of 4 mg/kg/day for decabromodiphenyl 
oxide based on a NOAEL of 1,120 mg/kg/day for liver pathology in rats that were exposed for 103 weeks 
(NTP 1986). 
 
IARC (1987) has classified decabromobiphenyl, hexabromobiphenyl, and octabromobiphenyl in 
Group 2B, possibly carcinogenic to humans.  NTP (2002) has classified decabromobiphenyl, octabromo-
biphenyl, and polybrominated biphenyl as reasonably anticipated to be human carcinogens.  EPA (IRIS 
2002) has classified decabromodiphenyl ether in Group D, as a possible human carcinogen, and nona-
bromodiphenyl ether, octabromodiphenyl ether, hexabromodiphenyl ether, pentabromodiphenyl ether, 
tetrabromodiphenyl ether, tribromodiphenyl ether, p,p’-dibromodiphenyl ether, and p-bromodiphenyl 
ether in Group D, not classifiable as to human carcinogenicity. 
 
The American Industrial Hygiene Association (AIHA) has established a Workplace Environmental 
Exposure Level (WEEL) of 5 mg/m3 for decaBPE (AIHA 1996). 
 
Industry is required to report health and safety data for PBDEs, including decabromodiphenyl ether, 
octabromodiphenyl ether, and pentabromodiphenyl ether, under the Toxic Substances Control Act 
(TSCA) (EPA 2002l). 
 
The European Union has banned the sale of products containing more than 0.1% penta- and octaBDE 
effective August 15, 2004 (EU 2003b).  In 2003, the state of California passed an identical ban, to go into 
effect January 1, 2008 (California Assembly 2003).  A subsequent proposed bill would change the 
implementation date to June 1, 2006 (California Assembly 2004). 
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12.  GLOSSARY 
 
Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
 
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.  
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Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
 
Immunological Effects—Functional changes in the immune response. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been 
reported to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation 
that has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a 
chemical is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed group. 
 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
 
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism.  Utilizing computational techniques, it provides the means of studying the 
absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.  
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical information 
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called 
biologically based tissue dosimetry models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL-from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
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Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may 
not be exceeded. 
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
 
Toxicokinetic—The study of the absorption, distribution, and elimination of toxic compounds in the 
living organism. 
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
 
Xenobiotic—Any chemical that is foreign to the biological system. 










APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 










are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333. 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name: Polybrominated Diphenyl Ethers (PBDEs) 
   [Lower Brominated Diphenyl Ethers] 
CAS number(s): 32534-81-9 (pentaBDE), 32536-52-0 (octaBDE)  
Date:   September 2, 2004 
Profile status:  Final Post Public Comment 
Route:   [X] Inhalation [ ] Oral 
Duration:  [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure:  3 
Species:  Rat 
 
Minimal Risk Level:   0.006 [ ] mg/kg/day [ ] ppm [X] mg/m3 
 
Reference:  Great Lakes Chemical Corporation.  2000.  A 90-day inhalation toxicity study of 
octabromodiphenyl oxide in albino rats, dated 04/04/02.  Submitted to the U.S. EPA under TCSA Section 
8E, Fiche no. OTS0574171-1. 
 
Experimental design:  This is an unpublished industry-sponsored study in which a commercial octaBDE 
product (Lot No. 9525DA23B, bromine content 78.7%, composition and purity not otherwise specified) 
was administered to groups of 10 male and 10 female Crl:CD(SD)IGS BR rats, via nose-only inhalation 
as a dust aerosol, in measured concentrations of 0 (filtered air-only), 1.1, 16 or 202 mg/m3 for 
6 hours/day, 5 days/week, for 13 weeks.  The mean MMADs in the low to high level groups were 2.0, 
2.7, and 2.8 microns; the corresponding mean GSDs were 3.37, 3.72, and 3.01.  Clinical and physical 
signs, body weight, food consumption, and survival were evaluated throughout the study.  Ophthalmic, 
hematology (11 indices), serum chemistry (18 indices), and serum thyroid hormone (TSH, total T3, and 
total T4) evaluations were performed near the end of the exposure period.  Urinalyses were not conducted.  
Comprehensive necropies, organ weight measurements, and histological examinations (including 
respiratory tract and thyroids) were performed following exposure termination.   
 
Effects noted in study and corresponding doses:  Hepatic, nasal, lung, thyroid, and ovarian effects were 
observed.  The liver was affected in both sexes as shown by dose-related increases in centrilobular 
hepatocellular hypertrophy at ≥16 mg/m3 and liver weight (absolute and relative) at 202 mg/m3.  Total 
incidences of centrilobular hepatocellular hypertrophy in the 0, 1.1, 16, and 202 mg/m3 groups were 
1/10 (minimal), 0/10, 3/10 (all minimal), and 10/10 (6 minimal, 2 mild, 2 moderate) in males, and 0/10, 
0/10, 3/10 (all minimal), and 6/10 (3 minimal, 3 mild) in females.  Changes in nasal Goblet cells were 
increased at 202 mg/m3, but showed no clear dose-related increasing trends for incidence and severity.  
Total incidences of Goblet cell hypertrophy (minimal or mild) were slightly increased in nasal level II of 
both sexes at ≥1.1 mg/m3; incidences in 0, 1.1, 16, and 202 mg/m3 exposure groups were 4/10 (all 
minimal), 9/10 (7 minimal, 2 mild), 6/10 (all minimal), and 10/10 (9 minimal, 1 mild) in males, and 
2/10 (all minimal), 6/10 (all minimal), 4/10 (all minimal), and 8/10 (all minimal) in females.  Goblet cell 
hypertrophy was also slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 0/10, 1/10, and 
8/10, all minimal severity, not increased in females).  Histological changes in the lungs included alveolar 
histiocytosis and chronic active inflammation that were only clearly induced at 202 mg/m3.  Total 
incidences of alveolar histiocytosis at 0, 1.1, 16, and 202 mg/m3 were 3/10 (2 mild, 1 minimal), 5/10 (all 
minimal), 5/10 (all minimal), and 10/10 (5 minimal, 3 mild, 2 moderate) in males, and 0/10, 5/10 (all 
minimal), 2/10 (all minimal), and 10/10 (1 minimal, 7 mild, 2 moderate) in females.  Corresponding total 
incidences of chronic active lung inflammation were 0/10, 0/10, 2/10 (both minimal), and 
10/10 (5 minimal, 4 mild, 1 moderate) in males, and 0/10, 1/10 (minimal), 1/10 (minimal), and 
10/10 (2 minimal, 5 mild, 3 moderate) in females.  Gross lung changes also occurred in both sexes at 
202 mg/m3; these included lung firmness and white discoloration and/or enlargement in the bronchial 










and/or mediastinal lymph nodes.  The lymph node effects correlated with the histological finding of 
granulomatous inflammation.  There were no exposure-related gross or histopathological changes in the 
spleen, bone marrow, thymus, or other tissues, including thyroid.  Thyroid hormone assessments, 
however, showed exposure-related decreases in mean thyroxine (total T4) at ≥16 mg/m3 in both sexes, and 
increases in thyroid stimulating hormone (TSH) at ≥16 mg/m3 in males and 202 mg/m3 in females.  The 
changes were usually statistically significant (p<0.05 or p<0.01) compared to controls and considered to 
be consistent with chemical-induced hypothyroidism.  There were no serum T3 changes.  Qualitative 
histological evaluations of step sections of ovaries showed an absence of corpora lutea in 3/10 females at 
202 mg/m3, compared to 0/10 in the control and lower exposure groups.  This 30% incidence was 
interpreted to be a treatment-related effect because an absence of corpora lutea was considered unusual in 
rats at 20 weeks of age. 
 
Other findings included some hematological alterations in 202 mg/m3 females that were not considered to 
be exposure-related (slightly increased mean activated partial thromboplastin time, and decreased mean 
MCH and MCHC without effects on RBC counts, hematocrit, or hemoglobin levels).  Serum chemistry 
evaluations showed that cholesterol was significantly increased (39.8% less than controls, p<0.01) in 
202 mg/m3 females, but the magnitude of the elevation was not considered toxicologically significant.  
Some other statistically significant serum chemistry alterations (increased mean globulin and total 
protein, decreased albumin/globulin ratio) also occurred in the 202 mg/m3 females, but were not 
considered exposure-related due to small magnitudes of changes and lack of similar findings in the males. 
 
Dose and end point used for MRL derivation:  1.1 mg/m3 
 
[X] NOAEL  [   ] LOAEL 
 
Considering the unclear adversity of minimal severity Goblet cell hypertrophy, lack of clear dose-related 
increasing trends for incidence and severity of this nasal effect, identification of both a NOAEL 
(1.1 mg/m3) and LOAEL (16 mg/m3) for changes in thyroid hormones, and abundant evidence for thyroid 
effects of PBDEs in oral studies, the NOAEL for effects on thyroid hormones is the most appropriate 
basis for derivation of the MRL. 
 
Uncertainty factors used in MRL derivation: 
 
[X]    3 for extrapolation from animals to humans with dosimetric adjustments 
[X]   10 for human variability 
[X]    3 modifying factor for incomplete data base 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  NA 
 
Was a conversion used from intermittent to continuous exposure?  The NOAEL was adjusted to 
continuous exposure as follows:  1.1 mg/m3 x 6 hours/24 hours x 5 days/7 days = 0.196 mg/m3 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  The 
human equivalent NOAEL (NOAELHEC) was calculated from the duration-adjusted NOAEL (NOAELADJ) 
using EPA RfC methodology as follows:  
 
 NOAELHEC = NOAELADJ x RDDR = 0.196 mg/m3 x 2.7 = 0.53 mg/m3 
 
The regional deposited dose ratio (RDDR) for the extrathoracic (ET) region was used to extrapolate 
deposited doses in rats to deposited doses in humans.  The following parameters were used to calculate 










the RDDR of 2.7:  mean particle size (MMAD) of 2.0 µm with a mean GSD (sigma g) of 3.37; default 
human body weight of 70 kg, and a default female F344 rat body weight of 180 g. 
 
Based on these values, the MRL is derived as follows: 
 
 MRL = NOAELHEC ÷ (UF x MF) = 0.53 ÷ (30 x 3) = 0.006 mg/m3  
 
Other additional studies or pertinent information that lend support to this MRL:  This is the only 
intermediate-duration inhalation study of PBDEs. 
 
The thyroid is a sensitive target of lower brominated BDEs in orally exposed animals.  A NOAEL for 
reduced serum T4 hormone levels in fetal rats that were exposed to pentaBDE (Zhou et al. 2002) was used 
as the basis for the acute oral MRL for lower brominated BDEs.  This study is supported by findings of 
reduced serum T4 levels in weanling rats that were acutely exposed to octaBDE and pentaBDE as 
neonates (Zhou et al. 2001).  Thyroid effects that mainly included reduced serum T4 hormone levels and 
follicular cell hyperplasia were observed in a number of other animal studies of acute- or intermediate-
duration oral exposure to penta- and octaBDEs (Fowles et al. 1994; Hallgren et al. 2001; WIL Research 
Laboratories 1984). 
 
Agency Contact (Chemical Manager):  Dr. Hana Pohl 
 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name: Polybrominated Biphenyls (PBBs) 
CAS number(s): 36355-01-8 (unspecified hexabromo mixture)  
Date:   September 2, 2004 
Profile status:  Final Post Public Comment 
Route:   [ ] Inhalation [X] Oral 
Duration:  [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure:  4 
Species:  Rat 
 
Minimal Risk Level:   0.01 [X] mg/kg/day [ ] ppm [ ] mg/m3 
 
Reference:  Allen-Rowlands CF, Castracane VD, Hamilton MG, et al.  1981.  Effect of polybrominated 
biphenyls (PBB) on the pituitary - thyroid axis of the rat.  Proc Soc Exp Biol Med 166:506-514.  
 
Experimental design:  Groups of 8–11 male rats were treated with 0, 1, 3, or 6 mg/kg/day doses of an 
unspecified mixture of PBBs in lecithin liposomes by gavage for 10 days.  Plasma T4 was assayed on 
treatment days 10 and 20.  Other end points were evaluated on treatment day 20; these included plasma 
TSH levels, 5-hour thyroid uptake of 131I, incorporation of 131I into monoiodotyrosine, diiodotyrosine, T3 
or T4, amount of intrathyroidal iodide, thyroid and liver weights, and body weights.  Differences between 
mean values for the measured parameters in the control and PBB-treated groups were analyzed with the 
Student’s t-test, with a P value of 0.05 considered as statistically significant. 
 
Effects noted in study and corresponding doses:  Plasma (T4) was significantly (p<0.05) decreased at 
≥3 mg/kg/day after 10 and 20 days; this reduction was both dose- and time-dependent.  Plasma TSH 
levels were significantly elevated (p<0.01) at 6 mg/kg/day.  The 6 mg/kg dose also produced a significant 
increase (p<0.01) in the 5-hour thyroid uptake of 131I and a significant depression (p<0.01) in the 
incorporation of 131I into monoiodotyrosine, without any apparent effect on the incorporation of 131I into 
diiodotyrosine, T3 or T4.  There was a significant increase (p<0.01) of intrathyroidal iodide (nine rats/dose 
evaluated).  At ≥3 mg/kg, the absolute thyroid weights were significantly increased (p<0.01) (not 
evaluated at 1 mg/kg).  Relative liver weight was significantly increased at ≥1 mg/kg/day, but no 
treatment related effects on body weight were observed.  The 1 mg/kg/day dose is considered a NOAEL. 
 
Despite the fact that the inappropriate statistical test (t-test, rather than an ANOVA with multiple 
comparison tests) was used to analyze these data, ATSDR is confident with the designation of the 
NOAEL and LOAEL values.  The data in the manuscript are presented graphically, with animal numbers 
presented as a range (8–11 animals/group); thus, an ANOVA could not be performed from the published 
report.  However, using the graphical data, the change in plasma T4 levels in the 3 mg/kg/day groups is 
clearly on the order of 20–30%, which represents a biologically significant change.  As such, the 
identification of 3 mg/kg/day as a LOAEL, and 1 mg/kg/day as a NOAEL, is not contraindicated by the 
lack of appropriate statistical analysis. 
 
Dose and end point used for MRL derivation: 
 
[X] NOAEL  [   ] LOAEL 
 
Uncertainty factors used in MRL derivation: 
 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability 











Was a conversion factor used from ppm in food or water to a mg/body weight dose?  NA (gavage study)  
 
Was a conversion used from intermittent to continuous exposure?  NA 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA 
 
Other additional studies or pertinent information that lend support to this MRL:  It is well documented in 
intermediate-duration studies that the thyroid is a target of PBBs showing a spectrum of effects, including 
decreases in serum T3 and T4 hormone, thyroid enlargement, effects in the follicular cells (e.g., reduced 
size, hyperplasia with columnar appearance, and papillary projections) and accumulation of colloid 
droplets (Akoso et al. 1982a, 1982b; Byrne et al. 1987; Gupta and Moore 1979; Kasza et al. 1978a; Norris 
et al. 1975a, 1975b, 1975c; NTP 1983; Sepkovic and Byrne 1984; Sleight et al. 1978). 
 
Agency Contact (Chemical Manager):  Dr. Hana Pohl 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name: Polybrominated Diphenyl Ethers (PBDEs) 
   [Lower Brominated Diphenyl Ethers] 
CAS number(s): 32534-81-9 (pentaBDE), 32536-52-0 (octaBDE)  
Date:   September 2, 2004 
Profile status:  Final Post Public Comment 
Route:   [ ] Inhalation [X] Oral 
Duration:  [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure:  27 
Species:  Rat 
 
Minimal Risk Level:   0.03 [X] mg/kg/day [ ] ppm [ ] mg/m3 
 
Reference:  Zhou T, Taylor MM, DeVito MJ, et al.  2002.  Developmental exposure to brominated 
diphenyl ethers results in thyroid hormone disruption.  Toxicol Sci 66:105-116. 
 
Experimental design:  Groups of 47, 47, 55, and 55 primparous Long-Evans rats were administered a 
technical pentaBDE mixture (DE-71) in corn oil by gavage from gestation day (GD) 6 through postnatal 
day (PND) 21, except for PND 0 (day of birth).  DE-71 is a technical mixture consisting primarily of tetra 
and penta congeners.  Dams were sacrificed on GD 20 and PND 22 and offspring were sacrificed on 
GD 20 and PNDs 4, 14, 36, and 90).  Serum and liver samples were obtained from a minimum of eight 
litters at each age point and analyzed for thyroid hormone (total T4 and T3) concentrations, liver weight, 
and hepatic microsomal enzyme (EROD, PROD, UDPGT) activities.  Serum T3 was not assayed in 
GD 20 fetuses due to insufficient serum sample volume.  Other study end points included number of pups 
delivered on GD 21, number and sex of pups on PNDs 4, 7, 14, and 21, body weight of pups on PNDs 4, 
7, 14, 21, 36, and 90, eye opening status (pups with at least one eye open) on PNDs 11–18, and maternal 
body weight on GD 6 through PND 21. 
 
The litter was the statistical unit for all analyses.  Analysis of variance (ANOVA) was used to analyze for 
effects of treatment and interactions.  If there was more than one independent variable, significant 
interactions were followed by step-down ANOVA tests for each independent variable (e.g., treatment and 
age).  A nested design was used when more than one reading for each litter was obtained (e.g., body 
weights for males and females from the same litter).  Repeated-measure ANOVAs were applied to data 
on dam body weights, preweaning offspring body weights (PNDs 4–21), and eye opening.  Postweaning 
offspring body weights (PNDs 36–91) were analyzed with a two-way ANOVA, with time and dose as 
independent variables and litter nested under treatment.  For significant effects of treatment, Duncan’s 
Multiple Comparison test was used for mean contrast comparisons.  The fetal T4 data were analyzed with 
the Kruskal-Wallis test followed by a Dunn Multiple Comparison tests (due to a lack of homogeneity of 
variance).  A significance level of 0.05 was used for all statistical tests.  Benchmark dose estimates were 
determined for alterations in thyroid hormones and hepatic enzyme activity using the U.S. EPA 
Benchmark Dose Software (BMDS, V 1.3). 
 
Effects noted in study and corresponding doses:  No treatment-related effects on gestation length, litter 
size, sex ratio, viability index (percent of pups surviving until day 4), maternal or offspring body weights, 
or offspring eye opening were observed.  The perinatal maternal exposure to PentaPBE caused significant 
(p<0.05) decreases in serum total T4 in dams at 30 mg/kg/day on GD 20 and PND 22 (48 and 44%, 
respectively, relative to controls), and in fetuses and offspring at ≥10 mg/kg/day on GD 20 (at least 15% 
reduced) and PNDs 4 and 14 (50 and 64% maximal in the 10 and 30 mg/kg/day groups, respectively).  
The effect on T4 concentrations in offspring was age-dependent as values returned to control levels by 
PND 36.  There were no exposure-related effects on serum total T3 concentrations at any time in the dams 










or offspring.  Relative liver weight was significantly (p<0.05) increased in dams from GD 20 to PND 22 
(approximately 8% above controls) at 30 mg/kg/day and offspring during the early preweaning period at 
≥10 mg/kg/day.  Liver weights in offspring were maximal at 30 mg/kg/day on PNDs 4 and 14 (35 and 
39% above controls, respectively) and returned to control levels by PND 36.  Microsomal enzyme activity 
was increased in both dams and offspring as shown by significantly elevated hepatic EROD and PROD at 
≥10 mg/kg/day in dams on GD 20 and PND 22 and offspring on GD 20 and PNDs 4, 14, and 36, and 
signficantly elevated UDPGT at 30 mg/kg/day in dams on GD 20 and PND 22 and offspring on GD 20 
and PNDs 4 and 14.  Benchmark dose analysis of the data found that the BMD and BMDL (95% lower 
confidence bound confidence limit on the effective dose) resulting in a 20% reduction of serum T4 
(LED20) were 2.36 and 0.94 mg/kg/day, respectively.  The respective BMD and BMDL resulting in 50% 
increased enzyme activity were 0.43 and 0.31 mg/kg/day for EROD, 0.48 and 0.36 mg/kg/day for PROD, 
and 5.50 and 3.41 mg/kg/day for UDPGT.  
 
Dose and end point used for MRL derivation: 
 
[X] NOAEL  [   ] LOAEL 
 
A NOAEL of 1 mg/kg/day and a LOAEL of 10 mg/kg/day were identified for reduced serum T4 levels in 
fetal rats on GD 20. 
 
Uncertainty factors used in MRL derivation: 
 
[X]  10 for extrapolation from animals to humans 
[X]    3 for human variability 
 
A component factor of 10 was not used for human variability because the MRL is based on effect levels 
identified in a sensitive subgroup (i.e., neonates exposed in utero). 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  NA (gavage study) 
 
Was a conversion used from intermittent to continuous exposure?  NA 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA 
 
Other additional studies or pertinent information that lend support to this MRL:  The NOAEL of 
1 mg/kg/day and LOAEL of 10 mg/kg/day for reduced serum T4 hormone levels in fetal rats that were 
exposed to pentaBDE in the acute MRL study (Zhou et al. 2002) are supported by a NOAEL of 
3 mg/kg/day and LOAEL of 10 mg/kg/day for reduced serum T4 levels in weanling rats that were exposed 
to octaBDE for 4 days (Zhou et al. 2001).  Thyroid hormone levels were determined in groups of eight 
weanling (28-day-old) female Long-Evans that were treated by gavage for 4 days with commercial 
mixtures of decaBDE (DE-83R) or octaBDE (DE-79) in doses of 0.3, 1, 3, 10, 30, 60, or 100 mg/kg/day, 
or pentaBDE (DE-71) in doses of 0.3, 1, 3, 10, 30, 100, or 300 mg/kg/day.  The animals were sacrificed 
on the day after the last exposure and evaluated for changes in serum total T4, total T3, and TSH, hepatic 
microsomal EROD, PROD, and UDPGT activities, and body and liver weight.  No dose-related effects on 
any of the measured parameters were observed for decaBDE.  OctaBDE and pentaBDE caused reduced 
thyroid hormone levels and increased microsomal enzyme activities. 
 
Effects of octaBDE included dose-related reductions in serum total T4 levels with statistically significant 
(p<0.05) decreases occurring at ≥10 mg/kg/day and a 70% maximum decrease compared to controls at 
100 mg/kg/day (Zhou et al. 2001).  Serum T3 levels were reduced less than T4 levels and were significant 
at ≥60 mg/kg/day with a maximum reduction of 25% at the highest dose of 100 mg/kg/day.  There were 










no exposure-related changes in serum total TSH concentrations.  Hepatic microsomal EROD and UDPGT 
activities and relative liver weight were significantly (p<0.05) increased at ≥30 mg/kg/day and PROD 
activity was increased at ≥10 mg/kg/day in dose-related responses.  No treatment-related effects on body 
weight or visible signs of toxicity were observed.  Benchmark dose analysis of the octaBDE data found 
that the BMD and BMDL resulting in a 20% reduction in thyroid hormones (LED20) were 9.25 and 
5.29 mg/kg/day, respectively, for serum T4 and 53.38 and 11.98 mg/kg/day, respectively, for serum T3.  
The respective BMD and BMDL resulting in 50% increased enzyme activity were 3.66 and 
2.45 mg/kg/day for EROD, 0.53 and 0.40 mg/kg/day for PROD, and 21.17 and 11.03 mg/kg/day for 
UDPGT. 
 
Effects of pentaBDE included dose-related reductions in serum total T4 levels with significant (p<0.05) 
decreases occurring at ≥30 mg/kg/day and an 80% maximum decrease compared to controls 
300 mg/kg/day (Zhou et al. 2001).  Serum total T3 levels were reduced less than T4 levels and were 
significant at ≥100 mg/kg/day with a maximum reduction of 30% at the highest dose of 300 mg/kg/day.  
There were no exposure-related changes in serum total TSH concentrations.  Hepatic microsomal EROD 
and PROD activities and relative liver weight were significantly (p<0.05) increased at ≥10 mg/kg/day and 
UDPGT activity was increased at ≥30 mg/kg/day in dose-related responses.  No treatment-related effects 
on body weight or visible signs of toxicity were observed.  The BMD and BMDL resulting in a 20% 
reduction in thyroid hormones (LED20) were 12.74 and 6.95 mg/kg/day, respectively, for serum T4 and 
32.94 and 8.56, mg/kg/day, respectively, for serum T3.  The respective BMD and BMDL resulting in 50% 
increased enzyme activity were 2.88 and 1.82 mg/kg/day for EROD, 0.81 and 0.54 mg/kg/day for PROD, 
and 9.51 and 5.83 mg/kg/day for UDPGT. 
 
Thyroid effects that mainly included reduced serum T4 hormone levels and follicular cell hyperplasia 
have been observed in a number of other studies of PBDEs in orally-exposed animals.  Other acute-
duration studies showed decreases in serum T4 in rats and mice exposed to ≥18 mg/kg/day pentaBDE for 
14 days (Fowles et al. 1994; Hallgren et al. 2001).  Effects observed in intermediate-duration studies 
include thyroid hyperplasia in rats exposed to ≥8 mg/kg/day octaBDE for 30 days (Norris et al. 1973, 
1975b) and reduced serum T4 in rats exposed to ≥10 mg/kg/day pentaBDE for 90 days (WIL Research 
Laboratories 1984).  Intermediate-duration exposure to a 77% decaBDE/22% nonaBDE commercial 
mixture caused thyroid hyperplasia in rats at doses ≥80 mg/kg/day for 30 days (Norris et al. 1973, 1975b).  
Chronic (103-week) exposure to high-purity decaBDE (≥97%) did not induce thyroid histopathological 
changes in rats at ≤2,550 mg/kg/day, although follicular cell hyperplasia developed in mice exposed to 
2,240 mg/kg/day (NTP 1986). 
 
Agency Contact (Chemical Manager):  Dr. Hana Pohl 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name: Polybrominated Diphenyl Ethers (PBDEs) 
   [Lower Brominated Diphenyl Ethers] 
CAS number(s): 32534-81-9 (pentaBDE), 32536-52-0 (octaBDE)  
Date:   September 2, 2004 
Profile status:  Final Post Public Comment 
Route:   [ ] Inhalation [X] Oral 
Duration:  [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure:  36 
Species:  Rat 
 
Minimal Risk Level:    0.007 [X] mg/kg/day [ ] ppm [ ] mg/m3 
 
Reference:  WIL Research Laboratories.  1984.  90-day dietary study in rats with pentabromodiphenyl 
oxide (DE-7) (Volume I-II).  Submitted to U.S. EPA under TSCA Section 8D, Fiche no. OTS0524336. 
 
Experimental design:  PentaBDE (commercial mixture DE-71) was administered to Sprague-Dawley rats 
in the diet at dosage levels of 0, 2, 10, or 100 mg/kg/day for 90 days.  Ten rats/sex/group were sacrificed 
after 4 weeks, 10 rats/sex/group were sacrificed at the end of the 90-day exposure period, and the 
remaining rats were sacrificed after a 6-week recovery period (5 rats/sex/group) or 24-week recovery 
period (5 rats/sex/group).  Animals were observed daily for general appearance, behavior, signs of overt 
toxicity, and mortality during the dosing and recovery periods.  Body weight and food consumption were 
measured during the dosing period and the first 4 weeks of the recovery period.  Hematology, clinical 
chemistry (including serum T3 and T4), and urinalysis parameters, urine and liver porphyrin levels, and 
serum bromide levels were evaluated in 10 rats/sex/group at weeks 4 and 13.  Bromine levels in liver, 
lung, kidney, thymus, and thyroid were evaluated at weeks 4, 13, 19, and 37.  Gross necropsies and organ 
weight measurements (brain, gonads, heart, liver, kidneys, thymus, and thyroid) were performed on all 
rats.  Histological examinations included liver, lung, kidney, thymus, thyroid, and gross lesions in all dose 
groups at the week 4, 13, 19, and 37 sacrifices and in all tissues (comprehensive evaluation) in the 0 and 
100 mg/kg/day groups. 
 
All statistical analyses were conducted using two-tailed tests for a minimum significance level of 5% 
comparing treatment groups to the controls.  Analysis of weekly body weights, body weight changes, 
food consumption, clinical laboratory values, and absolute and relative organ weights were analyzed by a 
one-way analysis of variance and Dunnett’s Test.  The one-tailed Kolmogorov-Smirnov test was used for 
the 4- and 13-week histopathological diagnoses. 
 
Effects noted in study and corresponding doses:  Effects observed were observed at ≥2 mg/kg/day and 
included histological changes in the liver after 4 and 13 weeks of exposure as well as increased bromine 
levels in essentially all measured tissues.  Hepatocytomegaly occurred in males at 2 mg/kg/day and both 
sexes were affected at the higher doses.  Incidences of hepatomegaly in the control to high dose groups at 
13 weeks were 0/10, 7/10, 10/10, and 10/10 in males and 0/10, 0/10, 8/10, and 10/10 (statistical tests not 
conducted) in females.  Some hepatocytes in affected areas had vacuoles, which were empty in tissue 
sections and reportedly likely contained neutral lipid.  Incidences of hepatocyte vacuolation at 13 weeks 
were 2/10, 4/10, 3/10, and 2/10 in males and 3/10, 5/10, 5/10, and 6/10 in females.  The 
hepatocytomegaly was similar in incidence and severity after 4 and 13 weeks, appeared to be dose-related 
with respect to severity, and was not completely reversible as it was still observed in males at 
≥10 mg/kg/day and in females at 100 mg/kg/day at 24 weeks postexposure in lessened severity and 
incidence.  Females in the 2 and 100 mg/kg/day groups appeared to have an increased incidence of 
degeneration and necrosis of individual liver parenchymal cells at 24 weeks postexposure; the 










investigators concluded that this condition may represent the final loss of previously damaged cells and 
probably should be considered compound-related.  Incidences of individual liver cell degeneration/ 
necrosis in the female control to high dose groups at 24 weeks postexposure were 2/5, 5/5, 2/5, and 5/5.  
Small increases in thyroid hyperplasia appeared to occur in lower dose groups; incidences in the control 
to high dose groups at 13 weeks were 0/10, 2/10, 2/10, and 5/10 in males and 0/10, 0/10, 1/10, and 4/10 in 
females.  The thyroid hyperplasia was very slight in severity at 2 and 10 mg/kg/day, very slight to slight 
severity at 100 mg/kg/day, and reversible in that it was no longer observed at 24 weeks postexposure in 
any animals; the thyroid changes therefore were mild and transient.  Serum T4 levels were significantly 
reduced in both sexes at ≥10 mg/kg/day, indicating that 10 mg/kg/day is the LOAEL for thyroid effects.  
The slight thyroid hyperplasia and reductions in plasma T4 levels are likely indirect consequences of 
hepatic enzyme induction.  No compound-related changes were observed in any tissues other than the 
liver and thyroid at any dose level.  Other effects observed at ≥10 mg/kg/day included increased serum 
bromide levels in both sexes at 4 weeks (only increased in both sexes at 100 mg/kg/day at 13 weeks), and 
increased urine porphyrins in both sexes and liver porphyrins in females (liver porphyrins increased in 
males at 100 mg/kg/day).  Effects observed at 100 mg/kg/day included decreased body weight gain in 
both sexes, decreased food consumption in females, and increased serum cholesterol in both sexes at 
weeks 4 and 13, and increased absolute and relative liver weights in both sexes at 13 weeks (returned to 
normal ranges after 24 weeks of recovery).   
 
Dose and end point used for MRL derivation: 
 
[  ] NOAEL  [X] LOAEL 
 
The lowest tested dose, 2 mg/kg/day, is a minimal LOAEL for hepatic effects (hypertrophy, mild 
degeneration, and slight necrosis). 
 
Uncertainty factors used in MRL derivation: 
 
[X]    3 for extrapolation from a minimal LOAEL to a NOAEL 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No (reported doses)  
 
Was a conversion used from intermittent to continuous exposure?  NA 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA 
 
Other additional studies or pertinent information that lend support to this MRL:  The hepatotoxic potential 
of PBDE mixtures is well-documented in animals by oral exposure.  The spectrum of observed hepatic 
effects includes microsomal enzyme induction, liver enlargement, and degenerative histopathologic 
alterations that progress to tumors.  Repeated dietary exposure to PBDEs typically caused liver 
enlargement with or without degenerative changes, and effects were generally dose-related in incidence 
and severity, more frequent and pronounced in males than females, and more severe with octaBDE and 
pentaBDE than decaBDE.  Hepatic effects induced by chronic exposure to decaBDE included 
degeneration and thrombosis in rats exposed to 2,240 mg/kg/day and centrilobular hypertrophy and 
granulomas in mice exposed to ≥3,200 mg/kg/day (NTP 1986).  Data from other intermediate-duration 
studies that support selection of the 2 mg/kg/day critical LOAEL include hepatic LOAELs of 
5 mg/kg/day for cytomegaly (with vacuolation and necrosis at higher doses) in rats exposed to octaBDE 
for 13 weeks (IRDC 1977), 8 mg/kg/day for hepatocellular enlargement and vacuolation in rats exposed 










to octaBDE for 30 days (Norris et al. 1973, 1975b), and 9 mg/kg/day for hepatocellular enlargement and 
increased liver weight in rats exposed to octaBDE or pentaBDE for 28 days (IRDC 1976). 
 
Agency Contact (Chemical Manager):  Dr. Hana Pohl 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name: Polybrominated Diphenyl Ethers (PBDEs) 
   [Decabromodiphenyl Ether (DecaBDPE)] 
CAS number(s): 1163-19-5  
Date:   September 2, 2004 
Profile status:  Final Post Public Comment 
Route:   [ ] Inhalation [X] Oral 
Duration:  [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure:  13 
Species:  Mouse 
 
Minimal Risk Level:  10 [X] mg/kg/day [ ] ppm [ ] mg/m3 
 
Reference:  Hardy ML, Schroeder R, Biesemeier J, et al.  2002.  Prenatal oral (gavage) developmental 
toxicity study of decabromodiphenyl oxide in rats.  Int J Toxicol 21:83-91. 
 
Experimental design:  A commercial decaBDPE product (97.34% DBDPO, 2.66% nonaBDE/octaBDE) 
was administered to groups of 25 mated female Sprague-Dawley rats by gavage in corn oil in daily doses 
of 0, 100, 300, or 1,000 mg/kg/day on gestation days 0 through 19.  Each female was sacrificed on 
gestation day 20 and necropsied.  End points examined included maternal clinical observations, maternal 
body weight/weight gain and food consumption, maternal gravid uterine and liver weights, maternal gross 
lesions, total number of corpora lutea, uterine implantations, early and late resorptions, viable and 
nonviable fetuses, and fetal weight and sex.  Fetuses were examined grossly (all fetuses), evaluated for 
skeletal/cartilaginous malformations and ossification variations (approximately half of each litter), and 
evaluated for visceral malformations (remaining fetuses). The experiment was designed to meet current 
(as of 2002) EPA/OPPTS and OECD guidelines for a prenatal developmental toxicity study.   
 
Effects noted in study and corresponding doses:  No effects on any maternal end points (e.g., clinical 
signs, body weight, pregnancy rate, implantation, liver weight, necropsy findings) or fetal endpoints (e.g., 
body weight, sex ratio, or external, visceral or skeletal malformations) were observed in any dose group.   
 
Dose and end point used for MRL derivation:  1,000 mg/kg/day 
 
[X] NOAEL  [   ] LOAEL 
 
No exposure-related maternal or developmental toxicity was found, indicating that the critical NOAEL is 
1,000 mg/kg/day, the highest tested dose.  
 
Uncertainty factors used in MRL derivation: 
 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability 
 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  NA 
 
Was a conversion used from intermittent to continuous exposure?  NA 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA 
 










Other additional studies or pertinent information that lend support to this MRL:  One intermediate-
duration oral systemic toxicity study of a high purity decaBDE commercial product was conducted.  A 
commercial decaBDE mixture (94B97% pure) was fed to F344 rats (10/sex/level) and B6C3F1 mice 
(10/sex/level) in dietary concentrations of 0, 3,100, 6,300, 12,500, 25,000, or 50,000 ppm for 13 weeks 
(NTP 1986).  Corresponding estimated daily doses are 0, 496, 992, 2,000, 4,000, or 8,000 mg/kg/day in 
rats, and 0, 589, 1,178, 2,375, 4,750, or 9,500 mg/kg/day in mice.  The daily doses (mg/kg body 
weight/day) were estimated by multiplying the dietary concentrations (ppm; mg/kg food) by food factors 
of 0.16 kg food/kg body weight/day for rats and 0.19 kg food/kg body weight/day for mice.  The food 
factors are based on the averages of male and female subchronic reference values for food consumption 
and body weight in F344 rats and B6C3F1 mice (EPA 1988a).  All animals were observed daily, weighed 
weekly, and necropsied at the end of the exposure period.  Comprehensive histological examinations were 
also performed at the end of the study, but were limited to the control and high-dose groups.  No 
compound-related clinical signs, deaths, body weight or food consumption changes, gross pathology, or 
histopathology were observed in either species at any level of exposure. 
 
Based on the findings of the NTP (1986) study, the intermediate-duration NOAELs for systemic toxicity 
are 8,000 mg/kg/day in rats and 9,500 mg/kg/day in mice.  The NOAEL for developmental toxicity is 
1,000 mg/kg/day (Hardy et al. 2002).  Because doses higher than 1,000 mg/kg/day have not been tested 
for developmental toxicity, and the NTP (1986) study indicates that this dose is also a NOAEL for 
systemic toxicity, the 1,000 mg/kg/day developmental toxicity NOAEL is used as the basis for the MRL. 
 





















APPENDIX B.  USER'S GUIDE 
 
Chapters 1 and 2 
 
Public Health Statement 
 
These chapters of the profile are health effects summaries written in non-technical language.  Their 
intended audience is the general public, especially people living in the vicinity of a hazardous waste site 
or chemical release.  If the Public Health Statements were removed from the rest of the document, it 
would still communicate to the lay public essential information about the chemical. 
 
The major headings in the Public Health Statements are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
 
Chapters 3 and 4 
 
Relevance to Public Health 
 
These chapters provide health effects summaries based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  These summaries are designed to present interpretive, 
weight-of-evidence discussions for human health end points by addressing the following questions. 
 
 1.  What effects are known to occur in humans? 
 
 2.  What effects observed in animals are likely to be of concern to humans? 
 
 3.  What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
The chapters cover end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.   
 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 5 Data Needs section. 
 
Interpretation of Minimal Risk Levels 
 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 











MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapters 3 
and 4, "Relevance to Public Health," contain basic information known about the substance.  Other 
sections such as Chapter 5 Section 5.9, "Interactions with Other Substances,” and Section 5.10, 
"Populations that are Unusually Susceptible" provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 







Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 5-1 and Figure 5-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
 
 











See Sample LSE Table 3-1 (page B-6) 
 
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exists, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Table 5-1, 5-2, and 5-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 5-1) and oral (LSE Figure 5-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
 
(2) Exposure Period.  Three exposure periods—acute (less than 15 days), intermediate (15–
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
 
(3) Health Effect.  The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
 
(4) Key to Figure.  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 5-1). 
 
(5) Species.  The test species, whether animal or human, are identified in this column.  Chapters 3 
and 4, "Relevance to Public Health," cover the relevance of animal data to human toxicity and 
Section 5.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
 
(6) Exposure Frequency/Duration.  The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
 
(7) System.  This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 











(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
 
(10) Reference.  The complete reference citation is given in Chapter 11 of the profile. 
 
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
 
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
 
LEGEND 
See Sample Figure 5-1 (page B-7) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure Period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
 
(14) Health Effect.  These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table. 
 
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) NOAEL.  In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
 
(17) CEL.  Key number 38r is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
 










(18) Estimated Upper-Bound Human Cancer Risk Levels.  This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
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(CEL, multiple organs) 
(CEL, lung tumors, nasal 
tumors) 











Less serious (ppm) 
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a   The number corresponds to entries in Figure 5-1. 
b   Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided  



































































APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 










DOT/UN/ Department of Transportation/United Nations/ 
    NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System   
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 










MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 










OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
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TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
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TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
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WBC white blood cell 
WHO World Health Organization 
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